

UNITED EUROPEAN  
GASTROENTEROLOGY

**ueg** week

sharing the future of digestive health

26<sup>th</sup> United European Gastroenterology Week  
Vienna, Austria  
October 20-24, 2018  
Venue: Austria Center Vienna

2018

Final Programme



## Table of Contents

5	Welcome Address	255	ESGE Learning Area	
7	About UEG	261	Ultrasound Learning Area	
8	Awards and Grants	263	Surgical Learning Area	
13	Scientific Information	269	UEG Evidence Based Medicine Course	
21	Young GI Network	271	22 <sup>nd</sup> ESGENA Conference	
25	Scientific Programme Overview	275	Common Interest Group Meetings	
35	Postgraduate Teaching Programme	277	Business Meetings	
Scientific Programme by Day				
46	Monday	October 22, 2018	279	Industry Sponsored Symposia
67	Tuesday	October 23, 2018	285	Congress Information
91	Wednesday	October 24, 2018	291	Metro Map of Vienna
E-Poster Sessions by Day				
106	Monday	October 22, 2018	292	Acknowledgements
110	Tuesday	October 23, 2018	295	List of Exhibitors and Exhibition Floor Plans
115	Wednesday	October 24, 2018	301	List of Reviewers
Poster Sessions by Day				
120	Monday	October 22, 2018	307	Index of Authors and Co-Authors
165	Tuesday	October 23, 2018	357	Floor Plans Austria Center Vienna
210	Wednesday	October 24, 2018		



## Welcome Address from the UEG President to UEG Week Vienna 2018

sharing the future of digestive health



Vienna has proven to be a highly successful host city for UEG Weeks over the last years. The development of the scientific programme for the 26<sup>th</sup> UEG Week will contain some exciting new initiatives, which will ensure that our science and postgraduate education in Gastroenterology and Hepatology remain at the ‘cutting edge’.

High quality continued professional education has become of utmost importance since revalidation and relicensing of medical practitioners is becoming more widely accepted. Although UEG Week is a congress firmly based in Europe, we are delighted to welcome increasing numbers of participants from around the world, this year from Asia, North and South America, the Middle East, Africa and Australia. Presentation of new research from countries outside Europe enriches our programme and provides the opportunity for European investigators to develop new international research collaborations. While there is no doubt that UEG will continue to engage with advanced digital technologies to enhance e-learning, notably through the expansion of our activities through

online learning or the UEG Week Live concept, the need for clinicians and scientists to meet face to face and to discuss clinical innovations and research challenges is still the main focus of the UEGW.

Do not miss this year’s newly introduced ‘crash courses’. These highly interactive sessions offer the ideal setting for clinicians to get a complete update on a common, distinct topic of their daily clinical routine.

I warmly welcome you in Vienna, the heart of Gastroenterology for UEG Week 2018 which I am certain, will be another resounding success.

A handwritten signature in blue ink, appearing to read 'Paul Fockens'. The signature is stylized and fluid, with a large loop at the end.

Paul Fockens  
UEG President

## About UEG and UEG Week

### Mission & Goals

The UEG's mission is continually to improve standards of care in gastroenterology, and promote ever greater understanding of digestive and liver disease – among the public and medical experts alike. As part of that work, UEG runs a number of education and training courses facilitated by highly respected experts. They also organise UEG Week – the largest and most prestigious meeting of its kind in Europe. UEG Week has been running since 1992, in a variety of major cities, and now attracts up to 14,000 people from across the world.

### UEG is committed to:

- Raising awareness and expanding knowledge of GI and liver diseases among the public and medical profession, to deliver benefits for patients
- Coordinating the activities of clinical and scientific associations in our field
- Harmonising and improving clinical standards across Europe
- Fostering basic and clinical research in the field, and raising the profile of this work worldwide
- Promoting and delivering excellence in clinical and scientific education.

UEG consisting of 17 Ordinary Member Societies and 47 National Societies is a vibrant organisation that constantly adapts to the changing requirements of scientific research and health care.

For detailed information please visit the websites [ueg.eu/about-ueg/structure/boards-committees/](http://ueg.eu/about-ueg/structure/boards-committees/) and [ueg.eu/about-ueg/who-we-are/](http://ueg.eu/about-ueg/who-we-are/)

### Organiser

**United European Gastroenterology GmbH**  
House of European Gastroenterology  
Wickenburggasse 1  
1080 Vienna, Austria  
T +43 1 997 16 39  
F +43 1 997 16 39 10  
[uegweek@ueg.eu](mailto:uegweek@ueg.eu)  
[ueg.eu](http://ueg.eu)

### UEG Week Official Registration and Housing Agency Mondial Congress & Events

Operngasse 20b  
1040 Vienna  
Austria  
T +43 1 58804 0  
F +43 1 58804 185  
[uegweek.registration@mondial-congress.com](mailto:uegweek.registration@mondial-congress.com)



Visit our social media profiles: Like us on Facebook at [facebook.com/myUEG](https://facebook.com/myUEG)




Tweet us on [@my\\_ueg](https://twitter.com/my_ueg)

## Awards and Grants

### UEG Research Prize

**Cisca Wijmenga**  
*UEG Research Prize 2018*  
Groningen, The Netherlands



---

#### € 100,000 awarded for the most outstanding research programme

The UEG Research Prize is awarded for excellence in basic science, translational or clinical research in the areas of gastroenterology, hepatology and related disciplines. The recipient's previous work must have had an impact in its field and its quality must be internationally recognised.

Cisca Wijmenga is awarded the distinguished UEG Research Prize 2018 for her outstanding project 'A celiac mucosal barrier-on-chip model to investigate its role in initiation of celiac disease'. Her research focuses on the understanding of genetic variation and how this leads to phenotypic variation, in particular the relationship to autoimmune diseases. Her work is interdisciplinary and includes genetics, epidemiology, immunology, computational biology and bioinformatics.

In her personal statement, Professor Wijmenga explained that 'the reason to start investigating the genetic of celiac disease was to contribute to a better life for patients' and that she hopes 'that her work will allow her to contribute

to that by pioneering work on building personalized models of celiac disease that can be used in many different ways.'

Cisca Wijmenga is currently holding the position of Lodewijk Sandkuijl Endowed Chair and Professor of Human Genetics at the University Medical Centre Groningen (UMCG) in the Netherlands. In 2016, she was elected as Member of the Royal Holland Society of Sciences and Humanities.

---

**Award Ceremony at the Opening Session**  
**Monday, October 22, 2018 // 08:00 – 12:00**  
**Room A**

08:57 – 09:12 Project Presentation and Award Ceremony

**Research Prize 2018:** A celiac mucosal barrier-on-chip model to investigate its role in initiation of celiac disease

## UEG Lifetime Achievement Award



**Colm O'Morain**  
*UEG Lifetime Achievement Award 2018*  
 Dublin, Ireland

---

### Recipients have proven lifelong excellence and leadership in the field

The UEG Lifetime Achievement Award recognizes outstanding individuals whose pioneering and inventiveness throughout their careers have improved the Federation and inspired others.

Professor O'Morain was Consultant Gastroenterologist and Professor of Medicine at the Faculty of Health Sciences in Trinity College Dublin and the Adelaide & Meath National Children's Hospital in Tallaght Dublin. As Dean of the Faculty and during his academic career, he has been a key opinion leader in three major fields of Gastroenterology. He was one of the first to establish that eradication of *H. pylori* could cure peptic ulcers permanently and was integrated worldwide in all aspects of *H. pylori* research and treatment. He led a laboratory based research programme focusing on fish oils, vitamins and the role of nutrition, as well as the role of heparin in the treatment of IBD. He was instrumental in advocating for colorectal cancer screening on a national as well as on a pan-European level.

Advocacy work by UEG in Brussels was initiated under his chairmanship of the UEG Public Affairs Committee. During his tenure as UEG President 2012-2013, the House of European Gastroenterology in Vienna was opened and he was active in the European Parliament in advocating for increased funding for health research in his position as President of the Alliance for Biomedical Research in Europe.

---

**Award Ceremony at the Opening Session**  
**Monday, October 22, 2018 // 08:00 – 12:00**  
**Room A**

09:30 – 09:40 Laudation and Presentation of the Award

## UEG Journal Best Paper Award



**Joaquín Cubiella**  
*UEG Journal Best Paper Award 2018*  
Ourense, Spain

---

### Recognition of the first-named author for the best original research, published in UEG Journal 2017

UEG Journal provides an international forum for research in gastroenterology, publishing original articles, which describe basic research, translational and clinical studies of interest to gastroenterologists and researchers in related fields. In 2017, UEG Journal continues to go from strength to strength with an impressive impact factor of 3,477 and a position of 28 out of 80 titles in the gastroenterology and hepatology category of the Journal Citation Reports®.

With the Best Paper Award, we recognize the first named author of the best original scientific research, published in UEG Journal in the past year. The winning article is selected by a panel of experts presided over by Chief Editor Professor Jan Tack.

The Journal Best Paper Award 2018 is awarded to Joaquín Cubiella as the first author of the winning article: *Correlation between adenoma detection rate in colonoscopy and fecal immunochemical testing-based colorectal cancer screening programs*. The article is available for download at [ueg.sagepub.com](http://ueg.sagepub.com)

Dr Joaquín Cubiella is a clinical researcher at the Complejo Hospitalario Universitario de Ourense, Ourense, Spain. His two main areas of research interest in the last 20 years have been the diagnosis and prevention of CRC and the coordination and integration with primary healthcare. He has participated in the development of several Spanish clinical practice guidelines, including the

2018 Update of the Spanish Diagnosis and Prevention of CRC clinical practice guideline, and he has been part of different initiatives for the improvement of assistance and the integration of healthcare levels within the Galician health service.

He has participated in national and international research projects in the field of diagnosis (COLONPREDICT), screening (COLONPREV), prevention (EPoS, Seguícol) and risk assessment in familial or hereditary forms of CRC (EPICOLON, EPIPOLIP, ParCoFIT).

In recent years, his research group in the Galicia Sur Health Research Institute has focused on the development, validation and evaluation of diagnostic biomarkers of CRC.

He has published more than 90 articles in journals indexed with an impact factor greater than 500 and an H-Index of 19.

---

#### Award Ceremony at the Opening Session

**Monday, October 22, 2018 // 08:00 – 12:00**

#### Room A

11:02 – 11:07 Presentation of the Award

**UEG Journal Best Paper Award 2018:** Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs

### International Scholarship Awards

UEG awards 30 International Scholarships to young gastroenterologists, aged 40 and below. Awardees get free registration for UEG Week, including the Postgraduate Teaching Programme, and € 1,000 to cover travel expenses related to UEG Week. The scholarships are restricted to citizens of countries with a Human Development Index (HDI) of less than 0.8 according to the latest Human Development Report.

### National Scholar Awards ✦

The National Scholarship is designed to support promising young investigators at a junior level and to encourage them to work towards the more senior UEG Rising Star Award. The award recognises the highest scoring abstract, presented by a colleague below the age of 35, from every UEG National Member country.

### Best Abstract Presentation Prizes

The best presenter of every abstract-based session and posters in the spotlight session is awarded this prize. The winners are selected by the session chairs, who take the quality of research, the originality of the presented work as well as the presentation itself into account. Prize winners receive a certificate of excellence.

### Poster Champ Awards

Every day during lunch break, the highest scoring posters are presented in the interactive Poster Champ Sessions at the E-poster Terminals in the Scientific Centre. The best presenter of each session receives the Poster Champ Award. Awardees receive a certificate and free registration to next year's UEG Postgraduate Teaching Programme.

### Rising Star Awards ✦

Every year, the UEG National Societies Committee and the UEG Scientific Committee jointly select 6-8 clinical scientists as UEG Rising Stars. The selection is based on a track record of international quality research and on scientific independence. This initiative provides a durable platform for these young researchers to further improve and progress in their professional career.

### Top Abstract Prizes ✦

The presenting first authors of the top five submitted abstracts to UEG Week are awarded the Top Abstract Prize every year. The prize money of € 10,000 is to be spent on future research. In case of industry sponsored multi-centre studies, the author is required to waive the monetary part of the prize. Awarded abstracts must neither been previously presented at an international meeting nor been fully published.

### Travel Grants

UEG offers 510 Travel Grants up to € 750 for clinical and basic scientists of 40 years of age and below, to the presenters of the best abstracts submitted to UEG Week.

International Scholars 2017





# Scientific Information

## Welcome by the Chair Scientific Committee

I would like to welcome all of you to UEG Week 2018 in Vienna – the place to be for clinicians and researchers!



This year's programme features the latest advances in clinical management, the best research in GI and liver disease and includes several different kinds of symposia and fora, where cutting-edge gastroenterology and hepatology is being discussed.

### I would like to draw your attention to some of the highlights in 2018:

- The **UEG Week Scientific Centre** – a place where all possibilities to present an abstract are united, featuring the UEG Week Hotspot, the E-Poster Terminals as well as the poster exhibition.
- **Clinical trials revisited** feature a recently published clinical trial, followed by a critical review and a panel discussion with experts in the field.
- **Posters in the Spotlight sessions, Poster Champ Sessions** and the **Exemplary Clinical Cases** promise exciting poster sessions.
- **Crash Courses** are highly interactive sessions that cover all facts, updates as well as best practice recommendations, which every clinician should know for his daily work.
- **Therapy updates**, where the current state-of-the-art treatment options in some of the major GI and liver diseases are presented.
- **From guidelines to clinical practice** give you a concise update on European guidelines and their implementation in everyday clinical practice.
- The **Translational/Basic Science** pathway including topics that will affect clinical practice within the near future, thereby being attractive for both basic/translational scientists and clinicians.
- The **Young GI track**, where sessions of special interest for young GI fellows will be highlighted in the programme. The mentoring programme for our young colleagues will be expanded additionally.
- Our clinically oriented one-day symposium within the meeting, entitled **advances in clinical gastroenterology and hepatology**, focusing on 'liver' this year.
- The **Today's Science; Tomorrow's Medicine** initiative with the topic 'Regenerative medicine in digestive disease', which will focus on research as well as clinical implications from one of the hottest research areas today.
- For the practical minded, we will again offer the popular **Live Endoscopy** sessions and the **Hands-on Training** areas: Here you can experience first-hand endoscopy, ultrasound and surgical procedures in the respective learning areas.

- Wednesday afternoon features the **What's new in...?** session, which will again provide delegates with a comprehensive summary of recent changes in the management of major GI and liver diseases, as well as major scientific advances.
- The **Postgraduate Teaching Programme 2018** is year two of the 3-year curriculum. Start or continue the curriculum now and get all major updates in GI and hepatology.
- As science remains the most important feature of our meeting, we have again worked hard to offer a large number of sessions devoted to original research.

As you can easily understand from this, UEG Week is the place to be for you!



Herbert Tilg  
Chair of the UEG Scientific Committee

UEG Scientific Committee

**Thank you!**



## Overview Scientific Programme

Saturday October 20, 2018	Sunday October 21, 2018	Monday October 22, 2018	Tuesday October 23, 2018	Wednesday October 24, 2018
Postgraduate Teaching Programme				
		Opening Session		
		Symposia		
		Translational / Basic Science Pathway		
		Today's Science; Tomorrow's Medicine (TSTM)	Advances in Clinical GI and Hepatology	
		UEG Week Hotspot		
			Live Endoscopy	Video Case Session
		Abstract-Based Sessions		
		Scientific Centre: Poster Exhibition / Poster Champ Sessions / Posters in the Spotlight		
		Case-Based Discussions		
Young GI Network				
ESGE Learning Area				
Ultrasound Learning Area				
Surgical Learning Area				
Association Meetings: Common Interest Group Meetings / Business Meetings				
	Industry Sponsored Symposia			
		Technical Exhibition		
22 <sup>nd</sup> ESGENA Conference				



## Format Descriptions

### Postgraduate Teaching Programme

The 2-days PGT programme provides profound updates of the latest developments in all GI and hepatology topics, with a strong focus on the relevance for the clinical day-to-day business – a perfect mix for gastroenterologists in training and in practice as well as for established GI physicians and general practitioners. It includes interactive session formats, such as tricky clinical cases, controversial debates and exciting video cases.

2018 is year 2 of the 3-year PGT Curriculum, which follows recommendations of the EBGH Blue Book and permits participants to get perfectly prepared for their professional career. Delegates can start the curriculum at any year of the 3-years cycle and will receive a certificate once they have attended each of the 3 years.

PGT syllabus contributions are available in the online programme, the congress app and at [ueg.eu/syllabus](http://ueg.eu/syllabus), where congress delegates can furthermore access recordings of all PGT sessions free of charge. The detailed curriculum and all learning objectives are available at [ueg.eu/week/postgraduate-teaching](http://ueg.eu/week/postgraduate-teaching).

*Please see further information on page 35 and following.*

### Opening Session

The Opening Session is held on Monday morning and includes official speeches and the opening of the core scientific programme, with a mixture of invited speakers and presentations of the best submitted abstracts. UEG awards the UEG Research Prize, the UEG Lifetime Achievement Award and the UEG Journal Best Paper Award at the Opening Session.

### Symposia

These interdisciplinary sessions include state-of-the-art lectures, covering new approaches to diagnosis and treatment with a major emphasis on innovative technical advances in the non-invasive management of gastrointestinal and hepatic disorders. **Therapy updates** on latest treatment options, **'From guidelines to clinical practice'** sessions and the one-day symposium **advances in clinical GI and hepatology on 'liver'** on Wednesday present the hot topics in 2018.

### Crash Courses

This year's newly introduced crash courses offer the ideal setting for clinicians to get a complete update on a common, distinct topic of their daily clinical routine. All

essential aspects are covered in these practically focused sessions, where clinical cases and best practice examples will contribute to its relevance for the clinical practice. The moderated crash courses are particularly interactive – the audience is invited to contribute with their comments and questions and to discuss openly with the chairs, speakers and the other auditors.

### Case-Based Discussions

Four experts will present and discuss a common clinical situation based on a case presentation. Four case-based discussions take place between 12:45 and 13:45 each day on Monday, Tuesday and Wednesday in the Rooms G, K, M and N1. There is no pre-booking required, but come early as there are limited seats which will be filled on a first-come, first-served basis.

### Translational/Basic Science Pathway

These sessions include topics that will potentially affect clinical practice within the near future, thereby being attractive for both, basic/translational scientists and clinicians.

### Interactive Formats

The UEG Scientific Committee aims at making the scientific programme a modern and interactive experience. Once again, UEG Week 2018 features many sessions with **audience voting** and the interactive **Q&A tool**, which permits the audience to send questions to the chairs. **Panel discussions** in symposia offer an in-depth insight on different points of views of the chairs and speakers. **Debates**, where two speakers argue opposing cases and **tandem talks**, where experts present different aspects of the same problem, feature among the most popular and lively presentations. We also encourage speakers to **include cases** to illustrate their talks and to increase their clinical relevance.

### Today's Science; Tomorrow's Medicine

UEG Week hosts again the two-days 'Today's Science; Tomorrow's Medicine' initiative in the main programme. In 2018, the theme is 'Regenerative medicine in digestive diseases'. Top class scientists have been invited to discuss how the current stage of knowledge is ready to be used in clinical practice, and to establish strategies to foster further progression of knowledge in this area. The Today's Science; Tomorrow's Medicine symposium is a combination of both, invited sessions featuring the world's top scientists and abstract-based sessions where work is presented by young and established researchers.

### UEG Week Hotspot

The UEG Week Hotspot is THE place to be at UEG Week 2018, where the most controversial sessions and the hottest debates will take place. These sessions promise to be most intense! Featured at the Hotspot are the **Clinical trials revisited sessions**, where the latest results from recent large clinical trials will be presented and discussed by experienced investigators. Do not miss to pass by and attend these exciting sessions taking place from Monday until Wednesday!

### Live Endoscopy

Live endoscopy is included in the core programme on Tuesday. Top international experts demonstrate cutting-edge techniques alongside basic procedures transmitted directly from the Gemelli Hospital in Rome to the auditorium. The use of multiple parallel cases and experienced chairs ensure interactive learning without unnecessary gaps.

### Abstract-Based Sessions

The most important feature of UEG Week is science and we are constantly trying to attract the best science to our meeting. This is recognised in the core programme with a large number of sessions devoted to original research, and an impressive number of **mixed sessions** where invited talks and abstract presentations alternate.

### Posters in the Spotlight

Posters in the Spotlight sessions boost science even further and have become a fixture at UEG Week. They are an excellent platform for in-depth scientific exchange with faculty and peers in a relaxed atmosphere and present an ideal opportunity to assist highly interactive and expert-led poster presentations.

### Poster Exhibition/E-Posters

Printed posters are displayed and changed daily from 09:00 – 17:00 (Mon & Tue) and 09:00 – 14:00 (Wed) in Hall X1. All accepted posters also have the opportunity to get published electronically in addition to the printed poster. All **E-Posters** which were uploaded prior to UEG Week can be searched for and viewed on the E-Poster Terminals in the poster exhibition, from Monday until Wednesday. E-Posters allow all poster presenters to include interactive media files, such as radiology images, endoscopy videos, etc.

### Poster Champ Sessions

There will be four Poster Champ Sessions in parallel from Monday until Wednesday from 12:30 – 13:30. 2-minute presentations of the highest scoring posters are followed by 3-minute Q&As from the chairs. The Poster Champ of each session will be awarded during the official award

ceremony at the Award Stage in Hall X2 at 13:45 each day and he will receive a certificate and free registration to the Postgraduate Teaching Programme of next year's UEG Week in Barcelona. Poster Champ Sessions take place at the E-Poster Terminals in Hall X1.

*Please see further information on page 105 and in the UEG Week App.*

### Video Case Session

The Video Case Session is an excellent platform for brief information on recent issues of endoscopy. During this session short videos showing examples of new, unexpected or exceptional endoscopic practice are presented and briefly discussed. Thus, the Video Case Session presents unusual cases or new technologies based on diagnostic and therapeutic endoscopy.

### ESGE Learning Area

The ESGE Learning Area incorporates different educational formats in order to provide both beginner endoscopists as well as proven experts a platform for skill enhancement and professional discourse. In cooperation with ESGENA, the Hands-on Training Centre gives practical insight into basic and advanced endoscopic techniques. Participants can test their skills under the guidance of expert doctor and nurse tutors. Lively talks between young experts and established senior discussants are held in the Lecture Theatre where debate on the how and why of current procedures prompts audience involvement. Video teaching is an essential part of endoscopy training. The DVD Learning Centre shows continuous films from the ESGE eLibrary and also includes videos contributed by the ASGE and JGES. The Learning Area is open to all delegates during the general opening hours of the congress.

*Please see further information on page 255 and in the UEG Week App.*

### The Ultrasound Learning Area

*Please see further information on page 261 and in the UEG Week App.*

### Surgical Learning Area

*Please see further information on page 263 and in the UEG Week App.*

### Business Meetings

#### > upon invitation only

Association, board and committee meetings for elected (UEG) leadership.

*Please see further information on page 277.*

### Common Interest Group Meetings

#### > open to all delegates

Activities taking place outside of the core scientific programme and open to all UEG Week delegates.

*Please see further information on page 275.*

### ESGENA Conference

The Conference of the European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) is an associated meeting at the congress with separate scientific programme and registration.

*Please see further information on page 271 and in the UEG Week App.*

---

### Other Scientific Information



UEG Week Vienna 2018, Austria, October 20–24, 2018, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 31 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Programme of The Royal College of Physicians and Surgeons of Canada.

In order to obtain CME credits, UEG requires feedback on its educational activities. Therefore, we kindly ask all delegates to complete the online evaluation form after conclusion of the congress. The evaluation form is available via the congress app and on [ueg.eu/myueg](http://ueg.eu/myueg). The CME Certificate of EACCME will be available for download after completion of the online evaluation.

---

### Disclosure Policy

UEG is committed to ensuring scientific rigour and objectivity in all of its educational activities. These include all aspects of the educational programme at UEG Week including those that are directly and jointly sponsored activities.

All presenters, whether invited faculty or abstract presenters, are required to disclose to those organising and attending meetings any relevant financial or other relationship that may lead to a potential bias. UEG reserves the right to review the information disclosed for potential conflicts of interest. Please note that the sole responsibility for the content of each presentation lies with the presenting author.

The UEG Scientific Committee requires all presenters to disclose any financial relationship with or any advisory role in the Biomedical Industry and the Biomedical Technology Industry during the past two years. These and any other potential conflicts of interest should be disclosed during introductory comments to the presentation.

Invited speakers and oral abstract presenters are requested to disclose potential conflicts of interest on a PowerPoint slide to be shown immediately at the beginning of the presentation. Poster presenters are requested to disclose potential conflicts of interest at the bottom of their poster.

Conflicts of interest may exist through a financial relationship or when the individual has the opportunity to influence the content of a presentation, and can involve grants, honoraria, shares, paid positions on advisory boards, etc. Conflicts of interest are frequent and expected, and do not preclude an individual from giving a presentation providing the conflict is disclosed. If there is any doubt about the relevance of a potential conflict of interest UEG requires all presenters to err on the safe side and to disclose it.





## Young GI Network

### Young GI Sessions

Join our special coaching and networking sessions and receive advice and guidance from senior experts! Registration is not required.

*Sunday, October 21*

13:00 – 14:00 Young GI Lounge

**Check your CV: Tips and tricks from experts**

*Monday, October 22*

13:00 – 14:00 Young GI Lounge

**Visiting Fellowship Programme Information Meeting**

14:00 – 15:30 N1

**Mistakes in...**

Presentations & discussions about the most common mistakes in GI practice and how to avoid them

15:45 – 18:00 Young GI Lounge

**Rising Stars in gastroenterology and hepatology from Europe and Japan**

Interactive session & get together

*Tuesday, October 23*

08:30 – 10:00 N1

**How to prepare a presentation**

13:00 – 14:00 Young GI Lounge

**Career Chat: Women as educators**

14:00 – 15:30 Young GI Lounge

**The European Specialty Examination in Gastroenterology and Hepatology: An important step in becoming a gastroenterologist**

For further details see the UEG Week App or the online programme at [ueg.eu/week/programme](http://ueg.eu/week/programme)

### Mentoring Programme

Established experts within different fields of gastroenterology, hepatology, endoscopy and GI research tell you how to get the most out of the scientific congress programme. They provide career advice and conduct a 'poster walk' with the mentees, where they engage with poster presenters.

**Registration is required;** remaining spots can be booked onsite in the Young GI Lounge on a first-come, first-served basis.

**Monday, October 22** > 10:00 – 10:30 // 12:00 – 13:00

**Tuesday, October 23** > 10:00 – 10:30 // 12:00 – 13:00

Meeting point for pre-registered delegates:  
10:00, Young GI Lounge

### Young GI Track

The Young GI Track, one of the UEG Week Pathways, highlights sessions that we consider of particular interest for junior congress delegates. You can access the Pathways Tool in the UEG Week App.

### Young GI Network – Let's meet!

This special event for young congress delegates takes place in mumok Hofstallung, MuseumsQuartier in Vienna's city centre. The informal atmosphere makes it easy to meet new colleagues and reunite with your old friends from all over the world.

The event is limited to congress delegates and registration is required. Remaining tickets can be purchased for € 15 at the congress registration counter on a first-come first-served basis. Guests are asked to present their ticket and congress badge at the entrance to the event. Booked tickets expire and might be resold after 20:30.

**Sunday, October 21** 19:00 – 24:00

mumok Hofstallung, MuseumsQuartier, Museumsplatz 1, 1070 Vienna

### Young GI Network – Facebook live discussions

Watch the experts debate exciting topics with young GIs! Join in the discussion and ask your questions live in the "Young GI Network" Facebook Group.

**Saturday, October 20** 17:00 – 18:00

Treating patients from bench to bedside (expert: Magnus Simrén, moderator: Henriette Heinrich)

**Tuesday, October 23** 17:30 – 18:30






How to improve work-life balance of doctors (experts: Carolina Ciacci, Péter Hegyi, moderator: Radislav Nakov)

# Scientific Programme Overview





The scientific programme is as of September 12, 2018.  
Later changes are published in the online programme  
and in the UEG Week congress app.

## Postgraduate Teaching Programme Overview






### Saturday, October 20, 2018

	Room A Voting Room	Room B Voting Room	Room C Voting Room	Room E1	Level 1		
09:00 – 10:30	<b>Plenary I</b>					09:00 – 18:00 ESGE Learning Area Surgical Learning Area Ultrasound Learning Area	
	Management of Crohn's disease						
 10:30 – 11:00 Coffee Break 							
11:00 – 13:00	<b>Video Case Session</b>	<b>Parallel Sessions</b>					
	Endoscopic assessment and treatment of gastrointestinal bleeding	Bariatric surgery	Autoimmune diseases of the liver and bile ducts	Gastric cancer			
 13:00 – 14:00 Lunch Break 							
14:00 – 16:30	<b>Video Case Session</b>	<b>Parallel Sessions</b>			14:00 – 17:30 ESGENA		
	Polyp handling and advanced endoscopic therapy	Colorectal cancer: Staging, surgery and adjuvant therapies	Therapy update in functional gastrointestinal disorders	Gallstones and complications			

### Sunday, October 21, 2018 ▶▶

	Room A Voting Room	Room B Voting Room	Room C Voting Room	Room E1	Room E2	Room M
08:30 – 10:30	<b>Parallel Sessions</b>					
	Advanced endoscopic techniques	Management of ulcerative colitis: The acute patient	Small bowel imaging and endoscopy	Cystic pancreatic lesions	Hepatocellular carcinoma (HCC)	
 10:30 – 11:00 Coffee Break 						
11:00 – 13:00	<b>Clinical Case-Based Sessions</b>					
	Lower GI bleeding	Hepatitis C	Colorectal polyps	Cancer and IBD	Management of Barrett's oesophagus and Barrett's neoplasia	Non-cardiac chest pain
 13:00 – 14:00 Lunch Break 						
14:00 – 16:00	<b>Plenary II</b>					
	Irritable bowel syndrome: Optimal management in 2018					
16:15 – 17:45 and 18:00 – 19:30 Industry Sponsored Symposia						



Room 1.61/1.62	Room N2	Room L7	Room L8	Level 1 	
				09:00 – 18:30  ESGENA	09:00 – 18:00  ESGE Learning Area  Surgical Learning Area  Ultrasound Learning Area
 10:30 – 11:00 Coffee Break 					
Clinical Case-Based Sessions					
Malabsorption	The liver and pregnancy	Cholangiocarcinoma: From diagnosis to treatment	Chronic diarrhoea		
 13:00 – 14:00 Lunch Break 					
				16:15 – 17:45 and 18:00 – 19:30 Industry Sponsored Symposia	




## Scientific Programme Overview

Monday, October 22, 2018



	Room A	Room D Voting Room	Room B	Room C	Room E1	Room E2	Room F1
07:00 – 08:00 Industry Sponsored Symposia							
08:00 – 10:00	Opening Session						
	Part I						
☕ 10:00 – 10:30 Coffee Break ☕							
10:30 – 12:00	Opening Session	Symposium	Symposium	Symposium	Symposium	Symposium	Abstract-Based Session
	Part II	Post-operative recurrence of Crohn's disease	Endoscopic resection of polyps	Constipation	Epidemiology and treatment options in NASH	Barrett's oesophagus	IBD: From epidemiology to costs and outcome
12:00 – 14:00	🍴 12:00 – 14:00 Lunch Break 🍴						
	Symposium	Symposium	Symposium	Late Breaking Abstracts	Symposium	Symposium	Symposium
14:00 – 15:30	Best of DDW	Early management of acute pancreatitis: What & when?	Therapy update in colorectal cancer	Late breaking abstracts I	Update in eosinophilic esophagitis (EoE)	From guidelines to clinical practice in Crohn's disease	Auto-immune hepatitis
	☕ 15:30 – 15:45 Coffee Break ☕						
15:45 – 17:15	Symposium	Symposium	Symposium	Late Breaking Abstracts	Abstract-Based Session	Symposium	Abstract-Based Session
	Luminal Crohn's disease and surgery	GORD resistant to PPI	Therapy update: <i>H. pylori</i> eradication regimen	Late breaking abstracts II	Cutting-edge endoscopy	From guidelines to clinical practice on faecal incontinence	Clinical features in IBD
17:45 – 19:15 Industry Sponsored Symposia							

\* CBD: Case-Based Discussion / TSTM: Today's Science; Tomorrow's Medicine

									Scientific Centre			Level 1 
Room F2 Voting Room	Room G	Room K	Room M	Room 1.61/1.62	Room N1	Room N2	Room L7	Room L8	E-Poster Terminals (Hall X1)	Hotspot (Hall X5)		
07:00 – 08:00 Industry Sponsored Symposia												
☕ 10:00 – 10:30 Coffee Break ☕												
<b>Symposium</b>	<b>Abstracts on Fire</b>	<b>Abstract-Based Session</b>	<b>Translational/ Basic Science</b>	<b>TSTM*</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>	<b>Symposium</b>	09:00 – 18:00  ESGE Learning Area  Surgical Learning Area  Ultrasound Learning Area
Functional disorders: Is testing necessary?	Pushing the limits of hepato-pancreatic and biliary diseases	Risk factors and risk assessment of GI bleeding	Barrier function and GI disease	Regeneration: From myth to mechanism	Hot topics from Latin America	Microbiota in IBS: From bench to bedside	Interventional EUS: Fifty shades of gray	Generic profiling and risk assessment in polyps and early CRC	Natural history and management of small bowel diseases	From microbiota to IBD	New metrics for colonoscopy	
	<b>CBD* 12:45 – 13:45</b> Biliary pancreatitis	<b>CBD* 12:45 – 13:45</b> Oesophageal motility disorders and dysphagia: How to diagnose? How to treat?	<b>CBD* 12:45 – 13:45</b> Anal pain and bleeding: Proctology		<b>CBD* 12:45 – 13:45</b> Diarrhea and fever	🍴 12:00 – 14:00 Lunch Break 🍴			 		<b>Symposium 12:45 – 13:30</b> Women in interventional endoscopy: Are women less attracted by invasive procedures?	
<b>Symposium</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Translational/ Basic Science</b>	<b>TSTM*</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>	<b>Symposium</b>	
Upper GI bleeding: The basics from the experts	Alcoholic liver disease	Advances in pancreato-biliary endoscopy	Novel technical developments in basic science	TSTM Abstract-based: Stem cells as a therapeutic option	'Mistakes in...'	Transitioning from viral hepatitis to NASH	Gastric carcinogenesis	Translational research in liver, biliary and pancreas	Diagnostic endoscopy	Novelties in the HPB diseases	Clinical trials revisited: Closing gaps and bleeders	
☕ 15:30 – 15:45 Coffee Break ☕												
<b>Symposium</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Translational/ Basic Science</b>	<b>TSTM*</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>			<b>Symposium</b>	
Biliary stones: Diagnosis and therapeutic management	Update on hereditary colorectal cancer syndromes	Management of Barrett's	Biomarkers and individualised medicine	Liver: Regenerative mechanism – lessons for other organs?	IBD pathogenesis	Coeliac disease: From basics to therapy	Unsolved issues in cirrhosis	Diagnosis and risk factors of pancreatic diseases			Multidisciplinary management of locally advanced rectal cancer	
17:45 – 19:15 Industry Sponsored Symposia												

## Scientific Programme Overview

Tuesday, October 23, 2018



	Room A	Room D Voting Room	Room B	Room C	Room E1	Room E2	Room F1	Room F2 Voting Room	Room G	Room K	Room M	Room 1.61/1.62	Room N1
07:00 – 08:00 Industry Sponsored Symposia													
08:30 – 10:00	Live endoscopy	Symposium	Symposium	Symposium	Symposium	Symposium	Symposium	Symposium	Abstract-Based Session	Abstract-Based Session	Translational/Basic Science	TSTM*	Symposium
		Future therapies in IBD	<b>Therapy update:</b> Acute pancreatitis	Screening for colorectal cancer across Europe	Microscopic colitis a neglected entity	<b>From guidelines to clinical practice:</b> Viral hepatitis	Pancreatic cancer: From bench to the bedside	Diagnosis and management of distal malignant biliary obstruction	Oesophageal disorders: Mechanisms and management	Help! I've got a bleeder!	Microbiota: Friends or foes?	TSTM Abstract-based: Mechanisms of intestinal inflammation	How to prepare a presentation
☕ 10:00 – 10:30 Coffee Break ☕													
10:30 – 12:00	Live endoscopy	Symposium	Symposium	Symposium	Symposium	Symposium	Abstract-Based Session	Symposium	Abstract-Based Session	Abstract-Based Session	Translational/Basic Science	TSTM*	Abstract-Based Session
		Crash course: Non-bleeding emergency upper GI patient	<b>Therapy update</b> in ulcerative colitis	European - Japanese perspectives	What to blame in pancreatitis: Nature or nurture?	<b>From guidelines to clinical practice:</b> Barrett's oesophagus	Clinical management and consequences of <i>H. pylori</i> eradication	Quality in endoscopy	IBD: From drug monitoring to immunogenicity	Faecal transplantation in <i>C. difficile</i> : How to do it right?	Functional disorders: Are they really functional?	Intestinal regeneration: Is the gut the new liver?	Cirrhosis: It's all about varices!
12:00 – 14:00	🍴 12:00 – 14:00 Lunch Break 🍴								CBD* 12:45 – 13:45	CBD* 12:45 – 13:45	CBD* 12:45 – 13:45		CBD* 12:45 – 13:45
									Acute liver failure: Beyond the obvious	Therapeutic management of patients with dyspeptic symptoms	Left lower quadrant pain: Acute diverticulitis		Renal failure in cirrhosis
14:00 – 15:30	Live endoscopy	Symposium	Symposium	Symposium	Symposium	Symposium	Abstract-Based Session	Symposium	Symposium	Abstract-Based Session	Translational/Basic Science	TSTM*	Symposium
		Is precision medicine in IBD possible?	<b>Therapy update:</b> Multimodality treatment of upper GI cancers	Liver cancer: New guidelines	Crash Course: When the liver starts talking	<b>From guidelines to clinical practice:</b> <i>H. pylori</i>	IBD clinical trials I	Screening for upper GI cancer	Therapeutic EUS: Drainage and beyond	Managing colorectal polyps	The mucosal immune system: Novel insights	Coeliac disease: Model of intestinal disease?	EU funding opportunities in digestive health
☕ 15:30 – 15:45 Coffee Break ☕													
15:45 – 17:15	Symposium	Symposium	Symposium	Symposium	Abstracts on Fire	Symposium	Abstracts on Fire	Symposium	Late Breaking Abstracts	Abstract-Based Session	Translational/Basic Science	TSTM*	Symposium
	Endoscopic management of complications after upper GI surgery	Long-term management and surveillance of IBD	<b>Therapy update:</b> Canulation access techniques in ERCP	Experiences in quality assessment in upper GI	Champion session in surgery and endoscopy	<b>From guidelines to clinical practice:</b> Cystic pancreatic lesions – differential diagnosis and management	IBD on fire	Rome IV: Has it changed clinical practice?	Late breaking abstracts III	Evaluation of colorectal cancer screening programmes	Novel insights in colorectal cancer	Regeneration of the intestinal microbiota: FMT and beyond	Classifications of gastric cancer: From laboratory to clinical practice
17:45 – 19:15 Industry Sponsored Symposia													

\* CBD: Case-Based Discussion / TSTM: Today's Science; Tomorrow's Medicine

			Scientific Centre			Level 1 
Room N2	Room L7	Room L8	E-Poster Terminals (Hall X1)		Hotspot (Hall X5)	
07:00 – 08:00 Industry Sponsored Symposia						
<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Exemplary Clinical Cases I</b> 09:00 – 10:00	<b>Exemplary Clinical Cases II</b> 09:00 – 10:00		09:00 – 18:00  ESGE Learning Area  Surgical Learning Area  Ultrasound Learning Area
Small bowel disorders	Murine models of intestinal inflammation	The gut-brain axis in the lower GI				
☕ 10:00 – 10:30 Coffee Break ☕						
<b>Abstract-Based Session</b>	<b>Symposium</b>	<b>Symposium</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>	<b>Symposium</b>	
New insights in cholestatic liver diseases	Palliation in upper GI cancer	Contrast-enhanced ultrasound (CEUS) for clinical problem solving: Safer than CT/MR	Colorectal carcinogenesis: From pathogenesis to diagnostics	Novelties in the HPB diseases	Precancerous conditions of the stomach	
🍴 12:00 – 14:00 Lunch Break 🍴			<div style="border: 2px solid green; border-radius: 50%; padding: 10px; text-align: center; color: white;"> <p>12:30 – 13:30 Poster Sessions &amp; Poster Champs</p> <p>13:45 Poster Award Ceremony </p> </div>			
<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>	<b>Symposium</b>	
Endoscopic submucosal dissection: When the going gets tough	From bench to the bedside in pancreatic cancer	Barrett's oesophagus: Pathogenesis and biomarkers	Evaluation of oesophageal and gastric function	Advanced endoscopy	Clinical trials revisited: Redefining the management of patients with decompensated cirrhosis and PBC	
☕ 15:30 – 15:45 Coffee Break ☕						
<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Exemplary Clinical Cases III</b>		<b>Symposium</b>	
Artificial intelligence: The rise of the machines	Obesity and nutrition	New therapeutic approach in pancreatitis			Non-IBD colitis	
17:45 – 19:15 Industry Sponsored Symposia						



## Scientific Programme Overview

Wednesday, October 24, 2018



	Room D	Room E1	Room E2	Room F1	Room F2 Voting Room
08:30 – 10:00	Symposium	<b>Advances in Clinical GI &amp; Hepatology</b>	<b>Video Case Session</b>	Symposium	Symposium
	Crash course: Perianal Crohn's disease	Advances in cholestatic liver diseases		New insights in the diagnosis of cystic pancreatic lesions	Management of superficial lesions of gastric cancer
 10:00 – 10:30 Coffee Break 					
10:30 – 12:00	Symposium	<b>Advances in Clinical GI &amp; Hepatology</b>	<b>Abstract-Based Session</b>	Symposium	Symposium
	Tips and tricks for the IBS patient	Drug induced liver injury (DILI)	IBD clinical trials II	The malignant polyp	IBD in young
12:00 – 14:00	 12:00 – 14:00 Lunch Break 				
	Symposium	<b>Advances in Clinical GI &amp; Hepatology</b>	Symposium	Symposium	Symposium
14:00 – 15:30	IBD: What's new in 2018?	Advances in the management of cirrhosis	Endoscopy: What's new in 2018?	Barrett's oesophagus: What's new in 2018?	Coeliac disease: What's new in 2018?





\* CBD: Case-Based Discussion

								Scientific Centre			Level 1 	
Room G	Room K	Room M	Room 1.61/1.62	Room N1	Room N2	Room L7	Room L8	E-Poster Terminals (Hall X1)		Hotspot (Hall X5)		
<b>Abstract-Based Session</b>	<b>Symposium</b>	<b>Translational/Basic Science</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>			
The broad spectrum of IBD management	East meets West: Current perspectives on GI cancer screening	New advances in NASH and ASH	The truth is under the microscope	Upper GI sensitivity and symptom generation	Congenital malformations: How to follow up in adulthood?	CRC in young adults and genetically predisposed patients	From microbiota to immune mechanisms in CRC carcinogenesis	<i>H. pylori</i> : Treatment resistance and progression to cancer	Novelties in the HPB diseases			
☕ 10:00 – 10:30 Coffee Break ☕												
<b>Symposium</b>	<b>Abstracts on Fire</b>	<b>Translational/Basic Science</b>	<b>Symposium</b>	<b>Symposium</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Abstract-Based Session</b>	<b>Posters in the Spotlight</b>	<b>Posters in the Spotlight</b>	<b>Symposium</b>	09:00 – 14:00	
Novelties in dyspepsia	An upper GI melange	Pancreatic cancer development	Cholangiopathies: How to avoid common mistakes	How to improve diagnostic accuracy in pancreatobiliary EUS	Primary liver cancer	Diarrhea and bloating in functional bowel disorders	Microbiota in IBD	IBD: From basic mechanisms to the clinic	Advanced endoscopy	Managing pain in chronic pancreatitis	ESGE Learning Area	
<b>CBD*</b> 12:45 – 13:45	<b>CBD*</b> 12:45 – 13:45	<b>CBD*</b> 12:45 – 13:45			<b>CBD*</b> 12:45 – 13:45							
Management of complications after upper GI surgery	Challenging cases for biliary drainage	Functional consequences of bariatric procedures			Infectious diseases	🍴 12:00 – 14:00 Lunch Break 🍴						
<b>Symposium</b>	<b>Symposium</b>	<b>Symposium</b>	<b>Symposium</b>	<b>Symposium</b>								
EUS: What's new in 2018?	IBS: What's new in 2018?	Hepatology: What's new in 2018?	Pancreatology: What's new in 2018?	Nutrition: What's new in 2018?								

12:30 – 13:30  
Poster Sessions  
& Poster Champs  
13:45  
Poster Award  
Ceremony 

# Postgraduate Teaching Programme

## Overview Icons

-  Live Stream
-  Q&A
-  Audience Voting
-  Recorded Session

---

### PGT Programme Taskforce

Matthieu Allez, France  
Marianna Arvanitakis, Belgium  
Ian Jenkins, United Kingdom  
Dominique Thabut, France  
Herbert Tilg, Austria

PGT Syllabus contributions are available in the online programme, the UEG Week App and in our UEG Library at [ueg.eu/syllabus](http://ueg.eu/syllabus).

The postgraduate teaching programme is as of September 12, 2018.

## Postgraduate Teaching Programme

Saturday, October 20, 2018

**Plenary I**

09:00 – 10:30 Room A

**Management of Crohn's disease**  
Chairs: Denis Franchimont, Belgium  
Britta Siegmund, Germany



12:00 – 12:30 IP010

**Obscure GI bleeding**  
Cesare Hassan, Italy

12:30 – 13:00 IP011

**Lower GI bleeding**  
Ian Gralnek, Israel

**Words of welcome**  
Paul Fockens, Netherlands

IP001

09:00 – 09:15 IP002

**Diagnosing Crohn's disease and use of diagnostics in follow-up**  
Christian Maaser, Germany

**Parallel Session**

11:00 – 13:00 Room B

**Bariatric surgery**  
Chairs: Pierre Eisendrath, Belgium  
Mario Morino, Italy



**Debate**  
09:15 – 09:30 IP003

**Drug monitoring: Pro**  
David Laharie, France

11:00 – 11:15 IP012

**Indication, techniques and results of surgical bariatric procedures**  
Cynthia-Michelle Borg, United Kingdom

09:30 – 09:45 IP004

**Drug monitoring: Con**  
Geert D'Haens, Netherlands

11:15 – 11:30 IP013

**Indication, techniques and results of endoscopic bariatric procedures**  
Mostafa Ibrahim, Belgium

**Tandem Talks**  
09:45 – 10:00 IP005

**Severe Crohn's disease: Medical options**  
Gerhard Rogler, Switzerland

11:30 – 12:00 IP014

**Management of complications and failed bariatric procedures: Endoscopic solution**  
Vincent Huberty, Belgium

10:00 – 10:15 IP006

**Severe Crohn's disease: Role of the surgeon**

Willem A. Bemelman, Netherlands

12:00 – 12:30 IP015

**Management of complications and failed bariatric procedures: Surgical solution**  
Luigi Angrisani, Italy

10:15 – 10:30 IP007

**Stable remission: EXIT strategies**  
Edouard Louis, Belgium

12:30 – 13:00 IP016

**Long-term physiological changes following bariatric surgery and metabolic complications**  
Francisca Joly, France

**Video Case Session**

11:00 – 13:00 Room A

**Endoscopic assessment and treatment of gastrointestinal bleeding**

Chairs: Lars Aabakken, Norway  
Mario Dinis-Ribeiro, Portugal



**Parallel Session**

11:00 – 13:00 Room C

**Autoimmune diseases of the liver and bile ducts**  
Chairs: Ulrich Beuers, Netherlands  
Vincent Leroy, France



11:00 – 11:30 IP008

**Variceal bleeding**  
Tomas Hucl, Czech Republic

11:00 – 11:30 IP017

**Autoimmune hepatitis**  
Ansgar Lohse, Germany

11:30 – 12:00 IP009

**Non-variceal upper GI bleeding**  
Georg Braun, Germany

11:30 – 12:00 IP018  
**Primary biliary cholangitis**  
 Marco Marzioni, Italy

12:00 – 12:30 IP019  
**Primary sclerosing cholangitis**  
 Jessica Dyson, United Kingdom

12:30 – 13:00 IP020  
**IgG4-associated cholangitis**  
 Ulrich Beuers, Netherlands

### Parallel Session

11:00 – 13:00 Room E1  
**Gastric cancer**  
 Chairs: George Hanna, United Kingdom  
 Tamara Matysiak Budnik, France



11:00 – 11:30 IP021  
**Microbiome and gastric cancer: *H. pylori* and beyond?**  
 Christian Schulz, Germany

11:30 – 12:00 IP022  
**Histological and molecular classifications of gastric cancer: Which markers are useful for clinical management of patients?**  
 Fatima Carneiro, Portugal

### Tandem Talks

12:00 – 12:15 IP023  
**Treatment of resectable gastric cancer: What type of surgery for different disease stages and locations?**  
 Suzanne S. Gisbertz, Netherlands

12:15 – 12:30 IP024  
**Treatment of resectable gastric cancer: What type of neoadjuvant chemotherapy?**  
 Yann Toucheffeu, France

### Tandem Talks

12:30 – 12:45 IP025  
**Quality of interventions in gastric cancer: Effect of the quality of endoscopic resection on clinical outcome**  
 Peter D. Siersema, Netherlands

12:45 – 13:00 IP026  
**Quality of interventions in gastric cancer: Effect of the quality of surgery on survival**  
 George Hanna, United Kingdom

### Video Case Session

14:00 – 16:30 ROOM A  
**Polyp handling and advanced endoscopic therapy**  
 Chairs: Soren Meisner, Denmark  
 Thierry Ponchon, France



14:00 – 14:30 IP027  
**Endoscopic assessment of colorectal lesions**  
 Michael John Bourke, Australia

14:30 – 15:00 IP028  
**Endoscopic therapy for large colorectal polyps**  
 Alessandro Repici, Italy

15:00 – 15:30 IP029  
**Endoscopic therapy for small colorectal polyps**  
 Maria Pellisé Urquiza, Spain

15:30 – 16:00 IP030  
**Endoscopic therapy for endoscopic complications**  
 Pierre Henri Deprez, Belgium

16:00 – 16:30 IP031  
**Endoscopic therapy for surgical complications**  
 Marianna Arvanitakis, Belgium

### Parallel Session

14:00 – 16:30 Room B  
**Colorectal cancer: Staging, surgery and adjuvant therapies**  
 Chairs: Thomas Aparicio, France  
 Eric Van Cutsem, Belgium



14:00 – 14:30 IP032  
**Update on prognostic markers in colorectal cancer**  
 Frédéric Bibeau, France

14:30 – 15:00 IP033  
**New modalities for adjuvant treatment: Learning from IDEA trial**  
 Thomas Aparicio, France

15:00 – 15:30 IP034  
**Strategies to improve tumour response in potentially resectable metastasis**  
 Eric Van Cutsem, Belgium

15:30 – 16:00 IP035

**Resectable metastatic colorectal cancer: Resection of primary or metastasis first?**

Réne Adam, France

16:00 – 16:30 IP036

**Improving surgery: Prehabilitation and enhanced recovery programmes**

Sebastiano Biondo, Spain

**Parallel Session**

14:00 – 16:30 Room C

**Therapy update in functional gastrointestinal disorders**

Chairs: Giovanni Barbara, Italy

Lesley Houghton, United Kingdom



14:00 – 14:30 IP037

**Functional oesophageal disorders**

John Pandolfino, United States

14:30 – 15:00 IP038

**Functional dyspepsia**

Vincenzo Stanghellini, Italy

15:00 – 15:30 IP039

**Constipation**

Lin Chang, United States

15:30 – 16:00 IP040

**Symptomatic diverticular disease**

Robin Spiller, United Kingdom

16:00 – 16:30 IP041

**Faecal incontinence**

Emma Carrington, United Kingdom

**Parallel Session**

14:00 – 16:30 Room E1

**Gallstones and complications**

Chairs: Arnaud Lemmers, Belgium

Andrea Tringali, Italy



14:00 – 14:30 IP042

**Bile duct stones: Seeing is believing!**

Maxime Palazzo, France

**Debate**

14:30 – 14:45 IP043

**Acute cholecystitis in a patient unfit for cholecystectomy: Percutaneous drainage – always!**

Andrea Phillips, United Kingdom

14:45 – 15:00 IP044

**Acute cholecystitis in a patient unfit for cholecystectomy: Endoscopic drainage – why not!**

Maria Chiara Petrone, Italy

15:00 – 15:30 IP045

**ERCP in biliary pancreatitis: Is it needed?**

Zoltan Gabor Szepes, Hungary

15:30 – 16:00 IP046

**Intra-operative ERCP: When, how and why?**

Ioannis Papanikolaou, Greece

**Tandem Talks**

16:00 – 16:15 IP047

**Medico-surgical management of common bile duct stones: ERCP**

Jörg Albert, Germany

16:15 – 16:30 IP048

**Medico-surgical management of common bile duct stones: Laparoscopy**

David Fuks, France

## Postgraduate Teaching Programme

### Sunday, October 21, 2018

**Parallel Session**

08:30 - 10:30 Room A

**Advanced endoscopic techniques**

Chairs: Marianna Arvanitakis, Belgium  
Mario Dinis-Ribeiro, Portugal



08:30 - 09:00 IP049  
**Resection techniques in the upper GI tract**  
Pedro Pimentel Nunes, Portugal

**Debate**

09:00 - 09:15 IP050  
**Resection techniques in the lower GI tract: You can do almost everything with EMR!**  
Siwan Thomas-Gibson, United Kingdom

09:15 - 09:30 IP051  
**Resection techniques in the lower GI tract: ESD and full thickness resections are the future!**  
Pradeep Bhandari, United Kingdom

09:30 - 10:00 IP052  
**ERCP for large stones**  
Lars Aabakken, Norway

10:00 - 10:30 IP053  
**Therapeutic EUS: Draining collections and beyond**  
Geoffroy Vanbiervliet, France

**Parallel Session**

08:30 - 10:30 Room B

**Management of ulcerative colitis: The acute patient**

Chairs: André D'Hoore, Belgium  
Julian Panés, Spain



08:30 - 09:00 IP054  
**Diagnostic workup of the hospitalised patient with severe colitis**  
Marc Ferrante, Belgium

**Tandem Talks**

09:00 - 09:15 IP055  
**Medical management of steroid failure: Ciclosporin!**  
Ingrid Ordàs Jimenez, Spain

09:15 - 09:30 IP056  
**Medical management of steroid failure: Infliximab**  
David Laharie, France

09:30 - 10:00 IP057  
**Toxic megacolon**  
Gert Van Assche, Belgium

10:00 - 10:30 IP058  
**Surgery: When, how and who should operate?**  
André D'Hoore, Belgium

**Parallel Session**

08:30 - 10:30 Room C

**Small bowel imaging and endoscopy**

Chairs: Edward Despott, United Kingdom  
Rami Eliakim, Israel



**Tandem Talks**

08:30 - 08:45 IP059  
**How to investigate the small bowel: Capsule endoscopy**  
Cristiano Spada, Italy

08:45 - 09:00 IP060  
**How to investigate the small bowel: Radiology**  
Peter Wylie, United Kingdom

09:00 - 09:30 IP061  
**Device assisted enteroscopy: Techniques**  
Andrea May, Germany

09:30 - 10:00 IP062  
**Small bowel bleeding: Investigation and management**  
Edward Despott, United Kingdom

**Tandem Talks**

10:00 - 10:15 IP063  
**Therapeutic intervention in the bowel beyond bleeding: Small bowel inflammatory and stricturing disease**  
Erasma Vlachou, Greece

10:15 - 10:30 IP064  
**Therapeutic intervention in the bowel beyond bleeding: Emerging indications and examples of 'frontline' use**  
Alberto Murino, United Kingdom

Parallel Session	
08:30 – 10:30	Room E1
<b>Cystic pancreatic lesions</b>	
Chairs: Peter Hegyi, Hungary Vinciane Rebours, France	



08:30 – 09:00	IP065
<b>Pancreatic cysts: The landscape</b>	
Julia Mayerle, Germany	

**Debate**

09:00 – 09:15	IP066
<b>Radiological assessment of cystic lesions: CT and MRI are enough</b>	
Raneem Albazaz, United Kingdom	

09:15 – 09:30	IP067
<b>Endoscopic assessment of cystic lesions: EUS is all we need</b>	
Maxime Palazzo, France	

09:30 – 10:00	IP068
<b>Mucinous neoplasm : When to neglect, when to resect, how to follow?</b>	
Djuna L. Cahen, Netherlands	

10:00 – 10:30	IP069
<b>Atypical resection: Pros and cons</b>	
Marco Del Chiaro, Sweden	

Parallel Session	
08:30 – 10:30	Room E2
<b>Hepatocellular carcinoma (HCC)</b>	
Chairs: Thomas Decaens, France Jean-François Dufour, Switzerland	



08:30 – 09:00	IP070
<b>Radiological diagnosis of HCC</b>	
Ahmed Ba-Ssalamah, Austria	

09:00 – 09:30	IP071
<b>Staging of HCC</b>	
Helen Reeves, United Kingdom	

09:30 – 10:00	IP072
<b>Treatment algorithms for HCC</b>	
Bruno Sangro, Spain	

10:00 – 10:30	IP073
<b>Transplantation for HCC</b>	
Patrizia Burra, Italy	

Clinical Case-Based Session	
11:00 – 13:00	Room A
<b>Lower GI bleeding</b>	
Chairs: Ian Gralnek, Israel Arnaud Hocquelet, Switzerland	
Moderator: Dieter Hahnloser, Switzerland	



11:00 – 11:30	IP074
<b>Case presentation: Acute lower GI bleeding</b>	
Stanislav Bezobchuk, Israel	

11:30 – 12:00	IP075
<b>Endoscopic treatments</b>	
Ian Gralnek, Israel	

12:00 – 12:30	IP076
<b>Case presentation: Chronic lower GI bleeding with iron deficiency anemia</b>	
Stanislav Bezobchuk, Israel	

12:30 – 13:00	IP077
<b>Interventional radiology</b>	
Arnaud Hocquelet, Switzerland	

Clinical Case-Based Session	
11:00 – 13:00	Room B
<b>Hepatitis C</b>	
Chairs: Alessio Aghemo, Italy Robert Flisiak, Poland	
Moderator: Dominique Thabut, France	



11:00 – 11:30	IP078
<b>Case presentation: Chronic HCV infection in the cirrhotic: Achieving a better outcome following repeated treatment failures</b>	
Mariusz Lucejko, Poland	

11:30 – 12:00	IP079
<b>Epidemiology, risk factors for transmission and therapeutic options for HCV infection</b>	
Robert Flisiak, Poland	

12:00 – 12:30	IP080
<b>Case presentation: Unexpected outcomes of anti-HCV treatment</b>	
Mariusz Lucejko, Poland	

12:30 – 13:00	IP081
<b>Tips and tricks in DAA treatment</b>	
Alessio Aghemo, Italy	



**Clinical Case-Based Session**

11:00 – 13:00 Room C

**Colorectal polyps**

Chairs: Evelien Dekker, Netherlands  
Monika Ferlitsch, Austria

Moderator: Mostafa Ibrahim, Belgium

11:00 – 11:30 IP082

**Case presentation: 'I can't see the wood for the trees' – a systematic approach to the patient with multiple polyps**

Yark Hazewinkel, Netherlands

11:30 – 12:00 IP083

**Endoscopic characterisation of polyps and familial polyposis syndromes**

Evelien Dekker, Netherlands

12:00 – 12:30 IP084

**Case presentation: Polypectomy done, but what comes next?**

Yark Hazewinkel, Netherlands

12:30 – 13:00 IP085

**Treatment strategies for colonic polyps and surveillance intervals**

Monika Ferlitsch, Austria

**Clinical Case-Based Session**

11:00 – 13:00 Room E1

**Cancer and IBD**

Chairs: Laurence Egan, Ireland  
Tine Jess, Denmark

Moderator: Henriette Heinrich, Switzerland

11:00 – 11:30 IP086

**Case presentation: The IBD patient at high risk of colorectal cancer**

Neil O'Morain, Ireland

11:30 – 12:00 IP087

**Colorectal cancer in IBD: Pathophysiology, magnitude of risk and surveillance**

Tine Jess, Denmark

12:00 – 12:30 IP088

**Case presentation: Dysplasia in an ulcerative colitis patient under surveillance**

Neil O'Morain, Ireland

12:30 – 13:00 IP089

**Management of dysplastic lesions in patients with IBD**

Laurence Egan, Ireland





**Clinical Case-Based Session**

11:00 – 13:00 Room E2

**Management of Barrett's oesophagus and Barrett's neoplasia**

Chairs: Raf Bisschops, Belgium  
Andrea May, Germany

Moderator: Pradeep Bhandari, United Kingdom

11:00 – 11:30 IP090

**Case presentation: Barrett's oesophagus under surveillance**

Mate Knabe, Germany

11:30 – 12:00 IP091

**Barrett's oesophagus under surveillance**

Raf Bisschops, Belgium

12:00 – 12:30 IP092

**Case presentation: Endoscopic therapy for an early Barrett's carcinoma**

Mate Knabe, Germany

12:30 – 13:00 IP093

**Endoscopic therapy of an early Barrett's carcinoma**

Andrea May, Germany

**Clinical Case-Based Session**

11:00 – 13:00 Room M

**Non-cardiac chest pain**

Chairs: Benoit Coffin, France  
Mark Fox, Switzerland

Moderator: Edoardo Savarino, Italy

11:00 – 11:30 IP094

**Case presentation: Pain here, there and everywhere**

Maja Gruber, Switzerland

11:30 – 12:00 IP095

**Oesophageal motility disorders as a cause of non-cardiac chest pain**

Mark Fox, Switzerland

12:00 – 12:30 IP096

**Case presentation: Pain here, there and everywhere**

Maja Gruber, Switzerland

12:30 – 13:00 IP097

**Reflux as a cause of non-cardiac chest pain**

Benoit Coffin, France

**Clinical Case-Based Session**

11:00 – 13:00 Room 1.61/1.62

**Malabsorption**

Chairs: Carolina Ciacci, Italy  
 Mircea Diculescu, Romania  
 Moderator: Ian Jenkins, United Kingdom



11:00 – 11:30 IP098

**Case presentation: Pancreatic exocrine insufficiency**  
 Fabiana Zingone, Italy

11:30 – 12:00 IP099

**Pathophysiology of malabsorption**  
 Mircea Diculescu, Romania

12:00 – 12:30 IP100

**Case presentation: Malabsorption**  
 Fabiana Zingone, Italy

12:30 – 13:00 IP101

**Cascades for diagnosis of malabsorption**  
 Carolina Ciacci, Italy

**Clinical Case-Based Session**

11:00 – 13:00 Room N2

**The liver and pregnancy**

Chairs: Filomena Morisco, Italy  
 C. Janneke van der Woude, Netherlands  
 Moderator: Vincent Leroy, France



11:00 – 11:30 IP102

**Case presentation: A severe rise in aminotransferase**  
 Alison de Lima-Karagiannis, Netherlands

11:30 – 12:00 IP103

**Work-up of aminotransferase elevation in pregnancy**  
 C. Janneke van der Woude, Netherlands

12:00 – 12:30 IP104

**Case presentation: A problematic twin pregnancy**  
 Alison de Lima-Karagiannis, Netherlands

12:30 – 13:00 IP105

**Work-up of cholestasis in pregnancy**  
 Filomena Morisco, Italy

**Clinical Case-Based Session**

11:00 – 13:00 Room L7

**Cholangiocarcinoma: From diagnosis to treatment**

Chairs: Jeanin E. van Hooft, Netherlands  
 Thomas Wirth, Germany  
 Moderator: Hjalmar C. van Santvoort, Netherlands



11:00 – 11:30 IP106

**Case presentation: An intrahepatic mass of unknown origin**  
 Wout Rohof, Netherlands

11:30 – 12:00 IP107

**Cholangiocarcinoma: From etiology to pre-operative work-up**  
 Thomas Wirth, Germany

12:00 – 12:30 IP108

**Case presentation: (Ir)resectable cholangiocarcinoma?**  
 Wout Rohof, Netherlands

12:30 – 13:00 IP109

**The role of endoscopy and radiology in cholangiocarcinoma palliation**  
 Jeanin E. van Hooft, Netherlands

**Clinical Case-Based Session**

11:00 – 13:00 Room L8

**Chronic diarrhoea**

Chairs: Jutta Keller, Germany  
 Stephan Vavricka, Switzerland  
 Moderator: Joost P.H. Drenth, Netherlands



11:00 – 11:30 IP110

**Case presentation: Chronic diarrhoea in a patient with typical histology**  
 Dorothea Jasper, Germany

11:30 – 12:00 IP111

**Clinical management in a patient with chronic diarrhoea and organic disease**  
 Stephan Vavricka, Switzerland

12:00 – 12:30 IP112

**Case presentation: Chronic diarrhoea and nonspecific gastrointestinal symptoms**  
 Dorothea Jasper, Germany

12:30 – 13:00 IP113

**How do we manage the patient with normal endoscopy and histology?**  
 Jutta Keller, Germany

**Plenary II**  
 14:00 – 16:00 Room A  
**Irritable bowel syndrome: Optimal management in 2018**  
 Chairs: Sabine Roman, France  
 Magnus Simrén, Sweden



**Debate**

14:00 – 14:15 IP114  
**Diagnostic approach: A positive diagnostic strategy is recommended!**  
 Brian Lacy, United States

14:15 – 14:30 IP115  
**Diagnostic approach: IBS, a diagnosis of exclusion!**  
 Fermin Mearín, Spain

14:30 – 15:00 IP116  
**Psychological treatments for IBS: What do we have to offer?**  
 Brjánn Ljotsson, Sweden

15:00 – 15:30 IP117  
**Diet and probiotics: From theory to therapy**  
 Heidi Staudacher, Australia

**Debate**

15:30 – 15:45 IP118  
**Centrally acting medications: The logical pharmacological choice for IBS!**  
 Lukas Van Oudenhove, Belgium

15:45 – 16:00 IP119  
**Peripherally acting medications: The logical pharmacological choice for IBS!**  
 Jan Tack, Belgium

UNITED EUROPEAN GASTROENTEROLOGY  
**ueg week**  
**HANDS-ON @ UEG WEEK**  
**Improve your practical skills on Level 1**  
 Visit the ESGE (endoscopic training in cooperation with ESGENA), the Ultrasound and the Surgical Learning Areas.  
 Find more information on pages 255-267

# Scientific Programme by Day

## Overview Icons



Live Stream



Q&A



Audience Voting



Recorded Session



Rising Star



Top Abstract Prize



National Scholar

The scientific programme is as of September 12, 2018.  
Later changes are published in the online programme  
and in the UEG Week App.

## Scientific Programme by Day

Monday, October 22, 2018

## Opening Session

08:00 – 10:00 Room A

## Opening Session: Part 1

Chairs: Paul Fockens, The Netherlands  
Herbert Tilg, Austria

08:00 – 08:05 IP120

## Words of welcome

Herbert Tilg, Austria

08:05 – 08:25 IP121

## The changing role of surgery in Crohn's disease

André D'Hoore, Belgium

08:25 – 08:37 OP001

## EARLY ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY WITH BILIARY SPHINCTEROTOMY OR CONSERVATIVE TREATMENT IN PREDICTED SEVERE ACUTE BILIARY PANCREATITIS (APEC): A MULTICENTER RANDOMIZED CONTROLLED TRIAL ★★

N. J. Schepers, The Netherlands; on behalf of the Dutch Pancreatitis Study Group

08:37 – 08:57 IP122

## PSC: From genes to microbiota

Tom Hemming Karlsen, Norway

08:57 – 09:00 IP123

## Introduction to the UEG Research Prize

Arthur Kaser, United Kingdom

09:00 – 09:12 IP124

## UEG Research Prize 2018

Cisca Wijmenga, The Netherlands

09:12 – 09:18 IP125

## Presidential address

Paul Fockens, The Netherlands

09:18 – 09:30 OP002

## A COMPREHENSIVE MOLECULAR CLASSIFICATION OF CROHN'S DISEASE USING GENE EXPRESSION DATA ★

Kevin Perez, France; Le Bourhis L.; Ngollo M.; Panés J.; Salas A.; Seksik P.; Haller D.; Daly M. J.; Allez M.

09:30 – 09:35 IP126

## Laudation for the UEG Lifetime Achievement Awardee

Laurence Egan, Ireland

09:35 – 09:40 IP127

## UEG Lifetime Achievement Award

Colm O'Morain, Ireland

## Tandem Talks

09:40 – 09:50 IP128

## Organoids: From bench to bedside

Fotis Sampaziotis, United Kingdom

09:50 – 10:00 IP129

## Organoids: From bench to bedside

Markus Neurath, Germany

## Opening Session

10:30 – 12:00 Room A

## Opening Session: Part 2

Chairs: Axel Dignass, Germany  
Herbert Tilg, Austria

10:30 – 10:50 IP130

## What's new in gastroenterology in 2018?

Julia Mayerle, Germany

10:50 – 11:02 OP003

## NLRP6 SUPPORTS SURVIVAL OF T HELPER 1 CELLS BY REGULATING APOPTOSIS ★

Radulovic K.; Kaya B.; Wuggenig P.; Hruz P.; Weigmann B.; Jan Hendrik Niess, Switzerland

11:02 – 11:07 IP131

## Journal Best Paper Award

Joaquín Cubiella, Spain

11:07 – 11:27 IP132

## What's new in endoscopy in 2018?

Heiko Pohl, United States

11:27 – 11:39 OP004

## EARLY SURGERY VERSUS STEP-UP PRACTICE INCLUDING ENDOSCOPY FOR CHRONIC PANCREATITIS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL [ESCAPE TRIAL] ★

Issa Y.; Marinus A. Kempeneers, The Netherlands; Bruno M. J.; Fockens P.; Poley J. W.; Ahmed Ali U.; Bollen T.; Busch O. R. C.; Dejong C. H.; Van Duijvendijk P.; van Dullemen H.; van Eijck C. H. J.; Goor H. V.; Hadithi M.; Haveman J. W.; Keulemans Y. C. A.; Nieuwenhuijs V.; Poen A. C.; Rauws E. A. J.; Tan A. C.; Thijs W. J.; Timmer R.; Witteman B. J. M.; Besselink M. G. H.; van Hooft J. E.; van Santvoort H. C.; Dijkgraaf M. G. W.; Boermeester M. A.

11:39 – 11:59 IP133

## What's new in hepatology in 2018?

Richard Moreau, France

Symposium	
10:30 – 12:00	Room D
<b>Post-operative recurrence of Crohn's disease</b>	
Chairs: Dieter Hahnloser, Switzerland David Laharie, France	



10:30 – 10:52	IP134
<b>Pathophysiology</b>	
Matthieu Allez, France	

10:52 – 11:14	IP135
<b>Treat-to-target?</b>	
Jack Satsangi, United Kingdom	

11:14 – 11:36	IP136
<b>Surgical factors</b>	
Ian Jenkins, United Kingdom	

11:36 – 11:58	IP137
<b>Post-operative therapy</b>	
Michael A. Kamm, Australia	

Symposium	
10:30 – 12:00	Room B
<b>Endoscopic resection of polyps</b>	
Chairs: Michael John Bourke, Australia Arnaud Lemmers, Belgium	



<b>Debate</b>	
10:30 – 10:40	IP138
<b>DISCARD: Current status in 2018 – ready for prime time?</b>	
Matthew David Rutter, United Kingdom	

10:40 – 10:50	IP139
<b>DISCARD: Will never succeed!</b>	
Maria Pellisé Urquiza, Spain	

10:50 – 11:12	IP140
<b>When to refer?</b>	
Helmut Messmann, Germany	

<b>Tandem Talks</b>	
11:12 – 11:22	IP141
<b>ESD</b>	
Naohisa Yahagi, Japan	

11:22 – 11:32	IP142
<b>Mucosectomy</b>	
Evelien Dekker, The Netherlands	

11:32 – 11:44	OP005
<b>ASSISTANCE OF A REAL-TIME AUTOMATIC COLON POLYP DETECTION SYSTEM INCREASES POLYP AND ADENOMA DETECTION DURING COLONOSCOPY: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY ✦</b>	
Pu Wang, China; Bharadwaj S.; Berzin T. M.; Becq A.; Li L.; Liu P.; Xiao X.; Song Y.; Zhang D.; Li Y.; Xu G.; Tu M.; Xiao X.; Zhang Z.; He J.; Yi X.; Pan W.; Liu J.; Liu X.	

11:44 – 11:56	OP006
<b>POTENTIAL ACCEPTABILITY OF A WATCH-AND-WAIT APPROACH FOR DIMINUTIVE COLORECTAL ADENOMAS: FIVE-YEAR INCIDENCE OF ADVANCED COLORECTAL NEOPLASIA IN INDIVIDUALS WITH UNTREATED DIMINUTIVE ADENOMAS</b>	
Masau Sekiguchi, Japan; Otake Y.; Kakugawa Y.; Matsumoto M.; Saito Y.; Matsuda T.	

Symposium	
10:30 – 12:00	Room C
<b>Constipation</b>	
Chairs: Asbjørn Drewes, Denmark Brian Lacy, United States	



10:30 – 10:40	IP143
<b>Clinical assessment</b>	
Jordi Serra, Spain	

10:40 – 10:50	IP144
<b>Manometry</b>	
Daniel Pohl, Switzerland	

10:50 – 11:00	IP145
<b>Imaging</b>	
Andrew Plumb, United Kingdom	

11:00 – 11:10	IP146
<b>Medical treatment</b>	
Viola Andresen, Germany	

11:10 – 11:20	IP147
<b>Biofeedback</b>	
Giuseppe Chiarioni, Italy	

11:20 – 11:30	IP148
<b>Surgical options</b>	
P. Ronan O'Connell, Ireland	

11:30 – 12:00	<b>PANEL DISCUSSION</b>
---------------	-------------------------

**Symposium**

10:30 – 12:00 Room E1  
**Epidemiology and treatment options in NASH**  
 Chairs: Vincent Leroy, France  
 Mária Papp, Hungary

**Tandem Talks**

10:30 – 10:40 IP149  
**Who is at risk and whom to biopsy? The clinician's point of view**  
 Jérôme Boursier, France

10:40 – 10:50 IP150  
**Who is at risk and whom to biopsy? The pathologist's point of view**  
 Beate Straub, Germany

10:50 – 11:12 IP151  
**Prognosis: Is it really all about liver?**  
 Elisabetta Bugianesi, Italy

11:12 – 11:24 OP007  
**SERUM SRAGE LEVELS ARE ASSOCIATED WITH LIFESTYLE AND WITH NON-ALCOHOLIC FATTY LIVER DISEASE** ✦  
 Dana Ivanovsky-Wajcman, Israel; Zelber-Sagi S.; Fliss Isakov N.; Webb M.; Shibolet O.; Kariv R.

11:24 – 11:36 OP008  
**HYPOXIA-INDUCIBLE FACTOR 2ALPHA IS CRITICAL FOR NASH-RELATED EXPERIMENTAL LIVER CARCINOGENESIS.** ✦  
 Beatrice Foglia, Italy; Morello E.; Sutti S.; Cannito S.; Novo E.; Bocca C.; Bruzzi' S.; Ramavath N. N.; Rosso C.; Younes R.; Bugianesi E.; Albano E.; Parola M.

**Debate**

11:36 – 11:46 IP152  
**Treatment: It's all about about lifestyle**  
 Jean-François Dufour, Switzerland

11:46 – 11:56 IP153  
**Treatment: It's all about drugs!**  
 Michael Trauner, Austria

**Symposium**

10:30 – 12:00 Room E2  
**Barrett's oesophagus**  
 Chairs: Jacques J. Bergman, The Netherlands  
 Oliver Pech, Germany



10:30 – 10:52 IP154  
**Role of GORD quantification and control in patients with Barrett's oesophagus**  
 Edoardo Savarino, Italy

10:52 – 11:14 IP155  
**Risk stratification with molecular markers**  
 Massimiliano di Pietro, United Kingdom

**Tandem Talks**

11:14 – 11:24 IP156  
**Endoscopic management of Barrett's oesophagus: Ablation**  
 Prateek Sharma, United States

11:24 – 11:34 IP157  
**Endoscopic management of Barrett's oesophagus: Non ablation**  
 Frédéric Prat, France

11:34 – 11:56 IP158  
**Minimal invasive surgical approach to early cancer in Barrett's oesophagus**  
 Suzanne S. Gisbertz, The Netherlands

**Abstract-Based Session**

10:30 – 12:00 Room F1  
**IBD: From epidemiology to costs and outcome**  
 Chairs: Tim Raine, United Kingdom  
 Iago Rodríguez-Lago, Spain



10:30 – 10:42 IP159  
**State-of-the-art introduction**  
 Tim Raine, United Kingdom

10:42 – 10:54 OP009  
**IS THERE A COST-SAVING EFFECT OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE? RESULTS FROM A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT**  
 Johan Burisch, Denmark; Vardi H.; Schwartz D.; Arebi N.; Lakatos P. L.; Fumery M.; Kupcinskas L.; Belousova E.; Oksanen P.; Hernández Ramírez V.; Langholz E.; Vegh Z.; Turcan S.; Valpiani D.; Giannotta M.; Magro F.; Duricova D.; Kievit L.; Dahlerup J. F.; Salupere R.; Nielsen K. R.; Kaimakliotis I.; Katsanos K. H.; Ellul P.; Cukovic-Cavka S.; D'Inca R.; Pedersen N.; Goldis A.; Andersen V.; Halfvarson J.; Sebastian S.; Munkholm P.; Odes S.

10:54 – 11:06 OP010

**EFFICACY AND SAFETY OF THE SEQUENTIAL USE OF A SECOND AND THIRD ANTI-TNF DRUG IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**

María José Casanova, Spain; Chaparro M.; Mínguez M.; Ricart E.; Taxonera C.; García-López S.; Guardiola J.; López-San Román A.; Iglesias E.; Nos P.; Sicilia B.; Vera M. I.; Hinojosa J.; Riestra S.; Domènech E.; Calvet X.; Pérez-Calle J. L.; Martín-Arranz M. D.; Aldeguez X.; Rivero M.; Monfort D.; Barrio J.; Esteve M.; Márquez L.; Lorente R.; García-Planella E.; De Castro L.; Bermejo F.; Merino O.; Rodríguez-Pérez A.; Martínez-Montiel P.; Van Domselaar M.; Alcaín G.; Domínguez-Cajal M.; Muñoz C.; Gomollón F.; Fernández-Salazar L.; García-Sepulcre M. F.; Rodríguez-Lago I.; Gutiérrez A.; Argüelles-Arias F.; Rodríguez C.; Rodríguez G. E.; Bujanda L.; Llaó J.; Varela P.; Ramos L.; Huguet J. M.; Almela P.; Romero P.; Navarro-Llavat M.; Abad A.; Ramírez-de la Piscina P.; Lucendo A. J.; Sesé E.; Madrigal R. E.; Charro M.; García-Herola A.; Pajares R.; Khorrami S.; Gisbert J. P.

11:06 – 11:18 OP011

**CLINICAL DIFFERENTIAL CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) OF ONSET IN PEDIATRIC AGE COMPARED TO PATIENTS DIAGNOSED IN ADULTHOOD**

María Chaparro, Spain; Garre A.; Ricart Gomez E.; García-Sánchez V.; Taxonera C.; Mañosa M.; Vera Mendoza I.; Mínguez M.; Argüelles F.; De Castro L.; Arroyo M.; Lopez-SanRoman A.; Rivero Tirado M.; Guardiola J.; Martín-Arranz M. D.; Beltran B.; Barrio J.; Riestra S.; García-Planella E.; Calvet X.; Alcaín G.; Sicilia Aladrén B.; García-López S.; Esteve M.; Márquez L.; Fernández Salazar L.; Gutierrez Casbas A.; Piqueras M.; Bermejo F.; Pérez Calle J. L.; Hinojosa J.; Rodríguez Pérez A.; Aldeguez X.; Garcia Sepulcre M. F.; Bujanda L.; Martínez Montiel M. P.; Lorente Poyatos R.; Rodríguez Gutiérrez C.; Merino O.; Cabriada J. L.; Roncero O.; Romero Cara P.; Navarro Llavat M.; Ber Y.; Madrigal R.; Van Domselaar M.; Barreiro de-Acosta M.; Llaó J.; Ramos L.; Riera J.; Lucendo A. J.; Herranz Hernández L.; Huguet-Malavés J. M.; Muñoz Villafranca C.; Almela P.; Charro M.; Ramírez de la Piscina P.; Sese E.; Abad La Cruz A.; Khorrami S.; Morales Alvarado V. J.; Legido Gil J.; Traperó Martínez A. M.; Pajares Villarroya R.; Acevedo J.; García Herola A.; Hernández Villalba L.; Muñoz E.; Novella Durán M. T.; Menacho M.; Navas Lopez V. M.; Retamero Orta M. D.; Bernardo D.; Domènech E.; Gisbert J. P.

11:18 – 11:30 OP012

**INDIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN A DANISH POPULATION-BASED INCEPTION COHORT AFTER TEN YEARS OF FOLLOW-UP.**

Bobby Lo, Denmark; Vind I.; Bendtsen F.; Vester-Andersen M. K.; Burisch J.

11:30 – 11:42 OP013

**IS CROHN DISEASE THE PRICE TO PAY TODAY FOR HAVING SURVIVED TO THE BLACK DEATH?**

Dumay A.; Gergaud O.; Roy M.; Jean-Pierre Hugot, France

11:42 – 11:54 OP014

**CROHN'S DISEASE: WHAT CAN WE EXPECT FROM THE COURSE OF THE DISEASE?**

Cátia Arieira, Portugal; Cúrdia Gonçalves T.; Dias de Castro F.; Moreira M. J.; Cotter J.

**Symposium**

10:30 – 12:00 Room F2

**Functional disorders: Is testing necessary?**

Chairs: Lesley Houghton, United Kingdom  
André Smout, The Netherlands



10:30 – 10:52 IP160

**Non-cardiac chest pain**

Frank Zerbib, France

10:52 – 11:14 IP161

**Dyspepsia**

Jan Tack, Belgium

**Debate**

11:14 – 11:24 IP162

**Mandatory in bloating**

Fermin Mearín, Spain

11:24 – 11:34 IP163

**Useless in bloating**

Magnus Simrén, Sweden

11:34 – 11:56 IP164

**Rising Star: Cellular and molecular basis in intestinal permeability in health and disease** ✦

Ricard Farre, Belgium

**Abstracts on Fire**

10:30 – 12:00 Room G

**Pushing the limits of hepato-pancreatic and biliary diseases**

Chairs: Marco J. Bruno, The Netherlands  
Elisabetta Buscarini, Italy

10:30 – 10:40 OP015

**FIRST-ROUND SCREENING RESULTS IN SUBJECTS AT RISK OF PANCREATIC CANCER FROM THE AISP (ITALIAN ASSOCIATION FOR THE STUDY OF THE PANCREAS) REGISTRY**

Salvatore Paiella, Italy; Capurso G.; Cavestro G. M.; Butturini G.; Pezzilli R.; Salvia R.; Signoretti M.; Crippa S.; Carrara S.; Frigerio I.; Bassi C.; Falconi M.; Iannicelli E.; Giardino A.; Zuppardo R.; Laghi A.; Laghi L.; Frulloni L.; Zerbi A.



10:40 - 10:50 OP016

**ACTIONABLE PERTURBATIONS IN THE DNA DAMAGE RESPONSE ESTABLISH SYNERGISTIC THERAPEUTIC ROUTES IN ATM DEFICIENT PANCREATIC CANCER** ✦  
Lukas Perkhof, Germany; Gout J.; Arnold F.; Frappart P.-O.; Kleger A.

10:50 - 11:00 OP017

**SINGLE MOLECULE REAL-TIME SEQUENCING UNVEILS THE EVOLUTION OF MULTI-DRUG RESISTANT HEPATITIS C VIRUS CLONES DURING DIRECT-ACTING ANTIVIRAL THERAPY.**  
Haruhiko Takeda, Japan; Ueda Y.; Takai A.; Ohtsuru S.; Sekine A.; Marusawa H.; Seno H.

11:00 - 11:10 OP018

**OUTCOMES OF EUS-GUIDED PHOTODYNAMIC THERAPY WITH CHLORIN E6 DERIVATIVES FOR UNRESECTABLE PANCREATIC CANCER: A PHASE I/II TRIAL**  
Hoonsu Sub, Republic of Korea; Yoo C. H.; Kim K.-P.; Lee S. S.; Kim S.-O.; Lee S. S.; Seo D.-W.; Lee S. K.; Park D. H.

11:10 - 11:20 OP019

**TREATMENT WITH OBETICHOIC ACID IN PATIENTS WITH NASH DOES NOT SHOW INCREASED MARKERS OF LIVER TOXICITY BASED ON EVALUATION OF DRUG-INDUCED SERIOUS HEPATOTOXICITY (EDISH)**  
Arun Sanyal, United States; Pockros P.; Shah A.; Shringarpure R.; Shapiro D.; MacConell L.

11:20 - 11:30 OP020

**MISFOLDING CARBOXYPEPTIDASE MUTANT INDUCES CHRONIC PANCREATITIS IN MICE** ✦  
Eszter Hegyi, United States; Sahin-Toth M.

11:30 - 11:40 OP021

**APPLYING EVIDENCE-BASED SOFTWARE FOR NGS IN PANCREATIC CANCER: FIRST RESULTS FROM THE PEPACAKA STUDY**  
 Kordes M.; Malgerud L.; Kaduthanam S.; Frödin J.-E.; Yachnin J.; Karimi M.; Moro C.; Ghazi S.; Heuchel R. L.; Wirta V.; Huelsewig C.; Stecker K.; Östman A.; Del Chiaro M.; Engstrand L.; Brock S.; Gustafsson-Liljefors M.; Matthias Löhr, Sweden

11:40 - 11:50 OP022

**STATIN USE AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B** ✦  
Myung Ji Goh, Republic of Korea; Paik N.; Sinn D. H.; Kang W.; Gwak G.-Y.; Paik Y.-H.; Choi M. S.; Lee J. H.; Koh K. C.; Paik S. W.

11:50 - 12:00 OP023

**MORTALITY, CAUSES OF DEATH AND MALIGNANCIES IN PATIENTS WITH CHRONIC HEPATITIS C: A NATIONWIDE REGISTRY STUDY IN FINLAND**  
Martti A. Färkkilä, Finland; Nieminen U.; Lappalainen M.; Bekthari A.; Kuusi M.; Pukkala E.

**Abstract-Based Session**

10:30 - 12:00 Room K

**Risk factors and risk assessment of GI bleeding**

Chairs: Madalina Ilie, Romania  
 Gregory Rubin, United Kingdom

10:30 - 10:42 IP165

**State-of-the-art introduction**

Gregory Rubin, United Kingdom

10:42 - 10:54 OP024

**RISK OF BOTH UPPER AND LOWER GASTROINTESTINAL BLEEDING ASSOCIATED WITH LOW-DOSE ACETYLSALICYLIC ACID AND PROTON PUMP INHIBITORS AMONG ~400,000 INDIVIDUALS IN ROUTINE GENERAL PRACTICE IN THE UNITED KINGDOM**

Luis Alberto García Rodríguez, Spain; Lanas A.; Soriano-Gabarró M.; Cea Soriano L.

10:54 - 11:06 OP025

**ACUTE UPPER GASTROINTESTINAL BLEEDING IN PATIENTS USING ANTITHROMBOTIC AND NON-STEROIDAL ANTI-INFLAMMATORY THERAPY: CONTRIBUTING FACTORS AND OUTCOMES** ✦

Zane Straume, Latvia; Proskurina A.; Pokrotnieks J.; Kalejs O.; Lapina A.; Derovs A.

11:06 - 11:18 OP026

**NO DIFFERENCES IN GI BLEEDING RISK BETWEEN CLOPIDOGREL-, TICAGRELOR- OR PRASUGREL-BASED DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION.**

Viviana Laredo De La Torre, Spain; Garcia Mateo S.; Barberan Bernardos A.; Velázquez Ortigas J.; Revilla Marti P.; Carrera-Lasfuentes P.; Sostres Homedes C.; Lanas A.

11:18 - 11:30 OP027

**OUTCOMES FOR UPPER GASTROINTESTINAL BLEEDING IN ELDERLY PATIENTS: THE EXPERIENCE OF A TERTIARY UNIVERSITY HOSPITAL**

Rita Jiménez-Rosales, Spain; Martínez-Cara J. G.; Vadillo-Calles F.; Valverde-López F.; Redondo-Cerezo E.

11:30 - 11:42 OP028

**SHOULD WE BE USING THE SHOCK INDEX TO ASSESS PATIENTS PRESENTING WITH UPPER GI BLEEDING?**

Clare Blackwell, United Kingdom; Laursen S. B.; Laine L.; Dalton H.; Ngu J. H.; Schultz M.; Stanley A. J.; Norton R.

11:42 - 11:54 OP029

**USE AND COMPARISON OF THE STRATE AND GLASGOW BLATCHFORD SCORES FOR RISK STRATIFICATION OF PATIENTS WITH ACUTE LOWER INTESTINAL BLEEDING .**

Maguire R.; Balachandran A.; Anthony D.; Sneha John, Australia

**Translational/Basic Science**

10:30 – 12:00 Room M  
**Barrier function and GI disease**  
 Chairs: Helena Cortez-Pinto, Portugal  
 Adam Donald Farmer, United Kingdom



10:30 – 10:52 IP166  
**The mucosal barrier: Basic knowledge**  
 Tim Vanuystel, Belgium

10:52 – 11:14 IP167  
**The microbiome and the immune system**  
 Philip Rosenstiel, Germany

11:14 – 11:36 IP168  
**Barrier function and liver disease**  
 Alexander R. Moschen, Austria

11:36 – 11:58 IP169  
**Barrier function and GI disease**  
 Giovanni Barbara, Italy

**Today's Science, Tomorrow's Medicine**

10:30 – 12:00 Room 1.61/1.62  
**Regeneration: From myth to mechanism**  
 Chairs: Michael Manns, Germany  
 Fabio Marra, Italy



10:30 – 10:52 IP170  
**Cellular mechanisms of limb regeneration: Implications for the field**  
 Dunja Knapp, Germany

10:52 – 11:14 IP171  
**Does the liver represent the model organ for regeneration in gastroenterology?**  
 Massimo Pinzani, United Kingdom

11:14 – 11:36 IP172  
**Can faecal microbiota transfer regenerate the host?**  
 Antonio Gasbarrini, Italy

11:36 – 11:58 IP173  
**Macrophages: A key cell population in regeneration?**  
 Frank Tacke, Germany

**Symposium**

10:30 – 12:00 Room N1  
**Hot topics from Latin America**  
 Chairs: Mauro Bafutto, Brazil  
 Paul Fockens, The Netherlands

10:30 – 10:52 IP174  
**Premalignant lesions and gastric cancer: Detection strategies and early diagnosis in Latin America**  
 Arnoldo Javier Riquelme Pérez, Chile

10:52 – 11:14 IP175

**Faecal incontinence: New approach**  
 Paulo José Pereira de Campos Carvalho, Brazil

11:14 – 11:26 SOP1

**A RANDOMIZED CONTROLLED TRIAL COMPARING PERORAL ENDOSCOPIC MYOTOMY (POEM) VERSUS LAPAROSCOPIC HELLER MYOTOMY IN THE TREATMENT OF ACHALASIA.**  
 de Moura E. T. H.; Farias G. F. A.; Coutinho L. M. d. A.; Delgado A. A. d. A.; Nasi A.; Queiroz N. S. F.; Falcão A. C. G. M.; Jayanthi S. K.; Bianchi E. T.; Sallum R. A. A.; Ceconello I.; Sakai P.; Eduardo Turiani Hounreux de Moura, Brazil

11:26 – 11:48 IP176

**Treating functional gastrointestinal disorders: A multi-cultural perspective**  
 Carlos de Magalhaes Francisconi, Brazil

11:48 – 12:00 SOP2

**COILS + CYANOACRYLATE VS. COILS ALONE IN THE ENDOSCOPIC ULTRASOUND-GUIDED MANAGEMENT OF GASTRIC VARICES [GOV-II AND IGV-I]: A RANDOMIZED, CONTROLLED THERAPEUTIC TRIAL.**  
Carlos Robles-Medrandá, Ecuador; Valero M.; Soria-Alcivar M.; Puga-Tejada M.; Oleas R.; De Britto S.; Autran-Nebel J.; Ospina-Arboleda J.; Alvarado-Escobar H.; Del Valle R.; Pitanga-Lukashok H.

**Abstract-Based Session**

10:30 – 12:00 Room N2  
**Microbiota in IBS: From bench to bedside**  
 Chairs: Marie Joossens, Belgium  
 Marcis Leja, Latvia

10:30 – 10:42 IP177  
**State-of-the-art introduction**  
 Marcis Leja, Latvia

10:42 – 10:54 OP030  
**GUT MICROBIOTA CHARACTERISTICS ASSOCIATE WITH IRRITABLE BOWEL SYNDROME AND SPECIFIC BOWEL SYMPTOMS IN A POPULATION-BASED STUDY FROM SWEDEN**  
 Brunkwall L.; Nilsson P.; Ericson U.; Orho-Melandar M.; Bodil Ohlsson, Sweden

10:54 – 11:06 OP031  
**BACTERIA MODIFIED BILE ACIDS - A POSSIBLE MECHANISM FOR SYMPTOMS SEVERITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME.**  
 Chou C. J.; Ringel-Kulka T.; Bruce S.; Henry H.; Lauber C. L.; Betrisey B.; Yehuda Ringel, Israel

11:06 – 11:18 OP032  
**RESTORING EPITHELIAL BARRIER IN IRRITABLE BOWEL SYNDROME: THE POTENTIAL ROLE OF ESCHERICHIA COLI NISSLE 1917**

Maria Raffaella Barbaro, Italy; Fuschi D.; Carapelle M.; Dino P.; Cremon C.; Capelli E.; Stanghellini V.; Barbara G.

11:18 – 11:30 OP033  
**THE EFFECT OF FAECAL MICROBIOTA TRANSFER ON VISCERAL HYPERSENSITIVITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME**

Holster S.; Brummer R. J.; Repsilber D.; Julia König, Sweden

11:30 – 11:42 OP034  
**THE MUCOSAL TRANSCRIPTOMIC HOST RESPONSE TO FAECAL MICROBIOTA TRANSFER IN IRRITABLE BOWEL SYNDROME**

Savanne Holster, Sweden; Brummer R.; Repsilber D.; König J.

11:42 – 11:54 OP035  
**FECAL MICROBIOTA TRANSPLANTATION ALTERS GUT MICROBIOTA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY**

Halkjær S. I.; Christensen A. H.; Lo B. Z. S.; Browne P.; Günther S.; Hansen L. H.; Andreas Munk Petersen, Denmark

#### Abstract-Based Session

10:30 – 12:00 Room L7  
**Interventional EUS: Fifty shades of gray**  
 Chairs: Marianna Signoretti, Italy  
 Ilaria Tarantino, Italy

10:30 – 10:42 IP178  
**State-of-the-art introduction**  
 Ilaria Tarantino, Italy

10:42 – 10:54 OP036  
**LONG TERM RESULTS OF ENDOSCOPIC-RADIOLOGIC RENDEZ-VOUS OF IATROGENIC COMPLETE TRANSECTION OF THE COMMON BILE DUCT**

Fausto Fiocca, Italy; Salvatori F. M.; Corona M.; Antypas P.; Ceci V.; Cereatti F.; Nardis P. G.; Fanello G.; Bezzi M.; Donatelli G.

10:54 – 11:06 OP037  
**ENDOSCOPIC MANAGEMENT OF POSTOPERATIVE PANCREATIC FISTULA: TRANSPAPILLARY VS TRANSMURAL EUS GUIDED DRAINAGE**

Gabriela Gujda, Belgium; Hubert C.; Moreels T.; Navez J.; Perez Cuadrado-Robles E.; Deprez P. H.

11:06 – 11:18 OP038  
**COMPARATIVE ANALYSIS OF EUS-GUIDED PSEUDOCYST AND WALLED-OFF NECROSIS DRAINAGE BETWEEN DIFFERENT METAL (HOT-AXIOSTM, NAGITM, SPAXUS-TM) AND PLASTIC (DOUBLE PIGTAIL) STENTS: A SINGLE CENTER-EXPERIENCE**

Carlos Robles-Medranda, Ecuador; Puga-Tejada M.; Oleas R.; Del Valle R.; Ospina-Arboleda J.; Alvarado-Escobar H.; Soria-Alcivar M.; Pitanga-Lukashok H.

11:18 – 11:30 OP039  
**TECHNICAL ISSUES DURING EUS-GUIDED PLACEMENT OF LUMEN APPOSING METAL STENTS: DEFINITION AND CLASSIFICATION, INCIDENCE AND RISK FACTORS, ENDOSCOPIC MANAGEMENT AND EFFECT ON PROCEDURE OUTCOMES.**

Sergio Sevilla-Ribota, Spain; Garcia-Alonso F. J.; Sanchez-Ocana R.; Peñas-Herrero I.; Mora N.; Becerro I.; Torres-Yuste R.; Cimavilla M.; De La Serna Higuera C.; Pérez-Miranda M.

11:30 – 11:42 OP040  
**ROLE OF EUS-GUIDED TRANSMURAL DRAINAGE IN COMBINED MALIGNANT BILIARY AND GASTRIC OUTLET OBSTRUCTION**

Mariano Villarroel, Argentina; Cimavilla M.; Sevilla-Ribota S.; Carbajo López A. Y.; Garcia-Alonso F. J.; Gonzalez-Cordero P. L.; de Benito Sanz M.; Gil-Simon P.; De La Serna Higuera C.; Pérez-Miranda M.

11:42 – 11:54 OP041  
**ENDOSCOPIC ULTRASOUND GUIDED GASTROENTEROSCOPY: WHAT IS THE LEARNING CURVE?**

Amy Tyberg, United States; Choi A.; Gaidhane M.; Nieto J.; Kahaleh M.

#### Abstract-Based Session

10:30 – 12:00 Room L8  
**Generic profiling and risk assessment in polyps and early CRC**  
 Chairs: Irina Korytko, Ukraine  
 Mathieu Pioche, France

10:30 – 10:42 IP179  
**State-of-the-art introduction**  
 Mathieu Pioche, France

10:42 – 10:54 OP042  
**SIGNIFICANTLY MUTATED GENE (SMG) ANALYSIS OF EARLY COLORECTAL CANCER (CRC) OBTAINED BY ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) AND ENDOSCOPIC MUCOSAL RESECTION (EMR) WITH REFERENCE TO BIG DATA OF TCGA ON ADVANCED CANCER**

Kenichiro Okimoto, Japan; Hirotsu Y.; Amemiya K.; Ishikawa K.; Akizue N.; Ohta Y.; Taida T.; Maruoka D.; Matsumura T.; Nakagawa T.; Arai M.; Kato N.; Mochizuki H.; Omata M.

10:54 – 11:06 OP043  
**EICOSAPENTAENOIC ACID (EPA) AND/OR ASPIRIN FOR PREVENTION OF COLORECTAL ADENOMAS (THE SEAFOOD POLYP PREVENTION TRIAL): A MULTICENTRE DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED 2X2 FACTORIAL PHASE 3 TRIAL**  
Mark A. Hull, United Kingdom; Sprange K.; Hepburn T.; Tan W.; Shafayat A.; Rees C. J.; Clifford G.; Logan R.; Loadman P. M.; Williams L.; Whitham D.; Montgomery A.; seAF0od Trial Collaborative G.

11:06 – 11:18 OP044  
**PRECEDING ENDOSCOPIC SUBMUCOSAL DISSECTION DOES NOT AFFECT FOR THE PROGNOSIS OF PATIENTS WITH T<sub>1</sub> COLORECTAL CARCINOMA ADVERSELY AFTER ADDITIONAL SURGERY: A PROPENSITY SCORE-MATCHED ANALYSIS**  
Ken Yamashita, Japan; Tanaka S.; Oka S.; Nagata S.; Hiraga Y.; Kuwai T.; Furudoi A.; Tamura T.; Kunihiro M.; Okanobu H.; Nakadoi K.; Kanao H.; Higashiyama M.; Tamaru Y.; Arihiro K.; Kuraoka K.; Shimamoto F.; Chayama K.

11:18 – 11:30 OP045  
**A STUDY OF POST COLONOSCOPY COLORECTAL CANCER (PCCRC) IN ENGLAND**  
Nick Burr, United Kingdom; Rutter M. D.; Smith A.; Shelton J.; Pearson C.; Morris E.; Valori R.

11:30 – 11:42 OP046  
**MOLECULAR PROFILING OF LONGITUDINALLY OBSERVED SMALL COLORECTAL POLYPS**  
Meta C. J. Van Lanschoot, The Netherlands; Carvalho B.; Tutein Nolthenius C. J.; Rausch C. R.; Snaebjornssen P.; Kuipers E. J.; Stoker J.; Dekker E.; Meijer G. A.

11:42 – 11:54 OP047  
**DO WE RECOGNIZE EARLY (T<sub>1</sub>) COLORECTAL CANCER? DATA FROM THE DUTCH NATIONAL SCREENING PROGRAM.**  
Lonne W. T. Meulen, The Netherlands; Bogie R. M. M.; Van De Wetering A. J. P.; Reumkens A.; Winkens B.; Cheng H. R.; Straathof J. W. A.; Keulen E.; Bakker M.; Hoge C. V.; de Ridder R.; Breukink S. O.; Stassen L.; Masclee A.; Sanduleanu-Dascalescu S.

### Symposium

10:30 – 12:00 Room Hotspot  
**New metrics for colonoscopy**  
 Chair: Michal Filip Kaminski, Poland



10:30 – 10:33 IP180  
**Introduction**  
 Michal Filip Kaminski, Poland

10:33 – 10:38 IP181  
**Patient experience**  
 Marek Bugajski, Poland

10:38 – 10:53  
**PANEL DISCUSSION**

10:53 – 10:58 IP182  
**Appropriate polypectomy technique**  
 Monika Ferlitsch, Austria

10:58 – 11:13  
**PANEL DISCUSSION**

11:13 – 11:18 IP183  
**Appropriate post-polypectomy surveillance**  
 Enrique Quintero Carrion, Spain

11:18 – 11:33  
**PANEL DISCUSSION**

11:33 – 11:38 IP184  
**Rate of adequate bowel preparation**  
 Cesare Hassan, Italy

11:38 – 11:53  
**PANEL DISCUSSION**

11:53 – 11:56 IP185  
**Conclusion**  
 Michal Filip Kaminski, Poland

### Case-Based Discussion

12:45 – 13:45 Room G  
**Biliary pancreatitis**  
 Chair: Markus M. Lerch, Germany  
 Experts: László Czakó, Hungary  
 Markus M. Lerch, Germany  
 Marcel Tantau, Romania  
 Ilaria Tarantino, Italy

### Case-Based Discussion

12:45 – 13:45 Room K  
**Oesophageal motility disorders and dysphagia: How to diagnose? How to treat?**  
 Chair: Arjan Bredenoord, The Netherlands  
 Experts: Torsten Beyna, Germany  
 Arjan Bredenoord, The Netherlands  
 Sabine Roman, France  
 Nathalie Rommel, Belgium

### Case-Based Discussion

12:45 – 13:45 Room M  
**Anal pain and bleeding: Proctology**  
 Chair: Danny De Looze, Belgium  
 Experts: Danny De Looze, Belgium  
 Dieter Hahnloser, Switzerland  
 Soren Meisner, Denmark  
 Catherine Van Kemseke, Belgium

**Case-Based Discussion**

12:45 – 13:45 Room N1  
**Diarrhoea and fever**  
 Chair: Axel Dignass, Germany  
 Experts: Franck Carbonnel, France  
 Mircea Diculescu, Romania  
 Axel Dignass, Germany  
 Charles Murray, United Kingdom

**Symposium**

12:45 – 13:30 Room Hotspot  
**Women in interventional endoscopy: Are women less attracted by invasive procedures?**  
 Chair: Marianna Arvanitakis, Belgium

12:45 – 13:00 IP186  
**Why is it important for our patients to have more women trained as endoscopists?**  
 Adi Lahat, Israel

13:00 – 13:15 IP187  
**How to get more females in the interventional endoscopy arena**  
 Bjorn Rembacken, United Kingdom

13:15 – 13:30 IP188  
**Hurdles and difficulties women face upon choosing interventional endoscopy**  
 Jeanin E. van Hooft, The Netherlands  
 Tessa Verlaan, The Netherlands

**Symposium**

14:00 – 15:30 Room A  
**Best of DDW**  
 Chairs: Paul Fockens, The Netherlands  
 David Lieberman, United States

14:00 – 14:18 IP189  
**Best of liver**  
 Guadalupe Garcia-Tsao, United States

14:18 – 14:36 IP190  
**Best of oesophagus and upper GI**  
 Ikuo Hirano, United States

14:36 – 14:54 IP191  
**Best of IBD**  
 Themistocles Dassopoulos, United States

14:54 – 15:12 IP192  
**Best of pancreatic disorders**  
 Suresh Thiruvenga Chari, United States

15:12 – 15:30 IP193  
**Best of GI oncology**  
 Andrew T. Chan, United States

**Symposium**

14:00 – 15:30 Room D  
**Early management of acute pancreatitis: What & when**  
 Chairs: Markus M. Lerch, Germany  
 Santhi Swaroop Vege, United States

14:00 – 14:22 IP194  
**Fluid replacement**  
 Enrique de-Madaria, Spain

14:22 – 14:44 IP195  
**Early endoscopic intervention**  
 Stephen Pereira, United Kingdom

14:44 – 15:06 IP196  
**Nutritional support**  
 Marc G. H. Besselink, The Netherlands

15:06 – 15:28 IP197  
**Antibiotics**  
 Peter Hegyi, Hungary

**Symposium**

14:00 – 15:30 Room B  
**Therapy update in colorectal cancer**  
 Chairs: Frédéric Bibeau, France  
 Ian Jenkins, United Kingdom

14:00 – 14:22 IP198  
**MSI testing: How to test and who should be tested?**  
 Magali Svrcek, France

14:22 – 14:32 IP199  
**Pathology of mucinous cancers**  
 Iris D. Nagtegaal, The Netherlands

14:32 – 14:44 OP048  
**MANAGEMENT OF LOCAL REGROWTHS IN A WATCH-AND-WAIT PROGRAMME FOR RECTAL CANCER.**  
 van der Sande M.; Figueiredo N.; Melenhorst J.; Parvaiz A.; Pares O.; Santiago I.; Beets-Tan R.; Carvalho C.; Geerard L. Beets, The Netherlands

14:44 – 15:06 IP200  
**Technical advances in endoscopic resection of early colon cancers**  
 Klaus Mönkemüller, Germany

15:06 – 15:28 IP201  
**Surgical advances in rectal cancer**  
 Albert Wolthuis, Belgium

**Late Breaking Abstracts**

14:00 – 15:30 Room C  
**Late breaking abstracts I**

Symposium	
14:00 – 15:30	Room E1
<b>Update in eosinophilic esophagitis (EoE)</b>	
Chairs: Frederic Gottrand, France Javier Molina Infante, Spain	



### Tandem Talks

14:00 – 14:10	IP202
<b>How not to miss EoE in children?</b>	
Jorge Amil Dias, Portugal	

14:10 – 14:20	IP203
<b>How not to miss EoE in adults?</b>	
Alain Schoepfer, Switzerland	

### Tandem Talks

14:20 – 14:30	IP204
<b>Role of endoscopy</b>	
Arjan Bredenoord, The Netherlands	

14:30 – 14:40	IP205
<b>Role of histology</b>	
Cord Langner, Austria	

14:40 – 15:02	IP206
<b>Dysmotility and EoE</b>	
Nikhil Thapar, United Kingdom	

15:02 – 15:24	IP207
<b>PPI responsive eosinophilia: GORD or EoE?</b>	
Alfredo J Lucendo, Spain	

Symposium	
14:00 – 15:30	Room E2
<b>From guidelines to clinical practice: Crohn's disease</b>	
Chairs: Christian Maaser, Germany Julian Panés, Spain	



IP208	
<b>Introduction into UEG Standards &amp; Guidelines activities</b>	
Axel Dignass, Germany	

### Tandem Talks

14:00 – 14:10	IP209
<b>Extraintestinal manifestations: Clinical case</b>	
Donata Lissner, Germany	

14:10 – 14:20	IP210
<b>Extraintestinal manifestations: Guidelines</b>	
Britta Siegmund, Germany	

### Tandem Talks

14:20 – 14:30	IP211
<b>Infectious complications: Clinical case</b>	
Claire Liefvernickx, Belgium	

14:30 – 14:40	IP212
<b>ECCO opportunistic infection guidelines</b>	
Jean François Rahier, Belgium	

14:40 – 15:02	IP213
<b>Surgery: When and how?</b>	
Willem A. Bemelman, The Netherlands	

15:02 – 15:24	IP214
<b>Medical ECCO guidelines</b>	
Axel Dignass, Germany	

Symposium	
14:00 – 15:30	Room F1
<b>Autoimmune hepatitis</b>	
Chairs: George Dalekos, Greece Francesco Negro, Switzerland	



14:00 – 14:22	IP215
<b>The changing face of autoimmune hepatitis</b>	
Michael Trauner, Austria	

14:22 – 14:44	IP216
<b>When to biopsy?</b>	
Ana Lleo, Italy	

14:44 – 14:56	OP049
<b>THE ANTI-INFLAMMATORY RECEPTOR TREM2 PROTECTS THE LIVER FROM CHOLESTATIC INJURY IN MICE.</b>	
<u>bone Labiano</u> , Spain; Esparza-Baquer A.; Sharif O.; Milkiewicz P.; Milkiewicz M.; Hijona E.; Jimenez-Agüero R.; Marzioni M.; Mann D. A.; Bujanda L.; Banales J. M.; Perugorría M. J.	

14:56 – 15:08	OP050
<b>TARGETING LIVER INFLAMMATION USING CD64-TARGETED LIPID NANOPARTICLES AS A NOVEL DRUG DELIVERY SYSTEM</b>	
Szachniewicz M.; Bartneck M.; Prakash J.; Tacke F.; Ruchi BansaI, The Netherlands	

15:08 – 15:30	IP217
<b>Rising Star: From pathogenesis to novel therapeutic options</b> ✦	
Rodrigo Liberal, Portugal	

Symposium	
14:00 – 15:30	Room F2
<b>Upper GI bleeding: The basics from the experts</b>	
Chairs: Lars Aabakken, Norway Mark Ivo van Berge Henegouwen, The Netherlands	



14:00 – 14:22	IP218
<b>Differential diagnosis and initial approaches: A step-wise approach</b>	
Ian Gralnek, Israel	

14:22 – 14:44 IP219  
**Endoscopic treatment: Tips and tricks for ulcer bleeding**  
 Michael Häfner, Austria

14:44 – 15:06 IP220  
**Endoscopic treatment: Tips and tricks for variceal bleeding**  
 Tomas Hucl, Czech Republic

15:06 – 15:28 IP221  
**Radiological treatment**  
 Otto van Delden, The Netherlands

### Symposium

14:00 – 15:30 Room G  
**Alcoholic liver disease**  
 Chairs: Alessio Aghemo, Italy  
 Rafael Banares, Spain

14:00 – 14:22 IP222  
**Epidemiology: What has changed in the 21st century?**  
 Nicholas Sheron, United Kingdom

14:22 – 14:44 IP223  
**Diagnosis: Beyond denial**  
 Christophe Moreno, Belgium

14:44 – 15:06 IP224  
**Treatment of alcohol abuse: Should we go for anti-tubuse drugs?**  
 Camille Barrault, France

15:06 – 15:28 IP225  
**Alcoholic hepatitis: Management**  
 Alexandre Louvet, France

### Abstract-Based Session

14:00 – 15:30 Room K  
**Advances in pancreatio-biliary endoscopy**  
 Chairs: László Czakó, Hungary  
 Dario Ligresti, Italy

14:00 – 14:12 IP226  
**State-of-the-art introduction**  
 László Czakó, Hungary

14:12 – 14:24 OP051  
**IMPACT OF ELECTRICAL PULSE CUT MODE DURING ENDOSCOPIC PAPILLECTOMY: A PROSPECTIVE MULTI-CENTER RANDOMIZED CLINICAL TRIAL.**  
Fisuke Iwasaki, Japan; Itoi T.; Minami K.; Yamamoto K.; Tsuji S.; Fukuhara S.; Kanai T.

14:24 – 14:36 OP052  
**LUMEN-APPPOSING METAL STENTS (LAMS) FOR PANCREATIC FLUID COLLECTIONS ARE SAFE AND ASSOCIATED WITH A LOW RATE OF DELAYED ADVERSE EVENTS AT THE TIME OF CLINICAL FOLLOW-UP: A MULTICENTER RETROSPECTIVE ANALYSIS**  
Dennis Yang, United States; Perbtani Y.; Kerdsirichairat T.; Prabhu A.; Manvar A.; Ho S.; Pannu D.; Keswani R.; Strand D.; Wang A.; Quintero E.; Buscaglia J.; Muniraj T.; Aslanian H.; Draganov P.; Siddiqui A.

14:36 – 14:48 OP053  
**OPTIMIZING OUTCOMES OF SINGLE OPERATOR CHOLANGIOSCOPY (SOC)-GUIDED BIOPSIES: RESULTS OF A RANDOMIZED TRIAL**  
Ji Young Bang, United States; Navaneethan U.; Hasan M.; Krall K.; Hawes R.; Varadarajulu S. S.

14:48 – 15:00 OP054  
**APPLICATIONS OF INTRAOPERATIVE PANCREATOSCOPY FOR THE INVESTIGATION OF PANCREATIC IPMNS**  
Roberto Valente, Italy; Arnelo U.; Pozzi Mucelli R.; Reuterwall M. H.; Rangelova E.; Fagerström N.; Del Chiaro M.

15:00 – 15:12 OP055  
**ENDOSONOGRAPHY-GUIDED BILIARY DRAINAGE FOLLOWING FAILED ERCP: EXPERIENCE FROM A UK TERTIARY REFERRAL CENTRE.**  
Nick Burr, United Kingdom; Keegan M.; Everett S.; Hegade V.; Smith A.; Macutkiewicz C.; Adair R.; Paranandi B.; Huggett M.

15:12 – 15:24 OP056  
**EUS GUIDANCE FOR BILIARY AND PANCREATIC DUCT ACCESS AND DRAINAGE IN A TERTIARY CARE CENTER**  
 Tejedor J.; Nájera Muñoz R.; Garcia-Alonso F. J.; Sanchez-Ocana R.; Peñas-Herrero I.; Gonzalez-Cordero P. L.; Mariano Villarroel, Argentina; Cimavilla M.; Sevilla-Ribota S.; De La Serna Higuera C.; Pérez-Miranda M.

### Translational/Basic Science

14:00 – 15:30 Room M  
**Novel technical developments in basic science**  
 Chairs: Dirk Haller, Germany  
 Nathalie Vergnolle, France



14:00 – 14:22 IP227  
**High resolution imaging in the GI tract**  
 Pieter Vanden Bergh, Belgium

14:22 – 14:34 OP057  
**DEVELOPMENT OF DECELLULARIZED HUMAN GUT AS A NATURAL 3D-PLATFORM FOR INTESTINAL BIOENGINEERING**  
 Paolo Giuffrida, Italy; Curti M.; Al-Akkad W.; Biel C.; Crowley C.; Frenguelli L.; Telese A.; Hall A.; Tamburrino D.; Spoletini G.; Fusai G.; Tinozzi F. P.; Pietrabissa A.; Corazza G. R.; De Coppi P.; Pinzani M.; Di Sabatino A.; Rombouts K.; Mazza G.

14:34 – 14:46 OP058  
**A COHERENT ROADMAP TO GENERATE EITHER PANCREATIC ACINAR OR DUCT-LIKE CELLS FROM HUMAN PLURIPOTENT STEM CELLS CHALLENGES PANCREATIC CANCER BIOLOGY**  
 Jessica Merkle, Germany; Breunig M.; Hohwieler M.; Heller S.; Seufferlein T.; Frappart P.-O.; Kleger A.

14:46 – 15:08 IP228  
**Emerging techniques for single cell analysis**  
 Alejandro Sifrim, Belgium

15:08 – 15:30 IP229  
**From organoids to 3D printing scaffolds**  
 Alan Faulkner-Jones, United Kingdom

#### Today's Science, Tomorrow's Medicine

14:00 – 15:30 Room 1.61/1.62  
**TSTM Abstract-based: Stem cells as a therapeutic option**  
 Chairs: Christoph Becker, Germany  
 Henner Farin, Germany

14:00 – 14:12 OP059  
**BIFIDOBACTERIUM ANIMALIS SUBSPECIES LACTIS ENGINEERED TO PRODUCE MYCOSPORIN-LIKE AMINO ACIDS IN COLORECTAL CANCER PREVENTION**  
 Hüseyin Sancar Bozkurt, Turkey; Quigley E. M.; Kara B.

14:12 – 14:24 OP060  
**LONG-TERM EFFICACY AND SAFETY OF ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS FOR PERIANAL FISTULAS IN PATIENTS WITH CROHN'S DISEASE: A 4-YEAR FOLLOW-UP STUDY**  
 Marieke Barnhoorn, The Netherlands; Molendijk I.; Bonsing B. A.; Roelofs H.; Maljaars J. P. W.; Peeters K.; Wasser M. N. J. M.; Oosten L. E. M.; Dijkstra G.; van der Woude C. J.; Duijvestein M.; Veenendaal R. A.; Zwaginga J.; Verspaget H. W.; Fibbe W. E.; Hommes D. W.; Van der Meulen - De Jong A.

14:24 – 14:36 OP061  
**QUANTITATIVE CHANGES OF ENTERIC NEURONS CORRELATE WITH CLINICAL FEATURES IN PATIENTS WITH SEVERE DYSMOTILITY**  
 Elisa Boschetti, Italy; Gori A.; Malagelada C.; Accarino Garaventa A.; Azpiroz F.; Sternini C.; Stanghellini V.; De Giorgio R.

14:36 – 14:48 OP062  
**DIFFERENTIATION OF DENTAL PULP-DERIVED MESENCHYMAL STEM CELLS INTO HEPATOCYTES AND THEIR REPOPULATION IN NUDE RAT LIVER.**  
 Shogo Ohkoshi, Japan; Hara H.; Ishikawa H.

14:48 – 15:00 OP063  
**ALTERED MICROVASCULATURE IN CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND MNGIE: A MORPHOMETRIC AND MOLECULAR ANALYSIS.**  
 Elisa Boschetti, Italy; D'Angelo R.; Rinaldi R.; Pugliese A.; Costa R.; Papa V.; Cenacchi G.; Carelli V.; Pironi L.; Tugnoli V.; Stanghellini V.; De Giorgio R.

15:00 – 15:12 OP064  
**CHARACTERISATION OF A NOVEL JUVENILE ONSET DIABETES (JOD) GENE USING HUMAN PLURIPOTENT STEM CELLS**  
 Heller S.; Hohwieler M.; Costa I.; Seufferlein T.; Alexander Kleger, Germany

15:12 – 15:24 OP065  
**LONG-LIVED SECRETORY CELLS RESIDING IN THE MOUSE PROXIMAL COLON SERVE AS RESERVE STEM CELLS UNDER DNA DAMAGE-INDUCED MUCOSAL INJURY.**  
 Konomi Kuwabara, Japan; Ishibashi F.; Kawamoto A.; Anzai S.; Takahashi J.; Nagata S.; Shimizu H.; Yui S.; Oshima S.; Tsuchiya K.; Nakamura T.; Watanabe M.; Okamoto R.

#### Symposium

14:00 – 15:30 Room N1  
**"Mistakes in..."**  
 Chair: Charles Murray, United Kingdom

14:00 – 14:05 IP230  
**Introduction**  
 Charles Murray, United Kingdom

14:05 – 14:17 IP231  
**Mistakes in medical management of IBD**  
 Tim Raine, United Kingdom

14:17 – 14:29 IP232  
**Mistakes in management of liver function test abnormalities**  
 Joost P. H. Drenth, The Netherlands

14:29 – 14:41 IP233  
**Mistakes in managing unexpected endoscopic findings**  
 Jacques Deviere, Belgium

14:41 – 14:53 IP234  
**Mistakes in managing cases on call**  
 Xavier Dray, France

14:53 – 15:05 IP235  
**Mistakes in management of upper GI bleeding**  
 Bjorn Rembacken, United Kingdom



15:05 – 15:17 IP236  
**Mistakes in GORD diagnosis and treatment**  
 Sabine Roman, France

15:17 – 15:29  
**Questions and answers**

### Abstract-Based Session

14:00 – 15:30 Room N2  
**Transitioning from viral hepatitis to NASH**  
 Chairs: Jérôme Boursier, France  
 Navjyot Hansi, United Kingdom

14:00 – 14:12 IP237  
**State-of-the-art introduction**  
 Jérôme Boursier, France

14:12 – 14:24 OP066  
**BAVENO VI CRITERIA FOR SCREENING VARICES IS ASSOCIATED WITH THE RISK OF HCC AFTER DAA THERAPY IN PATIENTS WITH HCV INFECTION AND ADVANCED FIBROSIS**  
Valentina Fazio, Italy; Bruzzone L.; Dulbecco P.; Campo N.; Malfatti F.; Martines H.; De Leo P.; Bartolacci V.; Grasso A.

14:24 – 14:36 OP067  
**ASSOCIATION BETWEEN SARCOPENIA AND NONALCOHOLIC FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN THE UNITED STATES**  
 Wijarnpreecha K.; Pascale Raymond, United States; Scribani M.; Kim D.

14:36 – 14:48 OP068  
**GENETIC SUSCEPTIBILITY TO INCREASED INTESTINAL PERMEABILITY IS ASSOCIATED WITH STEATOHEPATITIS, LIVER FIBROSIS AND TYPE 2 DIABETES MELLITUS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**  
 Miele L.; Petta S.; Giorgio V.; Antonio Liguori, Italy; Pastorino R.; Marrone G.; Biolato M.; Arzani D.; Alberelli M. A.; Rapaccini G. L.; Boccia S.; Gasbarrini A.; Craxi A.; Grieco A.

14:48 – 15:00 OP069  
**THE TRANSCRIPTION FACTOR C-JUN/AP-1 PROMOTES LIVER FIBROSIS DURING NON-ALCOHOLIC STEATOHEPATITIS BY REGULATING OSTEOPONTIN EXPRESSION**  
Isabel Schulien, Germany; Hockenjos B.; Schmitt-Graeff A.; Große Perdekamp M.; Follo M.; Thimme R.; Hasselblatt P.

15:00 – 15:12 OP070  
**LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT**  
Vincenza Calvaruso, Italy; Petta S.; Cacciola I.; Cabibbo G.; Cartabellotta F.; Di Rosolini A.; Davi A.; Cannavo M.; Russello M.; Di Stefano M.; Scifo G.; Di Lorenzo F.; Prestileo T.; La Rocca L.; Montineri A.; Fuduli G.; Di Giacomo A.; Cannizzaro M.; Madonia S.; Licata A.; Malizia G.; Alaimo G.; Bertino G.; Cacopardo B.; Iacobello C.; Averna A.; Guarneri L.; Scalisi I.; Mazzola G.; Mondello L.; Portelli V.; Squadrito G.; Camma C.; Raimondo G.; Craxi A.; Di Marco V.

15:12 – 15:24 OP071  
**BLOOD-BORNE HEV TRANSMISSION: TRANSFUSION-TRANSMITTED HEPATITIS E VIRUS INFECTIONS AND EXPERIENCE WITH ROUTINE HEV SCREENING AT A TERTIARY CENTRE**  
Thomas Horvatits, Germany; Westhölter D.; Hiller J.; Denzer U.; Ayuk F.; Rybczynski M.; Frauen R. C.; Peine S.; Polywka S.; Lohse A. W.; Lütgehetmann M.; Pischke S.

### Abstract-Based Session

14:00 – 15:30 Room L7  
**Gastric carcinogenesis**  
 Chairs: Juozas Kupcinskas, Lithuania  
 Tamara Matysiak Budnik, France

14:00 – 14:12 IP238  
**State-of-the-art introduction**  
 Juozas Kupcinskas, Lithuania

14:12 – 14:24 OP072  
**HELICOBACTER PYLORI, GASTRIC CARCINOGENESIS AND THE ASSOCIATION WITH ER-STRESS AND AUTOPHAGY**  
Michiel Mommersteeg, The Netherlands; Spaander M. C. W.; Bruno M. J.; Kuipers E. J.; Peppelenbosch M.; Fuhler G.

14:24 – 14:36 OP073  
**HELICOBACTER PYLORI INFLUENCES THE METAGENOMIC PROFILE OF HUMAN GASTRIC MUCOSA**  
 Kupriyanova E.; Malanin S.; Safina D.; Safin A.; Alieva I.; Ziyatdinov A.; Abdulkhakov S. R.; Abdulkhakov R. A.; Tatiana Grigoryeva, Russian Federation

14:36 – 14:48 OP074  
**CLINICOPATHOLOGICAL FEATURES OF EPSTEIN-BARR VIRUS ASSOCIATED GASTRIC CARCINOMA WITH SUBMUCOSAL INVASION**  
Hiroki Osumi, Japan; Kawachi H.; Yoshio T.; Horiuchi Y.; Ishiyama A.; Hirasawa T.; Tsuchida T.; Yamamoto N.; Fujisaki J.

14:48 – 15:00 OP075  
**FGFR2 SIGNALING CROSSTALKS WITH HIPPO PATHWAY TO DRIVE GASTRIC CARCINOGENESIS** ✦  
Yuhang Zhou, Hong Kong PRC; Zhang J.; Li H.; Wu F.; Cheng A. S. L.; Yu J.; To K. F.; Kang W.

15:00 – 15:12 OP076  
**MODIFICATION OF INFLAMMATORY MICRORNAS IN GASTRIC MUCOSA BY ASPIRIN, NSAIDS AND PROTON-PUMP INHIBITORS**  
 Vasapolli R.; Langner C.; Schirrmeister W.; Venerito M.; Weigt J.; Treiber G.; Wex T.; Malfertheiner P.; Alexander Link, Germany

15:12 – 15:24 OP077  
**PSCA SNP-HELICOBACTER PYLORI INTERACTION ASSOCIATES TO GASTRITIS PROGRESSION IN THE GASTRIC CANCER SEQUENCE AND PSCA EXPRESSION**  
Osamu Toyoshima, Japan; Tanikawa C.; Watanabe H.; Matsuda K.

## Abstract-Based Session

14:00 – 15:30 Room L8  
**Translational research in liver, biliary and pancreas**  
 Chairs: Silvia Carrara, Italy  
 Liyanne F. M. van de Laarschot,  
 The Netherlands

14:00 – 14:12 IP239  
**State-of-the-art introduction**  
 Silvia Carrara, Italy

14:12 – 14:24 OP078  
**THE ROLE OF METABOLOMICS IN THE DISEASE PROGRESSION AND DEVELOPMENT OF BILIARY DYSPLASIA AND CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS (PSC)**  
 Vidya Velagapudi, Finland; Pessia A.; Arola J.; Boyd S.; Jokelainen K.; Färkkilä M. A.

14:24 – 14:36 OP079  
**CYSTIC FIBROSIS RELATED PANCREATIC DUCTAL DAMAGE IN THE CYSTIC FIBROSIS NEWBORN FERRET AND PIG MODEL**  
 Emese Tóth, Hungary; Rotti G. P.; Pallagi P.; Venglovecz V.; Rakoncay Z. J.; Maléth J.; Uc A.; Engelhardt J.; Hegyi P.

14:36 – 14:48 OP080  
**MUSCLE MIR-34A IS ACTIVATED DURING NAFLD PROGRESSION, PROMOTING INSULIN RESISTANCE AND MITOCHONDRIAL DYNAMICS DYSFUNCTION**  
 André Lopes Simão, Portugal; Rodrigues P. M.; Afonso M. B.; Santos A. A.; Amaral A. J.; Gama-Carvalho M.; Cortez-Pinto H.; Rodrigues C. M. P.; Castro R. E.

14:48 – 15:00 OP081  
**THE SERUM LEVELS OF SERINE PALMITOYLTRANSFERASE LONG-CHAIN SUBUNIT 3 ARE ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE-RELATED HEPATOCARCINOGENESIS.**  
 Sho Ijuin, Japan; Oda K.; Tamai T.; Mawatari S.; Tashima S.; Kasai A.; Tabu K.; Kumagai K.; Moriuchi A.; Uto H.; Ido A.

15:00 – 15:12 OP082  
**THE EFFICACY OF PENTOXIFYLLINE ON ACUTE PANCREATITIS** ✦  
 Dhanusorn Wanichagool, Thailand; Techathuvanan K.

15:12 – 15:24 OP083  
**DELETION OF BRG1 PREVENTS LIVER FIBROSIS AFTER CCL4 INJECTION IN MICE**  
 Baocai Wang, Germany; Kaufmann B.; Zhang X.; Mogler C.; Friess H.; Hüser N.; von Figura G.; Hartmann D.

## Symposium

14:00 – 15:30 Room Hotspot  
**Clinical trials revisited: Closing gaps and bleeders**  
 Chair: Mario Dinis-Ribeiro, Portugal



14:00 – 14:15 IP240  
**Trial presentation: *H. pylori* therapy for the prevention of metachronous gastric cancer**  
 Marcis Leja, Latvia

14:15 – 14:30 IP241  
**Critical review**  
 Sergey V. Kashin, Russian Federation

14:30 – 14:45

## PANEL DISCUSSION

Sergey V. Kashin, Russian Federation  
 Marcis Leja, Latvia  
 Pedro Pimentel Nunes, Portugal

14:45 – 15:00 IP242  
**Trial presentation: Early application of hemostatic powder added to standard management for oesophago-gastric variceal bleeding: A randomised trial**  
 Mostafa Ibrahim, Belgium

15:00 – 15:15 IP243  
**Critical review**  
 Vincent Leroy, France

15:15 – 15:30

## PANEL DISCUSSION

Mostafa Ibrahim, Belgium  
 Vincent Leroy, France  
 Horst Neuhaus, Germany  
 Emmanuel Tsochatzis, United Kingdom

## Symposium

15:45 – 17:15 Room A  
**Luminal Crohn's disease and surgery**  
 Chairs: Matthieu Allez, France  
 Willem A. Bemelman, The Netherlands



15:45 – 16:07 IP244  
**Biologics and perioperative morbidity**  
 Ailsa Hart, United Kingdom

## Debate

16:07 – 16:17 IP245  
**Early resection in Crohn's disease: Pro**  
 Dieter Hahnloser, Switzerland

16:17 – 16:27 IP246  
**Early resection in Crohn's disease: Con**  
 Gert Van Assche, Belgium

16:27 – 16:49 IP247  
**Alternatives to intestinal resections**  
 André D'Hoore, Belgium

16:49 – 17:11 IP248  
**Should we perform oncological resections in Crohn's disease?**  
 Christianne Johanna Buskens, The Netherlands

### Symposium

15:45 – 17:15 Room D  
**GORD resistant to PPI**  
 Chairs: Sabine Roman, France  
 Edoardo Savarino, Italy



15:45 – 16:07 IP249  
**How can we define "refractory" GORD?**  
 André Smout, The Netherlands

### Debate

16:07 – 16:17 IP250  
**Endoscopy in GORD diagnosis: Always**  
 Arjan Bredenoord, The Netherlands

16:17 – 16:27 IP251  
**Endoscopy in GORD: Only for therapy**  
 Emmanuel Coron, France

### Debate

16:27 – 16:37 IP252  
**Is there any indication for anti-reflux surgery? Pro**  
 Nicole Bouvy, The Netherlands

16:37 – 16:47 IP253  
**Is there any indication for anti-reflux surgery? Con**  
 Radu Tutuian, Switzerland

16:47 – 17:09 IP254  
**Rising Star: Rediscovering the wandering nerve** ⬄  
 Adam Donald Farmer, United Kingdom

### Symposium

15:45 – 17:15 Room B  
**Therapy update: *H. pylori* eradication regimen**  
 Chairs: Sibylle Koletzko, Germany  
 Javier Gisbert, Spain



15:45 – 16:07 IP255  
**Proton pump inhibitors versus potassium-competitive acid blockers**  
 Chan Hyuk Park, Republic of Korea

16:07 – 16:29 IP256  
**What's new with bismuth?**  
 Peter Malfertheiner, Germany

16:29 – 16:51 IP257  
**Is there a role for probiotics?**  
 Antonio Gasbarrini, Italy

16:51 – 17:13 IP258  
**Resistance-based therapy versus empiric therapy**  
 Francis Megraud, France

### Late Breaking Abstracts

15:45 – 17:15 Room C  
**Late breaking abstracts II**



### Abstract-Based Session

15:45 – 17:15 Room E1  
**Cutting-edge endoscopy**  
 Chairs: Torsten Beyna, Germany  
 Maria Fragkaki, Greece



15:45 – 15:57 IP259  
**State-of-the-art introduction**  
 Torsten Beyna, Germany

15:57 – 16:09 OP084  
**THE EFFICACY OF SCISSOR-TYPE KNIFE IN ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL CANCER: A MULTI-CENTER RETROSPECTIVE STUDY**  
Mitsuru Esaki, Japan; Hayashi Y.; Ikehara H.; Horii T.; Ichijima R.; Shibuya H.; Suzuki S.; Kusano C.; Hirota A.; Gotoda T.; Moriyama M.

16:09 – 16:21 OP085  
**FEASIBILITY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR ESOPHAGEAL CANCER IN PATIENTS WITH A HISTORY OF ESOPHAGECTOMY OR GASTRECTOMY, A PILOT STUDY**  
Meidong Xu, China; Chu Y.; Li H.; Zhou P.

16:21 – 16:33 OP086  
**COMPARISON OF OUTCOMES OF PER-ORAL ENDOSCOPIC MYOTOMY (POEM) IN ACHALASIA PATIENTS WITH OR WITHOUT PRIOR LAPAROSCOPIC HELLER'S MYOTOMY (LHM)**  
Malav Prafulkumar Parikh, United States; Thota P. N.; Gupta N. M.; Sarvepalli S.; Lopez R.; Gabbard S.; Murthy S.; Raja S.; Sanaka M. R.

16:33 – 16:45 OP087  
**EFFICACY AND SAFETY OF ENDOSCOPIC RESECTION FOR SMALL SUBMUCOSAL TUMORS ORIGINATING FROM THE MUSCULARIS PROPRIA LAYER IN THE GASTRIC FUNDUS**  
 Bing L.; Zhou P.-H.; Yun-Shi Zhong, China

16:45 – 16:57 OP088  
**ENDOSCOPIC RESECTION VIA ANTRAL SUBMUCOSAL TUNNELING FOR SAFE EN BLOC REMOVAL OF TUMORS IN THE DUODENAL BULB**  
 Xiaobei Luo, China; Han Z.; Huang J.; Li A.; Bai Y.; Liu S.

16:57 – 17:09 OP089  
**THE POCKET-CREATION METHOD FACILITATES ENDOSCOPIC SUBMUCOSAL DISSECTION OF LARGE SESSILE AND SUBPEDUNCULATED TUMORS**  
 Takeshi Yamashina, Japan; Hayashi Y.; Hashimoto K.; Hiraoka Y.; Fukuda H.; Okada M.; Takezawa T.; Kobayashi Y.; Sakamoto H.; Miura Y.; Shinozaki S.; Sunada K.; Lefor A.; Yamamoto H.

### Symposium

15:45 – 17:15 Room E2  
**From guidelines to clinical practice: Faecal incontinence**  
 Chairs: Emma Carrington, United Kingdom  
 Mircea Diculescu, Romania



IP260  
**Introduction into UEG Standards & Guidelines activities**  
 Grainne Holleran, Ireland

### Tandem Talks

15:45 – 15:55 IP261  
**Clinical evaluation: Clinical case**  
 Nilay Danis, Turkey

15:55 – 16:05 IP262  
**Clinical evaluation: Guidelines**  
 Henriette Heinrich, Switzerland

16:05 – 16:27 IP263  
**Dynamic imaging**  
 Andrew Plumb, United Kingdom

16:27 – 16:49 IP264  
**Medical management and biofeedback**  
 Christine Norton, United Kingdom

16:49 – 17:11 IP265  
**Surgery**  
 Klaus Matzel, Germany

### Abstract-Based Session

15:45 – 17:15 Room F1  
**Clinical features in IBD**  
 Chairs: Rami Eliakim, Israel  
 Klaudia Farkas, Hungary



15:45 – 15:57 IP266  
**State-of-the-art introduction**  
 Rami Eliakim, Israel

15:57 – 16:09 OP090  
**EOSINOPHILIC OESOPHAGITIS WITH INFLAMMATORY BOWEL DISEASE: EPIDEMIOLOGY AND OUTCOMES FROM A LARGE POPULATION-BASED ANALYSIS**  
 Limketkai B.; Bellaguarda E.; Jean-Frederic Colombel, United States

16:09 – 16:21 OP091  
**LONG-TERM OUTCOME OF CROHN'S DISEASE COMPLICATED BY UPPER GASTROINTESTINAL STRICTURE : A GETAID COHORT STUDY**  
 Thomas Lambin, France; Amiot A.; Gornet J.-M.; Seksik P.; Laharie D.; Louis E.; Gilletta C.; Filippi J.; Fumery M.; Cadiot G.; Pineton de Chambrun G.; Nahon S.; Serrero M.; Coffin B.; Plastaras L.; Viennot S.; Dib N.; Peyrin-Biroulet L.; Pariente B.

16:21 – 16:33 OP092  
**ADICROHN PILOT STUDY: AN INNOVATIVE TREATMENT FOR REFRACTORY PERIANAL FISTULAS IN CROHN'S DISEASE: LOCAL INJECTION OF AUTOLOGOUS FAT AND ADIPOSE DERIVED STROMAL VASCULAR FRACTION**  
 Melanie Serrero, France; Philandrianos C.; Magalon J.; Visée C.; Desjeux A.; Veran J.; Jouve E.; Sabatier F.; Grimaud J.-C.

16:33 – 16:45 OP093  
**A PROPENSITY SCORE-MATCHED COMPARISON OF INFLIXIMAB AND ADALIMUMAB IN NAÏVE AND NON-NAÏVE PATIENTS WITH CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)**  
 Ambrogio Orlando, Italy; Macaluso F. S.; Fries W.; Privitera A. C.; Cappello M.; Siringo S.; Inserra G.; Magnano A.; Di Mitri R.; Mocciaro F.; Belluardo N.; Scarpulla G.; Magri G.; Trovatiello A.; Carroccio A.; Genova S.; Bertolami C.; Vassallo R.; Romano C.; Citrano M.; Accomando S.; Ventimiglia M.; Renna S.; Orlando R.; Rizzuto G.; Porcari S.; Ferracane C.; Cottone M.

16:45 – 16:57 OP094  
**TREATMENT PATTERNS AMONG PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN WESTERN EUROPE**  
 Alessandro Armuzzi, Italy; Tarallo M.; DiBonaventura M.; Bargo D.; Lucas J.; Bluff D.; Hoskin B.; Salese L.; Cappelleri J.; Gigante G.

16:57 – 17:09 OP095  
**EFFICACY AND SAFETY OF USTEKINUMAB INTRAVENOUS INDUCTION IN A COHORT OF PATIENTS WITH CROHN'S DISEASE REFRACTORY TO ANTI-TUMOR NECROSIS FACTOR AGENTS**  
 Aurélie Santoni, France; Serrero M.; Altwegg R.; Desjeux A.; Boivineau L.; Grimaud J.-C.

## Symposium

15:45 – 17:15 Room F2  
**Biliary stones: Diagnosis and therapeutic management**  
 Chairs: Erwan Bories, France  
 Aron Vincze, Hungary



15:45-16:07 IP267  
**Symptomatic biliary stones: Diagnosis**  
 Marianna Arvanitakis, Belgium

16:07 – 16:29 IP268  
**Symptomatic biliary stones: Therapeutic management**  
 Jan Werner Poley, The Netherlands

## Debate

16:29 – 16:39 IP269  
**When the endoscopist teams up with the surgeon:  
 ERCP before or after laparoscopic cholecystectomy!**  
 Leena Kylänpää, Finland

16:39 – 16:49 IP270  
**When the endoscopist teams up with the surgeon:  
 ERCP during laparoscopic cholecystectomy!**  
 Fredrik Swahn, Sweden

16:49 – 17:11 IP271  
**My patient has recurrent CBD stones!**  
 Andrea Tringali, Italy

## Symposium

15:45 – 17:15 Room G  
**Update on hereditary colorectal cancer syndromes**  
 Chair: Jaroslaw Regula, Poland  
 Yasmijn van Herwaarden, The Netherlands

15:45 – 16:07 IP272  
**FAP**  
 Andrew Latchford, United Kingdom

16:07 – 16:29 IP273  
**Lynch syndrome**  
 Francesc Balaguer, Spain

16:29 – 16:51 IP274  
**Other polyposis**  
 Rodrigo Jover Martínez, Spain

16:51 – 17:13 IP275  
**Timing and extent of surgery**  
 P. Ronan O'Connell, Ireland

## Abstract-Based Session

15:45-17:15 Room K  
**Management of Barrett's**  
 Chairs: Michael John Bourke, Australia  
 Manuele Furnari, Italy

15:45 – 15:57 IP276  
**State-of-the-art introduction**  
 Michael John Bourke, Australia

15:57 – 16:09 OP096  
**QUALITY INDICATORS FOR BARRETT'S ENDOTHERAPY (QBET): UK CONSENSUS STATEMENTS FOR PATIENT'S UNDERGOING ENDOSCOPIC THERAPY FOR BARRETT'S ESOPHAGUS NEOPLASIA**  
Durayd Alzoubaidi, United Kingdom; Ragunath K.; Wani S.; Penman I.; Trudgill N.; Jansen M.; Banks M.; Bhandari P.; Morris A. J.; Willert R.; Boger P.; Smart H.; Ravi N.; Attwood S.; Dunn J.; Gordon C.; Mannath J.; Mainie I.; di Pietro M.; Veitch A.; Thorpe S.; Bassett P.; Graham D.; Lovat L. B.; Pech O.; Sharma P.; Haidry R. J.

16:09 – 16:21 OP097  
**BARRETT'S OESOPHAGUS: ENDOSCOPIC TREATMENT OR SURVEILLANCE? A COMPARATIVE COST-EFFECTIVENESS ANALYSIS**  
Amir-Houshang Omidvari, The Netherlands; Ali A.; Hazelton W. D.; Lansdorp-Vogelaar I.; Kroep S.; Richmond E.; Kong C. Y.; Rubenstein J. H.; Luebeck G.; Hur C.; Inadomi J.

16:21 – 16:33 OP098  
**ACETIC ACID GUIDED BIOPSIES VERSUS MAPPING BIOPSIES FOR BARRETT'S SURVEILLANCE: THE ABBA STUDY**  
 Longcroft-Wheaton G.; Fogg C.; De Caestecker J.; Barr H.; Poller D.; Higgins B.; Basford P. J.; Li A.; Gordon C.; Green S.; Gadeke L.; Dewey A.; Mccord M.; Jankowski J.; Pradeep Bhandari, United Kingdom

16:33 – 16:45 OP099  
**OUTCOMES OF 360 EXPRESS RADIO-FREQUENCY ABLATION FOR BARRETT'S OESOPHAGUS RELATED NEOPLASIA**  
Cormac Gerard Magee, United Kingdom; Gordon C.; Dunn J.; Zeki S.; Penman I.; Willert R.; Smart H.; Ortiz-Fernández-Sordo J.; Ragunath K.; Pana M.; Everson M.; Alzoubaidi D.; Graham D.; Subramaniam S.; Narayanasamy R.; Morris A. J.; Bhandari P.; di Pietro M.; Lovat L. B.; Haidry R. J.

16:45 – 16:57 OP100  
**MULTICENTER FEASIBILITY STUDY OF COMBINED INJECTION AND ARGON PLASMA COAGULATION (HYBRID-APC) IN THE ABLATION THERAPY OF NEOPLASTIC BARRETT ESOPHAGUS**  
Thomas Rösch, Germany; Manner H.; May A.; Knabe M.; Schachschal G.; Ehlken H.; Neuhaus H.; Beyna T.; Kandler J.; Bergman J. J.; Weusten B. L. A. M.; Pech O.; Faiss S.; Anders M.; Ell C.

16:57 – 17:09 OP101

**FEASIBILITY, SAFETY, TOLERABILITY AND DOSE-RELATED EFFICACY OF A NOVEL SWIPE CRYOBALLOON ABLATION (90&#8304;-SCBA) DEVICE IN DYSPLASTIC BARRETT'S ESOPHAGUS**Anouk Overwater, The Netherlands; van Munster S. N.; Raicu G. M.; Seldenrijk C. A.; Nagengast W. B.; Schoon E. J.; Bergman J. J. G. H. M.; Weusten B. L. A. M.**Translational/Basic Science**

15:45 – 17:15 Room M

**Biomarkers and individualised medicine**Chairs: Frédéric Bibeau, France  
Eithne Costello-Goldring, United Kingdom

15:45 – 16:07 IP277

**Rising Star: Extracellular vesicles in hepatobiliary malignancies: From basic science to clinical implications** ✦  
Jesús M. Bañales, Spain

16:07 – 16:29 IP278

**Biomarkers in IBD as a guide to clinical management**  
Azucena Salas, Spain

16:29 – 16:51 IP279

**Genetic make-up and treatment of colorectal cancer**  
Pierre Laurent-Puig, France

16:51 – 17:13 IP280

**Biomarkers in pancreatic disease**  
Casper H. J. van Eijck, The Netherlands**Today's Science, Tomorrow's Medicine**

15:45 – 17:15 Room 1.61/1.62

**Liver: Regenerative mechanism - lessons for other organs?**Chairs: Marco Marzioni, Italy  
Michael Trauner, Austria

15:45 – 16:07 IP281

**Increase in liver volume: Pre-surgical and surgical strategies**

Johann Pratschke, Germany

16:07 – 16:29 IP282

**Liver organoids as a novel tool for disease modeling**  
Laura Broutier, United Kingdom

16:29 – 16:51 IP283

**More than antiviral treatment in hepatitis C: Decrease in fibrosis**

Fabio Marra, Italy

16:51 – 17:13 IP284

**Metabolic events during liver regeneration: Clinical implications**

Alexander R. Moschen, Austria

**Abstract-Based Session**

15:45 – 17:15 Room N1

**IBD pathogenesis**Chairs: Dirk Haller, Germany  
Moritz Leppkes, Germany

15:45 – 15:57 IP285

**State-of-the-art introduction**

Moritz Leppkes, Germany

15:57 – 16:09 OP102

**MIS-G, A MOLECULAR MEASURE OF INFLAMMATION IN IBD PATIENTS BASED ON TRANSCRIPTIONAL PROFILES FROM 2495 INTESTINAL BIOPSIES: DEFINITION, CHARACTERIZATION AND POTENTIAL USES.**Argmann C.; Irizar A.; Kosoy R.; Huang R.; Wei G.; Peters L.; Song W.-M.; Dinarzo A.; Wang W.; Castillo A.; Perrigoue J.; Zhang B.; Friedman J.; Stojmirovic A.; Hart A.; Curran M.; Dobrin R.; Plevy S.; Brodmerkel C.; Cho J.; Hao K.; Zhu J.; Colombel J. F.; Dubinsky M.; Sands B.; Schadt E.; Kasarskis A.; Losic B.; Mayte Suarez-Farinas, United States

16:09 – 16:21 OP103

**LUMINAL PROTEASE ACTIVITY IS INCREASED IN PATIENTS WITH POUCH INFLAMMATION**Sarit Hoffman, Israel; Carroll I.; Tulchinsky H.; Dotan I.; Maharshak N.

16:21 – 16:33 OP104

**PATHOGENICITY OF IN-VIVO GENERATED INTESTINAL TH17 LYMPHOCYTES IS IFNG DEPENDENT.**Federica Facciotti, Italy; Nizzoli G.; Burrello C.; Cribiù F. M.; Lovati G.; Ercoli G.; Botti F.; Trombetta E.; Porretti L.; Todoerti K.; Neri A.; Giuffrè M. R.; Geginat J.; Vecchi M.; Rescigno M.; Paroni M.; Caprioli F.

16:33 – 16:45 OP105

**HUMAN BONE MARROW DERIVED MESENCHYMAL STEM CELLS MEDIATE IMMUNOSUPPRESSION IN EXPERIMENTAL CROHN'S DISEASE BY SECRETING PROTAGLANDIN E2 AND REPROGRAMMING MACROPHAGES TO AN IMMUNOSUPPRESSIVE PHENOTYPE**Maneesh Dave, United States; Zhao N.; Palacios R. S.; Mahabaleshwar G.; Caplan A. I.; Cominelli F.

16:45 – 16:57 OP106

**THE INTERLEUKIN-6 RECEPTOR AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE; A MENDELIAN RANDOMISATION STUDY**Constantinos Parisinos, United Kingdom; Serghiou S.; Katsoulis M.; Patel R.; Hemingway H.; Hingorani A.

16:57 – 17:09 OP107  
**CD103+SIRP&#945;+ DENDRITIC CELLS ARE SPECIFICALLY DECREASED IN THE INFLAMED COLON FROM PATIENTS WITH ULCERATIVE COLITIS BUT NOT IN CROHN'S DISEASE.**  
 David Bernardo, Spain; Mora-Gutierrez I.; Marin A. C.; Fernandez-Tome S.; Ortega-Moreno L.; Moreno-Monteagudo J. A.; Casanova González M. J.; Santander C.; Chaparro M.; Gisbert J. P.

### Abstract-Based Session

15:45 – 17:15 Room N2  
**Coeliac disease: From basics to therapy**  
 Chairs: Laura Kivelä, Finland  
 Fabiana Zingone, Italy

15:45 – 15:57 IP286  
**State-of-the-art introduction**  
 Laura Kivelä, Finland

15:57 – 16:09 OP108  
**ARYL HYDROCARBON RECEPTOR HAVE A PROTECTIVE EFFECT IN CELIAC DISEASE MUCOSA AND IN A MOUSE MODEL OF POLY I:C-INDUCED SMALL INTESTINAL ATROPHY**  
 Irene Marafini, Italy; Dinallo V.; Di Fusco D.; Di Grazia A.; Laudisi F.; Dwairi R.; Paoluzi O. A.; Monteleone G.; Monteleone I.

16:09 – 16:21 OP109  
**TOLEROGENIC IMMUNE-MODIFYING NANOPARTICLES CONTAINING GLIADIN RESTORE TOLERANCE & ABROGATE DISEASE IN MURINE MODELS OF COELIAC DISEASE**  
 Tobias L. Freitag, Finland; Podojil J. R.; Messing M.; Andersson L. C.; Leskinen K.; Saavalainen P.; King N. J. C.; Shea L. D.; Miller S. D.; Meri S.; Getts D. R.

16:21 – 16:33 OP110  
**ABERRANT INTRA-EPITHELIAL LYMPHOCYTES CAUSE VILLOUS ATROPHY IN REFRACTORY CELIAC DISEASE TYPE II BY GRANZYME-B-INDUCED APOPTOSIS OF ENTEROCYTES MEDIATED VIA CD103(αE)β7-E-CADHERIN-INTERACTIONS**  
 Daan A. R. Castellijn, The Netherlands; van de Water J. M. W.; McGlinchy B.; van Leeuwen M.; de Baaij L. R.; Reijm M.; Hollander J.; Kooy-Winkelaar Y.; Koning F.; Bouma G.; Meijer C. J. L. M.; Bontkes H. J.; Mulder C. J. J.; Cillessen S. A. G. M.

16:33 – 16:45 OP111  
**CHILDREN FROM COELIAC FAMILIES BENEFIT FROM EARLY DIAGNOSIS AND TREATMENT: AN ANALYSIS OF THE PREVENTCD COHORT**  
 Meijer C.; Auricchio R.; Castillejo G.; Crespo Escobar P.; Gyimesi J.; Hartman C.; Kolacek S.; Koletzko S.; Korponay-Szabo I. R.; Martinez Ojinaga Nodal E.; Piescik-Lech M.; Polanco I.; Ribes Koninckx C.; Shamir R.; Szajewska H.; Szillat P.; Troncone R.; Werkstetter K.; Luisa Mearin, The Netherlands

16:45 – 16:57 OP112  
**COELIAC DISEASE DIAGNOSIS IN INDIVIDUALS ON A GLUTEN FREE DIET**  
 López Palacios N.; Fernández-Prieto M.; Laura Redero, Spain; Castaño M.; García-Gómez M.; Bodas A.; Martínez-Ojinaga E.; Pascual V.; Rey E.; Núñez C.

16:57 – 17:09 OP113  
**CLASSIFICATION OF REFRACTORY CELIAC DISEASE WITH FLUORESCENCE-ACTIVATED CELL SORTING OF INTESTINAL LYMPHOCYTES: DATA FROM A TERTIARY REFERRAL CENTER**  
 Federica Branchi, Germany; Itzlinger A.; Tangermann P.; Heldt C.; Bojarski C.; Daum S.; Schneider T.; Siegmund B.; Moos V.; Schumann M.

### Abstract-Based Session

15:45 – 17:15 Room L7  
**Unsolved issues in cirrhosis**  
 Chairs: Salvatore Piano, Italy  
 Philipp Schwabl, Austria

15:45 – 15:57 IP287  
**State-of-the-art introduction**  
 Salvatore Piano, Italy

15:57 – 16:09 OP114  
**RISK SCORE MODEL TO PREDICT EARLY READMISSION IN DECOMPENSATED CIRRHOSIS**  
 Lissa Maria Franco, Spain; Rodriguez M.; Navascues C. A.; Antón S.; Ferrusquía J.; Ríos A.; Fraile M.; Gonzalez-Dieguez L.; Valle C.; Varela M.; De la Vega J.; Graviss E.; Nguyen D.; Victor D. W.

16:09 – 16:21 OP115  
**RISK FACTORS FOR THE EMERGENCE OF MULTI-DRUG-RESISTANT ORGANISMS IN LIVER CIRRHOSIS** ✦  
 Luísa Martins Figueiredo, Portugal; Rafael M. A.; Alexandrino G.; Martins A.; Oliveira A. M.; Carvalho R.; Santos Nunes L.; Horta D.; Lourenço L. C. C.; Costa M. N.; Reis J.

16:21 – 16:33 OP116  
**EFFICACY AND SAFETY OF TRANSJUGULAR PORTOSYSTEMIC SHUNT IN DIFFICULT-TO-MANAGE HYDROTHORAX IN CIRRHOSIS** ✦  
 Ankur Jindal, India; Sarin S.

16:33-16:45 OP117  
**RANDOMIZED PLACEBO-CONTROLLED STUDY OF ORPHENADRINE IN TREATMENT OF MUSCLE CRAMPS IN PATIENTS WITH LIVER CIRRHOSIS.**  
 Sherief Abd-El salam, Egypt; Badawi R.; Ibrahim S.; Elfert A.

16:45 – 16:57 OP118  
**EFFECTIVENESS OF ACTIVE OUTPATIENT FOLLOW-UP PROGRAM ON LONG-TERM SURVIVAL OF PATIENTS WITH ALCOHOLIC LIVER DISEASE**  
Valeriy Lunkov, Russian Federation; Maevskaya M.; Ivashkin V.

16:57 – 17:09 OP119  
**THE BENEFICIAL EFFECTS OF NON-SELECTIVE BETABLOCKERS IN SECONDARY PROPHYLAXIS ARE MOST PRONOUNCED IN PATIENTS WITHOUT REFRACTORY ASCITES**  
Nikolaus Pfisterer, Austria; Dexheimer C.; Riedl F.; Mandorfer M.; Fuchs E.-M.; Pachofszky T.; Dolak W.; Bucsecs T.; Gessl I.; Schwabl P.; Sandrieser L.; Scheiner B.; Ferlitsch A.; Schöniger-Hekele M.; Peck-Radosavljevic M.; Madl C.; Trauner M.; Reiberger T.

### Abstract-Based Session

15:45 – 17:15 Room L8  
**Diagnosis and risk factors of pancreatic diseases**  
 Chairs: Enrique de-Madaria, Spain  
 Katalin Márta, Hungary

15:45 – 15:57 IP288  
**State-of-the-art introduction**  
 Katalin Márta, Hungary

15:57 – 16:09 OP120  
**DEFINING PANCREATITIS AS A RISK FACTOR FOR PANCREATIC CANCER: THE ROLE, INCIDENCE, AND TIMELINE OF DEVELOPMENT**  
 Syed A.; Shyam Thakkar, United States

16:09 – 16:21 OP121  
**THE EFFECT OF SMOKING IN THE CHRONIC PANCREATITIS PATIENTS**  
 Liu Y.; Hao L.; Jin-Huan Lin, China; Wang T.; Zhang D.; Bi Y.-W.; Guo H.-L.; Liao Z.; Li Z.-S.; Hu L.-H.

16:21 – 16:33 OP122  
**THE WAY FROM ABDOMINAL PAIN TO PEDIATRIC PANCREATITIS - THE PINEAPPLE STUDY**  
 Mosztabacher D.; Andrea Párniczky, Hungary; Tóth A.; Demcsák A.; Ila V.; Abu-El-Haija M.; Szabo F.; Tokodi I.; Fehér B.; Bakó K.; Kadenczki O.; Guthy I.; Cazacu I.; Kaán K.; Juhász F.; Horváth E.; Tél B.; Erös A.; Mosdósi B.; Nagy A.; Bódi P.; Földi M.; Kiss S.; Veres G.; Lásztity N.; Decsi T.; Szentesi A.; Hegyi P.

16:33 – 16:45 OP123  
**IS DIABETES BEING IGNORED IN PATIENTS WITH PANCREATIC CANCER?**  
 Syed A.; Shyam Thakkar, United States

16:45 – 16:57 OP124  
**PANCO: AN OPEN-LABEL, SINGLE-ARM PILOT STUDY OF ONCOSIL™ IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA IN COMBINATION WITH FOLFIRINOX OR GEMCITABINE+NAB-PACLITAXEL CHEMOTHERAPIES**  
Daniel Croagh, Australia; Kwan V.; Nguyen N.; Williams D.; Phillips N.; Godfrey E.; Kraszewski A.; Maher T.; Ross P.

16:57 – 17:09 OP125  
**RISK FACTORS AND NOMOGRAM FOR PANCREATIC STONE FORMATION IN CHRONIC PANCREATITIS: A COHORT OF 2,153 PATIENTS**  
 Liu Y.; Hao L.; Jin-Huan Lin, China; Wang T.; Zhang D.; Bi Y.-W.; Zeng X.-P.; Liao Z.; Li Z.-S.; Hu L.-H.

### Symposium

15:45 – 17:15 Room Hotspot  
**Multidisciplinary management of locally advanced rectal cancer**  
 Chairs: Helmut Messmann, Germany  
 Bojan Tepes, Slovenia



15:45 – 16:07 IP289  
**MRI**  
 Elleke Dresen, Belgium

16:07 – 16:29 IP290  
**Neoadjuvant concepts**  
 Yann Touchefeu, France

**Debate**  
 16:29 – 16:39 IP291  
**Strategies in obstructing rectal cancer: Pro stent**  
 Soren Meisner, Denmark

16:39 – 16:49 IP292  
**Strategies in obstructing rectal cancer: Pro surgery**  
 Sebastiano Biondo, Spain

16:49 – 17:11 IP293  
**Watchful waiting after chemo radiotherapy?**  
 Geerard L. Beets, The Netherlands



**Young GI Activity**

15:45 - 17:45	Young GI Lounge
<b>Rising Stars in gastroenterology and hepatology from Europe and Japan</b>	
Chairs: Vinciane Rebours, France Luigi Ricciardiello, Italy	
15:45 - 15:55	IP294
<b>Tips and tricks: How to become a UEG Rising Star</b>	
Luigi Ricciardiello, Italy	
15:55 - 15:58	IP295
<b>Introduction of Fumiaki Ishibashi, JSGE Rising Star</b>	
15:58 - 16:10	IP296
<b>Cell plasticity in intestinal tissue regeneration and tumorigenesis</b>	
Fumiaki Ishibashi, Japan	
16:10 - 16:15	
<b>Questions and answers</b>	
16:15 - 16:18	IP297
<b>Introduction of Rodrigo Liberal, UEG Rising Star 2018</b>	
16:18 - 16:30	IP298
<b>Unmet needs and research opportunities in autoimmune liver disease</b>	
Rodrigo Liberal, Portugal	

16:30 - 16:35

**Questions and answers**

16:35 - 16:38

IP299

**Introduction of Sho Suzuki, JSGE Rising Star**

16:38 - 16:50

IP300

**State of the art treatment and prevention of early gastric cancer**

Sho Suzuki, Japan

16:50 - 16:55

**Questions and answers**

16:55 - 16:58

IP301

**Introduction of Emmanuel Tsochatzis, UEG Rising Star 2014**

16:58 - 17:10

IP302

**Non-invasive assessment of cirrhosis and portal hypertension**

Emmanuel Tsochatzis, United Kingdom

17:10 - 17:15

**Questions and answers**

17:15 - 17:45

IP303

**How to become a Rising Star: Open discussion**

## Scientific Programme by Day

Tuesday, October 23, 2018

Live Endoscopy	
08:30 – 10:00	Room A
<b>Live Endoscopy I</b>	
Chairs: Lars Aabakken, Norway Helmut Messmann, Germany Cristiano Spada, Italy	
Experts: Pradeep Bhandari, United Kingdom Pierre Henri Deprez, Belgium Marc Giovannini, France Alessandro Repici, Italy Vincenzo Perri, Italy Lucio Petruziello, Italy Maria Riccioni, Italy Andrea Tringali, Italy	



Transmission from the Gemelli Hospital in Rome, Italy

Symposium	
08:30 – 10:00	Room D
<b>Future therapies in IBD</b>	
Chairs: Silvio Danese, Italy Gerhard Rogler, Switzerland	



08:30 – 08:52 IP304  
**Manipulating the immune response**  
Yehuda Chowers, Israel

08:52 – 09:14 IP305  
**Modifying the microbiota**  
Cyril Y. Ponsioen, The Netherlands

09:14 – 09:36 IP306  
**Are small molecules a better option?**  
Markus Neurath, Germany

**Tandem Talks**  
09:36 – 09:46 IP307  
**Haematopoietic stem cells**  
Marc Ferrante, Belgium

09:46 – 09:56 IP308  
**Mesenchymal stem cells**  
Julian Panés, Spain

Symposium	
08:30 – 10:00	Room B
<b>Therapy update: Acute pancreatitis</b>	
Chairs: Peter Hegyi, Hungary Markus M. Lerch, Germany	



08:30 – 08:52 IP309  
**Fluid replacement**  
Xavier Molero, Spain

08:52 – 09:14 IP310  
**Nutrition**  
Ross Carter, United Kingdom

09:14 – 09:36 IP311  
**Management of biliary pancreatitis**  
Julia Mayerle, Germany

09:36 – 09:58 IP312  
**Management of fluid collections**  
Hjalmar C. van Santvoort, The Netherlands

Symposium	
08:30 – 10:00	Room C
<b>Screening for colorectal cancer across Europe</b>	
Chairs: Monika Ferlitsch, Austria Michal Filip Kaminski, Poland	



08:30 – 08:40 IP313  
**Overview on methodology**  
Adrian Saftoiu, Romania

08:40 – 08:50 IP314  
**The Central European experience**  
Evelien Dekker, The Netherlands

08:50 – 09:00 IP315  
**The Eastern European experience: Slovenia**  
Bojan Tepes, Slovenia

09:00 – 09:10 IP316  
**The Eastern European experience: Poland**  
Jaroslaw Regula, Poland

09:10 – 09:20 IP317  
**Health economics**  
Sophie Whyte, United Kingdom

09:20 – 09:30 IP318  
**Patients perspective**  
Jola Gore-Booth, United Kingdom

09:30 – 10:00  
**PANEL DISCUSSION**

Tuesday, October 23, 2018

Symposium	
08:30 – 10:00	Room E1
<b>Microscopic colitis: A neglected entity</b>	
Chairs: Michael A. Kamm, Australia James C. Lee, United Kingdom	



08:30 – 08:52	IP319
<b>Epidemiology</b>	
Andreas Münch, Sweden	

08:52 – 09:14	IP320
<b>Histopathology</b>	
Daniela Aust, Germany	

09:14 – 09:36	IP321
<b>Drug-induced microscopic colitis</b>	
Stephan Miehke, Germany	

09:36 – 09:58	IP322
<b>Treatment update</b>	
Anna Wickbom, Sweden	

Symposium	
08:30 – 10:00	Room E2
<b>From guidelines to clinical practice: Viral hepatitis</b>	
Chairs: Alessio Aghemo, Italy Jean-François Dufour, Switzerland	



	IP323
<b>Introduction into UEG Standards &amp; Guidelines activities</b>	
Wafaa Khannoussi, Morocco	

08:30 – 08:52	IP324
<b>Hepatitis B</b>	
Marcel Tantau, Romania	

08:52 – 09:14	IP325
<b>Hepatitis C</b>	
Vincent Leroy, France	

09:14 – 09:36	IP326
<b>Hepatitis D</b>	
Heiner Wedemeyer, Germany	

09:36 – 09:58	IP327
<b>Hepatitis A and E</b>	
Francesco Negro, Switzerland	

Symposium	
08:30 – 10:00	Room F1
<b>Pancreatic cancer: From bench to bedside</b>	
Chairs: Hana Algül, Germany Robert Sutton, United Kingdom	



08:30 – 08:52	IP328
<b>Rising Star: Research in pancreatic cancer: Stem cells</b> ★	
Alexander Kleger, Germany	

08:52 – 09:14	IP329
<b>Rising Star: Research in pancreatic cancer: Mice</b> ★	
Ilse Rooman, Belgium	

09:14 – 09:36	IP330
<b>Early diagnosis of pancreatic cancer</b>	
Thomas M. Gress, Germany	

09:36 – 09:58	IP331
<b>Novel concepts in locally advanced resectable pancreatic cancer</b>	
Marc G. H. Besselink, The Netherlands	

Symposium	
08:30 – 10:00	Room F2
<b>Diagnosis and management of malignant distal biliary obstruction</b>	
Chairs: Marianna Arvanitakis, Belgium Ioannis Papanikolaou, Greece	



08:30 – 08:52	IP332
<b>Diagnostic work-up: Avoiding the wrong diagnosis</b>	
Zoltan Gabor Szepes, Hungary	

08:52 – 09:14	IP333
<b>Endoscopic drainage: When and how</b>	
Benedetto Mangiavillano, Italy	

	IP334
<b>Tandem Talks</b>	
09:14 – 09:24	
<b>What to do when endoscopy fails? EUS guided drainage</b>	
Erwan Bories, France	

	IP335
09:24 – 09:34	
<b>What to do when endoscopy fails? Percutaneous transhepatic cholangiography (PTC)!</b>	
Andrea Phillips, United Kingdom	

	OP126
09:34 – 09:46	
<b>ANTIREFLUX METAL STENT VS. CONVENTIONAL COVERED METAL STENT FOR NONRESECTABLE DISTAL MALIGNANT BILIARY OBSTRUCTION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL</b>	
Tsuayoshi Hamada, Japan; Isayama H.; Nakai Y.; Iwashita T.; Ito Y.; Mukai T.; Yagioka H.; Saito T.; Togawa O.; Ryozaawa S.; Hirano K.; Mizuno S.; Yamamoto N.; Kogure H.; Yasuda I.; Koike K.	

09:46 – 09:58 OP127  
**EUS-GUIDED BILIARY DRAINAGE VERSUS ERCP FOR THE PRIMARY PALLIATION OF MALIGNANT BILIARY OBSTRUCTION: A MULTICENTER RANDOMIZED CLINICAL TRIAL**  
 Do Hyun Park, Republic of Korea; Paik W. H.; Lee T. H.; Choi J.-H.; Jang S.; Kim D.-U.; Kim S.-O.; Shim J. H.; Song T. J.; Lee S. S.; Seo D.-W.; Lee S. K.; Kim M.-H.

### Abstract-Based Session

08:30 – 10:00 Room G  
**Oesophageal disorders: Mechanisms and management**  
 Chairs: Manuele Furnari, Italy  
 Hubert Louis, Belgium

08:30 – 08:42 IP336  
**State-of-the-art introduction**  
 Hubert Louis, Belgium

08:42 – 08:54 OP128  
**HYPERCONTRACTILE (JACKHAMMER) ESOPHAGUS DEMONSTRATES EXCESSIVE EXCITATORY AND ABNORMAL INHIBITORY DYSFUNCTION ON PROVOCATIVE TESTING DURING HIGH RESOLUTION MANOMETRY (HRM)**  
 Farhan Quader, United States; Mauro A.; Ghisa M.; Edelman K.; Jha L.; Tolone S.; De Bortoli N.; Savarino E.; Penagini R.; Gyawali C. P.

08:54 – 09:06 OP129  
**MANAGEMENT OF SUPRAGASTRIC BELCHING: PREDICTORS OF SUCCESS AND FOLLOW UP OUTCOMES 6-12-MONTHS AFTER INITIAL TREATMENT WITH COGNITIVE BEHAVIOURAL THERAPY (CBT)**  
 Anastasi N.; Green A.; Wynter E.; Glasinovic E.; Hajek P.; Daniel Sifrim, United Kingdom

09:06 – 09:18 OP130  
**LARYNGOPHARYNGEAL REFLUX AND COUGH REFLEX SENSITIVITY** ✨  
 Martin Duricek, Slovakia; Banovcin P.; Nosakova L.; Hyrdel R.; Kollarik M.

09:18 – 09:30 OP131  
**ANTI-REFLUX ENDOSCOPIC SURGERY: ENDOSCOPIC CARDIOPLASTY USING ENDOSCOPIC MUCOSAL RESECTION MAY EFFECTIVELY TREAT REFRACTORY GASTRO-ESOPHAGEAL REFLUX DISEASE**  
 Eun Ju Jeong, Republic of Korea; Yoo I. K.; Kim W. H.; Hong S. P.; Cho J. Y.

09:30 – 09:42 OP132  
**EFFICACY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: ANALYSIS OF THE STEROID-REFRACTORY SUBGROUP FROM THE HEROES STUDY**  
 Evan Dellon, United States; Collins M.; Assouline-Dayan Y.; Evans L.; Gupta S.; Schoepfer A.; Straumann A.; Sfroneeva E.; Woo A.; Opiteck G.; Olson A.; Aranda R.; Rothenberg M.; Hirano I.

09:42 – 09:54 OP133  
**FIRST-LINE THERAPEUTIC OPTIONS AND EFFECTIVENESS RATES IN EUROPEAN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: INITIAL RESULTS FROM THE EOE CONNECT REGISTRY**  
 Emilio J Laserna-Mendieta, Spain; Santander C.; Savarino E.; Perelló A.; Barrio J.; Guagnozzi D.; Guardiola Arévalo A.; Asensio T.; de la Riva S.; Casabona-Francés S.; Lucendo A. J.

### Abstract-Based Session

08:30 – 10:00 Room K  
**Help! I've got a bleeder!**  
 Chairs: Ian Gralnek, Israel  
 Markus Peck-Radosavljevic, Austria

08:30 – 08:42 IP337  
**State-of-the-art introduction**  
 Markus Peck-Radosavljevic, Austria

08:42 – 08:54 OP134  
**APPROPRIATE USE OF RED BLOOD TRANSFUSION IN ACUTE LOWER GASTROINTESTINAL BLEEDING.**  
 Leticia Hernández, Spain; Martínez-Bauer E.; García-Iglesias P.; Machlab S.; Lira A.; Marmol C.; Libre G.; Da Costa J.; Brunet E.; Gallach M.; Melcarne L.; Puig-Divi V.; Junquera F.; Campo Fernandez R.; Calvet Calvo X.; Brullet E.

08:54 – 09:06 OP135  
**RISK OF POST-POLYPECTOMY BLEEDING WITH UNINTERRUPTED CLOPIDOGREL THERAPY: AN INDUSTRY INDEPENDENT, DOUBLE-BLIND, RANDOMIZED TRIAL**  
 Francis Ka-leung Chan, Hong Kong PRC; Kyaw M. H.; Hsiang J. C.; Suen B. Y.; Kee K. M.; Tse Y. K.; Ching J.; Cheong P. K.; Ng D.; Lam K. L. Y.; Ng S. C.

09:06 – 09:18 OP136  
**CAN PROPHYLACTIC ARGON PLASMA COAGULATION REDUCE DELAYED POST-PAPILLECTOMY BLEEDING? A PROSPECTIVE RANDOMIZED MULTICENTER TRIAL**  
 Tae Hoon Lee, Republic of Korea; Hyun J. J.; Lee Y.-N.; Choi J.-H.; Yang J.; Jeong S.; Kwon C.-I.; Choi H. J.; Moon J. H.; Park S.-H.

09:18 – 09:30 OP137  
**EUS GUIDED MULTI MODALITY TREATMENT OF PERIPANCREATIC PSEUDO-ANEURYSMS**  
 Piyush Somani, India; Sharma M.

09:30 – 09:42 OP138  
**HEMOSTATIC ENDOSCOPIC TREATMENT OF GASTRODUODENAL VARICES BY CHEMICAL GLUE MIXED WITH GLUCOSE SERUM: EXPERIENCE OF HASSAN II UNIVERSITY HOSPITAL CENTER**  
 Benjira R.; Omar Laalji, Morocco; Lamine Sejai A.; Lahlali M.; Abid H.; Nada L.; Aqodad N.; El Abkari M.; Ibrahim A.; Benajah D.-A.

09:42 – 09:54 OP139  
**EUS GUIDED THROMBOLYSIS OF PORTAL VENOUS SYSTEM**  
 Sharma M.; [Piyush Somani](#), India

#### Translational/Basic Science

08:30 – 10:00 Room M  
**Microbiota: Friends or foes?**  
 Chairs: Premysl Bercik, Canada  
 Mirjana Rajilic-Stojanovic, Serbia



08:30 – 08:52 IP338  
**Fungi and viruses: Neglected players?**  
 Harry Sokol, France

08:52 – 09:14 IP339  
**Microbiota: How do they contribute to homeostasis?**  
 Dirk Haller, Germany

09:14 – 09:36 IP340  
**How do bugs fool the host?**  
 Patrice Cani, Belgium

09:36 – 09:58 IP341  
**How to select the right microbiota for interventions?**  
 Fergus Shanahan, Ireland

#### Today's Science, Tomorrow's Medicine

08:30 – 10:00 Room 1.61/1.62  
**TSTM Abstract-based: Mechanisms of intestinal inflammation**  
 Chairs: Raja Atreya, Germany  
 Stefan Schreiber, Germany

08:30 – 08:42 OP140  
**FOOD-DERIVED BIOACTIVE PEPTIDE LUNASIN EXERTS AN IMMUNOMODULATORY ROLE IN THE HEALTHY HUMAN INTESTINAL MUCOSA**  
[Samuel Fernández-Tomé](#), Spain; [Indiano-Romacho P.](#); [Marin A .C.](#); [Ortega-Moreno L.](#); [Pérez-Rodríguez L.](#); [Casanova M. J.](#); [Moreno-Monteaquedo J. A.](#); [Santander C.](#); [Chaparro M.](#); [Gisbert J. P.](#); [Hernández-Ledesma B.](#); [Bernardo D.](#)

08:42 – 08:54 OP141  
**PREVENTIVE EFFECT OF SPONTANEOUS PHYSICAL ACTIVITY ON GUT-ADIPOSE TISSUE CROSS-TALK IN MICE MODEL MIMICKING CROHN'S DISEASE SUSCEPTIBILITY**  
[Maillard F.](#); [Vazeille E.](#); [Sauvanet P.](#); [Sirvent P.](#); [Bonnet R.](#); [Combaret L.](#); [Chausse P.](#); [Otero Y.](#); [Delcros G.](#); [Chavanelle V.](#); [Boisseau N.](#); [Nicolas Barnich](#), France

08:54 – 09:06 OP142  
**SMALL INTESTINAL EPITHELIAL ENDOPLASMIC RETICULUM STRESS DRIVES A MICROBIOTA-INDEPENDENT IGA RESPONSE THAT PREVENTS FROM EXTENSIVE SMALL INTESTINAL INFLAMMATION**  
[Joep Grootjans](#), United States; [Krupka N.](#); [Hosomi S.](#); [Matute J.](#); [Saveljeva S.](#); [Gensollen T.](#); [Ganal-Vonarburg S.](#); [Limenitakis J.](#); [Conner M. E.](#); [Glickman J.](#); [McKoy K.](#); [Macpherson A.](#); [Kaser A.](#); [Blumberg R. S.](#)

09:06 – 09:18 OP143  
**CATESTATIN AMELIORATES INTESTINAL INFLAMMATION BY ORCHESTRATING TIGHT JUNCTION DYNAMICS VIA STAT3-DEPENDENT PATHWAY**  
[Nour Eissa](#), Canada; [Hussein H.](#); [Bernstein C. N.](#); [Ghia J.-E.](#)

09:18 – 09:30 OP144  
**HPMSCS COTRANSPLANTED WITH CHITOSAN-IGF-1C HYDROGEL AMELIORATE TNBS-INDUCED COLITIS BY SECRETING PGE2**  
[Liyun Duan](#), China; [Cao X.](#); [Liu Y.](#); [Li Z.](#); [Hou H.](#); [Han Z.](#)

09:30 – 09:42 OP145  
**POLYUNSATURATED FATTY ACIDS INDUCE FERROPTOTIC INFLAMMATION IN THE INTESTINE ✦**  
[Lisa Mayr](#), Austria; [Grabherr F.](#); [Gehmacher T.](#); [Schwärzler J.](#); [Niederreiter L.](#); [Gerner R. R.](#); [Feistritzer C.](#); [Ran Q.](#); [Moschen A. R.](#); [Kaser A.](#); [Tilg H.](#); [Adolph T. E.](#)

09:42 – 09:54 OP146  
**EMERGING ROLE OF MIRNA-320 INDUCED BY IL-33 IN PROMOTING RECOVERY AND GUT MUCOSAL WOUND HEALING AFTER ACUTE COLITIS.**  
[Loris Riccardo Lopetuso](#), Italy; [De Salvo C.](#); [Di Martino L.](#); [Rana N.](#); [Goodman W.](#); [Scaldeferri F.](#); [Gasbarrini A.](#); [Pizarro T. T.](#)

#### Young GI Activity

08:30 – 10:00 Room N1  
**How to prepare a presentation**  
 Chairs: [Johan Burisch](#), Denmark  
[Grainne Holleran](#), Ireland



08:30 – 08:45 IP342  
**Preparation and structure: Create your presentation's storyboard**  
[Nathalie Rommel](#), Belgium

08:45 – 09:00 IP343  
**Visual aids and graphs: Transport the message of your data**  
[Georgina L. Hold](#), United Kingdom

09:00 – 09:15 IP344  
**Slide formatting: The art of simplicity**  
[Natalie Wood](#), United Kingdom

09:15 – 09:30 IP345  
**Stand and deliver: How to present well and capture the audience**  
 Mark Fox, Switzerland

09:30 – 09:45 IP346  
**Best and worst presentations of my life**  
 Bjorn Rembacken, United Kingdom

09:45 – 10:00  
**Questions and answers**

**Abstract-Based Session**

08:30 – 10:00 Room N2  
**Small bowel disorders**  
 Chairs: Mikko Pakarinen, Finland  
 Carmen Monica Preda, Romania

08:30 – 08:42 IP347  
**State-of-the-art introduction**  
 Mikko Pakarinen, Finland

08:42 – 08:54 OP147  
**CHRONIC INTESTINAL FAILURE: WHEN CHILDREN BECOME ADULTS**  
 Schubert L.; Boehm V.; [Francisca Joly](#), France; Billiauws L.

08:54 – 09:06 OP148  
**OUTCOMES OF TEDUGLUTIDE TREATMENT AT 6 MONTHS IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME AND CHRONIC INTESTINAL FAILURE: A NATIONWIDE FRENCH PROSPECTIVE OBSERVATIONAL COHORT STUDY**  
[Francisca Joly](#), France; Quilliot D.; Nuzzo A.; Beau P.; Chambrier C.; Poullenet F.; Armengol Debeir L.; Layec S.; Thibault R.; Boehm V.; Seguy D.; Schneider S.

09:06 – 09:18 OP149  
**EFFICACY AND SAFETY OF LANREOTIDE IN POSTOPERATIVE DUMPING SYNDROME: A PHASE III, DOUBLE-BLIND PLACEBO-CONTROLLED CROSS-OVER STUDY** ✨  
[Lucas Wauters](#), Belgium; Arts J.; Caenepeel P.; Tack J.; Vanuytsel T.; Bisschops R.

09:18 – 09:30 OP150  
**PROTEIN-LOSING ENTEROPATHY AFTER FONTAN SURGERY IS ASSOCIATED WITH LIVER DAMAGE AND HIGH LEVELS OF FECAL CALPROTECTIN: A CASE-CONTROL STUDY FROM A PROSPECTIVE DATABASE**  
[Luis Téllez](#), Sudan; Rodríguez de Santiago E.; Garrido Lestache E.; Aguilera Castro L.; Olavarria A.; Garrido E.; Gea Rodríguez F.; Romera R.; Del Cerro M. J.; Albillos Martínez A.

09:30 – 09:42 OP151  
**ORAL ANTIBIOTICS PREVENT INTESTINAL NECROSIS IN ACUTE MESENTERIC ISCHEMIA: A PROSPECTIVE COHORT STUDY.**  
[Alexandre Nuzzo](#), France; Maggiori L.; Cazals-Hatem D.; Paugam-Burtz C.; Hugué A.; Ronot M.; Becq A.; Castier Y.; Weiss E.; Joly F.; Panis Y.; Bouhnik Y.; Gault N.; Corcos O.

09:42 – 09:54 OP152  
**BOWEL PREPARATION FOR SMALL BOWEL CAPSULE ENDOSCOPY – THE LATER, THE BETTER!**  
 Xavier S.; [Bruno Rosa](#), Portugal; Monteiro S.; Arieira C.; Magalhães R.; Cúrdia Gonçalves T.; Carvalho P. B.; Magalhães J.; Moreira M. J.; Cotter J.

**Abstract-Based Session**

08:30 – 10:00 Room L7  
**Murine models of intestinal inflammation**  
 Chairs: Christoph Becker, Germany  
 Carla Felice, Italy

08:30 – 08:42 IP348  
**State-of-the-art introduction**  
 Christoph Becker, Germany

08:42 – 08:54 OP153  
**LOSS OF PTPN2 IN DENDRITIC CELLS PROMOTES T CELL ACTIVATION AND DIFFERENTIATION INTO TH1 CELLS BUT DOES NOT AFFECT REGULATORY T CELLS**  
[Larissa Hering](#), Switzerland; Katkeviciute E.; Gottier C.; Lang S.; Becher B.; Rogler G.; Scharl M.; Spalinger M. R.

08:54 – 09:06 OP154  
**LACK OF SUCNR1 PROTECTS FROM INTESTINAL FIBROSIS**  
[Jesus Cosin-Roger](#), Spain; Asensi-Canto P.; Ortiz-Masia D.; Macias-Ceja D.; Gisbert-Ferrandiz L.; Salvador P.; Hausmann M.; Rogler G.; Calatayud S.; Barrachina M. D.

09:06 – 09:18 OP155  
**RELEASE OF UNCONTROLLED ACTIVE ELASTASE BY INTESTINAL EPITHELIAL CELLS PARTICIPATES TO MUCOSAL INFLAMMATION IN IBD**  
[Celine Deraison](#), France; Rolland C.; Edir A.; Denadaï-Souza A.; Rousset P.; Bonnart C.; Motta J. P.; Alric L.; Bonnet D.; Vergnolle N.

09:18 – 09:30 OP156  
**LOSS OF PTPN2 IN DENDRITIC CELLS RESULTS IN REDUCED TUMOR BURDEN IN THE AOM/DSS COLON TUMOR MOUSE MODEL** ✨  
[Egle Katkeviciute](#), Switzerland; Hering L.; Scharl M.; Spalinger M. R.

09:30 – 09:42 OP157  
**TP53 MUTATION ENHANCES CELL PROLIFERATION AND STEMNESS IN HUMAN COLON EPITHELIAL ORGANOID AND PROMOTES A RESISTANCE AGAINST LONG-TERM INFLAMMATION.**  
[Sho Watanabe](#), Japan; Tsuchiya K.; Shirasaki T.; Hibiya S.; Nishimura R.; Katsukura N.; Oshima S.; Okamoto R.; Tetsuya N.; Watanabe M.

09:42 – 09:54 OP158  
**THE CHANGE OF THE TH17/TREG ON EXPERIMENTAL COLITIS MICE AND THE RESEARCH ABOUT PROTECTIVE EFFECT OF MICA**  
[Mengdie Shen](#), China; Zhang B.; Lv B.; Meng L.-N.

**Abstract-Based Session**

08:30 – 10:00 Room L8

**The gut-brain axis in the lower GI**Chairs: Lukas Van Oudenhove, Belgium  
Daniel Keszthelyi, The Netherlands

08:30 – 08:42 IP349

**State-of-the-art introduction**

Lukas Van Oudenhove, Belgium

08:42 – 08:54 OP159

**ELASTOLYTIC HOMEOSTASIS: A MAJOR COMPONENT OF COLONIC HYPERSENSITIVITY ASSOCIATED WITH IRRITABLE BOWEL SYNDROME**Castro M.; Rousset P.; Rolland C.; Motta J. P.; Edir A.; Bonnard C.; Vanner S.; Barbara G.; Cenac N.; Deraison C.; [Nathalie Vergnolle](#), France

08:54 – 09:06 OP160

**NO UNCONSCIOUS ATTENTIONAL BIAS FOR GI-SALIENT TERMS IN SUBJECTS WITH FUNCTIONAL GI DISORDERS OBJECTIVELY MEASURED BY ELECTROENCEPHALOGRAPHY (EEG)**Ejova A.; Talley N. J.; Holtmann G.; Koloski N. A.; Badcock N.; [Michael Jones](#), Australia

09:06 – 09:18 OP161

**ANTI-TNF-A ALTERS CONNECTIVITY BETWEEN INTRACEREBELLAR SENSORY CORTEX AND AMYGDALA IN CROHN'S DISEASE PATIENTS**[Marcus Gray](#), Australia; Chao C.-Y.; Talley N. J.; Galloway G.; Mountford C.; Holtmann G.

09:18 – 09:30 OP162

**PROLIFERATION AND MORPHOLOGICAL ALTERATIONS OF ENTERIC GLIA STIMULATED BY STRESS MEDIATORS ARE ASSOCIATED WITH INDUCTION OF NEURONAL ELONGATION FACTORS: POSSIBLE MECHANISM(S) OF VISCERAL HYPERSENSITIVITY IN THE ENTERIC NERVOUS SYSTEM**[Tominaga Kazunari](#), Japan; Yoshiko F.; Kazuhide H.

09:30 – 09:42 OP163

**UNDERSTANDING THE ROLE OF NEURO-IMMUNE INTERACTIONS AND NERVE SPROUTING IN PATIENTS WITH DIVERTICULAR DISEASE.**[Maria Raffaella Barbaro](#), Italy; Cremon C.; Fuschi D.; Scaiola E.; Marasco G.; Capelli E.; Festi D.; Stanghellini V.; Barbara G.

09:42 – 09:54 OP164

**GENETIC ASSOCIATIONS OF IRRITABLE BOWEL SYNDROME AND DEPRESSIVE DISORDER THROUGH WHOLE EXOME POOLED-SEQUENCING**[Shiwei Zhu](#), China; Wang Z.; Duan L.**Live Endoscopy**

10:30 – 12:00 Room A

**Live Endoscopy II**Chairs: Tomas Hucl, Czech Republic  
Horst Neuhaus, Germany  
Cristiano Spada, Italy  
Experts: Fabia Attili, Italy  
Pradeep Bhandari, United Kingdom  
Mariachiara Campanale, Italy  
Pierre Henri Deprez, Belgium  
Marc Giovannini, France  
Alberto Larghi, Italy  
Silvia Pecere, Italy  
Alessandro Repici, Italy*Transmission from the Gemelli Hospital in Rome, Italy***Symposium**

10:30 – 12:00 Room D

**Crash course: Non-bleeding upper GI emergencies**Chairs: Suzanne S. Gisbertz, The Netherlands  
Ian Gralnek, Israel

Moderator: Marianna Arvanitakis, Belgium



10:30 – 10:52 IP350

**Diagnosing upper GI perforations and ischemia**

Martina Scharitzer, Austria

**Debate**

10:52 – 11:02 IP351

**Perforations: Endoscopy can solve it**

Grigorios Paspatis, Greece

11:02 – 11:12 IP352

**Perforations: Always a surgical case?**

Ross Carter, United Kingdom

11:12 – 11:34 IP353

**Foreign bodies: A forgotten emergency**

Alexander Meining, Germany

11:34 – 11:56 IP354

**Treatment of caustic ingestions**

Mircea Chirica, France

**Symposium**

10:30 – 12:00 Room B

**Therapy update in ulcerative colitis**Chairs: Axel Dignass, Germany  
Iris Dotan, Israel

10:30 – 10:52 IP355

**Current standards in medical treatment**

Gerhard Rogler, Switzerland

10:52 – 11:14 IP356  
**Novel developments: Jak-inhibitors in medical treatment**  
 Marc Ferrante, Belgium

11:14 – 11:36 IP357  
**Faecal microbiota transplantation (FMT): Current value?**  
 Patrizia Katharina Kump, Austria

**Debate**  
 11:36 – 11:46 IP358  
**Surgery: Ileorectal anastomosis**  
 Pär Myrelid, Sweden

11:46 – 11:56 IP359  
**Surgery: Ileo-anal pouch anastomosis**  
 Janindra Warusavitarnne, United Kingdom

**Symposium**

10:30 – 12:00 Room C  
**European-Japanese perspectives: A novel endoscopic approach for benign digestive diseases – Commemorate the 10<sup>th</sup> anniversary of POEM**  
 Chairs: Thierry Ponchon, France  
 Hisao Tajiri, Japan



10:30 – 10:40 IP360  
**Development of POEM and its clinical impact for Achalasia**  
 Haruhiro Inoue, Japan

10:40 – 10:50 IP361  
**Clinical results of POEM: European experience**  
 Barbara A. J. Bastiaansen, The Netherlands

10:50 – 11:00 IP362  
**POET (STER) for SMT**  
 Hironari Shiwaku, Japan

11:00 – 11:10 IP363  
**Other endoscopic therapies for SMT**  
 Karel Caca, Germany

11:10 – 11:20 IP364  
**Endoscopic plicature for GORD**  
 Pietro Familiari, Italy

11:20 – 11:30 IP365  
**ARMS**  
 Hitomi Minami, Japan

**Symposium**

10:30 – 12:00 Room E1  
**What to blame in pancreatitis: Nature or nurture?**  
 Chairs: Peter Hegyi, Hungary  
 Jonas Rosendahl, Germany



10:30 – 10:52 IP366  
**Acute pancreatitis: It is all genetics!**  
 Markus M. Lerch, Germany

10:52 – 11:14 IP367  
**Acute pancreatitis: It is all enviromental!**  
 Robert Sutton, United Kingdom

11:14 – 11:36 IP368  
**Chronic pancreatitis: It is all genetics!**  
 Miklos Sahin-Toth, United States

11:36 – 11:58 IP369  
**Chronic pancreatitis: It is all enviromental!**  
 Vinciane Rebours, France

**Symposium**

10:30 – 12:00 Room E2  
**From guidelines to clinical practice: Barrett's oesophagus**  
 Chairs: Jacques J. Bergman, The Netherlands  
 Prateek Sharma, United States



IP370  
**Introduction into UEG Standards & Guidelines activities**  
 Hubert Louis, Belgium

10:30 – 10:52 IP371  
**ESGE guidelines on Barrett's oesophagus**  
 Bas L. A. M. Weusten, The Netherlands

10:52 – 11:14 IP372  
**American guidelines on Barrett's oesophagus**  
 Prateek Sharma, United States

11:14 – 11:36 IP373  
**How to treat dysplasia?**  
 Emmanuel Coron, France

**Debate**  
 11:36 – 11:46 IP374  
**Surveillance: Always!**  
 Oliver Pech, Germany

11:46 – 11:56 IP375  
**Surveillance: Not cost-effective in most cases!**  
 Krish Ragunath, United Kingdom

Tuesday, October 23, 2018



## Abstract-Based Session

10:30 – 12:00 Room F1  
**Clinical management and consequences of *H. pylori* eradication**  
 Chairs: Francis Megraud, France  
 Kentaro Sugano, Japan



10:30 – 10:42 IP376  
**State-of-the-art introduction**  
 Kentaro Sugano, Japan

10:42 – 10:54 OP165  
**SPANISH PRIMARY CARE SURVEY ON THE MANAGEMENT OF *H. PYLORI* INFECTION: PREFERENCES, ACCESS TO TECHNOLOGY, AND DECISIONS.**  
 Adrian Gerald McNicholl, Spain; Amador J.; Ricote Belinchon M.; Cañones-Garzón P. J.; Gene E.; Calvet Calvo X.; Gisbert J. P.

10:54 – 11:06 OP166  
**PCR TEST FOR HELICOBACTER PYLORI DETECTION AND CLARITHROMYCIN RESISTANCE PREDICTION ON FECAL AND BIOPTIC SAMPLES: COMPARISON OF ACCURACIES**  
 Pavoni M.; Turello G.; Saracino I. M.; Giulia Fiorini, Italy; Saccomanno L.; Lazzarotto T.; Vaira B.; Beckman E.

11:06 – 11:18 OP167  
**GENOTYPIC RESISTANCE GUIDED VERSUS EMPIRICAL THERAPY FOR REFRACTORY HELICOBACTER PYLORI INFECTION – A RANDOMIZED TRIAL**  
 Jyh-Ming Liou, Taiwan; Chen C.-C.; Lin J.-T.; El-Omar E.; Wu M.-S.

11:18 – 11:30 OP168  
**SHIFTS IN HUMAN GUT MICROBIOTA AFTER HELICOBACTER PYLORI ERADICATION THERAPY: SHORT AND LONG-TERM EFFECTS**  
 Dilyara Safina, Russian Federation; Markelova M.; Abdulkhakov S. R.; Grigoryeva T.; Boulygina E.; Malanin S.; Vasilyev I.; Siniagina M.; Abdulkhakov R.

11:30 – 11:42 OP169  
**THE IMPACT OF HELICOBACTER PYLORI INFECTION, ERADICATION THERAPY AND PROBIOTIC SUPPLEMENTATION ON GUT MICROENVIRONMENT HOMEOSTASIS: AN OPEN-LABEL, PROSPECTIVE CLINICAL TRIAL**  
 Luyi Chen, China; Xu W.; Huang B.; He J.; Wang L.; Chen S.

11:42 – 11:54 OP170  
**HELICOBACTER PYLORI ERADICATION THERAPY IN LOCALIZED GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A PROSPECTIVE, NATIONWIDE, MULTICENTER STUDY IN JAPAN**  
 Tari A.; Toshiro Sugiyama, Japan; Kitadai Y.; Oda I.; Nakamura S.; Sugizaki K.; Yoshino T.

## Symposium

10:30 – 12:00 Room F2  
**Quality in endoscopy**  
 Chairs: Raf Bisschops, Belgium  
 Michal Filip Kaminski, Poland



10:30 – 10:45 IP377  
**Current status of quality measurement in Europe**  
 Raf Bisschops, Belgium

10:45 – 11:07 IP378  
**How to facilitate electronic reporting**  
 Matthew David Rutter, United Kingdom

11:07 – 11:17 IP379  
**How to implement performance measures in your country: The Netherlands**  
 Evelien Dekker, The Netherlands

11:17 – 11:27 IP380  
**How to implement performance measures in your country: Portugal**  
 Miguel Areia, Portugal

11:27 – 11:37 IP381  
**How to implement performance measures in your country: Austria**  
 Elisabeth Waldmann, Austria

11:37 – 11:47 IP382  
**How to implement performance measures in your country: Russia**  
 Sergey V. Kashin, Russian Federation

11:47 – 12:00 IP383  
**What if you don't have electronic reporting in your hospital: The ESGE PM app**  
 Raf Bisschops, Belgium

## Abstract-based Session

10:30 – 12:00 Room G  
**IBD: From drug monitoring to immunogenicity**  
 Chairs: Yehuda Chowers, Israel  
 Tim Raine, United Kingdom

10:30 – 10:42 IP384  
**State-of-the-art introduction**  
 Yehuda Chowers, Israel

10:42 – 10:54 OP171  
**INDUCTION AND EARLY MAINTENANCE VEDOLIZUM-AB TROUGH LEVELS PREDICT MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE** ✦  
 Jurij Hanžel, Slovenia; Sever N.; Compennolle G.; Tops S.; Ferkolj I.; Štabuc B.; Smrekar N.; Koželj M.; Kurent T.; Novak G.; Gils A.; Drobne D.

10:54 – 11:06 OP172  
**MAINTENANCE LEVELS OF VEDOLIZUMAB DO NOT CORRELATE WITH CLINICAL REMISSION IN IBD PATIENTS** ✦  
Jenna Tessolini, Canada; Bajaj G.; Zezos P.; Silverberg M. S.

11:06 – 11:18 OP173  
**INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL**  
Xavier Roblin, France; Paul S.; Boschetti G.; Phelip J. M.; Deltedesco E.; Nancey S.; Williet N.; Flourie B.

11:18 – 11:30 OP174  
**PREDICTORS OF IMMUNOGENICITY TO ANTI-TNF THERAPY IN IBD: RESULTS OF THE ABIRISK STUDY**  
Matthieu Allez, France; Hassler S.; Carbonnel F.; Chowers Y.; Bouhnik Y.; Maria N.; Cadiot G.; Trang C.; Seksik P.; Buisson A.; Chanteloup E.; Nancey S.; Louis E.; Hebuterne X.; Simon M.; Szely N.; Gleizes A.; Hacein-Bey S.; Birchler M.; Hincelin-Mery A.; Deisenhammer F.; Pallardy M.; Broet P.

11:30 – 11:42 OP175  
**MAGNETIC RESONANCE ENTEROGRAPHY ASSESSMENT OF MUCOSAL HEALING WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE: RESULTS FROM THE VERSIFY STUDY**  
Jordi Rimola, Spain; Danese S.; Feagan B. G.; Sandborn W. J.; Colombel J. F.; Vermeire S.; Brennan K.; Yardibi O.; Jones S.; Siegelman J.

11:42 – 11:54 OP176  
**SOLUBLE MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 AND RETINOIC ACID ARE POTENTIAL TOOLS FOR THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A PROOF OF CONCEPT STUDY.**  
Stephane Paul, France; Nancey S.; Williet N.; Filippi J.; Berger A.-E.; Flourie B.; Roblin X.

**Abstract-Based Session**

10:30 – 12:00 Room K  
**Faecal transplantation in C. difficile: How to do it right?**  
 Chairs: Antonio Gasbarrini, Italy  
 Christoph Högenauer, Austria

10:30 – 10:42 IP385  
**State-of-the-art introduction**  
 Antonio Gasbarrini, Italy

10:42 – 10:54 OP177  
**DEVELOPING MICROBIOME RESTORATION BIOMARKERS FOR CLOSTRIDIUM DIFFICILE INFECTIONS: CONTINUED EVALUATION OF A PROTOTYPE MICROBIOME HEALTH INDEX**  
Ken Blount, United States; Jones C.; Deych E.; Shannon B.

10:54 – 11:06 OP178  
**TWO YEARS OF EXPERIENCES IN CLOSTRIDIODES DIFFICILE TREATMENT OF THE The Netherlands DONOR FECES BANK.**  
Elisabeth Mariko Terveer, The Netherlands; Ooijevaar R.; Hornung B. V. H.; Goorhuis A.; Vendrik K. E.; Bauer M. P.; Nood van E.; Van Beurden Y. H.; Verspaget H. W.; Keller J.; Kuijper E.

11:06 – 11:18 OP179  
**FROZEN DONOR STOOL FOR FECAL MICROBIOTA TRANSPLANTATION IS AS EFFECTIVE AS FRESH STOOL IN INDUCING RESPONSE AND REMISSION IN ACTIVE ULCERATIVE COLITIS.**  
Florian Rainer, Austria; Blesl A.; Petritsch W.; Wenzl H. H.; Baumann-Durchschein F.; Posch A.; Streit A.; Gorkiewicz G.; Gröchenig H. P.; Kump P. K.; Högenauer C.

11:18 – 11:30 OP180  
**A CULTUROMICS-BASED SYNTHETIC MICROBIOTA CONSORTIUM, DERIVED FROM SUCCESSFUL BACTERIAL ENGRAFTERS, IS A SAFE AND EFFECTIVE TREATMENT FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION: A PILOT STUDY**  
 Cammarota G.; Gianluca Janiro, Italy; Masucci L.; Quaranta G.; Paroni Sterbini F.; Simonelli C.; Maletesta L.; Gasbarrini A.; Sanguinetti M.

11:30 – 11:42 OP181  
**RANDOMISED CLINICAL TRIAL: SINGLE INFUSION-VERSUS MULTIPLE INFUSION-FAECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE CLOSTRIDIUM DIFFICILE INFECTION REFRACTORY TO ANTIBIOTICS**  
Gianluca Janiro, Italy; Masucci L.; Quaranta G.; Simonelli C.; Lopetuso L. R.; Napoli M.; Sanguinetti M.; Gasbarrini A.; Cammarota G.

11:42 – 11:54 OP182  
**A NON-FROZEN, LYOPHILIZED, ORAL MICROBIOTA-BASED DRUG RBX7455 IS SAFE, REDUCES CLOSTRIDIUM DIFFICILE INFECTION RECURRENCE, AND RESTORES THE MICROBIOME: CLINICAL EVIDENCE FROM 3 PATIENT COHORTS**  
Sahil Khanna, United States; Pardi D.; Gerding D.; Blount K.; Jones C.; Shannon B.; Deych E.

**Translational/Basic Science**  
 10:30 – 12:00 Room M  
**Functional disorders: Are they really functional?**  
 Chairs: Lin Chang, United States  
 Fermin Mearín, Spain

10:30 – 10:52 IP386  
**Visceral pain: Triggers and pathways**  
 Nathalie Vergnolle, France

Tuesday, October 23, 2018

10:52 – 11:14 IP387  
**Immune activation in FBD**  
 Guy E. Boeckstaens, Belgium

11:14 – 11:36 IP388  
**Microbiome-gut-brain axis**  
 Mirjana Rajilic-Stojanovic, Serbia

11:36 – 11:58 IP389  
**How does this translate into the clinic?**  
 Magnus Simrén, Sweden

**Today's Science, Tomorrow's Medicine**  
 10:30 – 12:00 Room 1.61/1.62  
**Intestinal regeneration: Is the gut the new liver?**  
 Chairs: Arthur Kaser, United Kingdom  
 Azucena Salas, Spain



10:30 – 10:52 IP390  
**Stem cell-derived organoids as genetic models for rare intestinal disorders and somatic mutations in colon cancer**  
 Henner Farin, Germany

10:52 – 11:14 IP391  
**Correlating the regenerative capacity to the response to treatment**  
 Raja Atreya, Germany

11:14 – 11:36 IP392  
**Autologous stem cell transplantation as a reset option?**  
 Matthieu Allez, France

11:36 – 11:58 IP393  
**Novel therapeutic strategies: Immunological reprogramming?**  
 Stefan Schreiber, Germany

**Abstract-Based Session**  
 10:30 – 12:00 Room N1  
**Cirrhosis: It's all about varices!**  
 Chairs: Guadalupe Garcia-Tsao, United States  
 Salvatore Piano, Italy

10:30 – 10:42 IP394  
**State-of-the-art introduction**  
 Guadalupe Garcia-Tsao, United States

10:42 – 10:54 OP183  
**TREATMENT OF GASTRIC FUNDAL VARICES WITH EUS GUIDED EMBOLISATION COMBINING COIL PLACEMENT WITH THROMBIN INJECTION**  
Chander Shekhar, United Kingdom; Orourke J.; Tripathi D.; Forde C.; Mahon B. S.

10:54 – 11:06 OP184  
**PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION OF LUSUTROMBOPAG, A NOVEL THROMBOPOIETIN RECEPTOR AGONIST, FOR TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING INVASIVE PROCEDURES**  
Takayuki Katsube, Japan; Shimizu R.; Fukuhara T.; Kano T.; Wajima T.

11:06 – 11:18 OP185  
**MEASUREMENT OF SPLENIC STIFFNESS IN THE PREDICTION OF ESOPHAGEAL VARICES AND THE RESPONSE TO CARVEDILOL THERAPY IN PORTAL HYPERTENSIVE PATIENTS**  
Mohammed Khorshid, Egypt; Elsharkawy A.; Hamza I.; Yosry A.

11:18 – 11:30 OP186  
**RANDOMISED TRIAL OF BALLOON-OCCLUDED RETROGRADE TRANSVENOUS OBLITERATION VERSUS CYANOACRYLATE INJECTION FOR PREVENTION OF GASTRIC VARICEAL REBLEEDING**  
Xuefeng Luo, China; Yang L.

11:30 – 11:42 OP187  
**FEASIBILITY OF DIRECT EUS GUIDED EMBOLISATION OF RECURRENT BLEEDING PARASTOMAL VARICES.**  
Chander Shekhar, United Kingdom; Orourke J.; Tripathi D.; Forde C.; Mahon B. S.

11:42 – 11:54 OP188  
**WITHDRAWN**

**Abstract-Based Session**  
 10:30 – 12:00 Room N2  
**New insights in cholestatic liver diseases**  
 Chairs: Marta Bento Afonso, Portugal  
 Tom Hemming Karlsen, Norway

10:30 – 10:42 IP395  
**State-of-the-art introduction**  
 Tom Hemming Karlsen, Norway

10:42 – 10:54 OP189  
**WITHDRAWN**

10:54 – 11:06 OP190  
**SURVIVAL OF PRIMARY SCLEROSING CHOLANGITIS: A POPULATION-BASED STUDY IN FINLAND.**  
Nina Barner-Rasmussen, Finland; Färkkilä M. A.

11:06 – 11:18 OP191  
**LIPIDOMICS ANALYSES IN BILE IDENTIFIED SEVERAL CANDIDATE BIOMARKERS FOR DIAGNOSIS AND DISEASE PROGRESSION OF PRIMARY SCLEROSING CHOLANGITIS AND BILIARY DYSPLASIA**  
Vidya Velagapudi, Finland; Pessia A.; Arola J.; Boyd S.; Jokelainen K.; Färkkilä M. A.

11:18 - 11:30 OP192  
**INFLUENCE OF ANTIBIOTIC DURATION IN CHOLANGITIS AFTER SUCCESSFUL DRAINAGE BY ERCP**  
 ten Böhmer B.; [Sylke Haal](#), The Netherlands; Balkema S.; Depla A. C. T. M.; Fockens P.; van Hooft J. E.; Jansen J. M.; Kuiken S. D.; Liberov B. I.; van Soest E.; Voermans R. P.

11:30 - 11:42 OP193  
**HUNTING THE ENVIRONMENTAL TRIGGER IN PRIMARY SCLEROSING CHOLANGITIS: DISEASE CLUSTERING WITH AFFLUENCE AND RURAL LOCATION**  
[Jessica Dyson](#), United Kingdom; Blain A.; Jones D. E. J.; Rushton S. P.; Hudson M.

11:42 - 11:54 OP194  
**DURABLE RESPONSE IN THE MARKERS OF CHOLESTASIS THROUGH 36 MONTHS OF OPEN-LABEL EXTENSION STUDY OF OBETICHOIC ACID IN PRIMARY BILIARY CHOLANGITIS**  
[Michael Trauner](#), Austria; Shiffman M.; Drenth J. P. H.; Bowlus C. L.; Vargas V.; Andreone P.; Pencek R.; Smoot Malecha E.; MacConell L.; Shapiro D.

**Symposium**

10:30 - 12:00 Room L7  
**Palliation in upper GI cancer**  
 Chairs: Mario Morino, Italy  
 Andrea Phillips, United Kingdom

10:30 - 10:52 IP396  
**Nutritional support**  
 Jann Arends, Germany

10:52 - 11:14 IP397  
**Endoscopy: Stents and beyond?**  
 Peter D. Siersema, The Netherlands

11:14 - 11:36 IP398  
**Chemo and/or radiotherapy?**  
 Anna Dorothea Wagner, Switzerland

11:36 - 11:58 IP399  
**Palliative surgery**  
 Bas P. L. Wijnhoven, The Netherlands

**Symposium**

10:30 - 12:00 Room L8  
**Contrast-enhanced ultrasound (CEUS) for clinical problem solving: Safer than CT/MR**  
 Chairs: Odd Helge Gilja, Norway  
 Adrian Saftoiu, Romania

10:30 - 10:52 IP400  
**New guidelines on CEUS**  
 Odd Helge Gilja, Norway

10:52 - 11:14 IP401  
**CEUS in pancreatic diseases**  
 Dieter Nuernberg, Germany

11:14 - 11:36 IP402  
**CEUS improves detection of liver metastasis**  
 Adrian Saftoiu, Romania

11:36 - 11:58 IP403  
**CEUS in IBD patients: Any value?**  
 Kim Nylund, Norway

**Symposium**

10:30 - 12:00 Room Hotspot  
**Precancerous conditions of the stomach**  
 Chair: Mario Dinis-Ribeiro, Portugal



10:30 - 10:33 IP404  
**Introduction**  
 Mario Dinis-Ribeiro, Portugal

10:33 - 10:38 IP405  
**Extension of intestinal metaplasia is the best marker of risk for gastric adenocarcinoma**  
 Cord Langner, Austria

10:38 - 10:53

**PANEL DISCUSSION**

10:53 - 10:58 IP406  
**Endoscopy is enough for the assessment of intestinal metaplasia extension**  
 Pedro Pimentel Nunes, Portugal

10:58 - 11:13

**PANEL DISCUSSION**

11:13 - 11:18 IP407  
**Serological risk assessment**  
 Marcis Leja, Latvia

11:18 - 11:33

**PANEL DISCUSSION**

11:33 - 11:38 IP408  
**Cost-effectiveness of follow-up**  
 Manon C. W. Spaander, The Netherlands

11:38 - 11:53

**PANEL DISCUSSION**

11:53 - 11:56 IP409  
**Conclusion**  
 Mario Dinis-Ribeiro, Portugal

**Case-Based Discussion**

12:45 - 13:45 Room G  
**Acute liver failure: Beyond the obvious**  
 Chair: Michael Manns, Germany  
 Experts: Patrizia Burra, Italy  
 Audrey Coilly, France  
 Michael Manns, Germany  
 Detlef Schuppan, Germany

**Case-Based Discussion**

12:45 – 13:45 Room K  
**Therapeutic management of patients with dyspeptic symptoms**  
 Chair: Jan Tack, Belgium  
 Experts: Guillaume Gourcerol, France  
 Jutta Keller, Germany  
 Vincenzo Stanghellini, Italy  
 Jan Tack, Belgium

**Case-Based Discussion**

12:45 – 13:45 Room M  
**Left lower quadrant pain: Acute diverticulitis**  
 Chair: Sebastiano Biondo, Spain  
 Experts: Sebastiano Biondo, Spain  
 Christianne Johanna Buskens, The Netherlands  
 Thomas Mang, Austria  
 Antonio Tursi, Italy

**Case-Based Discussion**

12:45 – 13:45 Room N1  
**Renal failure in cirrhosis**  
 Chair: Markus Peck-Radosavljevic, Austria  
 Experts: Rafael Banares, Spain  
 Christophe Moreno, Belgium  
 Markus Peck-Radosavljevic, Austria  
 Frank Tacke, Germany

**Young GI Activity**

13:00 – 14:00 Young GI Lounge  
**Career Chat: Women as educators**  
 Chairs: Øistein Hovde, Norway  
 Yasmijn van Herwaarden, The Netherlands  
 Experts: Carolina Ciacci, Italy  
 Martina Müller-Schilling, Germany  
 Gigi Veereman, Belgium

**Live Endoscopy**

14:00 – 15:30 Room A  
**Live Endoscopy III**  
 Chairs: Mario Dinis-Ribeiro, Portugal  
 Thierry Ponchon, France  
 Cristiano Spada, Italy  
 Experts: Federico Barbaro, Italy  
 Pradeep Bhandari, United Kingdom  
 Ivo Boskoski, Italy  
 Vincenzo Bove, Italy  
 Pierre Henri Deprez, Belgium  
 Marc Giovannini, France  
 Rosario Landi, Italy  
 Alessandro Repici, Italy



Transmission from the Gemelli Hospital in Rome, Italy

**Symposium**

14:00 – 15:30 Room D  
**Is precision medicine in IBD possible?**  
 Chairs: Ailsa Hart, United Kingdom  
 Michael A. Kamm, Australia



14:00 – 14:22 IP410  
**Rising Star: Genes and disease course** ★  
 James C. Lee, United Kingdom

14:22 – 14:44 IP411  
**Prediction of therapeutic responses**  
 Raja Atreya, Germany

**Debate**  
 14:44 – 14:54 IP412  
**Treat-to-target and tight monitoring: Pro**  
 Filip Baert, Belgium

14:54 – 15:04 IP413  
**Treat-to-target and tight monitoring: Con**  
 Iris Dotan, Israel

15:04 – 15:26 IP414  
**Strategies on the long term: Can we deescalate the treatment?**  
 Catherine Reenaers, Belgium

**Symposium**

14:00 – 15:30 Room B  
**Therapy update: Multimodality treatment of upper GI cancers**  
 Chairs: Mark Ivo van Berge Henegouwen, The Netherlands  
 Eric Van Cutsem, Belgium



**Tandem Talks**  
 14:00 – 14:10 IP415  
**Locally advanced oesophageal cancer: Treat**  
 Eric Van Cutsem, Belgium

14:10 – 14:20 IP416  
**Locally advanced oesophageal cancer: Wait and see**  
 Bas P. L. Wijnhoven, The Netherlands

14:20 – 14:42 IP417  
**Locally advanced gastric cancer**  
 Anna Dorothea Wagner, Switzerland

14:42 – 15:04 IP418  
**Upper GI cancer surgery**  
 Mark Ivo van Berge Henegouwen, The Netherlands

15:04 – 15:26 IP419  
**MALT lymphoma**  
 Markus Raderer, Austria

**Symposium**

14:00 – 15:30 Room C

**Liver cancer: New guidelines**  
 Chairs: Massimo Pinzani, United Kingdom  
 Heiner Wedemeyer, Germany



14:00 – 14:22 IP420

**Screening and diagnosis**  
 Markus Peck-Radosavljevic, Austria

14:22 – 14:44 IP421

**Curative treatments**  
 Peter Robert Galle, Germany

14:44 – 15:06 IP422

**Palliative treatments**  
 Thomas Decaens, France

15:06 – 15:28 IP423

**Open questions on the role of liver transplantation**  
 Patrizia Burra, Italy

**Symposium**

14:00 – 15:30 Room E1

**Crash course: When the liver starts talking**  
 Chairs: Beate Appenrodt, Germany  
 Jean-François Dufour, Switzerland  
 Moderator: Alessio Aghemo, Italy



14:00 – 14:22 IP424

**Jaundice**  
 George Dalekos, Greece

14:22 – 14:44 IP425

**Ascites**  
 Mária Papp, Hungary

14:44 – 15:06 IP426

**GI bleeding**  
 Dominique Thabut, France

15:06 – 15:28 IP427

**Liver failure**  
 Richard Moreau, France

**Symposium**

14:00 – 15:30 Room E2

**From guidelines to clinical practice: *H. pylori***  
 Chairs: Francis Megraud, France  
 Michael Vieth, Germany



IP428

**Introduction into UEG Standards & Guidelines activities**  
 Luigi Ricciardiello, Italy

14:00 – 14:22 IP429

**Maastricht V: The key recommendations on therapy**  
 Peter Malfertheiner, Germany

14:22 – 14:44 IP430

**Kyoto global consensus**  
 Kentaro Sugano, Japan

14:44 – 15:06 IP431

**ESPGHAN guideline update: What's new?**  
 Sibylle Koletzko, Germany

15:06 – 15:28 IP432

**What is the real practice in Europe: Choice and effectiveness of eradication therapies**  
 Javier Gisbert, Spain

**Abstract-Based Session**

14:00 – 15:30 Room F1

**IBD clinical trials I**  
 Chairs: Silvio Danese, Italy  
 Edouard Louis, Belgium

14:00 – 14:12 IP433

**State-of-the-art introduction**  
 Silvio Danese, Italy

14:12 – 14:24 OP195

**EFFICACY AND SAFETY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 2B STUDY U-ACHIEVE**  
William J. Sandborn, United States; Ghosh S.; Panés J.; Schreiber S.; D'Haens G.; Tanida S.; Siffledeen J.; Enejosa J.; Zhou W.; Othman A.; Huang B.; Higgins P. D. R.

14:24 – 14:36 OP196

**CANNABIS INDUCES CLINICAL RESPONSE BUT NO ENDOSCOPIC RESPONSE IN CROHN'S DISEASE PATIENTS**  
Timna Naftali, Israel; Bar-Lev Schlieder L.; Konikoff F.; Benjaminov F.; Lish I.; Sergeev I.; Ringel Y.

14:36 – 14:48 OP197

**TOFACITINIB 15 MILLIGRAMS TWICE DAILY FOR PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM 8-WEEK INDUCTION STUDIES OCTAVE INDUCTION 1 & AMP; 2**  
 Rubin D. T.; Motoya S.; Stefan Schreiber, Germany; Quirk D.; Nduaka C. I.; Lawendy N.; Woodworth D. A.; Wang W.; Su C.; Higgins P. D. R.

14:48 – 15:00 OP198  
**EFFICACY AND SAFETY OF GASTRO-RESISTANT PHOSPHATIDYLCHOLINE (LT-02) FOR INDUCTION OF REMISSION IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS REFRACTORY TO MESALAZINE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (PCG-2)**  
Axel Dignass, Germany; Reinisch W.; Horynski M.; Poyda O.; Armerding P.; Langhorst J.; Fellermann K.; Kühbacher T.; Novacek G.; Hasselblatt P.; Stein J.; Übel P.; Heinemann H.; Müller R.; Greinwald R.; Stremmel W.

15:00 – 15:12 OP199  
**A PHASE 3 STUDY OF VEDOLIZUMAB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: EFFECTS ON TIME TO DISEASE WORSENING AND TREATMENT FAILURE**  
Satoshi Motoya, Japan; Watanabe K.; Ogata H.; Kanai T.; Matsui T.; Suzuki Y.; Shikamura M.; Sugiura K.; Oda K.; Hori T.; Araki T.; Watanabe M.; Hibi T.

15:12 – 15:24 OP200  
**ROLE OF CONCOMITANT IMMUNOSUPPRESSION IN THE EFFICACY AND SAFETY OF USTEKINUMAB: POST-HOC ANALYSES OF UNITI**  
Subrata Ghosh, United Kingdom; Sattin B.; Jacobstein D.; Gao L. L.; Gasink C.; Rutgeerts P.; Hanauer S. B.

#### Symposium

14:00 – 15:30 Room F2  
**Screening for upper GI cancer**  
 Chairs: Miguel Areia, Portugal  
 Naohisa Yahagi, Japan



14:00 – 14:22 IP434  
**Population-based and risk-based screening**  
 Manon C. W. Spaander, The Netherlands

14:22 – 14:44 IP435  
**Screening for squamous cell carcinoma**  
 Reza Malekzadeh, Iran

14:44 – 15:06 IP436  
**Screening for Barrett's neoplasia**  
 Jesper Lagergren, Sweden

15:06 – 15:28 IP437  
**Screening for gastric cancer**  
 Marcis Leja, Latvia

#### Symposium

14:00 – 15:30 Room G  
**Therapeutic EUS: Drainage and beyond**  
 Chairs: Marco J. Bruno, The Netherlands  
 Maria Chiara Petrone, Italy

14:00 – 14:22 IP438  
**Pancreatic collections**  
 Santhi Swaroop Vege, United States

14:22 – 14:44 IP439  
**Biliary access and drainage**  
 Manuel Pérez-Miranda, Spain

14:44 – 15:06 IP440  
**Pancreatic duct drainage**  
 Jan Werner Poley, The Netherlands

15:06 – 15:28 IP441  
**Ablative therapies**  
 Marc Barthet, France

#### Abstract-Based Session

14:00 – 15:30 Room K  
**Managing colorectal polyps**  
 Chairs: Anna Mackiewicz, Poland  
 Helmut Messmann, Germany

14:00 – 14:12 IP442  
**State-of-the-art introduction**  
 Helmut Messmann, Germany

14:12 – 14:24 OP201  
**COLD SNARE POLYPECTOMY IS SAFE YET UNDER-UTILISED: AN ANALYSIS OF 281,194 POLYPECTOMIES BY UK ENDOSCOPY TRAINEES OVER 9 YEARS**  
David James Tate, Australia; Wheatley D.; Anderson J.; Dunckley P.

14:24 – 14:36 OP202  
**LONG TERM RATES OF SURGERY AND ADENOMA RECURRENCE ARE SIMILAR FOR LATERALLY SPREADING LESIONS RESECTED EN BLOC OR BY PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION**  
David James Tate, Australia; Awadie H.; Desomer L.; Sidhu M.; Burgess N.; Hourigan L. F.; Moss A.; Raftopoulos S.; Singh R.; Brown G.; Bourke M. J.

14:36 – 14:48 OP203  
**A NEW METHOD OF ENDOSCOPIC RESECTION FOR COLORECTAL ADENOMA, "UNDERWATER COLD SNARE POLYPECTOMY": A PROPENSITY SCORE MATCHING ANALYSIS WITH CONVENTIONAL COLD SNARE POLYPECTOMY**  
Daisuke Maruoka, Japan; Matsumura T.; Arai M.; Ishikawa K.; Akizue N.; Okimoto K.; Nakagawa T.; Kato N.

14:48 – 15:00 OP204  
**ENDOSCOPIC FULL THICKNESS RESECTION IN THE COLON: 3-YEAR MULTICENTRE UK EXPERIENCE**  
Imdadur Rahman, United Kingdom; Hu M.; Ishaq S.; Bhandari P.; Pugh S.; Green S.; Suzuki N.; Hopper A.; Martin J.; Thomas-Gibson S.; Patel P.; Boger P.

15:00 – 15:12 OP205  
**LIMITATIONS OF ENDOSCOPIC RESECTION FOR COLORECTAL SUBMUCOSAL INVASIVE CARCINOMA ARISING IN SESSILE SERRATED ADENOMA/POLYP**  
Takashi Murakami, Japan; Sakamoto N.; Ritsuno H.; Tajima Y.; Ueyama H.; Matsumoto K.; Shibuya T.; Yao T.; Nagahara A.

15:12 – 15:24 OP206  
**ENDOSCOPIC RESECTIONS IN INFLAMMATORY BOWEL DISEASE**  
 Sreedhari Thayalasekaran, United Kingdom; Alkandari A.; Bhandari M.; Przybysz A.; Bugajski M.; Kandiah K.; Subramaniam S.; Maselli R.; Galtieri P.; Spychalski M.; Hayee B.; Haji A.; Kaminski M. F.; Repici A.; Bhandari P.

**Translational/Basic Science**

14:00 – 15:30 Room M  
**The mucosal immune system: Novel insights**  
 Chairs: Geert D'Haens, The Netherlands  
 Philip Rosenstiel, Germany



14:00 – 14:22 IP443  
**Ontogeny of the intestinal immune system: Novel insights**  
 Charlotte Scott, Belgium

14:22 – 14:44 IP444  
**Exhaustion of the immune system: Consequences for disease**  
 Eoin F. McKinney, United Kingdom

14:44 – 15:06 IP445  
**Tissue environment and tumour fate**  
 Christoph Becker, Germany

15:06 – 15:28 IP446  
**New roles for neutrophils in disease (NETs)**  
 Moritz Leppkes, Germany

**Today's Science, Tomorrow's Medicine**

14:00 – 15:30 Room 1.61/1.62  
**Coeliac disease: Model of intestinal disease?**  
 Chairs: Georgia Malamut, France  
 Alexander R. Moschen, Austria



14:00 – 14:22 IP447  
**Cellular mechanism responsible for gluten-specific effect**  
 Michael Schumann, Germany

14:22 – 14:44 IP448  
**Bypassing the strict gluten free diet**  
 Detlef Schuppan, Germany

14:44 – 15:06 IP449  
**Type II refractory sprue and lymphomagenesis in coeliac disease**  
 Nadine Cerf-Bensussan, France

15:06 – 15:28 IP450  
**Refractory coeliac disease type II: Current concepts**  
 Chris J. J. Mulder, The Netherlands

**Symposium**

14:00 – 15:30 Room N1  
**EU funding opportunities in digestive health**  
 Chairs: Arthur Kaser, United Kingdom



14:00 – 14:10 IP451  
**UEG: Facilitator in pan-European digestive health research**  
 Arthur Kaser, United Kingdom

14:10 – 14:25 IP452  
**Writing a successful ERC Advanced Grant application**  
 Guy E. Boeckstaens, Belgium

14:25 – 14:40 IP453  
**Writing a successful Marie-Curie-Fellowship application**  
 Camille Danne, France

14:40 – 14:55 IP454  
**Writing a successful International Training Network application**  
 Paul Enck, Germany

14:55 – 15:10 IP455  
**Relevant Horizon 2020 calls in gastroenterology and hepatology: How to find them and how to apply**  
 Ameli Schwalber, Germany

15:10 – 15:25 IP456  
**Discussion audience - best practice experts**

15:25 – 15:30 IP457  
**Take home messages**  
 Arthur Kaser, United Kingdom

**Abstract-Based Session**

14:00 – 15:30 Room N2  
**Endoscopic submucosal dissection: When the going gets tough**  
 Chairs: Diogo Libânio Monteiro, Portugal  
 Hisao Tajiri, Japan

14:00 – 14:12 IP458  
**State-of-the-art introduction**  
 Hisao Tajiri, Japan

14:12 – 14:24 OP219  
**VONOPRAZAN FOR PREVENTING POST-ESD BLEEDING SHOULD BE FIRST ADMINISTERED SHORTLY AFTER ESD**  
 Yuhei Sakata, Japan; Kushiya N.; Nakahira A.; Yamamoto K.; Yasui Y.; Ochiai T.; Nakahara K.; Hirata N.; Suekane T.; Sugimori S.; Yamasaki T.; Nebiki H.

14:36 – 14:48 OP221  
**ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC TUMORS UNDER THE CONTINUOUS ADMINISTRATION OF ANTICOAGULANTS** ✨  
 Taisuke Obata, Japan; Takenaka R.; Kawai D.; Takei K.; Miura K.; Takemoto K.; Tsugeno H.; Fujiki S.



14:48 – 15:00 OP222  
**THE SIMPLENESS AND EASINESS OF HEMOSTASIS IN ENDOSCOPIC SUBMUCOSAL DISSECTION USING DUAL RED IMAGING**  
Ai Fujimoto, Japan; Akimoto T.; Kiguchi Y.; Nakayama A.; Ochiai Y.; Maehata T.; Goto O.; Kato M.; Sasaki M.; Uraoka T.; Yahagi N.

15:00 – 15:12 OP223  
**EFFICACY OF ORAL MIXTURE OF HYDROCORTISONE SODIUM SUCCINATE AND ALUMINUM PHOSPHATE GEL FOR THE PREVENTION OF STRICTURE AFTER &#8805;2/3 CIRCUMFERENTIAL ENDOSCOPIC SUBMUCOSAL DISSECTION(ESD) FOR ESOPHAGEAL CANCER**  
Yonghui Huang, China; Yan X.; Nie D.

15:12 – 15:24 OP224  
**A RANDOMIZED CONTROLLED ANIMAL STUDY TO EVALUATE THE TECHNICAL FEASIBILITY OF CHEMICALLY ASSISTED SUBMUCOSAL DISSECTION TECHNIQUE WITH THE CONTINUOUS APPLICATION OF MESNA**  
Akio Koizumi, Japan

#### Abstract-Based Session

14:00 – 15:30 Room L7  
**From bench to the bedside in pancreatic cancer**  
 Chairs: Alexander Kleger, Germany  
 Sebastian Krug, Germany

14:00 – 14:12 IP459  
**State-of-the-art introduction**  
 Sebastian Krug, Germany

14:12 – 14:24 OP207  
**INTERNATIONAL VALIDATION OF THE 8TH EDITION AMERICAN JOINT COMMITTEE ON CANCER (AJCC) TNM STAGING SYSTEM IN PATIENTS WITH RESECTED PANCREATIC CANCER**  
Stijn van Roessel, The Netherlands; Kasumova G.; Verheij J.; Najarian R.; Maggino L.; De Pastena M.; Malleo G.; Marchegiani G.; Salvia R.; Ng S. C.; de Geus S.; Lof S.; Giovinazzo F.; van Dam J.; Kent T.; Busch O. R. C.; Groot Koerkamp B.; Abu Hilal M.; Bassi C.; Tseng J.; Besselink M. G. H.

14:24 – 14:36 OP208  
**THE ROLE OF GASTROKINE 1, A GASTRIC TUMOR SUPPRESSOR, IN PANCREATIC CARCINOGENESIS**  
Sabrina Steiner, Switzerland; Seleznik G. M.; Reding T.; Gupta A.; Lenggenhager D.; Endhardt K.; Graf R.

14:36 – 14:48 OP209  
**EXPRESSION OF TN ANTIGEN PROMOTES PANCREATIC CARCINOGENESIS IN A TRANSGENIC MOUSE MODEL**  
Baris Mercanoglu, Germany; Wolters-Eisfeld G.; Güngör C.; Izbicki J. R.; Bockhorn M.

14:48 – 15:00 OP210  
**AN Ro-RESECTABLE, GENETICALLY ENGINEERED MOUSE MODEL OF PANCREATIC CANCER MIMICS THE RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN HUMAN PANCREATIC CANCER**  
Carmen Mota-Reyes, Germany; Mundt B.; Brooks J.; Konukiewitz B.; Kühnel F.; Friess H.; Ceyhan G. O.; Demir I. E.

15:00 – 15:12 OP211  
**SITE-SPECIFIC ANGIOGENESIS MAY PROMOTE ISOLATED PULMONARY METASTASIS IN PANCREATIC CANCER**  
Theresa Krauss, Germany; Teller S.; Friess H.; Ceyhan G. O.; Demir I. E.

15:12 – 15:24 OP212  
**IDENTIFICATION OF PERINEURAL INVASION-PROMOTING GENETIC ALTERATIONS IN PANCREATIC CANCER VIA PIGGYBAC-TRANSPOSON-MUTAGENESIS**  
Pavel Stupakov, Germany; Teller S.; Rad R.; Friess H.; Ceyhan G. O.; Demir I. E.

#### Abstract-Based Session

14:00 – 15:30 Room L8  
**Barrett's oesophagus: Pathogenesis and biomarkers**  
 Chairs: Massimiliano di Pietro, United Kingdom  
 Jacques J. Bergman, The Netherlands

14:00 – 14:12 IP460  
**State-of-the-art introduction**  
 Massimiliano di Pietro, United Kingdom

14:12 – 14:24 OP213  
**BARRETT'S METAPLASIA ORIGINATES FROM HOXA13-POSITIVE CELLS IN THE GASTRO-ESOPHAGEAL JUNCTION**  
Vincent Janmaat, The Netherlands; Spaander M. C. W.; Verhaar A. P.; Silva R.; Phillips W.; Magierowski M.; Van Der Winkel A.; Stadler S.; Sandoval-Guzmán T.; van der Laan L.; Kuipers E. J.; Fuhler G.; Smits R.; Bruno M. J.; Clemons N.; Peppelenbosch M.

14:24 – 14:36 OP214  
**NOTCH SIGNALING PROMOTES PROGRESSION FROM BARRETT ESOPHAGUS TO ADENOCARCINOMA THROUGH NFKB SIGNALING**  
Frederik Wein, Germany; Kunze B.; Fang H.-Y.; Anand A.; Baumeister T.; Ingermann J.; Wang T. C.; Abrams J. A.; Quante M.

14:36 – 14:48 OP215  
**SHORTENING OF TELOMERES ACCELERATES CARCINOGENESIS IN A MOUSE MODEL FOR BARRETT'S ESOPHAGUS AND EMERGES AS A BIOMARKER FOR PROGRESSION TO ESOPHAGEAL ADENOCARCINOMA**  
Vincenz Sahn, Germany; Maurer C.; Anand A.; Wang T. C.; Schmid R. M.; Quante M.

14:48 – 15:00 OP216  
**MINICHROMOSOMAL MAINTENANCE COMPONENT COMPLEX 5 (MCM5) AS A MARKER OF BARRETT'S OESOPHAGUS RELATED NEOPLASIA – A FEASIBILITY STUDY**

Martin Everson, United Kingdom; Magee C.; Alzoubaidi D.; Brogden S.; Graham D.; Lovat L. B.; Haidry R. J.

15:00 – 15:12 OP217  
**PREDICTION IN SURVEILLANCE OF BARRETT'S ESOPHAGUS: THE EFFECT OF MULTIPLE MEASUREMENTS OF BIOMARKERS ON THE ESTIMATED NEOPLASTIC PROGRESSION RISK**

Carlijn A. M. Roumans, The Netherlands; Spaander M. C. W.; Lansdorp-Vogelaar I.; Biermann K.; Bruno M. J.; Steyerberg E. W.; Rizopoulos D.

15:12 – 15:24 OP218  
**OMEPRAZOLE INHIBITS CDX2 AND SOX9 EXPRESSION THROUGH EFFECTS ON HEDGEHOG SIGNALING AND BMP4 SIGNALING IN BARRETT'S ESOPHAGUS CELLS**  
Hua Xiong, China; Huang J.; Liu H.; Fang J.; Hong J.

### Symposium

14:00 – 15:30 Room Hotspot  
**Clinical trials revisited: Redefining the management of patients with decompensated cirrhosis and PBC**  
 Chair: Michael Manns, Germany



14:00 – 14:15 IP461  
**Trial presentation: Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial**  
 Salvatore Piano, Italy

14:15 – 14:30 IP462  
**Critical review**  
 Rafael Banares, Spain

14:30 – 14:45  
**PANEL DISCUSSION**

Rafael Banares, Spain  
 Audrey Coilly, France  
 Christophe Moreno, Belgium  
 Salvatore Piano, Italy

14:45 – 15:00 IP463  
**Trial presentation: A placebo-controlled trial of bezafibrate in primary biliary cholangitis**  
 t.b.a.

15:00 – 15:15 IP464  
**Critical review**  
 Annarosa Floreani, Italy

15:15 – 15:30  
**PANEL DISCUSSION**

Annarosa Floreani, Italy  
 Peter L. M. Jansen, The Netherlands  
 Ana Lleo, Italy

### Young GI Activity

14:00 – 15:30 Young GI Lounge  
**The "European Specialty Examination in Gastroenterology and Hepatology": An important step in becoming a gastroenterologist**  
 Chairs: Henriette Heinrich, Switzerland  
 Radislav Nakov, Bulgaria

14:00 – 14:05 IP465  
**Introduction**  
 Henriette Heinrich, Switzerland

14:05 – 14:25 IP466  
**What is the EBGH exam?**  
 Zeljko Krznaric, Croatia

14:25 – 14:45 IP467  
**What is an EBGH accredited centre and how to become one?**  
 Isabelle Cremers, Portugal

14:45 – 15:00 IP468  
**Tough but doable: A personal view on the exam**  
 Anthea Pisani, Malta

15:00 – 15:30 IP469  
**PANEL DISCUSSION**

**How to succeed at the EBGH exam - a survivor's guide**

### Symposium

15:45 – 17:15 Room A  
**Endoscopic management of complications after upper GI surgery**  
 Chairs: Edward Despott, United Kingdom  
 Pietro Familiari, Italy



### Tandem Talks

15:45 – 15:55 IP470  
**Upper GI leaks: Endoscopic treatment**  
 Alexander Meining, Germany

15:55 – 16:05 IP471  
**Upper GI leaks: Sugical treatment**  
 Suzanne S. Gisbertz, The Netherlands

16:05 – 16:27 IP472  
**Endoscopic stitching of leaks: Fiction or fact?**  
 Vincent Huberty, Belgium

16:27 – 16:49 IP473  
**Endosponge treatment of leaks**  
 Stefan Seewald, Switzerland

16:49 – 17:11 IP474  
**Treatment strategies in stenosis**  
 Jeanin E. van Hooft, The Netherlands

### Symposium

15:45 – 17:15 Room D  
**Long-term management and surveillance of IBD**  
 Chairs: Matthieu Allez, France  
 Tine Jess, Denmark



15:45 – 16:07 IP475  
**Surveillance in primary sclerosing cholangitis: Colon and biliary tract**  
 Martti A. Färkkilä, Finland

### Tandem Talks

16:07 – 16:17 IP476  
**Surveillance of disease progression in Crohn's disease: Radiology**  
 Stuart Taylor, United Kingdom

16:17 – 16:27 IP477  
**Surveillance of disease progression in Crohn's disease: Gastroenterology**  
 Johan Burisch, Denmark

16:27 – 16:49 IP478  
**Risks with immunosuppressants and biologics**  
 Laurent Beaugerie, France

16:49 – 17:11 IP479  
**Management in the elderly**  
 Guillaume Savoye, France

### Symposium

15:45 – 17:15 Room B  
**Therapy update: Cannulation techniques in ERCP**  
 Chairs: Leena Kylänpää, Finland  
 Jan Werner Poley, The Netherlands



15:45 – 16:07 IP480  
**Biliary access: Standard and advanced techniques**  
 Thierry Ponchon, France

16:07 – 16:29 IP481  
**ERCP in altered anatomy: Don't get lost!**  
 Lars Aabakken, Norway

16:29 – 16:51 IP482  
**Pancreatic access techniques: Major and minor papilla**  
 Jacques Deviere, Belgium

16:51 – 17:13 IP483  
**How to avoid post procedural pancreatitis**  
 Aron Vincze, Hungary

### Symposium

15:45 – 17:15 Room C  
**Experiences of quality assessment in upper GI**  
 Chairs: Helmut Messmann, Germany  
 Mark Ivo van Berge Henegouwen, The Netherlands



15:45 – 16:07 IP484  
**Pathology: Results of quality assessment**  
 Michael Vieth, Germany

16:07 – 16:29 IP485  
**Upper GI endoscopy: Where do we stand in quality assessment?**  
 Miguel Areia, Portugal

16:29 – 16:51 IP486  
**Surgery: Results from the UK upper GI cancer audit**  
 Mark Ivo van Berge Henegouwen, The Netherlands

16:51 – 17:13 IP487  
**Patients reported outcome measures: What can we do with the results?**  
 Pedro Pimentel Nunes, Portugal

### Abstracts on Fire

15:45 – 17:15 Room E1  
**Champion session in surgery and endoscopy**  
 Chairs: Marianna Arvanitakis, Belgium  
 Ian Jenkins, United Kingdom



15:45 – 15:55 OP225  
**LAPAROSCOPIC VERSUS OPEN PANCREATODUODENECTOMY (LEOPARD-2): A MULTICENTER, PATIENT-BLIND-ED, RANDOMIZED CONTROLLED TRIAL** ✦  
 Jony van Hilst, The Netherlands; de Rooij T.; Bosscha K.; Brinkman D.; van Dieren S.; Dijkgraaf M. G. W.; Gerhards M. F.; de Hingh I.; Karsten T.; Lips D. J.; Luyer M.; Busch O. R. C.; Festen S.; Besselink M. G. H.

15:55 – 16:05 OP226  
**A STEP-UP APPROACH OR OPEN NECROSECTOMY FOR NECROTIZING PANCREATITIS: LONG-TERM OUTCOMES OF A RANDOMIZED TRIAL**  
 Robbert Anne Hollemans, The Netherlands; Bakker O. J.; Boermeester M. A.; Bollen T.; Bosscha K.; Bruno M. J.; Buskens E. J.; Dejong C. H. C.; Van Duijvendijk P.; van Eijck C. H. J.; Fockens P.; Goor H. V.; van Grevenstein W. M. U.; van der Harst E.; Heisterkamp J.; Hesselink E.; Hofker S.; Houdijk A.; Karsten T.; Kruyt P. M.; van Laarhoven C.; Lameris J.; van Leeuwen M. S.; Manusama E.; Molenaar I. Q.; Nieuwenhuijs V.; Ramshorst B. V.; Roos D.; Rosman C.; Schaapherder A.; van der Schelling G.; Timmer R.; Verdonk R. C.; de Wit R.; Gooszen H.; Besselink M. G. H.; van Santvoort H. C.

16:05 – 16:15 OP227  
**WIRE-GUIDED BILIARY CANNULATION IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY: A PROSPECTIVE RANDOMIZED COMPARISON BETWEEN MICRO AND CONVENTIONAL GUIDEWIRE**  
 Akihiro Mori, Japan; Ito S.; Hayashi S.; Shibuya T.; Hachiya H.; Yumura T.; Ohashi N.

16:15 – 16:25 OP228  
**MOTORIZED SPIRAL ENTEROSCOPY: FINAL RESULTS A TWO-CENTER PROSPECTIVE CLINICAL TRIAL**  
 Torsten Beyna, Germany; Arvanitakis M.; Schneider M.; Van Gossum A.; Deviere J.; Neuhaus H.

16:25 – 16:35 OP229  
**REAL-TIME ARTIFICIAL INTELLIGENCE “FULL COLO-NOSCOPY WORKFLOW” FOR AUTOMATIC DETECTION FOLLOWED BY OPTICAL BIOPSY OF COLORECTAL POLYPS**  
 Michael Byrne, Canada; Soudan F.; Henkel M.; Oertel C.; Chapados N.; Echague F.; Hamidi Ghalehjeh S.; Guizard N.; Giguere S.; Macphail M.; Sullivan A.; Chandelier F.; Rex D.

16:35 – 16:45 OP230  
**OPTICAL DIAGNOSIS OF DIMINUTIVE POLYPS IN THE DUTCH CRC SCREENING PROGRAM: ARE WE READY TO START?**  
 Alouisa J. P. van de Wetering, The Netherlands; Bogie R. M. M.; Reumkens A.; Meulen L. W. T.; Winkens B.; Cheng H. R.; Straathof J. W. A.; Keulen E.; Bakker M.; Hoge C. V.; de Ridder R.; Masclee A.; Sanduleanu-Dascalescu S.

16:45 – 16:55 OP231  
**WITHDRAWN**

16:55 – 17:05 OP232  
**SIMPLE ENDOSCOPIC TREATMENT OF ADENOMA RECURRENCE AFTER WIDE FIELD ENDOSCOPIC MUCOSAL RESECTION IS EFFECTIVE: A PROSPECTIVE STUDY OF 1558 LESIONS WITH LONG TERM FOLLOW UP**  
 David James Tate, Australia; Desomer L.; Awadie H.; Sidhu M.; Burgess N. G.; Bourke M. J.

17:05 – 17:15 OP233  
**BLEEDING DURING ENDOSCOPIC SUBMUCOSAL DISSECTION: A RANDOMISED CONTROLLED TRIAL OF A NOVEL HAEMOSTATIC AGENT** ✨  
 Sharmila Subramaniam, United Kingdom; Kandiah K.; Thayalasekaran S.; Longcroft-Wheaton G.; Bhandari P.

**Symposium**

15:45 – 17:15 Room E2  
**From guidelines to clinical practice: Cystic pancreatic lesions - differential diagnosis and management**  
 Chairs: Marco Del Chiaro, Sweden  
 Thomas M. Gress, Germany



IP488  
**Introduction into UEG Standards & Guidelines activities**  
 Andreas Sturm, Germany

15:45 – 16:07 IP489  
**Case presentation: Cystic pancreatic lesions**  
 Djuna L. Cahen, The Netherlands

16:07 – 16:29 IP490  
**Differential diagnosis through morphological imaging**  
 Celso Matos, Belgium

**Debate**

16:29 – 16:39 IP491  
**Pathology is the standard**  
 Irene Esposito, Germany

16:39 – 16:49 IP492  
**Biomarkers are the standard**  
 Anne Marie Lennon, United States

16:49 – 17:11 IP493  
**IPMN: From sidebranch to main duct**  
 Philippe Lévy, France

**Abstracts on Fire**

15:45 – 17:15 Room F1  
**IBD on fire**  
 Chairs: James C. Lee, United Kingdom  
 Britta Siegmund, Germany

15:45 – 15:55 OP234  
**DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF CT-P13 (INFLIXIMAB): MAINTENANCE SUBCUTANEOUS ADMINISTRATION MAY ELICIT LOWER IMMUNOGENICITY COMPARED TO INTRAVENOUS TREATMENT**  
 Shomron Ben-Horin, Israel; Reinisch W.; Ye B. D.; Westhovens R.; Yoo D. H.; Lee S. J.; Lee S. Y.; Kim M. R.; Schreiber S.

15:55 – 16:05 OP235  
**NOVEL PROTEIN BIOMARKERS IN SERUM EXTRACELLULAR VESICLES FOR THE DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) IN PATIENTS WITH ULCERATIVE COLITIS (UC)**  
Ainhoa Lapitz, Spain; Arbelaz A.; Azkargorta M.; Krawczyk M.; Santos-Laso Á.; Perugorria M. J.; Jimenez-Aguero R.; Lacasta A.; Ibarra C.; Sanchez-Campos A.; Gonzalez E.; Lammert F.; Milkiewicz P.; Marzoni M.; Marin J. J.; Hemming Karlsen T.; Falcon-Perez J.; Chaparro M.; Gisbert J. P.; Elortza F.; Bujanda Fernández de Piérola L.; Bañales J. M.

16:05 – 16:15 OP236  
**IMPROVEMENT IN PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 52-WEEK DATA FROM THE CELEST STUDY**  
Laurent Peyrin-Biroulet, France; Louis E.; Loftus Jr E.; Lee W.-J.; Cataldi F.; Lacerda A.; Ghosh S.

16:15 – 16:25 OP237  
**DEEP MURAL HISTOLOGICAL ALTERATIONS AT ILEAL RESECTION MARGINS ARE ASSOCIATED WITH A HIGHER RISK OF POST-OPERATIVE ENDOSCOPIC RECURRENCE IN CROHN'S DISEASE**  
Nassim Hammoudi, France; Cazals-Hatem D.; Gardair C.; Ngollo M.; Auzolle C.; Nancey S.; Pariente B.; Buisson A.; Treton X.; Fumery M.; Fléjou J.-F.; Bezault M.; Remind S. G.; Seksik P.; Le Bourhis L.; Allez M.

16:25 – 16:35 OP238  
**TIME TO THERAPEUTIC INTERVENTION FOLLOWING ILEOCECAL RESECTION COMPARED TO INFlixIMAB FOR ILEOCECAL CROHN'S DISEASE: LONG-TERM FOLLOW UP OF THE LIRIC TRIAL**  
Toer Stevens, The Netherlands; Haasnoot L. M.; D'Haens G. R.; Buskens C. J.; de Groof E. J.; Bemelman W. A.; Ponsioen C. Y.

16:35 – 16:45 OP239  
**PRESENCE OF MUCOSA-ASSOCIATED ESCHERICHIA COLI, ESPECIALLY ADHERENT-INVASIVE E. COLI, ON THE SURGICAL SPECIMEN IN ILEAL CROHN'S DISEASE AS A GOOD PREDICTOR OF ENDOSCOPIC POSTOPERATIVE RECURRENCE: A STUDY FROM THE REMIND GROUP**  
Nicolas Barnich, France; Buisson A.; Auzolle C.; Rodrigues M.; Stefanescu C.; Nancey S.; Desreumaux P.; Marteau P.; Fumery M.; Sokol H.; Treton X.; Seksik P.; Allez M.

16:45 – 16:55 OP240  
**MOLECULAR PROFILING OF ULCERATIVE COLITIS PATIENTS FROM THE TURANDOT TRIAL UNCOVERS NOVEL PHARMACODYNAMIC AND CLINICAL EFFICACY BIOMARKERS AND A MECHANISTIC RATIONALE FOR A NON-MONOTONIC DOSE RESPONSE**  
Mina Hassan-Zahraee, United States; Xi L.; O'Neil S.; Lee J.; Stewart Z.; Zhan Y.; Zhao S.; Zhang Y.; Huang A.; Page K.; Zhang B.; Gorelick K.; Ziemek D.; Fitz L.; Cataldi F.; Vincent M.; von Schack D.; Pradhan V.; Hung K.; Zhou H.

16:55 – 17:05 OP241  
**PRO-INFLAMMATORY/PRO-FIBROTIC MACROPHAGES MAY ACT AS A SOURCE OF WNT2B IN INTESTINAL TISSUE FROM B3 CROHN'S DISEASE PATIENTS**  
Pedro Salvador Escribano, Spain; Macias Ceja D. C.; Navarro-Vicente F.; Alos R.; Gisbert Ferrándiz L.; Cosin Roger J.; Calatayud S.; Barrachina M. D.; Ortiz Masia D.

17:05 – 17:15 OP242  
**A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY**  
William J. Sandborn, United States; Peyrin-Biroulet L.; Trokan L.; Zhang J.; Kühbacher T.; Chiorean M.; Lee S.; Vermeire S.; Yacyshyn B.; Naik S. U.; Klassen P.; Panés J.

### Symposium

15:45 – 17:15 Room F2  
**Rome IV: Has it changed clinical practice?**  
 Chairs: Fermin Mearín, Spain  
 Magnus Simrén, Sweden



### Debate

15:45 – 15:55 IP494  
**Functional oesophageal disorders: Pro**  
 Frank Zerbib, France

15:55 – 16:05 IP495  
**Functional oesophageal disorders: Con**  
 Arjan Bredenoord, The Netherlands

### Debate

16:05 – 16:15 IP496  
**Functional gastroduodenal disorders: Pro**  
 Vincenzo Stanghellini, Italy

16:15 – 16:25 IP497  
**Functional gastroduodenal disorders: Con**  
 Peter Malfertheiner, Germany

**Debate**

16:25 – 16:35

IP498

**Functional bowel disorders: Pro**  
Brian Lacy, United States

16:35 – 16:45

IP499

**Functional bowel disorders: Con**  
Viola Andresen, Germany

**Debate**

16:45 – 16:55

IP500

**Functional anorectal disorders: Pro**  
Giuseppe Chiarioni, Italy

16:55 – 17:05

IP501

**Functional anorectal disorders: Con**  
Emma Carrington, United Kingdom

**Late Breaking Abstracts**

15:45 – 17:15

Room G

Late breaking abstracts III

**Abstract-Based Session**

15:45 – 17:15

Room K

**Evaluation of colorectal cancer screening programmes**  
Chairs: Marek Bugajski, Poland  
Michal Zorniak, Poland

15:45 – 15:57

IP502

**State-of-the-art introduction**  
Marek Bugajski, Poland

15:57 – 16:09

OP243

**THE EFFECT OF THE TWO-WEEK WAIT REFERRAL SYSTEM ON THE DETECTION OF AND MORTALITY FROM COLORECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OVER 90000 PATIENTS.**  
Ella Mozdiak, United Kingdom; Wedeselassie Y.; McFarlane M.; Tabuso M.; Widlak M. M.; Dunlop A.; Arasardnam R.

16:09 – 16:21

OP244

**RESULTS OF THE DUTCH FIT-BASED COLORECTAL CANCER SCREENING PROGRAM IN 2016: IMPACT OF INCREASING THE CUT-OFF LEVEL ON PARTICIPATION AND YIELD IN THE SECOND ROUND**  
Arthur Kooyker, The Netherlands; Toes-Zoutendijk E.; Spaander M. C. W.; Dekker E.; Buskermolen M.; van Vuuren A. J.; Kuipers E. J.; Van Kemenade J.; Thomeer M. G. J.; van Veldhuizen H.; Nagtegaal I. D.; Velthuisen M. F.; Ramakers C.; van Ballegooijen M.; de Koning H.; van Leerdam M.; Lansdorp-Vogelaar I.

16:21 – 16:33

OP245

**COST-UTILITY ANALYSIS OF COLONOSCOPY OR FAECAL IMMUNOCHEMICAL TEST FOR COLORECTAL CANCER SCREENING**

Miguel Areia, Portugal; Fuccio L.; Hassan C.; Dekker E.; Dias-Pereira A.; Dinis-Ribeiro M.

16:33 – 16:45

OP246

**PREDICTION OF ADVANCED COLONIC NEOPLASM IN SYMPTOMATIC PATIENTS: A SCORING SYSTEM BASED ON THE FAECAL IMMUNOLOGICAL TEST TO PRIORITIZE COLONOSCOPY IN THE FAST-TRACK REFERRAL SYSTEM (COLONOFIT STUDY)**

Fernando Fernández-Bañares, Spain; Clèries R.; Boadas J.; Ribes J.; Oliva J. C.; Alsius A.; Sanz X.; Martínez-Bauer E.; Galter S.; Pujals M.; Pujol M.; del Pozo P.; Campo R.

16:45 – 16:57

OP247

**POST COLONOSCOPY COLORECTAL CANCER IN THE ENGLISH NATIONAL HEALTH SERVICE BOWEL CANCER SCREENING PROGRAMME**

Edmund Derbyshire, United Kingdom; Nickerson C.; Wright S.; Moores B.; Morris E.; Valori R.; Rutter M. D.

16:57 – 17:09

OP248

**HIGH-RISK LESIONS ARE A STRONGER PREDICTOR FOR INTERVAL CANCER THAN ADENOMA DETECTION RATE**  
Elisabeth Waldmann, Austria; Sinkovec H.; Heinze G.; Penz D.; Majcher B.; Hinterberger A.; Trauner M.; Ferlitsch M.

**Translational/Basic Science**

15:45 – 17:15

Room M

**Novel insights in colorectal cancer**  
Chairs: Rodrigo Jover Martínez, Spain  
Thomas Wirth, Germany



15:45 – 16:07

IP503

**Screening for colorectal cancer**  
David Lieberman, United States

16:07 – 16:29

IP504

**Molecular taxonomy of colorectal cancer**  
Pierre Laurent-Puig, France

16:29 – 16:51

IP505

**Immune classification of colorectal cancer**  
Wolf Hervé Fridman, France

16:51 – 17:13

IP506

**When and how to test for MSI?**  
Magali Svrcek, France

## Today's Science, Tomorrow's Medicine

15:45 - 17:15

Room 1.61/1.62

**Regeneration of the intestinal microbiota: FMT and beyond**Chair: Antonio Gasbarrini, Italy  
Dirk Haller, Germany

15:45 - 16:07

IP507

**Which environmental and host factors determine our microbiota?**

Doris Vandeputte, Belgium

16:07 - 16:29

IP508

**FMT donor selection: Selecting the perfect donor for each individual**

Marie Joossens, Belgium

16:29 - 16:51

IP509

**Ulcerative colitis: Promising FMT strategies to induce remission**

Michael A. Kamm, Australia

16:51 - 17:13

IP510

**Clostridium difficile: State of the art for FMT and current standards**

Gianluca Ianaro, Italy

## Symposium

15:45 - 17:15

Room N1

**Classifications of gastric cancer: From laboratory to clinical practice**Chairs: Cord Langner, Austria  
Marcis Leja, Latvia

15:45 - 16:07

IP511

**Molecular classification of gastric cancer**

Tamara Matysiak Budnik, France

16:07 - 16:29

IP512

**Clinical consequences from molecular testing**

Thomas Seufferlein, Germany

16:29 - 16:51

IP513

**Is immunotherapy applicable in gastric cancer?**

Eric Van Cutsem, Belgium

16:51 - 17:13

IP514

**Genetic testing for hereditary gastric cancer**

Carla Oliveira, Portugal

## Abstract-Based Session

15:45 - 17:15

Room N2

**Artificial intelligence: The rise of the machines**Chairs: Sergey V. Kashin, Russian Federation  
Enrique Perez-Cuadrado-Robles, Belgium

15:45 - 15:57

IP515

**State-of-the-art introduction**

Sergey V. Kashin, Russian Federation

15:57 - 16:09

OP249

**AUTOMATIC DETECTION OF EARLY GASTRIC CANCER IN ENDOSCOPIC IMAGES USING A TRANSFERRING CONVOLUTIONAL NEURAL NETWORK**Keisuke Hori, Japan; Takemoto S.; Sakai Y.; Shinmura K.; Yoda Y.; Ohno Y.; Ikematsu H.; Yokota H.; Yano T.

16:09 - 16:21

OP250

**CAN ARTIFICIAL INTELLIGENCE USING CONVOLUTIONAL NEURAL NETWORKS DIAGNOSE ESOPHAGEAL CANCER.**Yoshimasa Horie, Japan; Yoshio T.; Aoyama K.; Fujisaki J.; Tada T.

16:21 - 16:33

OP251

**THE ARGOS PROJECT: FIRST RESULTS OF A DEEP LEARNING ALGORITHM FOR THE DETECTION OF BARRETT NEOPLASIA.**Jeroen de Groof, The Netherlands; van der Putten J.; van der Sommen F.; Zinger S.; Curvers W. L.; Bisschops R.; Pech O.; Meining A.; Neuhaus H.; Schoon E. J.; de With P.; Bergman J. J.

16:33 - 16:45

OP252

**NOVEL COMPUTER-ASSISTED SYSTEM FOR THE DETECTION AND CLASSIFICATION OF COLORECTAL POLYPS USING ARTIFICIAL INTELLIGENCE**Tsuyoshi Ozawa, Japan; Ishihara S.; Fujishiro M.; Tanimoto T.; Kumagai Y.; Shichijo S.; Aoyama K.; Tada T.

16:45 - 16:57

OP253

**COMPUTERIZED IMAGE ANALYSIS MAY PREDICT DELAYED BLEEDING AFTER COLONIC ENDOSCOPIC MUCOSAL RESECTION**Shaleve Y.; Sabo E.; Bourke M.; Amir Klein, Israel

16:57 - 17:09

OP254

**NOVEL COMPUTER-AIDED DIAGNOSIS SYSTEM USING CONVOLUTIONAL NEURAL NETWORKS FOR ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS**Junichi Shibata, Japan; Ozawa T.; Ishihara S.; Fujishiro M.; Matsuo K.; Saito H.; Kumagai Y.; Shichijo S.; Aoyama K.; Tada T.

## Abstract-Based Session

15:45 - 17:15

Room L7

**Obesity and nutrition**Chairs: Heidi Staudacher, Australia  
Annieke C. G. van Baar, The Netherlands

15:45 - 15:57

IP516

**State-of-the-art introduction**

Heidi Staudacher, Australia

15:57 - 16:09

OP255

**ENDOGENOUS GLP-1 AFFECTS CENTRAL REGULATION OF APPETITE IN HEALTHY LEAN MALES**Anne Christin Meyer-Gerspach, Switzerland; Ly H. G.; Beglinger C.; Van Oudenhove L.; Wölnerhanssen B.

16:09 – 16:21 OP256  
**ENDOSCOPIC SLEEVE GASTROPLASTY (ESG): A METABOLIC PROCEDURE**  
Ludovica Guerriero, France; Fiorillo C.; Vix M.; Boskoski I.; Bove V.; Quero G.; Mutter D.; Marescaux J.; Costamagna G.; Perretta S.

16:21 – 16:33 OP257  
**SAFETY, TOLERABILITY AND EFFICACY OF A NOVEL SELF-USE BIODEGRADABLE DEVICE FOR OBESITY**  
Haim Shirin, Israel; Abramowich D.; Matalon S.; Maliar A.; Shahar E.; Broide E.

16:33 – 16:45 OP258  
**EFFICACY OF A TAILORED HELICOBACTER PYLORI ERADICATION THERAPY BASED ON BODY WEIGHT IN OBESE PATIENTS**  
Oscar Laudanno, Argentina; Ahumarán G.; Gollo C. P.; Thome M.; Mastruzzo M.; Gonzalez P.

16:45 – 16:57 OP259  
**EFFECTS OF DIETARY FIBRES ON INDOMETHACIN-INDUCED INTESTINAL PERMEABILITY IN ELDERLY: A RANDOMISED PLACEBO CONTROLLED PARALLEL CLINICAL TRIAL** ✦  
John-Peter Ganda Mall, Sweden; Fart F.; Sabet J.; Lindqvist C.-M.; Keita Å. V.; Brummer R. J.; Schoultz I.

16:57 – 17:09 OP260  
**PERCUTANEOUS TRANSESOPHAGEAL GASTROTUBING (PTEG) AS THE SUITABLE PROCEDURE FOR THE PATIENTS THAT PERCUTANEOUS ENDOSCOPIC GASTROTOMY (PEG) INSERTION IS CONTRAINDICATED**  
Masato Murakami, Japan; Nishino K.; Okamoto T.; Muakami S.; Mori K.; Murakami B.; Azuma M.; Tanabe S.; Kida M.; Koizumi W.

**Abstract-Based Session**

15:45 – 17:15 Room L8  
**New therapeutic approach in pancreatitis**  
 Chairs: Johanna Laukkarinen, Finland  
 József Maléth, Hungary

15:45 – 15:57 IP517  
**State-of-the-art introduction**  
 Johanna Laukkarinen, Finland

15:57 – 16:09 OP261  
**PMCA PUMP DYSFUNCTION CAUSES CA2+ OVERLOAD AND PANCREATIC DUCTAL EPITHELIAL CELL DAMAGE IN CYSTIC FIBROSIS**  
Tamara Madacsy, Hungary; Varga A.; Schmidt A.; Fanczal J.; Pallagi P.; Rakonczay Z.; Hegyi P.; Razga Z.; Kleger A.; Nemeth I.; Gray M.; Maléth J.

16:09 – 16:21 OP262  
**HIGH FAT DIET AND ANTIBIOTICS INCREASE PATHOBIOME-ASSOCIATED MORTALITY IN EXPERIMENTAL NECROTIZING PANCREATITIS**  
Fons F. van den Berg, The Netherlands; van Dalen D.; Hyoju S. K.; Zaborina O.; Boermeester M. A.; Alverdy J. C.

16:21 – 16:33 OP263  
**GENETIC INHIBITION OF CYCLOPHILIN D PROTECTS AGAINST BILE ACID OR ETHANOL AND FATTY ACID INDUCED PANCREATIC DUCTAL EPITHELIAL CELL DAMAGE IN MICE** ✦  
Emese Tóth, Hungary; Maléth J.; Erdős R.; Závogyán N.; Tretter L.; Horváth G.; Rakonczay Z. J.; Hegyi P.

16:33 – 16:45 OP264  
**NNOS INHIBITION RELIEVES PAIN IN CHRONIC PANCREATITIS**  
Ihsan Ekin Demir, Germany; Heinrich T.; Carty D. G.; Saricaoglu Ö. C.; Klauss S.; Diakopoulos K. N.; Lesina M.; Algül H.; Friess H.; Ceyhan G. O.

16:45 – 16:57 OP265  
**PERICYTES ENHANCE NEUROGENESIS IN PANCREATIC CANCER**  
Laura Fangmann, Germany; Teller S.; Friess H.; Ceyhan G. O.; Demir I. E.

16:57 – 17:09 OP266  
**HIGH EXPRESSION OF SERUM EXOSOMAL MIR-21-5P IN TYPE 1 AUTOIMMUNE PANCREATITIS**  
Koh Nakamaru, Japan; Tomiyama T.; Ikeura T.; Uchida K.; Okazaki K.

**Symposium**

15:45 – 17:15 Room Hotspot  
**Non-IBD colitis**  
 Chairs: Christoph Högenauer, Austria  
 Edouard Louis, Belgium



15:45 – 16:07 IP518  
**Update on ischemic colitis**  
 Armando Peixoto, Portugal

16:07 – 16:29 IP519  
**Enterocolitis in the immunocompromised patient**  
 Georgia Malamut, France

16:29 – 16:51 IP520  
**Segmental colitis associated with diverticulosis**  
 Antonio Tursi, Italy

16:51 – 17:13 IP521  
**Drug-induced colitis**  
 Franck Carbonnel, France



## Scientific Programme by Day Wednesday, October 24, 2018

Symposium	
08:30 – 10:00	Room D
<b>Crash course: Perianal Crohn's disease</b>	
Chairs: Matthieu Allez, France Janindra Warusavitarne, United Kingdom	
Moderator: Britta Siegmund, Germany	



### Tandem Talks

08:30 – 08:40 IP522

#### Clinical approach

Josef Watfah, United Kingdom

08:40 – 08:50 IP523

#### Imaging: MRI

Elleke Dresen, Belgium

08:50 – 09:12 IP524

#### Combined stepwise approach: Gastroenterology

Geert D'Haens, The Netherlands

09:12 – 09:34 IP525

#### Combined stepwise approach: Surgery

Antonino Spinelli, Italy

09:34 – 09:56 IP526

#### New treatment modalities: Stem cells and other

Gert Van Assche, Belgium

### Advances in Clinical GI & Hepatology

08:30 – 10:00 Room E1

#### Advances in cholestatic liver diseases

Chairs: Jesús M. Bañales, Spain  
Marco Marzioni, Italy



08:30 – 08:52 IP527

#### New therapeutic options: PBC

Marco Marzioni, Italy

08:52 – 09:14 IP528

#### New therapeutic options: PSC

Michael Trauner, Austria

09:14 – 09:36 IP529

#### Rising Star: Modulating bile acid transporters in intestine and liver to treat metabolic and inflammatory diseases

Stan van de Graaf, The Netherlands

09:36 – 09:58 IP530

#### Managing symptoms

Annarosa Floreani, Italy

### Video Case Session

08:30 – 10:00 Room E2

#### Video case-based session

Chairs: Lars Aabakken, Norway  
Tomas Hucl, Czech Republic

08:30 – 08:39 VC01

#### ENDOSCOPIC APPENDICEAL FECALITH EXTRACTION BY NOTES TECHNIQUE

Bing L.; Zhou P.-H.; Yun-Shi Zhong, China

08:39 – 08:48 VC02

#### JEJUNAL DIVERTICULUM: A RARE CAUSE OF LIFE-THREATENING MIDGUT BLEEDING SUCCESSFULLY TREATED BY DOUBLE-BALLOON ENTEROSCOPY (DBE) (WITH VIDEO)

Lazaridis N.; Murino A.; Telese A.; Nikolaos Koukias, United Kingdom; Hayashi Y.; Despott E. J.

08:48 – 08:57 VC03

#### FIRST REPORT OF A COMBINED RESECTION TECHNIQUE USING A NOVEL NON-THERMAL, AUTOMATED MECHANICAL RESECTION SYSTEM OF A GIANT, FIBROTIC, CIRCUMFERENTIAL LESION INVOLVING THE WHOLE DUODENAL BULB (WITH VIDEO)

Alberto Murino, United Kingdom; Lazaridis N.; Telese A.; Koukias N.; Hayashi Y.; Despott E. J.

08:57 – 09:06 VC04

#### UNDERWATER PANCREATOSCOPY THROUGH THE DUCT OF SANTORINI: DIRECT VISUAL GUIDED BIOPSIES OF AN INTESTINAL-TYPE IPMN.

Roberto Di Mitri, Italy; Conte E.; Mocciano F.; Magro B.; Bonaccorso A.; Unti E.; Scibetta N.

09:06 – 09:15 VC05

#### ENDOSCOPIC TREATMENT OF A DIVERTICULAR OESOPHAGEAL DUPLICATION

Landi R.; Gibiino G.; Pietro Familiari, Italy; Mangiola F.; D'Aversa F.; Bove V.; Boskoski I.; Perri V.; Tringali A.; Costamagna G.

09:15 – 09:24 VC06

#### INTRALUMINAL SUBMUCOSAL MYOTOMY FOR TREATMENT OF MID-OESOPHAGEAL DIVERTICULAE ASSOCIATED WITH OESOPHAGEAL MOTILITY DISORDERS

Mayanaaz Sidhu, Australia; Tate D. J.; Bourke M. J.

09:24 – 09:33 VC07

#### A COMBINATION OF ENDOSCOPIC TECHNIQUES FOR MANAGEMENT OF BURIED BUMPER SYNDROME

Nikolaos Lazaridis, United Kingdom; Murino A.; Telese A.; Koukias N.; Despott E. J.

09:33 – 09:42 VC08  
**THE BRIDGING METHOD ASSOCIATED WITH A PERCUTANEOUS DRAINAGE OF THE LATERAL LIVER PART IN THE SAME OPERATIVE TIME**  
Coline Bosshardt, France; Caillof F.; Bories E.; Presenti C.; Ratone J. P.; Giovannini M.

09:42 – 09:51 VC09  
**A CASE OF A BILIARY CAST SYNDROME MIMICKING INTRAHEPATIC CHOLANGIOCARCINOMA.**  
William Soub Defeu, Belgium; Mostafa I.; Boon N.; El Koulali M.; Gustot T.; Moreno C.; Degre D.; Pezzullo M.; Lucidi V.; Arvanitakis M.; Eisendrath P.; Le Moine O.; Deviere J.; Lemmers A.

09:51 – 10:00 VC10  
**RECTAL BAND LIGATION FOR THE TREATMENT OF RADIATION PROCTITIS (WITH VIDEO)**  
Benedetto Mangiavillano, Italy; Bianchetti M.; Eusebi L. H.; Semeraro R.; Repici A.

#### Symposium

08:30 – 10:00 Room F1  
**New insights in the diagnosis of cystic pancreatic lesions**  
 Chairs: Celso Matos, Belgium  
 Santhi Swaroop Vege, United States



#### Tandem Talks

08:30 – 08:40 IP531  
**Morphology of pancreatic cysts: Cross-sectional imaging**  
 Raneem Albazaz, United Kingdom

08:40 – 08:50 IP532  
**Morphology of pancreatic cysts: EUS**  
 Ulrike Walburga Denzer, Germany

08:50 – 09:12 IP533  
**In vivo endomicroscopy**  
 Maxime Palazzo, France

09:12 – 09:34 IP534  
**Pancreatic fluid analyses**  
 Michael Goggins, United States

09:34 – 09:46 OP267  
**EFFECT OF ASPIRIN, ACE INHIBITORS/SARTANS AND STATINS USE ON THE PROGRESSION OF BD-IPMN IN FOLLOW UP: A MULTICENTER STUDY**  
Roberto Valente, Italy; Crippa S.; Vanella G.; Zerboni G.; Fogliati A.; Arnelo U.; Zanantonello L.; Falconi M.; Del Chiaro M.; Capurso G.

09:46 – 09:58 OP268  
**REDUCING PANCREATIC CYST SURVEILLANCE: DEVELOPMENT OF THE DUTCH AMERICAN RISK STRATIFICATION TOOL (DART-I) TO IDENTIFY IPMN WITH LOW RISK TO PROGRESS AND FULFILL RESECTION CRITERIA**  
Kasper Alexander Overbeek, The Netherlands; Alblas M.; Gausman V.; Kandel P.; Brooks C.; Van Riet P. A.; Wallace M. B.; Gonda T. A.; Cahen D. L.; Bruno M. J.

#### Symposium

08:30 – 10:00 Room F2  
**Management of superficial gastric cancer**  
 Chairs: Mario Dinis-Ribeiro, Portugal  
 Oliver Pech, Germany



#### Debate

08:30 – 08:40 IP535  
**Pre-therapeutic assessment: Endoscopy is enough**  
 Edward Despott, United Kingdom

08:40 – 08:50 IP536  
**Pre-therapeutic assessment: Biopsies are mandatory**  
 Michael Vieth, Germany

#### Debate

08:50 – 09:00 IP537  
**ESD: For all cases**  
 Mathieu Pioche, France

09:00 – 09:10 IP538  
**ESD: Consider surgery and the patients' perspective**  
 Pedro Pimentel Nunes, Portugal

09:10 – 09:20 OP269  
**ATROPHIC GASTRITIS IN ALL-CAUSE UPPER GASTRO-INTESTINAL ENDOSCOPY AT A TERTIARY ENDOSCOPIC CENTER: SEVERITY ACCORDING TO THE OLGA STAGING SYSTEM**  
Kryssia Rodriguez-Castro, Italy; Franceschi M.; Baldassarre G.; Ferronato A.; Miraglia C.; Cuoco L.; Panozzo M. P.; Antico A.; Morini A.; Gasparri L. R.; Sella D.; Pertoldi B.; Rugge M.; Di Mario F.

09:20 – 09:30 OP270  
**IN ATROPHIC GASTRITIS 3-YEARS ENDOSCOPIC SURVEILLANCE ACCORDING TO MAPS (MANAGEMENT OF PRECANCEROUS CONDITIONS AND LESIONS IN THE STOMACH) GUIDELINES SEEMS SATISFACTORY TO EARLY DETECT POTENTIAL NEOPLASTIC LESIONS**  
 Dilaghi E.; Esposito G.; Galli G.; Conti L.; Angeletti S.; Carabotti M.; Annibale B.; Edith Lahner, Italy

09:30 – 09:40 OP271  
**CLINICAL OUTCOMES OF EARLY GASTRIC CANCER BEYOND EXPANDED CRITERIA AFTER ENDOSCOPIC RESECTION**  
Hyun Ju Kim, Republic of Korea; Kim S. G.; Kim J.; Chung H.; Jung H. C.

09:40 - 09:50 OP272  
**WITHDRAWN**

**Abstract-Based Session**

08:30 - 10:00 Room G  
**The broad spectrum of IBD management**  
 Chairs: Franck Carbonnel, France  
 Donata Lissner, Germany

08:30 - 08:42 IP539  
**State-of-the-art introduction**  
 Franck Carbonnel, France

08:42 - 08:54 OP273  
**EARLY VERSUS LATE INTERVENTION WITH ANTI-TNF- $\alpha$  ANTIBODIES IN CROHN'S DISEASE: EFFECT ON MUCOSAL HEALING, DEVELOPMENT OF STRICTURES AND NEED FOR RESECTIVE SURGERY. A RETROSPECTIVE COHORT ANALYSIS**  
 Seitz T.; Schnitzler F.; Borchardt J.; Howaldt S.; Janelidze S.; Thomas Ochsenkühn, Indonesia

08:54 - 09:06 OP274  
**POST-COLONOSCOPY COLORECTAL CANCER RATES IN IBD ARE HIGH AND VARY BY NHS TRUST IN ENGLAND.**  
Nick Burr, United Kingdom; Valori R.; Subramanian V.; Hull M. A.; Smith A.; Morris E.; Rutter M. D.

09:06 - 09:18 OP275  
**VEDOLIZUMAB TROUGH LEVELS AND HISTOLOGICAL HEALING IN ULCERATIVE COLITIS**  
Lieven Pouillon, France; Rousseau H.; Busby-Venner H.; De Carvalho Bittencourt M.; Choukour M.; Gauchotte G.; Zallot C.; Danese S.; Baumann C.; Peyrin-Biroulet L.

09:18 - 09:30 OP276  
**POSITIVE HISTOLOGIC MARGINS IS A RISK FACTOR OF RECURRENCE AFTER ILEOCAECAL RESECTION IN CROHN'S DISEASE** ✦  
 Riault C.; Diouf M.; Chatelain D.; Le Mouel J. P.; Loreau J.; Turpin J.; Yzet C.; Brazier F.; Sabbagh C.; Dupas J.-L.; Nguyen-Khac E.; Mathurin Fumery, France

09:30 - 09:42 OP277  
**EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASES**

Maria Chaparro, Spain; Garre A.; Ricart Gómez E.; Iborra M.; Mesonero Gismero F.; Vera M.; Riestra Menéndez S.; García-Sánchez V.; De Castro L.; Martin-Cardona A.; Aldeguer X.; Mínguez M.; Barreiro de-Acosta M.; Rivero M.; Muñoz F.; Andreu M.; Bargallo A.; García-Planella E.; Pérez Calle J. L.; García-Sepulcre M. F.; Bermejo F.; Huguet J. M.; Cabriada J. L.; Gutierrez Casbas A.; Mañosa M.; Villoria A.; Carbajo A. Y.; Lorente R.; García-López S.; Piqueras M.; Hinojosa E.; Arjol C.; Sicília B.; Macho Conesa A.; Sainz E.; Almela P.; Llaó J.; Roncero O.; Camo P.; Taxonera C.; van Domseelaar M.; Pajares R.; Legido J.; Madrigal R.; Lucendo A. J.; Alcaín G.; Alfaro I.; Nos P.; López San-Román A.; Calvo Moya M.; de Francisco R.; Iglesias Flores E.; Pineda J. R.; Esteve M.; Busquet D.; Navarro P.; Baston I.; García M. J.; Piñero C.; Márquez Mosquera L.; Navarro-Llavat M.; González-Muñoz C.; López Serrano P.; Jiménez N.; Algaba A.; Ruiz L.; Rodríguez-Pescador A.; Sempere Robles L.; Clos-Parals A.; Calvet X.; Barrio J.; Verdejo C.; Llorente Barrio M.; Mena R.; Maroto N.; Guardiola J.; Arias García L.; Fernández-Salazar L.; Sesé E.; Muñoz M.; Giménez Roca A.; Domínguez M.; Alba C.; Blázquez Gómez I.; Manceñido Marcos N.; Arias Rodríguez L.; Santamaría A.; Angueira T.; García A.; Bernardo D.; Domènech E.; Gisbert J. P.

09:42 - 09:54 OP278  
**CLINICAL RESPONSE TO TREATMENT, DISEASE PHENOTYPE AND SEROLOGY COMBINED ARE STRONG PREDICTORS OF THE NEED FOR SURGERY IN CHILDREN WITH CROHN'S DISEASE TWO YEARS AFTER DIAGNOSIS: RESULTS FROM THE PROSPECTIVE MULTICENTRE GROWTH STUDY**  
 Levine A.; Chanchlani N.; Ziv-Baran T.; Escher J. C.; Amil Dias J.; Veres G.; Koletzko S.; Turner D.; Kolho K.-L.; Paerregaard A.; Staiano A.; Lionetti P.; Nuti F.; Sladek M.; Shaoul R.; Martín de Carpi J.; Sigall Boneh R.; Cohen-Dolev N.; Pfeffer-Gik T.; Richard K Russell, United Kingdom

**Symposium**

08:30 - 10:00 Room K  
**East meets West: Current perspectives on GI cancer screening**  
 Chairs: Haruhiro Inoue, Japan  
 Horst Neuhaus, Germany



08:30 - 08:52 IP540  
**Colonic lateral spreading tumours: EMR always**  
 Michael John Bourke, Australia

08:52 – 09:14 IP541  
**Colonic lateral spreading tumours: ESD always**  
 Naohisa Yahagi, Japan

09:14 – 09:36 IP542  
**Gastroesophageal carcinoma: ESD is mandatory**  
 Philip Wai Yan Chiu, Hong Kong PRC

09:36 – 09:58 IP543  
**Gastroesophageal carcinoma: ESD is not needed**  
 Torsten Beyna, Germany

### Translational/Basic Science

08:30 – 10:00 Room M  
**New advances in NASH and ASH**  
 Chairs: Jean-François Dufour, Switzerland  
 Helen Reeves, United Kingdom



08:30 – 08:52 IP544  
**Microbiota**  
 Gabriel Perlemuter, France

08:52 – 09:14 IP545  
**Role of adipose tissue**  
 Kristiaan Wouters, The Netherlands

09:14 – 09:36 IP546  
**Role of macrophages**  
 Frank Tacke, Germany

09:36 – 09:58 IP547  
**Novel treatment options**  
 Helena Cortez-Pinto, Portugal

### Abstract-Based Session

08:30 – 10:00 Room 1.61/1.62  
**The truth is under the microscope**  
 Chairs: Irene Esposito, Germany  
 Vasile Sandru, Romania

08:30 – 08:42 IP548  
**State-of-the-art introduction**  
 Irene Esposito, Germany

08:42 – 08:54 OP279  
**FACTORS ASSOCIATED WITH PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH OESOPHAGEAL CANCER: RESULTS FROM A NATIONWIDE STUDY.**

Ali Al-Kaabi, The Netherlands; van der Werf L. R.; Wijnhoven B. P. L.; Rosman C.; van der Post R. S.; Hulshof M. C. C. M.; van Laarhoven H. W. M.; Verhoeven R.; Siersema P. D.

08:54 – 09:06 OP280  
**WITHDRAWN**

09:06 – 09:18 OP281  
**MICROSCOPIC POSITIVE TUMOR MARGIN DOES NOT INCREASE THE RATE OF RECURRENCE IN ENDOSCOPIC RESECTED GASTRIC MESENCHYMAL TUMORS COMPARED TO NEGATIVE TUMOR MARGIN**  
Yan Zhu, China; Xu M.-D.; Zhou P.-H.; Li Q.-L.

09:18 – 09:30 OP282  
**RISK STRATIFICATION OF SYMPTOMATIC PATIENTS SUSPECTED OF COLORECTAL CANCER USING FAECAL BIOMARKERS (FAECAL IMMUNOCHEMICAL TEST AND FAECAL CALPROTECTIN) AND URINARY VOLATILE ORGANIC COMPOUNDS**

Monika Maria Widlak, United Kingdom; Neal M.; Daulton E.; Thomas C. L.; Tomkins C.; Singh B.; Harmston C.; Wicaksono A.; Evans C.; Smith S.; Savage R. S.; Covington J. A.; Arasaradnam R. P.

09:30 – 09:42 OP283  
**CLINICOPATHOLOGICAL STUDY OF LATERALLY SPREADING TUMORS OF THE COLORECTUM**  
Masahiro Iwabuchi, Japan; Sugimura M.; Sato K.; Endo Y.; Kusano K.; Sekino A.; Mano Y.; Ukai K.

09:42 – 09:54 OP284  
**CLINICAL, ENDOSCOPIC AND MOLECULAR BIOMARKERS IN PREDICTING METACHRONOUS ADVANCED LESIONS FROM POPULATION-BASED SCREENING FOR COLORECTAL CANCER (CRC)**

Laura Carot, Spain; Naranjo-Hans D.; Iglesias Coma M.; Dalmases A.; Navarro G.; Fernández L.; González M.; Batlle M.; Buron A.; Bessa X.; Andreu Garcia M.; Alvarez-Urturi C.

### Abstract-Based Session

08:30 – 10:00 Room N1  
**Upper GI sensitivity and symptom generation**  
 Chairs: Dan Lucian Dumitrascu, Romania  
 Ricard Farre, Belgium

08:30 – 08:42 IP549  
**State-of-the-art introduction**  
 Dan Lucian Dumitrascu, Romania

08:42 – 08:54 OP285  
**GENETIC VARIATION IS ASSOCIATED WITH WORSE AFFECT SCORES, HIGHER SYMPTOM BURDEN, AND MUCOSAL INJURY IN PATIENTS WITH ESOPHAGEAL SYMPTOMS**

Stephen Hasak, United States; Patel A.; Nix B.; Sayuk G.; Newberry R.; Gyawali C. P.

08:54 – 09:06 OP286  
**GASTRIC TRPA1 STIMULATION BY ALLICIN-CONTAINING GARLIC POWDER INDUCES SPECIFIC EPIGASTRIC SYMPTOMS THAT DIFFER FROM SYMPTOMS INDUCED BY TRPV1 STIMULATION AND GASTRIC DISTENSION**  
 Führer M.; Dejaco C.; Kopp B.; Johann Hammer, Austria

09:06 – 09:18 OP287  
**THE INCREASE OF EFFECTOR MEMORY T-CELLS IN SMALL INTESTINE OF FUNCTIONAL GASTROINTESTINAL DISORDER (FGID) PATIENTS RELATING TO GUT BACTERIA AND SYMPTOM GENERATION** ✦  
Anh Do, Australia; Shanahan E.; Fairlie T.; Hansen T.; Koloski N.; Keely S.; Walker M.; Talley N. J.; Morrison M.; Holtmann G. J.

09:18 – 09:30 OP288  
**EVIDENCE OF A DYSREGULATED STRESS HORMONE RESPONSE RELATED TO NLRP6 INFLAMMASOME ACTIVATION IN PATIENTS WITH FUNCTIONAL DYSPEPSIA.**  
Jessica Bruce, Australia; Burns G.; Mathe A.; Foster P.; Koloski N.; Holtmann G.; Walker M.; Talley N. J.; Keely S.

09:30 – 09:42 OP289  
**EXPLORATORY STUDY: COGNITIVE RESTRAINT ASSOCIATED WITH BASELINE VAGAL TONE AND POSTPRANDIAL RESPONSE TO INTERCEPTIVE STIMULUS IN HEALTHY LEAN ADULTS**  
Heather Evelyn Fitzke, United Kingdom; Albusoda A.; Fried R.; Mackay J. L.; Farmer A. D.; Van Oudenhove L.; Aziz Q.

09:42 – 09:54 OP290  
**RANDOMIZED CONTROLLED TRIAL: THE EFFECT OF TRANSCUTANEOUS VAGAL NERVE STIMULATION ON REVERSING ACID – INDUCED OESOPHAGEAL HYPERSENSITIVITY IN HUMANS**  
Ahmed Albusoda, United Kingdom; Ruffle J.; Fitzke H.; Idrees R.; Fried R.; Aziz Q.; Farmer A. D.

**Symposium**

08:30 – 10:00 Room N2  
**Congenital malformations: How to follow up in adulthood?**  
 Chairs: Kaija-Leena Kolho, Finland  
 René M. H. Wijnen, The Netherlands

**Tandem Talks**  
 08:30 – 08:40 IP550  
**Oesophageal atresia: What is it all about?**  
 Frederic Gottrand, France

08:40 – 08:50 IP551  
**Is oesophageal atresia a risk factor for cancer?**  
 Manon C. W. Spaander, The Netherlands

08:50 – 09:12 IP552  
**Biliary atresia: Ways to improve outcomes**  
 Mikko Pakarinen, Finland

09:12 – 09:34 IP553  
**Functional outcomes of Hirschsprung's disease**  
 Kaija-Leena Kolho, Finland

09:34 – 10:00  
**PANEL DISCUSSION**

**Abstract-Based Session**  
 08:30 – 10:00 Room L7  
**CRC in young adults and genetically predisposed patients**  
 Chairs: Dora Colussi, Italy  
 Andrew Latchford, United Kingdom

08:30 – 08:42 IP554  
**State-of-the-art introduction**  
 Andrew Latchford, United Kingdom

08:42 – 08:54 OP291  
**THE OLD VERSUS THE NEW: WHAT IS DIFFERENT IN COLORECTAL CANCER?**  
Aslam Syed, United States; Thakkar P.; Abdul-Baki H.; Farah K.; Thakkar S.

08:54 – 09:06 OP292  
**INCREASING INCIDENCE OF COLORECTAL CANCER IN YOUNG ADULTS IN EUROPE**  
Fanny E. R. Vuik, The Netherlands; Nieuwenburg S. A. V.; Bardou M.; Dinis-Ribeiro M.; Bento M. J.; Zadnik V.; Esteban L.; Pellisé M.; Kaminski M. F.; Suchanek S.; Ngo O.; Májek O.; Leja M.; Kuipers E. J.; Spaander M. C. W.

09:06 – 09:18 OP293  
**SCREENING FOR COLORECTAL CANCER BASED ON POLYGENIC RISK AND FAMILY HISTORY**  
Dayna Cenin, The Netherlands; Naber S.; de Weerd T.; Jenkins M.; Preen D.; Ee H.; O'Leary P.; Lansdorp-Vogelaar I.

09:18 – 09:30 OP294  
**YIELD OF LYNCH SYNDROME SURVEILLANCE FOR INDIVIDUAL GMMR GENES**  
Anne Goverde, The Netherlands; Wagner A.; Viskil E.; Bruno M. J.; Hofstra R. M. W.; Spaander M. C. W.

09:30 – 09:42 OP295  
**HIGH DEFINITION WHITE-LIGHT COLONOSCOPY VERSUS CHROMOENDOSCOPY FOR SURVEILLANCE OF LYNCH SYNDROME. A MULTICENTER, RANDOMIZED AND CONTROLLED STUDY (ENDOLYNCH STUDY)** ✦  
Liseth Rivero Sánchez, Spain; Arnau Colell C.; Balaguer F.; Herrero Rivas J. M.; Remedios Espino D.; Alvarez Sanchez M. V.; Albéniz Arbizu E.; Calvo Aranda P.; Gordillo J.; Puig I.; López Vicente J.; Huerta Madrigal A.; López-Cerón M.; Salces I.; Peñas García B.; Parejo Carbonell S.; Herraiz Bayod M.; Gimeno A.; Saperas Franch E.; Alvarez Urturi C.; Moreno L.; Rodriguez de Miguel C.; Diaz Centeno M.; Ocaña T.; Moreira L.; Cuatrecasas M.; Carballal S.; Sánchez García A.; Llach J.; Pellisé Urquiza M.

09:42 – 09:54 OP296  
**RESULTS OF THE DANISH POLYPOSIS REGISTRY - FOCUS ON COLORECTAL CANCER IN THE 20TH CENTURY**  
John Gásdal Karstensen, Denmark; Burisch J.; Aalling L.; Højen H.; Jespersen N.; Pommergaard H. C.; Schmidt P. N.; Bülow S.

**Abstract-Based Session**

08:30 – 10:00 Room L8  
**From microbiota to immune mechanisms in CRC carcinogenesis**  
 Chairs: Herbert Tilg, Austria  
 Markus Tschurtschenthaler, Germany

08:30 – 08:42 IP555  
**State-of-the-art introduction**  
 Herbert Tilg, Austria

08:42 – 08:54 OP297  
**PROFILES OF BACTERIA-DERIVED EXTRACELLULAR VESICLES IN STOOL, SERUM AND URINE IN PATIENTS WITH COLORECTAL CANCER: A PRELIMINARY STUDY**  
 Jae Ho Cho, Republic of Korea; Shin C.-M.; Lee D. H.; Kim Y. K.; Yang J.; Lee W. H.; Seol M. J.; Lee Y. R.; Kim K. M.; Song D. J.; Yoon H.; Kim N.-Y.; Park Y. S.

08:54 – 09:06 OP298  
**FUSOBACTERIUM NUCLEATUM PROMOTE METASTASIS OF COLORECTAL CANCER**  
 Su T.; Chen S.; He Jiamin, China; Zhang Y.

09:06 – 09:18 OP299  
**CONCOMITANT REDUCTION OF CD4CD8AA LYMPHOCYTES IN BLOOD AND OF FAECALIBACTERIUM PRAUSNITZII IN INTESTINAL MICROBIOTA IN PATIENTS WITH COLORECTAL CANCER.**  
 Yann Toucheffeu, France; Bruley Des Varannes S.; Alameddine J.; Mirallié E.; Matysiak Budnik T.; Jotereau F.; Montassier E.

09:18 – 09:30 OP300  
**ROLE OF INFLAMMATORY RESPONSE, INSULIN RESISTANCE AND ENVIRONMENTAL FACTORS IN NON-FILIATED ATTENUATED POLYPOSIS**  
 Miren Alustiza-Fernandez, Spain; Hernandez-Illán E.; Mira C.; Giner Calabuig M.; Juarez M.; Murcia O.; Guarinos C.; Martinez-Cardona C.; Frances Guarinos R.; Martínez R. J.

09:30 – 09:42 OP301  
**COMBINED LOW DENSITIES OF FOXP3+ AND CD3+ TUMOR-INFILTRATING LYMPHOCYTES FOR THE INTRA-STAGE II IDENTIFICATION OF COLORECTAL CANCERS WITH THE HIGHEST RISK OF PROGRESSION.**  
 Cavalleri T.; Bianchi P.; Basso G.; Celeti G.; Bossi P.; Grizzi F.; Greco L.; Pitrone C.; Valtorta E.; Mauri G.; Truini M.; Dall'Olivo F. G.; Brandi G.; Sartore Bianchi A.; Ricciardiello L.; Torri V.; Siena S.; Mantovani A.; Malesci A.; Luigi Laghi, Italy

09:42 – 09:54 OP302  
**RNASEH2 GUIDED RIBONUCLEOTIDE EXCISION REPAIR PREVENTS INTESTINAL TUMORIGENESIS**  
 Konrad Aden, Germany; Bartsch K.; Esser D.; Dahl J.; Reijns M.; Wottawa F.; Mishra N.; Welz L.; Tran F.; Lipinski S.; Kakavand N.; Boeger C.; Roecken C.; Clevers H.; Schreiber S.; Rabe B.; Rosenstiel P.

**Symposium**

10:30 – 12:00 Room D  
**Tips and tricks for the IBS patient**  
 Chairs: Lin Chang, United States  
 Lesley Houghton, United Kingdom



10:30 – 10:52 IP556  
**Diagnosis in clinical practice**  
 Brian Lacy, United States

10:52 – 11:14 IP557  
**Management of visceral pain**  
 Adam Donald Farmer, United Kingdom

11:14 – 11:36 IP558  
**Management of bloating**  
 Fernando Azpiroz, Spain

11:36 – 11:58 IP559  
**The low FODMAP diet: Selecting the right candidate**  
 Heidi Staudacher, Australia

**Advances in Clinical GI & Hepatology**

10:30 – 12:00 Room E1  
**Drug induced liver injury (DILI)**  
 Chairs: Helena Cortez-Pinto, Portugal  
 Alexandre Louvet, France



10:30 – 10:52 IP560  
**Advances in diagnosis and clinical management**  
 Raul Andrade, Spain

10:52 – 11:14 IP561  
**Immunotherapy induced DILI**  
 Audrey Coilly, France

11:14 – 11:36 IP562  
**Herbal medicine and supplements**  
 Michael Manns, Germany

11:36 – 11:58 IP563  
**Biological therapy and the liver**  
 Joost P. H. Drenth, The Netherlands

**Abstract-Based Session**

10:30 – 12:00 Room E2  
**IBD clinical trials II**  
 Chairs: Tim Raine, United Kingdom  
 Christina Kapizioni, Greece



10:30 – 10:42 IP564  
**State-of-the-art introduction**  
 Tim Raine, United Kingdom

10:42 – 10:54 OP303  
**EFFICACY AND SAFETY OF MIRIKIZUMAB (LY3074828) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN A PHASE 2 STUDY**  
 William J. Sandborn, United States; D'Haens G.; Ferrante M.; Bhandari R.; Berliba E.; Feagan B. G.; Laskowski J.; Friedrich S.; Tuttle J.; Durante M.

10:54 – 11:06 OP304  
**CORRELATION BETWEEN CLINICAL AND ENDOSCOPIC ENDPOINTS AND REMISSION PER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE IN PATIENTS WITH CROHN'S DISEASE: DATA FROM CELEST**  
 Remo Panaccione, Canada; Schreiber S.; Van Assche G.; Reinisch W.; Louis E.; Zisman T.; Yacyshyn B.; Ghosh S.; Sedghi S.; Goteti S.; Lee W.-J.; Lacerda A. P.

11:06 – 11:18 OP305  
**TIME TO LOSS OF EFFICACY FOLLOWING TOFACITINIB INTERRUPTION IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM OCTAVE SUSTAIN**  
 Dubinsky M. C.; Clarke K.; Klaus J. G.; Yoram Bouhnik, France; Soonasra A.; Thorpe A. J.; Zhang H.; Friedman G. S.; Woodworth D. A.; Lawendy N.; Su C.

11:18 – 11:30 OP306  
**EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS**  
 William J. Sandborn, United States; Rutgeerts P.; Jacobstein D.; Gasink C.; Patel R.; Zou B.; Johanns J.; Sands B. E.; Hanauer S. B.; Targan S.; Ghosh S.; de Villiers W.; Colombel J.-F.; Feagan B. G.

11:30 – 11:42 OP307  
**LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY**  
 Marc Ferrante, Belgium; Panés J.; Baert F.; Louis E.; Kaser A.; Gustafson D.; Hall D.; Böcher W. O.; Herichova I.; Liao X.; Wallace K.; Kalabic J.; D'Haens G.

11:42 – 11:54 OP308  
**LONG-TERM SAFETY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTI-BODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)**  
 Walter Reinisch, Austria; Sandborn W. J.; Danese S.; Hébuterne X.; Salzberg B.; Klopocka M.; Tarabar D.; Vanásek T.; Greguš M.; Hellstern P.; Kim J. S.; Sparrow M. P.; Gorelick K. J.; Goetsch M.; Bliss C.; Cataldi F.; Vermeire S.

**Symposium**  
 10:30 – 12:00 Room F1  
**The malignant polyp**  
 Chairs: Mario Dinis-Ribeiro, Portugal  
 P. Ronan O'Connell, Ireland



10:30 – 10:52 IP565  
**Endoscopic classification**  
 James Edward East, United Kingdom

10:52 – 11:14 IP566  
**Pathological classification**  
 Cord Langner, Austria

**Debate**  
 11:14 – 11:24 IP567  
**Malignant polyp in the rectum: Endoscopic treatment**  
 Horst Neuhaus, Germany

11:24 – 11:34 IP568  
**Malignant polyp in the rectum: Surgical treatment**  
 Mario Morino, Italy

**Debate**  
 11:34 – 11:44 IP569  
**Surveillance after complete resection? Yes**  
 Jaroslaw Regula, Poland

11:44 – 11:54 IP570  
**Surveillance after complete resection? No**  
 Cesare Hassan, Italy

**Symposium**  
 10:30 – 12:00 Room F2  
**IBD in young**  
 Chairs: Kaija-Leena Kolho, Finland  
 C. Janneke van der Woude, The Netherlands



10:30 – 10:52 IP571  
**Very early onset colitis: Always monogenic?**  
 Sibylle Koletzko, Germany

10:52 – 11:14 IP572  
**Update on ulcerative colitis**  
 Richard K Russell, United Kingdom

11:14 – 11:36 IP573  
**Nutritional intervention**  
 Arie Levine, Israel

11:36 – 11:58 IP574  
**How and when to use biologics**  
 Gigi Veereman, Belgium

## Symposium

10:30 – 12:00 Room G

## Novelties in dyspepsia

Chairs: Daniel Pohl, Switzerland  
Jordi Serra, Spain

10:30 – 10:52 IP575

**Which examination may help to investigate dyspepsia?**  
Jutta Keller, Germany

10:52 – 11:14 IP576

**Medical therapeutic options: Current and future perspectives**

Guillaume Gourcerol, France

11:14 – 11:36 IP577

**Can dietary advice help patients with dyspepsia?**  
Benoit Coffin, France

11:36 – 11:58 IP578

**Is there a room for endoscopic treatment?**  
Marc Barthet, France

## Abstracts on Fire

10:30 – 12:00 Room K

## An upper GI melange

Chairs: Danny De Looze, Belgium  
Wafaa Khannoussi, Morocco

10:30 – 10:40 OP309

**A 3-BIOMARKER PANEL ON BIOPSIES TARGETED BY ADVANCED ENDOSCOPIC IMAGING CAN PREDICT PROGRESSION TO DYSPLASIA IN PATIENTS WITH BARRETT'S OESOPHAGUS**Andreas V Hadjinicolaou, United Kingdom;  
van Munster S.; Santiago Garcia J.; Ragunath K.; Bergman J. J.; Fitzgerald R. C.; di Pietro M.

10:40 – 10:50 OP310

**PATIENT DERIVED ORGANOID-BASED PREDICTION OF CONCURRENT CHEMO-RADIOTHERAPY RESPONSE IN ESOPHAGEAL CANCER**Su Youn Nam, Republic of Korea; Jeon S. W.; Kwon Y.-H.; Lee H. S.; Lee S. W.

10:50 – 11:00 OP311

**THE GUT MICROBIOME INFLUENCES PROGRESSION FROM METAPLASIA TO DYSPLASIA IN THE IL-1&#946; MOUSE MODEL OF BARRETT OESOPHAGUS**Jonas Ingermann, Germany; Stephens Münch N.; Fang H.-Y.; Islam Sayin S.; Haller D.; Clavel T.; Muthupalani S.; Whary M. T.; Fox J. G.; Wang T. C.; Quante M.

11:00 – 11:10 OP312

**LONG-TERM EFFICACY AND SAFETY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE OPEN-LABEL EXTENSION OF THE HEROES STUDY**Evan Dellon, United States; Collins M. H.; Assouline-Dayana Y.; Evans L.; Gupta S.; Schoepfer A.; Straumann A.; Safroneeva E.; Woo A.; Olson A.; Opiteck G. J.; Aranda R.; Hirano I.

11:10 – 11:20 OP313

**PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): INTERIM ANALYSIS OF 16,600 FIRST-LINE TREATMENTS**Adrian Gerald McNicholl, Spain; Perez Nyssen O.; Bordin D.; Tepes B.; Perez-Aisa A.; Vaira D.; Caldas Álvarez M.; Bujanda Fernández de Piérola L.; Castro-Fernandez M.; Lerang F.; Leja M.; Rodrigo L.; Rokkas T.; Kupcinskas L.; Perez-Lasala J.; Jonaitis L.; Shvets O.; Gasbarrini A.; Simsek H.; Axon A.; Buzás G. M.; Machado J. C. L.; Niv Y.; Boyanova L.; Goldis A.; Lamy V.; Katicic M.; Przytulski K.; Beglinger C.; Venerito M.; Bytzer P.; Capelle L.; Milosavljevic T.; Veijola L.; Molina Infante J.; Vologzhanina L.; Fadeenko G.; Ariño I.; Fiorini G.; Ramas M.; G. Donday M.; Megraud F.; O'Morain C.; Gisbert J. P.

11:20 – 11:30 OP314

**STATIN USE AND GASTRIC CANCER RISK IN H. PYLORI-ERADICATED SUBJECTS: A TERRITORY-WIDE COHORT STUDY WITH PROPENSITY SCORE ADJUSTMENT**Wai Keung Leung, Hong Kong PRC; Chan E.; Chen L.; Wong I.; Cheung K. S.

11:30 – 11:40 OP315

**GENETIC CHARACTERIZATION OF ADULT PATIENTS WITH SEVERE ENTEROPATHIES REVEALS MONOGENIC DISORDER IN HALF OF CASES**Charbit-Henrion F.; Duclaux-Loras R.; Cellier C.; Khater S.; Aubourg A.; Allez M.; Bruneau J.; Goulet O.; Cerf-Bensussan N.; Georgia Malamut, France

11:40 – 11:50 OP316

**EXTERNAL VALIDATION OF THE INTERNATIONAL BLEEDING RISK SCORE IN BOTH UPPER AND LOWER GI BLEEDING: AN INTERNATIONAL MULTICENTRE STUDY**Laursen S. B.; Oakland K.; Laine L.; Bieber V.; Marmo R.; Redondo Cerezo E.; Dalton H.; Ngu J. H.; Schultz M.; Galnek I. M.; Jairath V.; Murray I. A.; Adrian J Stanley, United Kingdom

11:50 – 12:00 OP317

**ASSESSMENT OF MICROPLASTIC CONCENTRATIONS IN HUMAN STOOL – PRELIMINARY RESULTS OF A PROSPECTIVE STUDY**Philipp Schwabl, Austria; Liebmann B.; Köppel S.; Königshofer P.; Bucsecs T.; Trauner M.; Reiberger T.



**Translational/Basic Science**

10:30 – 12:00 Room M  
**Pancreatic cancer development**  
 Chairs: Alexander Kleger, Germany  
 Julia Mayerle, Germany



10:30 – 10:52 IP579  
**Molecular sequence of pancreatic cancer development: Is it still applicable?**  
 Michael Goggins, United States

10:52 – 11:14 IP580  
**Proteomics and diagnostic markers**  
 Eithne Costello-Goldring, United Kingdom

11:14 – 11:36 IP581  
**Immunity and pancreatic cancer**  
 Christian Bauer, Germany

11:36 – 11:58 IP582  
**Implications for clinical management**  
 Thomas Seufferlein, Germany

**Symposium**

10:30 – 12:00 Room 1.61/1.62  
**Cholangiopathies: How to avoid common mistakes**  
 Chairs: Jacques Deviere, Belgium  
 Jessica Dyson, United Kingdom

10:30 – 10:52 IP583  
**Clinical spectrum of cholangiopathies**  
 Arnaud Lemmers, Belgium

**Tandem Talks**  
 10:52 – 11:02 IP584  
**How to optimise diagnosis: Radiology**  
 Sarah Poetter-Lang, Austria

11:02 – 11:12 IP585  
**How to optimise diagnosis: Pathology**  
 Irene Esposito, Germany

11:12 – 11:34 IP586  
**ERCP in diagnosis and management**  
 Cyriel Y. Ponsioen, The Netherlands

11:34 – 11:56 IP587  
**Medical management and timing of liver transplantation**  
 Tom Hemming Karlsen, Norway

**Symposium**

10:30 – 12:00 Room N1  
**How to improve diagnostic accuracy in pancreatobiliary EUS**  
 Chairs: Pierre Eisendrath, Belgium  
 Mostafa Ibrahim, Belgium

10:30 – 10:52 IP588  
**Optimising EUS guided tissue sampling**  
 Maria Chiara Petrone, Italy

10:52 – 11:14 IP589  
**Elastography and contrast: Does it really help?**  
 Adrian Saftoiu, Romania

**Tandem Talks**  
 11:14 – 11:24 IP590  
**New kids on the block: Confocal microscopy**  
 Mostafa Ibrahim, Belgium

11:24 – 11:34 IP591  
**New kids on the block: Through the needle biopsies**  
 Luca Barresi, Italy

11:34 – 11:46 OP318  
**EFFICACY OF CONTRAST-ENHANCED ENDOSCOPIC ULTRASONOGRAPHY FOR LYMPHADENOPATHY: A PROSPECTIVE MULTICENTER PILOT STUDY**  
 Kensaku Yoshida, Japan; Iwashita T.; Mita N.; Uemura S.; Ando N.; Iwata K.; Kawaguchi J.; Mukai T.; Shimizu M.

11:46 – 11:58 OP319  
**CHANGING TREND IN EUS-GUIDED TISSUE ACQUISITION: IN MEMORIAM - FNA, BIRTH - FNB**  
 Ji Young Bang, United States; Kirtane S.; Krall K.; Navaneethan U.; Hasan M.; Hawes R.; Varadarajulu S.

**Abstract-Based Session**

10:30 – 12:00 Room N2  
**Primary liver cancer**  
 Chairs: Chiara Becchetti, Italy  
 Thomas Decaens, France

10:30 – 10:42 IP592  
**State-of-the-art introduction**  
 Thomas Decaens, France

10:42 – 10:54 OP320  
**SERUM AND URINE EXTRACELLULAR VESICLES CONTAIN MRNA BIOMARKERS FOR PRIMARY SCLEROSING CHOLANGITIS (PSC) AND CHOLANGIOCARCINOMA (CCA)**  
 Pedro M Rodrigues, Spain; Arbelaz A.; Lapitz A.; Krawczyk M.; Lavín J. L.; Santos-Laso Á.; Perugorria M. J.; Jimenez-Aguero R.; Lacasta A.; Ibarra C.; Sanchez- Campos A.; Jimeno J. P.; Gonzalez E.; Lammert F.; Marzioni M.; Macias R. I. R.; Marin J. J.; Karlsen T. H.; Falcon-Perez J.; Aransay A. M.; Bujanda Fernández de Piérola L.; Bañales J. M.

10:54 – 11:06 OP321  
**PREDICTIVE VALUE OF PAGE-B SCORE IN TUNISIAN PATIENTS WITH CHRONIC HEPATITIS B UNDER ENTECAVIR.** ✦  
Bellil Nawel, Tunisia; Ennaifer R.; Bouchabou B.; Rania Z.; Ben Romdhane H.

11:06 – 11:18 OP322  
**DOUBLECORTIN-LIKE KINASE 1 (DCLK1) EXPRESSION CHARACTERIZES SPECIFIC SUBPOPULATIONS OF CANCER STEM CELLS (CSCS) IN HUMAN CHOLANGIOCARCINOMA (CCA) AND ITS INHIBITION EXERTS ANTI-CANCER EFFECTS.**  
Lorenzo Nevi, Italy; Di Matteo S.; Carpino G.; Cardinale V.; Zizzari I.; Ambrosino V.; Costantini D.; Safarikia S.; Manzi E.; De Peppo V.; De Rose A. M.; Melandro F.; Bragazzi M. C.; Grazi G.; Berloco P. B.; Giuliante F.; Gaudio E.; Alvaro D.

11:18 – 11:30 OP323  
**DIAGNOSTIC AND PROGNOSTIC VALUES OF BOTH S100 CALCIUM BINDING PROTEIN A4 (S100A4) AND GLYPICAN 3 IN THE TISSUES OF HEPATOCELLULAR CARCINOMA IN EGYPTIAN CIRRHOTIC HCV PATIENTS: A TISSUE MICROARRAY BASED STUDY.**  
Mahmoud El-Bendary, Egypt; Farid K.; El-Mesery A.; Abdullah T.; Arafa M.; El-Kashef W.

11:30 – 11:42 OP325  
**PERCUTANEOUS INJECTION OF ETHANOL AND MITOXANTHRONE VERSUS RADIOFREQUENCY ABLATION IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA.**  
Besher Mohamed, United Kingdom; Emara Elzanan M. H.; Elshamy M.; Tai C.

### Abstract-Based Session

10:30 – 12:00 Room L7  
**Diarrhea and bloating in functional bowel disorders**  
 Chairs: Henriette Heinrich, Switzerland  
 Knut-Arne Wensaas, Norway

10:30 – 10:42 IP593  
**State-of-the-art introduction**  
 Knut-Arne Wensaas, Norway

10:42 – 10:54 OP326  
**EFFICACY OF PHARMACOLOGICAL THERAPIES FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**  
Pavit Luthra, United Kingdom; Burr N.; Brenner D. M.; Ford A. C.

10:54 – 11:06 OP327  
**EPIDEMIOLOGY OF DIVERTICULAR DISEASE OF THE COLON: AN ANALYSIS FROM THE INTERNATIONAL "DICA" PROSPECTIVE STUDY**  
 Tursi A.; Brandimarte G.; Francesco Di Mario, Italy; Elisei W.; Picchio M.; Allegretta L.; Annunziata M. L.; Bafutto M.; Bassotti G.; Bianco M. A.; Conigliaro R. L.; Costin S.; Danese S.; Dumitrascu D. L.; Escalante R.; Faggiani R.; Franceschi M.; Graziani M. G.; Lammert F.; Latella G.; Maconi G.; Nardone G.; Camara de Castro Oliveira L.; Oliveira E. C.; Papa A.; Papagrigoriadis S.; Penna A.; Pietrzak A.; Reichert M.; Rodinò S.; Poskus T.; Regula J.; Scaldaferrri F.; Vassallo R.; Zullo A.; Walker M.

11:06 – 11:18 OP328  
**OUTLET DYSFUNCTION IS PREVALENT IN SEVERE FUNCTIONAL BLOATING: A PROSPECTIVE, MULTI-CENTER, ITALIAN STUDY**  
Paola Iovino, Italy; Neri M. C.; D'Alba L.; Chiarioni G.

11:18 – 11:30 OP329  
**SENSORY AFFERENT INNERVATION AND CORTICAL ACTIVATION ARE IMPORTANT PATHOPHYSIOLOGICAL FACTORS IN FECAL INCONTINENCE IN WOMEN**  
Lluís Mundet, Spain; Cabib C.; Ortega Fernández O.; Rofes L.; Clavé P.

11:30 – 11:42 OP330  
**PREVALENCE OF, AND PREDICTORS OF, A POSITIVE SEHCAT SCAN FOR BILE ACID DIARRHOEA IN GASTROENTEROLOGY OUTPATIENTS: A FOLLOW-UP STUDY.**  
Shujing Jane Lim, United Kingdom; Black C.; Clegg I.; Chowdhury F.; Ford A. C.

11:42 – 11:54 OP331  
**A PROSPECTIVE VALIDATION STUDY: 7&#945;-HYDROXY-4-CHOLESTEN-3-ONE IS SUPERIOR TO FIBROBLAST GROWTH FACTOR-19 STIMULATED WITH A MEAL PLUS CHENODEOXYCHOLIC ACID FOR DIAGNOSING BILE ACID DIARRHOEA** ✦  
Christian Borup, Denmark; Wildt S.; Rumessen J. J.; Graff J.; B. Andersen T.; Zaremba A.; Vinter-Jensen L.; Nøjgaard C.; B. Timm H.; Gregersen T.; German Jørgensen S. P.; Bouchelouche P.; Rainteau D.; Layani-Moreno S.; Munck L. K.

### Abstract-Based Session

10:30 – 12:00 Room L8  
**Microbiota in IBD**  
 Chairs: Julia König, Sweden  
 Harry Sokol, France

10:30 – 10:42 IP594  
**State-of-the-art introduction**  
 Harry Sokol, France

10:42 – 10:54 OP332  
**EXPOSURE TO MICROBIOTA EARLY IN LIFE DETERMINES COLITIS SEVERITY IN ADULT MICE**  
Ziad Al Nabhani, France; Dulauroy S.; Polomack B.; Eberl G.

10:54 – 11:06 OP333  
**ULCERATIVE COLITIS PATIENTS IN LONG-TERM STABLE REMISSION RECOVER EUBIOTIC CHARACTERISTICS OF THEIR MICROBIOTA**  
 Claudia Herrera de Guise, Spain; Varela E.; Robles V.; Casellas F.; Borrueal Sainz N.; Guarner Aguilar F.

11:06 – 11:18 OP334  
**COMPARISON OF INTESTINAL MICROBIOTA COMPOSITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES DEPENDING ON THE PLACE OF RESIDENCE (URBAN OR RURAL) ✦**  
 Danilova N.; Maria Markelova, Russian Federation; Abdulkhakov S.; Grigoryeva T.; Odintsova A.; Abdulkhakov R.

11:18 – 11:30 OP335  
**DONOR MICROBIOTA AS A DETERMINANT FACTOR FOR RESPONSE TO FMT IN PATIENTS WITH ULCERATIVE COLITIS**  
 Tarkan Karakan, Turkey; Karatas; A.; Demirbas; Yuceldi S.; Gök Z.; Cindoruk M.; Akgun A.

11:30 – 11:42 OP336  
**LINKING MUCUS DEPLETION AND MICROBIOME ALTERATIONS IN UC TO MUCOSAL ENERGY SUPPLY**  
 Sünderhauf A.; Bär F.; Hirose M.; Küstner A.; Pagel R.; Ibrahim S.; Derer S.; Christian Sina, Germany

11:42 – 11:54 OP337  
**IDENTIFICATION OF A BILE ACID PROFILE AND GUT MICROBIOME COMMUNITY STRUCTURE ASSOCIATED WITH EARLY FLARE AFTER NUTRITIONAL THERAPY IN PAEDIATRIC CROHN'S DISEASE**  
 Allott J.; Dunn K.; Connors J.; Bandsma R.; Whitehouse S.; MacIntyre B.; Noble A.; Rashid M.; Otleay A.; Bielawski J.; Johan Van Limbergen, Canada

**Symposium**  
 10:30 – 12:00 Room Hotspot  
**Managing pain in chronic pancreatitis**  
 Chairs: Matthias Löhr, Sweden



10:30 – 10:33 IP595  
**Introduction**  
 Matthias Löhr, Sweden

10:33 – 10:38 IP596  
**Pain due to early chronic pancreatitis exists!**  
 Suresh Thiruvenka Chari, United States

10:38 – 10:53 IP597  
**PANEL DISCUSSION**

10:53 – 10:58 IP597  
**No smoking and no alcohol makes the pain go away!**  
 J. Enrique Dominguez-Munoz, Spain

10:58 – 11:13 IP598  
**PANEL DISCUSSION**  
 11:13 – 11:18  
**Medical therapy is the key to effective treatment of pancreatic pain**  
 Asbjørn Drewes, Denmark

11:18 – 11:33 IP599  
**PANEL DISCUSSION**  
 11:33 – 11:38  
**Never call the surgeon first**  
 Marco J. Bruno, The Netherlands

11:38 – 11:53 IP600  
**PANEL DISCUSSION**  
 11:53 – 11:56  
**Conclusion**  
 Matthias Löhr, Sweden

**Case-Based Discussion**  
 12:45 – 13:45 Room G  
**Management of complications after upper GI surgery**  
 Chair: Bas L. A. M. Weusten, The Netherlands  
 Experts: Jacques Deviere, Belgium  
 Andrea May, Germany  
 Bas L. A. M. Weusten, The Netherlands  
 Bas P. L. Wijnhoven, The Netherlands

**Case-Based Discussion**  
 12:45 – 13:45 Room K  
**Challenging cases for biliary drainage**  
 Chair: Benedetto Mangiavillano, Italy  
 Experts: Raneem Albazaz, United Kingdom  
 Benedetto Mangiavillano, Italy  
 Maxime Palazzo, France  
 Manuel Pérez-Miranda, Spain

**Case-Based Discussion**  
 12:45 – 13:45 Room M  
**Functional consequences of bariatric procedures**  
 Chair: Mario Morino, Italy  
 Experts: Nicole Bouvy, The Netherlands  
 Mario Morino, Italy  
 Salvatore Tolone, Italy  
 Radu Tutuian, Switzerland

**Case-Based Discussion**  
 12:45 – 13:45 Room N1  
**Infectious diseases**  
 Chair: Christoph Högenauer, Austria  
 Experts: Christoph Högenauer, Austria  
 Alain Schoepfer, Switzerland  
 Gigi Veereman, Belgium  
 Knut-Arne Wensaas, Norway

<b>Symposium</b>			
14:00 – 15:30	Room D	14:22 – 14:44	IP610
<b>IBD: What's new in 2018?</b>		<b>In the colon and the rectum</b>	
Chairs: Raja Atreya, Germany Iris Dotan, Israel		Heiko Pohl, United States	
		14:44 – 15:06	IP611
		<b>In ERCP</b>	
		Jacques Deviere, Belgium	
		15:06 – 15:28	IP612
14:00 – 14:22	IP601	<b>In the small bowel</b>	
<b>Ulcerative colitis in 2018</b>		Cristiano Spada, Italy	
Silvio Danese, Italy			
14:22 – 14:44	IP602	<b>Symposium</b>	
<b>Crohns disease in 2018</b>		14:00 – 15:30	Room F1
James C. Lee, United Kingdom		<b>Barrett's oesophagus: What's new in 2018?</b>	
14:44 – 15:06	IP603	Chairs: Raf Bisschops, Belgium Oliver Pech, Germany	
<b>Imaging evaluation of disease activity and treatment response</b>			
Stuart Taylor, United Kingdom			
15:06 – 15:28	IP604	14:00 – 14:22	IP613
<b>Novel surgical developments in 2018</b>		<b>Is there a room for non-invasive testing?</b>	
Willem A. Bemelman, The Netherlands		Massimiliano di Pietro, United Kingdom	
<b>Advances in Clinical GI &amp; Hepatology</b>		14:22 – 14:44	IP614
14:00 – 15:30	Room E1	<b>Improving neoplasia detection during endoscopy</b>	
<b>Advances in the management of cirrhosis</b>		Raf Bisschops, Belgium	
Chairs: Beate Appenrodt, Germany Helen Reeves, United Kingdom		14:44 – 15:06	IP615
		<b>Is there a next step in endoscopic management?</b>	
		Jacques J. Bergman, The Netherlands	
		15:06 – 15:28	IP616
14:00 – 14:22	IP605	<b>Surveillance and when to refer</b>	
<b>Identification and surveillance of patients with portal hypertension</b>		Bas L. A. M. Weusten, The Netherlands	
Dominique Thabut, France		<b>Symposium</b>	
14:22 – 14:44	IP606	14:00 – 15:30	Room F2
<b>Management of bleeding</b>		<b>Coeliac disease: What's new in 2018?</b>	
Rafael Banares, Spain		Chairs: Jorge Amil Dias, Portugal Sabine Roman, France	
14:44 – 15:06	IP607		
<b>Management of ascites</b>			
Richard Moreau, France		14:00 – 14:22	IP617
15:06 – 15:28	IP608	<b>Pathogenesis</b>	
<b>Screening and Management of HCC in viral cirrhosis</b>		Detlef Schuppan, Germany	
Pierre Nahon, France		14:22 – 14:44	IP618
<b>Symposium</b>		<b>Changing the clinical picture in young patients</b>	
14:00 – 15:30	Room E2	Kalle Kurppa, Finland	
<b>Endoscopy: What's new in 2018?</b>		14:44 – 15:06	IP619
Chairs: Tomas Hucl, Czech Republic Rodrigo Jover Martínez, Spain		<b>Refractory coeliac disease</b>	
		Georgia Malamut, France	
		15:06 – 15:28	IP620
14:00 – 14:22	IP609	<b>Therapy besides gluten-free diet</b>	
<b>In oesophago-gastro disorders</b>		Roberto De Giorgio, Italy	
Krish Ragunath, United Kingdom			

**Symposium**  
 14:00 – 15:30 Room G  
**EUS: What's new in 2018?**  
 Chairs: Luca Barresi, Italy  
 Alexander Meining, Germany



14:00 – 14:22 IP621  
**FNB needles: What are the advantages to obtaining histology samples?**  
 Silvia Carrara, Italy

14:22 – 14:44 IP622  
**Through-the-needle diagnostic tools: Current status and perspectives**  
 Marcin Polkowski, Poland

14:44 – 15:06 IP623  
**What's new in EUS-guided drainage and anastomosis?**  
 Marc Barthet, France

15:06 – 15:28 IP624  
**What's new in EUS-guided tumour therapy?**  
 Julio Iglesias-Garcia, Spain

**Symposium**  
 14:00 – 15:30 Room K  
**IBS: What's new in 2018?**  
 Chairs: Viola Andresen, Germany  
 Lesley Houghton, United Kingdom



14:00 – 14:22 IP625  
**Pathophysiology**  
 Guy E. Boeckxstaens, Belgium

14:22 – 14:44 IP626  
**Biomarkers**  
 Lin Chang, United States

14:44 – 15:06 IP627  
**Diet and microbiota**  
 Premysl Bercik, Canada

15:06 – 15:28 IP628  
**Novel treatments**  
 Giovanni Barbara, Italy

**Symposium**  
 14:00 – 15:30 Room M  
**Hepatology: What's new in 2018?**  
 Chairs: Vincent Leroy, France  
 Marco Marzioni, Italy



14:00 – 14:22 IP629  
**Cholestatic liver diseases**  
 Ana Lleo, Italy

14:22 – 14:44 IP630  
**Viral hepatitis**  
 Heiner Wedemeyer, Germany

14:44 – 15:06 IP631  
**NASH**  
 Stuart McPherson, United Kingdom

15:06 – 15:28 IP632  
**Cirrhosis**  
 Mária Papp, Hungary

**Symposium**  
 14:00 – 15:30 Room 1.61/1.62  
**Pancreatology: What's new in 2018?**  
 Chairs: Suresh Thiruvenga Chari, United States  
 Thomas M. Gress, Germany

14:00 – 14:22 IP633  
**Acute pancreatitis**  
 Santhi Swaroop Vege, United States

14:22 – 14:44 IP634  
**Chronic pancreatitis**  
 Matthias Löhr, Sweden

14:44 – 15:06 IP635  
**Pancreatic cancer**  
 Hana Algül, Germany

15:06 – 15:28 IP636  
**Cystic pancreatic lesions**  
 Djuna L. Cahen, The Netherlands

**Symposium**  
 14:00 – 15:30 Room N1  
**Nutrition: What's new in 2018?**  
 Chairs: Marianna Arvanitakis, Belgium  
 Francisca Joly, France

14:00 – 14:22 IP637  
**Diet as first line therapy in eosinophilic esophagitis**  
 Javier Molina Infante, Spain

14:22 – 14:44 IP638  
**Low FODMAP diet in IBS: Is it really useful?**  
 Magnus Simrén, Sweden

14:44 – 15:06 IP639  
**When to use probiotics: Recent novelties**  
 Fergus Shanahan, Ireland

15:06 – 15:28 IP640  
**Nutrition in IBD**  
 Stephan Bischoff, Germany

# E-Poster Sessions by Day

## Overview Icons



Poster in the Spotlight



Poster Champ



Clinical Case Session

Poster Champs are awarded in the following categories:

1. Upper gastrointestinal diseases
2. Lower gastrointestinal diseases
3. Liver, biliary and pancreatic diseases
4. Surgery, endoscopy and imaging

Four sessions run in parallel from Monday until Wednesday from 12:30 – 13:30 at the e-poster terminals in the poster exhibition in Hall X1. 2-minutes presentations of the highest scoring posters are followed by 3-minutes Q&As from the chairs.

All UEG Week 2018 attendees are kindly invited to join these sessions and the Poster Champ award ceremony held at the award stage 13:45 every day.

Posters in the Spotlight will be presented additionally in dedicated sessions held daily at the E-Poster terminals 1 and 4.

There are three dedicated clinical case sessions on Tuesday, taking place at the E-Poster terminals 1 and 4.

## E-Poster Sessions by Day

### Monday, October 22, 2018

#### Posters in the Spotlight

10:30 – 12:00 E-Poster Terminal 1 (Hall X1)

**Natural history and management of small bowel diseases**

Chairs: Roberto De Giorgio, Italy  
Georgia Malamut, France



P0593

**PREDICTIVITY OF AUTOIMMUNE STIGMATA FOR GLUTEN SENSITIVITY IN SUBJECTS WITH MICROSCOPIC ENTERITIS: A RETROSPECTIVE STUDY**

P0619

**NATURAL HISTORY OF POTENTIAL CELIAC DISEASE: FACTORS PREDICTING EVOLUTION TO VILLOUS ATROPHY**

P0598

**MICRORNA PROFILING AS A GUIDE TO PERSONALIZED MEDICINE IN ENTEROPATHY ASSOCIATED T-CELL LYMPHOMA AND REFRACTORY CELIAC DISEASE**

P0601

**FEASIBILITY OF DOUBLE-BALLOON ENDOSCOPY-ASSISTED ENDOSCOPIC BALLOON DILATION OF STRICTURES SECONDARY TO PRIMARY SMALL INTESTINAL LYMPHOMA**

P0604

**PROGRAMMED CELL DEATH LIGAND-1 EXPRESSION IS ASSOCIATED WITH MICROSATELLITE INSTABILITY IN NON-FAMILIAL SMALL BOWEL CARCINOMAS: RESULTS FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM**

P0558

**SAFETY AND EFFICACY OF THE NEW THULIUM / ERBIUM LASER SYSTEM IN PATIENTS WITH GASTROINTESTINAL BLEEDING FROM VASCULAR LESIONS.**

#### Posters in the Spotlight

10:30 – 12:00 E-Poster Terminal 4 (Hall X1)

**From microbiota to IBD**

Chairs: Franck Carbonnel, France  
Gianluca Ianiro, Italy



P0392

**DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION**

P0389

**FAECAL MICROBIAL TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE INFECTION- A NATIONAL ISRAELI EXPERIENCE**

P0435

**SCAR-BIOPSIES AFTER MALIGNANT COLORECTAL POLYPECTOMY OF UNCERTAIN RADICALITY**

P0288

**IMPAIRED BUTYRATE INDUCED ANTI-INFLAMMATORY IMMUNE REGULATION IN LAMINA PROPRIA CELLS FROM PATIENTS WITH ACTIVE ULCERATIVE COLITIS**

P0291

**THE PREVALENCE OF GASTROINTESTINAL CANCERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A DANISH NATIONWIDE COHORT STUDY**

P0320

**VALIDATION AND INVESTIGATION OF THE OPERATING CHARACTERISTICS OF THE ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY**

#### Poster Champ Session

12:30 – 13:30 E-Poster Terminal 1 (Hall X1)

**Poster Champ Session: Surgery, endoscopy and imaging**

Chairs: Ulrich Nitsche, Germany  
Salvatore Tolone, Italy



P0175

**FULLY AUTOMATED DIAGNOSIS SYSTEM WITH ARTIFICIAL INTELLIGENCE USING ENDOCYTOSCOPY TO IDENTIFY HISTOLOGICAL INFLAMMATION ASSOCIATED WITH ULCERATIVE COLITIS**

P0192

**CLASSIFICATION OF NUCLEAR MORPHOLOGY OF EC FINDINGS IN COLORECTAL ENDOCYTOSCOPY**

P0260

**A COMPREHENSIVE COMPARISON OF THE FIVE LEADING SCORINGS SYSTEMS FOR PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORIGIN TO SELECT CRS/HIPEC CANDIDATES WITH MRI.**

P0149

**ENDOSCOPIC INTERVENTION FOR PANCREATIC FLUID COLLECTIONS HAS BETTER OUTCOMES THAN PERCUTANEOUS OR SURGICAL DRAINAGE- A META-ANALYSIS**

P0125

**CLINICAL VALUES OF DENTAL FLOSS TRACTION ASSISTANCE IN ENDOSCOPIC FULL-THICKNESS RESECTION FOR SUBMUCOSAL TUMORS ORIGINATING FROM THE MUSCULARIS PROPRIA LAYER IN THE GASTRIC FUNDUS**



P0141

**NARROW BAND IMAGING ENDOSCOPY VERSUS LUGOL CHROMOENDOSCOPY IN EARLY DETECTION OF ESOPHAGEAL CANCER IN PATIENTS WITH HEAD AND NECK CANCERS: RANDOMIZED TRIAL**

P0143

**RISK FACTORS OF METACHRONOUS GASTRIC NEOPLASM BEYOND 5 YEARS AFTER ENDOSCOPIC RESECTION FOR EARLY GASTRIC CANCER.**

P0208

**FEASIBILITY OF A NEW SHORT-TYPE DOUBLE-BALLOON ENDOSCOPE WITH ADVANCED FORCE TRANSMISSION AND ADAPTIVE BENDING FOR PANCREATICOBILIARY INTERVENTION IN PATIENTS WITH SURGICALLY ALTERED ANATOMY: A PROPENSITY-MATCHED ANALYSIS**

P0147

**AND WHEN NBI DOESN'T SHOW GASTRIC INTESTINAL METAPLASIA: DO WE STILL NEED TO SEPARATE BIOPSY SAMPLES INTO DIFFERENT VIALS?**

P0151

**THE CLINICAL IMPACT OF CLOSURE OF THE MUCOSAL DEFECT AFTER DUODENAL ESD**

P0162

**INCREASED WITHDRAWAL TIME ALONE MAY NOT IMPROVE ADENOMA DETECTION RATE: A MULTI-CENTRE STUDY ON IMPACT OF INDIVIDUAL QUALITY SCORECARDS**

P0209

**POSITIVE CORRELATION BETWEEN PANCREATIC PARENCHYMAL VOLUME AND PEP**

### Poster Champ Session

12:30 – 13:30 E-Poster Terminal 2 (Hall X1)

**Poster Champ Session: Liver, biliary and pancreatic diseases**

Chairs: Peter Robert Galle, Germany

Maxime Palazzo, France



P0034

**DERIVATION AND VALIDATION OF A STATISTICAL MODEL TO FORECAST LONG TERM ALL-CAUSE MORTALITY IN PEOPLE WITH CIRRHOSIS**

P0035

**SAFETY AND EFFICACY OF RIFAXIMIN IN PROPHYLAXIS OF SPONTANEOUS BACTERIAL PERITONITIS: IS THIS TIME TO ABANDON FLUOROQUINOLONES FOR PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS? : A SYSTEMATIC REVIEW.**

P0021

**ANTIOXIDANT PROPERTIES OF CELECOXIB REDUCE HEPATIC VASCULAR RESISTANCE AND PORTAL PRESSURE IN CIRRHOTIC RATS**

P0045

**REAL-WORLD DATA OF DIRECT-ACTING ANTIVIRALS FOR 2,063 JAPANESE CHRONIC HEPATITIS C PATIENTS: THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP (KULDS)**

P0048

**COMPARISON OF THE LEVELS OF CIRCULATING MICRORNA-122 IN HCV-RELATED CIRRHOSIS PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA**

P0025

**OUTCOMES OF LARGE VOLUME PARACENTESIS IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS.**

P0042

**DENGUE HEPATITIS: A DIFFERENTIAL DIAGNOSIS TO REMEMBER IN EUROPE**

P0059

**COMPARISON OF THE DIAGNOSTIC ACCURACIES OF MAGNETIC RESONANCE TECHNIQUE AND TRANSIENT ELASTOGRAPHY FOR EVALUATING HEPATIC STEATOSIS IN NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS**

P0064

**TRUE SEVERITY OF LIVER STEATOSIS AND FIBROSIS IN TYPE 2 DIABETES MELLITUS PATIENTS**

P0112

**PANCREATIC CANCER CELLS ENRICH PHOSPHO-PAXILIN IN THEIR FILOPODIA DURING NEURAL INVASION**

P0020

**TM6SF2 AND MBOAT7 GENE VARIANTS ARE NOT ASSOCIATED WITH THE RISK OF DEVELOPING LIVER FIBROSIS AND CIRRHOSIS IN AN EASTERN EUROPEAN POPULATION**

P0033

**DERIVATION AND VALIDATION OF A STATISTICAL MODEL TO FORECAST THREE-MONTH, ALL CAUSE MORTALITY IN SUBJECTS ADMITTED WITH INCIDENT DIAGNOSIS OF CIRRHOSIS**



## Poster Champ Session

12:30 – 13:30 E-Poster Terminal 3 (Hall X1)  
**Poster Champ Session: Lower gastrointestinal diseases**  
 Chairs: Adam Donald Farmer, United Kingdom  
 Klaus Mönkemüller, Germany



P0463  
**PREVENTING COLON CANCER VS. EARLY DIAGNOSIS, WHAT IS BEST? A META-ANALYSIS OF THE U.S. PREVENTIVE SERVICES TASK FORCE EVIDENCE REPORT ON SCREENING TESTS**

P0333  
**VALIDATION OF THE RIDA@QUICK ADM MONITORING: A RAPID TEST FOR ADALIMUMAB DRUG CONCENTRATION MONITORING WHICH SUPPORTS TIMELY DOSE ADJUSTMENTS IN CLINICAL PRACTICE**

P0348  
**INDUCTION THERAPY OF UPADACITINIB IS ASSOCIATED WITH IMPROVED SYMPTOMS IN BOWEL URGENCY AND ABDOMINAL PAIN FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE**

P0297  
**LONG TERM STABILITY OF SEROLOGICAL ANTIBODIES IN A POPULATION-BASED INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE – THE IBSEN STUDY**

P0379  
**ENTERIC RESECTION IN CROHN'S DISEASE - IS THERE A RELATIONSHIP BETWEEN THE TIMING OF IMMUNOSUPPRESSION ONSET AND THE EXTENSION OF THE RESECTED SMALL BOWEL?**

P0431  
**RAID-LS: A NON-INVASIVE TOOL BASED ON A FAECAL BACTERIAL SIGNATURE FOR LYNCH SYNDROME SURVEILLANCE**

P0329  
**THE ASSOCIATION BETWEEN DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN EUROPE**

P0423  
**PEDUNCULATED MORPHOLOGY IS AN INDEPENDENT RISK FACTOR FOR A FAVORABLE ONCOLOGIC OUTCOME IN PATIENTS WITH T1 COLORECTAL CANCER**

P0272  
**NEUTROPHIL EXTRACELLULAR TRAPS SUSTAIN INFLAMMATORY SIGNALS IN ULCERATIVE COLITIS**

P0315  
**IBD PATIENTS ARE FOUR TIMES MORE LIKELY TO DEVELOP ALL TYPES OF SKIN CANCER POSSIBLY RELATED TO HIGH RATES OF IMMUNOSUPPRESSION; WITH YOUNG PATIENTS PARTICULARLY AT RISK OF MELANOMA**

P0345  
**ANTI-TNF INDUCED LUPUS (ATIL) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.**

P0404  
**COMPARISON OF COLORECTAL POLYPS WITH SIZE BETWEEN 6 AND 20 MILLIMETERS IN YOUNGER AND OLDER INDIVIDUALS**

## Poster Champ Session

12:30 – 13:30 E-Poster Terminal 4 (Hall X1)  
**Poster Champ Session: Upper gastrointestinal diseases**  
 Chairs: Julio Iglesias-Garcia, Spain  
 Madalina Ilie, Romania



P0560  
**QUANTIFYING EXCESS CARDIO-RESPIRATORY EVENTS AND ADMISSIONS FOLLOWING DAY CASE DIAGNOSTIC GASTROSCOPY**

P0615  
**SAFETY AND EFFECTIVENESS OF PER-ORAL ENDOSCOPIC MYOTOMY IN CHILDREN WITH ACHALASIA: A COMPARISON OF THE RESULTS IN PAEDIATRIC AND ADULT PATIENTS**

P0574  
**MEDICATION DIARY CARD ON THE ERADICATION RATE AND SYMPTOM REMISSION OF PATIENTS INFECTED BY HELICOBACTER PYLORI**

P0466  
**IDENTIFYING FGF18 AS A POTENTIAL ONCOGENE AND MIR-590-5P TARGET IN GASTRIC TUMORIGENESIS.**

P0520  
**SELF-SIZING RADIOFREQUENCY ABLATION BALLOON FOR ERADICATION OF BARRETT'S ESOPHAGUS: RESULTS OF AN INTERNATIONAL MULTICENTER RANDOMIZED TRIAL COMPARING THREE DIFFERENT TREATMENT REGIMENS.**

P0579  
**SUSCEPTIBILITY-BASED TAILORED VS. EMPIRIC AMOXICILLIN MODIFIED BISMUTH QUADRUPLE THERAPY AS HELICOBACTER PYLORI THERAPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL**



P0474

**EFFECT OF MYD88 DEFICIENCY ON INTESTINAL INFLAMMATION AND MICROBIOTA IN COLITIS MICE**

P0479

**AIMS65 IS THE MOST ACCURATE RISK-SCORING SYSTEM FOR PREDICTING PROGNOSIS OF PATIENTS WITH DUODENAL ULCER BLEEDING.**

P0489

**MORTALITY RATE AND RISK FACTORS FOR GASTROINTESTINAL BLEEDING IN ELDERLY PATIENTS**

P0515

**HOW TO HANDLE TISSUE SPECIMENS AFTER ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ESOPHAGUS RELATED NEOPLASIA: A MULTICENTER RANDOMIZED TRIAL COMPARING THREE SPECIMEN HANDLING METHODS.**

P0529

**ENDOSCOPIC CRYOBALLOON ABLATION IS SAFE, WELL-TOLERATED AND HIGHLY EFFECTIVE IN THE ERADICATION OF ESOPHAGEAL SQUAMOUS CELL NEOPLASIA**

P0613

**EXCESSIVE BODY FATNESS AT YOUNG AGE INCREASES RISK OF COLORECTAL CANCER: META-ANALYSIS AND DOSE-RESPONSE ANALYSIS**

#### Posters in the Spotlight

14:00 – 15:30 E-Poster Terminal 1 (Hall X1)

**Diagnostic endoscopy**

Chairs: Jörg Albert, Germany  
Cesare Hassan, Italy



P0174

**OPTICAL BIOPSY OF DIMINUTIVE COLORECTAL POLYPS WITH REAL-TIME USE OF "ARTIFICIAL INTELLIGENCE"-ASSISTED ENDOSCOPY**

P0173

**COMPARISON OF COLONOSCOPY WITH VIRTUAL CHROMOENDOSCOPY USING THIRD GENERATION NARROW BAND IMAGING SYSTEM TO CHROMOENDOSCOPY WITH INDIGO CARMINE IN LYNCH PATIENTS.**

P0159

**SUPERIOR HIGH-QUALITY COLON CLEANSING WITH 1L NER1006 VERSUS SODIUM PICOSULFATE + MAGNESIUM CITRATE, 2L POLYETHYLENE GLYCOL + ASCORBATE, OR ORAL SULFATE SOLUTION: POST HOC POOLED ANALYSIS OF THREE RANDOMISED PHASE 3 CLINICAL TRIALS**

P0179

**DEVELOPMENT OF A REAL-TIME ENDOSCOPIC IMAGE DIAGNOSIS SUPPORT SYSTEM USING DEEP LEARNING TECHNOLOGY IN COLONOSCOPY**

P0194

**CLINICOPATHOLOGICAL FEATURES OF LOCAL RECURRENCE CASES RESECTED BY JUMBO FORCEPS BIOPSY USING NARROW BAND IMAGING ENDOSCOPY IN PATIENTS WITH DIMINUTIVE POLYPS**

P0185

**RATIO OF RIGHT-SIDED TO LEFT-SIDED DYSPLASTIC COLONIC POLYPS IS A VALID KEY PERFORMANCE INDICATOR**

#### Posters in the Spotlight

14:00 – 15:30 E-Poster Terminal 4 (Hall X1)

**Novelties in the HPB diseases**

Chairs: Elisabetta Bugianesi, Italy  
Dominique Thabut, France



P0055

**A NOVEL UK REGIONAL REAL-WORLD REGISTRY FOR PRIMARY BILIARY CHOLANGITIS (PBC) ALLOWING DATA LINKAGE FROM PRIMARY AND SECONDARY CARE**

P0075

**PRONOSTIC FACTORS IN PATIENTS WITH PORTAL CAVERNOMA: RESULTS OF A PROSPECTIVE COHORT OF 131 CASES**

P0108

**DIFFERENCES IN IMAGING STUDY BETWEEN LOCALIZED AUTOIMMUNE PANCREATITIS AND PANCREATIC CANCER : A MATCHED CASE-CONTROL STUDY**

P0115

**PANCREATIC ULTRASOUND ELASTOGRAPHY AND ITS CLINICAL USE IN PREDICTING THE RISK OF PANCREATIC FISTULAS AFTER PANCREATIC RESECTION**

P0032

**LONG TERM PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY IS POSSIBLE WITH LACTULOSE ALONE BUT MORE EFFECTIVE IF COMBINED WITH RIFAXIMIN: A SYSTEMATIC REVIEW WITH NUMBER NEEDED TO TREAT ANALYSES OF RANDOMISED CONTROLLED TRIALS**

P0069

**THE ALBI AND P-ALBI GRADES PREDICT SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING TRANSARTERIAL CHEMOEMBOLIZATION (TACE)**

## E-Poster Sessions by Day

### Tuesday, October 23, 2018

#### Poster Session

09:00 – 10:00 E-Poster Terminal 1 (Hall X1)

##### Exemplary Clinical Cases I

Chairs: Jörg Albert, Germany  
Aron Vincze, Hungary



CC085

#### DYSPHAGIA WITH SCHATZKI'S RING OR STEAKHOUSE SYNDROME: BETTER TO SCOPE THAN TO WATCH

Kyawzaw Lin, United States; Lin A. N.; Patel P.; Liauw M. X. W.; Reddy M.

CC086

#### D-LACTIC ACIDOSIS: RARE AND POTENTIALLY SEVERE COMPLICATION OF SHORT BOWEL SYNDROME

Masa Cavlina, Croatia; Ljubas-Kelecic D.; Barisic A.; Krznaric Z.

CC087

#### LATE METACHRONOUS ISOLATED PANCREATIC METASTASIS FROM RENAL CELL CARCINOMA MIMICKING A PANCREATIC NEUROENDOCRINE TUMOR

Hyung Ku Chon, Republic of Korea; Kim T. H.

CC089

#### ENDOSCOPIC FULL-THICKNESS RESECTION OF A T2 GASTRIC ADENOCARCINOMA IN A NON-SURGICAL PATIENT

Eduard Brunet, Spain; Junquera F.; Puig Diví V.; Martínez-Bauer E.; Orellana R.; Machlab S.; Miquel M.; Gallach M.; Brullet E.; Campo R.

CC090

#### MULTIPLE LYMPHOMATOUS POLYPOSIIS OF THE GASTROINTESTINAL TRACT SECONDARY TO MANTLE CELL LYMPHOMA: A CASE REPORT OF A 45-YEAR-OLD MALE.

Joana Carvão, Portugal; Magno Pereira V.; Faria M. G.; Sousa Andrade C.; Oliveira A.; Luís E.; CapelinhA A.; Jasmins L.

#### Poster Session

09:00 – 10:00 E-Poster Terminal 4 (Hall X1)

##### Exemplary Clinical Cases II

Chairs: Viola Andresen, Germany  
Patrizia Katharina Kump, Austria



CC091

#### INCREASED GASTRIC RETENTION CAPACITY AFTER APC TREATMENT OF DILATED GASTROJEJUNAL ANASTOMOSIS

Marco Silva, Portugal; Barrichello S.; de Quadros L. G.; Neto M. G.; Grecco E.; Souza T. F.; Moura E. G. H.; Santos A. L.; Macedo N.

CC092

#### KLEBSIELLA ENTERITIS ON THE BACKGROUND OF COMMON VARIABLE IMMUNODEFICIENCY AND BRONCHIECTASIS

Sun Mi Ha, United Kingdom; Al-Hasani H.; Sikafi R.; Bollas I.; Humphries A.; Kant T.; Mallet M.; Sattianayagam P.

CC093

#### BILIARY STENT COMBINED WITH APATINIB FOR ADVANCED HILAR CHOLANGIOCARCINOMA AFTER FAILURE OF HEPATIC ARTERIAL INFUSION: A CASE REPORT

Niu Hongtao, China; Sha J.; Wu J.; Dong Y.

CC094

#### CLOSURE OF ENTEROCUTANEOUS FISTULA AFTER DISSEMINATED TUBERCULOSIS TREATMENT IN A PATIENT WITH CROHN'S DISEASE - CHALLENGES IN BIOLOGIC THERAPY

João Carlos Silva, Portugal; Rodrigues A.; Silva A.P.; Rodrigues J.; Sousa M.; Ribeiro Gomes A.C.; Carvalho J.

CC095

#### LATE ONSET COLONIC CANCER OF A HOUSEWIFE IN A LI-FRAUMENI SYNDROME FAMILY WHOSE FATHER AND SON DIED YOUNG FROM BRAIN CANCER

Kenji Sasaki, Japan

CC096

#### DIFFUSE GANGLIONEUROMATOSIS OF THE COLON

Hubertus Heinrich Nietsch, Germany

#### Posters in the Spotlight

10:30 – 12:00 E-Poster Terminal 1 (Hall X1)

##### Colorectal carcinogenesis: From pathogenesis to diagnostics

Chairs: Dora Colussi, Italy  
Thomas Seufferlein, Germany



P1039

#### LIQUID BIOPSY IN COLORECTAL CANCER: DECIPHERING NOVEL NON-INVASIVE METHYLATION BIOMARKERS FOR COLORECTAL CANCER SCREENING IN SERUM CIRCULATING CELL-FREE DNA

P1033

#### MOLECULAR CHARACTERISTICS OF THE DEPRESSED EARLY COLORECTAL CANCERS (DEPRESSED CRC)

P1032

#### EMILIN2, A MATRICELLULAR MOLECULE, IMPACTS ON MDSC RECRUITMENT AND MACROPHAGE POLARIZATION IN A MODEL OF COLORECTAL CARCINOGENESIS AND CORRELATES WITH IMMUNOSCORE IN CRC PATIENTS.



P1035  
**COMPARISON OF IMMUNOPROFILING BETWEEN COLITIS-ASSOCIATED CANCER AND SPORADIC COLORECTAL CANCER**

P1030  
**INTEGRATIVE ANALYSIS OF GENE MUTATIONS AND DNA METHYLATION IN COLORECTAL SERRATED LESIONS**

P1034  
**ANALYSIS OF METHYLATION FIELD DEFECT IN SERRATED POLYPOSIS SYNDROME**

**Posters in the Spotlight**

10:30 – 12:00 E-Poster Terminal 4 (Hall X1)  
**Novelties in the HPB diseases**  
 Chairs: Laura Broutier, United Kingdom  
 Elisabetta Buscarini, Italy



P0727  
**CHRONIC USE OF STATINS AND AMINOSALICYLIC ACID AND INCIDENCE OF POST-ERCP ACUTE PANCREATITIS. PRELIMINARY DATA FROM THE STARK STUDY, A PROSPECTIVE INTERNATIONAL, MULTICENTER, COHORT STUDY**

P0743  
**A COMPOSITE LIQUID BIOMARKER FOR NON-INVASIVE DIAGNOSIS OF RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA**

P0703  
**TREND IN HOSPITALIZATION RATE FOR ALCOHOL HEPATITIS IN VENETO REGION (NORTHEAST ITALY)**

P0717  
**PEDIATRIC SUB-ACUTE HEPATIC FAILURE IN DEVELOPING COUNTRIES: RISK FACTORS THAT DETERMINE OUTCOME**

**Poster Champ Session**

12:30 – 13:30 E-Poster Terminal 1 (Hall X1)  
**Poster Champ Session: Surgery, endoscopy and imaging**  
 Chairs: Arjan Bredenoord, Netherlands  
 Antonino Spinelli, Italy



P0820  
**ENDOSCOPIC FEATURES OF RESPONSE TO NEOADJUVANT (CHEMO)RADIO THERAPY FOR RECTAL CANCER: PRELIMINARY RESULTS.**

P0793  
**FACTORS INFLUENCING ACHIEVEMENT OF ADEQUATE BOWEL PREPARATION: ANALYSIS OF THE EUROPEAN COLONOSCOPY QUALITY INVESTIGATION GROUP (EQI) PROCEDURE QUESTIONNAIRE**

P0852  
**UTILITY OF LIVER AND SPLEEN EUS-ELASTOGRAPHY AS A DIAGNOSTIC TOOL FOR PREDICTING LIVER CIRRHOSIS AND PORTAL HYPERTENSION: A PROSPECTIVE CASE-CONTROL STUDY.**

P0862  
**ADENOMA DETECTION RATES IS ASSOCIATED WITH RESPECTIVE WITHDRAWAL TIME IN DIFFERENT COLON SEGMENTS.**

P0762  
**CLINICAL EFFICACY OF THE OVER-THE SCOPE CLIP DEVICE: A SYSTEMATIC REVIEW**

P0832  
**INITIAL EXPERIENCES WITH TRANSPANCREATIC PRE-CUT SPHINCTEROTOMY**

P0796  
**DEEP LEARNING FOR REAL-TIME AUTOMATED POLYP LOCALISATION IN COLONOSCOPY VIDEOS**

P0884  
**CLINICOPATHOLOGIC CHARACTERISTICS RELATED TO LYMPH NODE METASTASIS IN EARLY GASTRIC CANCER AFTER GASTRECTOMY**

P0766  
**A STUDY OF THE POSSIBILITY OF COMPUTER-AIDED DIAGNOSIS USING MULTIPLE MACHINE LEARNING MODELS FOR THE DIAGNOSIS OF UPPER GASTROINTESTINAL ENDOSCOPIC IMAGING.**

P0813  
**DOES POLYP DETECTION RATE CORRELATE WITH MEAN ADENOMA PER COLONOSCOPY?**

P0822  
**WHICH FACTORS ARE RELATED TO A RISK OF DEVELOPING A PERFORATION AFTER A COLONOSCOPY IN AN ORGANISED POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME? A NESTED CASE-CONTROL STUDY**

P0837  
**IMPACT OF PERIAMPULLARY DIVERTICULUM ON ERCP PERFORMANCE: A MATCHED CASE-CONTROL STUDY**

## Poster Champ Session

12:30 – 13:30 E-Poster Terminal 2 (Hall X1)

Poster Champ Session: Liver, biliary and pancreatic diseases

Chairs: Mariusz Lucejko, Poland  
Ioannis Papanikolaou, Greece

P0714  
ASSESSMENT OF RISK FACTORS OF POST-PARACENTESIS CIRCULATORY DYSFUNCTION WITH MULTIPLE LARGE VOLUME PARACENTESIS IN CHILDREN WITH CHRONIC LIVER DISEASE: PROSPECTIVE LONGITUDINAL STUDY

P0676  
DIFFUSION-WEIGHTED MR IMAGING AND MICRO-RNA IN DIAGNOSIS AND STAGING OF HEPATIC FIBROSIS IN CHRONIC HEPATITIS C

P0671  
COMPARISON BETWEEN TWO POPULATION-BASED SEROSURVEYS, SIXTEEN YEARS AFTER THE IMPLEMENTATION OF UNIVERSAL HEPATITIS B VACCINATION IN A HEPATITIS DELTA ENDEMIC AREA IN GREECE.

P0681  
IMMEDIATE DIRECT-ACTING ANTIVIRAL THERAPY (DAA) OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION IMPROVES POST-TRANSPLANT SURVIVAL: SINGLE CENTRE EXPERIENCE (2014-2017).

P0679  
FROM ALFA-INTERFERON TO DAAS: IMPACT ON HOSPITALIZATION RATE FOR HCV LIVER RELATED DISEASES FROM 2000 TO 2016 IN NORTH EST ITALY

P0662  
THE POLYMORPHIC VARIANT OF SERPINB3 (SCCA-PD) IS ASSOCIATED WITH THE SEVERITY OF PORTAL HYPERTENSION AND COMPLICATIONS ONSET IN PATIENTS WITH ADVANCED LIVER DISEASE

P0692  
HEPATOCELLULAR CARCINOMA IN THE ELDERLY: CLINICAL CHARACTERISTICS, OUTCOMES AND TREATMENT EFFICACY, SAFETY IN OLDER THAN 75 YEARS

P0733  
RINT1 IS ESSENTIAL TO PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) HOMEOSTASIS

P0736  
PANCREATIC CYST SURVEILLANCE IMPOSES LOW PSYCHOLOGICAL BURDEN: PRELIMINARY RESULTS OF THE PACYFIC STUDY

P0739  
K-RAS MUTATION ANALYSIS BY DIGITAL PCR IN EUS-GUIDED FNA CYTOLOGY SPECIMENS AND CTDNA IMPROVE PANCREATIC CANCER DIAGNOSIS

P0677  
IMPROVEMENT OF LIVER STIFFNESS, INDIRECT PARAMETERS OF PORTAL HYPERTENSION IN CHRONIC HEPATITIS C VIRUS PATIENTS ONE YEAR AFTER SUSTAINED VIROLOGICAL RESPONSE TO DIRECT ACTING ANTIVIRALS.

P0707  
CLINICAL UTILITY OF NEWLY DEVELOPED MICROFLUIDIC DEVICE FOR DETECTING CIRCULATING TUMOR CELLS IN THE BLOOD OF PANCREATO-BILIARY MALIGNANCIES.

## Poster Champ Session

12:30 – 13:30 E-Poster Terminal 3 (Hall X1)

Poster Champ Session: Lower gastrointestinal diseases

Chairs: Yehuda Chowers, Israel  
Christian Maaser, Germany

P1005  
FAECAL CALPROTECTIN IN HEALTHY CHILDREN (0 TO 18 YEARS OLD) AND THE INFLUENCE OF AGE, GENDER AND ANTHROPOMETRY.

P0984  
SWITCH OF INFLIXIMAB ORIGINATOR TO BIOSIMILAR CT-P13 IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS IN A LARGE GERMAN IBD CENTER. A ONE YEAR, RANDOMIZED AND PROSPECTIVE TRIAL.

P0945  
THERAPEUTIC DRUG MONITORING OF ADALIMUMAB: A COMPARATIVE STUDY OF A NEW POINT-OF-CARE QUANTITATIVE TEST WITH THREE ESTABLISHED ELISA ASSAYS

P1081  
STRUCTURED PATIENT GROUP EDUCATION VERSUS STRUCTURED PATIENT EDUCATION VIA THE INTERNET FOR PATIENTS WITH IBS: A RANDOMIZED, CONTROLLED TRIAL

P0901  
SUCCINATE INDUCES EMT THROUGH SUCNR1

P0940  
GASTROINTESTINAL SYMPTOMS ARE COMMON IN U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS

P1023  
COMPARISON OF FIT-BASED COLORECTAL CANCER SCREENING PROGRAMMES

P1058  
ARTIFICIAL INTELLIGENCE CAN DETERMINE THE NEED FOR ADDITIONAL SURGERY AFTER ENDOSCOPIC RESECTION OF T1 COLORECTAL CANCER: ANALYSIS BASED ON BIG DATA FOR MACHINE LEARNING



P1019

**INHIBITORY EFFECT OF URSODEOXYCHOLIC ACID ON CLOSTRIDIUM DIFFICILE GERMINATION IS INSUFFICIENT TO PREVENT C. DIFFICILE COLITIS: A STUDY IN HAMSTERS AND HUMANS.**

P1027

**CLINICOPATHOLOGICAL AND COMPREHENSIVE ANALYSIS BY NEXT GENERATION SEQUENCING (NGS) IN APPENDICEAL MUCINOUS TUMOR**

P1038

**RISK FOR LYMPH NODE METASTASIS AND RECURRENT CANCER IN NON-PEDUNCULATED T1 COLORECTAL CARCINOMA STRATIFIED FOR CONSENSUS MOLECULAR SUBTYPES AND THE IMMUNOSCORE**

P0914

**MEDIATORS OF APOPTOSIS IN CIRCULATING LYMPHOCYTES OF IBD PATIENTS ARE DECREASED AND BCL-2 IS AN ACCURATE MARKER OF IBD**

#### Poster Champ Session

12:30 – 13:30 E-Poster Terminal 4 (Hall X1)  
**Poster Champ Session: Upper gastrointestinal diseases**  
 Chairs: Angelo Parello, Italy  
 Mathieu Pioche, France



P1162

**THE IMPACT OF THE POLICY-PRACTICE GAP ON COST-EFFECTIVENESS OF BARRETT'S OESOPHAGUS MANAGEMENT**

P1196

**OPTIMIZATION OF <sup>13</sup>C UREA BREATH TEST THRESHOLD LEVELS FOR THE DETECTION OF HELICOBACTER PYLORI INFECTION IN A NATIONAL REFERRAL LABORATORY**

P1152

**THE NEW P-CAB X482 WAS SAFE, TOLERABLE AND PROVIDED 24H INTRAGASTRIC CONTROL, AFTER SINGLE ORAL DOSES IN HEALTHY VOLUNTEERS**

P1208

**PAN-EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 1,200 PATIENTS**

P1211

**SINGLE-CAPSULE BISMUTH-BASED QUADRUPLE THERAPY AS SECOND-LINE OR SALVAGE TREATMENT FOR HELICOBACTER PYLORI INFECTION: A NEW WINDOW OF OPPORTUNITY IN A SOUTH-EUROPEAN COUNTRY?**

P1144

**DO WE HAVE TO EXCLUDE EPIGASTRIC SYMPTOMS TO DIAGNOSE GERD?**

P1188

**GENETIC EVENTS AND CLONAL DIFFERENCES IN MULTIPLE OCCURRENCE OF GASTRIC CANCER**

P1103

**DEVELOPMENT OF A NEW SCORE TO PREDICT MORTALITY AND INTERVENTION IN UPPER GASTROINTESTINAL BLEEDING. THE HA(MA)SH SCORE**

P1207

**META-ANALYSIS OF BISMUTH QUADRUPLE THERAPY IN SINGLE CAPSULE FOR THE ERADICATION OF HELICOBACTER PYLORI**

P1226

**IS SEROLOGY PREDICTIVE OF PERSISTING VILLOUS ATROPHY IN PATIENTS WITH ESTABLISHED COELIAC DISEASE?**

P1234

**ORAL AND EXTRA-ORAL BITTER TASTE RECEPTOR EXPRESSION IN A MODEL OF ANTIBIOTIC-INDUCED DYSBIOSIS**

P1096

**CHARACTERIZATION OF MUCOSAL AND FLUID MICROBIOME ACROSS STAGES OF GASTRIC CARCINOGENESIS**

#### Posters in the Spotlight

14:00 – 15:30 E-Poster Terminal 1 (Hall X1)  
**Evaluation of oesophageal and gastric function**  
 Chairs: Guillaume Gourcerol, France  
 Nathalie Rommel, Belgium



P1115

**HOW CAN WE MEASURE ACID SECRETION IN THE SINGLE PATIENT? A VALIDATED NON-INVASIVE SURROGATE TEST COMPARED WITH MAXIMAL ACID OUTPUT IN 600 PEOPLE**

P1124

**LONG BREAKS IN PERISTALTIC INTEGRITY SEEN IN FRAGMENTED AND FAILED SWALLOWS ON ESOPHAGEAL HIGH RESOLUTION MANOMETRY (HRM) PREDICT ABNORMAL REFLUX BURDEN BETTER THAN WEAK CONTRACTION VIGOR**

P1148

**ESOPHAGEAL HIGH RESOLUTION MANOMETRY CAN UNRAVEL THE MECHANISMS BY WHICH DIFFERENT BARIATRIC TECHNIQUES PRODUCE DIFFERENT REFLUX EXPOSURE**

P1135

**IMPACT OF ITOPRIDE AND DOMPERIDONE ON THE SENSITIVITY OF GASTRIC DISTENTION AND GASTRIC ACCOMMODATION IN HEALTHY VOLUNTEERS**

P1119

**EFFECT OF INTRACOLONIC GAS ON GASTRIC TONE AND SATIETY IN PATIENTS WITH CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME AND DYSPEPTIC SYMPTOMS**

P1120

**EVALUATION OF THE EFFECT OF ITRACONAZOLE, A POTENT CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF TAK-906, A PERIPHERALLY-SELECTIVE D<sub>2</sub>/D<sub>3</sub> DOPAMINE RECEPTOR ANTAGONIST**

### Posters in the Spotlight

14:00 – 15:30 E-Poster Terminal 4 (Hall X1)

#### Advanced endoscopy

Chairs: Nicole Bouvy, Netherlands  
James Edward East, United Kingdom



P0757

**A COMPARISON STUDY WITH ENDOSCOPIC ROBOT MANIPULATOR IN ESD : NOVICE AND EXPERT**

P0877

**LONG-TERM OUTCOME OF EUS-GUIDED GALLBLADDER DRAINAGE VS. PERCUTANEOUS GALLBLADDER DRAINAGE IN PATIENTS WHO ARE UNFIT FOR CHOLECYSTECTOMY: WHICH IS BETTER?**

P0839

**TOTALLY-ENDOSCOPIC ENTERAL ANASTOMOSES: A NEW EFFECTIVE WAY TO CHANGE THE TREATMENT OF POSTSURGICAL LATE COMPLICATIONS OF HEPATICO-JEJUNOSTOMY**

P0779

**COMBINED TREATMENT OF OVERWEIGHT WITH INTRAGASTRIC BALLOON AND LIRAGLUTIDE AT HIGH DOSE: IS IT WORTH?**

P0875

**EUS-GUIDED CHOLEDOCHODUODENOSTOMY USING A LUMEN APPOSING METAL STENT FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A RESTROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE**

P0777

**AN AUSTRALIAN EXPERIENCE WITH ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) FOR WEIGHT LOSS**

### Poster Session

15:45 – 17:15

E-Poster Terminal 1 (Hall X1)

#### Exemplary Clinical Cases III

Chairs: Georg Braun, Germany  
Rami Eliakim, Israel



CC097

**A CASE OF EPIDERMOLYSIS BULLOSA DYSTROPHICA WITH PROGRESSIVE DYSPHAGIA**

Salem O. E.; [Hussein Mahmoud Saad](#), Egypt

CC098

**SUPERIOR MESENTERIC ARTERY SYNDROME AND ANULAR PANCREAS REVEALED BY CHRONIC VOMITING: CASE REPORT**

[Amina Amjahdi](#), New Zealand; Akkaoui A.

CC099

**COMPLETE REMOVAL OF A LARGE GASTRIC DUPLICATION CYST THROUGH ENDOSCOPIC SUBMUCOSAL DISSECTION: A CASE REPORT**

[Angelique Elga Lo](#), Philippines; Prodigalidad P. A.; Galang R. L.; Ishida T.

CC100

**SUDDEN DYSPNEA IN A PATIENT WITH ULCERATIVE COLITIS**

[Juliana Costa](#), Portugal; Carvalho S. D.; Costeira F.; Vieira F.; Rolo R.; Gonçalves R.; Soares J. B.

CC101

**A CASE OF GAUZOMA SUCCESSFULLY TREATED WITH ENDOSCOPIC ULTRASOUND-GUIDED INTERVENTION.**

[Noriko Ishigaki](#), Japan; Harada T.; Shiraishi R.; Hanada H.

CC102

**AUTOIMMUNE HEPATITIS IN A YOUNG MAN WITH LIVER CIRRHOSIS – FIRST EPISODE WITH ACUTE DECOMPENSATION OF THE DISEASE AND AN IDENTICAL RELAPSE – A CLINICAL CASE WITH HERPES SIMPLEX VIRUS-1 INVOLVEMENT.**

[Ivan Valkov](#), Bulgaria; Antonov K.; Alexiev A.

CC103

**FEASIBLE AND EFFICACY OF ENDOSCOPIC SUTURING CLOSURE OF GASTRIC-GALLBLADDER FISTULA**

Li X.; Zhang W.; [Guoxin Zhang](#), China

CC104

**ENDOSCOPIC ULTRASOUND-GUIDED RECANALIZATION OF COMPLETE COLORECTAL ANASTOMOTIC STENOSIS USING LUMEN-APPPOSING METAL STENT**

[Gonçalo Nunes](#), Portugal; Pinto Marques P.; Allen M.

CC105

**DIAGNOSTIC CHALLENGE AND THERAPEUTIC APPROACH IN CYSTIC DYSTROPHY OF THE DUODENAL WALL (CDDW)**

[Alina Constantin](#), Samoa; Copescu C.; Saftoiu A.



## E-Poster Sessions by Day

### Wednesday, October 24, 2018

#### Posters in the Spotlight

09:00 – 10:00 E-Poster Terminal 1 (Hall X1)  
**H. pylori: Treatment resistance and progression to cancer**  
 Chairs: Cord Langner, Austria  
 Peter Malfertheiner, Germany



P1819  
**PAN-EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): BACTERIAL RESISTANCE OF 2,684 H. PYLORI ISOLATES**

P1838  
**HELICOBACTER PYLORI INFECTION AND THE INTERLEUKIN 8 -251 T&GT;A POLYMORPHISM MIGHT BE A RISK FACTOR OF GASTRIC CANCER**

P1834  
**INTERACTION OF H. PYLORI WITH TOLL-LIKE RECEPTOR 2 -196 TO -174,DEL POLYMORPHISM, IS ASSOCIATED WITH GASTRIC CANCER SUSCEPTIBILITY BUT NOT POOR PROGNOSIS IN CHINESE PATIENTS**

P1833  
**HELICOBACTER PYLORI CAGA PROMOTES EPITHELIAL MESENCHYMAL TRANSITION IN GASTRIC CARCINOGENESIS VIA TRIGGERING ONCOGENIC YAP PATHWAY**

#### Posters in the Spotlight

09:00 – 10:00 E-Poster Terminal 4 (Hall X1)  
**Novelties in the HPB diseases**  
 Chairs: Madalina Ilie, Romania  
 Stuart McPherson, United Kingdom



P1262  
**FATTY LIVER PROMOTES GAMMA-GLUTAMYL TRANSEPTIDASE ACTIVITY-INDUCED ARTERIAL PLAQUE FORMATION**

P1263  
**THE ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND MILD COGNITIVE IMPAIRMENT IN THE ELDERLY**

P1295  
**NEW IFN FREE TREATMENT IMPROVES METABOLIC PROFILE IN HCV-RELATED LIVER TRANSPLANT RECIPIENTS**

P1327  
**MONOFOCAL HEPATOCELLULAR CARCINOMA (HCC): SHOULD THE 5 CM CUT-OFF BE CONSIDERED AS FUNDAMENTAL? AN ANALYSIS OF THE ITA.LI.CA DATABASE**

#### Posters in the Spotlight

10:30 – 12:00 E-Poster Terminal 1 (Hall X1)  
**IBD: From basic mechanisms to the clinic**  
 Chairs: Edouard Louis, Belgium  
 Stephan Vavricka, Switzerland



P1534  
**TARGETED ANALYSIS OF SERUM PROTEINS ENCODED AT KNOWN INFLAMMATORY BOWEL DISEASE RISK LOCI**

P1654  
**THE GUT MICROBIOTA INFLUENCES INTESTINAL EPITHELIAL PROLIFERATIVE POTENTIAL**

P1552  
**A COMBINATION OF CLINICAL, SEROLOGICAL AND GENETIC FACTORS PREDICTS COMPLICATED DISEASE COURSE IN PAEDIATRIC-ONSET CROHN'S DISEASE: RESULTS FROM A POPULATION-BASED STUDY**

P1522  
**HIGH FAT DIET AGGRAVATES DEXTRAN SULFATE SODIUM (DSS)-INDUCED COLITIS THROUGH REGULATING IMMUNE RESPONSES OF GUT-ASSOCIATED LYMPHOID TISSUE**

P1586  
**PERSONALISED CARE WITH THE TELEMEDICINE TOOL MYIBDcoach IS COST-EFFECTIVE. A COST-UTILITY ANALYSIS OF THE MYIBDcoach TRIAL.**

P1583  
**QUANTIFIED TERMINAL ILEAL MOTILITY DURING MR ENTEROGRAPHY AS A BIOMARKER OF CROHN'S DISEASE ACTIVITY: A PROSPECTIVE STUDY**

#### Posters in the Spotlight

10:30 – 12:00 E-Poster Terminal 4 (Hall X1)  
**Advanced endoscopy**  
 Chairs: Francesc Balaguer, Spain  
 Alberto Murino, United Kingdom



P1379  
**SAFETY AND EFFICACY OF SUBMUCOSAL TUNNELING ENDOSCOPIC SEPTUM DIVISION FOR EPIPHEMIC DIVERTICULUM**

P1384  
**PER ORAL ENDOSCOPIC MYOTOMY USING TRIANGLE TIP KNIFE WITH OR WITHOUT WATER JET FUNCTION**



P1394  
**PERORAL ENDOSCOPIC MYOTOMY (POEM) IS EFFECTIVE IN TREATMENT OF NON CARDIAC CHEST PAIN CAUSED BY HYPERCONTRACTILE ESOPHAGEAL MOTILITY DISORDERS**

P1408  
**ROBOTIC FLEXIBLE ENDOSCOPY ALLOWING INTRA-LUMINAL SURGICAL TRIANGULATION FOR COMPLEX ENDOSCOPIC PROCEDURES: PRECLINICAL EXPERIENCE WITH 20 COLONIC ENDOSCOPIC MUCOSAL DISSECTIONS**

P1471  
**DO WE NEED ENDOSCOPIC ULTRASONOGRAPHY IN THE WORKUP OF PATIENTS WITH ACHALASIA?**

P1504  
**POSTOPERATIVE OUTCOMES OF THE DUTCH UPPER GASTROINTESTINAL CANCER AUDIT ACCORDING TO THE PLATFORM OF THE ESOPHAGEAL COMPLICATIONS CONSENSUS GROUP**

#### Poster Champ Session

12:30 – 13:30 E-Poster Terminal 1 (Hall X1)  
**Poster Champ Session: Surgery, endoscopy and imaging**  
 Chairs: Sarah Poetter-Lang, Austria  
 Fredrik Swahn, Sweden



P1490  
**POST IMAGING COLORECTAL CANCER IN THE ENGLISH NATIONAL HEALTH SERVICE BOWEL CANCER SCREENING PROGRAMME**

P1515  
**NAVIGATION SURGERY FOR LATERAL LYMPH NODE DISSECTION USING THREE-DIMENSIONAL PELVIC MODEL PRODUCED BY 3D PRINTER**

P1430  
**SCREENING COLONOSCOPY IN YOUNGER ADULTS- WHEN SHOULD WE START?**

P1448  
**POST-ERCP PANCREATITIS (PEP): MINIMIZING ROLE OF PANCREATIC DUCT (PD) STENTING WITH NON-INVASIVE COMBINATION THERAPY IN DIFFICULT CASES**

P1382  
**FLUORESCENT ENDOSCOPY DURING ESOPHAGEAL CARCINOGENESIS IN A MOUSE MODEL**

P1434  
**CHROMOENDOSCOPY WITH INDIGO CARMINE VERSUS ENDOCUFF FOR ADENOMA DETECTION RATE IN COLONOSCOPY: A RANDOMIZED CONTROLLED TRIAL.**

P1438  
**LONG TERM COLORECTAL CANCER INCIDENCE AND MORTALITY IN RELATION TO QUALITY OF A SINGLE NEGATIVE SCREENING COLONOSCOPY.**

P1439  
**SEDOANALGESIA COMPLICATIONS DURING A COLONOSCOPY. WHICH FACTORS ARE INVOLVED?**

P1484  
**FEASIBILITY AND SAFETY OF ROBOTICALLY CONTROLLED MAGNETIC CAPSULE ENDOSCOPY IN THE VISUALIZATION OF UPPER GASTROINTESTINAL TRACT**

P1513  
**SURGICAL RESECTION FOR TREATMENT OF COLORECTAL POLYPS: A SINGLE CENTRE RETROSPECTIVE COHORT STUDY**

P1375  
**A NOVEL TECHNIQUE FOR ENDOSCOPIC ENBLOC RESECTION FOR LESIONS UP TO 30 MM (EMR+)**

P1391  
**ENDOSCOPIC MUCOSAL AUTOGRAFT FOR REVERSING THE REFRACTORY ESOPHAGEAL CAUSTIC STRICTURE: THE PRELIMINARY HUMAN EXPERIENCE**

#### Poster Champ Session

12:30 – 13:30 E-Poster Terminal 2 (Hall X1)  
**Poster Champ Session: Liver, biliary and pancreatic diseases**  
 Chairs: Ana Lleo, Italy  
 Jonas Rosendahl, Germany



P1329  
**FUNCTIONAL CHANGES OF PANETH CELL IN THE INTESTINAL EPITHELIUM OF MICE WITH OBSTRUCTIVE JAUNDICE AND AFTER INTERNAL AND EXTERNAL BILIARY DRAINAGE**

P1260  
**DOES THE COFFEE VIA GUT-LIVER AXIS PLAY A BENEFICIAL EFFECT ON LIVER DAMAGE?**

P1291  
**NON-ALCOHOLIC FATTY LIVER DISEASE AFTER LIVER TRANSPLANTATION IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND CRYPTOGENIC CIRRHOSIS: THE IMPACT OF PRE-TRANSPLANT GRAFT STEATOSIS**

P1255  
**PLGA NANOPARTICLES BASED DELIVERY OF SRC KINASE SIGNALING PATHWAY INHIBITOR KX2-391 FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS**

P1341  
**DOPAMINE D2 RECEPTOR SIGNALING CONTROLS INFLAMMATORY STATUS OF MACROPHAGES IN ACUTE PANCREATITIS THROUGH INHIBITION OF OXIDATIVE STRESS-INDUCED NF- $\kappa$ B AND INFLAMMASOME ACTIVATION**



P1343  
**SMALLER PORTAL SYSTEM VEIN DIAMETERS PREDICT COMPLICATIONS AND OUTCOME IN ACUTE PANCREATITIS**

P1368  
**PREDICTION OF LOCAL RESECTABILITY OF PANCREATIC DUCTAL ADENOCARCINOMA: ARTIFICIAL INTELLIGENCE BEATS HUMAN INTELLIGENCE?**

P1253  
**MICRORNA-199A-3P PROMOTES THE ACTIVATION OF HEPATIC STELLATE CELLS AND LIVER FIBROSIS BY SUPPRESSING CAVEOLIN-2**

P1254  
**THE COMBINATION OF AN ANDROGEN, A BILE ACID AND AN EICOSANOID IS A PROMISING BIOMARKER FOR LIVER FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS**

P1259  
**MUCOSAL-ADHERENT ESCHERICHIA COLI NF73-1 ISOLATED FROM A PATIENT WITH NON-ALCOHOLIC STEATOHEPATITIS INDUCES LIVER INJURY IN HIGH FAT DIET MICE**

P1267  
**UDCA IMPROVED INSULIN SENSITIVITY AND METABOLIC PARAMETERS IN NASH PATIENTS**

P1367  
**ASSOCIATION BETWEEN PROGRESSION OF LOW RISK IPMNS AND DIABETES MELLITUS**

**Poster Champ Session**

12:30 - 13:30 E-Poster Terminal 3 (Hall X1)  
**Poster Champ Session: Lower gastrointestinal diseases**  
 Chairs: Johan Burisch, Denmark  
 Iris Dotan, Israel



P1652  
**KLOTHO SUPPRESSES SENESCENT MESENCHYMAL CELLS AND THE PROGRESSION OF COLORECTAL CANCER BY INHIBITING THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE VIA THE NF- $\kappa$ B PATHWAY**

P1668  
**ACID-RESPONSIVE DRUG-COMPLEXED POLYPEPTIDE NANOPARTICLE EFFECTIVELY AND SAFELY TREATS COLORECTAL CANCER**

P1670  
**ENDOSCOPIC FULL-THICKNESS RESECTION OF NEURO-ENDOCRINE TUMORS IN THE RECTUM - A SUBGROUP ANALYSIS OF THE GERMAN FTRD-REGISTRY**

P1689  
**ADENOSINE A2B RECEPTOR REGULATES COLONIC FLUID SECRETION IN MICE**

P1560  
**SERUM SIALIC-ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN (SIGLEC)-7 AS A FIBROGENIC BIOMARKER IN CROHN'S DISEASE**

P1563  
**ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE**

P1528  
**EXPLORING THE DIVERSITY OF MUTATIONAL LANDSCAPES IN IBD BY TISSUE PROFILING USING A TARGETED NEXT-GENERATION SEQUENCING (NGS) TUMOR PANEL**

P1580  
**PATIENT-NEAR ADALIMUMAB TROUGH-LEVEL TESTING BY A NOVEL QUANTITATIVE RAPID TEST; THE QUANTUM BLUE ADALIMUMAB ASSAY. IDA LINDSJØ, LISS-ANITA TOLLEFSEN, \*MILADA C. SMÅSTUEN. ARNE RØSETH. LOVISENBERG DIAKONALE HOSPITAL, \* OSLO METROPOLITAN UNIVERSITY, OSLO, NORWAY.**

P1617  
**SECONDARY LOSS OF RESPONSE TO VEDOLIZUMAB: EXPERIENCE FROM A SINGLE UNIVERSITY CENTRE**

P1656  
**SCNN1B FUNCTIONS AS A TUMOR SUPPRESSOR IN COLORECTAL CANCER BY INHIBITING THE MEK-ERK PATHWAY**

P1536  
**SHALLOW WHOLE GENOME SEQUENCING PREDICTS THE FUTURE CANCER RISK OF LOW GRADE DYSPLASTIC LESIONS ARISING IN ULCERATIVE COLITIS**

P1635  
**CHANGES OF HUMAN GUT MICROBIOTA FUNCTIONAL POTENTIAL AFTER HELICOBACTER PYLORI ERADICATION THERAPY**

**Poster Champ Session**

12:30 - 13:30 E-Poster Terminal 4 (Hall X1)  
**Poster Champ Session: Upper gastrointestinal diseases**  
 Chairs: Mikko Pakarinen, Finland  
 Pedro Pimentel Nunes, Portugal



P1746  
**RELATIONSHIP BETWEEN ESOPHAGEAL MOTILITY ABNORMALITIES AND SKIN INVOLVEMENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS: MULTIVARIATE ANALYSIS**

P1877

LOW CIRCULATING LEVELS OF CITRULLINE AND FGF19 PREDICT CHRONIC CHOLESTASIS AND POOR SURVIVAL IN ADULT PATIENTS WITH CHRONIC INTESTINAL FAILURE: DEVELOPMENT OF A MODEL FOR END-STAGE INTESTINAL FAILURE (MESIF RISK SCORE)

P1788

PLANNED SEMI-CIRCULAR ENDOSCOPIC SUBMUCOSAL DISSECTION FOR WIDESPREAD SUPERFICIAL ESOPHAGEAL CANCER

P1803

ENDOSCOPIC AND HISTOPATHOLOGICAL FINDINGS OF PATIENTS WITH GASTROINTESTINAL TRACT 18-FDG ACCUMULATION OF INCIDENTALLY FOUND ON PET/CT

P1858

IMPACT OF THE TIMING OF CAPSULE ENDOSCOPY IN OVERT OBSCURE GASTROINTESTINAL BLEEDING ON YIELD AND REBLEEDING RATE - IS SOONER THAN 14 D ADVISABLE?

P1848

DISTINCT MUCOSAL AND BLOOD MIRNA EXPRESSION PATTERNS MAY REPRESENT A RELIABLE MARKER FOR POSITIVE DISEASE DIAGNOSIS IN NON CELIAC GLUTEN SENSITIVITY

P1866

ASSESSING THE EFFECTS OF TWO PROBIOTIC FORMULATIONS ON CACO-2 CELL EPITHELIUM BARRIER MODEL

P1715

GASTROINTESTINAL BLEEDING AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION IS ASSOCIATED WITH A SHIFT TOWARD A PRO-ANGIOGENIC PHENOTYPE IN THE ANGIOPOIETIN AXIS

P1728

REBLEEDING AND MORTALITY ARE HIGHER IN PATIENTS WITH GASTROINTESTINAL BLEEDING TREATED WITH ANTICOAGULANTS THAN ANTI-PLATELETS

P1745

OESOPHAGEAL APERISTALSIS IS UNDER INVESTIGATED IN THOSE WITHOUT ACHALASIA OR REFLUX

P1751

PYLORIC DISTENSIBILITY MEASUREMENT AFTER GASTRIC SURGERY: WHICH SURGERY IS ASSOCIATED WITH PYLOROSPASM?


P1759

QUANTITATIVE PCR AS A NOVEL APPROACH TO DETERMINE INFLUENCE OF DENSITY OF BACTERIAL COLONISATION ON HEALTH AND DISEASE

## We give your ideas green light!

UEG provides a great collection of awards, fellowships and prizes to encourage research.

Find out more, visit [ueg.eu/awards-grants](http://ueg.eu/awards-grants)



# Poster Sessions by Day

## Overview Icons



Poster in the Spotlight



Poster Champ



Clinical Case Session

Posters are displayed from Monday, October 22 until Wednesday, October 24 in the poster exhibition in Hall X1. The posters are changed daily and are at display during the following times:



Monday	October 22	09:00 – 17:00
Tuesday	October 23	09:00 – 17:00
Wednesday	October 24	09:00 – 14:00

## Visit the E-Poster Terminals & Poster Champ Sessions

Find posters also electronically  
on the e-poster terminals in  
Hall X1.

Additionally 4 Poster Champ  
Sessions run in parallel each  
day from 12:30 – 13:30 in the  
poster exhibition and a Poster  
Champ will be selected out  
of the Posters of Excellence in  
each category.



E-Posters will  
be published on  
[ueg.eu/week/24-7](http://ueg.eu/week/24-7)

## Poster Sessions by Day Monday, October 22, 2018

### Poster Session

09:00 – 17:00

Hall X1

### Liver and Biliary I

#### Molecular biology, inflammation and fibrosis

P0001

#### MEDICAL EVALUATION ON SUSPICION OF NON-ALCOHOLIC STEATO-HEPATITIS (NASH): REAL WORLD OUTCOME FROM A COMMUNITY NASH CLINIC

Mohamed Ebrahim, Denmark; Schiødt F.; Willemoe G. L.; Dahl E. E.; Christensen E.; Rashid S.; Holm O.; Zander M.; Heitmann M.; Hansen M. B.

P0002

#### A METHOD FOR DETERMINING LIVER FIBROSIS USING A 13C-METHACETIN BREATH TEST

Yurii Medvedev, Russian Federation; Bakulin I.; Saiganov S.; Bakulina N.

P0003

#### INSULIN LIKE GROWTH FACTOR<sub>1</sub> AS A MARKER OF SEVERITY OF LIVER CIRRHOSIS

Ehab Ahmed Abdelatti, Egypt; Fathy W.; El Zorkany K.; Farag I.

P0004

#### METABOLOMICS IDENTIFIES ADVANCED FIBROSIS IN CHRONIC HCV INFECTION

Corina Radu, Romania; Grigorescu M.; Suciu A.; Stefanescu H.; Abrudan C.; Socaciu C.; Al Hajjar N.; Cavasi A.; Tantau M.; Vesa S.; Crisan D.

P0005

#### THE INFLUENCE OF HYPERGASTRINEMIA ON MOTILITY AND LIVER HISTOLOGICAL PECULIARITIES

Antonina Antonenko, Ukraine; Dvorshchenko K. O.; Pylypenko S.; Beregova T.; Ostapchenko L. I.

P0006

#### AMNION-DERIVED MESENCHYMAL STEM CELLS AMELIORATES SCLEROSING CHOLANGITIS IN RATS

Ryo Sugiura, Japan; Ohnishi S.; Ohara M.; Ishikawa M.; Miyamoto S.; Onishi R.; Yamamoto K.; Kawakubo K.; Kuwatani M.; Sakamoto N.

**Metabolic/genetic disorders**

P0007

**BODY MASS INDEX(BMI) AND ALCOHOL CONSUME ARE DIRECTLY RELATED WITH LIVER STEATOSIS. RESULTS FROM A PROSPECTIVE MULTICENTER STUDY OF PATIENTS REFERRED FOR HYPERFERRITINEMIA.**

Agustín Castiella, Spain; Zapata E.; Urreta I.; Zubiaurre L.; Otazua P.; Alustiza J. M.; Salvador E.; Letamendi G.; Arrizabalaga B.; Emparanza J. I.

P0008

**DYSMETABOLIC IRON OVERLOAD SYNDROME AND ITS RELATIONSHIP WITH HFE GENE MUTATIONS AND WITH LIVER STEATOSIS**

Agustín Castiella, Spain; Zapata E.; Urreta I.; Zubiaurre L.; Otazua P.; De Juan M.-D.; Alustiza J. M.; Salvador E.; Letamendi G.; Arrizabalaga B.; Emparanza J. I.

P0009

**NONALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH CORONARY ARTERY CALCIFICATION IN ASYMPTOMATIC INDIVIDUALS**

Young Min Sohn, Republic of Korea; Jeon Y.

P0010

**A POTENTIAL LINK BETWEEN POLYCYSTIC OVARY SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE: AN UPDATE META-ANALYSIS**

Xiaoyong Wang, China; Wu J.

P0011

**UDCA EFFICACY IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE**

Irina Pirogova, Russian Federation; Yakovleva S.; Neuymina T.

P0012

**HIGHER NON-INVASIVE FATTY LIVER INDEXES PREDICT COLORECTAL NEOPLASM AMONG YOUNG POPULATION**

Ssu Han Wang, Taiwan; Lin C.-K.; Chiu C.-M.; Chiu Y.-L.; Chung C.-S.

P0013

**MOLECULAR INVERSION PROBE ASSAY TO IDENTIFY NOVEL GENES ASSOCIATED WITH POLYCYSTIC LIVER DISEASE.**

Liyanne F. M. van de Laarschot, The Netherlands; te Morsche R. H. M.; Hoischen A.; Cnossen W. R.; Roepman R.; Drenth J. P. H.

P0014

**LOW BISPHENOL A CONCENTRATION INDUCES PROLIFERATION, OXIDATIVE STRESS AND EX-NOVO SYNTHESIS OF STEROID HORMONES IN HEPATOMA CELL LINE**

Marcello Dallio, Italy; Lama S.; Vanacore D.; Nicolucci C.; Errico S.; Diano N.; Loguercio C.; Stiuso P.; Federico A.

P0015

**TRANSIENT ELASTOGRAPHY, APRI AND FIB-4 SCORES FOR STAGING OF FIBROSIS AND CIRRHOSIS IN WILSON DISEASE**

Rafael Paternostro, Austria; Stättermayer A.; Trauner M.; Ferenci P.; Ferlitsch A.

P0016

**US-FLI SCORE – IS IT POSSIBLE TO PREDICT THE STEATOSIS GRADE WITH AN ULTRASONOGRAPHIC SCORE?**

Xavier S.; Sara Monteiro, Portugal; Arieira C.; Magalhães J.; Leite S.; Marinho C.; Cotter J.

P0017

**IDENTIFYING THE NEXT TREATMENT FOR POLYCYSTIC LIVER DISEASE USING A DRUG SCREENING LIBRARY.**

Liyanne F. M. van de Laarschot, The Netherlands; van Spijk A.; van der Ende K.; Morsche R. H. M.; Drenth J. P. H.

P0018

**LIVER FIBROSIS RISK IN ALPHA1-ANTITRYPSIN DEFICIENCY IS NOT LIMITED TO HOMOZYGOUS PATIENTS (PI\*ZZ GENOTYPE)**

Vitor Magno Pereira, Portugal; Gaspar R.; Simões C.; Garrido M.; Costa D.; Bento-Miranda M.; Cardoso M.; Pereira F.; Sousa M.; Mendez Santos S.; Carvão J.; Oliveira A.; Faria G.; Teixeira V.; Sousa C.; Sucena M.; Santos C.; Gomes J.; Gomes C.; Sousa C.; Lages J.; Gonçalves G.; Freitas S.; Maia L.; Abreu I.; Alves J.; Carvalhana S.; Cortez-Pinto H.; Mandorfer M.; Trauner M.; Cardoso H.; Liberal R.; Macedo G.; Jasmins L.

**Cirrhosis and complications: Basic aspects**

P0019

**THE ROLE OF 5-HT2A RECEPTORS AND POST-RECEPTOR SIGNALING MECHANISMS IN VASCULAR HYPO-RESPONSIVENESS IN A RODENT MODEL OF CIRRHOSIS**

Syed Hasnain Alishah, Pakistan; Mehmood M. H.; Iqbal K.; Ahmed T.; Hassan Z.; Haider G.

P0020

**TM6SF2 AND MBOAT7 GENE VARIANTS ARE NOT ASSOCIATED WITH THE RISK OF DEVELOPING LIVER FIBROSIS AND CIRRHOSIS IN AN EASTERN EUROPEAN POPULATION** ✦

Viktorija Basyte - Bacevice, Lithuania; Skiecevicene J.; Kupcinskas L.; Valantiene I.; Sumskiene J.; Petrenkiene V.; Kondrackiene J.; Petrauskas D.; Lammert F.; Kupcinskas J.

P0021

**ANTIOXIDANT PROPERTIES OF CELECOXIB REDUCE HEPATIC VASCULAR RESISTANCE AND PORTAL PRESSURE IN CIRRHOTIC RATS**

Yang Tai, China; Gao J.; Zhang L.; Tong H.; Tang S.; Jia X.; Gan C.; Tang C.

P0022

**THE ROLE OF VON WILLEBRAND FACTOR AS A MORTALITY PREDICTOR IN DECOMPENSATED LIVER CIRRHOSIS**

Richard Azevedo, Portugal; Pereira F.; Linhares M.; Ribeiro H.; Pinto J.; Leitão C.; Caldeira A.; Sousa R.; Pereira E.; Tristan Barros J.; Banhudo A. J.

P0023

**GRAM-NEGATIVE BACTERIA INDUCE CELL-CYCLE ARREST AND INTESTINAL EPITHELIAL BARRIER DESTABILIZATION – AN IN VITRO MODEL FOR THE STUDY OF BACTERIAL TRANSLOCATION IN LIVER CIRRHOSIS**

Marika Haderer, Germany; Wächter L.; Aschenbrenner E.; Pollinger K.; Schlosser S.; Kunst C.; Müller-Schilling M.

P0024

**INFLAMMATORY ACTIVITY IN ASCITIC FLUID OF LIVER CIRRHOSIS PATIENTS – ON THE WAY TO NOVEL POTENTIAL BIOMARKERS FOR DIAGNOSIS OF SPONTANEOUS BACTERIAL PERITONITIS**

Sophia Scherm, Germany; Haderer M.; Aschenbrenner E.; Pollinger K.; Schlosser S.; Kunst C.; Müller-Schilling M.

**Cirrhosis and complications: Clinical aspects**P0025 **OUTCOMES OF LARGE VOLUME PARACENTESIS IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS.**

Hafiz Abdul Basit Siddiqui, Pakistan; Alishah S. H.; Azmat R.

P0026

**WITHDRAWN**

P0027

**ROLE OF APRI AND FIB4 AS A NON INVASIVE TESTS FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV INFECTION**

Mona Ahmed Amin, Egypt; Fawzi Tolba M.; Sayed Hasan M.; Kamal M.

P0028

**HEALTH RELATED QUALITY OF LIFE IN PRIMARY BILIARY CIRRHOSIS**

Dusan Popovic, Serbia; Nikolic V.; Bojovic K.; Jovic J.; Markovic Denic L.; Milosavljevic T.; Milovanovic T.

P0029

**EFFECT OF THE PROPRANOLOL THERAPY ON THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS: A RETROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CENTER**

Nurettin Suna, Turkey; Özer Etik D.; Öcal S.

P0030

**LIVER CIRRHOSIS AND LEFT VENTRICLE DIASTOLIC DYSFUNCTION: RETROSPECTIVE STUDY**

Julija Šarnelytė, Lithuania; Stundienė; I.; Valantinas J.

P0031

**NON INVASIVE PARAMETERS FOR ASSESSMENT OF ESOPHAGEAL VARICES**

Ehab Ahmed Abdelatti, Egypt; Elshayeb E.; Badr M.; Mousa W.

P0032 **LONG TERM PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY IS POSSIBLE WITH LACTULOSE ALONE BUT MORE EFFECTIVE IF COMBINED WITH RIFAXIMIN: A SYSTEMATIC REVIEW WITH NUMBER NEEDED TO TREAT ANALYSES OF RANDOMISED CONTROLLED TRIALS**

Schuchmann M.; Mason N.; Mark Hudson, United Kingdom

P0033 **DERIVATION AND VALIDATION OF A STATISTICAL MODEL TO FORECAST THREE-MONTH, ALL CAUSE MORTALITY IN SUBJECTS ADMITTED WITH INCIDENT DIAGNOSIS OF CIRRHOSIS**

Craig J. Currie, United Kingdom; Murphy D.; Amlani B.; Berni E.; Whitehouse J.; Conway P.; Orr J.; Hudson M.

P0034 **DERIVATION AND VALIDATION OF A STATISTICAL MODEL TO FORECAST LONG TERM ALL-CAUSE MORTALITY IN PEOPLE WITH CIRRHOSIS**

Craig J. Currie, United Kingdom; Murphy D.; Amlani B.; Berni E.; Whitehouse J.; Orr J.; Conway P.; Hudson M.

P0035 **SAFETY AND EFFICACY OF RIFAXIMIN IN PROPHYLAXIS OF SPONTANEOUS BACTERIAL PERITONITIS: IS THIS TIME TO ABANDON FLUOROQUINOLONES FOR PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS? : A SYSTEMATIC REVIEW.**

Sherief Abd-Elsalam, Egypt; Menshawy A.; Elgebaly A.

P0036

**EFFECTS OF FOOD AND CALCIUM CARBONATE ON PHARMACOKINETICS OF LUSUTROMBOPAG, A NOVEL THROMBOPOIETIN RECEPTOR AGONIST**

Takayuki Katsube, Japan; Wajima T.; Fukuhara T.; Kano T.

P0037

**INFECTIONS IN THE CIRRHOTIC PATIENTS AND THE IMPACT OF PROTON PUMP INHIBITORS**

Sonia Bernardo, Portugal; Cristino A.; Simões C.; Carvalhana S.; Raimundo M.; Marinho R. T.; Cortez-Pinto H.

P0038

**ABCPS: A NEW SCORE PREDICTING IN-HOSPITAL MORTALITY IN CIRRHOTIC PATIENTS**

Cátia Arieira, Portugal; Cúrdia Gonçalves T.; Dias de Castro F.; Magalhães J.; Marinho C.; Cotter J.

P0039

**VALIDATION OF EXPANDED BAVENO VI CRITERIA FOR PREDICTING ESOPHAGEAL VARICES**

Mafalda Sousa, Portugal; Fernandes S.; Silva A. P.; Leite S.; Rodrigues J.; Silva J. C.; Ribeiro Gomes A. C.; Carvalho J.

P0040

**RESISTANCE PATTERNS IN HOSPITAL ACQUIRED URINARY TRACT INFECTIONS IN PATIENTS WITH LIVER CIRRHOSIS: SINGLE CENTER EXPERIENCE**

Tamara Milovanovic, Serbia; Velickovic J.; Nikolic V.; Stojkovic Lalosevic M.; Pavlovic Markovic A.; Milosavljevic T.

**Viral hepatitis: Basic aspects**

P0041

**ASSOCIATION OF GENETIC POLYMORPHISMS IN CHEMOKINES (CCL2 AND CCL5) AND CHEMOKINE RECEPTOR(CCR2) WITH THE OUTCOME OF HCV INFECTION IN EGYPTIAN FAMILIES: A MULTICENTER STUDY.**

Mahmoud El-Bendary, Egypt; Neamatallah M. A.; Elalfy H.; Besheer T.; El-Setouhy : M.; Mahfouz M.; Zein M.; Elhammady D.; Hegazy A.; Esmat G.

P0042 **DENGUE HEPATITIS: A DIFFERENTIAL DIAGNOSIS TO REMEMBER IN EUROPE**

Vitor Magno Pereira, Portugal; Carvão J.; Oliveira A.; Faria G.; Alves J.; Andrade G.; Jasmins L.

P0043

**THE RELATION OF QUANTITATIVE INDICATORS OF PLASMACYTOID DENDRITIC CELLS IN THE BACKGROUND OF APPLICATION OF VARIOUS TREATMENT REGIMENS IN PATIENTS WITH CHC**

Olga N Khokhlova, Russian Federation; Serebrovskaya L. V.; Makashova V. V.; Ivanova L. A.; Reizis A. R.

**Viral hepatitis C: Clinical aspects**

P0044

**THE EFFECTIVENESS OF SOFOSBUVIR AND DA-CLATASVIR IN THE TREATMENT OF HEPATITIS C IN THALASSEMIA MAJOR PATIENTS AND THEIR EFFECT ON HEMATOLOGICAL FACTORS**

Jamshid Vafaieimanesh, Iran; Zamani F.; Ajdarkosh H.; Safarnezhad Tameshkel F.

P0045 **REAL-WORLD DATA OF DIRECT-ACTING ANTIVIRALS FOR 2,063 JAPANESE CHRONIC HEPATITIS C PATIENTS: THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP (KULDS)**

Akira Kawano, Japan; Ogawa E.; Furusyo N.; Nomura H.; Dohmen K.; Higashi N.; Takahashi K.; Azuma K.; Satoh T.; Nakamura M.; Koyanagi T.; Shimoda S.; Kato M.; Kajiwara E.; Hayashi J.

P0046

**RISK OF RECURRENT HEPATOCELLULAR CARCINOMA AFTER HEPATITIS C VIRUS ELIMINATION FOLLOWING DIRECT-ACTING ANTI-VIRAL TREATMENT**

Akira Kawano, Japan; Shigematsu H.; Miki K.; Ichiki Y.; Morita C.; Yanagita K.; Takahashi K.; Dohmen K.; Nomura H.; Ishibashi H.; Shimoda S.

P0047

**TREATMENT OUTCOME OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION WITH DIRECTLY ACTING ANTIVIRALS (DAA) IN PATIENTS WITH EXTRAHEPATIC MALIGNANCIES**

Srijan Mazumdar, India; Sundaram S.; Kale A.; Dodmani M.

P0048 **COMPARISON OF THE LEVELS OF CIRCULATING MICRORNA-122 IN HCV-RELATED CIRRHOSIS PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA** ✦

Foda E.; Ibrahim W.; Saleh S.; Mohamed A.; Hagar Elessawy, Egypt; Abdulhafiz E.; Agwa S.; Abd Elsamee A.

P0049

**PREVALENCE OF OCCULT HEPATITIS C INFECTION AMONG EGYPTIAN PATIENTS WITH SUSTAINED VIROLOGIC RESPONSE TREATED WITH SOFOSBUVIR/ DACLATASVIR**

Mohamed Abdelsabour Mekky, Egypt; Abdel-malek M. O.; Sayed H. A.; Hetta H. F.

P0050

**DIRECTLY ACTING ANTIVIRALS ARE SAFE, EFFECTIVE AND NOT ASSOCIATED WITH TUMOR RECURRENCE IN HCV PATIENTS WITH NON-HEPATIC CANCER.**

Laura Lamonaca, Italy; Boccaccio V.; Leo De Nalda A.; Ceriani R.; Rimassa L.; Personeni N.; Colombo M.; Bruno S.; Aghemo A.

P0051

**DO WE SCREEN HEPATITIS C BEFORE SURGERY FOR THE BENEFIT OF THE SURGEON OR FOR THE PATIENT?**

Ilkay Gulturk, Turkey; Bal K.; Hatemi I.; Kocazeybek B.; Yuksel P.; Demir B.; Karabulut E.

**Immunology, autoimmune liver disease**

P0052

**PREVALENCE OF HEPATO-BILIARY MANIFESTATION IN IBD**

Radia Osmane, Algeria; Gherib I.; Aissaoui M.; Mahiou H.; Zmiri Y.; Boutaleb A. F.; Saoula H.; Hamidouche N.; Mitiche A.; Aissat Y.; Nakmouche M.

P0053

**CHANGE IN BILIRUBIN WITH OBETICHOIC ACID TREATMENT IN PRIMARY BILIARY CHOLANGITIS PATIENTS WITH HIGH BASELINE BILIRUBIN: A RETROSPECTIVE ANALYSIS OF POISE, 201, AND 202**

Hirschfield G.; Shiffman M.; Pares A.; Smoot Malecha E.; Richard Pencek, United States; MacConell L.; Shapiro D.



P0054

**DEVIATIONS IN PERIPHERAL BLOOD SUBPOPULATIONS ARE CONNECTED WITH THE PRESENCE OF PRURITUS IN PRIMARY BILIARY CHOLANGITIS PATIENTS**Agata Michalak, Poland; Cichoż-Lach H.; Kowalik A.; Grywalska E.; Roliński J.; Kasztelan-Szczerbińska B.P0055 **A NOVEL UK REGIONAL REAL-WORLD REGISTRY FOR PRIMARY BILIARY CHOLANGITIS (PBC) ALLOWING DATA LINKAGE FROM PRIMARY AND SECONDARY CARE**Marinos Pericleous, United Kingdom; Kelly C.; de Lusignan S.; Ala A.

P0056

**THE EFFECTIVENESS OF STANDARD TREATMENT ON CHRONIC AND ACUTE PRESENTATION-AUTOIMMUNE HEPATITIS MAY BE SIMILAR**Shen Y.; Xiaoli Fan, China; Yang X.; Men R.; Yang L.

P0057

**URSODEOXYCHOLIC ACID FOR THE TREATMENT OF PRIMARY BILIARY CIRRHOSIS/CHOLANGITIS AND PRIMARY SCLEROSING CHOLANGITIS: ARE OUR PATIENTS UNDERDOSED?**Yvonne Abbey, United Kingdom; Olsen M.; Farrant M.; Gunasekera A. V.**Imaging, radiology (incl. interventional radiology)**

P0058

**DIAGNOSIS OF TYPICAL FOCAL NODULAR HYPERPLASIA IN THE LIVER – USE OF A NOVEL ULTRASONIC VASCULAR DOPPLER TECHNIQUE**Mikael Sawatzki, Switzerland; Semela D.; Neuweiler J.; Stephan B.P0059 **COMPARISON OF THE DIAGNOSTIC ACCURACIES OF MAGNETIC RESONANCE TECHNIQUE AND TRANSIENT ELASTOGRAPHY FOR EVALUATING HEPATIC STEATOSIS IN NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS**Li Cen, China; Pan J.; Yu C.; Li Y.; Shen Z.; Chen W.

P0060

**PORTAL HYPERTENSION IN CIRRHOTIC PATIENTS WITH HEPATITIS B VIRUS: DIAGNOSTIC ACCURACY OF LIVER AND SPLEEN STIFFNESS BY SHEAR WAVE ELASTOGRAPHY**Ding H.; Zhu Y.; Fu T.; Peng S.; Wu S.; Wang W.; Wei Ma, China

P0061

**PREDICTIVE FACTORS OF HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT – TEN YEARS OF EXPERIENCE OF A PORTUGUESE CENTER**Ana Laranjo, Portugal; Correia M.; Costa J.; Carvalho M.; Rei A.; Veloso F.; Bilhim T.; Coimbra É.

P0062

**INTER-OBSERVER REPRODUCIBILITY OF VTQ (ARFI TECHNIQUE) FOR THE EVALUATION OF FOCAL LIVER LESIONS STIFFNESS**Ana Maria Ghiuchici, Romania; Pascaru A.; Popescu A.; Sirli R.; Sporea I.; Danila M.

P0063

**RECTUS ABDOMINIS ULTRASOUND MAY DETECT SARCOPENIA AND PREDICT SURVIVAL IN PATIENTS WITH LIVER CIRRHOSIS**Maria Ciocîrlan, Romania; Mănuc M.; Diculescu M.; Ciocîrlan M.P0064 **TRUE SEVERITY OF LIVER STEATOSIS AND FIBROSIS IN TYPE 2 DIABETES MELLITUS PATIENTS**Sporea I.; Ruxandra-Georgeta Mare, Romania; Lupusoru R.; Sirli R. L. D.; Popescu S. A.; Silviu N.; Sima A.; Timar R.**Liver neoplasia: Clinical**

P0065

**SEGMENTAL DISTRIBUTION OF HEPATOCELLULAR CARCINOMA CORRELATES WITH MICROVASCULAR INVASIONS IN LIVER EXPLANTS (UNDERGOING TRANSPLANTATION).**Yasir Al-Azzawi, United States; Spaho L.; Rouanet E.; Malik H.; Devuni D.; Barnard G.; Szabo G.

P0066

**TRANSIENT ELASTOGRAPHY AS A PREDICTOR OF DE NOVO HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIRECT ACTING ANTIVIRAL DRUGS (DAAS)**Mohamed Rady, Egypt; Kohla M.; Alsabaawy M.; Allam M.; Helal A.

P0067

**SERUM PEROXIREDOXIN – 3 AS A USEFUL BIOMARKER FOR DETECTION OF HEPATOCELLULAR CARCINOMA**Ehab Ahmed Abdelatti, Egypt; Gasser Al-Azab G.; Efat A.; Alghobashy Y.

P0068

**MODIFIED ALBI-T SCORE AS PROGNOSTIC MODEL IN THE EVALUATION OF PATIENTS WITH HEPATOCELLULAR CARCINOMA.**Omar Elshaarawy, Germany; Alkhatieb Z.; Alhelbawy M.; Gomaa A.; Allam N.; Alsebaey A.; Rewisha E.; Waked I.P0069 **THE ALBI AND P-ALBI GRADES PREDICT SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING TRANSARTERIAL CHEMOEMBOLIZATION (TACE)**Claudia Campani, Italy; Vitale A.; Dragoni G.; Arena U.; Giannini E. G.; Trevisani F.; Marra F.; Ita. Li. Ca G.

P0070

**HCC RECURRENCE AFTER DAA TREATMENT IN HCV PATIENTS**

Guarino M.; Bruzzese D.; Di Costanzo G. G.; Guarracino M.; Morando F.; Donnarumma L.; Rinaldi L.; Persico M.; Salomone Megna A.; Coppola N.; Caporaso N.; Filomena Morisco, Italy

P0071

**EVALUATION OF SERUM ENDOGLIN LEVEL AS A NEW DIAGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA**

Mohamed Talkhan, Egypt; El sayed E. Y.; Fouad M. H. A.; Ghait R. S. A.

P0072

**THE EFFECT OF DIRECT ACTING ANTIVIRALS ON THE OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA: META-ANALYSIS OF 1438 PATIENTS**

Sherief Abd-El salam, Egypt; Elgebaly A.; Menshawy A.

P0073

**PROGNOSTIC VALUE OF ALBUMIN BILIRUBIN SCORE AND ALBUMIN BILIRUBIN RATIO IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH TRANS-ARTERIAL CHEMOEMBOLIZATION.**

Elalfy H.; Besheer T.; Abd El Maksoud M.; Hassany M.; Ahmed Mohammed El Sayed Ahmed, Egypt

**Vascular diseases of the liver, bile duct or pancreas**

P0074

**DYNAMIC DETERMINANTS OF PORTAL HYPERTENSION ARE IDENTIFIED BY HISTOLOGICAL COLLAGEN PROPORTIONATE AREA ESTIMATIONS**

Philipp Königshofer, Austria; Brusilovskaya K.; Stift J.; Lampichler K.; Simbrunner B.; Schwabl P.; Mandorfer M.; Trauner M.; Reiberger T.

P0075 **PRONOSTIC FACTORS IN PATIENTS WITH PORTAL CAVERNOMA: RESULTS OF A PROSPECTIVE COHORT OF 131 CASES**

Rachid Ouldgougam, Algeria; Zemmouchi S.; Chikhi Y.; Cheraitia S.; Lounes F.; Kherat N.; Kouihal W.; Belala Z.; Taharouchet B.; Asselah H.; Lahcene M.

P0076

**SGC STIMULATION AND PDE5 INHIBITION DECREASE SINUSOIDAL RESISTANCE AND REDUCE FIBROSIS IN RATS WITH BILIARY CIRRHOSIS**

Ksenia Brusilovskaya, Austria; Königshofer P.; Lampach D.; Szodl A.; Supper P.; Bauer D.; Beer A.; Stift J.; Podesser B. K.; Seif M.; Zinober K.; Rohr-Udilova N.; Trauner M.; Reiberger T.; Schwabl P.

P0077

**SUBCLINICAL PORTAL HYPERTENSION: RESULTS AND CONCORDANCE OF DIFFERENT MEANS OF NON-INVASIVE DIAGNOSIS**

Raida Harbi, Tunisia; Elleuch N.; Hammami A.; Ksaa M.; Jaziri H.; Braham A.; Ajmi S.; Ben Slama A.; Jmaa A.

**Cholestasis and gallstones: Clinical**

P0078

**A MULTICENTER RANDOMIZED TRIAL OF LASER VERSUS ELECTROHYDRAULIC LITHOTRIPSY FOR DIFFICULT BILE DUCT STONES**

Dong Hee Koh, Republic of Korea; Moon S.-H.; Jeong S.; Moon J. H.; Choi H. J.; Lee I.-S.; Shim C. S.; Lee T. Y.; Lee J. K.; Han J.-H.; Cho J. H.; Kim H. G.; Lee S.-H.; Seo D.-W.

P0079

**LONG-TERM OUTCOME OF ENDOSCOPIC PAPILLARY LARGE-BALLOON DILATION FOR BILE DUCT STONES**

Toji Murabayashi, Japan; Kanno Y.; Ito K.; Koshita S.; Ogawa T.; Masu K.; Kusunose H.; Sakai T.; Yonamine K.; Kawakami Y.; Fujii Y.; Miyamoto K.; Kozakai F.; Noda Y.

P0080

**BILIRUBIN LEVEL AT ADMISSION AS PREDICTOR OF CONCOMITANT CHOLEDOCHOLITHIASIS IN PATIENTS WITH ACUTE CHOLECYSTITIS AND RATE OF READMISSION FOR BILIARY COMPLICATIONS IN PATIENTS WITH DELAYED SURGERY FOR SUSPECTED BILIARY DUCT OBSTRUCTION.**

Carmen Lara Romero, Spain; Belvis Jiménez M.; Cadena Herrera M. L.; Romero Vazquez J.; Cordero Ruiz P.; Bellido Muñoz F.; Caunedo Álvarez Á.

P0081

**LONG TERM OUTCOME OF ACUTE ACALCULOUS CHOLECYSTITIS TREATED BY NON-SURGICAL MANAGERMENTS**

Tae Nyeun Kim, Republic of Korea; Kim S. B.; Cho J. H.; Kim K. H.; Kim K. O.; Lee S. H.; Jang B. I.

P0082

**PREVALENCE OF FUNCTIONAL GASTRO-INTESTINAL DISEASES IN PATIENTS WITH UNCOMPLICATED CHOLECYSTOLITHIASIS; A SYSTEMATIC REVIEW AND META-ANALYSIS**

Carmen S. S. Latenstein, The Netherlands; de Jong J. J.; Eppink J. J.; van Laarhoven C. J. H. M.; de Reuver P. R.; Drenth J. P. H.

P0083

**WITHDRAWN**

P0084

**VALIDATION OF TOKYO GUIDELINE 2013 FOR TREATMENT OF ACUTE CHOLECYSTITIS BY REAL WORLD DATA**

Harai S.; Amano H.; Miura Y.; Ashizawa H.; Nakagomi K.; Yoshimura D.; Takaoka S.; Hosoda K.; Suzuki Y.; Yuichiro Kojima, Japan; Mochizuki H.; Omata M.

P0085

**PRACTICE PATTERNS FOR THE MANAGEMENT OF CONCOMITANT GALLSTONES AND CHOLEDOCHOLITHIASIS**Abdilla Y.; [Jurgen Gerada](#), Malta

P0086

**PREVALENCE AND RISK FACTORS OF CHOLELITHIASIS IN CROHN'S DISEASE**[Igor Sturdik](#), Slovakia; [Krajcovicova A.](#); [Leskova Z.](#); [Jalali Y.](#); [Decka R.](#); [Cernotova V.](#); [Toth J.](#); [Koller T.](#); [Huorka M.](#); [Hlavaty T.](#)

## Poster Session

09:00 – 17:00

Hall XI

## Pancreas I

**Cell biology/secretion/enzymology/physiology**

P0087

**P8 DEFICIENCY LEAD TO ELEVATED PANCREATIC BETA CELL MASS BUT DOES NOT CONTRIBUTE TO INSULIN RESISTANCE IN MICE FED WITH HIGH FAT DIET**[Marcus Hollenbach](#), Germany; [Klötting N.](#); [Sommerer I.](#); [Lorenz J.](#); [Heindl M.](#); [Kern M.](#); [Mössner J.](#); [Blüher M.](#); [Hoffmeister A.](#)

P0088

**HISTOLOGICAL ANALYSIS OF THE OBESTATIN/G-PROTEIN COUPLED RECEPTOR 39 (GPR39) SYSTEM IN HUMAN PANCREAS.**[Lara Estévez-Pérez](#), Spain; [Leal-López S.](#); [Sánchez-Temprano A.](#); [Otero-Alen B.](#); [Seoane-Mosteiro C.](#); [Gallego-Gómez R.](#); [Dominguez-Muñoz J. E.](#); [García-Caballero T.](#); [Dominguez-Munoz J. E.](#); [Pérez-Camiña J.](#); [Pazos Y.](#)

P0089

**OBESTATIN PROMOTES MIGRATION AND INVASION OF ACTIVATED HUMAN PANCREATIC STELLATE CELLS**[Lara Estévez-Pérez](#), Spain; [Leal-López S.](#); [Sánchez-Temprano A.](#); [Otero-Alen B.](#); [Seoane-Mosteiro C.](#); [Gallego-Gómez R.](#); [Löhr M.](#); [Dominguez-Munoz J. E.](#); [Pazos Y.](#)

P0090

**THE RELATIONSHIP BETWEEN CHOLECYSTOKININ SECRETION, INSULIN RELEASE AND PANCREATIC [11C] METHIONINE UPTAKE IN PATIENTS AFTER PARTIAL PANCREATODUODENECTOMY.**[Emanuel Steiner](#), Austria; [Kazianka L.](#); [Breuer R.](#); [Rehfeld J.](#); [Karanikas G.](#); [Miholic J.](#)**Pancreatitis, acute**

P0091

**INFLUENCE AND ROLE OF RAMP1 ON THE INNATE IMMUNE RESPONSE DURING ACUTE PANCREATITIS**[Georgios Odysseos](#), Germany; [Fahrenkrog-Petersen L.](#); [Hidalgo-Sastre A.](#); [Zhong S.](#); [Dannemann A.](#); [Hüser N.](#); [Hartmann D.](#); [Holzmann B.](#); [Steiger K.](#); [Schmid R. M.](#); [von Figura G.](#)

P0092

**CLINICAL STUDY OF IMPROVEMENTS IN PANCREATIC BLOOD FLOW AS MEASURED BY PERFUSION COMPUTED TOMOGRAPHY IN PATIENTS WITH SEVERE ACUTE PANCREATITIS AND ADMINISTERED RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN**[Takaaki Eguchi](#), Japan; [Tsuji Y.](#); [Tsujiamae M.](#); [Kanamori A.](#); [Matsumoto K.](#); [Yamashita H.](#); [Okada A.](#)

P0093

**ALCOHOL CONSUMPTION AND SMOKING SYNERGIZE WITH EACH OTHER AND INCREASE THE RISK OF LOCAL COMPLICATIONS IN ACUTE PANCREATITIS**[Gyömbér Z.](#); [Vincze A.](#); [Izbéki F.](#); [Hamvas J.](#); [Hajdúne Dr. Varga M. M.](#); [Gódi S.](#); [Gede N.](#); [Sallinen V.](#); [Macarie M.](#); [Torok I.](#); [Góg C.](#); [Szentkereszty Z.](#); [Pécsi D.](#); [Varjú P.](#); [Nemeth B.](#); [Szepes Z. G.](#); [Takács T.](#); [Andrea Szentesi](#), Hungary; [Parniczky A.](#); [Hegyi P.](#)

P0094

**IMPACT OF VISCERAL ADIPOSITY ON SEVERITY OF ACUTE PANCREATITIS**[Jiarong Xie](#), China; [Xu L.](#)

P0095

**ABDOMINAL ADIPOSITY AND ECTOPIC FAT PHENOTYPES ASSOCIATED WITH THE PRESENCE OF DIABETES AFTER ACUTE PANCREATITIS**[Ruma Singh](#), New Zealand; [Cervantes A.](#); [Kim J. U.](#); [Nguyen N. N.](#); [DeSouza S.](#); [Drury M.](#); [Pendharker S.](#); [Petrov M.](#)

P0096

**DIETARY FAT PATTERNS AND OUTCOMES IN ACUTE PANCREATITIS**[Enrique de-Madaria](#), Spain; [Varela-Moreiras G.](#); [Cárdenas-Jaén K.](#); [Bozhychko M.](#); [Closa D.](#); [García-Rayado G.](#)

P0097

**BODY-MASS INDEX CORRELATES WITH SEVERITY AND MORTALITY IN ACUTE PANCREATITIS – A META-ANALYSIS**[Dalma Dobszai](#), Hungary; [Mátraí P.](#); [Gyöngyi Z.](#); [Matuz M.](#); [Csupor D.](#); [Bajor J.](#); [Erőss B.](#); [Mikó A.](#); [Szakó L.](#); [Meczer Á.](#); [Hágendorn R.](#); [Márta K.](#); [Szentesi A.](#); [Hegyi P.](#)

P0098

**GENERAL AND ADIPOSE TISSUE-SPECIFIC INSULIN RESISTANCE AFTER AN EPISODE OF ACUTE PANCREATITIS**  
[Ruma Singh](#), New Zealand; Pendharkar S.; Cervantes A.; Cho J.; Miranda-Soberanis V.; Petrov M.

P0099

**COMBINATION OF HEPARANASE INHIBITORS AND ASPIRIN DRAMATICALLY AMELIORATES ACUTE PANCREATITIS IN ANIMAL MODEL**

[Khamaysi I.](#); [Dalit Ben Hemo](#), Israel; [Bhattacharya U.](#); [Kinaneh S.](#); [Ilan N.](#); [Vlodavsky I.](#); [Abassi Z.](#)

P0100

WITHDRAWN

P0101

**CENTRALIZED CARE OF ACUTE PANCREATITIS SIGNIFICANTLY IMPROVES ITS OUTCOMES**

[Szilárd Gódi](#), Hungary; [Erőss B.](#); [Vincze A.](#); [Farkas N.](#); [Parniczky A.](#); [Szentesi A.](#); [Mikó A.](#); [Gyömbér Z.](#); [Márta K.](#); [Sarlós P.](#); [Bajor J.](#); [Takács T.](#); [Czakó L.](#); [Szepes Z. G.](#); [Hegyí P.](#)

### Pancreatitis, chronic (including hereditary disorders)

P0102

**GENISTEIN INHIBITS THE ACTIVATION OF PANCREATIC STELLATE CELLS BY PI3K/AKT/MTOR SIGNALING PATHWAY**

[Ran Xue](#), China; [Hao J.](#)

P0103

**DIAGNOSIS, TREATMENT AND LONG-TERM OUTCOMES OF AUTOIMMUNE PANCREATITIS IN SWEDEN**

[Miroslav Vujasinovic](#), Sweden; [Valente R.](#); [Haas S. L.](#); [Del Chiaro M.](#); [Arnelo U.](#); [Löhr J.-M.](#)

P0104

**DEFICIENCY OF FAT-SOLUBLE VITAMINS, MINERALS AND TRACE ELEMENTS IN PATIENTS WITH CHRONIC PANCREATITIS OF DIFFERENT ETIOLOGY**

[Miroslav Vujasinovic](#), Sweden; [Maisonneuve P.](#); [Hedström A.](#); [Valente R.](#); [Haas S. L.](#); [Löhr J.-M.](#)

P0105

**PREDICTION OF PANCREATIC ATROPHY AFTER STEROID THERAPY USING EQUILIBRIUM CONTRAST CT IMAGING IN AUTOIMMUNE PANCREATITIS**

[Yasutaka Yamada](#), Japan; [Masuda A.](#); [Sofue K.](#); [Shiomi H.](#); [Sakai A.](#); [Kobayashi T.](#); [Fujigaki S.](#); [Nakano R.](#); [Tanaka T.](#); [Kutsumi H.](#); [Zen Y.](#); [Murakami T.](#); [Kodama Y.](#)

P0106

**INCIDENTAL FINDINGS OF FATTY PANCREAS ON COMPUTED TOMOGRAPHY ASSOCIATED WITH IMPAIRED BONE METABOLISM**

[Michael De Gregorio](#), Australia; [Knipe H.](#); [Stella D.](#); [Metz A.](#)

P0107

**METABOLIC BONE DISEASE IN CHRONIC PANCREATITIS; A SINGLE CENTRE EXPERIENCE**

[Fahd Rana](#), United Kingdom; [Bekkali N.](#); [Charnley R.](#); [Logue J.](#); [Nayar M.](#); [Oppong K.](#); [Leeds J.](#)

P0108



**DIFFERENCES IN IMAGING STUDY BETWEEN LOCALIZED AUTOIMMUNE PANCREATITIS AND PANCREATIC CANCER : A MATCHED CASE-CONTROL STUDY**

[Toshifumi Kin](#), Japan; [Takigawa Y.](#); [Takahashi K.](#); [Hayashi T.](#); [Yane K.](#); [Nagai K.](#); [Tanaka K.](#); [Kobayashi Y.](#); [Utsunomiya R.](#); [Katanuma A.](#)

P0109

**THE FIRST DEFINITION FOR EARLY CHRONIC PANCREATITIS**

[Peter Hegyi](#), Hungary; [Erőss B.](#); [Mátrai P.](#); [Hamvas J.](#); [Pécsi D.](#); [Németh B.](#); [Illés A.](#); [Bajor J.](#); [Kovács G.](#); [Macarie M.](#); [Tüzün Ince A.](#); [Szepes Z.](#); [Szepes A.](#); [Varga M.](#); [Halász A.](#); [Izbéki F.](#); [Vincze A.](#); [Szentesi A.](#); [Parniczky A.](#); [Hegyí P.](#)

### Pancreatic cancer: Basic

P0110

**HYPERTHERMIA ENHANCES SENSITIVITY OF PANCREATIC CANCER SW1990 CELLS TO GEMCITABINE THROUGH ROS/JNK SIGNALING**

[Hangbin Jin](#), China; [Zhao Y.](#); [Lu L.](#); [Yang J.](#); [Zhang X.](#); [Ma S.](#)

P0111

**FAS SPECIFICALLY MEDIATES NEURAL INVASION IN PANCREATIC CANCER**

[Hossam Taher](#), Germany; [Teller S.](#); [Demir I. E.](#); [Friess H.](#); [Ceyhan G. O.](#)

P0112



**PANCREATIC CANCER CELLS ENRICH PHOSPHO-PAXILIN IN THEIR FILOPODIA DURING NEURAL INVASION**

[Xiaobo Wang](#), Germany; [Teller S.](#); [Friess H.](#); [Ceyhan G. O.](#); [Demir I. E.](#)

P0113

**PANCREATIC STELLATE CELLS AUGMENT NEURAL INVASION IN PANCREATIC CANCER**

[Xiaobo Wang](#), Germany; [Teller S.](#); [Friess H.](#); [Ceyhan G. O.](#); [Demir I. E.](#)

P0114

**GLYOXALASE-I: A NOVEL TARGET FOR PANCREATIC CANCER?**

[Marcus Hollenbach](#), Germany; [Lorenz J.](#); [Sommerer I.](#); [Sonnenberg S.](#); [Michel M.](#); [Mössner J.](#); [Rosendahl J.](#); [Michl P.](#); [Hoffmeister A.](#)

**Pancreatic cancer: Clinical**P0115 **PANCREATIC ULTRASOUND ELASTOGRAPHY AND ITS CLINICAL USE IN PREDICTING THE RISK OF PANCREATIC FISTULAS AFTER PANCREATIC RESECTION**Giovanni Marasco, Italy; Ricci C.; Colecchia A.; Alvisi M.; Serra C.; Grasso V.; Ravaioli F.; Minni F.; Casadei R.; Festi D.

P0116

**A PROSPECTIVE, RANDOMIZED, MULTICENTER CLINICAL TRIAL COMPARING 25-GAUGE AND 20-GAUGE PROCORE NEEDLES FOR ENDOSCOPIC ULTRASOUND-GUIDED SAMPLING OF SOLID PANCREATIC LESIONS**Eunae Cho, Republic of Korea; Park C. H.; Kim T. H.; Cho C. M.; Seo D. W.; Choi J. H.; Moon S.-H.; Kim J.

P0117

**CLINICOPATHOLOGICAL FEATURES OF PANCREATIC DUCTAL ADENOCARCINOMA CONCOMITANT WITH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS**Yujiro Kawakami, Japan; Koshita S.; Ito K.; Kanno Y.; Ogawa T.; Kusunose H.; Masu K.; Sakai T.; Yonamine K.; Fujii Y.; Miyamoto K.; Murabayashi T.; Kozakai F.; Okada T.; Oikawa M.; Noda Y.; Sawai T.

P0118

**AN EXAMINATION OF THE USEFULNESS OF MASPIN STAINING IN EUS-FNA SAMPLES FOR PANCREATIC CANCER**Koh Fukushi, Japan; Tsuchida K.; Sakuma F.; Nagashima K.; Minaguchi T.; Abe K.; Kanamori A.; Izawa N.; Iwasaki M.; Jinnai H.; Tunemi M.; Irisawa A.

P0119

**DIAGNOSTIC USEFULNESS OF LOCALIZED STENOSIS OF THE MAIN PANCREATIC DUCT FOR DETECTION OF EARLY PANCREATIC CANCER**Yoshihide Kanno, Japan; Koshita S.; Ogawa T.; Kusunose H.; Masu K.; Sakai T.; Yonamine K.; Kawakami Y.; Fujii Y.; Murabayashi T.; Kozakai F.; Noda Y.; Ito K.

P0120

**APPROPRIATENESS OF PANCREATIC SURGERY IN HIGH-RISK INDIVIDUALS FOR FAMILIAL PANCREATIC DUCTAL ADENOCARCINOMA**Louis de Mestier, France; Muller M.; Cros J.; Vullierme M.-P.; Vernerey D.; Maire F.; Dokmak S.; Rebourvs V.; Sauvanet A.; Lévy P.; Hammel P.

P0121

**WITHDRAWN**

P0122

**PREDICTION OF LIVER METASTASIS AFTER SURGICAL RESECTION OF INVASIVE DUCTAL CARCINOMA OF THE PANCREAS BASED ON PREOPERATIVE ENDOSCOPIC ULTRASONOGRAPHY FINDINGS AND PATHOLOGICAL EXAMINATION**Yoshihiro Hamada, Japan; Kato D.

P0123

**ROLE OF RAPID ON SITE EVALUATION (ROSE) FOR ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION (EUS-FNA) OF SOLID PANCREATIC LESIONS: "ON SITE" MULTIDISCIPLINARY TEAM IS MORE IMPORTANT THAN TECHNIQUE FOR AN ACCURATE DIAGNOSIS.**Nicola Olivari, Italy; Milluzzo S. M.; Graffeo M.; Lovera M.; Bianchi D.; Padolecchia E.; Spada C.**Poster Session**

09:00 - 17:00

Hall X1

**Endoscopy and Imaging I****Endoscopy, upper GI**

P0124

**WATER-POCKET ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL GASTRIC NEOPLASMS: A PROSPECTIVE STUDY**Hideaki Harada, Japan; Nakahara R.; Murakami D.; Suehiro S.; Nagasaka T.; Ujihara T.; Sagami R.; Katsuyama Y.; Hayasaka K.; Amano Y.P0125 **CLINICAL VALUES OF DENTAL FLOSS TRACTION ASSISTANCE IN ENDOSCOPIC FULL-THICKNESS RESECTION FOR SUBMUCOSAL TUMORS ORIGINATING FROM THE MUSCULARIS PROPRIA LAYER IN THE GASTRIC FUNDUS**  
Qiang Shi, China; Zhong Y.-S.; Zhou P.-H.

P0126

**PURSE-STRING SUTURES USING NOVEL ENDOLOOPS AND REPOSITIONABLE CLIPS FOR THE CLOSURE OF LARGE IATROGENIC DUODENAL PERFORATIONS WITH SINGLE-CHANNEL ENDOSCOPE**Shu Huang, China; Zhu S.; Lin J.; Wang M.

P0127

**TO ASSESS THE ANAESTHETIC REQUIREMENTS AND MODIFICATIONS REQUIRED IN PER ORAL ENDOSCOPIC MYOTOMY ( POEM ) FOR SAFE PROCEDURE AND PREVENTION OF COMPLICATIONS. A RETROSPECTIVE ANALYSIS OF PROTOCOL FOR ANESTHESIA IN POEM DEvised AT OUR CENTRE. A STUDY OF 175 CASES.**Pankaj N. Desai, India; Kabrawala M.; Jha A.

P0128

**SAFETY OF PROPOFOL-BASED SEDATION WITHOUT ENDOTRACHEAL INTUBATION DURING ENDOSCOPIC SUBMUCOSAL DISSECTION IN THE ESOPHAGUS AND STOMACH**Steffi Elisabeth Maria Van de Ven, The Netherlands; Leliveld L.; Klimek M.; Hilkemeijer T. R. H.; Bruno M. J.; Koch A. D.

P0129

**CLINICAL OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR ESOPHAGEAL NEOPLASIA PROXIMAL TO THE PREVIOUS ESD SCAR**

Yasuaki Nagami, Japan; Ominami M.; Fukunaga S.; Otani K.; Hosomi S.; Tanaka F.; Taira K.; Yamagami H.; Tanigawa T.; Shiba M.; Watanabe T.; Fujiwara Y.

P0130

**USEFULNESS OF DEMARCATION OF EARLY GASTRIC CANCERS AFTER HELICOBACTER PYLORI ERADICATION BY MAGNIFYING ENDOSCOPY WITH NARROW-BAND IMAGING**

Yoichi Akazawa, Japan; Ueyama H.; Yao T.; Ikeda A.; Yatagai N.; Komori H.; Izumi K.; Matsumoto K.; Ueda K.; Matsumoto K.; Hojo M.; Nagahara A.

P0131

**RISK FACTORS FOR ACUTE BLEEDING AND DELAYED BLEEDING AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION IN PATIENTS WITH EARLY GASTRIC CANCER**

Satoshi Tanabe, Japan; Yano T.; Ishido K.; Wada T.; Watanabe A.; Azuma M.; Katada C.; Koizumi W.

P0132

**EFFICACY OF ORAL MIXTURE OF HYDROCORTISONE SODIUM SUCCINATE AND ALUMINUM PHOSPHATE GEL FOR THE PREVENTION OF RESTENOSIS AFTER ENDOSCOPIC BALLOON DILATION(EBD) FOR BENIGN ESOPHAGEAL STRICTURE**

Yonghui Huang, China; Yan X.; Nie D.

P0133

**NARROW BAND IMAGING CHARACTERISTICS OF POLYPOID GASTRIC LESIONS: A SINGLE CENTER PROSPECTIVE STUDY**

Gianluca Esposito, Italy; Angeletti S.; Cazzato M.; Galli G.; Conti L.; Lahner E.; Di Giulio E.; Annibale B.

P0134

**ELDERLY PATIENTS VS NON-ELDERLY PATIENTS IN CLINICAL OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION; PROPENSITY SCORE MATCHING ANALYSIS**

Misato Esaki, Japan; Esaki M.; Abe Y.; Takaoka S.; Furutani K.; Kato T.; Okubo M.; Kobayashi K.; Sekigawa K.; Mitsui H.

P0135

**PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL COMPARING HEMOSTATIC POWDER VERSUS OPTIMAL CLINICAL TREATMENT IN THE MANAGEMENT OF GASTROINTESTINAL BLEEDING FROM MALIGNANCY**

Bruno Da Costa Martins, Brazil; Corsato Scomparin R.; Batista Pires C.; Haendchen Bento L.; Kawaguti F. S.; Lenz Tolentino L. H.; Franco M.; Pennacchi C. M. P. S.; Ribeiro U.; Safatle-Ribeiro A. V.; Maluf-Filho F.

P0136

**ENDOSCOPIC MUCOSAL RESECTION OF DUODENAL ADENOMAS: SUCCESS, COMPLICATIONS, RECURRENCE, AND SURGERY-FREE OUTCOMES IN A UK TERTIARY CENTRE**  
Richard Lord, United Kingdom; Mundre P.; Gold M.; Hamshaw L.; Kane J.; Mohammed N.; Rembacken B.; Sood R.

P0137

**A META-ANALYSIS OF SCLEROLIGATION VERSUS BAND LIGATION FOR ERADICATION OF ESOPHAGEAL VARICES. A META-ANALYSIS OF SCLEROLIGATION VERSUS BAND LIGATION FOR ERADICATION OF ESOPHAGEAL VARICES.**  
Sherief Abd-El Salam, Egypt; Morshedy A.; El-Shirbeny H.; Fayoud M.; Marzouk O.

P0138

**CAP-ASSISTED REMOVAL OF IMPACTED ESOPHAGEAL FOOD BOLUS: "THE EASY WAY"**

Mahmoud Wahba, Egypt; Farag A.; El Mazny A.; Aref W.; Ashoush O.

P0139

**LONG-TERM OUTCOME OF HYBRID APC FOR ABLATION OF DYSPLASTIC BARRETT'S ESOPHAGUS IN A LOW PREVALENCE COUNTRY.**

Sergey V. Kashin, Russian Federation; Vidyayeva N.; Kuvaev R.; Kraynova E.; Manner H.

P0140

**THE FOLLOW UP OF PATIENTS WITH EARLY GASTRIC CANCER AFTER NON-CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION. THE EUROPEAN SINGLE CENTRE STUDY.**

Natlie Botke, Poland; Gawel K.; Józwa M.; Białek J.; Ławniczak M.; Marlicz W.M.; Karpińska K.; Białek A.

P0141 **NARROW BAND IMAGING ENDOSCOPY VERSUS LUGOL CHROMOENDOSCOPY IN EARLY DETECTION OF ESOPHAGEAL CANCER IN PATIENTS WITH HEAD AND NECK CANCERS: RANDOMIZED TRIAL ✦**

Anna Chaber-Ciopinska, Poland; Kaminski M. F.; Wieszczy P.; Kraszewska E.; Bielasik A.; Bugajski M.; Januszewicz W.; Kiprian D.; Jarzabski A.; Rolski W.; Niemiec M.; Kawecki A.; Regula J.

P0142

**EFFICACY AND SAFETY OF GASTRIC POEM (G-POEM): RESULTS OF A PILOT SERIES**

Hendrik Manner, Germany; Cornelius C.; Rey J. W.; Hoffman A.; Kiesslich R.

P0143 **RISK FACTORS OF METACHRONOUS GASTRIC NEOPLASM BEYOND 5 YEARS AFTER ENDOSCOPIC RESECTION FOR EARLY GASTRIC CANCER.**

Eunwoo Lee, Republic of Korea; Kim S. G.; Kim J. L.; Kim J.; Chung H.; Jung H. C.

P0144

**EFFICACY OF FULL-SPECTRUM ENDOSCOPY (FUSE) TO VISUALIZE THE AMPULLA OF VATER IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP): A PROSPECTIVE OBSERVATIONAL STUDY**

Ryoji Ichijima, Japan; Abe S.; Tagawa T.; Kobayashi S.; Minagawa T.; Nakajima T.; Yamada M.; Sakamoto T.; Takamaru H.; Sekiguchi M.; Oda I.; Saito Y.

P0145

**ENDOSCOPIC SCORING SYSTEM FOR PREDICTING THE ANASTOMOTIC COMPLICATIONS AFTER ESOPHAGECTOMY: A PROSPECTIVE COHORT STUDY.**

Shinichiro Kobayashi, Japan; Kanetaka K.; Yoneda A.; Nagata Y.; Yamaguchi N.; Kobayashi K.; Matsumoto R.; Okada S.; Takatsuki M.; Eguchi S.

P0146

**A COMPARISON OF THE STRENGTH OF ENDOSCOPIC SUTURE : PARTIAL-THICKNESS SUTURE AND FULL – THICKNESS SUTURE**

Choi S. J.; Choi H.-S.; Park S.; Chun H. J.; Jang S.; Lee J. M.; Lee J. M.; Kim S. H.; Kim E. S.; Keum B.; Jeon Y. T.; Lee H. S.; Chun H. J.; Kim C. D.; Ji Hyeong Kim, Republic of Korea

P0147 **AND WHEN NBI DOESN'T SHOW GASTRIC INTESTINAL METAPLASIA: DO WE STILL NEED TO SEPARATE BIOPSY SAMPLES INTO DIFFERENT VIALS?**

Rui Castro, Portugal; Esposito G.; Dinis-Ribeiro M.; Pimentel Nunes P.

P0148

**ENDOSCOPIC DIAGNOSIS OF HELICOBACTER PYLORI ERADICATION HISTORY USING LINKED COLOR IMAGING AND DEEP LEARNING: A SINGLE CENTER PROSPECTIVE STUDY**

Hiroataka Nakashima, Japan; Kawahira H.; Kawachi H.; Sakaki N.

P0149 **ENDOSCOPIC INTERVENTION FOR PANCREATIC FLUID COLLECTIONS HAS BETTER OUTCOMES THAN PERCUTANEOUS OR SURGICAL DRAINAGE- A META-ANALYSIS**  
Lajos Szakó, Hungary; Mátrai P.; Hegyi P.; Eross B.; Szakács Z.; Márta K.; Pécsi D.; Vincze A.

P0150

**COMPARISON BETWEEN ENDOSCOPIC SUBMUCOSAL DISSECTION AND SUBMUCOSAL TUNNELING ENDOSCOPIC RESECTION FOR ESOPHAGEAL SUBMUCOSAL TUMORS ORIGINATING FROM THE MUSCULARIS PROPRIA LAYER**

Junyu Zhu, China; Li Q.; Chen T.; Zhou P.

P0151 **THE CLINICAL IMPACT OF CLOSURE OF THE MUCOSAL DEFECT AFTER DUODENAL ESD**

Yasutoshi Ochiai, Japan; Kato M.; Kiguchi Y.; Akimoto T.; Nakayama A.; Maehata T.; Yahagi N.

P0152

**GASTRIC DYSPLASIA IN FAMILIAL ADENOMATOUS POLYPOSIS – WHAT IS THE RELEVANCE?**

Sofia Saraiva, Portugal; Currais P.; Ferreira S.; Rosa I.; Rodrigues P.; Lage P.; Filipe B.; Claro I.; Albuquerque C.; Chaves P.; Dias Pereira A.

P0153

**CLINICAL SCORE TO PREDICT THE CHANCE OF SUCCESSFUL ENDOSCOPIC APPROACH OF ESOPHAGEAL LEAKS: CAN IT GUIDE OUR CLINICAL PRACTICE?**

Richard Azevedo, Portugal; Gouveia C.; Coelho M.; Mão Ferro S.; Loureiro R.; Freire R.; Mangualde J.; Casaca R.; Maio R.; Cravo M.; Dias Pereira A.

**Endoscopy, colon**

P0154

**CLINICAL MANAGEMENT OF ENDOSCOPICALLY RESECTED PT1 COLORECTAL CANCER.**

Giulio Antonelli, Italy; Angeletti S.; Berardi G.; Ruggeri M.; Corleto V. D.; D'Ambra G.; Pílozzi E.; Hassan C.; Di Giulio E.

P0155

**PINE-CONE AND VILLI PATTERNS ARE ENDOSCOPIC SIGNS SUGGESTIVE OF ULCERATIVE COLITIS-ASSOCIATED COLORECTAL CANCER AND DYSPLASIA**

Takahide Shinagawa, Japan; Hata K.; Morikawa T.; Takiyama H.; Emoto S.; Muroto K.; Kaneko M.; Sasaki K.; Nishikawa T.; Tanaka T.; Kawai K.; Fukayama M.; Nozawa H.

P0156

**IMPACT OF ACTIVE MONITORING ON QUALITY INDICATORS OF COLONOSCOPY**

Rola Saadi, Lebanon; Chemaly M.; Achkar M.; Khalife S.; Rassam P.; Hoteit B.; Amara J.; Yaghi C.

P0157

**LOWER GASTROINTESTINAL SYMPTOMS AND SYMPTOM BASED TRIAGING SYSTEMS ARE POOR PREDICTORS OF CLINICAL SIGNIFICANT DISEASE ON COLONOSCOPY**

Muhammad Ismail, Mozambique; Aoko O.; Omorogbe J.; Sihag S.; O'Connor A.; Ryan B.; Breslin N.; McNamara D.

P0158

**WARFARIN OR DIRECT ORAL ANTICOAGULANT; WHICH IS RISKY FOR POST-POLYPECTOMY BLEEDING?**

Yuichi Shimodate, Japan; Mizuno M.; Miyake M.; Takezawa R.; Doi A.; Nishimura N.; Mouri H.; Matsueda K.; Yamamoto H.

P0159 **SUPERIOR HIGH-QUALITY COLON CLEANSING WITH 1L NER1006 VERSUS SODIUM PICOSULFATE + MAGNESIUM CITRATE, 2L POLYETHYLENE GLYCOL + ASCORBATE, OR ORAL SULFATE SOLUTION: POST HOC POOLED ANALYSIS OF THREE RANDOMISED PHASE 3 CLINICAL TRIALS**

Alessandro Repici, Italy; Amlani B.; Uebel P.; Schreiber S.

P0160

**RO RESECTION MARGIN, A NEW QUALITY MEASURE IN ERA OF NATIONAL BOWEL SCREENING?**Vikrant Parihar, Ireland; Sopheno Falco J.; Benz E.; Cooney A.; Keohane J.; Sengupta S.

P0161

**COMPARING THE EFFICACY AND SAFETY BETWEEN UNDERWATER ENDOSCOPIC MUCOSAL RESECTION AND CONVENTIONAL ENDOSCOPIC MUCOSAL RESECTION IN RESECTING SESSILE COLORECTAL NEOPLASMS: A PROPENSITY SCORE MATCHED COHORT STUDY.**Pingshin Hsieh, Taiwan; Chien H.P0162 **INCREASED WITHDRAWAL TIME ALONE MAY NOT IMPROVE ADENOMA DETECTION RATE: A MULTI-CENTRE STUDY ON IMPACT OF INDIVIDUAL QUALITY SCORECARDS**Soh Ee Lee, Sri Lanka; Lee J.; Wong R.; Ong E. H. D.; Cheong W.-K.; Yang W. L.; Fong S. S.; Dan Y. Y.; Lim L. L.; Koh C.; Zhu F.; Yeoh K. G.

P0163

**USEFULNESS OF JNET CLASSIFICATION WITH DUAL-FOCUS MAGNIFICATION FOR DIAGNOSIS OF COLORECTAL TUMORS: SINGLE CENTER RETROSPECTIVE STUDY.**Yohei Koyama, Japan; Fukuzawa M.; Suguro M.; Matsumoto T.; Uchida K.; Madarame A.; Morise T.; Yamaguchi H.; Aoki Y.; Sugimoto A.; Yamauchi Y.; Kono S.; Kawai T.; Itoi T.

P0164

**EFFECTIVENESS OF SUBMUCOSAL EPINEPHRINE INJECTION FOR LARGE COLON POLYP EMR**Takashi Ikeya, Japan; Takasu A.; Nakamura K.; Okamoto T.; Fukuda K.

P0165

**THE EFFECT OF PROPHYLACTIC CLIP PLACEMENT ON DELAYED BLEEDING FOLLOWING ENDOSCOPIC MUCOSAL RESECTION OF LARGE COLORECTAL LESIONS: A META-ANALYSIS**Fares Ayoub, United States; Westerveld D.; Forde J.; Forsmark C.; Draganov P.; Yang D.

P0166

**PROPER INTERVAL TO SECOND COLONOSCOPY AFTER PREPARATION FAILURE IN THE FIRST PROCEDURE - PROSPECTIVE RANDOMIZED TRIAL -**Beom Jin Kim, Republic of Korea; Kim J. W.; Choi C. H.; Chang S. K.; Kim S.-J.

P0167

**1L NER1006 ACHIEVES HIGH-QUALITY BOWEL CLEANSING WITH LOWER TOTAL FLUID VOLUME INTAKE THAN STANDARD 2L POLYETHYLENE GLYCOL + ASCORBATE: A POST-HOC ANALYSIS**Lucy Clayton, United Kingdom; Amlani B.; Hassan C.

P0168

**ENDOSCOPIC FEATURE OF DEPRESSED TYPE COLORECTAL NEOPLASMS IN MAGNIFYING ENDOSCOPY AND ENDOCYTOSCOPY**Shinei Kudo, Japan; Mochizuki K.; Mori Y.; Mochida K.; Kouyama Y.; Sakurai T.; Ichimasa K.; Matsudaira S.; Nakamura H.; Yagawa Y.; Toyoshima N.; Misawa M.; Ogata N.; Kudo T.; Hisayuki T.; Hayashi T.; Wakamura K.; Sawada N.; Baba T.; Hidaka E.; Ishida F.

P0169

**COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION (CR-ESD): THE PATHOLOGICAL POINT OF VIEW. DOES THE RISK OUTWEIGH THE BENEFITS? A SPANISH PROSPECTIVE MULTICENTRE STUDY**José C. Marín-Gabriel, Spain; Ramos-Zabala F.; Herreros de Tejada A.; Múgica-Aguinaga F.; De la Peña-García J.; Rosón-Rodríguez P. J.; Albéniz-Arbizu E.; Sánchez-Yagüe A.; Amorós-Tenorio A.; Dolz-Abadía C.; Fernández-Esparrach G.; Álvarez-Delgado A.; Terán-Lantarón A.; Cortés-Pérez H.; Nogales-Rincón Ó.; Goikoetxea-Rodero U.; Guarner-Argente C.; Cañete-Ruiz Á.; Arribas-Anta J.; Conde-García B.; Thomas-Salom G.; García-Morales T.; Del Pozo-García A. J.; Díaz-Tasende J.

P0170

**IMPACT OF A LOW FIBER DIET ON BOWEL CLEANSING QUALITY BEFORE COLONOSCOPY: PRELIMINARY DATA FROM A RANDOMIZED STUDY COMPARING 1 DAY VERSUS 3 DAYS**Raquel de la Barreda, Spain; Gimeno Garcia A. Z.; Reygosa C.; Hernandez A.; Nicolas D.; Romero R.; Alarcón O.; Gonzalez Y.; Hernandez M.; Mascareño I.; Adrian Z.; Alonso I.; Hernandez D.; Delgado R.; Lara J.; Jimenez A.; Quintero E.

P0171

**PERIOPERATIVE HEPARIN BRIDGING FOR ENDOSCOPIC RESECTION OF THE COLORECTAL TUMOR FOR PATIENTS RECEIVING ANTICOAGULATION RESULTED IN A HIGHER INCIDENCE OF BLEEDING COMPLICATION THAN OTHER HIGH-RISK ENDOSCOPIC PROCEDURES.**Daisuke Yoshimura, Japan; Ochiai T.; Chaen T.; Fukuda S.; Nakano K.; Kitagawa Y.; Ichida K.

P0172

**1L NER1006 EVENING/MORNING DOSING SUSTAINS SUCCESSFUL COLON CLEANSING IN 7 OUT OF 8 PATIENTS EVEN 7+ HOURS AFTER THE SECOND DOSE: POST HOC ANALYSIS OF OVERNIGHT SPLIT-DOSING REGIMENS OF 1L NER1006 VERSUS 2L POLYETHYLENE GLYCOL + ASCORBATE OR ORAL SULFATE SOLUTION**Amlani B.; Lucy Clayton, United Kingdom; Hassan C.



P0173 **COMPARISON OF COLONOSCOPY WITH VIRTUAL CHROMOENDOSCOPY USING THIRD GENERATION NARROW BAND IMAGING SYSTEM TO CHROMOENDOSCOPY WITH INDIGO CARMINE IN LYNCH PATIENTS.**

Samaha E.; Colas C.; Dhooge M.; Saurin J. C.; Lecomte T.; Coron E.; Rahmi G.; Guillaume Perrod, France; Lorenceau-Savale C.; Chaussade S.; Bellanger J.; Pereira H.; Chatellier G.; Cellier C.

P0174 **OPTICAL BIOPSY OF DIMINUTIVE COLORECTAL POLYPS WITH REAL-TIME USE OF "ARTIFICIAL INTELLIGENCE"-ASSISTED ENDOSCOPY**

Yuichi Mori, Japan; Kudo S.; Misawa M.; Saito Y.; Ikematsu H.; Hotta K.; Ohtsuka K.; Urushibara F.; Kataoka S.; Ogawa Y.; Maeda Y.; Takeda K.; Nakamura H.; Ichimasa K.; Kudo T.; Hayashi T.; Wakamura K.; Ishida F.; Inoue H.; Ito H.; Oda M.; Mori K.

P0175 **FULLY AUTOMATED DIAGNOSIS SYSTEM WITH ARTIFICIAL INTELLIGENCE USING ENDOCYTOSCOPY TO IDENTIFY HISTOLOGICAL INFLAMMATION ASSOCIATED WITH ULCERATIVE COLITIS**

Yasuharu Maeda, Japan; Kudo S.; Mori Y.; Misawa M.; Ogata N.; Ogawa M.; Ogawa Y.; Sasanuma S.; Ichimasa K.; Takeda K.; Kudo T.; Hayashi T.; Wakamura K.; Ishida F.; Inoue H.; Ohtsuka K.; Itoh H.; Oda M.; Mori K.

P0176

**WHAT IS THE COST OF ENDOSCOPIC SUBMUCOSAL DISSECTION IN FRANCE? A PROSPECTIVE MEDICO-ECONOMIC STUDY.**

Martin Dahan, France; Legros R.; Carrier P.; Sautereau D.; Loustaud-Ratti V.; Pauliat E.; Tailleux A.; Merle L.; Richard V.; Livat Yonnet S.; Brischoux S.; Kerever S.; Jacques J.

P0177

**REAL TIME DIAGNOSTIC SYSTEM FOR COLORECTAL CANCER USING ARTIFICIAL INTELLIGENCE**

Kenichi Takeda, Japan; Kudo S.; Mori Y.; Saito Y.; Ikematsu H.; Hotta K.; Ohtsuka K.; Mochizuki K.; Minegishi Y.; Watanabe T.; Kataoka S.; Maeda Y.; Ogawa Y.; Nakamura H.; Ichimasa K.; Misawa M.; Kudo T.; Wakamura K.; Hayashi T.; Ishida F.; Inoue H.; Itoh H.; Oda M.; Mori K.

P0178

**TRAINEES' INFLUENCE ON ADENOMA DETECTION AND FOLLOW-UP RECOMMENDATIONS AT SCREENING AND SURVEILLANCE COLONOSCOPIES**

Kheder J.; Eckardt A. J.; Basil A.; Silverstein T.; Patel K.; Mahmood M.; Yasir Al-Azzawi, United States; Ellis D.; Carrasquillo Vega Y.; Gillespie W.; Levey J.

P0179 **DEVELOPMENT OF A REAL-TIME ENDOSCOPIC IMAGE DIAGNOSIS SUPPORT SYSTEM USING DEEP LEARNING TECHNOLOGY IN COLONOSCOPY**

Masayoshi Yamada, Japan; Saito Y.; Imaoka H.; Kamijo K.; Kimura T.; Saiko M.; Takamaru H.; Sakamoto T.; Yamada S.; Kondo H.; Kuchiba A.; Shibata T.; Hamamoto R.

P0180

**GRADING OF DYSPLASIA FOR DIAGNOSING COLORECTAL ADENOMAS USING ENDOCYTOSCOPY (EC)**

Kenichi Suzuki, Japan; Kudo T.; Mori Y.; Misawa M.; Maeda Y.; Ichimasa K.; Takeda K.; Toyoshima N.; Hayashi T.; Wakamura K.; Ishida F.; Inoue H.; Kudo S.

P0181

**DEVELOPMENT OF A MODIFIED SMSA SCORING SYSTEM WITH IMPROVED ACCURACY IN THE PREDICTION OF COMPLICATIONS OF ENDOSCOPIC MUCOSAL RESECTION IN THE COLON**

Jaime Pereira Rodrigues, Portugal; Pinho R.; Sousa M.; Silva J. C.; Gomes C.; Freitas T.; Carvalho J.

P0182

**MAP SIGNIFICANTLY CORRELATES WITH ADR BUT NOT WITH PDR FOR BOTH SCREENING AND ALL COLONOSCOPIES**

Ivana Mikoviny Kajzrlíkova, Czech Republic; Vitek P.; Chalupa J.; Kuchar J.; Platos J.; Reha P.; Klvana jr. P.

P0183

**CORRELATION BETWEEN ADR OF SCREENING AND ALL COLONOSCOPIES – IS IT POSSIBLE TO CALCULATE ADR FOR ALL COLONOSCOPIES IN PRACTICE?**

Ivana Mikoviny Kajzrlíkova, Czech Republic; Vitek P.; Chalupa J.; Kuchar J.; Platos J.; Reha P.; Klvana jr. P.

P0184

**WITHDRAWN**P0185 **RATIO OF RIGHT-SIDED TO LEFT-SIDED DYSPLASTIC COLONIC POLYPS IS A VALID KEY PERFORMANCE INDICATOR**

Mariusz Madalinski, United Kingdom

P0186

**LAPAROSCOPY ENDOCYTOSCOPY COOPERATIVE SURGERY (LECS) TO OVERCOME THE LIMITATIONS OF ENDOCYTOSCOPY RESECTION FOR COLORECTAL TUMORS**

Yoshiro Tamegai, Japan; Fukunaga Y.; Chino A.; Saito S.; Hiki N.; Muto T.

P0187

**FEASIBILITY AND SAFETY OF "WATCH AND WAIT STRATEGY" OF DELAYED BLEEDING AFTER COLORECTAL ENDOCYTOSCOPIC SUBMUCOSAL DISSECTION: IS EMERGENCY COLONOSCOPY REALLY NEEDED?**

Jun Arimoto, Japan; Chiba H.; Tachikawa J.; Ashikari K.; Kuwabara H.; Nakaoka M.; Goto T.

P0188

**COMPUTER-AIDED DETECTION FOR COLONOSCOPY USING DEEP LEARNING**

Masashi Misawa, Japan; Kudo S.; Mori Y.; Cho T.; Kataoka S.; Nakamura H.; Ichimasa K.; Takeda K.; Toyoshima N.; Kudo T.; Hisayuki T.; Hayashi T.; Wakamura K.; Ishida F.; Itoh H.; Oda M.; Mori K.

P0189

**AUTOMATIC ANATOMICAL CLASSIFICATION OF COLONOSCOPIC IMAGES USING DEEP CONVOLUTIONAL NEURAL NETWORKS**

Hiroaki Saito, Japan; Tanimoto T.; Aoyama K.; Endo Y.; Okuzono T.; Suzuki K.; Maeda Y.; Yamaoka H.; Hirasawa D.; Matsuda T.; Nakahori M.; Chonan A.; Tada T.

P0190

**VALIDITY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LARGE COLORECTAL TUMORS ACCORDING TO PIT PATTERN ANALYSES BY MAGNIFICATION ENDOSCOPY**

Kae Nagao, Japan; Kuroda K.; Fujii M.; Shirasaka D.; Tsuda K.; Kaku H.; Tanaka S.; Miyazaki H.; Hiemori A.; Asada Y.

P0191

**COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION FOR NOVICE ENDOSCOPISTS: THE UTILITY OF SUBMUCOSAL POCKET CREATION USING A TRACTION DEVICE**

Ide D.; Hiroyuki Hatamori, Japan; Saito S.; Nishikawa Y.; Horie Y.; Yasue C.; Chino A.; Masahiro I.; Ohya T. R.; Saruta M.; Fujisaki J.

P0192 **CLASSIFICATION OF NUCLEAR MORPHOLOGY OF EC FINDINGS IN COLORECTAL ENDOCYTOSCOPY**

Yosuke Minegishi, Japan; Kudo T.; Suzuki K.; Mori Y.; Misawa M.; Maeda Y.; Ichimasa K.; Takeda K.; Toyoshima N.; Hayashi T.; Wakamura K.; Ishida F.; Inoue H.; Kudo S.

P0193

**EARLY-STAGE COLORECTAL PROTRUDED TUMOR WITH DEPRESSION MAY ORIGINATE FROM "DE NOVO" CANCER**

Haruka Miyazaki, Japan; Kuroda K.; Fujii M.; Shirasaka D.; Tsuda K.; Kaku H.; Tanaka S.; Nagao K.; Hiemori A.; Asada Y.

P0194 **CLINICOPATHOLOGICAL FEATURES OF LOCAL RECURRENCE CASES RESECTED BY JUMBO FORCEPS BIOPSY USING NARROW BAND IMAGING ENDOSCOPY IN PATIENTS WITH DIMINUTIVE POLYPS**

Yuzuru Tamaru, Japan; Kuwai T.; Yamada T.; Toyokawa T.; Iwase H.; Kudo T.; Esaka N.; Ota H.; Yamashita H.; Hosoda Y.; Watanabe N.; Harada N.

P0195

**LONG-TERM OUTCOMES AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION WITH THE STAG BEETLE KNIFE JR FOR EARLY COLORECTAL NEOPLASMS**

Toshio Kuwai, Japan; Tamaru Y.; Kuroki K.; Tao K.; Konishi H.; Miura R.; Sumida Y.; Miyasako Y.; Yamaguchi A.; Kouno H.; Kohno H.; Ishaq S.

P0196

**MUCOSAL FLATTENING ASSISTED COLONOSCOPY (FAC) FOR IMPROVING ADENOMA DETECTION RATE: A SYSTEMATIC REVIEW WITH PAIRWISE AND NETWORK META-ANALYSIS.**

Marmo Clelia, Italy; Frazzoni L.; Fuccio L.; Bhandari P.; Thayalasekaran S.; Hassan C.; Marmo R.

**Endoscopy, ERCP**

P0197

**FORWARD-VIEWING ENDOSCOPE FOR ERCP IN PATIENTS WITH BILLROTH II GASTRECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Tae Young Park, Republic of Korea; Bang C. S.; Yang Y. J.; Shin S. P.; Suk K. T.; Baik G. H.; Kim D. J.

P0198

**LIVER HYDATID CYST - WHEN DO WE NEED BILIARY STENTING IN MANAGEMENT PROTOCOL. A STUDY OF 56 CASES FROM A TERTIARY REFERRAL CENTRE IN INDIA**

Pankaj N. Desai, India; Mangukiya D.; Bhatt K.

P0199

**COMPARISON OF DEXMEDETOMIDINE WITH MIDAZOLAM VERSUS MIDAZOLAM ALONE FOR SEDATION DURING ERCP: A PROSPECTIVE OBSERVATIONAL STUDY.**

Keisuke Yamakita, Japan; Kitano Y.; Takahashi K.; Iwamoto H.; Ota T.

P0200

**UTILITY OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY FOR THE MANAGEMENT OF SYMPTOMATIC PANCREAS DIVISUM IN CHILDREN: EXPERIENCE FROM A SINGLE CENTER IN CHINA**

Guang-Xing Cui, China; Yang J.; Lu W.; Lu L.; Zhang X.

P0201

**PANCREATIC DUCT PERFORATION DURING GUIDEWIRE CANNULATION IN THERAPEUTIC BILIARY ERCP**

Jesus Garcia Cano, Spain; Taberna-Arana L.

P0202

**EUS-GUIDED PANCREATIC DRAINAGE: A STEEP LEARNING CURVE**

Amey Tyberg, United States; Kedia P.; Tarnasky P.; Ali Khan M.; Novikov A.; Shah S.; Gaidhane M.; Ardengh J. C.; Kahaleh M.

P0203

**EUS GUIDED GALLBLADDER DRAINAGE : A LEARNING CURVE MODIFIED BY TECHNICAL PROGRESS**Amy Tyberg, United States; Shah S.; Kedia P.; Gaidhane M.; Kahaleh M.

P0204

**SINGLE-OPERATOR CHOLANGIOSCOPY REDUCES PATIENT RADIATION EXPOSURE IN THE MANAGEMENT OF DIFFICULT BILE DUCT STONES AND INDETERMINATE BILE DUCT STRICTURES: A SINGLE-CENTRE, HISTORICAL COMPARISON STUDY.**Konstantina D. Paraskeva, Greece; Tsapaki V.; Papastergiou V.; Giannakopoulos A.; Angelogiannopoulou N.; Theocharis S.; Mathou N.; Triantopoulou C.

P0205

**PREDICTIVE MODEL TO DETERMINE THE NEED OF REPEATING ERCP AFTER ENDOSCOPIC TREATMENT OF BILIARY LEAKS**Jaime Pereira Rodrigues, Portugal; Pinho R.; Sousa M.; Silva J. C.; Gomes C.; Freitas T.; Carvalho J.

P0206

**EVALUATION OF ENDOSCOPIC SPHINCTEROTOMY WITH ANTITHROMBOTIC THERAPY**Kenji Hayasaka, Japan; Sagami R.; Ujihara T.; Nakahara R.; Murakami D.; Satoshi S.; Katsuyama Y.; Harada H.; Amano Y.

P0207

**IS THERE AN ASSOCIATION BETWEEN THE MAJOR PAPILLA MORPHOLOGY AND THE SIZE OF THE TERMINAL COMMON BILE DUCT? – A PROSPECTIVE COHORT STUDY**João Silva Fernandes, Portugal; Costa I.; Fonseca J.; Canena J.; Lopes L.P0208 **FEASIBILITY OF A NEW SHORT-TYPE DOUBLE-BALLOON ENDOSCOPE WITH ADVANCED FORCE TRANSMISSION AND ADAPTIVE BENDING FOR PANCREATICOBILIARY INTERVENTION IN PATIENTS WITH SURGICALLY ALTERED ANATOMY: A PROPENSITY-MATCHED ANALYSIS**Atsuo Yamada, Japan; Kogure H.; Nakai Y.; Takahara N.; Mizuno S.; Tada M.; Koike K.P0209 **POSITIVE CORRELATION BETWEEN PANCREATIC PARENCHYMAL VOLUME AND PEP**Hirotsugu Maruyama, Japan; Shiba M.; Ishikawa-Kakiya Y.; Otani K.; Hosomi S.; Nagami Y.; Tanaka F.; Taira K.; Kamata N.; Yamagami H.; Tanigawa T.; Watanabe T.; Fujiwara Y.

P0210

**INITIAL MULTICENTRE DATA FROM THE HUNGARIAN ERCP REGISTRY**Dániel Pécsi, Hungary; Szentesi A.; Hegyi P.; Altörjay I. F.; Czákó L.; Gódi S.; Gyökéres T.; Pakodi F.; Patai Á.; Szepes Z. G.; Vincze Á.

P0211

**USE OF THE FORWARD-VIEWING ENDOSCOPE CAN BE A RISK FACTOR FOR POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PANCREATITIS: A PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY**Koki Chikugo, Japan; Endoh B.; Mizumoto Y.; Nakai Y.; Kusumoto K.; Itokawa Y.; Suzuki T.; Kawakami T.; Suzuki A.; Inatomi O.; Bamba S.; Tanaka K.

P0212

**SINGLE-OPERATOR PERORAL CHOLANGIOPANCREATOSCOPY-GUIDED LITHOTRIPSY FOR DIFFICULT BILIARY AND PANCREATIC STONES – A PROSPECTIVE MULTI-CENTER STUDY**João Silva Fernandes, Portugal; Alexandrino G.; Lourenço L.; Barreiro P.; Horta D.; Giestas S.; Araújo T.; Libânio D.; Reis J.; Bana e Costa T.; Lopes L.; Canena J.

P0213

**DOES THE MORPHOLOGY OF THE MAJOR PAPILLA INFLUENCE BILIARY CANNULATION? – A MULTICENTER PROSPECTIVE STUDY**João Silva Fernandes, Portugal; Costa I.; Fonseca J.; Giestas S.; Araújo T.; Libânio D.; Martinez-Ares D.; Alexandrino G.; Horta D.; Lourenço L.; Reis J.; Ramada J.; Canena J.; Lopes L.

P0214

**THERAPEUTIC ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY IN PATIENTS WITH ALTERED GASTROINTESTINAL ANATOMY**Rikako Koyama, Japan; Sato Y.; Tamura T.; Koizumi Y.; Imamura T.**Endosonography**

P0215

**A MULTICENTER RANDOMIZED TRIAL COMPARING A 25G EUS FINE NEEDLE ASPIRATION DEVICE WITH A NOVEL 20G EUS FINE NEEDLE BIOPSY DEVICE**Priscilla Van Riet, The Netherlands; Larghi A.; Attili F.; Rindi G.; Nguyen Q. N.; Ruzskiewicz A.; Kitano M.; Chikugo T.; Aslanian H.; Farrell J. J.; Robert M.; Adeniran A.; van der Merwe S.; Roskams T.; Chang K.; Lin F.; Arcidiacono P. G.; Petrone M. C.; Doglioni C.; Iglesias-Garcia J.; Abdulkader I.; Giovannini M.; Bories E.; Poizat F.; Santo E.; Scapa E.; Marmor S.; Bucobo J. C.; Buscaglia J.; Heimann A.; Wu M.; Baldaque-Silva F.; Fernández-Moro C.; Erler N.; Biermann K.; Poley J. W.; Cahen D. L.; Bruno M. J.

P0216

**CHOLANGITIS AFTER ENDOSCOPIC ULTRASOUND IN PATIENTS WITH BILIARY STRICTURES AND ASSOCIATED RISK FACTORS**Kenji Ikezawa, Japan; Shigekawa M.; Tamura T.; Sato K.; Urabe M.; Sueyoshi H.; Yamai T.; Suda T.; Kegasawa T.; Yoshioka T.; Sakamori R.; Tatsumi T.; Takehara T.

P0217

**EFFICACY AND SAFETY OF ENDOSCOPIC RADIOFREQUENCY ABLATION FOR METASTATIC PANCREATIC RENAL CELL CARCINOMA: A MONOCENTRIC EXPERIENCE.**  
Giovannini M.; Chanez B.; Walz J.; Ratone J. P.; Pignot G.; Caillol F.; Thomassin J.; Pesenti C.; Brunelle S.; Salem N.; Dermeche S.; [Erwan Bories](#), France; Gravis G.

P0218

**GRANULOMATOUS LYMPHADENITIS - TO REACH A DEFINITIVE DIAGNOSIS IN INDIAN POPULATION. A PROTOCOL BASED STUDY.**  
[Pankaj N. Desai](#), India; [Kabrawala M.](#); [Patel C.](#)

P0219

**WHICH APPROACH IS BETTER FOR PANCREATIC NECROSECTOMY – COMPARING DATA IN A TERTIARY REFERRAL CENTRE IN INDIA**  
[Desai P. N.](#); [Kabrawala M.](#); [Chintan Patel](#), India; [Bhatt K.](#); [Mangukiya D.](#)

P0220

**ROLE OF ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE ASPIRATION OF PORTAL VEIN THROMBUS IN THE DIAGNOSIS AND STAGING OF HEPATOCELLULAR CARCINOMA**  
[Ahmed Altonbary](#), Egypt; [Hakim H.](#); [Eskandere D.](#); [Hamed M.](#)

P0221

**EVALUATION OF THE ROLE OF ENDOSCOPIC ULTRASOUND-GUIDED GASTRIC BOTULINUM TOXIN INJECTIONS IN THE TREATMENT OF OBESITY**  
[Ahmed Altonbary](#), Egypt; [Bahgat M.](#); [Sief S.](#); [Ragab M.](#); [Abd El-Ghany M.](#); [Gameel A.](#); [Hakim H.](#)

P0222

**PROSPECTIVE MULTICENTER STUDY OF EUS-GUIDED THROUGH-THE-NEEDLE BIOPSY FOR THE EVALUATION OF PANCREATIC CYST: AN INTERIM ANALYSIS**  
[Dennis Yang](#), United States; [Trindade A.](#); [Benias P.](#); [Nieto J.](#); [Advani R.](#); [Manvar A.](#); [Ho S.](#); [Ansari N.](#); [Sethi A.](#); [Yachimski P.](#); [Gonda T. A.](#); [Draganov P.](#)

P0223

**PROSPECTIVE MULTICENTER STUDY OF EUS-GUIDED THROUGH-THE-NEEDLE BIOPSY FOR SOLID LESIONS: AN INTERIM ANALYSIS**  
[Dennis Yang](#), United States; [Trindade A.](#); [Benias P.](#); [Advani R.](#); [Manvar A.](#); [Ansari N.](#); [Sethi A.](#); [Yachimski P.](#); [Gonda T. A.](#); [Draganov P.](#)

P0224

**SURVEY STUDY ON THE PRACTICE PATTERNS OF THE EVALUATION AND MANAGEMENT OF INCIDENTAL PANCREATIC CYSTS**  
[Donevan Westerveld](#), United States; [Harris N.](#); [Khullar V.](#); [Forde J.](#); [Draganov P.](#); [Forsmark C.](#); [Yang D.](#)

P0225

WITHDRAWN

P0226

**CHRONIC PANCREATITIS FINDINGS BY ENDOSCOPIC ULTRASONOGRAPHY IN THE PANCREATIC PARENCHYMA OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM AND PANCREATIC CANCER CONCOMITANT WITH INTRA-DUCTAL PAPILLARY MUCINOUS NEOPLASM**  
[Takeshi Tanaka](#), Japan; [Masuda A.](#); [Takenaka M.](#); [Shiomi H.](#); [Toyama H.](#); [Kobayashi T.](#); [Sakai A.](#); [Fujigaki S.](#); [Nakano R.](#); [Yamada Y.](#); [Kutsumi H.](#); [Fukumoto T.](#); [Zen Y.](#); [Kodama Y.](#)

P0227

**EUS-DIRECTED TRANSGASTRIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (EDGE): THE FIRST LEARNING CURVE**  
[Amy Tyberg](#), United States; [Kedia P.](#); [Tarnasky P.](#); [Millman J.](#); [Gaidhane M.](#); [Nieto J.](#); [Kahaleh M.](#)

P0228

**NEWLY DEVELOPED MODEL FOR TRAINING EUS-FNA AND PSEUDOCYST DRAINAGE PROCEDURE.**  
[Mitsuhiro Kida](#), Japan; [Hasegawa R.](#); [Miyata E.](#); [Kaneko T.](#); [Yamauchi H.](#); [Okuwaki K.](#); [Iwai T.](#); [Imaizumi H.](#)

P0229

**THE FEASIBILITY AND EFFICACY OF ENDOSCOPIC ULTRASOUND-GUIDED LIVER BIOPSY USING A CORE NEEDLE FOR HEPATIC SOLID MASSES**  
[Hyung Ku Chon](#), Republic of Korea; [Kim T. H.](#)

### Capsule endoscopy

P0230

**A MULTI-CRITERION, FULLY AUTOMATED, HIGH-PERFORMANCE, RAPID TOOL ASSESSING THE MUCOSAL VISUALIZATION QUALITY OF STILL IMAGES IN SMALL BOWEL CAPSULE ENDOSCOPY**  
[Sarra Qumrani](#), France; [Histace A.](#); [Abou Ali E.](#); [Pietri O.](#); [Becq A.](#); [Houist G.](#); [Nion Larmurier I.](#); [Camus M.](#); [Florent C.](#); [Dray X.](#)

P0231

**A NEURAL NETWORK ALGORITHM FOR DETECTION OF GASTROINTESTINAL ANGIODYSPLASIA DURING SMALL BOWEL CAPSULE ENDOSCOPY**  
[Romain Leenhardt](#), France; [Vasseur P.](#); [Li C.](#); [Saurin J. C.](#); [Rahmi G.](#); [Cholet F.](#); [Becq A.](#); [Mesli F.](#); [Vanbiervliet G.](#); [Leandri C.](#); [Nion-Larmurier I.](#); [Delvaux M.](#); [Gerard R.](#); [Sacher-Huvelin S.](#); [Duburque C.](#); [Amiot X.](#); [Le Mouel J. P.](#); [Lecleire S.](#); [Jacob P.](#); [Simon-shane C.](#); [Marteau P.](#); [Romain O.](#); [Histace A.](#); [Dray X.](#)

P0232

**CAD-CAP: A 26000 IMAGES DATABASE SERVING THE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE FOR CAPSULE ENDOSCOPY**

Romain Leenhardt, France; Li C.; Le Mouel J. P.; Rahmi G.; Saurin J. C.; Cholet F.; Leandri C.; Leclaire S.; Amiot X.; Delvaux M.; Duburque C.; Gerard R.; Mesli F.; Vanbiervliet G.; Nion-Larmurier I.; Sacher-Huvelin S.; Simon-Chane C.; Romain O.; Histace A.; Dray X.

P0233

**DIABETES MELLITUS AND VIDEO CAPSULE ENDOSCOPY: SOME OF THEM JUST NEED MORE TIME.**

Ilija Sergeev, Israel; Stein A.; Ringel Y.

P0234

**VIDEOCAPSULE ENDOSCOPY IN UNEXPLAINED IRON DEFICIENCY ANEMIA: A RETROSPECTIVE COHORT STUDY**

Antonella Contaldo, Italy; Losurdo G.; Albano F.; Iannone A.; Ierardi E.; Principi M.; Di Leo A.

P0235

**A ROPEWAY CAPSULE ENDOSCOPY FOR EXPLORING THE ENTIRE GASTROINTESTINAL TRACT WITH A NON-PER OS PREPARATION AND A SHORTER EXAMINATION TIME**

Hidetoshi Ohta, Japan; Katsuki S.; Sagawa T.

P0236

**CAPSULE ENDOSCOPY: IS THE SOFTWARE TOP 100 A RELIABLE TOOL IN MID-GASTROINTESTINAL BLEEDING?**

Cátia Arieira, Portugal; Monteiro S.; Dias de Castro F.; Boal Carvalho P.; Rosa B.; Moreira M. J.; Cotter J.

P0237

**SIGNIFICANCE OF INCIDENTAL FINDINGS IN VIDEO CAPSULE ENDOSCOPY**

Jordan Smtih, Israel; Maza I.; Klein A.

P0238

**THE EFFECTIVENESS OF IMPROVED USE OF CHEWING GUM IN INFLUENCING CAPSULE ENDOSCOPY TRANSIT TIME – A PROSPECTIVE RANDOMIZED, CONTROLLED PILOT STUDY**

Yue Hu, China; Huang L.; Lyu B.

**Biliary and pancreatic stenting**

P0239

**ENDOSCOPIC ULTRASOUND-GUIDED TRANSMURAL GALLBLADDER DRAINAGE USING ELECTROCAUTERY-ENHANCED LUMEN-APPPOSING METAL STENT VERSUS STANDARD TUBULAR METAL STENT**

Jocelyn Privat, France; Demmak H.; Fetche S. N.; Keita B. A.; Lemaire M. A.; Rebillard E.

P0240

**STENT PATENCY ACCORDING TO THE CHEMOTHERAPY AND ITS REGIMEN**

Jinwoo Kang, Republic of Korea; Lee S. H.; Choi Y. H.; Paik W. H.; Ryu J. K.; Kim Y.-T.

P0241

**DRAINAGE OF THE RIGHT LIVER UNDER EUS: BRIDGE TECHNIQUE WITH HEPATICOGASTROSTOMY ALLOWING DRAINAGE OF THE RIGHT LIVER THROUGH THE LEFT LIVER INTO THE STOMACH.**

Fabrice Caillol, France; Boschardt C.; Reimao S.; Francioni E.; Pesenti C.; Bories E.; Ratone J. P.; Giovannini M.

P0242

**FULLY COVERED SELF-EXPANDABLE METALLIC STENT, AS SUPERIOR TREATMENT OPTION FOR BILIARY ANASTOMOSIS STRICTURE AFTER LIVER TRANSPLANTATION COMPARED TO PLASTIC STENTS: A CASE-CONTROL STUDY**

Jung Hyun Jo, Republic of Korea; Chun H.; Kang H.; Lee H. S.; Park J. Y.; Bang S.; Park S. W.; Song S. Y.; Chung M. J.

P0243

**IN VIVO EVALUATION OF A NOVEL ANTIREFLUX BILIARY METAL STENT**

Chang-Il Kwon, Republic of Korea; Koh D. H.; Kim G.; Moon J. P.; Park H.; Jeong S.; Ko K. H.; Kang D.-H.

P0244

**INTRADUCTAL MIGRATION OF BILIARY AND PANCREATIC STENTS, HOW TO MANAGE SUCH COMPLICATION? MONO-CENTERED EVALUATION OF A RETRIEVAL TECHNIQUE USING RAT-TOOTH FORCEPS**

Jean-Michel Gonzalez, France; Debourdeau A.; Bodiou J.; Barthet M.

P0245

**URGENT ERCP AND PANCREATIC DUCT STENTING FOR THE MANAGEMENT OF POST-ERCP PANCREATITIS.**

Shapovalianz S.; Budzinskiy S.; Fedorov E.; Aza Kotieva, Russian Federation

**Interventional radiology**

P0246

**MAGNETIC RESONANCE IMAGING OF THE COLON – AN ANALYSIS OF FECAL VOLUME AND STOOL DRYNESS**

Esbén Bolvig Mark, Denmark; Bødker M. B.; Grønlund D.; Wegeberg A. L.; Østergaard L. R.; Frøkjær J. B.; Drewes A. M.

P0247

**THE SAFETY TRIAL OF SONODYNAMIC THERAPY FOR UNRESECTABLE INTRACTABLE CANCER**

Atsushi Sofuni, Japan; Muragaki Y.; Fujita M.; Asai Y.; Iseki H.; Masamune K.; Okamoto A.; Konishi Y.; Horise Y.; Izumi M.; Ikuta S.; Kishimoto S.; Yoshizawa S.; Umemura S.; Sano T.; Itoi T.

P0248

**SAFETY AND EFFECTIVENESS OF EUS-GUIDED HEPATICOGASTROSTOMY (EUS-HGS) COMPARED WITH PTBD IN PATIENTS WITH MALIGNANT BILIARY OBSTRUCTION**

Masato Matsuyama, Japan; Sawada M.; Katagiri T.; Kanata R.; Sasaki T.; Ozaka M.; Takano K.; Sasahira N.

P0249

**ROLE OF INTERVENTIONAL RADIOLOGY IN PEDIATRIC GASTROINTESTINAL DISEASES – A LARGE TERTIARY CENTER EXPERIENCE**

Zaheer Nabi, India; Singh J.; Chavan R.; Shava U.; Reddy D. N.

P0250

**PERCUTANEOUS TRANSHEPATIC BILIARY DRAINAGE HAS LOW CLINICAL SUCCESS AND HIGH COMPLICATION RATE IN PATIENTS WITH MALIGNANT BILIARY STRICTURES**

Ted Stoklosa, Australia; Liu K.; Wong J.; Koh Y.; Baars J.; Bhate P.; Joanne Manlapig Rubio M.; Su F.; Perera N.; Kortt N.; Tsoutsman T.; Kaffes A.; Saxena P.

P0251

**OUTCOMES AND SAFETY OF PERCUTANEOUS TRANSHEPATIC BILIARY DRAINAGE AFTER LIVER TRANSPLANTATION**

Ted Stoklosa, Australia; Liu K.; Wong J.; Koh Y.; Baars J.; Bhate P.; Joanne Manlapig Rubio M.; Su F.; Perera N.; Kortt N.; Tsoutsman T.; Majumdar A.; Kaffes A.; Saxena P.

**Poster Session**

09:00 – 17:00

Hall X1

**Surgery I****Oesophagus/stomach/duodenum**

P0252

**RISK FACTORS OF LYMPH NODE METASTASIS IN PATIENTS WITH EARLY PURE AND MIXED SIGNET RING CELL GASTRIC CARCINOMAS**

Guifang Xu, China

P0253

**OUR EDUCATIONAL ACTIVITY FOR PERCUTANEOUS TRANS-ESOPHAGEAL GASTRO-TUBING**

Hideto Oishi, Japan; Iino T.

P0254

**INTENSITY OF ESOPHAGEAL PERISTALSIS IS A FACTOR IN PROLONGED POSTOPERATIVE PAIN BEFORE PERORAL ENDOSCOPIC MYOTOMY**

Ryo Kato, Japan; Sugihara Y.; Okamoto Y.; Sakae H.; Kinugasa H.; Kawano S.; Manabe N.; Kawahara Y.; Otsuka F.; Okada H.

P0255

**WITHDRAWN**

P0256

**ENDOSCOPIC PAPILLECTOMY IN TREATMENT OF PATIENTS WITH AMPULLARY NEOPLASMS: A SINGLE-CENTER EXPERIENCE.**

Klyueva K.; Shishin K.; Ivan Nedoluzhko, Russian Federation; Kurushkina N.; Shumkina L.

P0257

**ENDOSCOPIC VACUUM THERAPY FOR TREATMENT OF UPPER GASTROINTESTINAL ANASTOMOTIC LEAKAGES: FIRST EXPERIENCE.**

Pyatakova A.; Shishin K.; Ivan Nedoluzhko, Russian Federation; Shumkina L.; Kurushkina N.

P0258

**THE SMART APPROACH TO SURGICAL TREATMENT FOR GASTRIC AND DUODENAL GISTS BASED ON PREOPERATIVE EUS-TYPING**

Seda Dzhantukhanova, Russian Federation; Starkov Y.; Vybornyi M.

**Small bowel/colorectal and anal**

P0259

**WITHDRAWN**

P0260

**A COMPREHENSIVE COMPARISON OF THE FIVE LEADING SCORINGS SYSTEMS FOR PERITONEAL CARCINOMATOSIS FROM COLORECTAL ORIGIN TO SELECT CRS/HIPEC CANDIDATES WITH MRI.**

Engbersen M.; van 't Sant-jansen I.; van Eden H.; Lambregts D. M.; Velzing J.; Beets-Tan R.; Aalbers A.; Kok N.; Max Lahaye, The Netherlands

P0261

**DEVELOPEMENT OF 3D MODEL OF PERIANAL DISEASE IN CD. SINGLE CENTRE EXPERIENCE.**

Guz W.; Ożóg Ł.; Truskiewicz A.; Solińska A.; Pękała A.; Rafal Filip, Poland

P0262

**THE POTENTIAL OF HUMAN FOETAL GUT MESOANGIOBLASTS-LIKE CELLS FOR ENTERIC SMOOTH MUSCLE REGENERATION**

Silvia Perin, United Kingdom; McCann C.; Natarajan D.; De Coppi P.; Thapar N.

P0263

**IMAGE-GUIDED PATHOLOGY FOR EVALUATION OF RESECTION MARGINS IN LOCALLY ADVANCED RECTAL CANCER USING THE NEAR-INFRARED FLUORESCENT TRACER BEVACIZUMAB-800CW**

S. J. de Jongh, The Netherlands; Tjalma J. J. J.; Koller M.; Linssen M. D.; Jorritsma-Smit A.; Karrenbeld A.; Havenga K.; Hemmer P. H. J.; de Vries E. G. E.; Hospers G. A. P.; van Etten B.; Ntziachristos V.; van Dam G. M.; Nagengast W. B.

P0264

**SNAPSHOT STUDY ON MRI RESTAGING AFTER CHEMORADIO THERAPY AND INTERVAL TO SURGERY IN RECTAL CANCER; INFLUENCE ON SHORT AND LONG-TERM OUTCOMES.**

Robin Detering, The Netherlands; Borstlap W. A. A.; Broeders L.; Hermus L.; Marijnen C. A. M.; Beets-Tan R. G. H.; Bemelman W. A.; Van Westreenen E. L.; Tanis P. J.



P0265

**LAPAROSCOPIC VENTRAL RECTOPEXY FOR OBSTRUCTED DEFECATION FUNCTIONAL RESULTS AND QUALITY OF LIFE**  
[Silvia Degasperj](#), Italy; Scarpa M.; Saadeh L. M.; Marcellan E.; Zini O.; Bardini R.; Angriman I.

P0266

**ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) VERSUS TRANSANAL ENDOSCOPIC MICROSURGERY (TEM) FOR THE TREATMENT OF EARLY RECTAL CANCER: COMPARISON OF LONG TERM OUTCOMES** ✦  
[Cintia Kimura](#), Brazil; Kawaguti F. S.; Saporapan Marques C. F.; Nahas C. S. R.; Segateli V.; da Costa Martins B.; Lenz Tolentino L. H.; Ribeiro U.; Maluf-Filho F.; Nahas S. C.

### Poster Session

09:00 – 17:00

Hall X1

IBD I

### Basic/pathogenesis/pathology

P0267

**CROSTALK BETWEEN SEROTONIN AND ENDOCANNABINOID SYSTEMS IN THE GUT CONTRIBUTES TO THE ABDOMINAL PAIN IN COLITIS**  
[Maciej Salaga](#), Poland; Binienda A.; Piscitelli F.; Di Marzo V.; Fichna J.

P0268

**UROTENSIN II RECEPTOR EXPRESSION IN ULCERATIVE COLITIS: RELATIONSHIP WITH ENDOSCOPIC AND HISTOLOGICAL ACTIVITY OF THE DISEASE**  
[Gravina A. G.](#); [Marcello Dallio](#), Italy; Tuccillo C.; Martorano M.; Loguercio C.; Federico A.

P0269

**DS-1093A, A NOVEL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR, HAS A THERAPEUTIC POTENTIAL IN INFLAMMATORY BOWEL DISEASE.**  
[Yuki Toyoshima-Kawabata](#), Japan; Nezu Y.; Takahashi S.; Fukuda T.; Nakamura K.; Yabe Y.; Nakamura K.; Yamaguchi K.

P0270

**LOWER FECAL BACTERIAL ABUNDANCE IS ASSOCIATED WITH DISEASE RECURRENCE ONE YEAR AFTER ILEOCAECAL RESECTION IN PATIENTS WITH CROHN'S DISEASE**  
[Anna Strömbeck](#), Sweden; Strid H.; Magnusson M. K.; Isaksson S.; Stotzer P.-O.; Lasso A.; Öhman L.

P0271

**RELATIONSHIP BETWEEN BIOPSY LOCATION, HISTOLOGICAL DISEASE ACTIVITY, AND MRNA EXPRESSION IN ENDOSCOPICALLY ACTIVE CROHN'S DISEASE**  
[Gregor Novak](#), Slovenia; Stevens T.; Vande Castele N.; Bossuyt P.; Stabuc B.; Van Viegen T.; Jeyarajah J.; Gaemers I.; Shackelton L.; Khanna R.; van den Brink G. R.; Sandborn W. J.; Feagan B. G.; Pai R.; Jairath V.; D'Haens G.

P0272 

**NEUTROPHIL EXTRACELLULAR TRAPS SUSTAIN INFLAMMATORY SIGNALS IN ULCERATIVE COLITIS**  
[Irene Marafini](#), Italy; Dinallo V.; Di Fusco D.; Laudisi F.; Franze E.; Di Grazia A.; Caprioli F.; Stolfi C.; Monteleone I.; Monteleone G.

P0273

**THE SYSTEMIC INFLAMMATORY PROTEIN PROFILES DEVIATE BETWEEN PATIENTS WITH INFLAMMATORY AND FUNCTIONAL GASTROINTESTINAL DISEASES**  
[Luiza Moraes](#), Sweden; Magnusson M. K.; Jonefjäll B.; Polster A.; Sundin J.; Törnblom H.; Strid H.; Simrén M.; Öhman L.

P0274

**TISSUE REMODELLING IN TERMINAL ILEAL STRICTURING CROHN'S DISEASE**  
[Uday Nagesh Shivaji](#), United Kingdom; Evans M.; Critchlow T.; Gui X.; Smith S. C. L.; Iacucci M.; Ghosh S.; Skordilis K.; Cooney R.

P0275

**B CELL-MEDIATED ILEOCECAL IMMUNE RESPONSE IN AN EXPERIMENTAL COLITIS MODEL ANALYZED VIA INTRAVITAL IMAGING**  
[Yudai Kojima](#), Japan; Nagaishi T.; Watabe T.; Tsugawa N.; Jose N.; Yamada D.; Hosoya A.; Adachi T.; Watanabe M.

P0276

**THE CHANGE OF THE ANGI II, ACE2 AND ANG 1-7 ON TNBS-INDUCED EXPERIMENTAL COLITIS IN MICE AND THE RESEARCH ABOUT PROTECTIVE EFFECT OF MICA**  
[Zhang B.](#); [Mengdie Shen](#), China; Ye L.; Lv B.; Meng L.-N.

P0277

**TAUROURSODEOXYCHOLIC ACID ATTENUATES COLITIS-ASSOCIATED COLON CANCER BY INHIBITING NUCLEAR FACTOR KAPPA B SIGNALING**  
[Kim J. H.](#); [Seong-joon Koh](#), Republic of Korea

P0278

**ANTI-TNF-ALPHA THERAPY INDUCES MICROBIAL AND IMMUNOLOGICAL CHANGES IN DEXTRAN SODIUM SULPHATE ACUTE COLITIS**  
[Valentina Petito](#), Italy; Fossati M.; Graziani C.; Lopetuso L. R.; Scannone D.; Quaranta G.; Masucci L.; Battaglia A.; Sgambato A.; Sanguinetti M.; Gasbarrini A.; Scaldaferrì F.

P0279

**SHORT-TERM ORAL ANTIBIOTICS TREATMENT PROMOTES INFLAMMATORY ACTIVATION OF COLONIC INKT AND CONVENTIONAL CD4+ T CELLS**  
[Federica Facciotti](#), Italy; Burrello C.; Garavaglia F.; Cribiù F. M.; Ercoli G.; Bosari S.; Caprioli F.



P0280

**THERAPEUTIC POTENTIAL OF GLEPAGLUTIDE, A LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 RECEPTOR AGONIST, IN A RAT MODEL OF RECURRENT INDOMETHACIN-INDUCED SMALL INTESTINAL INFLAMMATION**  
[Jolanta Skarbaliene](#), Denmark; [Thorildsen C.](#); [Berners-Hansen M.](#); [Russell W.](#)

P0281

**CHARACTERISTICS OF MUCOSA-ASSOCIATED GUT MICROBIOTA DURING TREATMENT IN CROHN'S DISEASE**  
[Cong He](#), China; [Wang H.](#); [Zhu X.](#); [Liao W.](#); [Zhu Z.](#)

P0282

**AUTOPHAGY-RELATED HOST FACTORS ARE INVOLVED IN THE INCAPABILITY OF MACROPHAGES FROM CROHN'S DISEASE PATIENTS TO ELIMINATE ADHERENT-INVASIVE ESCHERICHIA COLI**  
[Clara Douadi](#), France; [Buisson A.](#); [Ouchchane L.](#); [Goutte M.](#); [Hugot J.-P.](#); [Dubois A.](#); [Minet-Quinard R.](#); [Bouvier D.](#); [Bommelaer G.](#); [Vazeille E.](#); [Barnich N.](#)

P0283

**MUCOSAL AND SYSTEMIC IMMUNE PROFILES DIFFER DURING EARLY AND LATE PHASE OF THE DISEASE IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS**  
[Georgios Mavroudis](#), Sweden; [Magnusson M. K.](#); [Simrén M.](#); [Öhman L.](#); [Strid H.](#)

P0284

**LOW LEVEL OF KNOWLEDGE OF PREGNANCY-RELATED ISSUES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN POLISH POPULATION.**  
[Monika Kukulska](#), Poland

P0285

**ALTERED TUFT CELL POPULATION OF HUMAN COLONIC EPITHELIUM IN INFLAMMATORY BOWEL DISEASES**  
[Jensen T. S. R.](#); [Sebastian Kjærgaard](#), Denmark; [Feddersen U. R.](#); [Poulsen S. S.](#); [Grunddal K. V.](#); [Berners-Hansen M.](#); [Bindslev N.](#)

P0286

**MICE OVEREXPRESSING MKL1 IN MACROPHAGES EXPERIENCE FULMINANT COLITIS**  
[An J.](#); [Takashi Nagaishi](#), Japan; [Watabe T.](#); [Naruse T.](#); [Watanabe M.](#); [Kimura A.](#)

P0287

**REGULATORY B CELLS CONTRIBUTE TO ALLEVIATE THE ACUTE COLITIS IN CD19<sup>-/-</sup> MICE**  
[Xia Li](#), China; [Tan J.](#); [Xue Q.](#); [Li Y.](#); [Wang J.](#)

P0288 

**IMPAIRED BUTYRATE INDUCED ANTI-INFLAMMATORY IMMUNE REGULATION IN LAMINA PROPRIA CELLS FROM PATIENTS WITH ACTIVE ULCERATIVE COLITIS**  
[Maria K Magnusson](#), Sweden; [Isaksson S.](#); [Öhman L.](#)

P0289

**IN VITRO ASSESSMENT OF THE EFFECT OF MESENCHYMAL STEM CELL ORIGIN AND QUALITY ON MACROPHAGE POLARIZATION**  
[El-Sayed M.](#); [Ali El-Feky M.](#); [Mohammed Tag-Adeen](#), Egypt; [El-Amir M.](#); [Li T.-S.](#)

### Aetiology/epidemiology

P0290

**DOES ASTHMA INCREASE THE RISK OF INFLAMMATORY BOWEL DISEASE? A META-ANALYSIS OF CASE-CONTROL AND COHORT STUDIES**  
[Hiroyuki Yuhara](#), Japan; [Inoue T.](#); [Takahara H.](#); [Watanabe K.](#)

P0291 

**THE PREVALENCE OF GASTROINTESTINAL CANCERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A DANISH NATIONWIDE COHORT STUDY**  
[Petra Weimers](#), Denmark; [Ankersen D.](#); [Burisch J.](#); [Munkholm P.](#)

P0292

**NATURAL HISTORY OF ACUTE SEVERE ULCERATIVE COLITIS IN ELDERLY: A POPULATION BASED STUDY.**  
[Laura Bril](#), France; [Leroyer A.](#); [Fumery M.](#); [Charpentier C.](#); [Pariente B.](#); [Sarter H.](#); [Laharie D.](#); [Gower-Rousseau C.](#); [Savoie G.](#)

P0293

**WITHDRAWN**

P0294

**SMOKING REMAINS A MAJOR CONTRIBUTOR TO THE BURDEN OF CROHN'S DISEASE IN IRELAND AND WARRANTS THE DEVELOPMENT OF A SPECIFIC TARGETED SMOKING CESSATION INTERVENTION**  
[Atiyekeogbebe Rita Douglas](#), Ireland; [Mohess X.](#); [Sari Z.](#); [Cotter I.](#); [Seow H.](#); [Gallagher C.](#); [Ryan B.](#); [McNamara D.](#)

P0295

**OCULAR MANIFESTATIONS IN A TERTIARY IBD CENTER: BETTER TO KEEP AN EYE ON**  
[Gianenrico Rizzatti](#), Italy; [Gerardi S.](#); [Manganelli C.](#); [Petito V.](#); [Graziani C.](#); [Holleran G.](#); [Lopetuso L. R.](#); [Schiavoni E.](#); [Napolitano D.](#); [Pizzoferrato M.](#); [Laterza L.](#); [Ianiro G.](#); [Caporossi A.](#); [Papa A.](#); [Armuzzi A.](#); [Gasbarrini A.](#); [Scaldaferri F.](#)

P0296

**INTESTINAL AND EXTRA-INTESTINAL CANCER IN IBD PATIENTS ADMITTED TO AN ITALIAN TERTIARY CENTRE**  
[Gianenrico Rizzatti](#), Italy; [Pistone M. T.](#); [Poscia A.](#); [Ojetti V.](#); [Lopetuso L. R.](#); [Pizzoferrato M.](#); [Ianiro G.](#); [Volpe M.](#); [Schiavoni E.](#); [Gaetani E.](#); [Sgambato A.](#); [Franceschi F.](#); [Papa A.](#); [Cammarota G.](#); [Gasbarrini A.](#); [Scaldaferri F.](#)



P0297 **LONG TERM STABILITY OF SEROLOGICAL ANTIBODIES IN A POPULATION-BASED INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE – THE IBSEN STUDY**Vendel A. Kristensen, Norway; Cvancarova M.; Høivik M. L.; Moum B.; Vatn M. H.

P0298

**INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE; CHARACTERIZATION AND RISK FACTORS IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS**Livia Biancone, Italy; Armuzzi A.; Scribano M. L.; Castiglione F.; D'Incà R.; Daperno M.; Papi C.; Vecchi M.; Fries W.; Riegler G.; Alvisi P.; Mocchiari F.; Ruffa A.; Neri B.; Festa S.; Testa A.; Calabrese E.; Di Mitri R.; De Cristofaro E.; Gesuale C.; Spina L.; Rogai F.; Renna S.; Meucci G.; Guidi L.; Rossi A.; Orlando A.; Pallone F.

P0299

**WHAT FACTORS CAN IMPROVE THE EXPERIENCE OF PATIENTS WITH CHRONIC HEALTH CARE? A SURVEY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE**Marín-Jiménez I.; Casellas F.; García-Sepulcre M. F.; Cortés X.; Berta Juliá, Sudan; Soto N.; Mosquera M.; Cea-Calvo L.

P0300

**PATIENT-REPORTED COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN IBD: 10 YEARS OF OBSERVATION AMONG PATIENTS INCLUDED IN A NATIONAL COHORT**Valerie Pittet, Switzerland; Aslan N.; Fournier N.; Decollogny A.; Schoepfer A.; Seibold F.; Rodondi P.-Y.**Diagnosis and monitoring**

P0301

**FECAL CALPROTECTIN MAY BE A SENSITIVE BIOMARKER IN ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS** ✦Tamara Knezevic Ivanovski, Serbia; Knezevic Usaj S.; Svorcan P.; Protic-Nedeljkovic M.

P0302

**GASTROENTEROLOGIST PERFORMED POINT-OF-CARE GASTROINTESTINAL ULTRASOUND IMPROVED PATIENT UNDERSTANDING OF DISEASE ACTIVITY, SYMPTOMATOLOGY, MANAGEMENT DECISIONS AND CLINICAL OUTCOMES**Friedman A. B.; Asthana A. K.; Knowles S.; Aphra Robbins, Australia; Gibson P. R.

P0303

**THE EFFECT OF ARYLESTERASE AND PARAOXONASE-1 LEVELS ON ULCERATIVE COLITIS: A RANDOMISED CONTROLLED STUDY**Memduh Sahin, Turkey; Bobusoglu O.; Ates F.

P0304

**WHITE CELL COUNT (WCC) AND MEAN CORPUSCULAR VOLUME (MCV) AS SURROGATE MARKERS FOR THIOPURINE MONITORING IN INFLAMMATORY BOWEL DISEASE TREATMENT: A SINGLE CENTRE EXPERIENCE**Brian Christopher, Ireland; Altamimi K.; Campbell N.; R-Lyons R.; Alakkari A.; O'Connor A.; McNamara D.; Breslin N.; Ryan B.

P0305

**PLASMA REG3 $\alpha$  CAN BE A USEFUL NON-INVASIVE BIOMARKER FOR DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS**Seungjun Gim, Republic of Korea; Lee B.-I.; Cho M.-L.; Park J.-S.; Kwon J. Y.; Lee H.-H.; Kim J.; Cho Y.-S.; Choi M.-G.

P0306

**REAL-TIME BIOLOGIC DRUG MONITORING USING BREATH IN INFLAMMATORY BOWEL DISEASE (IBD) – EARLY RESULTS**Akira Tiele, United Kingdom; Wicaksono A.; Kansara J.; James K.; Arasaradnam R.; Covington J.

P0307

**INCIDENCE AND NATURAL HISTORY OF INFLAMMATORY BOWEL DISEASE DIAGNOSED IN COLORECTAL CANCER SCREENING.**Zippi M.; Pierluigi Fracasso, Italy; Pica R.; Cocco A.; Traversa G.; De Felici I.; Febbraro I.; Occhigrossi G.

P0308

**THE IMPACT OF TOTAL AND FREE ANTI-DRUG ANTIBODIES ON THE LONG-TERM CLINICAL RESPONSE TO INFLIXIMAB THERAPY**Lidia Roque Ramos, Portugal; Nunes G.; Matoso P.; Patita M.; Vieira A.; Demengeot J.; Garçês S.

P0309

**CHROMOENDOSCOPY IS SUPERIOR TO WHITE LIGHT ENDOSCOPY FOR THE DETECTION OF ADVANCED COLONIC NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**Michael Chiorean, United States; Kim K. O.

P0310

**A CLEAR LOOK INTO THE BOWEL WITHOUT CLEANING IT – SIMULTANEOUS PET/MRI ENTEROGRAPHY (18F-FDG) FOR MONITORING INFLAMMATORY ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS – A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL**Jost Langhorst, Germany; Li Y.; Koch A. K.; Dechêne A.; Herrmann K.; Dobos G. J.; Beiderwellen K.; Lauenstein T.; Umutlu L.

P0311

**FECAL BIOMARKERS COMPARED TO MAGNETIC RESONANCE IMAGING USING THE MARIA AND CLERMONT SCORES FOR MONITORING INFLAMMATORY ACTIVITY IN PATIENTS WITH CROHN'S DISEASE**Jost Langhorst, Germany; Koch A. K.; Boone J. H.; Rueffer A.; Herrmann K.; Dobos G. J.; Umutlu L.; Li Y.

P0312

**ENDOSCOPIC FOLLOW-UP ALLOWS GOOD CONTROL OF COLORECTAL CANCER INCIDENCE IN IBD PATIENTS WITH LOW AND HIGH-GRADE DYSPLASIA: A FRENCH MULTI-CENTRIC PROSPECTIVE COHORT.**Benech N.; Vinet O.; Malamut G.; Bourreille A.; Nancey S.; Bulois P.; Chevaux J.-B.; Lamarque D.; Coumaros D.; Rivory J.; Pioche M.; Jean Christophe Saurin, France

P0313

**QUESTIONING CONSENSUS IN CROHN'S DISEASE: CT AND MR PERIANAL EXTENSION HAS MINIMAL DIAGNOSTIC YIELD AND INCURS ADDITIONAL RADIATION EXPOSURE**Joana Roseira, Portugal; Carneiro C.; Contente L. F.; Marreiros A.; Tavares de Sousa H.; Brito J.

P0314

**PHOTOPROTECTIVE IBD EDUCATIONAL VIDEO ANIMATION ("TAGG SUNCARE VIDEO") IS PREFERRED BY PATIENTS AND IS AN EFFECTIVE WAY OF IMPROVING PATIENT KNOWLEDGE AND AWARENESS**Catriona Gallagher, Ireland; Murphy A.; Condon M.; Tersaruolo C.; Ryan B.; O'Connor A.; Tobin A. M.; McNamara D.P0315 **IBD PATIENTS ARE FOUR TIMES MORE LIKELY TO DEVELOP ALL TYPES OF SKIN CANCER POSSIBLY RELATED TO HIGH RATES OF IMMUNOSUPPRESSION; WITH YOUNG PATIENTS PARTICULARLY AT RISK OF MELANOMA ✦**Catriona Gallagher, Ireland; MacMahon F.; White L.; Ismail S.; Ryan B.; O'Connor A.; Tobin A. M.; McNamara D.

P0316

**HEPCIDIN LEVELS IN DIAGNOSING IRON DEFICIENCY ANEMIA IN IBD PATIENTS**Milica Stojkovic Lalošević, Serbia; Pavlovic Markovic A.; Jovicic I.; Vojnovic M.; Kojic D.; Stankovic S.; Kiurski S.; Stojkovic M.

P0317

**MONITORING HISTOLOGICAL ACTIVITY IN ULCERATIVE COLITIS - CORRELATION OF FECAL BIOMARKERS WITH THE RILEY SCORE AND THE NANCY INDEX**Jost Langhorst, Germany; Schroeder D.; Koch A.; Dobos G. J.; H. Boone J.; Rueffer A.; Juette H.; Tannapfel A.

P0318

**AZATHIOPRINE METABOLITE (6-TGN) LEVELS WITHIN A DEFINED THERAPEUTIC RANGE ARE ASSOCIATED WITH LOWER FECAL CALPROTECTIN IN CROHN'S DISEASE - A RETROSPECTIVE ANALYSIS**Essmann J.; Keil C.; Unruh O.; Otte A.; Manns M.; Oliver Bachmann, Germany

P0319

**DEVELOPMENT AND VALIDATION OF A SIMPLIFIED MAGNETIC RESONANCE INDEX OF ACTIVITY (SMARIA) FOR CROHN'S DISEASE.**Ingrid Ordàs Jimenez, Spain; Rimola J.; Alfaro Perez I. J.; Rodriguez Gomez S.; Castro Poceiro J.; Gallego M.; Giner A.; Barastegui R.; Vara A.; Masamunt J.; Ricart Gomez E.; Panés J.P0320 **VALIDATION AND INVESTIGATION OF THE OPERATING CHARACTERISTICS OF THE ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY**Djuna de Jong, The Netherlands; Samaan M.; Lowenberg M.; Koumoutsos I.; Irving P.

P0321

**FATIGUE AS A POSSIBLE MARKER OF SARCOPENIA IN INFLAMMATORY BOWEL DISEASE PATIENTS**Pizzoferrato M.; Gianenrico Rizzatti, Italy; Ingravalle F.; Petito V.; Graziani C.; Martone A. M.; Landi F.; Mele M. C.; Mentella M. C.; Armuzzi A.; Gasbarrini A.; Scaldaferrì F.

P0322

**USE OF SYNTHETIC AND BIOLOGICAL BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ENTEROPATHIC SPONDYLOARTHRITIS: A COMBINED GASTRO-RHEUMATOLOGICAL APPROACH IN PROSPECTIVE STUDY AT 2 YEARS**Chimenti M. S.; Conigliaro P.; Triggianese P.; Claudia Canofari C. C.; Cedola F.; Onali S.; Calabrese E.; Romeo S.; Neri B.; Ruffa A.; Perricone R.; Livia Biancone, Italy

P0323

**EVALUATION OF CROHN'S DISEASE BY USING A NOVEL CAPSULE ENDOSCOPY SCORING METHOD: CROHN'S DISEASE ACTIVITY IN CAPSULE ENDOSCOPY (CDACE)**Teppei Omori, Japan; Yasuhiro K.; Murasugi S.; Kambayashi H.; Ito A.; Yonezawa M.; Nakamura S.; Tokushige K.

P0324

**LONG-TERM OBSERVATION REGISTRY -CEDUR - IN GERMAN IBD PATIENTS**Stefanie Howaldt, Germany; Ochsenkuehn T.

P0325

**A RETROSPECTIVE ANALYSIS OF THE MULTIGENE ANALYSIS TEST DIBICOL® TO DIFFERENTIATE BETWEEN ULCERATIVE COLITIS, CROHN'S DISEASE AND NON-IBD**  
Admyre C.; [Thomas Knittel](#), Sweden; [Öst Å.](#); [Löfberg R.](#); [Zargari A.](#)

P0326

**FAECAL CALPROTECTIN DISCRIMINATES CRYPTOGLANDULAR FROM CROHN'S DISEASE PERIANAL FISTULAE**  
[Toer Stevens](#), The Netherlands; [D'Haens G.](#); [Duijvestein M.](#); [Buskens C. J.](#); [Bemelman W. A.](#); [Gecse K. B.](#)

P0327

**QUALITY OF LIFE IS ASSOCIATED WITH WEARABLE-BASED PHYSICAL ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE, OBSERVATIONAL STUDY**

[Miriam Wiestler](#), Germany; [Kockelmann F.](#); [Kück M.](#); [Tegtbur U.](#); [Manns M.](#); [Attaran-Bandarabadi M.](#); [Bachmann O.](#)

P0328

**ABNORMAL MENTAL HEALTH IS DIFFERENT AND MORE SEVERE IN CROHN'S DISEASE COMPARED WITH ULCERATIVE COLITIS**

[Doron Schwartz](#), Israel; [Slonim-Nevo V.](#); [Sergienko R.](#); [Sarid O.](#); [Friger M.](#); [Greenberg D.](#); [Vardi H.](#); [Chernin E.](#); [Odes S.](#)

P0329

**THE ASSOCIATION BETWEEN DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN EUROPE**  
[Alessandro Armuzzi](#), Italy; [Tarallo M.](#); [DiBonaventura M.](#); [Bargo D.](#); [Lucas J.](#); [Bluff D.](#); [Hoskin B.](#); [Salese L.](#); [Cappelleri J.](#); [Gigante G.](#)

P0330

**A PILOT [11C]PBR28 TSPO PET IMAGING STUDY TO EVALUATE INFLAMMATION IN CROHN'S DISEASE**

[Qi Guo](#), United States; [Rizzo G.](#); [Searle G.](#); [Genius J.](#); [Russo E.](#); [Walther M.](#); [Luce M.](#); [Luo Y.](#); [Rabiner E. A.](#); [Comley R.](#); [Saleem A.](#)

P0331

**DEPENDENCE OF THE LEVEL OF INFLAMMATION MARKERS ON THE PRESENCE OF CLOSTRIDIAL INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.**

[Knyazev O.](#); [Anna Kagrananova](#), Russian Federation; [Lishchinskaya A.](#); [Korneeva I.](#); [Parfenov A.](#)

P0332

**MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN CLINICAL PRACTICE: A PILOT STUDY ON IBD PATIENTS**

[Sonia Facchin](#), Italy; [Buda A.](#); [Perini B.](#); [D'inca R.](#); [Savarino E. V.](#)

P0333

**VALIDATION OF THE RIDA®QUICK ADM MONITORING: A RAPID TEST FOR ADALIMUMAB DRUG CONCENTRATION MONITORING WHICH SUPPORTS TIMELY DOSE ADJUSTMENTS IN CLINICAL PRACTICE**

[Barthel C.](#); [Bian S.](#); [Wagenhäuser K.](#); [Fichtner D.](#); [Rameil S.](#); [Thomas Van Stappen](#), Germany

P0334

**TARGET GOLIMUMAB LEVELS TO ACHIEVE MUCOSAL HEALING IN PATIENTS WITH CROHN'S DISEASE**

[Karen Boland](#), Canada; [Greener T.](#); [Tessolini J.](#); [Li R.](#); [Soriano J.](#); [Kabakchiev B.](#); [Stempak J.](#); [Croitoru K.](#); [Nguyen G. C.](#); [Steinhart A. H.](#); [Weizman A. V.](#); [Silverberg M. S.](#)

### Treatment-medical

P0335

**EFFICACY AND SAFETY OF ADALIMUMAB IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE**

[Baili Chen](#), China; [Gao X.](#); [Zhong J.](#); [Ren J.](#); [Zhu X.](#); [Liu Z.](#); [Wu K.](#); [Kalabic J.](#); [Huang B.](#); [Doan T.](#); [Robinson A. M.](#); [Chen M.](#)

P0336

**IMPROVED PATIENT-REPORTED OUTCOMES WITH UPA-DACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE**  
[Ghosh S.](#); [Colombel J.-F.](#); [Vermeire S.](#); [Lee S.](#); [Lee W.-J.](#); [Wen Zhou](#), United States; [Cataldi F.](#); [Lacerda A.](#); [Danese S.](#)

P0337

**MUCOSAL 5-ASA CONCENTRATION IN THE LEFT HEMI-COLON AND RECTUM IN PATIENTS WITH QUIESCENT ULCERATIVE COLITIS**

[Maya Olaisen](#), Norway; [Spigset O.](#); [Sandvik A. K.](#); [Albrektsen G.](#); [Røyset E. S.](#); [Martinsen T. C.](#); [Fossmark R.](#)

P0338

**EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY**

[William J. Sandborn](#), United States; [Ferrante M.](#); [Bhandari B. R.](#); [D'Haens G.](#); [Berliba E.](#); [Feagan B. G.](#); [Klekotka P.](#); [Laskowski J.](#); [Durante M.](#); [Tuttle J.](#); [Naegeli A.](#)

P0339

**COMPARATIVE FREQUENCY OF CLOSTRIDIAL INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MESENCHYMAL STROMAL CELLS AND BIOLOGICAL PREPARATIONS.**

[Knyazev O.](#); [Kagrananova A.](#); [Albina Lishchinskaya](#), Russian Federation; [Donchenko I.](#); [Parfenov A.](#); [Fadeeva N.](#); [Zvyaglova M.](#)

P0340

**CORRELATION OF BIOMARKERS OF INFLAMMATION WITH CLINICAL AND ENDOSCOPIC ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: DATA FROM CELEST**Jean-Frederic Colombel, United States; Peyrin-Biroulet L.; Danese S.; Travis S.; Dryden G.; Hardi R.; Epstein M.; Zhou W.; Cataldi F.; Huang B.; Lacerda A. P.; Panés J.

P0341

**EARLY INFLIXIMAB TROUGH LEVELS PREDICT LATE EFFICACY OF INFLIXIMAB IN A RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE CROHN'S DISEASE COMPARING CT-P13 AND INNOVATOR INFLIXIMAB**Jae Hee Cheon, Republic of Korea; Lee K.-M.; Kim Y.-H.; Ye B. D.; Eun C.; Lee S. Y.; Lee S. G.; Lee J. H.; Kim H.; Selema P.; Cheung R.; Schreiber S.

P0342

**ADDITIONAL POWER OF ELEMENTAL DIET ON MAINTENANCE BIOLOGICS THERAPY IN CROHN'S DISEASE (ADORE STUDY) - A MULTICENTER, PROSPECTIVE, COHORT STUDY**Tetsuya Ishida, Japan; Hirai F.

P0343

**EARLY OPTIMIZATION OF GOLIMUMAB DOSE INDUCES DELAYED RESPONSE AND LONG-TERM CLINICAL BENEFIT IN ULCERATIVE COLITIS**Cristina Alba, Spain; Iborra M.; Bosca-Watts M. M.; Rubio S.; Nantes O.; Higuera R.; Bertoletti F.; Martínez-Montiel P.; Sierra-Ausin M.; Manceñido N.; Pérez-Calle J. L.; Algaba A.; Olivares D.; Taxonera C.

P0344

**BASELINE DEMOGRAPHIC FEATURES OF ULCERATIVE COLITIS PATIENTS AS PREDICTORS OF CLINICAL RESPONSE TO ADSORPTIVE DEPLETION OF MYELOID LINEAGE LEUCOCYTES AS REMISSION INDUCTION THERAPY**Tomotaka Tanaka, Japan; Goishi H.; Iiboshi T.; Kajihara T.; Miura T.P0345 **ANTI-TNF INDUCED LUPUS (ATIL) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.**Sherman Picardo, Australia; So K.; Venugopal K.

P0346

**MEDICAL AND SURGICAL MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: AN INTERNATIONAL COMPARISON BETWEEN CHINA, INDIA, AND THE UNITED STATES**Sanskriti Varma, United States; Mehta A.; Hu J.; Zhang Y.; Park A.; Song Y.; Banerjee R.; Parekh N.; Zhi M.; Hutfless S.

P0347

**EXPOSURE-RESPONSE ANALYSES OF UPADACITINIB (ABT-494) EFFICACY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS-ANALYSES OF A PHASE 2 DOSE RANGING INDUCTION STUDY**Mukul Minocha, United States; Engelhardt B.; Stodtmann S.; Zhou W.; Othman A. A.P0348 **INDUCTION THERAPY OF UPADACITINIB IS ASSOCIATED WITH IMPROVED SYMPTOMS IN BOWEL URGENCY AND ABDOMINAL PAIN FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE**Subrata Ghosh, United Kingdom; Louis E.; Lee S.; Cataldi F.; Huang B.; Lee W.-J.; Loftus Jr E. V.

P0349

**AN IBD RISK VARIANT WITHIN THE PTPN22 GENE LOCUS ENHANCES ANTI-INFLAMMATORY EFFECTS OF SPERMIDINE IN INTESTINAL EPITHELIAL CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS FROM IBD PATIENTS**Anna Niechcial, Switzerland; Butter M.; Obialo N.; Bähler K.; van der Lely L.; Lang S.; Gottier C.; Scharl M.; Spalinger M. R.

P0350

**VEDOLIZUMAB IN REFRACTORY MICROSCOPIC COLITIS: AN INTERNATIONAL CASE SERIES.**Pauline Riviere, Belgium; Münch A.; Michetti P.; Chande N.; De Hertogh G.; Schoeters P.; Ferrante M.; Vermeire S.; Van Assche G.

P0351

**DEFINING 'EARLY DISEASE' IN INFLAMMATORY BOWEL DISEASE: THE RESULTS OF A SYSTEMATIC LITERATURE REVIEW**Peyrin-Biroulet L.; Jairath V.; Wright D.; Demuth D.; Sarah Campbell-Hill, United Kingdom; Dulai P. S.

P0352

**LACK OF EARLY RESPONSE AND MUCOSAL HEALING IS ASSOCIATED WITH COLECTOMY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB IN THE PURSUIT-M TRIAL.**Colombel J.-F.; Marano C. W.; Philip G.; Huyck S.; Yao R.; Freddy Cornillie, United States

P0353

**VEDOLIZUMAB OUTCOMES IN REAL-WORLD BIO-NAIVE ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS (EVOLVE) IN CANADA: TREATMENT PATTERNS, CLINICAL EFFECTIVENESS AND SAFETY**Bressler B.; Bassel M.; Stein D.; Soni M.; Radulescu G.; Greenup A.-J.; Khalid J. M.; Dirk Demuth, United Kingdom

P0354

**FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: A PILOT RANDOMIZED, SINGLE-BLIND, SHAM-CONTROLLED TRIAL**

Harry Sokol, France; Landman C.; Seksik P.; Berard L.; Montil M.; Nion-Larmurier I.; Bourrier A.; Legall G.; Lalande V.; Kirchgessner J.; Dagueneil A.; Cachanado M.; Rousseau A.; Drouet E.; Dray X.; Marteau P.; Beaugerie L.; Simon T.

P0355

**TOPICAL APPLICATION OF HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS GEL MATRIX ACCELERATE THE CLOSURE OF ENTEROCUTANEOUS FISTULA ON MOUSE MODEL**

Huixing Hou, China; Cao X.; Li K.; He A.; Liu G.; Liu Y.; Duan L.; Han Z.

P0356

**MEASURING THIOGUANINE NUCLEOTIDE (6-TGN) LEVELS AND CLINICAL RESPONSE IN IBD.**

Yalchin M.; Kamieniarz L.; Cama R.; Tribich S.; Lake L.; Joyce H.; Andreas Koutsoumpas, United Kingdom

P0357

**EPIDEMIOLOGY, DIAGNOSTIC WORK-UP AND PHARMACOLOGICAL TREATMENTS OF INFLAMMATORY BOWEL DISEASE IN SPAIN: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU**

Maria Chaparro, Spain; Barreiro de-Acosta M.; Benítez J. M.; Cabriada Nuño J. L.; Casanova González M. J.; Ceballos D.; Esteve M.; Fernández Rosaenz H.; Ginard D.; Gomollón García F.; Lorente Poyatos R.; Nos Mateu P.; Riestra Menéndez S.; Rivero M.; Robledo Andrés P.; Rodríguez C.; Sicília Aladrén B.; Torrella Cortes E. A.; García-Esquinas E.; Rodríguez-Artalejo F.; Gisbert J. P.; on behalf of the EpidemiBD group

P0358

**ENDOSCOPIC DILATION THERAPY FOR STRICTURING CROHN'S DISEASE OF THE SMALL INTESTINE USING BALLOON-ASSISTED ENDOSCOPY - A COMBINED ANALYSIS OF 773 ENDOSCOPIC BALLOON DILATION PROCEDURES**

Dominik Bettenworth, Germany; Bokemeyer A.; Lopez R.; Rieder F.

P0359

**LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MADCAM-1 MONOCLONAL ANTIBODY SHP647 IN CROHN'S DISEASE: THE OPERA II STUDY**

Geert D'Haens, The Netherlands; Reinisch W.; Lee S. D.; Tarabar D.; Louis E.; Klopocka M.; Klaus J.; Schreiber S.; Park D. I.; Hebuterne X.; Cataldi F.; Martin S. W.; Nayak S.; Banerjee A.; Gorelick K. J.; Sandborn W. J.

P0360

**FMT CAPSULES DECREASES FECAL CALPROTECTIN AND IMPROVES SYMPTOMS IN ULCERATIVE COLITIS PATIENTS - A PILOT STUDY**

Frederik Cold, Denmark; Günther S.; Browne P.; Petersen A.; Halkjær S. I.; Hansen L.; Christensen A. H.

P0361

**POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF SHP647, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 (ANTI-MADCAM-1), IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE**

Yi Wang, United States; Marier J. F.; Lavigne J.; Kassir N.; Martin P.

P0362

**EFFICACY OF TOFACITINIB AND BIOLOGICS AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**

David Rubin, United States; Ashaye A.; Zhang Y.; Fahrbach K.; Freitag A.; Kayhan C.; Lohan C.; Cappelleri J.; DiBonaventura M.

P0363

**PREDICTING OUTCOME IN ACUTE SEVERE ULCERATIVE COLITIS: COMPARISON OF THE OXFORD, EDINBURGH, LINDGREN AND ENDOSCOPIC MAYO SCORES**

Sonia Bernardo, Portugal; Fernandes S.; Gonçalves A. R.; Baldaia C.; Valente A.; Moura dos Santos P.; Correia L.

P0364

**RISK OF VENOUS THROMBOEMBOLISM BY DISEASE ACTIVITY, HOSPITALIZATION, AND SURGERY IN INFLAMMATORY BOWEL DISEASE: A NATIONWIDE COHORT STUDY**

Heo C. M.; Tae Jun Kim, Republic of Korea; Kim E. R.; Hong S.-N.; Chang D.-K.; Yang M.; Kim S. W.; Kim Y.-H.

P0365

**SURGICAL AND HOSPITAL ADMISSION IN ADULTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE IN THE BIOLOGICAL ERA IN SPAIN: RESULTS OF THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU**

Maria Chaparro, Spain; Barreiro de-Acosta M.; Benítez J. M.; Cabriada J. L.; Casanova M. J.; Ceballos D.; Esteve M.; Fernández Rosáenz H.; Ginard D.; Gomollón F.; Lorente Poyatos R.; Nos P.; Riestra Menéndez S.; Rivero M.; Robledo P.; Rodríguez C.; Sicília B.; Torrella Cortés E.; García-Esquinas E. G.; Rodríguez-Artalejo F.; Gisbert J. P.; on behalf of the EpidemiBD group

P0366

**SHORT TERM AZATHIOPRINE CO-TREATMENT DOES NOT IMPACT LONG TERM CLINICAL OUTCOME IN INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB, BUT HAS INFLIXIMAB-SPARING EFFECT**

David Drobne, Slovenia; Kurent T.; Golob S.; Svegl P.; Rajar P.; Hanzel J.; Kozelj M.; Novak G.; Smrekar N.; Ferkolj I.; Stabuc B.

P0367

**MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY**Colombel J.-F.; Walter Reinisch, Austria; Osterman M. T.; Thorpe A. J.; Nduaka C. I.; Zhang H.; Lawendy N.; Friedman G. S.; Su C.

P0368

**TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 4.9 YEARS OF TREATMENT**Lichtenstein G. R.; Loftus Jr. E. V.; Stuart Bloom, United Kingdom; Lawendy N.; Chan G.; Friedman G. S.; Zhang H.; Wang W.; Thorpe A. J.; Nduaka C. I.; Su C.

P0369

**SEVEN-YEAR EFFICACY AND SAFETY OF AZATHIOPRINE TREATMENT IN THE MAINTAINANCE OF STEROID-FREE REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENTS**Claudio Cassieri, Italy; Pica R.; Avallone E. V.; Brandimarte G.; Zippi M.; Crispino P.; De Nitto D.; Lecca P. G.; Vernia P.; Paoluzi P.; Corazziari E. S.

P0370

**EARLY CHANGE OF PATIENT-REPORTED RECTAL BLEEDING AND STOOL FREQUENCY SCORE AND FECAL CAL-PROTECTIN LEVEL ARE ASSOCIATED WITH COLECTOMY OUTCOME AT 1 YEAR IN PURSUIT-MAINTENANCE TRIAL.**Freddy Cornillie, United States; Khalifa A.; Philip G.; Peyrin-Biroulet L.

P0371

**MEASURING THIOGUANINE NUCLEOTIDE (6-TGN) LEVELS AND CLINICAL RESPONSE IN IBD; COMPARING SINGLE AND COMBINED THERAPIES.**Yalchin M.; Kamieniarz L.; Cama R.; Tribich S.; Lake L.; Joyce H.; Andreas Koutsoumpas, United Kingdom

P0372

**SAFETY AND EFFECTIVENESS OF GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS FOR 90 PATIENTS WITH CORTICOSTEROIDS NAÏVE ULCERATIVE COLITIS PATIENTS: A MULTICENTER COHORT STUDY**Toshihide Ohmori, Japan; Ishiguro Y.; Umemura K.; Iizuka M.

P0373

**ADVANCES IN OPTIMALIZATION OF THERAPEUTIC DRUG MONITORING USING MUCOSAL TNF EXPRESSION AND ANTI-TNF CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICALS – PRELIMINARY RESULTS FROM A SINGLE CENTER STUDY**Kludia Farkas, Hungary; Elekes G.; Kata D.; Földesi I.; Ferenci T.; Madacsy T.; Rutka M.; Balint A.; Bor R.; Fabian A.; Milassin Á.; Lada S.; Szepes Z. G.; Nagy F.; Maléthy J.; Molnár T.

P0374

**ANTI-TNF&#945; VS. CONVENTIONAL TREATMENT FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. A META-ANALYSIS**Adrienn Eros, Hungary; Farkas N.; Hegyi P.; Veres G.; Bajor J.; Erőss B.; Sarlós P.

P0375

**EFFICACY AND SAFETY OF GRANULOCYTE ADSORPTION APHERESIS IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS**Ayumi Ito, Japan; Murasugi S.; Omori T.; Tokushige K.

P0376

**DOES ANY CONNECTION EXIST BETWEEN BLOOD THIO-PURINE LEVEL AND ANTI TNF DRUG LEVEL OR BODY COMPOSITION PARAMETERS – A CROSS-SECTIONAL STUDY IN A HUNGARIAN IBD CENTRE**Kata Szántó, Hungary; Fabian A.; Sziártó A. L.; Földesi I.; Kata D.; Mezei Z. A.; Balint A.; Bor R.; Farkas K.; Milassin Á.; Rutka M.; Szepes Z. G.; Nagy F.; Bubán T.; Lovas S.; Palatka K.; Molnár T.**Treatment-surgical**

P0377

**STRICTURING CROHN'S DISEASE – CAN WE PREDICT NEED FOR SURGERY AT FIRST HOSPITALIZATION?**Xavier S.; Tiago Cúrdia Gonçalves, Portugal; Castro F. D.; Magalhães J. L. T. M.; Moreira M. J.; Cotter J.

P0378

**THE ROLE OF STOMA FOR COLONIC AND PERIANAL CROHN'S DISEASE IN THE BIOLOGICAL ERA**Rocha M.; João Correia-Sousa, Portugal; Salgado M.; Lago P.; Caetano C.; Ferreira D.; Santos M.; Rocha A.; Pedroto I.

P0379

**ENTERIC RESECTION IN CROHN'S DISEASE - IS THERE A RELATIONSHIP BETWEEN THE TIMING OF IMMUNO-SUPPRESSION ONSET AND THE EXTENSION OF THE RESECTED SMALL BOWEL?**Pedro Costa-Moreira, Portugal; Andrade P.; Lopes S.; Santos A. L.; C. R. Nunes A.; Macedo G.

P0380

**HIGHER BMI BUT NOT SYSTEMIC IMMUNE SUPPRESSION INCREASES THE RISK OF SHORT-TERM POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE PATIENTS**Dusan Podmanicky, Slovakia; Bak V.; Krizko M.; Zelinkova Z.

P0381

**USING PATIENT'S PREFERENCE IN RANDOMIZED CONTROLLED TRIALS**Karin Wasmann, The Netherlands; Wijsman P.; van Dieren S.; Bemelman W. A.; Buskens C. J.

P0382  
**EARLY CLOSURE OF ILEAL POUCH-ANAL ANASTOMOTIC LEAKAGE PRESERVES POUCH FUNCTION; A PROSPECTIVE COHORT STUDY**

Karin Wasmann, The Netherlands; Reijntjes M.; Stellingwerf M.; Ponsioen C. Y.; Buskens C. J.; Hompes R.; Tanis P.; Bemelman W. A.

**Poster Session**

09:00 – 17:00

Hall Xi

**Other Lower GI Disorders I**

**Lower GI Immunology, immunity, inflammation (NOT IBD)**

P0383  
**WITHDRAWN**

P0384  
**CLINICOPATHOLOGICAL FEATURES OF NIVOLUMAB-INDUCED COLITIS**

Shunichi Yanai, Japan; Kawasaki K.; Nakamura S.; Toya Y.; Ishida K.; Sugai T.; Matsumoto T.

P0385  
**FECAL TRANSPLANTATION FOR AUTISM SPECTRUM DISORDERS**

Vaidotas Urbonas, Lithuania; Cervinskiene J.; Sakalinskiene J.

P0386  
**COMPARISON OF STAINING TECHNIQUES AND MULTI-PLEX NESTED PCR FOR DIAGNOSIS AND TREATMENT OF ACUTE DIARRHEA**

Jung Min Kim, Republic of Korea; Park S. J.; Cheon J. H.; Kim T. I.; Kim W. H.; Park Y. H.


P0387  
**FECAL MICROBIOTA TRANSPLANTATION IN CLOSTRIDIUM DIFFICILE INFECTION: REAL-LIFE EXPERIENCE FROM AN ACADEMIC ITALIAN HOSPITAL.**

Brigida Barberio, Italy; Facchin S.; Savarino E. V.; D'Inca R.; Zingone F.; Cola M.; Ghisa M.; Lorenzon G.; Rigo A.; Marinelli C.; Inferrera M.; Sturniolo G. C.

**Lower GI infections**

P0388  
**GASTRIC ACID SUPPRESSION MAY LEAD TO AN INCREASED RISK OF VANCOMYCIN-RESISTANT ENTEROCOCCUS COLONIZATION**

So Youn Shin, Republic of Korea; Baeg M. K.; Ko S. H.; Kim J.; Jeong S. H.; Kim Y. J.; Myung Y. S.

P0389   
**FECAL MICROBIAL TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE INFECTION- A NATIONAL ISRAELI EXPERIENCE**

Sharon A. Greenberg, Israel; Youngster I.; Cohen N. A.; Livovsky D.; Strahilevitz J.; Israeli E.; Melzer E.; Paz K.; Maharshak N.

P0390  
**THE IMPACT OF CLOSTRIDIUM DIFFICILE INFECTION ON HOSPITALIZATION IN VENETO REGION**

Saia M.; Diego Caroli, Italy; Rosa-Rizzotto E.; De Lazzari F.

P0391  
**WITHDRAWN**

P0392   
**DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION**

Gianluca Ianiro, Italy; Murri R.; Impagnatiello M.; Masucci L.; Giovannenze F.; Simonelli C.; Cauda R.; Sanguinetti M.; Gasbarrini A.; Fantoni M.; Cammarota G.

P0393  
**FAECAL MICROBIOTA TRANSPLANTATION: ESTABLISHMENT OF A DONOR STOOL BANK BASED ON TISSUE ACT CRITERIA**

Anne Rode Olsen, Denmark; Bytzer P.; Engberg J.

P0394  
**RISING BURDEN OF DIFFICULT TO TREAT AND MULTI-DRUG RESISTANT ABDOMINAL TUBERCULOSIS IN ASIAN CHILDREN**

Moinak Sen Sarma, India; Tripathi P. R.; Thunga C. K.; Yachha S. K.; Srivastava A.; Poddar U.

P0395  
**IMMUNOHISTOCHEMISTRY APPLICATION AS ONE STEP FOR DIAGNOSING HUMAN INTESTINAL SPIROCHETOSIS**

Sho Ogata, Japan; Shimizu K.; Nakanishi K.

**Lower GI bleeding**

P0396  
**LOW INTESTINAL BLEEDING: WHAT AND WHEN WE SHOULD BE LOOKING AT COLONOSCOPY?**

Alexey Korotkevich, Russian Federation; Leontyev A.; Plusnin R.; Shestak I.

P0397  
**DO CLINICAL CHARACTERISTICS AND OUTCOME IN NONAGENARIANS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING DIFFER FROM YOUNGER PATIENTS?**

Georgia Diamantopoulou, Greece; Konstantakis C.; Theocharis G.; Skroubis G.; Triantos C.; Kalafateli M.; Tsolias C.; Thomopoulos K.

P0398  
**MANAGEMENT OF ANTITHROMBOTIC AGENTS IN PATIENTS WITH PRESUMPTIVE DIVERTICULAR HEMORRHAGE**

Avaka Takasu, Japan; Ikeya T.; Fukuda K.; Nakamura K.

P0399

**CUMULATIVE LEVELS OF FAECAL HAEMOGLOBIN IN CONSECUTIVE ROUNDS OF FIT NEGATIVE PARTICIPANTS FOR IMPROVING COLORECTAL CANCER SCREENING MANAGEMENT**Josep Maria Auge Fradera, Spain; Carot L.; Grau J.; Buron A.; Pellise M.; Hernandez C.; Tora I.; Castells X.; Diaz M.; Macia F.; Castells A.; Bessa X.

P0400

**TO IDENTIFY A LOW RISK GROUP OF INDIVIDUALS WITH IRON DEFICIENCY ANAEMIA WITHOUT GASTROINTESTINAL SYMPTOMS**May Wong, Australia; Bagust A.; Tanudisastro M. P.; Chiam D.; Majumdar A.; Saxena P.; Kaffes A.**Lower GI malignant disease-epidemiology**

P0401

**ASSOCIATION OF COLORECTAL CANCERS AND SYNCHRONOUS POLYPS IN A PERIOD OF 15 YEARS: CHANGING PATTERN?**Spyridon Vrakas, Greece; Michalopoulos G.; Ntoulis V.; Makris K.; Kapizioni C.; Milioni K.; Koutoufaris G.; Kourkoulis P.; Giannelis P.; Xourgias V.

P0402

**AGE AT MENARCHE AND RISK OF COLORECTAL ADENOMA**Seul Ki Kim, Republic of Korea; Kim N. H.; Park J. H.; Park D. I.; Sohn C. I.; Choi K.; Jung Y. S.

P0403

**METABOLIC FACTORS, LIFESTYLE HABITS AND AGING ARE ASSOCIATED WITH DEVELOPMENT OF COLORECTAL NEOPLASIA IN JAPAN**Nagamu Inoue, Japan; Kashiwagi K.; Yoshida T.; Sugino Y.; Iwao Y.P0404 **COMPARISON OF COLORECTAL POLYPS WITH SIZE BETWEEN 6 AND 20 MILLIMETERS IN YOUNGER AND OLDER INDIVIDUALS**Chun-Wei Chen, Taiwan; Lin W.-R.; Chiu C.-T.

P0405

**SHORTER LIFE EXPECTANCY OF INTERVAL COLORECTAL CANCER AND LEAD TIME BIAS**Wei-Ying Chen, Taiwan; Wang J.-D.; Cheng H.-C.; Cheng W.-C.; Sheu B.-S.**Lower GI malignant disease, pathogenesis**

P0406

**ACTIVATION OF STAT3 MEDIATES SURVIVAL OF CANCER STEM-LIKE TUMORS SPHERES IN EGFR-POSITIVE COLORECTAL CANCERS: ANALYSIS BY RNASEQ AND THERAPEUTICS SCREENING**Cheng C.-C.; Liao P.-N.; Lim K.-H.; Chang Y.-F.; Chang C.-C.; Ai-Sheng Ho, Taiwan

P0407

**PATIENT-DERIVED COLORECTAL CANCER EXPLANTS – ADEQUATE MODELS FOR CHEMOTHERAPY TESTING?**Isadora Rosa, Portugal; Mata S.; Abreu S.; Fonseca R.; Filipe B.; Morgado S.; Mesquita M.; Mendes T. F.; Francisco I.; Albuquerque C.; Chaves P.; Dias Pereira A.; Boghaert E.; Espirito Santo V.; Brito C.

P0408

**HDAC6 SELECTIVE INHIBITOR, ACY1215, INHIBIT CELL GROWTH OF COLON CANCER CELL LINE HCT116**Yuyong Tan, China; Zhang S.; Huo J.; Liu D.

P0409

**PEDIATRIC COLORECTAL CANCER – A HETEROGENEOUS ENTITY**João Cortez-Pinto, Portugal; Claro I.; Francisco I.; Lage P.; Filipe B.; Rodrigues P.; Albuquerque C.; Chaves P.; Dias Pereira A.

P0410

**CANCER ASSOCIATED FIBROBLASTS PROMOTES COLORECTAL CANCER THROUGH SECRETION OF TNFSF4 AND IGF2**Hui Li, Hong Kong PRC; Zhang J.; Zhou J.; Huang T.; Wong C. C.; Yu J.; Kang W.; To K. F.

P0411

**MALIGNANT POTENTIAL OF EARLY-STAGE SERRATED ADENOCARCINOMA BASED ON GENETIC ANALYSIS**Yuji Urabe, Japan; Tanaka S.; Hirano D.; Nakamura K.; Ninomiya Y.; Yuge R.; Hayashi R.; Oka S.; Kitadai Y.; Chayama K.

P0412

**MBD2 AND EZH2 REGULATE SFRP1 EXPRESSION WITHOUT AFFECTING ITS HYPERMETHYLATION IN COLORECTAL CANCER CELL LINE**Jian Qi, China; Yu J.

P0413

**IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS IN THE TUMOR MICROENVIRONMENT OF COLORECTAL CANCER**Eiichiro Yamamoto, Japan; Yorozu A.; Aoki H.; Suzuki H.**Lower GI malignant disease, diagnosis/histopathology**

P0414

**SYSTEMATIC REVIEW AND META-ANALYSIS: DIAGNOSTIC ACCURACY OF QUANTITATIVE FECAL IMMUNOCHEMICAL TESTS FOR COLORECTAL CANCER DETECTION IN SYMPTOMATIC PATIENTS**Pin Vieito N.; Zarraquiños S.; Joaquín Cubiella, Spain



P0415  
**ACCURACY OF QUANTITATIVE FECAL IMMUNOCHEMICAL TEST TO DETECT COLORECTAL CANCER. REAL-LIFE DATA IN 22,819 PATIENTS FROM THE GENERAL PRACTICE SETTING IN SPAIN.**

Pin Vieito N.; García Nimo L.; Bujanda Fernández de Piérola L.; Román M. B.; Gutierrez-Stampa M. Á.; Aguilar-Gama V.; [Joaquín Cubiella](#), Spain

P0416  
**HIGH-QUALITY CLEANSING IMPROVES LESION DETECTION DURING COLONOSCOPY COMPARED TO ADEQUATE CLEANSING: POST HOC ANALYSIS OF 1170 CENTRAL-READER ASSESSED PATIENTS IN THREE RANDOMISED PHASE 3 TRIALS**

[Cesare Hassan](#), Italy; Manning J.; Halonen J.; Amlani B.; Epstein M.

P0417  
**HIGHER HAREFIELD CLEANSING SCALE SCORES ARE ASSOCIATED WITH IMPROVED LESION DETECTION: POST HOC ANALYSIS OF THREE RANDOMISED AND CENTRAL READER-ASSESSED PHASE 3 CLINICAL TRIALS**

[Jonathan Manning](#), United Kingdom; Hassan C.; Halonen J.; Amlani B.; Epstein M.

P0418  
**RAID-CRC: A NOVEL NON-INVASIVE TOOL FOR COLORECTAL CANCER SCREENING BASED ON BACTERIAL SIGNATURES CAPABLE OF REDUCING THE FAECAL IMMUNOCHEMICAL TEST FALSE-POSITIVE RESULTS**

[Marta Malagón](#), Spain; Ramió-Pujol S.; Serrano M.; Serra-Pagès M.; Amoedo J.; Oliver L.; Bahí A.; Mas-de-Xaxars T.; Torrealba L.; Gilabert P.; Miquel-Cusachs O.; García-Nimo L.; Saló J.; Guardiola J.; Piñol V.; Cubiella J.; Castells A.; Aldeguer X.; Garcia-Gil J.

P0419  
**CLINICAL AND PATHOLOGICAL OVERLAP AMONG THE HAMARTOMATOUS POLYPOSIS SYNDROMES CAN RESULT IN ERRONEOUS DIAGNOSIS**

[Ophir Gilad](#), Israel; Rozner G.; Aharon-Kaspi S.; Fliss -Isakov N.; Gluck N.; Kariv R.

P0420  
**ERCC6L PROMOTES CELL GROWTH AND INVASION IN HUMAN COLORECTAL CANCER**

Xie Y.; Yu J.; Wang F.; Li M.; Liu Y.; [Jian Qi](#), China

P0421  
**TARGETED UPLC-MS METABOLOMIC ANALYSIS OF HUMAN FAECES REVEALS NOVEL LOW-INVASIVE CANDIDATE MARKERS FOR COLORECTAL CANCER**

[Joaquín Cubiella](#), Spain; Clos-García M.; Alonso C.; Martínez I.; Pérez-Cormenzana M.; Cabrera D.; Barrenetxea Z.; Berganza J.; Rodríguez-Llopis I.; D'Amato M.; Bujanda Fernández de Piérola L.; Díaz-Ondina M.; Falcón-Pérez J. M.

P0422  
**CLINICOPATHOLOGICAL STUDY OF SERRATED LESIONS OF THE COLORECTUM.**

[Mikako Sugimura](#), Japan; Iwabuchi M.; Mano Y.; Ukai K.

### Lower GI malignant disease, management

P0423   
**PEDUNCULATED MORPHOLOGY IS AN INDEPENDENT RISK FACTOR FOR A FAVORABLE ONCOLOGIC OUTCOME IN PATIENTS WITH T1 COLORECTAL CANCER**

[Koen Kessels](#), The Netherlands; Backes Y.; Elias S. G.; van den Blink A.; Offerhaus G. J. A.; Van Bergeijk J. D.; Groen J. N.; Seerden T. C. J.; Schwartz M. P.; de Vos tot Nederveen Cappel W. H.; Spanier B. W. M.; Geesing J. M. J.; Kerkhof M.; Siersema P. D.; Didden P.; Boonstra J. J.; Alvarez Herrero L.; Wolfhagen F. H. J.; ter Borg F.; van Lent A. U.; Terhaar Sive Droste J. S.; Hazen W. L.; Schrauwen R. W. M.; Vleggaar F. P.; Lacle M. M.; Moons L. M. G.

P0424  
**LONG-TERM ONCOLOGIC OUTCOMES OF SELF-EXPANDING METALLIC STENTS AS A BRIDGE TO SURGERY IN MALIGNANT LEFT-SIDED COLON OBSTRUCTION COMPARED WITH EMERGENCY SURGERY**

[Seung Yeop Oh](#), Republic of Korea

P0425  
**HIGH PRETREATMENT PLASMA D-DIMER LEVELS ARE ASSOCIATED WITH POOR SURVIVAL AFTER CURATIVE RESECTION IN PATIENTS WITH COLON CANCER.**

[Hiroyuki Anzai](#), Japan; Kazama S.; Kawashima Y.; Sakamoto H.

P0426  
**ARE ADDITIONAL TREATMENTS REALLY NEEDED AFTER ENDOSCOPIC RESECTION FOR RECTAL SMALL NEUROENDOCRINE TUMORS?**

[Da Hyun Jung](#), Republic of Korea; Lee H. J.

P0427  
**IMPACT OF PRIMARY TUMOR LOCATION AS A PREDICTIVE FACTOR IN CYTOTOXIC ANTI-CANCER AGENT FOR COLORECTAL CANCER (CRC) BASED ON COLLAGEN GEL DROPLET-EMBEDDED DRUG SENSITIVITY TEST (CD-DST)**

[Takumi Ochiai](#), Japan; Abe Y.; Kishine K.; Sato T.; Sakuyama N.; Nagayasu K.; Nakatani A.; Kitajima M.; Watanabe T.; Nishimura K.; Nagaoka I.

P0428  
**RANDOMIZED COMPARISON OF SURVEILLANCE AFTER COLONOSCOPIC REMOVAL OF ADENOMATOUS POLYPS: ENDOCUFF-ASSISTED COLONOSCOPY VERSUS THE STANDARD COLONOSCOPY**

[Yoshiki Wada](#), Japan; Wada M.; Fukuda M.; Ohtsuka K.; Wada Y.; Wada K.; Fukuma Y.

P0429

**INCOMPLETE RESECTION IS A MAJOR CAUSE OF POST-COLONOSCOPY COLORECTAL CANCER AFTER RESECTION OF A POLYP WITH INTRAMUCOSAL CARCINOMA**  
[Koen Kessels](#), The Netherlands; [Backes Y.](#); [Bosman A.](#); [Didden P.](#); [Elferink M. A. G.](#); [Seerden F.](#); [Offerhaus G. J. A.](#); [Siersema P. D.](#); [Lacle M. M.](#); [Elias S. G.](#); [Moons L. M. G.](#)

P0430

**A COMPARATIVE STUDY BETWEEN COLORECTAL NEOPLASMS DETECTED AT THE INITIAL COLONOSCOPY AND THOSE DETECTED AT THE FOLLOW-UP COLONOSCOPES**  
[Seiji Kimura](#), Japan; [Tanaka M.](#)

P0431 

**RAID-LS: A NON-INVASIVE TOOL BASED ON A FAECAL BACTERIAL SIGNATURE FOR LYNCH SYNDROME SURVEILLANCE**  
[Marta Malagón](#), Spain; [Ramíó-Pujol S.](#); [Serrano M.](#); [Serra-Pagès M.](#); [Amoedo J.](#); [Oliver L.](#); [Bahí A.](#); [Guardiola J.](#); [Navarro M.](#); [Piñol V.](#); [Pineda M.](#); [Capellà G.](#); [Castells A.](#); [García-Gil J.](#); [Aldeguer X.](#); [Brunet J.](#)

P0432

**COMPARISON OF THREE LYMPH NODE STAGING SCHEMES FOR PREDICTING SURVIVAL IN PATIENTS WITH COLORECTAL CANCER: A LARGE POPULATION DATABASE AND CHINESE MULTICENTER VALIDATION**  
[Qing-Wei Zhang](#), China; [Zhang C.-H.](#); [Li X.-B.](#); [Ge Z.-Z.](#)

P0433

**ATTEMPTS AND LONG-TERM OUTCOMES OF LOCAL RESECTION FOLLOWED BY ADJUVANT CHEMORADIOTHERAPY FOR PATIENTS WITH HIGH RISK PT1 RECTAL CANCER**  
[Kensuke Shinmura](#), Japan; [Ikematsu H.](#); [Minamide T.](#); [Yamamoto Y.](#); [Yoda Y.](#); [Hori K.](#); [Oono Y.](#); [Kawazoe A.](#); [Sasaki T.](#); [Ito M.](#); [Akimoto T.](#); [Yano T.](#)

P0434

**WITHDRAWN**P0435 

**SCAR-BIOPSIES AFTER MALIGNANT COLORECTAL POLYPECTOMY OF UNCERTAIN RADICALITY**  
[Kim Mariet Gijbbers](#), The Netherlands; [Post Z.](#); [Koch A. D.](#); [Dekker E.](#); [van Milligen de Wit A. W.](#); [Schrauwen R. W. M.](#); [Witteman E.](#); [Slangen R.](#); [Veenstra R.](#); [Epping-Stippel L.](#); [Bisseling T.](#); [Alderlieste Y.](#); [van Lelyveld N.](#); [Tang T. J.](#); [Bac D. J.](#); [Moons L. M. G.](#); [ter Borg F.](#)

P0436

**ALCOHOL CONSUMPTION IS ASSOCIATED WITH THE RISK OF DEVELOPING COLORECTAL NEOPLASIA: PROPENSITY SCORE MATCHING ANALYSIS**  
[Young Joo Yang](#), Republic of Korea; [Bang C. S.](#); [Baik G. H.](#)

P0437

**LONG-TERM OUTCOMES AFTER ENDOSCOPIC VERSUS SURGICAL RESECTION OF T1 COLORECTAL CARCINOMA**  
[Hyeong Han Lee](#), Republic of Korea; [Cho Y.-S.](#); [Lee H.-H.](#); [Lim C.-H.](#); [Kim J.](#); [Lee B.-I.](#); [Choi M.-G.](#)

P0438

**QUALITY OF LIFE AND WORRY ABOUT CANCER RECURRENT IN T1 COLORECTAL CANCER PATIENTS TREATED WITH ENDOSCOPIC OR SURGICAL TUMOUR RESECTION**  
[Hao Dang](#), The Netherlands; [De Vos Tot Nederveen Cappel W. H.](#); [van der Zwaan S. M. S.](#); [van den Akker-van Marle M. E.](#); [Van Westreenen E.](#); [Backes Y.](#); [Moons L. M. G.](#); [Holman F. A.](#); [Peeters K. C. M. J.](#); [van der Kraan J.](#); [Langers A. M. J.](#); [Lijfering W. M.](#); [Hardwick J. C. H.](#); [Boonstra J. J.](#)

**Lower GI motility disorders: Clinical**

P0439

**THREE-DIMENSIONAL HIGH-RESOLUTION ANORECTAL MANOMETRY IN FUNCTIONAL ANORECTAL DISORDERS: RESULTS FROM A LARGE OBSERVATIONAL COHORT STUDY**  
[Charlotte Andrianjafy](#), France; [Luciano L.](#); [Bazin C.](#); [Baumstarck K.](#); [Bouvier M.](#); [Viton V.](#)

P0440

**THREE-DIMENSIONAL HIGH-RESOLUTION ANORECTAL MANOMETRY CAN PREDICT RESPONSE TO BIOFEED-BACK THERAPY IN DEFECATION DISORDERS**  
[Charlotte Andrianjafy](#), France; [Bazin C.](#); [Luciano L.](#); [Loundou A.](#); [Bouvier M.](#); [Viton V.](#)

P0441

**WHOLE AND REGIONAL ASSESSMENT OF CONTRACTILITY, TEMPERATURE AND PH PROFILE IN PATIENTS WITH FUNCTIONAL CONSTIPATION, IRRITABLE BOWEL SYNDROME WITH CONSTIPATION AND HEALTHY VOLUNTEERS USING WIRELESS MOTILITY CAPSULE**  
[Enrique Coss-Adame](#), Mexico; [Remes-Troche J. M.](#); [Amieva-Balmori M.](#); [García Cedillo M. F.](#)

P0442

**LONG-TERM LINK BETWEEN THE SEVERITY OF FAECAL INCONTINENCE AND THE EXTENT OF THE OBSTETRICAL ANAL SPHINCTER DISRUPTION**  
[Luciano L.](#); [Charlotte Andrianjafy](#), France; [Baumstarck K.](#); [Bouvier M.](#); [Viton V.](#)

P0443

**POLYETHYLENE GLYCOL 3350 PLUS ELECTROLYTES FOR CHRONIC CONSTIPATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MEDIUM-TERM STUDY WITH AN EXTENSIONAL 52 WEEKS OPEN-LABEL, LONG-TERM STUDY.**  
[Atsushi Nakajima](#), Japan; [Shinbo K.](#); [Ota A.](#); [Kinoshita Y.](#)

P0444

**CHOLESTYRAMINE AS AN ADJUNCT TO PERCUTANEOUS TIBIAL NERVE STIMULATION FOR THE MANAGEMENT OF FECAL INCONTINENCE**  
[Amir Mari](#), United Kingdom; [Zarate Lopez N.](#); [Raeburn A.](#); [Pasanati V.](#); [Emmanuel A.](#)

P0445

**EFFECT OF GREEN KIWIFRUIT ON TRANSIT AND TOLERANCE TO INTESTINAL GAS IN HUMANS**Benslaiman B.; Caballero N.; [Ingrid Marin](#), Spain; Ansell J.; Serra J.

P0446

**CHANGES IN PSYCHOLOGICAL PROCESSES THROUGHOUT ANORECTAL BIOFEEDBACK THERAPY: CORRELATIONS WITH DYSSENERGIC DEFECATION AND FAECAL INCONTINENCE OUTCOMES**[Alissa Beath](#), Australia; Mazor Y.; Malcolm A.; Kellow J.; Sequeira C.; Prott G.; Jones M. P.

P0447

**VALIDATION OF THE "FAILURE TO PROVIDE ADEQUATE RELIEF" (F-PAR) SCALE IN A SPECIALIST CLINICAL SETTING**[Amir Mari](#), United Kingdom; Passananti V.; Pesce M.; Zarate-Lopez N.; Emmanuel A.**Diverticular disease**

P0448

**RISK OF COLONIC DIVERTICULAR REBLEEDING ACCORDING TO ENDOSCOPIC APPEARANCE**[Koki Kawanishi](#), Japan; Kitano M.

P0449

**THE "DICA" ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS**Tursi A.; Brandimarte G.; [Francesco Di Mario](#), Italy; Allegretta L.; Annunziata M. L.; Astegiano M.; Baldi F.; Bianco M. A.; Cambiè G.; Capezuto E.; Caroli A.; Cassieri C.; Cìcu A. S.; Colucci R.; Conigliaro R. L.; Damiani A.; De Colibus P.; De Medici A.; De Pretis G.; Del Favero G.; Della Valle N.; Di Cesare L.; Elisei W.; Ferrini L.; Fiorella S.; Forti G.; Franceschi M.; Frunzio A.; Germana' B.; Graziani M. G.; Lai M.; Latella G.; Lecca P. G.; Lisi D.; Lopetuso L. R.; Maconi G.; Mandelli E. D.; Marmo R.; Maurano A.; Nardone G.; Pigo F.; Pallotta L.; Papa A.; Parmeggiani F.; Penna A.; Pontone S.; Pranzo G.; Ricciardelli C.; Rizzo G. L.; Rodinò S.; Savarino E.; Scaccianoce G.; Scaldaferrì F.; Schiffino L.; Semeraro C.; Stroppa I.; Urgesi R.; Vassallo R.; Violi A.; Zampaletta C.; Zilli M.; Zullo A.; Scarpignato C.; Picchio M.

P0450

**LONG-TERM EFFICACY OF RIFAXIMIN IN MANAGING SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON**[Francesco Di Mario](#), Italy; Crafa P.; Miraglia C.; Franzoni L.; Tursi A.; Brandimarte G.; Nouvenne A.; Elisei W.; Picchio M.; Franceschi M.; Scarpignato C.

P0451

**DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH TREATMENT USE IN PATIENTS WITH DIVERTICULAR DISEASE: RESULTS FROM THE ITALIAN NATIONAL REGISTRY REMAD**[Cesare Cremon](#), Italy; Carabotti M.; Cuomo R.; Pace F.; Andreozzi P.; Annibale B.; Barbara G.

P0452

**ACUTE COLON DIVERTICULITIS HOSPITALIZATION TRENDS IN VENETO REGION (NORTHEAST ITALY)**[Diego Caroli](#), Italy; Saia M.; Rosa-Rizzotto E.; De Lazzari F.

P0453

**MAJOR GENETIC RISK VARIANTS IN DIVERTICULOSIS AND DIVERTICULITIS**[Matthias Reichert](#), Germany; Kupcinkas J.; Krawczyk M.; Jüngst C.; Casper M.; Grünhage F.; Appenrodt B.; Zimmer V.; Weber S.; Tamelis A.; Lukosiene J. I.; Pauziene N.; Kiudelis G.; Jonaitis L.; Schramm C.; Goeser T.; Schulz A.; Malinowski M.; Glanemann M.; Kupcinkas L.; Lammert F.**Ano-rectal disorders other than IBD or motility-related**

P0454

**EVALUATION OF HIGH-RESOLUTION ANOSCOPY AS A SCREENING TOOL FOR ANAL INTRAEPITHELIAL NEOPLASIA (AIN): A COMPARISON TO THE GOLD STANDARD ANAL MAPPING BIOPSIES**Baumeler S.; [Jan Borovicka](#), Switzerland; Marti L.; Bock S.; Jochum W.; Schmid P.; Maurus C.

P0455

**DIAGNOSIS OF HIRSCHSPRUNG'S DISEASE IN CHILDREN - PRELIMINARY EVALUATION OF A NOVEL ENDOSCOPIC TECHNIQUE FOR RECTAL BIOPSY**[Zaheer Nabi](#), India; Chavan R.; Reddy D. N.; Sekharan A.

P0456

**HEMORROITEQ STUDY: PROSPECTIVE EVALUATION OF FOUR NON-SURGICAL INSTRUMENTAL MODALITIES FOR THE TREATMENT OF PROLAPSED HEMORRHOIDAL DISEASE**[Joana Roseira](#), Portugal; Vieira A. M.; Tavares de Sousa H.; Gago T.; Cunha A. C.; Campelo P.; Contente L. F.; Guerreiro H.

P0457

**HIGH-INTENSITY CONTRAST IMAGING ASSISTED HIGH-RESOLUTION ANOSCOPY FOR ANAL CARCINOMA SCREENING IN HIV INFECTED PATIENTS**[Martin Sprinzl](#), Germany; Kremer M.; Kohlwes E.; Kittner J.; Schattenberg J.; Rahman K. F.; Thieringer F.; Roth W.; Galle P. R.; Neumann H.

P0458

**A EUROPEAN MULTICENTRE POST-AUTHORISATION STUDY OF ORAL TRISULPHATE SOLUTION AS A BOWEL CLEANSING PREPARATION: COMPLIANCE WITH INSTRUCTIONS OF USE, TOLERABILITY AND SAFETY IN REAL-LIFE SETTING**

Jaroslaw Regula, Poland; Spaander M. C. W.; Suchanek S.; Kornowski A.; Perrot V.; Fischbach W.

**Lower GI health services research**

P0459

**OPTIMAL TIMING OF ADDING SIMETHICONE FOR BETTER BOWEL PREPARATION USING POLYETHYLENE GLYCOL PLUS ASCORBIC ACID; A DOUBLE-BLIND RANDOMIZED TRIAL**

Haewon Kim, Republic of Korea; Goong H. J.; Ko B. M.; Jung Y.; Jeon S. R.; Kim H. G.; Kim J.-O.; Lee M. S.

P0460

**PUBLIC ATTITUDES TO COLONOSCOPY: HOW MUCH BOWEL PREPARATION LIQUID MUST BE DRUNK BEFORE A COLONOSCOPY?**

Bharat Amlani, United Kingdom; Radaelli F.; Bhandari P.

P0461

**GENOMIC MEDICINE IN GASTROENTEROLOGY, PRESENT AND FUTURE: A NATIONWIDE SURVEY OF UK GASTROENTEROLOGY TRAINEES**

Ibrahim Al Bakir, United Kingdom; Sebeos-Rogers G. M.; Burton H.; Monahan K. J.

P0462

**FEAR-OF-CANCER-RELATED PSYCHOLOGICAL BARRIERS TO COLONOSCOPY IN FECAL OCCULT BLOOD TEST (FOB-T)-POSITIVE COLONOSCOPY REFUSERS**

Lev Lichtenstein, Israel; Hazan R.; Heruti I.; Dickman R.

P0463

**PREVENTING COLON CANCER VS. EARLY DIAGNOSIS, WHAT IS BEST? A META-ANALYSIS OF THE U.S. PREVENTIVE SERVICES TASK FORCE EVIDENCE REPORT ON SCREENING TESTS**

Swartz A.; Eberth J.; Scott Strayer, United States

**Poster Session**

09:00 – 17:00

Hall X1

Oesophageal, Gastric and Duodenal Disorders I

**Cell/molecular biology/pathology**

P0464

**ANCILLARY D2-40 AND ELASTIN STAINS CAN IMPROVE INTEROBSERVER AGREEMENT AND DETECTION OF LYMPHOVASCULAR INVASION IN EARLY GASTRIC CANCER**

Kazunori Takada, Japan; Yoshida M.; Aizawa D.; Sato J.; Kawata N.; Kakushima N.; Takizawa K.; Kishida Y.; Ito S.; Imai K.; Hotta K.; Ishiwatari H.; Matsubayashi H.; Sugino T.; Ono H.

P0465

**LYMPHOVASCULAR INVASION IN EARLY GASTRIC CANCER: INTEROBSERVER AGREEMENT AMONG EXPERT PATHOLOGISTS**

Masao Yoshida, Japan; Takada K.; Aizawa D.; Sato J.; Kawata N.; Kakushima N.; Takizawa K.; Kishida Y.; Ito S.; Imai K.; Hotta K.; Ishiwatari H.; Matsubayashi H.; Sugino T.; Ono H.

P0466

**IDENTIFYING FGF18 AS A POTENTIAL ONCOGENE AND MIR-590-5P TARGET IN GASTRIC TUMORIGENESIS.**

Jinglin Zhang, Hong Kong PRC; Zhou Y.; Huang T.; Wu F.; Li H.; Yu J.; Kang W.; To K. F.

P0467

**ABERRANT EXPRESSION OF SPP1 THROUGH DOWNREGULATION OF HELIOS IN GASTRIC CANCER**

Chen W.-M.; Cheng-Shyong Wu, Taiwan; Wei K.-L.; Deng Y.-F.; Chang Y.-L.; Hsu W.-T.; Wu S.-F.; Li C.

P0468

**METHYLOMICS ANALYSIS IDENTIFIES SPG20 AS A SENSITIVE NON-INVASIVE BIOMARKER FOR EARLY DETECTION OF GASTRIC CANCER**

Kuo-Liang Wei, Taiwan; Wu C.-S.; Chen Y.-C.; Chan M. W. Y.

P0469

**2,4-DIAMINO-QUINAZOLINE, A SMALL MOLECULE INHIBITOR OF WNT/β-CATENIN SIGNALING, REDUCES PROLIFERATION AND MIGRATION/INVASION BEHAVIOR OF GASTRIC CANCER**

Wu C.-S.; Chang T.-S.; Wei K.-L.; Lu C.-K.; Yi-Hsing Chen, Taiwan; Chiang M.-K.

P0470

**THE CYTOTOXIC EFFECT OF HYPERTHERMIA IN ADDITION TO CISPLATIN IS ENHANCED BY PRIOR HO-1 SILENCING IN OVARIAN BUT NOT GASTRIC CANCER CELLS**

Vaidotas Cesna, Lithuania; Sukovas A.; Jasukaitiene A.; Silkuniene G.; Paskauskas S.; Dambrauskas Z.; Gulbinas A.

**Immunity and inflammation (not *H. pylori*)**

P0471

**HEALTHY CHILDREN FROM 4 TO 12 YEARS OF AGE: FECAL CALPROTECTIN AND EOSINOPHIL-DERIVED NEUROTOXIN LEVELS**

Roca M.; Rodriguez Varela A.; Donat E.; Cano F.; Armisen A.; Vaya M. J.; Ekoff H.; Hervas D.; Rydell N.; Masip E.; Polo B.; Carmen Ribes Koninckx, Spain

P0472

**EFFECTIVENESS OF REBAMIPIDE IN THE PREVENTION OF ESOPHAGEAL STRICTURE FORMATION IN ADVANCED CORROSIVE ESOPHAGITIS: A PROSPECTIVE RANDOMIZED CONTROL STUDY**

Mark Lester Sy, Philippines; Prieto R. J.; Pang A.; Chu M. A.; Gatchalian L.; Domingo Jr. F.; Naval M.

P0473  
WITHDRAWN

P0474  EFFECT OF MYD88 DEFICIENCY ON INTESTINAL INFLAMMATION AND MICROBIOTA IN COLITIS MICE  
Fang Xiao, China; Ye Z.; Li J.; Han J.; Liao J.; Zhou Q.; Liu M.; Seidler U.; Tian D. A.

P0475 PILOT STUDY ON THE EFFECTIVENESS OF THE COMBINATION OF HYALURONIC ACID, COINDRITIN SULFATE AND POLOXAMER 407 IN SCAR HEALING AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF THE ESOPHAGUS IN PORCINE IN-VIVO MODEL

Ana Amorós Tenorio, Spain; Caballero Cansino M. J.; Brito Casillas Y.; Rodríguez Grau-Bassas E.; San Juan Acosta M.

### Infections (not *H. pylori*)

P0476 PANCOLITIS INCREASES THE MORTALITY RISK OF CYTOMEGALOVIRUS COLITIS IN PATIENTS WITHOUT INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT STUDY  
Puo-Hsien Le, Taiwan; Chiu C.-T.

P0477 CLOSTRIDIUM DIFFICILE ISOLATION AND CHARACTERISATION – RESULTS OF A PILOT STUDY  
Pintar Š.; Rupnik M.; Pavel Skok, Slovenia

### Upper GI and small intestinal bleeding

P0478 UNIVERSAL ANTIBIOTIC PROPHYLAXIS MAY BE UNNECESSARY IN ACUTE VARICEAL BLEEDING: A SINGLE-CENTER RETROSPECTIVE STUDY  
Masayuki Ueno, Japan; Kayahara T.; Takabatake H.; Morimoto Y.; Mizuno M.

P0479  **AIMS65 IS THE MOST ACCURATE RISK-SCORING SYSTEM FOR PREDICTING PROGNOSIS OF PATIENTS WITH DUODENAL ULCER BLEEDING.**  
Ryosuke Hirai, Japan; Shimodate Y.; Ishikawa S.; Kanatani T.; Minami M.; Doi A.; Nishimura N.; Mouri H.; Matsueda K.; Yamamoto H.; Mizuno M.

P0480 EFFECTS OF ASPIRIN ON MORTALITY AND RE-BLEEDING IN PATIENTS WITH NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS  
Roni Aoun, Lebanon; Hashash J.; El-Majzoub N.; Khamis A.; Rockey D.; Akl E.; Barada K.

P0481 OPTIMAL ENDOSCOPY TIMING ACCORDING TO THE SEVERITY OF UNDERLYING LIVER DISEASE IN PATIENTS WITH ACUTE VARICEAL BLEEDING  
Cheal Wung Huh, Republic of Korea; Jung D. H.; Kim J. S.

P0482 FORREST CLASSIFICATION DOES NOT PROPERLY ASSESS REBLEEDING RISK OR MORTALITY IN HIGH RISK UPPER GI BLEEDING  
Eduardo Redondo-Cerezo, Spain; Jimenez-Rosales R.; Vadillo-Calles F.; Valverde López F.; Lopez de Hierro M.; Martínez-Cara J.

P0483 RISK FACTORS OF POOR PROGNOSIS AND IMPAIRMENT OF ACTIVITIES OF DAILY LIVING IN PATIENTS WITH HEMORRHAGIC GASTRODUODENAL ULCERS  
Junya Arai, Japan; Toda N.; Kurokawa K.; Shibata C.; Kurosaki S.; Funato K.; Kondou M.; Takagi K.; Kojima K.; Ooki T.; Seki M.; Kato J.; Tagawa K.

P0484 PALBI - THE PLATELET-ALBUMIN-BILIRUBIN SCORE – A BETTER PREDICTOR OF OUTCOME OF ACUTE VARICEAL BLEEDING.  
Omar Elshaarawy, Germany; Abdelsamiae E.; Gomaa A.; Allam N.; Rewisha E.; Waked I.

P0485 UPPER GASTROINTESTINAL BLEEDING NOT ASSOCIATED TO PORTAL HYPERTENSION: ASPECTS OF EPIDEMIOLOGY AND MANAGEMENT IN A SOUTHERN SPANISH AREA  
José Alberto Díaz Jiménez, Spain; Leal Téllez J.; Calle Gómez A. R.; Correro Aguilar F. J.

P0486 UPPER GASTROINTESTINAL BLEEDING ASSOCIATED TO PORTAL HYPERTENSION: ASPECTS OF EPIDEMIOLOGY AND MANAGEMENT IN A SOUTHERN SPANISH AREA.  
José Alberto Díaz Jiménez, Spain; Leal Téllez J.; Calle Gómez A. R.; Correro Aguilar F. J.

P0487 PREDICTOR OF MORTALITY IN UPPER GASTROINTESTINAL BLEEDING IN PATIENTS ALREADY HOSPITALIZED FOR ANOTHER CONDITION: A PROSPECTIVE STUDY  
Rita Jiménez-Rosales, Spain; Vadillo-Calles F.; Ortega-Suazo E. J.; Martínez Cara J. G.; Redondo-Cerezo E.

P0488 RISKS OF UPPER GASTROINTESTINAL BLEEDING IN PATIENTS WHO FAILED INITIAL HELICOBACTER PYLORI ERADICATION THERAPY: A PROPENSITY SCORE MATCHING STUDY  
Guo C.-G.; Cheung K. S.; Chen L.; Wai Keung Leung, Hong Kong PRC

P0489 **MORTALITY RATE AND RISK FACTORS FOR GASTROINTESTINAL BLEEDING IN ELDERLY PATIENTS**

Marco Vincenzo Lenti, Italy; Pasina L.; Cococcia S.; Cortesi L.; Miceli E.; Caccia Dominioni C.; Pisati M.; Mannucci P. M.; Perticone F.; Corazza G. R.; Nobili A.; Di Sabatino A.

**Upper GI nerve-gut and motility: Brain-gut and gut-brain axes, neuro-hormonal, neural-immune and visceral sensitivity**

P0490

**MAST CELLS INFILTRATION AND SPACIAL RELATIONSHIP TO MUCOSAL AFFERENT NERVES IN PATIENTS WITH REFLUX DISEASE.**

Kornilia Nikaki, United Kingdom; Silva R.; Ooi J. L. S.; Grassi F.; Lee C.; Woodland P.; Souza M.; Sifrim D.

P0491

**THE EFFECT OF A SINGLE AND REPEATED DOSES OF MEMANTINE ON GASTRIC MYOELECTRIC ACTIVITY IN EXPERIMENTAL PIGS.**

Marcela Kopacova, Czech Republic; Kvetina J.; Radochova V.; Tachecí I.; Zdarova Karasova J.; Peterova E.; Tumova E.; Rejchrt S.; Douda T.; Bures J.

P0492

**RELATIONSHIP BETWEEN ABUSE AND GASTROINTESTINAL SYMPTOMS IN NON PATIENTS WOMEN**

Nadia Pallotta, Italy; Pezzotti P.; Belardi F.; Ciccantelli B.; Rivera M.; Vincoli G.; Corazziari E. S.

P0493

**MOTOR ACTIVITY OF ESOPHAGUS AND STOMACH IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: AN OBSERVATIONAL STUDY**

Giuseppina Vincoli, Italy; Miscioscia A.; Biviano I.; Onesti E.; di Bari S.; Gori M. C.; Carbone A.; Inghilleri M.; Badiali D.; Pallotta N.

P0494

**DOPAMINE ANTAGONISM DOES NOT MODULATE ESOPHAGEAL SENSITIVITY IN HEALTH**

Ans Pauwels, Belgium; Broers C.; Geysen H.; Tack J.

**Upper GI motility disorders: Clinical**

P0495

**ANALYSIS OF FULL-LAYER MUCOSAL HISTOLOGY IN ACHALASIA**

Hiroki Sato, Japan; Takahashi K.; Mizuno K.-I.; Hashimoto S.; Ikarashi S.; Hayashi K.; Yokoyama J.; Terai S.

P0496

**HIGH RESOLUTION OESOPHAGEAL MANOMETRY WITH A SOLID TEST MEAL IMPROVES DIAGNOSTIC SENSITIVITY AND SPECIFICITY FOR EVALUATION OF OESOPHAGEAL DYSMOTILITY: VALIDATION STUDY IN A MULTIRACIAL ASIAN COHORT.**

Ang D.; Kim-Wei Lim, Singapore; Lee M.-Y.; Zhang M.-M.; Ang T.-L.; Fox M.

P0497

**EFFECT OF EGJ BARRIER AND PERISTALTIC DYSFUNCTION ON ESOPHAGEAL CLEARANCE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE**

Viet Hang Dao, Japan; Matsumura T.; Okimoto K.; Ishikawa K.; Akizue N.; Kikuchi A.; Fujie M.; Saito K.; Maruoka D.; Nakagawa T.; Arai M.; Kato N.

P0498

**LONG TERM OUTCOMES OF PER ORAL ENDOSCOPIC MYOTOMY IN CHILDREN**

Zaheer Nabi, India; Ramchandani M.; Chavan R.; Reddy D. N.

P0499

**AGING AND INCREASED PSYCHOLOGICAL STRESS ARE USEFUL PREDICTORS OF SLOWER GASTRIC EMPTYING FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE - A HOSPITAL-BASED INVESTIGATION IN THE ASIA-PACIFIC REGION**

Wang K.-Y.; Chen Y.-W.; Wang T.-N.; Huang J.-Y.; Yu-Chung Su, Taiwan

P0500

**PERORAL ENDOSCOPIC MYOTOMY (POEM) IS EQUALLY EFFECTIVE AND DOES NOT LEAD TO INCREASED ACID REFLUX IN OBESE AS COMPARED TO NON-OBESE PATIENTS WITH ACHALASIA.**

Malav Prafulkumar Parikh, United States; Thota P. N.; Gupta N. M.; Sarvepalli S.; Lopez R.; Gabbard S.; Murthy S.; Raja S.; Sanaka M. R.

P0501

**ROLE OF HIGH RESOLUTION MANOMETRY IN THE DIAGNOSTIC AND THERAPEUTIC APPROACH OF POST FUNDOPLICATION DYSPHAGIA**

Armando Peixoto, Portugal; Morais R.; Lanas Gimeno A.; Pérez Fernández T.; Casabona Francés S.; Macedo G.; Santander Vaquero C.

P0502

**THERAPEUTIC OUTCOMES FOLLOWING ENDOTHERAPY FOR REFRACTORY GASTROPARESIS**

Gupta A.; Vardar U.; Everson M.; Haidry R. J.; Banks M.; Bown S.; Graham D.; Kalp Patel, United Kingdom; Qarage L.; Mari A.; Zarate-Lopez N.; Lovat L.; Sweis R.

**Reflux disease, pathogenesis**

P0503  
**CLINICAL IMPACT OF LOWER ESOPHAGEAL SPHINCTER FUNCTION ON THE SYMPTOM ASSESSMENT OF NON-EROSIVE REFLUX DISEASE**  
Beom Jin Kim, Republic of Korea; Park J. Y.; Kim J. G.

P0504  
**WITHDRAWN**

P0505  
**LACK OF IMPROVEMENT OF IMPAIRED CHEMICAL CLEARANCE CHARACTERIZES PPI-REFRACTORY REFLUX-RELATED HEARTBURN IN NON-EROSIVE REFLUX DISEASE PATIENTS**  
 Frazzoni M.; Frazzoni L.; Della Coletta M.; Tolone S.; De Bortoli N.; Savarino V.; Edoardo Savarino, Italy

P0506  
**ESOPHAGEAL INTRALUMINAL MICROBIOTA IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE AND HEALTHY CONTROLS**  
Diana Rummyantseva, Russian Federation; Paraskevova A.; Storonova O.; Kudryavtseva A.; Krasnov G.; Ponomarev A.; Trukhmanov A.; Ivashkin V.

P0507  
**MACROPHAGE FUNCTIONAL ACTIVITY CHANGES IN DIFFERENT CLINICAL VARIANTS OF GASTROESOPHAGEAL REFLUX DISEASE DEPENDING ON REFLUXATE PH VALUES**  
Svetlana Lyamina, Russian Federation; Klodovikova O.; Kalish S.; Maev I.; Malyshev I.

**Reflux disease, diagnosis**

P0508  
**THE VALIDATION OF PEPTEST, A NEW NON-INVASIVE TECHNOLOGY FOR THE DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE IN CHINA**  
Peter Dettmar, United Kingdom; Fang J.; Yu X.-F.; Shen X.-Z.; Liu F.; Yang C.; Liu Z.; Zhong J.; Li J.-N.; Lan Y.; Woodcock A.

P0509  
**EROSIVE ESOPHAGITIS – NEW APPROACHES TO DIAGNOSIS**  
Dmitry Danilov, Russian Federation; Shuleshova A.

P0510  
**MOTOR ABNORMALITIES IN EROSION GASTROESOPHAGEAL REFLUX DISEASE**  
Valeria Kaibysheva, Russian Federation; Fedorov E. D.; Shapovaliantc S.

P0511  
**HEALTH-RELATED QUALITY OF LIFE IMPACT AMONG GASTROESOPHAGEAL REFLUX DISEASE PHENOTYPES IN ECUADORIANS´ PROTON PUMP INHIBITOR NON-RESPONDERS: A PROSPECTIVE COHORT**  
Roberto Oleas, Ecuador; Pitanga-Lukashok H.; Puga-Tejada M.; Valero M.; Sanchez-Carriel M.; Ospina-Arboleda J.; Alvarado-Escobar H.; Soria-Alcivar M.; Del Valle R.; Robles-Medranda C.

P0512  
**FIRST SPANISH VALIDATED TRANSLATION OF A SINGLE HEALTH-RELATED QUALITY OF LIFE SURVEY FOR BROAD USE ACROSS DIFFERENT CHRONIC ESOPHAGEAL DISEASES: A PSYCOMETRIC EVALUATION OF THE NEQOL SURVEY IN AN ECUADORIAN POPULATION** ✦  
Roberto Oleas, Ecuador; Pitanga-Lukashok H.; Puga-Tejada M.; Valero M.; Sanchez-Carriel M.; Acosta-Crow A.; Ospina-Arboleda J.; Muñoz-Jurado G.; Alvarado-Escobar H.; Soria-Alcivar M.; Del Valle R.; Robles-Medranda C.

P0513  
**DIAGNOSTIC VALUE OF HIGH-RESOLUTION MANOMETRY IN HIATAL HERNIA DETECTION**  
Valeria Kaibysheva, Russian Federation; Fedorov E. D.; Shapovaliantc S.

P0514  
**ACCURACY OF HIGH RESOLUTION MANOMETRY IN DIAGNOSIS OF HIATAL HERNIA IN MORBIDLY OBESE PATIENTS.**  
Antonella Santonicola, Italy; Angrisani L.; Perrotta T. A.; Tolone S.; Ciacci C.; Iovino P.

**Barrett's oesophagus: Clinical**

P0515   
**HOW TO HANDLE TISSUE SPECIMENS AFTER ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ESOPHAGUS RELATED NEOPLASIA: A MULTICENTER RANDOMIZED TRIAL COMPARING THREE SPECIMEN HANDLING METHODS.**  
Anouk Overwater, The Netherlands; van der Meulen K. E.; Künzli H. T.; Schoon E. J.; Bergman J. J. G. H. M.; Raicu G. M.; Seldenrijk C. A.; Weusten B. L. A. M.

P0516  
**HPV EXPOSURE AND SEXUAL BEHAVIOUR ARE SIGNIFICANT RISK FACTORS FOR BARRETT'S DYSPLASIA/ESOPHAGEAL ADENOCARCINOMA**  
May Wong, Australia; Wang B.; Yang A.; Khor A.; Xuan W.; Rajendra S.

P0517

**THE ARGOS PROJECT: COMPUTER AIDED DETECTION SYSTEM CAN DETECT BARRETT NEOPLASIA ON ENDOSCOPIC IMAGES WITH HIGH ACCURACY.**

Jeroen de Groof, The Netherlands; van der Sommen F.; van der Putten J.; Zinger S.; Curvers W. L.; Bisschops R.; Pech O.; Meining A.; Neuhaus H.; Schoon E. J.; de With P.; Bergman J.

P0518

**ARTIFICIAL INTELLIGENCE IDENTIFIES EARLY BARRETT'S NEOPLASIA IN IN-VIVO BIOPSY-CORRELATED VOLUMETRIC LASER ENDOMICROSCOPY IMAGES**

Struyvenberg M. R.; Jeroen de Groof, The Netherlands; van der Sommen F.; van der Putten J.; Schoon E. J.; Zinger S.; de With P.; Curvers W. L.; Bergman J. J.

P0519

**BLUE LIGHT IMAGING HAS AN ADDITIONAL VALUE TO WHITE LIGHT ENDOSCOPY IN VISUALIZATION OF EARLY BARRETT'S NEOPLASIA. AN INTERNATIONAL MULTI-CENTER COHORT STUDY.**

Jeroen de Groof, The Netherlands; Swager A.-F.; Pouw R.; Weusten B. L. A. M.; Schoon E. J.; Bisschops R.; Pech O.; Meining A.; Neuhaus H.; Curvers W.; Bergman J. J.

P0520 **SELF-SIZING RADIOFREQUENCY ABLATION BALLOON FOR ERADICATION OF BARRETT'S ESOPHAGUS: RESULTS OF AN INTERNATIONAL MULTICENTER RANDOMIZED TRIAL COMPARING THREE DIFFERENT TREATMENT REGIMENS.**

Kamar Belghazi, The Netherlands; Pouw R.; Koch A. D.; Weusten B. L. A. M.; Schoon E. J.; Curvers W. L.; Gotink A. W.; Haidry R. J.; Pech O.; Bergman J. J.; Bisschops R.

**Oesophageal neoplasia: Basic**

P0521

**CD147 EXPRESSION CORRELATED WITH TREATMENT RESPONSE AND SURVIVAL IN PATIENTS WITH ESOPHAGEAL CANCER RECEIVED CHEMORADIOTHERAPY**

Lee C.-T.; Hsu M.-H.; Wang H.-P.; Wen-Lun Wang, Taiwan

P0522

**EFFICACY OF ARGON PLASMA COAGULATION WITH PRIOR SUBMUCOSAL INJECTION FOR THE ESOPHAGEAL LESIONS - IN VIVO PORCINE MODEL STUDY.**

Satoshi Abiko, Japan; Shimizu Y.; Ohnishi S.; Mizushima T.; Tsuda M.; Ishikawa M.; Matsuda K.; Miyamoto S.; Yamamoto K.; Ono S.; Kudo T.; Sakamoto N.

P0523

**PREVENTION OF ESOPHAGEAL STRICTURE AFTER COMPLETE CIRCULAR ENDOSCOPIC SUBMUCOSAL DISSECTION IN PIGS USING STENT WITH ACELLULAR PORCINE DERMAL MATRIX**

Radek Dolezel, Czech Republic; Walterova B.; Vackova Z.; Kollar M.; Juhas S.; Martinek J.

P0524

**ELIMINATION OF NFKB SIGNALLING IN VIMENTIN+ STROMAL CELLS ATTENUATES ESOPHAGEAL CARCINOGENESIS IN A MOUSE MODEL OF BARRETT'S ESOPHAGUS**

Akanksha Anand, Germany; Fang H.-Y.; Ingermann J.; Baumeister T.; Knörndel J.; Schmid R. M.; Wang T. C.; Quante M.

**Oesophageal neoplasia: Clinical**

P0525

**CLINICAL SIGNIFICANCES AND PREDICTORS OF ESOPHAGEAL GLANDULAR DUCTAL INVOLVEMENT IN EARLY ESOPHAGEAL SQUAMOUS CELL NEOPLASIA**

Wang W.-L.; Hsu M.-H.; Wang H.-P.; Ching-Tai Lee, Taiwan

P0526

**PREDICTION OF INDIVIDUALS AT HIGH ABSOLUTE RISK OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA**

Qiao-Li Wang, Sweden; Lagergren J.; Xie S.-H.

P0527

**DURABILITY OF RADIOFREQUENCY ABLATION FOR TREATMENT OF ESOPHAGEAL SQUAMOUS CELL NEOPLASIA: 5 YEAR FOLLOW-UP OF A PROSPECTIVE STUDY IN CHINA**

Yu X.; Sanne van Munster, The Netherlands; Zhang Y.; Xue L.; Fleischer D.; Weusten B. L. A. M.; Lu N.; M Dawsey S.; Bergman J. J.; Wang G. Q.

P0528

**CHEMORADIOTHERAPY FOR LYMPH NODES RECURRENCE AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER**

Satoru Matono, Japan; Tanaka T.; Mori N.; Hino H.; Saisho K.; Akagi Y.

P0529 **ENDOSCOPIC CRYOBALLOON ABLATION IS SAFE, WELL-TOLERATED AND HIGHLY EFFECTIVE IN THE ERADICATION OF ESOPHAGEAL SQUAMOUS CELL NEOPLASIA**

Yan K.; Sanne van Munster, The Netherlands; Chen J.; Liu F.; Zhao D.; Li W.; He S.; Zhang Y.; Dou L.; Liu Y.; Liu X.; Xue L.; Lu N.; Dawsey S.; Bergman J. J.; Weusten B. L. A. M.; Wang G. Q.

P0530

**LONG-TERM OUTCOMES OF ENDOSCOPIC RESECTION VERSUS SURGICAL RESECTION FOR MM-SM1 OESOPHAGUS SQUAMOUS CELL CARCINOMA USING PROPENSITY SCORE ANALYSIS**

Kenji Yamauchi, Japan; Iwamuro M.; Matsueda K.; Takenaka R.; Inaba T.; Yoshioka M.; Toyokawa T.; Tanaka S.; Kanzaki H.; Kawano S.; Kawahara Y.; Okada H.

P0531

**CLINICOPATHOLOGICAL EXAMINATION OF DUCTAL INVOLVEMENT IN T1A ESOPHAGEAL SQUAMOUS CELL CARCINOMA**

Tsuneo Oyama, Japan; Takahashi A.; Shiozawa S.



P0532

**CLINICOPATHOLOGIC CHARACTERISTICS OF SYNCHRONOUS MULTIPLE EARLY ESOPHAGEAL NEOPLASTIC LESIONS**Xiaonan Zhu, China; Wu J.; Gan T.; Yang J.**Acid peptic disease (includes NSAIDS, but NOT *H. pylori*), pathogenesis**

P0533

**GASTROPROTECTIVE EFFECT OF PANTOPRAZOLE ON MORPHOLOGICAL CHANGES OF GASTRIC MUCOSA IN RATS DURING ANTIPLATELET THERAPY**Vernygorodskiy S.; Paliy I.; Zaika S.; Natalia Kondratiuk, Ukraine

P0534

**DOES PPI PLAY A PROTECTIVE ROLE IN GASTRIC MUCOSA IN PATIENTS TAKING DOACs?**Yuji Shimada, Japan; Matsumoto K.; Tomishima K.; Amano N.; Sato S.; Murata A.; Tsuzura H.; Sato S.; Kanemitsu Y.; Iijima K.; Nagahara A.; Genda T.

P0535

**FACTORS OF PROTON PUMP INHIBITOR RESISTANCE MODELED BY COMPARATIVE DISSOLUTION TESTING**Daria Kurguzova, Russian Federation; Serebrova S.; Drozdoz V.; Prokofiev A.; Svistunov A.; Smolyarchuk E.; Vasilenko G.; Krasnykh L.; Barkov A.**Gastroduodenal neoplasia: Clinical**

P0536

**COMPARISON OF SAFETY AND OUTCOMES BETWEEN ENDOSCOPIC AND SURGICAL RESECTIONS OF SMALL ( $\leq 5$  CM) PRIMARY GASTRIC GASTROINTESTINAL STROMAL TUMORS**Guifang Xu, China

P0537

**LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS OF NON-CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC CANCER IN ELDERLY PATIENTS**Yosuke Toya, Japan; Endo M.; Nakamura S.; Akasaka R.; Yanai S.; Kawasaki K.; Eizuka M.; Uesugi N.; Sugai T.; Matsumoto T.

P0538

**CORRELATION OF ENDOSCOPIC FINDINGS OF GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA WITH RECURRENCE AFTER COMPLETE REMISSION**Dong Jin Song, Republic of Korea; Shin D. W.; Cho J. H.; Lee D. H.

P0539

**FLAP FORMATION TIME AS A NEW ENDPOINT OF TECHNICAL SUCCESS OF ESD FOR SUPERFICIAL DUODENAL EPITHELIAL TUMORS; A TIMELINE ANALYSIS**Atsushi Nakayama, Japan; Kato M.; Ochiai Y.; Kiguchi Y.; Akimoto T.; Maehata T.; Yahagi N.

P0540

**EFFECT OF THE DURATION TIME OF UPPER GASTRO-INTESTINAL ENDOSCOPY ON THE DETECTION RATE OF GASTRIC NEOPLASTIC LESIONS**Yoshinori Sato, Japan; Yasuda H.; Kato M.; Kiyokawa H.; Yamashita M.; Matsuo Y.; Yamamoto H.; Itoh F.

P0541

**VALIDITY OF SUBMUCOSAL PATTERN ANALYSIS OF EUS FOR PREDICTING DEPTH OF INVASION IN ULCERATIVE EARLY GASTRIC CANCER**Ji Hyun Kim, Republic of Korea

P0542

**FEASIBILITY AND OUTCOMES OF SECONDARY (REDO) ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LOCALLY RECURRENT OR INCOMPLETELY RESECTED GASTRIC NEOPLASMS**Da Hyun Jung, Republic of Korea; Youn Y.-H.; Kim J.-H.; Park J. J.; Park H.

P0543

**A NEW HISTOPATHOLOGICAL CLASSIFICATION OF GASTRIC ADENOCARCINOMA OF FUNDIC GLAND TYPE AND CLINICOPATHOLOGICAL FEATURES OF GASTRIC ADENOCARCINOMA OF FUNDIC GLAND MUCOSAL TYPE (A MULTICENTER STUDY OF 80 CASES)**Hiroya Ueyama, Japan; Yao T.; Ikeda A.; Yatagai N.; Akazawa Y.; Komori H.; Izumi K.; Ueda K.; Matsumoto K.; Hojo M.; Nagahara A.

P0544

**RISK FACTORS FOR EARLY AND DELAYED POST-OPERATIVE BLEEDING AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF GASTRIC NEOPLASMS**Yusuke Nakamoto, Japan; Sato Y.; Yasuda H.; Kiyokawa H.; Kato M.; Yamashita M.; Matsuo Y.; Yamamoto H.; Itoh F.

P0545

**IS C-REACTIVE PROTEIN A PROGNOSTIC FACTOR FOR THE WHOLE GEP-NET GROUP?**Goksel Bengi, Turkey; Komaç Ö.; Sağol Ö.; Akarsu M.

P0546

**ACCURACY OF ENDOSCOPIC SIZE MEASUREMENTS OF EARLY GASTRIC SIGNET RING CELL CARCINOMA**Ju Seok Kim, Republic of Korea; Kang S. H.; Moon H. S.; Sung J. K.; Jeong H. Y.

P0547

**INCREASED INCIDENCE OF RECURRENT NEOPLASM AFTER ENDOSCOPIC RESECTION IN PATIENTS WITH SYNCHRONOUS GASTRIC NEOPLASM.**Ga-Yeong Shin, Republic of Korea; Park J. M.; Lim C.-H.; Cho Y.-S.; Lee B.-I.; Choi M.-G.

P0548

**MATRIX METALLOPROTEINASE MULTIPLEX SCREENING IDENTIFIES INCREASED TIMP-4 SERUM CONCENTRATIONS IN GASTRIC CANCER PATIENTS**Liu J.; Zhou L.; [Yan Xue](#), China; Lin S.; Yao B.; Zhou J.; Yan X.; Lu J.; Cui R.; Xiao S.

P0549

**CLINICAL COURSE AFTER NON-CURATIVE ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY GASTRIC CANCER WITHOUT ADDITIONAL SURGERY**[Tomohiro Shimada](#), Japan; Yamagata T.; Ohira T.; Harada Y.; Kanno Y.; Koike Y.; Tanaka M.; Ito K.

P0550

**RISK ASSESSMENT OF LYMPH NODE METASTASES IN EARLY GASTRIC ADENOCARCINOMA FULFILLING EXPANDED ENDOSCOPIC RESECTION CRITERIA**[Fernanda Cristina Simões Pessorrusso](#), Brazil; Felipe-Silva A.; Jacob C. E.; Ramos M. F. K. P.; Alves V. A. F.; Zilberstein B.; Mello E. S.; Pereira M. A.; Cecconello I.; Ribeiro U.; Maluf-Filho F.

P0551

**COMPARATIVE EFFICACY OF VARIOUS ANTI-ULCER MEDICATIONS AFTER GASTRIC ENDOSCOPIC RESECTION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**[Jae Gon Lee](#), Republic of Korea; Kim E. H.; Park S. W.; Park C. H.

P0552

**SERUM PEPSINOGEN II AS A POTENTIAL BIOMARKER FOR DETECTION OF DIFFUSE TYPE GASTRIC CANCER AMONG YOUNG ADULTS IN KOREA**[Sung Min Baek](#), Republic of Korea; Kim N.; Kwon Y. J.; Lee H. S.; Lee J.; Yoon H.; Shin C.-M.; Park Y.-S.; Lee D.-H.**Gastroduodenal neoplasia: Basic**

P0553

**ABOUT CLASSIFICATION OF CHRONIC GASTRITIS**[Alexey Korotkevich](#), Russian Federation; Aksenov P.

P0554

**CLINICOPATHOLOGIC IMPACTS OF TP53 AND SMAD4 INACTIVATION IN GASTRIC ADENOCARCINOMA WITH ENTEROBLASTIC DIFFERENTIATION**[Noboru Yatagai](#), Japan; Saito T.; Yanai Y.; Tsuyama S.; Hayashi T.; Ikeda A.; Akazawa Y.; Komori H.; Izumi K.; Matsumoto K.; Ueda K.; Ueyama H.; Matsumoto K.; Hojo M.; Yao T.; Nagahara A.

P0555

**COMPREHENSIVE BIOINFORMATIC ANALYSIS OF ABERRANTLY EXPRESSED PROFILES OF MIRNAS AND LNCRNAs WITH THE ASSOCIATED CERNA NETWORK IN GASTRIC CANCER**[Xiaoying Zhou](#), China

P0556

**ADIPOCYTES CAN INCREASE THE INVASIVE POTENTIAL OF PERITONEAL METASTASIS FORMATION IN GASTRIC CANCER.**[Sachio Fushida](#), Japan; Yamaguchi T.; Kinoshita J.; Ohta T.

P0557

**THE EXPRESSION OF WNT-SIGNALING PATHWAY COMPONENTS IN DIFFUSE GASTRIC CANCER**[Maja Sremac](#), Croatia; Nikuseva Martić T.; Rustemovic N.; Krznaric Z.**Upper GI vascular disorders**

P0558

**SAFETY AND EFFICACY OF THE NEW THULIUM / ERBIUM LASER SYSTEM IN PATIENTS WITH GASTROINTESTINAL BLEEDING FROM VASCULAR LESIONS.**[Gian Eugenio Tontini](#), Italy; Rimondi A.; Neumann H.; Annunziata M. L.; Cavallaro F.; Lagoussis P.; Spina L.; Vavassori S.; Pastorelli L.; Vecchi M.**Upper GI/Intestinal health services research**

P0559

**IS GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION FEASIBLE UNDER THE DIRECT ORAL ANTICOAGULANTS ADMINISTRATION?**[Ryotaro Nakahara](#), Japan; Harada H.; Ujihara T.; Murakami D.; Sagami R.; Satoshi S.; Katsuyama Y.; Hayasaka K.; Amano Y.

P0560

**QUANTIFYING EXCESS CARDIO-RESPIRATORY EVENTS AND ADMISSIONS FOLLOWING DAY CASE DIAGNOSTIC GASTROSCOPY**[Colin Crooks](#), United Kingdom; West J.; Card T. R.

P0561

**THE ITALIAN SOCIETY FOR DIGESTIVE ENDOSCOPY (SIED) ACCREDITATION PROGRAM 2014-2018: AN UPDATE**[Giancarlo Spinzi](#), Italy; Brosolo P.; Capelli M.; Da Massa Carrara P.; Labardi M.; Merighi A.; Milano A.; Riccardi L.; Torresan F.

P0562

**THE ROLE OF THE CLINIC AND OF THE ORGANIZATIONAL COMPLEXITY ON THE MORTALITY FROM ACUTE UPPER GASTROINTESTINAL BLEEDING**Marmo R.; [Marco Soncini](#), Italy; Marmo C.

P0563

**SIMPLE "PURE" ENDOSCOPIC TECHNIQUE OF PEG-J-PLACEMENT IN ADVANCED PARKINSON'S DISEASE- A RETROSPECTIVE SINGLE-CENTER STUDY**[Petko Karagyozov](#), Bulgaria; Georgieva Z.; Tishkov I.; Boeva I.; Koynarski V.; Mitova V.

P0564  
**GASTROINTESTINAL SYMPTOMS IMPACTING ON QUALITY OF LIFE: A COMPARATIVE COHORT STUDY IN PATIENTS WITH ORGANIC AND FUNCTIONAL GASTROINTESTINAL DISORDERS (FGIDS) IN THE TERTIARY HOSPITAL OUTPATIENT SETTING**  
Ayesha Shah, Australia; Rich J.; Ghasemi P.; Koloski N.; Talley N. J.; Walker M.; Jones M. P.; Holtmann G.

Poster Session

09:00 - 17:00

Hall X1

*H. Pylori I*

**Pathogenesis: Host factors/immunology/inflammation**

P0565  
**INCREASE OF BMI AND DECREASE OF SERUM LEVEL OF LIPID WERE OBSERVED AFTER *H. PYLORI* ERADICATION WITHOUT CORRESPONDING CHANGE OF DAILY INTAKE OF NUTRIENT IN JAPANESE FEMALES.**  
Satoru Nakagawa, Japan; Shimoyama T.; Chinda D.; Fukuda S.

P0566  
**RACK1 IS A NEW REGULATOR IN THE NF- $\kappa$ B SIGNALING PATHWAY INDUCED BY HELICOBACTER PYLORI INFECTION**  
Yi Hu, China; Liu J.-P.; Li X.-Y.; Cai Y.; Xie C.; He C.; Zhu Y.; Lu N.-H.

P0567  
**ENTEROENDOCRIN CELL COMPARTMENT SIZE DECREASES DURING *H. PYLORI* INFECTION IN PATIENTS WITH INTESTINAL METAPLASIA BUT IS RESTORED AFTER ERADICATION.**  
Michiel Mommersteeg, The Netherlands; Spaander M. C. W.; Bruno M. J.; Kuipers E. J.; Peppelenbosch M.; Fuhler G.

**Diagnosis**

P0568  
**PEPSINOGEN  $\frac{I}{II}$  RATIO IS AN EXCELLENT BIOMARKER TO ESTIMATE THE GRADE OF GASTRIC ATROPHY IN BOTH HELICOBACTER PYLORI-INFECTED AND NONINFECTED SUBJECTS: OPTIMAL CUTOFF POINT TO IDENTIFY SEVERE ATROPHIC GASTRITIS**  
Hideaki Taniguchi, Japan; Iwasaki Y.; Aimi M.; Okada H.

P0569  
**APPLICATION OF CONVOLUTIONAL NEURAL NETWORKS IN THE DIAGNOSIS OF HELICOBACTER PYLORI INFECTION STATUS BASED ON ENDOSCOPIC IMAGES**  
Satoki Shichijo, Japan; Endo Y.; Aoyama K.; Ozawa T.; Takiyama H.; Matsuo K.; Fujishiro M.; Ishihara S.; Ishihara R.; Tada T.

P0570  
**THD FECAL TEST FOR NON-INVASIVE HELICOBACTER PYLORI DETECTION: A DIAGNOSTIC ACCURACY STUDY**  
 Iannone A.; Losurdo G.; Giorgio F.; Russo F.; Riezzo G.; Girardi B.; Pricci M.; Palmer S. C.; Barone M.; Principi M.; Strippoli G. F. M.; Ierardi E.; Alfredo Di Leo, Italy

P0571  
**ENDOSCOPIC DIAGNOSIS OF HELICOBACTER PYLORI BASED ON THE ARRANGEMENT OF COLLECTING VENULES IN A EUROPEAN POPULATION**  
 Garces Duran R.; García-Rodríguez A.; Cordova Guevara H.; Gines A.; Gonzalez Suarez B.; Araujo I.; Sendino Garcia O.; Vargas Castillo E.; Rodríguez de Miguel C.; Llach Vila J.; Maria Gloria Fernández-Esparrach, Spain

P0572  
**COMPARISON OF STOOL ANTIGEN TEST MONOLAB® AND UREA BREATH TEST FOR DIAGNOSIS OF HELICOBACTER PYLORI INFECTION.**  
Ana Campillo, Spain; Amorena E.; Concepción P.; Ubieta V.; Garcia J. J.; Martinez-Acitores D.; Leon H.; Zabalza L.; Kutz M.; Bolado Concejo F.; Ostiz M.; Laiglesia M.; Voltá T.

P0573  
**PHOTOMETRY OF RAPID UREASE TEST FOR DIAGNOSTICS OF HELICOBACTER PYLORI IN PATIENTS WITH DYSPEPTIC SYMPTOMS**  
Boris Starostin, Russian Federation

**Treatment**

P0574   
**MEDICATION DIARY CARD ON THE ERADICATION RATE AND SYMPTOM REMISSION OF PATIENTS INFECTED BY HELICOBACTER PYLORI**  
Mengdie Shen, China; Li J.; Meng L.-N.; Lv B.

P0575  
**THE EFFECT OF PERIODONTAL THERAPY FOR GASTRIC HELICOBACTER PYLORI ERADICATION: A PROSPECTIVE RANDOMIZED CONTROLLED CLINICAL TRIAL IN THAILAND**  
Taweesak Tongtawe, Thailand

P0576  
**EVALUATION OF BACKGROUND FACTORS AFFECTING THE SUCCESS RATE OF FIRST-LINE TRIPLE THERAPY WITH VONOPRAZAN FOR HELICOBACTER PYLORI INFECTION**  
Hiroyuki Tamaki, Japan; Noda T.; Morita M.; Omura A.; Kubo A.; Ogawa C.; Matsunaka T.; Shibatoge M.

P0577  
**THE IMPACT OF HELICOBACTER PYLORI ERADICATION ON THE NUTRITIONAL HEALTH IN HEMODIALYSIS PATIENTS**  
Atsushi Majima, Japan; Sawai Y.; Tomita Y.; Watanabe N.; Shigemori K.; Morisawa T.; Yoh T.; Ishikawa H.; Akamatsu N.

P0578

**COMPARISON OF STANDARD, SEQUENTIAL, AND CONCOMITANT FIRST LINE ERADICATION THERAPY FOR HELICOBACTER PYLORI**Eun Hye Park, Republic of KoreaP0579 **SUSCEPTIBILITY-BASED TAILORED VS. EMPIRIC AMOXICILLIN MODIFIED BISMUTH QUADRUPLE THERAPY AS HELICOBACTER PYLORI THERAPY: A MULTICENTER RANDOMIZED CONTROLLED TRIAL**Qi Chen, China; Long X.; Ji Y.; Liang X.; Li D.; Gao H.; Xu B.; Liu M.; Chen Y.; Sun Y.; Zhao Y.; Xu G.; Song Y.; Yu L.; Zhang W.; Liu W.; Lu H.

P0580

**TRIPLE THERAPY OF VONOPRAZAN, AMOXICILLIN AND SITAFLOXACIN IS USEFUL FOR THE THIRD-LINE HELICOBACTER PYLORI ERADICATION THERAPY IN JAPAN.**Kazunori Takahashi, Japan; Shimoyama T.; Nakagawa S.; Chinda D.; Fukuda S.

P0581

**CHANGE IN HALITOSIS VALUE AFTER HELICOBACTER PYLORI ERADICATION: A SINGLE INSTITUTIONAL PROSPECTIVE ANALYSIS**Yui Kudo, Japan; Kudo S.; Miyachi H.; Ichimasa K.; Suzuki K.; Kouyama Y.; Sakurai T.; Ogawa Y.; Gotoda T.

P0582

**HOW TO GET RELIABLE INFORMATION ABOUT THE EFFICACY OF A *H. PYLORI* REGIMEN IN PATIENTS HARBOURING RESISTANT STRAINS?**Gatta L.; Scarpignato C.; Giulia Fiorini, Italy; Belsey J.; Saracino I. M.; Ricci C.; Vaira D.

P0583

**THE EFFICACY OF A SIMPLE 14-DAY MODIFIED QUADRUPLE THERAPY CONTAINING AMOXICILLIN, TETRACYCLINE AND HIGH DOSE METRONIDAZOLE AND PROTON-PUMP INHIBITORS AS EMPIRICAL THIRD LINE ERADICATION TREATMENT IN TAIWAN**Lin C.-Y.; Chih-Chien Yao, Taiwan; Tai W.-C.; Wu K.-L.; Kuo C.-M.; Huang H.-T.; Liang C.-M.; Chuah S.-K.

P0584

**USING A NOVEL DEVELOPED HIGH RESOLUTION MELT CURVE ASSAY FOR THE ANALYSIS OF PREDOMINANCE OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE**Tsachi Tsadok Perets, Israel; Ashorov O.; Boltin D.; Dickman R.; Niv Y.

## Poster Session

09:00 - 17:00

Hall X1

## Small Intestinal I

**Enterocyte biology/pathology and nutrient/water transport/electrolyte transport**

P0585

**THE PROTECTIVE EFFECT OF ANGIOTENSIN(1-7) ON NSAID-INDUCED SMALL INTESTINAL INJURY IN RATS**Wang M.; Ye L.; Lv B.; Li-Na Meng, China

P0586

**INTESTINOTROPHIC EFFECTS OF GLEPAGLUTIDE FOLLOWING CHRONIC EXPOSURE IN RATS AND DOGS**Peter Glerup, Denmark; Sonne K.; Shaun Russell W.; Walton C.; Chesher C.**Microbiology**

P0587

**EMERGING ROLE OF RIFAXIMIN IN THE MANAGEMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS ON CHRONIC PPI TREATMENT.**De Bastiani R.; Loris Riccardo Lopetuso, Italy; De Bastiani M.; Pirrotta E.; Turnava L.; Sanna G.; Gasbarrini A.

P0588

**THE IMBALANCE OF THE HOMEOSTASIS SERINE PROTEASES-INHIBITORS IN INFLAMMATORY BOWEL DISEASE NAIVE PATIENTS: A HORIZON FOR NEW PERSPECTIVES THERAPIES?**Roua Kallel, Tunisia; Chtourou L.; Amouri A.; Jablaoui A.; Ali G.; Boudabbous M.; Hela G.; Rhimi M.; Mnif L.; Nabil T.**Coeliac disease (adult)**

P0589

**FREQUENCY OF SERONEGATIVE VILLOUS ATROPHY IN FUNCTION OF THE DEFINITION USED: DIAGNOSTIC UTILITY OF TRANSGLUTAMINASE DEPOSITS AND GAMMA-DELTA+ CELL COUNTING.**Beatriz Arau, Spain; Tristán E.; Ferrer C.; Garcia-Puig R.; Carrasco A.; Ruiz Campos L.; Ruiz P.; Esteve M.; Fernández-Bañares F.

P0590

**TISSUE TRANSGLUTAMINASE DEPOSITS COMPARED TO THE SCORE 'COELIAC-LITE' IN THE DIAGNOSIS OF COELIAC DISEASE WITHOUT VILLOUS ATROPHY**Yamile Zabana, Spain; Tristán E.; Carrasco A.; Garcia-Puig R.; Arau B.; Aceituno M.; Horta Sangenis D.; Ruiz P.; Esteve M.; Fernández-Bañares F.

P0591

**COELIAC DISEASE IN SELECTIVE IGA DEFICIENCY. SAME PATHOLOGY, DIFFERENT APPROACH TO DIAGNOSIS AND SURVEILLANCE.**

Farras S.; [Diana Fresneda](#), Spain; Blas J.; Romero A.; Blas L.; Rodríguez S.; Varela A.; Porres J.; Martínez-Becerra J.

P0592

**WITHDRAWN**P0593 **PREDICTIVITY OF AUTOIMMUNE STIGMATA FOR GLUTEN SENSITIVITY IN SUBJECTS WITH MICROSCOPIC ENTERITIS: A RETROSPECTIVE STUDY**

[Giuseppe Losurdo](#), Italy; Principi M.; Giangaspero A.; Iannone A.; Amoroso A.; Barone M.; Ierardi E.; Di Leo A.

P0594

**COGNITIVE IMPAIRMENT IN COELIAC DISEASE: NORMALIZATION FOLLOWING GLUTEN-FREE DIET**

[Vendel A. Kristensen](#), Norway; Valeur J.; Tveito K.

P0595

**DO CLINICAL SYMPTOMS OR SEROLOGY CORRELATE WITH CAPSULE ENDOSCOPY FINDINGS IN COELIAC DISEASE?**

[Stefania Chetcuti Zammit](#), United Kingdom; Kurien M.; Sanders D. S.; Sidhu R.

P0596

**WHAT IS THE ROLE OF CAPSULE ENDOSCOPY IN EVALUATING PATIENTS WITH REFRACTORY COELIAC DISEASE?**

[Stefania Chetcuti Zammit](#), United Kingdom; Sanders D. S.; Sidhu R.

P0597

**FREQUENCY AND DIFFERENTIAL CHARACTERISTICS OF ULTRASHORT CELIAC DISEASE**

Mata-Romero P.; Martín-Holgado D.; Dueñas-Sadornil C.; Gonzalez-Cordero P. L.; Ferreira-Nossa H. C.; Izquierdo-Martín A.; Barros-García P.; Ionescu D. F.; Cámara-Hijón C.; Fernandez-Pereira L.; [Javier Molina Infante](#), Spain

P0598 **MICRORNA PROFILING AS A GUIDE TO PERSONALIZED MEDICINE IN ENTEROPATHY ASSOCIATED T-CELL LYMPHOMAS AND REFRACTORY CELIAC DISEASE**

[Luca Elli](#), Italy; Gaudio G.; Laginestra A.; Pileri S.; Ferrero S.; Bosari S.; Di Sabatino A.; Vanoli A.; Vecchi M.; Roncoroni L.; Lombardo V.; Vaira V.

**Small intestinal neoplasia**

P0599

**PRIMARY GASTROINTESTINAL FOLLICULAR LYMPHOMA: A PROSPECTIVE, LONG TERM FOLLOW-UP CLINICAL STUDY OF 27 CASES**

Matysiak-Budnik T.; [Philippe Jamet](#), France; Fabiani B.; Coppo P.; Ruskone - Fourmestreaux A.

P0600

**NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT ARISING IN INFLAMMATORY BOWEL DISEASES: MORE THAN A COINCIDENCE?**

[Stefano Rizza](#), Italy; Canavese G.; Ribaldone D.; Cassoni P.; Astegiano M.; Venezia L.; Cortegoso Valdivia P.; De Angelis C. G.

P0601 **FEASIBILITY OF DOUBLE-BALLOON ENDOSCOPY-ASSISTED ENDOSCOPIC BALLOON DILATION OF STRICTURES SECONDARY TO PRIMARY SMALL INTESTINAL LYMPHOMA**

[Masahiro Okada](#), Japan; Magome S.; Sakamoto H.; Yano T.; Hayashi Y.; Kobayashi Y.; Takezawa T.; Sunada K.; Shinozaki S.; Lefor A.; Yamamoto H.

P0602

**CHARACTERISTICS OF THE SMALL INTESTINAL GIST DIAGNOSED BY BALLOON-ASSISTED ENDOSCOPY.**

[Takamitsu Umeda](#), Japan; Mitsui K.; Fumihiko H.; Hiroaki K.; Takagi S.; Nishimoto T.; Omori J.; Sato W.; Akimoto N.; Yonezawa M.; Tanaka S.; Tatsuguchi A.; Fujimori S.; Iwakiri K.

P0603

**TUMOUR DETECTION RATES AT CAPSULE ENDOSCOPY PERFORMED FOR THE INVESTIGATION OF IRON DEFICIENCY ANAEMIA**

[Benjamin Cooper](#), United Kingdom; Martin H.; Macedo M.; McStay M.

P0604 **PROGRAMMED CELL DEATH LIGAND-1 EXPRESSION IS ASSOCIATED WITH MICROSATELLITE INSTABILITY IN NON-FAMILIAL SMALL BOWEL CARCINOMAS: RESULTS FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM**

[Paolo Giuffrida](#), Italy; Vanoli A.; Martino M.; Persichella A.; Viglio A.; Furlan D.; Klersy C.; Grillo F.; Fiocca R.; Mescoli C.; Rugge M.; Nesi G.; Fociani P.; Sampietro G. M.; Arduzzone S.; Luinetti O.; Calabrò A.; Tonelli F.; Volta U.; Santini D.; Caio G.; Elli L.; Ferrero S.; Latella G.; Ciardi A.; Caronna R.; Solina G.; Rizzo A.; Ciacci C.; D'Armiento F. P.; Salemme M.; Villanacci V.; Cannizzaro R.; Canzonieri V.; Reggiani Bonetti L.; Biancone L.; Monteleone G.; Orlandi A.; Santeusano G.; Macciomei M. C.; D'Incà R.; Perfetti V.; Sandri G.; Silano M.; Florena A. M.; Giannone A. G.; Papi C.; Coppola L.; Usai P.; Maccioni A.; Astegiano M.; Migliora P.; Lenti M. V.; Rovedatti L.; Sessa F.; Solcia E.; Corazza G. R.; Paulli M.; Di Sabatino A.

## Poster Session

09:00 – 17:00

Hall X1

Nutrition I

## Obesity

P0605

GUT MICROBIOTA COMPOSITION AND OBESITY IN AP-  
ARENTLY HEALTHY INDIVIDUALS FROM MOSCOWDaria Kashtanova, Russian Federation; Tkacheva O.; Kotovskaya Y.; Doudinskaya E.

P0606

STRESS RESPONSE IN HIGH-FAT DIET-INDUCED OBESE  
MICE : FOCUS ON INTESTINAL PERMEABILITY.Wafa Bahlouli, France; L'Huillier C.; Nobis S.; Salameh E.; Atmani K.; Boulete I.; Goïchon A.; Belmonte L.; Bôle-Feysot C.; Ducrotté P.; Dechelotte P.; Coëffier M.

P0607

OVERNIGHT OR MORNING ONLY SPLIT DOSING WITH 1  
L POLYETHYLENE GLYCOL NER1006 CAN DELIVER 92%  
OR HIGHER RATES OF SUCCESSFUL OVERALL COLON  
CLEANSING IN NORMAL WEIGHT AND OBESE PATIENTS  
Amlani B.; Juha Halonen, United Kingdom; Clayton L.

P0608

DUODENO-JEJUNAL BYPASS LINER FOR THE TREAT-  
MENT OF DIABETES MELLITUS IN OBESE PATIENTS:  
COMPLETENESS OF DUODENAL BLINDING AS THE KEY  
FACTOR FOR EFFICACYMarek Benes, Czech Republic; Drastich P.; Hucl T.; Spicak J.

P0609

THE EFFECT OF THE DIETICIAN SUPPORT AND BE-  
HAVIOURAL THERAPY IN PATIENTS UNDERGOING  
INTRAGASTRIC BALLOON TREATMENT FOR OBESITY  
Sonia Solito, Italy; Vadala di Prampero S. F.; Faleschini G.;  
Panic N.; Picci A.; Pinese E.; Piva R.; Bulajic M.;  
Marino M.; Rossitti P.; Zilli M.

P0610

ADHERENCE TO VITAMIN SUPPLEMENTATION AND NEW  
LIFESTYLES AFTER BARIATRIC SURGERYAntonella Santonicola, Italy; Cersosimo G.; Angrisani L.;  
Caputo C.; Ciacci C.; Iovino P.

P0611

THE EFFECTS OF OAT &#946;-GLUCAN CONSUMPTION  
AT BREAKFAST ON APPETITE AND FOOD INTAKE, AS  
WELL AS BLOOD GLUCOSE, PLASMA INSULIN AND PLAS-  
MA GLP-1 CONCENTRATIONS IN HEALTHY SUBJECTSSuzanne M. M Zaremba, United Kingdom; Gow I. F. ;  
Drummond S.; McCluskey J. T.; Steinert R. E.

P0612

VARIABILITY IN THE NIGHT PROFILE OF TOTAL GHRELIN  
IN OBESE PATIENTS WITH OBSTRUCTIVE SLEEP APNEA.Pardak P.; Rafal Filip, Poland; Krzaczek M.; Woliński J.

P0613

EXCESSIVE BODY FATNESS AT YOUNG AGE INCREASES  
RISK OF COLORECTAL CANCER: META-ANALYSIS AND  
DOSE-RESPONSE ANALYSISXuelian Lei, China; Geng C.; Li X.; Wang C.

## Poster Session

09:00 – 17:00

Hall X1

Paediatric: Upper GI

## Paediatric oesophageal disorders

P0614

WITHDRAWN

P0615

SAFETY AND EFFECTIVENESS OF PER-ORAL ENDO-  
SCOPIC MYOTOMY IN CHILDREN WITH ACHALASIA: A  
COMPARISON OF THE RESULTS IN PAEDIATRIC AND  
ADULT PATIENTSKanefumi Yamashita, Japan; Shiwaku H.; Ohmiya T.;  
Okada H.; Inoue H.; Hasegawa S.Paediatric *H. pylori*

P0616

CHANGES OF MORPHOLOGICAL DISORDERS OF GASTRIC  
MUCOSA IN CHILDREN WITH CHRONIC GASTRITIS  
CO-INFECTED WITH HELICOBACTER PYLORI AND EP-  
STEIN-BARR VIRUS AFTER A COURSE OF ANTIHELICO-  
BACTER THERAPYEugeniy Spivak, Russian Federation; Levit R.; Zaytseva O.

## Coeliac disease (paediatric)

P0617

SEVERITY OF HISTOLOGICAL DAMAGE IN COELIAC  
DISEASE: ASSOCIATED FACTORS AND LONG-TERM  
SIGNIFICANCELaura Kivelä, Finland; Kröger S.; Arvola T.; Huhtala H.;  
Kaukinen K.; Kurppa K.

P0618

DIAGNOSTIC DELAYS IN CHILDREN WITH COELIAC DIS-  
EASE IN THE CENTRAL EUROPEAN REGION IN 2016Petra Riznik, Slovenia; De Leo L.; Dolinsek J.;  
Gyimesi J.; Klemenak M.; Koletzko B.; Koletzko S.;  
Korponay-Szabo I. R.; Krencnik T.; Not T.; Palcevski G.;  
Sblattero D.; Vogrincic M.; Werkstetter K. J.; Dolinsek J.

P0619

NATURAL HISTORY OF POTENTIAL CELIAC DISEASE: FAC-  
TORS PREDICTING EVOLUTION TO VILLOUS ATROPHY  
Auricchio R.; Roberta Mandile, Italy; Galatola M.;  
Maglio M.; Discepolo V.; Miele E.; Troncione R.; Greco L.

P0620

WITHDRAWN

P0621

**CLINICAL PRESENTATION OF COELIAC DISEASE IN CHILDREN AND ADOLESCENTS FROM CENTRAL EUROPEAN REGION IN 2016**

Petra Riznik, Slovenia; De Leo L.; Dolinsek J.; Gyimesi J.; Klemenak M.; Koletzko B.; Koletzko S.; Korponay-Szabo I. R.; Krencnik T.; Not T.; Palcevski G.; Sblattero D.; Vogrincic M.; Werkstetter K. J.; Dolinsek J.

P0622

**UTILISATION OF DIAGNOSTIC TOOLS FOR COELIAC DISEASE IN CHILDREN IN 2016-2017 - A NATION-WIDE SURVEY**

Ilma Rita Korponay-Szabó, Hungary; Gyimesi J.; Barkaszi-Szabó Z.; Riznik P.; Balogh M.; Tokodi I.; Pollák É.; Guthy I.; Horváth Á.; Werkstetter K.; Koletzko S.; Bódi P.; Kis I.; Bajor J.; Csoszanszki N.; Nemes É.; Kadenczki O.; B. Kovács J.; Dolinsek J.; Dolinsek J.

P0623

**EXPRESSION OF IRON TRANSPORTER PROTEINS IN THE SMALL BOWEL MUCOSA OF CHILDREN WITH CELIAC DISEASE**

Marleena Repo, Finland; Kurppa K.; Taavela J.; Hiltunen P.; Popp A.; Kaukinen K.; Lindfors K.

P0624

**THE RELATIONSHIP BETWEEN THE STATUS OF VITAMIN D AND P53 PROTEIN IN CHILDREN WITH CELIAC DISEASE.**

Oltinoy Kamilova, Uzbekistan; Alieva N.

**Malabsorption syndromes, food enteropathies and other small intestinal disorders (paediatric)**

P0625

**H. PYLORI INFECTION MAY EXACERBATE SMALL INTESTINAL MUCOSAL INJURY IN CONCOMITANT NON-SELECTIVE NSAIDS AND PPI TREATMENT.**

Takayoshi Nishimoto, Japan; Fujimori S.; Mitsui K.; Akimoto N.; Oomori J.; Iwakiri K.

P0626

**EVALUATION OF QUALITATIVE AND QUANTITATIVE SMALL BOWEL BACTERIAL OVERGROWTH SYNDROME IN CHILDREN WITH CHRONIC DIARRHEA USING JEJUNAL FLUID BACTERIAL CULTURE AND BREATH TESTS**

Moinak Sen Sarma, India; Yachha S. K.; Misra R.; Prasad K. N.; Srivastava A.

**Paediatric nutrition**

P0627

**A FIRST APPROACH FOR AN EVIDENCE-BASED METHOD TO ADJUST PANCREATIC ENZYME REPLACEMENT THERAPY IN CYSTIC FIBROSIS**

Calvo-Lerma J.; Hulst J.; Boon M.; Masip E.; Fornés V.; Garriga M.; Colombo C.; Roca M.; Crespo P.; Woodcock S.; Claes I.; de Boeck K.; Etna Ribes-Koninckx, Spain

**Poster Session**

09:00 – 17:00

Hall X2/X1

Clinical Cases I

**Liver/Biliary/Pancreas**

CC001

**SYPHILIS: AN ETIOLOGY OF ACUTE HEPATITIS TO ALWAYS KEEP IN MIND**

Pedro Marcos, Portugal; Leal C.; Eliseu L.; Henriques M.; Vasconcelos H.

CC002

**AN UNEXPECTED CAUSE OF LIVER NODULE**

Rui Morais, Portugal; Cardoso H.; Santos A. L.; Gullo I.; Pardal J.; Aral M.; Abreu C.; Costa J.; Carneiro F.; Macedo G.

CC003

**THE IMPORTANCE OF DIFFERENTIAL DIAGNOSIS: A CASE OF OVERESTIMATED HEPATIC ENCEPHALOPATHY.**

Mariangela Antonelli, Italy; Tarli C.; Rando M. M.; Sestito L.; Mosoni C.; Gasbarrini A.; Addolorato G.

CC004

**ACUTE-ON-CHRONIC LIVER FAILURE RESULTING FROM SPONTANEOUS BACTERIAL PERITONITIS AND UPPER GASTROINTESTINAL BLEEDING IN A MAN WITH DECOMPENSATED LIVER CIRRHOSIS – A CLINICAL CASE.**

Antonia Topalova, Bulgaria; Valkov I.; Antonov K.

CC005

**ACUTE LIVER FAILURE AS THE FIRST MANIFESTATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY**

Zaimi Y.; Myriam Ayari, Tunisia; Belhadjmabrouk E.; Nsibi S.; Eljeri K.; Said Y.; Mouelhi L.; Debbeche R.

CC006

**CASE REPORT: CHALLENGES FACING SIMULTANEOUS LIVING DONOR COMBINED LIVER-KIDNEY TRANSPLANTATION - DOES IT WORTHY?**

Mohamed Talkhan, Egypt; El Fouly A.; Montasser I. F.; Abdo M.; Ghazy M. S.; Hassan M. S.; Abdelrazek A.; Mukhtar A.; Eweeda K. M.; Abdelaal A.

CC007

**NON-CIRRHOTIC PORTAL HYPERTENSION AS A COMPLICATION OF T-DM1 TREATMENT FOR BREAST CANCER.**

Luis Gerardo Alcalá, Spain; Mínguez B.; Merino X.; Salcedo M. T.; Alonso-Cotoner C.

CC008

**PORTAL CHOLANGIOPATHY – A RARE CASE OF MECHANICAL JAUNDICE**

Vinnitskaya E. V.; Sandler J. G.; Brezgin A. G.; Anton N Ivanov, Russian Federation



CC009

**LIVER TRANSPLANTATION FOR ABERNETHY SYNDROME IN A PATIENT WITH WIDESPREAD SUBVERSION OF THE LIVER PARENCHYMA.**Ponziani F. R.; Faccia M.; Zocco M. A.; De Matthaeis N.; Pizzolante F.; Riccardi L.; [Antonio Gasbarrini](#), Italy; Pompili M.; Rapaccini G. L.

CC010

**MULTIDISCIPLINARY APPROACH IN PAEDIATRIC CHOLANGITIS – BREAKING BARRIERS**[Verónica Pavão Borges](#), Portugal; Alves R.; Capela T.; Teixeira A.; Silva M. J.; Donato P.; Almeida V.; Cordeiro A. M.; Fraga J.; Ramos G.; Canena J.; Mateus Dias A.; Coimbra J.

CC011

**A CASE OF SELECTIVE DEFECTIVE LIPOLYSIS OF LONG CHAIN FATS.**[Atchariya Chanpong](#), United Kingdom; Lindley K. J.**Surgery/Endoscopy/Imaging**

CC012

**SUCCESSFUL EN BLOC ENDOSCOPIC SUBMUCOSAL EXCAVATION OF A GIANT CERVICAL ESOPHAGEAL LEIOMYOMA ORIGINATING FROM MUSCULARIS PROPRIA**  
Huang S.; [Sumin Zhu](#), China

CC013

**ESOPHAGEAL NECROSIS POST PANCREATIC PSEUDO-CYST DRAINAGE**[Jo Collins](#), United Kingdom; Carroll N.

CC014

**ESOPHAGEAL CYST CONTAINING HETEROTOPIC GASTRIC GLANDS**[Bingyi Zhou](#), China; Tan Y.; Yang J.; Liu D.

CC015

**GASTRIC ANISAKIASIS**[Sonia Bernardo](#), Portugal; Castro-Poças F.

CC016

**PRIMARY GASTRIC MELANOMA – IS IT REALLY EXIST?**[Rachel Gingold-Belfer](#), Israel; Konikoff T.; Boltin D.; Lucille Hayman Manzur L.; Dotan I.

CC017

**GASTRIC ULCERA FOLLOWING SIRT**[Doerte Wichmann](#), Germany; Schempf U.; Goetz M.; Stueker D.

CC018

**SUBMUCOSAL TUNNELING ENDOSCOPIC RESECTION FOR A GIANT ESOPHAGEAL SUBMUCOSAL TUMOR PROTRUDED INTO THE MEDIASTINUM**[Shi-Lan Zhang](#), China; Tan Y.-Y.; Liu D.

CC019

**ENDOSCOPIC TREATMENT OF GASTRIC AND HEPATIC PERFORATION BY FISH BONE**[Joao Correia-Sousa](#), Portugal; Maia L.; Rocha M.; Ferreira J. M.; Pedroto I.

CC020

**DUODENAL METASTASIS FROM LUNG ADENOCARCINOMA**[Flávio Pereira](#), Portugal; Azevedo R.; Linhares M.; Pinto J.; Ribeiro H.; Leitão C.; Caldeira A.; Tristan J.; Pereira E.; Banhudo A.

CC021

**GASTRIC AND PANCREATIC PERFORATION SECONDARY TO ACCIDENTAL FOREIGN BODY INGESTION.**[Joao Correia-Sousa](#), Portugal; Castro-Poças F.

CC022

**A RARE HETEROTOPIC GASTRIC MUCOSA**[Haihua Wang](#), China; Tan Y.; Guo T.; Liu D.

CC023

**RARE VARIANT OF PANCREATICOBILIARY MALJUNCTION ASSOCIATED WITH PANCREAS DIVISUM IN A CHILD DIAGNOSED AND TREATED WITH ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY: A CASE REPORT**  
[Guang-Xing Cui](#), China; Lu W.; Yang J.; Jin H.; Lu L.; Zhang X.

CC024

**A CASE OF HILAR CHOLANGIOPANCREATITIS WHICH WAS CURATIVELY RESECTED OWING TO PREOPERATIVE PRECISE EVALUATION USING SPYGLASS DS**[Saburo Matsubara](#), Japan; Suda K.; Fujita T.; Otsuka T.; Yakabi K.; Kogure R.; Komagome M.; Miyata Y.; Mitsui T.; Ninomiya R.; Nakazawa A.; Maki A.; Beck Y.

CC025

**SPYGLASS RESCUE TREATMENT OF COMMON BILE DUCT IMPACTED FOREIGN BODIES.**[Roberto Di Mitri](#), Italy; Mocciaro F.; Conte E.; Magro B.; Bonaccorso A.

CC026

**ENDOSCOPIC INFRA-PAPILLARY DEPLOYMENT OF THREE SIDE-BY-SIDE SELF-EXPANDING METAL STENTS FOR HILAR CHOLANGIOPANCREATITIS.**[Javed Iqbal](#), United Kingdom; Giles B.; Tanwar S.

CC027

**MELENA AFTER TWO YEARS OF WHIPPLE PROCEDURE, WHAT COULD BE THE CAUSE?**[Ali Farag](#), Egypt; Aref W.; Wahba M.

CC028

**ACUTE MESENTERIC ISCHEMIA DIAGNOSED AFTER EMERGENT SINGLE-BALLOON ENTEROSCOPY**Ribeiro Gomes A. C.; Pinho R. T.; Rodrigues J.; Sousa M.; [João Carlos Silva](#), Portugal; Carvalho J.



CC029  
**THE PAPILOMATOSIS OF BILIARY DUCT: ABOUT A CASE AND A REVIEW OF LITERATURE.**  
[Sara Jama](#), Morocco; [Seddik H.](#); [Loubaris K.](#); [Touibi Y.](#); [El Koti I.](#); [Zentar A.](#); [Benkirane A.](#)

### Lower GI

CC030  
**ULCERATIVE COLITIS AND BUDD CHIARI SYNDROME , RARE PRESENTATION : CASE REPORT**  
[Safwat E.](#); [Talkhan M.](#); [Lotfy M.](#); [Islam Badr Ezzeldin](#), Egypt; [Elsabagh A.](#)

CC031  
**CYTOMEGALOVIRUS ENTEROCOLITIS IN A PATIENT WITH SEVERE ULCERATIVE COLITIS**  
[Carolina Simões](#), Portugal; [de Sousa Damião F.](#); [Gonçalves A. R.](#); [Ferreira P.](#); [Correia L.](#); [Marinho R. T.](#)

CC032  
**A CASE OF COLITIS IN A PATIENT WITH METASTATIC NON SMALL CELL LUNG CANCER.**  
[Walker H.](#); [Paul Brennan](#), United Kingdom; [Carey F.](#); [Walsh S.](#); [Groome M.](#)

CC033  
**AN UNCOMMON CAUSE OF SEVERE INTRACTABLE DIARRHEA IN A PATIENT WITH A MALIGNANT THYMOMA**  
[Jacqueline Yang](#), Singapore; [Chau C.](#); [Liang R.](#); [Chuah K. B.](#)

CC034  
**CAP POLYPOSIS: CASE REPORT AND REVIEW OF THE LITERATURE**  
[Juliana Castro](#), Brazil; [Vieira da Rocha E. C.](#); [Mendonça T.](#); [Cabral J. G.](#); [Regis G.](#); [Koyama F.](#); [Nakagawa W.](#)

### Upper GI

CC035  
**POST PARTUM EOSINOPHILIC GASROENTERITIS**  
[Mohammed Shater](#), Egypt

CC036  
**LEFT ATRIAL DILATATION AND DYSPHAGIA. IMAGE IN HIGH RESOLUTION MANOMETRY.**  
[Pau Sendra](#), Spain; [García Caparrós C.](#); [Bosque López M. J.](#); [Payeras Capó M. A.](#)

CC037  
**MIGRATION OF A GASTRIC BEZOAR TO ESOPHAGUS: A RARE CAUSE OF ACUTE DYSPHAGIA**  
[Talat Ayyıldız](#), Turkey; [Yildirim B.](#); [Goren I.](#); [Kaymazlı M.](#); [Bektas A.](#)

CC038  
**HIGH RESOLUTION MANOMETRY – DOES IT HELP IN CHEST PAIN?**  
[Rocha M.](#); [Barrias S.](#); [Pereira G.](#); [Joao Correia-Sousa](#), Portugal; [Souto-Moura M.](#); [Küttner-Magalhães R.](#); [Pedroto I.](#)

CC039  
**MAY THE USING OF DOUBLE FILLED TABLETS ESOME- PRAZOLE/IBANDRONIC ACID OR ESOME- PRAZOLE/ NON-STEROIDAL ANTI-INFLAMMATORY DRUGS PREVENT DRUGS RELATED GASTRIC AND DUODENAL ULCERS**  
[Dokoski Gjoko](#), Macedonia; [Dokoska S.](#)

CC040  
**CELIAC DISEASE AGGRAVATED BY OLMESARTAN OR OLMESARTAN ENTEROPATHY AB INITIO?**  
[Filipe de Sousa Damião](#), Portugal; [Noronha Ferreira C.](#); [Fernandes S. R.](#); [Gonçalves A. R.](#); [Araújo Correia L.](#); [Tato Marinho R.](#)

CC041  
**A RARE CAUSE OF CHRONIC DIARRHEA DIAGNOSED BY DOUBLE BALLOON ENTEROSCOPY**  
[Farag A.](#); [Omar Ashoush](#), Egypt; [Wahba M.](#)

CC042  
**SMALL INTESTINAL BACTERIAL OVERGROWTH WITH MASSIVE GAS IN INTESTINAL BOWEL SEGMENTS**  
[Hüseyin Sancar Bozkurt](#), Turkey

**Focus on  
original research:  
Posters in the  
Spotlight**



Up to 6 posters featuring hot topic research will be presented in the Posters in the Spotlight Sessions at the e-poster terminals in Hall X1.

A following discussion is led by two moderators and experts in the field. At the end of each session, the Best Abstract Presentation Prize will be awarded to the best presenter.

**E-Posters will be published on  
[ueg.eu/week/24-7](http://ueg.eu/week/24-7)**

**Poster Sessions by Day  
Tuesday, October 23, 2018**

Poster Session	
09:00 – 17:00	Hall X1
Liver & Biliary II	

**Molecular biology, inflammation and fibrosis**

P0628

**IMPACT OF CYP2R1, CYP27A1 AND CYP27B1 GENETIC POLYMORPHISMS CONTROLLING VITAMIN D METABOLISM ON SUSCEPTIBILITY TO HCV INFECTION IN A HIGH-RISK CHINESE POPULATION**

Yang J.-J.; Yue M.; Xie C.-N.; Huang P.; Fan H.-Z.; Tian T.; Wu M.-P.; Yu R.-B.; Yi H.-G.; Zhang Y.; Jie Wang, China

P0629

**INHIBITION OF CYCLOOXYGENASE-2 AMELIORATES LIVER CIRRHOSIS BY TARGETING SPLENIC ABNORMALITIES**

Shihang Tang, China; Gao J.; Tai Y.; Su W.; Jia X.; Gan C.; Tang C.

P0630

**CELECOXIB ATTENUATES HEPATOCYTE APOPTOSIS THROUGH INHIBITION OF ENDOPLASMIC RETICULUM STRESS IN CIRRHOTIC RATS**

Wei Su, China; Tai Y.; Tang S.; Gao J.; Tang C.

P0631

**THE PREDICTIVE ABILITY OF LABORATORY INDICES IN ASSESSING ADVANCED HEPATIC FIBROSIS AMONG CHRONIC HEPATITIS C PATIENTS WITH DIFFERENT STATUSES OF ANTI-VIRAL TREATMENT AND BODY MASS INDEX**

Chun-Han Cheng, Taiwan; Chu C.-Y.; Chen H.-L.; Lin I.-T.; Wu C.-H.; Lee Y.-K.; Bair M.-J.

P0632

**DENDRITIC CELL CONTRIBUTES TO AUTOIMMUNE HEPATITIS VIA AUTOPHAGY INHIBITION**

Xiaoli Fan, China; Men R.; Wang T.; Wen M.; Ye T.; Yang L.

P0633

**ROLE OF ADIPOCYTE FATTY ACID BINDING PROTEIN (AFABP) IN THE DIAGNOSIS OF NAFLD**

Tary Salman, Egypt; Al Haddad O.; Ehsan N.; Obada M.; Abdelsameea E.; Elgendy W.

**Regeneration, stem cells and nutrition**

P0634

**ANGIOCRINE HGF SIGNALING PLAYS A CRUCIAL ROLE IN THE EARLY STAGE OF LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IN MICE**

Xue-Jun Zhang, Germany; Wang B.; Wang Y.; Olsavszky V.; Schledzewski K.; Géraud C.; Hüser N.; Friess H.; Figura G. V.; Hartmann D.

P0635

**EXTRACELLULAR VESICLES FROM AMNION-DERIVED MESENCHYMAL STEM CELLS AMELIORATE HEPATIC INFLAMMATION AND FIBROSIS IN RATS**

Masatsugu Ohara, Japan; Ohnishi S.; Yamamoto K.; Yuyama K.; Nakamura H.; Fu Q.; Maehara O.; Suda G.; Sakamoto N.

P0636

**INTRODUCTION OF CRYOPRECIPITATE INTO THE LIVER LEADS TO IMPROVEMENT OF PORTAL BLOOD FLOW**

Daria Kazakova, Russian Federation; Poluektov Y.; Karpova R.

P0637

**TOLL-LIKE RECEPTOR 3 PROMOTES LIVER REGENERATION AFTER PARTIAL HEPATECTOMY**

Christian Stöß, Germany; Wang B.; Schulze S.; Lu M.; Hartmann D.; Friess H.; Hüser N.; Holzmann B.

P0638

**DEVELOPMENT OF SELF-RENEWING 3D ORGANOID CULTURE FROM HUMAN FETAL BILIARY TREE STEM CELLS (HBTS CS) AS A POTENTIAL SYSTEM FOR REGENERATIVE MEDICINE AND DISEASE MODELLING.**

Samira Safarikia, Italy; Vincenzo C.; Costantini D.; di matteo S.; Nevi L.; Carpino G.; Bosco D.; Gaudio E.; Alvaro D.

P0639

**ORAL BRANCHED CHAIN AMINO ACID SUPPLEMENTATION INCREASES LIVER PROTEIN SYNTHESIS AND REGENERATION VIA MTOR/4E-BP1 AND AKT IN HEPATECTOMIZED MICE**

Yujing Chi, China; Wu Z.; Zhang Y.; Liu Y.

**Metabolic/genetic disorders**

P0640

**NEW OPPORTUNITIES OF COMBINED DIAGNOSTICS OF HEPATIC FIBROSIS AND STEATOSIS IN CLINICAL PRACTICE**

Irina Pirogova, Russian Federation; Yakovleva S.; Neuymina T.

P0641

**DHEA-S LEVEL AS MARKER OF INFLAMMATION AND FIBROSIS IN NAFLD PATIENTS.**

Carmen Daniela Neagoe, Romania; Ianosi G.; Zlatian O.; Farmazon A.; Ianosi S.; Popescu M.

P0642

**BERBERIS ARISTATA, ELAEIS GUINEENSIS AND COFFEA CANEPHORA EXTRACTS IMPROVE HEPATIC STEATOSIS THROUGH THE MODULATION OF THE METABOLIC PROFILE AND OF MIR-122 LEVELS IN AN ANIMAL MODEL OF NAFLD**

Lembo V.; Valentina Cossiga, Italy; Nigro C.; Mirra P.; Mazzone G.; Rossi A.; D'Argenio G.; Leone A.; Beguinot F.; Miele C.; Caporaso N.; Morisco F.

P0643

**MANAGEMENT THE PATIENTS WITH GALLSTONE DISEASE**

Irina Pirogova, Russian Federation; Ufimtceva I.

P0644

**DRUG HOLIDAY IN PATIENTS WITH POLYCYSTIC LIVER DISEASE TREATED WITH SOMATOSTATIN ANALOGUES: A NOVEL TREATMENT STRATEGY.**

René M. M. van Aerts, The Netherlands; Kolkman M.; Kievit W.; Gevers T. J. G.; Nevens F.; Drenth J. P. H.

P0645

**WITHDRAWN**

P0646

**SQLE DRIVES NON-ALCOHOLIC FATTY LIVER DISEASE AND SERVES AS A THERAPEUTIC TARGET**

Dabin Liu, Hong Kong PRC; Li C.; Wong C. C.; Zhou Y.; Zhao L.; Yu J.

P0647

**EVALUATION OF CIRCULATING HORMONES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AS POTENTIAL BIOMARKERS**

Marta Bento Afonso, Portugal; Marques V.; Baur N.; Santos-Laso A.; Jimenez-Agüero R.; Eizaguirre E.; Bujanda L.; Pareja M. J.; Cortez-Pinto H.; Banales J.; Castro R. E.; Normann A.; Rodrigues C. M. P.

P0648

**HIGH PREVALENCE OF DYSLIPIDEMIA BUT INSUFFICIENT STATIN USE IN PATIENTS WITH NON-CIRRHOTIC AND CIRRHOTIC LIVER DISEASE**

Lukas Unger, Austria; Forstner B.; Schneglberger S.; Muckenhuber M.; Eigenbauer E.; Scheiner B.; Mandorfer M.; Gnant M.; Trauner M.; Reiberger T.

P0649

**COMPARISON BETWEEN M AND XL PROBES OF TRANSIENT ELASTOGRAPHY FOR THE ASSESSMENT OF HEPATIC STEATOSIS WITH CONTROLLED ATTENUATION PARAMETER (CAP)**

Doghri I.; Ben Abbes M.; Jendoubi N.; Bousnina O.; Zarrouk S.; Lamia Kallel, Tunisia

P0650

**WITHDRAWN****Cirrhosis and complications: Clinical aspects**

P0651

**NEUTROPHIL-TO-LYMPHOCYTE RATIO: AN ACCURATE METHOD FOR PREDICTING INFECTION IN CIRRHOSIS**

Rui Magalhães, Portugal; Magalhães J.; Pinto B.; Cúrdia Gonçalves T.; Rosa B.; Marinho C.; Cotter J.

P0652

**HOSPITAL READMISSION RATES IN HEPATIC CIRRHOSIS: WHICH PATIENTS PRESENT HIGHER RISK?**

Cátia Arieira, Portugal; Cúrdia Gonçalves T.; Dias de Castro F.; Magalhães J.; Marinho C.; Cotter J.

P0653

**CEREBRAL VASCULAR RESISTANCE IS INCREASED IN CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY AND REMAINS UNCHANGED AFTER MEDICAL TREATMENT**

Ponziani F. R.; Funaro B.; Ainora M. E.; Lupascu A.; Riccardi L.; Annicchiarico B. E.; Garcovich M.; Quadarella A.; Siciliano M.; Tondi P.; Gasbarrini G.; [Antonio Gasbarrini](#), Italy; Pompili M.; Zocco M. A.

P0654

**ACUTE OCCLUSION OF EXPANDED POLYTETRAFLUORO-ETHYLENE-COVERED TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT: INCIDENCE, CLINICAL OUTCOMES, AND PROGNOSTIC FACTORS**

[Xuefeng Luo](#), China; Yang L.

P0655

**NEUTROPHIL TO LYMPHOCYTE RATIO AS PREDICTOR OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND MORTALITY IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS**

[Ana Gonzalez Mendez](#), Russian Federation; Maevskaya M.; Zharkova M.; Lunkov V.; Tsvetaeva E.; Ivashkin V.

P0656

**HEPATIC OSTEODYSTROPHY - IS THERE CLINICAL RELEVANCE?**

[Flávio Pereira](#), Portugal; Azevedo R.; Linhares M.; Pinto J.; Ribeiro H.; Leitão C.; Caldeira A.; Tristan J.; Pereira E.; Sousa R.; Banhudo A.

P0657

**ROYAL FREE HOSPITAL CIRRHOSIS GLOMERULAR FILTRATION RATE (RFHC-GFR): APPLICATION AND IMPLICATIONS FOR LIVER CIRRHOSIS IN CLINICAL PRACTICE**

[Joana Carvão](#), Portugal; Magno Pereira V.; Oliveira A.; Sousa Andrade C.; Faria M. G.; Jasmins L.

P0658

**DANAPAROID SODIUM AND ANTITHROMBIN &#8546; FOR PORTAL VEIN THROMBOSIS: EXPERIENCE OF A SINGLE JAPANESE HOSPITAL**

[Shingo Usui](#), Japan; Yamaguchi A.; Takatori Y.; Hosoda Y.

P0659

**RESULTS OF LIVER CIRRHOSIS REGISTRY IN IRAN: EPIDEMIOLOGY, UNDERLYING CAUSES AND COMPLICATIONS**

[Ahad Eshraghian](#), Iran; Ahmadi V.; Safarpour A. R.; Fattahi M. R.

P0660

**SPONTANEOUS BACTERIAL PERITONITIS: ARE WE FOLLOWING GUIDELINES?**

[Sun Mi Ha](#), United Kingdom; Al-Hasani H.; Jeyaprakash V.; Crisan L.; Siddique N.

P0661

**STAGE 1 OF ACUTE KIDNEY INJURY IN CIRRHOSIS - THE SUBCLASS REALLY MATTERS!**

[Sara Monteiro](#), Portugal; Magalhães J.; Cúrdia Gonçalves T.; Leite S.; Marinho C.; Cotter J.

P0662

**THE POLYMORPHIC VARIANT OF SERPINB3 (SCCA-PD) IS ASSOCIATED WITH THE SEVERITY OF PORTAL HYPERTENSION AND COMPLICATIONS ONSET IN PATIENTS WITH ADVANCED LIVER DISEASE**

[Andrea Martini](#), Italy; Marafatto F.; Turato C.; Novo E.; Parola M.; Biasiolo A.; Quarta S.; Ruvoletto M.; Angeli P.; Pontisso P.

P0663

**LONGITUDINAL MONITORING OF LIVER FIBROSIS STATUS BY TRANSIENT ELASTOGRAPHY IN CHRONIC HEPATITIS B PATIENTS DURING LONG-TERM ENTECAVIR TREATMENT**

[Wei Ma](#), China; Wu S.; Jiang W.

P0664

**RESOLUTION OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER SUSTAINED VIROLOGIC RESPONSE TO INTERFERON-FREE REGIMENS PREVENTS HEPATIC DECOMPENSATION**

[Mattias Mandorfer](#), Austria; Kozbial K.; Schwabl P.; Chromy D.; Scheiner B.; Paternostro R.; Staettermayer A. F.; Munda P.; Ferlitsch A.; Trauner M.; Peck-Radosavljevic M.; Ferenci P.; Reiberger T.

P0665

**NUTRITIONAL PARAMETERS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS, THEIR INFLUENCE IN EARLY READMISSION AND 1-YEAR MORTALITY**

[Lissa Maria Franco](#), Spain; Rodriguez M.; A. Navascues C.; Fraile M.; Siguauro O.; Fernandez C.; Ferrusquia J.; Gonzalez-Dieguez L.; Valle C.; Varela M.; Víctor III D. W.

P0666

**SEROLOGICAL INDICES OF LIVER FIBROSIS IN THE COURSE OF ALCOHOLIC LIVER CIRRHOSIS - A PILOT STUDY**

[Agata Michalak](#), Poland; Cichoż-Lach H.; Guz M.; Cybulski M.; Kasztelan-Szczerbińska B.

**Viral hepatitis B: Clinical aspects**

P0667

**HEPATITIS B VIRUS (HBV) IN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH DIRECT ANTIVIRAL AGENTS (DAA) IN THE SOUTHERN REGION OF MADRID**

Gutierrez Garcia M. L.; [Juan Angel Ferrer](#), Spain; Manzano M. L.; Muñoz R.; Alonso Lopez S.; Fernandez I.; Fernandez Rodriguez C.

P0668

**WITHDRAWN**

P0669

**ASSOCIATION BETWEEN LOW VITAMIN D SERUM CONCENTRATION WITH HIGH LEVELS OF HEPATITIS B VIRUS REPLICATION IN CHRONIC HEPATITIS B PATIENTS FROM ALGERIA**Khellaf Amalou, Algeria; Belghanem F.; Kezzoula D.; Bousselob A.; Rekab R.

P0670

**EFFICACY OF ANTI CHRONIC B HEPATITIS VACCINATION IN CHRONIC HEMODIALYSIS PATIENTS**Bochra Bouchabou, Tunisia; Hayfa B. R.; Nawel B.; Rania Z.; Ennaifer R.P0671 **COMPARISON BETWEEN TWO POPULATION-BASED SEROSURVEYS, SIXTEEN YEARS AFTER THE IMPLEMENTATION OF UNIVERSAL HEPATITIS B VACCINATION IN A HEPATITIS DELTA ENDEMIC AREA IN GREECE.**Vasilis Papastergiou, Greece; Ntetskas G.; Papakonstantinou F.; Chasiou A.; Stampori M.; Kozikopoulou D.; Karatapanis S.

P0672

**THE USE OF THE PATIENT SAFETY FORM APPLICATION IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY CAN IMPROVE THE LOW RATES OF HEPATIS B VIRUS SCREENING AND ANTIVIRAL PROPHYLAXIS IN REAL LIFE**  
Mehmet Demir, Turkey; Celik M. M.; Ucar E.

P0673

**REACTIVATION OF HEPATITIS B VIRUS INFECTION DURING TREATMENT OF HEPATITIS C WITH DIRECT-ACTING ANTIVIRALS**Luísa Martins Figueiredo, Portugal; Alexandrino G.; Costa M. N.; Carvalho R.; Folgado Alberto S.; Martins A.

P0674

**ROLE OF BIOLOGICAL NON-INVASIVE TESTS IN PREDICTING FIBROSIS IN CHRONIC HEPATITIS B**Ons Gharbi, Tunisia; Mohamed G.; Ben Abdelwahed M.; Boughoula K.; Ben Slimane B.; Bizid S.; Ben Abdallah H.; Bouali M. R.; Abdelli M. N.

P0675

**SERO-PREVALENCE OF DELTA HEPATITIS ANTIBODIES, LIVER FUNCTION TEST PROFILE AND SEVERITY OF LIVER DISEASE AMONG INDIVIDUALS WITH CHRONIC HEPATITIS B INFECTION SEEN IN A TERTIARY HOSPITAL IN ABUJA, NIGERIA.**Lukman Olaitan Abdulkareem, Nigeria; Uhumwangho A. O.; Ndububa D. A.; Yunusa T.**Viral hepatitis C: Clinical aspects**P0676 **DIFFUSION-WEIGHTED MR IMAGING AND MICRO-RNA IN DIAGNOSIS AND STAGING OF HEPATIC FIBROSIS IN CHRONIC HEPATITIS C**Besheer T.; Elalfy H.; Abd El-Maksoud M.; Abd El-Razek A.; Taman S.; Zalata K.; Elkashef W.; Zaghoul H.; Elshahawy H.; Raafat D.; Elemshaty W.; Elsayed E.; El-Gilany A.-H.; Mahmoud El-Bendary, EgyptP0677 **IMPROVEMENT OF LIVER STIFFNESS, INDIRECT PARAMETERS OF PORTAL HYPERTENSION IN CHRONIC HEPATITIS C VIRUS PATIENTS ONE YEAR AFTER SUSTAINED VIROLOGICAL RESPONSE TO DIRECT ACTING ANTIVIRALS.**Mattia Crespi, Italy; Demarzo M. G.; Bodini G.; Furnari M.; Marabotto E.; Zentilin P.; Savarino V.; Giannini E. G.

P0678

**A REPORT OF EFFICACY AND SAFETY OF THERAPY WITH OMBITASVIR, PARITAPREVIR/ R+DASABUVIR+RIBAVIRIN IN 5853 PATIENTS WITH LIVER CIRRHOSIS**Carmen Monica Preda, Romania; Baicus C.; Popescu C.; Sandra I.; Voiosu T. A.; Ceausu E.; Pop C. S.; Proca D.; Oproiu A.; Diculescu M.; Manuc M.P0679 **FROM ALFA-INTERFERON TO DAAS: IMPACT ON HOSPITALIZATION RATE FOR HCV LIVER RELATED DISEASES FROM 2000 TO 2016 IN NORTH EST ITALY**Diego Caroli, Italy; Saia M.; Rosa-Rizzotto E.; Scribano L.; De Lazzari F.; Lobello S.

P0680

**HIGH EFFICACY OF THE CURRENTLY RECOMMENDED REGIMENS OF 2 DIRECT ACTING ANTIVIRALS (DAAS-)+RIBAVIRIN (R) IN HCV GENOTYPE 4 (GT4) PATIENTS (PTS) WITH ADVANCED FIBROSIS OR CIRRHOSIS IN HERACLIS REAL-WORLD COHORT**Ioannis Goulis, Greece; Elefsiniotis I.; Karatapanis S.; Koskinas J.; Ioannidou P.; Manolakopoulos S.; Vlachogiannakos J.; Oikonomopoulou M.; Samonakis D.; Manesis E.; Deutsch M.; Kapatais A.; Dalekos G.; Sinakos E.; Schina M.; Sevastianos V.; Ketikoglou I.; Vassiliadis T.; Alexopoulou A.; Triantos C.; Papadopoulos N.; Mimidis K.; Papageorgiou M.-V.; Koukoufiki A.; Petalidis I.; Barla G.; Kranidioti H.; Karagiannakis D.; Ntetskas G.; Koulentaki M.; Karaoulani T.; Saitis A.; Lymberopoulos D.; Mpellou A.; Tsolias C.; Mylopoulou T.; Voulgaris T.; Kourikou A.; Koulias E.; Akriviadis E.; Cholongitas E.; Papatheodoridis G.

P0681 

**IMMEDIATE DIRECT-ACTING ANTIVIRAL THERAPY (DAA) OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION IMPROVES POST-TRANSPLANT SURVIVAL: SINGLE CENTRE EXPERIENCE (2014-2017).**  
Frankova S.; Sperl J.; Chmelova K.; Senkerikova R.; Merta D.; Kreidlova M.; [Julius Spicak](#), Czech Republic

P0682

**EFFICACY AND SAFETY OF DASABUVIR, OMBITASVIR, PARITAPREVIR AND RITONAVIR TREATMENT IN ROMANIAN PATIENTS WITH HEPATITIS C, WITH MULTIPLE CO-MORBID CONDITIONS AND ADVANCE FIBROSIS**  
[Liliana Baroiu](#), Romania; Baroiu N.; Drăgănescu M.; Debita M.; Iancu A. V.; Arbune M.

P0683

**HEPATITIS C SCREENING PROGRAMME IN MILITARY MEDICAL ACADEMY, SOFIA, BULGARIA – SINGLE CENTRE EXPERIENCE**  
[Marieta Simonova](#), Bulgaria; Popov R.; Mekushinov K.; Kunchev M.; Gotzeva A.; Mutafchiyski V.; Katzarov K.

### Acute liver failure, transplantation/surgery

P0684

**PROCALCITONIN AS EARLY PREDICTOR OF ACUTE LIVER INJURY IN ACETAMINOPHEN POISONING – A PROSPECTIVE COHORT STUDY IN 116 PATIENTS**  
[Alexandre Nuzzo](#), France; Salem S.; Malissin I.; Goury A.; Voicu S.; Deye N.; Gourelain H.; Labat L.; Laplanche J.-L.; Vicaut E.; Mégarbane B.

P0685

**POST-TRANSPLANT DE NOVO MALIGNANCIES: IS HCC AN ADDITIONAL RISK FACTOR?**  
[Sarah Shalaby](#), Italy; Taborelli M.; Boccagni P.; Zanetto A.; Ferrarese A.; Becchetti C.; Sciarrore S. S.; Gambato M.; Germani G.; Senzolo M.; Russo F. P.; Zanusi G.; Cillo U.; Piselli P.; Serraino D.; Burra P.

P0686

**ASSOCIATION OF TOLL-LIKE RECEPTOR -2 GENETIC POLYMORPHISM AND ITS SERUM LEVEL WITH INFECTION IN RECIPIENTS AFTER LIVING DONOR LIVER TRANSPLANTATION :A SINGLE CENTRE STUDY.**  
[Mahmoud El-Bendary](#), Egypt; Naemattalah M.; Yassen A.; Mousa N. H.; Sultan A. M.; Abdel-Wahab M.

P0687

**PROTECTIVE EFFECT OF APELIN PRECONDITIONING IN A RAT MODEL OF HEPATIC ISCHEMIA REPERFUSION INJURY; POSSIBLE INTERACTION BETWEEN APELIN/APJ SYSTEM, ANGIOTENSIN II/ANGIOTENSIN I RECEPTOR (ANG II/AT1R) SYSTEM AND ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS)**  
[Nagwa Ramadan](#), Egypt; Sabry M.; Al-Drainy B.; Rashed L. A.; Abo-El-Enein A.

P0688

**CORRELATES OF MORTALITY IN PATIENTS ON WAITING LIST OF LIVER TRANSPLANTATION: A 4 YEARS PROSPECTIVE COHORT STUDY**  
[Kamran Bagheri Lankarani](#), Iran; Honarvar B.; Raeisi Shahrahi H.; Seifi V.; Geramizadeh B.; Salahi H.; Nikeghbalian S.; Shamsaefar A.; Malekhosseini S. A.

P0689

**METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION: LONG-TERM FOLLOW UP IN A PROSPECTIVE COHORT**  
[Chiara Becchetti](#), Italy; Ferrarese A.; Zanetto A.; Sciarrore S. S.; Shalaby S.; Ruzzarin A.; Zeni N.; Senzolo M.; Gambato M.; Russo F. P.; Burra P.; Germani G.

P0690

**GENDER DISPARITY IN DONOR-RECIPIENT IN LIVER TRANSPLANTATION AND GRAFT FAILURE**  
[Ana Laranjo](#), Portugal; Saraiva S.; Sousa X.; Fernandes A.; Perdigoto R.; Barroso E.; Marcelino P.

### Liver neoplasia: Clinical

P0691

**IMPACT OF ENTECAVIR IN REDUCING THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B RELATED CIRRHOSIS**  
[Yosra Said](#), Tunisia; Mensi A.; El Jeri K.; Khedher S.; Bouguerra C.; Debbeche R.

P0692 

**HEPATOCELLULAR CARCINOMA IN THE ELDERLY: CLINICAL CHARACTERISTICS, OUTCOMES AND TREATMENT EFFICACY, SAFETY IN OLDER THAN 75 YEARS**  
[Ji Ho Seo](#), Republic of Korea; Kim D. H.; Cho E.; Jun C. H.; Park S. Y.; Cho S. B.; Park C. H.; Kim H. S.; Choi S. K.; Rew J. S.

P0693

**WITHDRAWN**

P0694

**IS THERE STILL A ROLE FOR ALPHA-FETOPROTEIN IN HEPATOCELLULAR CARCINOMA SCREENING?**  
[João Carlos Silva](#), Portugal; Silva A. P.; Leite S.; Fernandes S.; Ponte A.; Rodrigues J.; Sousa M.; Ribeiro Gomes A. C.; Carvalho J.

P0695

**CANCER-ASSOCIATED FIBROBLASTS PROMOTE THE CANCER STEM CELL PLASTICITY OF CD24+ LIVER STEM CELLS VIA PARACRINE SIGNALLING**  
Cheng B.; [Yawen Li](#), China; Wang R.

P0696

**LIVER STIFFNESS AS A PREDICTOR OF HEPATOCELLULAR CARCINOMA BEHAVIOR IN PATIENTS WITH HEPATITIS C RELATED LIVER CIRRHOSIS**  
[Sameh Aldesoky Lashen](#), Egypt; El-shafae M. M.

P0697

**CAPECITABINE IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER EXPERIENCE**

[Filippo Pelizzaro](#), Italy; [Sammarco A.](#); [Pastorelli D.](#); [Giovanis P.](#); [Lombardi G.](#); [Dadduzio V.](#); [Peserico G.](#); [Imondi A.](#); [Sartori A.](#); [Maddalo G.](#); [Farinati F.](#)

P0698

**"TORONTO HCC RISK INDEX" USEFUL TO PREDICT HEPATOCELLULAR CARCINOMA IN ALL PATIENTS WITH CIRRHOSIS, REGARDLESS OF ETIOLOGY?**

[Rui Gaspar](#), Portugal; [Patita M.](#); [Andrade P.](#); [Macedo G.](#)

P0699

**COMBINED BLOOD INDICES AND MELD SCORE AS PROGNOSTIC PREDICTORS FOR EARLY RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER TRANS-ARTERIAL CHEMOEMBOLIZATION**

[Elalfy H.](#); [Besheer T.](#); [Abd El Maksoud M.](#); [Farid K.](#); [Elegezy M.](#); [Ahmed Mohammed El Sayed Ahmed](#), Egypt; [AbdelAziz M.](#); [Abd El Khalik A.](#); [Elmorsy A.](#); [Elmokadem A.](#); [El Samanoudy A.](#); [El-Bendary M.](#)

**Liver health services research**

P0700

**QUALITY OF SLEEP IN PATIENTS WITH LIVER TRANSPLANT: A MULTICENTER, PROSPECTIVE STUDY IN A COHORT FROM SOUTH ITALY**

[Antonella Santonicola](#), Italy; [Caputo C.](#); [Coppola C.](#); [Staiano L.](#); [Iovino P.](#); [Ciacci C.](#)

P0701

**TRANSLATING POLICY TO REAL WORLD IN RARE LIVER DISEASES REGISTRIES; A EUROPEAN PERSPECTIVE**

[Marinos Pericleous](#), United Kingdom; [Kelly C.](#); [de Lusignan S.](#); [Ala A.](#)

P0702

**TRACK & TRACE: RESULTS FROM A RETRIEVAL STRATEGY TO IDENTIFY LOST TO FOLLOW-UP CHRONIC HEPATITIS C PATIENTS.**

[Munsterman I.](#); [Marleen van Dijk](#), The Netherlands; [van Berlo J.](#); [Rahamat-Langendoen J.](#); [Drenth J. P. H.](#); [Tjwa E. T. T. L.](#)

P0703 **TREND IN HOSPITALIZATION RATE FOR ALCOHOL HEPATITIS IN VENETO REGION (NORTHEAST ITALY)**

[Rosa-Rizzotto E.](#); [Diego Caroli](#), Italy; [Saia M.](#); [Vicario S.](#); [Lobello S.](#)

P0704

**DEFINING AND CHARACTERISING THE BLUEPRINT FOR THE DEVELOPMENT OF A SUCCESSFUL REGISTRY FOR RARE LIVER DISEASES**

[Marinos Pericleous](#), United Kingdom; [Kelly C.](#); [de Lusignan S.](#); [Ala A.](#)

P0705

**OBESITY STARTS WITH THE ACCUMULATION OF FAT IN THE SUBCUTANEOUS ADIPOSE TISSUE IN ASSOCIATION WITH NONALCOHOLIC FATTY LIVER DISEASE**

[Yasushi Imamura](#), Japan; [Mawatari S.](#); [Kure T.](#); [Oda K.](#); [Kumagai K.](#); [Hiramine Y.](#); [Miyahara H.](#); [Kanmura S.](#); [Moriuchi A.](#); [Uto H.](#); [Horiuchi M.](#); [Ido A.](#)

**Biliary neoplasia: Clinical**

P0706

**EUS-FNA FOR EXTRAHEPATIC CHOLANGIOCARCINOMA IS A SAFER TISSUE SAMPLING METHOD THAN ERCP**

[Takumi Onoyama](#), Japan; [Matsumoto K.](#); [Takeda Y.](#); [Kawata S.](#); [Kurumi H.](#); [Koda H.](#); [Yamashita T.](#); [Ikebuchi Y.](#); [Kawaguchi K.](#); [Yashima K.](#); [Isomoto H.](#)

P0707 **CLINICAL UTILITY OF NEWLY DEVELOPED MICROFLUIDIC DEVICE FOR DETECTING CIRCULATING TUMOR CELLS IN THE BLOOD OF PANCREATIC-BILIARY MALIGNANCIES.**

[Naoki Konno](#), Japan; [Suzuki R.](#); [Takagi T.](#); [Sugimoto M.](#); [Sato Y.](#); [Irie H.](#); [Hikichi T.](#); [Watanabe K.](#); [Nakamura J.](#); [Takasumi M.](#); [Hashimoto M.](#); [Ohira H.](#)

P0708

**PERORAL CHOLANGIOSCOPY BY SPYGLASS DS VERSUS CHF-B260 FOR EVALUATION OF THE LATERAL SPREAD OF EXTRAHEPATIC CHOLANGIOCARCINOMA**

[Yoshihide Kanno](#), Japan; [Koshita S.](#); [Ogawa T.](#); [Kusunose H.](#); [Masu K.](#); [Sakai T.](#); [Yonamine K.](#); [Kawakami Y.](#); [Fujii Y.](#); [Murabayashi T.](#); [Kozakai F.](#); [Noda Y.](#); [Ito K.](#)

P0709

**RISK FACTORS FOR RECURRENT BILIARY OBSTRUCTION AFTER ENDOSCOPIC METALLIC STENT PLACEMENT IN PATIENTS WITH UNRESECTABLE MALIGNANT DISTAL BILIARY OBSTRUCTION**

[Takahisa Ogawa](#), Japan; [Ito K.](#); [Koshita S.](#); [Kanno Y.](#); [Masu K.](#); [Kusunose H.](#); [Sakai T.](#); [Yonamine K.](#); [Kawakami Y.](#); [Fujii Y.](#); [Murabayashi T.](#); [Kozakai F.](#); [Noda Y.](#)

P0710

**PREOPERATIVE BILIARY DRAINAGE USING PLASTIC STENTS VERSUS SELF-EXPANDABLE METAL STENTS FOR PERIAMPULLARY CANCER**

[Haruka Toyonaga](#), Japan; [Taniguchi Y.](#); [Wada M.](#); [Inokuma T.](#)

**Biliary health services research**

P0711

**ASSOCIATION BETWEEN APPENDECTOMY AND RISK OF PRIMARY SCLEROSING CHOLANGITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS**

[Wijarnpreecha K.](#); [Pascale Raymond](#), United States; [Panjawatanan P.](#); [Mousa O.](#); [Cheungpasitporn W.](#); [Pungpapong S.](#); [Ungprasert P.](#)

P0712

**SERVICE EVALUATION OF A DEDICATED PSC PROGRAMME: IDENTIFYING NEEDS AND BARRIERS TO TRANSITIONING TO A 21ST CENTURY APPROACH TO CARE.**

Katherine Arndtz, United Kingdom; Parry J.; Ferguson J.; Hirschfield G.

P0713

**INVESTIGATING THE ACCEPTABILITY TO PATIENTS OF INTRODUCING A VIRTUAL CLINIC INTO TERTIARY HEPATOLOGY OUTPATIENT CARE: AN AUDIT OF PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS**

Katherine Arndtz, United Kingdom; O'Connell Franschichetto E.; Rahman F.; Damery S.; Combes G.; Parry J.; Ferguson J.; Hirschfield G.

**Poster Session**

09:00 - 17:00

Hall X1

**Paediatric: Liver, Biliary and Pancreas****Paediatric liver disease**P0714 **ASSESSMENT OF RISK FACTORS OF POST-PARACENTESIS CIRCULATORY DYSFUNCTION WITH MULTIPLE LARGE VOLUME PARACENTESIS IN CHILDREN WITH CHRONIC LIVER DISEASE: PROSPECTIVE LONGITUDINAL STUDY**  
Moinak Sen Sarma, India; Yachha S. K.; Bhatia V.; Srivastava A.

P0715

**HEMODYNAMIC CHANGES IN THE VESSELS OF THE ABDOMINAL CAVITY IN THE POSTPRANDIAL PHASE IN HEALTHY CHILDREN**Olga Zaytseva, Russian Federation; Spivak E.; Akkuratova I.

P0716

**THE NATURE OF THE HEMODYNAMIC CHANGES OF THE ABDOMINAL CAVITY IN CYSTIC FIBROSIS IN CHILDREN**Eugeniy Spivak, Russian Federation; Zaytseva O.P0717 **PEDIATRIC SUB-ACUTE HEPATIC FAILURE IN DEVELOPING COUNTRIES: RISK FACTORS THAT DETERMINE OUTCOME**Moinak Sen Sarma, India; Singh S. K.; Yachha S. K.; Srivastava A.; Poddar U.**Paediatric biliary disease**

P0718

**CONGENITAL DILATATION OF THE BILIARY TRACT: RADIOLOGICAL ASPECTS AND THERAPEUTIC MANAGEMENT**Meriam S.; Roua Kallel, Tunisia; Bibani N.; Kchaou-Ouakaa A.; Trad D.; Rym K.; Elloumi H.; Gargouri D.; Kharrat J.**Poster Session**

09:00 - 17:00

Hall X1

**Pancreas II****Pancreatitis, acute**

P0719

**ANTIBIOTICS IN ACUTE PANCREATITIS IN THE LAST YEARS - EXPERIENCE OF A TERTIARY REFERRAL CENTER**  
Joana Rita Carvalho, Portugal; Fernandes S. R.; Antunes M. T.; Velosa J.; Marinho R. T.

P0720

**PREDICTIVE NATURE AND CLINICAL CHARACTERISTICS OF PAIN ON ADMISSION IN ACUTE PANCREATITIS**  
Mária Földi, Hungary; Bajor J.; Vincze A.; Gede N.; Török I.; Varjú P.; Crai S.; Novák J.; Szabó I.; Ramirez Maldonado E.; Sümegy J.; Fehér E.; Vitális Z.; Gajdán L.; Szepes Z. G.; Hamvas J.; Izbéki F.; Szentesi A.; Párniczky A.; Hegyi P.

P0721

**PRE-EXISTING DIABETES ELEVATES RISK OF RENAL FAILURE AND LOCAL COMPLICATIONS IN ACUTE PANCREATITIS**Alexandra Mikó, Hungary; Farkas N.; Hegyi P.; Czakó L.

P0722

**ALTERED LEVEL OF CONSCIOUSNESS DETERIORATES THE SEVERITY OF ACUTE PANCREATITIS**Alexandra Mikó, Hungary; Vincze A.; Izbéki F.; Gervain J.; Gódi S.; Illés A.; Sarlós P.; Farkas N.; Illés D.; Varjú P.; Márta K.; Torok I.; Vitális Z.; Bod B.; Hamvas J.; Szepes Z. G.; Takács T.; Szentesi A.; Parniczky A.; Hegyi P.

P0723

**OPPOSITE EFFECTS OF YOUNGER AND OLDER AGES ON SEVERITY AND MORTALITY IN ACUTE PANCREATITIS. A META-ANALYSIS BASED ON 191 678 PATIENTS**Katalin Márta, Hungary; Lazarescu A. M.; Farkas N.; Cazacu I.; Ottóffy M.; Hegyi P.

P0724

**CLINICAL EVALUATION OF INTERVENTIONAL EUS DRAINAGE AND SEQUENTIAL DIRECT ENDOSCOPIC NECROSECTOMY USING A NEW BIFLANGED METAL STENT FOR PANCREATIC FLUID COLLECTION**Hiroyuki Kojima, Japan; Itoi T.; Sofuni A.; Tsuchiya T.; Tanaka R.; Tonozuka R.; Honjo M.; Mukai S.; Fujita M.; Yamamoto K.; Matsunami Y.; Asai Y.; Kurosawa T.

P0725

**METABOLIC SYNDROME ELEVATES THE RISK FOR MORTALITY AND SEVERITY IN ACUTE PANCREATITIS.**Andrea Szentesi, Hungary; Parniczky A.; Vincze A.; Bajor J.; Gódi S.; Sarlós P.; Gede N.; Izbéki F.; Halász A.; Illés D.; Kui B.; Márta K.; Dobszai D.; Torok I.; Papp M.; Varga M.; Hamvas J.; Czakó L.; Takács T.; Hegyi P.



P0726

**NSAIDS AMELIORATES PANCREAS INJURY AND INHIBITS INFLAMMATORY CYTOKINES IN RAT POST-ERCP PANCREATITIS**Geng C.; Li X.; Lei X.; [Chunhui Wang](#), ChinaP0727 **CHRONIC USE OF STATINS AND AMINOSALICYLIC ACID AND INCIDENCE OF POST-ERCP ACUTE PANCREATITIS. PRELIMINARY DATA FROM THE STARK STUDY, A PROSPECTIVE INTERNATIONAL, MULTICENTER, COHORT STUDY**[Karina Cárdenas Jaén](#), Spain; [Archibugi L.](#); [Poropat G.](#); [Korpela T.](#); [Capurso G.](#); [Aparicio J. R.](#); [Casellas J. A.](#); [Di Giulio E.](#); [Vanella G.](#); [Stimac D.](#); [Hauser G.](#); [Udd M.](#); [Kylänpää L.](#); [Arcidiacono P. G.](#); [Mariani A.](#); [de Madaria E.](#)

P0728

**META-ANALYSIS AND TRIAS SEQUENTIAL ANALYSIS OF PROPHYLACTIC ANTIBIOTICS FOR ACUTE PANCREATITIS**[Goran Poropat](#), Croatia; [Kresovic A.](#); [Lackovic A.](#);[Loncaric A.](#); [Marusic M.](#); [Stimac D.](#)

P0729

**SERUM TATI, TRYPSINOGENS 1-3, AND COMPLEX OF TRYPSIN-2 AND  $\alpha_1$ -ANTITRYPSIN IN THE DIAGNOSIS OF ACUTE PANCREATITIS**[Mia Rainio](#), Finland; [Lindström O.](#); [Penttilä A.](#); [Itkonen O.](#); [Kempainen E.](#); [Stenman U.-H.](#); [Kylänpää L.](#)**Pancreatic cancer: Basic**

P0730

**INFLAMMATION PLAYS A KEY ROLE IN PANCREATIC CARCINOGENESIS INDUCED BY ELECTROPORATION**[Xintong Jia](#), China; [Tu Q.](#); [Tang S.](#); [Gan C.](#); [Zhao X.](#); [Tang C.](#)

P0731

**INCREASED CATHEPSIN D EXPRESSION HAS A NEGATIVE PROGNOSTIC EFFECT ON SURVIVAL IN GEMCITABINE TREATED PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA**[Mahajan U. M.](#); [Elisabetta Goni](#), Germany; [Kruger S.](#); [Ormanns S.](#); [Beyer G.](#); [Weiss F. U.](#); [Kirchner T.](#); [Werner J.](#); [D'Haese J.](#); [von Bergwelt M.](#); [Heinemann V.](#); [Lerch M. M.](#); [Böck S.](#); [Mayerle J.](#)

P0732

**THE IMPORTANCE OF BIOMARKERS IN EARLY DIAGNOSIS OF PANCREATIC CANCER: GLYPICAN 1**[Malya F. U.](#); [Elmas Biberci Keskin](#), Turkey; [Köker I. H.](#); [Tüzün Ince A.](#); [Senturk H.](#)P0733 **RINT1 IS ESSENTIAL TO PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) HOMEOSTASIS**[Frank Arnold](#), Germany; [Kaminska E. K.](#); [Gout J.](#); [Perkhofer L.](#); [Frappart P.-O.](#); [Kleger A.](#)

P0734

**PANCREATIC CANCER AND PANCREATIC PRE-MALIGN LESIONS HAVE DISTINCT POLYAMINE PROFILE**[Samuli Ilpo Nissinen](#), Finland; [Roine A.](#); [Hakkinen M.](#); [Vepsäläinen J.](#); [Kumpulainen P.](#); [Venäläinen M.](#); [Oksala N.](#); [Rantanen T.](#)

P0735

**PROBE BASED CONFOCAL LASER ENDOMICROSCOPY ASSESSMENT OF PANCREATIC DUCTAL ADENOCARCINOMA, N EX-VIVO STUDY WITH PATHOLOGICAL CORRELATION**[Bogdan Ungureanu](#), Romania; [Pirici D.](#); [Dima S. O.](#); [Popescu I.](#); [Gheonea D.-I.](#); [Ciurea T.](#); [Surlin V.](#); [Saftoiu A.](#)**Pancreatic cancer: Clinical**P0736 **PANCREATIC CYST SURVEILLANCE IMPOSES LOW PSYCHOLOGICAL BURDEN: PRELIMINARY RESULTS OF THE PACYFIC STUDY**[Kasper Alexander Overbeek](#), The Netherlands; [Kamps A.](#); [Van Riet P. A.](#); [Di Marco M. C.](#); [Zerboni G.](#); [Van Hooft J. E.](#); [Carrara S.](#); [Ricci C.](#); [Gonda T. A.](#); [Schoon E. J.](#); [Polkowski M.](#); [Beyer G.](#); [Honkoop P.](#); [Van der Waaij L.](#); [Casadei R.](#); [Capurso G.](#); [Bruno M. J.](#); [Bleiker E. M. A.](#); [Cahen D. L.](#)

P0737

**PANCREATIC DUCTAL ADENOCARCINOMA RESECTABILITY ASSESSMENT: WHAT ARE THE REALLY REQUIRED PREOPERATIVE IMAGING MODALITIES?**[Mohammed Tag-Adeen](#), Egypt; [Ozawa E.](#); [Ohnita K.](#); [Adachi T.](#); [Sumida Y.](#); [Hassan M.](#); [Nakao K.](#)

P0738

**PROGNOSTIC SIGNIFICANCE OF ADIPOSE TISSUE-DERIVED HORMONS IN PANCREATIC CANCER PATIENTS**[Aida Saray](#), Bosnia and HerzegovinaP0739 **K-RAS MUTATION ANALYSIS BY DIGITAL PCR IN EUS-GUIDED FNA CYTOLOGY SPECIMENS AND CTDNA IMPROVE PANCREATIC CANCER DIAGNOSIS**[Ronghua Wang](#), China; [Cheng B.](#); [Wang J.](#)

P0740

**COST-EFFECTIVENESS OF PANCREATIC CANCER SURVEILLANCE IN HIGH-RISK INDIVIDUALS: AN ECONOMIC ANALYSIS**[Juan E Corral](#), United States; [Das A.](#); [Bruno M. J.](#); [Wallace M. B.](#)

P0741

**IMPACT OF INCONCLUSIVE OR NEGATIVE ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION RESULTS IN THE MANAGEMENT OF SUSPICIOUS SOLID PANCREATIC MASSES**[Rui Gaspar](#), Portugal; [Andrade P.](#); [Moutinho Ribeiro P.](#); [Vilas Boas F.](#); [Lopes S.](#); [Barroca H.](#); [Lopes J.](#); [Carneiro F.](#); [Macedo G.](#)

P0742

**SURVIVAL TRENDS FOR RESECTABLE PANCREATIC CANCER USING A MULTIDISCIPLINARY CONFERENCE**

Aslam Syed, United States; Garg M.; Moussaide G.; Farah K.; Morrissey S.; Dhawan M.; Kulkarni A.; Mitre M.; Thakkar S.

P0743 **A COMPOSITE LIQUID BIOMARKER FOR NON-INVASIVE DIAGNOSIS OF RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA**

Thomas J. Ettrich, Germany; Berger A. W.; Reinacher-Schick A.; Algül H.; König A.; Gallmeier E.; Wille K.; Daum S.; Geissler M.; Tannapfel A.; Uhl W.; Seufferlein T.

P0744

**EARLY DETECTION OF PANCREATIC CANCER IN PATIENTS WITH CHRONIC LIVER DISEASE UNDER SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA: A RETROSPECTIVE COHORT STUDY FROM JAPAN**

Yoshiki Imamura, Japan; Kumagi T.; Terao T.; Yokota T.; Azemoto N.; Kuroda T.; Uesugi K.; Kisaka Y.; Tanaka Y.; Shibata N.; Koizumi M.; Ohno Y.; Yukimoto A.; Tange K.; Nishiyama M.; Miyake T.; Miyata H.; Hiasa Y.

**Endocrine tumours of the pancreas**

P0745

**IMAGING AND HISTOLOGICAL DIAGNOSTIC ABILITY OF PANCREATIC NEUROENDOCRINE NEOPLASMS LESS THAN 20 MM IN SIZE**

Yukiko Takigawa, Japan; Kin T.; Utsunomiya R.; Tanaka K.; Nagai K.; Kobayashi Y.; Yane K.; Hayashi T.; Takahashi K.; Katanuma A.

P0746

**IGF2BP RNA-BINDING PROTEINS: POTENTIAL REGULATORS OF EPIGENETIC FACTORS IN PANCREATIC NEUROENDOCRINE TUMOR-CELLS**

Florian Sperling, Germany; Nietfeld L.; Michl P.; Griesmann H.

P0747

**EXENDIN-IRDYE700DX FOR PHOTODYNAMIC THERAPY OF GLP-1R POSITIVE LESIONS**

Marti Boss, The Netherlands; Brom M.; Bos D.; Frielink C.; Bronkhorst P.; Buitinga M.; Gotthardt M.

P0748

**LOCALIZATION OF INSULINOMAS WITH 68GA-NODAGA-EXENDIN-4 PET/CT**

Marti Boss, The Netherlands; Mikkola K.; Buitinga M.; Brom M.; Wild D.; Prasad V.; Brouwers A.; Pattou F.; Nuutila P.; Gotthardt M.

P0749

**CLINICAL AND PATHOLOGICAL CHARACTERIZATION OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS: RETROSPECTIVE SINGLE-CENTER STUDY.**

Miguel Saraiva, Portugal; Dias E.; Moutinho Ribeiro P.; Macedo G.

P0750

**THE DIAGNOSTIC YIELD OF EUS-GUIDED FINE-NEEDLE ASPIRATION REGARDING PANCREATIC NEUROENDOCRINE NEOPLASM**

Nakamura K.; Okamoto T.; Ikeya T.; Takasu A.; Fukuda K.; Yoshiyuki Fujita, Japan

**Poster Session**

09:00 - 17:00

Hall X1

**Endoscopy and Imaging II****Endoscopy, upper GI**

P0751

**ENDOSCOPIC APPLICATION OF AUTOLOGOUS PLATELET RICH PLASMA ON GASTRIC ULCER AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION: A PILOT STUDY**

In Tae So, Republic of Korea; Lee Y. J.; Choi J. H.; Lee S. Y.; Lee J. Y.; Lee H. J.; Kim E.-S.; Park K. S.; Cho K.-B.

P0752

**ENDOSCOPIC VACUUM THERAPY FOR THE TREATMENT OF UPPER GASTROINTESTINAL TRANSMURAL DEFECTS: INITIAL EXPERIENCE**

Rui Morais, Portugal; Rodrigues-Pinto E.; Liberal R.; Gaspar R.; Fernandes C.; Vilas Boas F.; Pereira P. R.; Macedo G.

P0753

**A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL OF VONOPRAZAN VERSUS LANSOPRAZOLE IN THE TREATMENT OF ARTIFICIAL GASTRIC ULCERS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION.**

Mikako Ishiguro, Japan; Takenaka R.; Kawai D.; Takei K.; Miura K.; Takemoto K.; Tsugeno H.; Fujiki S.

P0754

**THE EFFECTIVENESS AND SAFETY OF ORAL PHLOROGLUCIN AS PREMEDICATION FOR NON-SEDATIVE ESOPHAGOGASTRODUODENOSCOPY: A DOUBLE BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL.**

Jung H. I.; Yoo-Jin Lee, Republic of Korea; So I. T.; Lee S. Y.; Lee J. Y.; Lee H. J.; Cho K.-B.; Park K. S.

P0755

**RISK FACTORS ASSOCIATED WITH TREATMENT FAILURE OF SOFT-MODE THERMAL COAGULATION FOR BLEEDING PEPTIC ULCERS**

Kensuke Takei, Japan; Takenaka R.; Miura K.; Kawai D.; Takemoto K.; Tsugeno H.; Fujiki S.

P0756

**LAUNCHING AN ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) PROGRAM IN A EUROPEAN ACADEMIC HOSPITAL: REVIEW OF THE FIRST 34 MONTHS OF EXPERIENCE.**Arnaud Lemmers, Belgium; Huberty V.; Bucalau A.-M.; Musala C.; Demetter P.; Verset L.; Van Laethem J.-L.; Buggenhout A.; El Nakadi I.; Deviere J.P0757 **A COMPARISON STUDY WITH ENDOSCOPIC ROBOT MANIPULATOR IN ESD : NOVICE AND EXPERT**Yoon-Tae Jeon, Republic of Korea; Jeon H. J.; Jang S. H.; Kim S. H.; Kim J. H.; Choi S. J.; Lee J. M.; Kim S. H.; Lee J. M.; Choi H.-S.; Kim E.-S.; Keum B.; Lee H.; Chun H.-J.; Kim C. D.

P0758

**DOES SECOND-LOOK ENDOSCOPY PREVENT POSTOPERATIVE BLEEDING IN HIGH-RISK PATIENTS AFTER GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION?: A PROPENSITY SCORE-MATCHING ANALYSIS**Kentaro Ishikawa, Japan; Maruoka D.; Arai M.; Matsumura T.; Akizue N.; Okimoto K.; Nakagawa T.; Kato N.

P0759

**OLGA AND OLGIM STAGE ACCORDING TO AGE AND RISK FACTORS INFLUENCE HIGH RISK OF GASTRIC CANCER**Zhang M.; Bin Lv, China

P0760

**ARGON PLASMA COAGULATION FOR SUPERFICIAL SQUAMOUS CELL CARCINOMA IN THE RESIDUAL ESOPHAGUS AFTER ESOPHAGECTOMY**Kohei Saisho, Japan; Tanaka T.; Matono S.; Naoki M.; Haruhiro H.; Yoshito A.

P0761

**THE EFFECTIVENESS OF "HANDMADE MULTI-BENDING SYSTEM OF THE ENDOSCOPE" FOR ENDOSCOPIC SUBMUCOSAL DISSECTION OF THE DIFFICULT-TO-APPROACH SUPERFICIAL GASTRIC NEOPLASMS**Katsumi Yamamoto, Japan; Tanaka K.; Hayashi S.; Tatsumi N.; Michida T.; Ito T.P0762 **CLINICAL EFFICACY OF THE OVER-THE SCOPE CLIP DEVICE: A SYSTEMATIC REVIEW**Nicholas Bartell, United States; Rajabalan A.; Kaul V.; Kothari T.; Bittner K.; Kothari S.

P0763

**CONFOCAL LASER ENDOMICROSCOPY IN THE ASSESSMENT OF PERSISTENT OR RECURRENT INTESTINAL METAPLASIA/NEOPLASIA AFTER ENDOSCOPIC TREATMENT OF BARRETT'S ESOPHAGUS RELATED NEOPLASIA**Jana Krajciová, Czech Republic; Kollar M.; Malusková J.; Kment M.; Vacková Z.; Spicak J.; Martinek J.

P0764

**THE ROLE OF ENDOSCOPIC DILATION AND STENTS IN THE REFRACTORY BENIGN ESOPHAGEAL STRICTURES: A RETROSPECTIVE ANALYSIS.**Lu Q.; Xiaonan Zhu, China; Ma H.; Yang J.

P0765

**ENDOSCOPIC SUBMUCOSAL DISSECTION IN EARLY GASTRIC CANCER WITH PAPILLARY HISTOLOGICAL TYPE**Jung-Hwan Lee, Republic of Korea; Kim Y.-I.; Lee J. Y.; Kim C. G.; Choi I. J.; Cho S.-J.P0766 **A STUDY OF THE POSSIBILITY OF COMPUTER-AIDED DIAGNOSIS USING MULTIPLE MACHINE LEARNING MODELS FOR THE DIAGNOSIS OF UPPER GASTROINTESTINAL ENDOSCOPIC IMAGING.**Ryoichi Yamakawa, Japan; Harada M.; Kawauchi K.; Nyuzuki S.; Iwata M.

P0767

**SIZE DISCREPANCY BETWEEN ENDOSCOPIC AND PATHOLOGIC ESTIMATES AFTER ESD IN GASTRIC EPITHELIAL NEOPLASM**Jinwoong Cho, Republic of Korea; Kim J.; Lee Y.; Yun S.; Yang M.; Kim B.

P0768

**THE DIAGNOSIS OF INVASION DEPTH IN SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA: EFFICACY OF ENDOSCOPIC ULTRASONOGRAPHY – A SINGLE CENTER TRIAL**Noriko Matsuura, Japan; Ishihara R.; Kanesaka T.; Shichijo S.; Maekawa A.; Takeuchi Y.; Higashino K.; Uedo N.

P0769

**EVALUATION OF FACTORS TO DECIDE ON ESD INDICATION FOR GASTRIC ADENOMAS DIAGNOSED WITH ENDOSCOPIC BIOPSY**Hideki Matsuo, Japan; Motokawa Y.; Oyama M.; Mori H.; Kubo T.; Shibamoto A.; Fujimoto Y.; Kobe D.; Aihara Y.; Nagamatsu S.; Uejima M.; Nakatani T.; Kikuchi E.; Tamura T.; Ishida E.

P0770

**HOW DOES LINKED COLOR IMAGE(LCI) WHICH IS ONE MODALITY OF IMAGE ENHANCED ENDOSCOPY(IEE) CONTRIBUTE TO DETECT OF THE MINUTE TO SMALL EARLY GASTRIC CANCER ? A PILOT STUDY**Tohru Itoh, Japan; Sadafumi A.; Ken K.; Michiyo T.; Junji K.; Lica K.; Kazu H.; Hidekazu K.

P0771

**COMPARATIVE STUDY OF ESD AND SURGICAL RESECTION FOR GASTRIC SETS ORIGINATED FROM MUSCULARIS PROPRIA**Chang Beom Ryu, Republic of Korea; Lee M. S.; Bae J. Y.

P0772

**SHOULD NARROW BAND IMAGING (NBI) BE ROUTINELY USED DURING ESOPHAGUS INSPECTION? A RANDOMIZED PROSPECTIVE STUDY.**Marcin Romańczyk, Poland; Romańczyk T.; Waluga M.; Bołdys H.; Hartleb M.

P0773

**EFFICACY OF HAEMOSPRAV THERAPY ON RE-BLEED AND MORTALITY RATES - A UK SINGLE CENTRE EXPERIENCE**Thazin Min, United Kingdom; Mothey M.; Sharrack N.; Panikkar M.; Agrawal A.

P0774

**MUCOSAL LOSS IS THE CRITICAL MECHANISM OF ESOPHAGEAL STRICTURE AFTER MUCOSAL RESECTION: A PILOT EXPERIMENT IN A PORCINE MODEL**Bingrong Liu, China; Ullah S.

P0775

**ENDOSCOPIC SUBMUCOSAL DISSECTION WITH SPLASH M-KNIFE: A SINGLE CENTER CONSECUTIVE CASE SERIES**Masayoshi Ono, Japan; Fujishiro M.; Tsuji Y.; Saito I.; Yoshida S.; Sakaguchi Y.; Minatsuki C.; Niimi K.; Yamamichi N.; Koike K.

P0776

**DEVELOPMENT AND VALIDATION OF ENDOSCOPIC PREDICTION MODEL FOR GASTRIC CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH RENAL TRANSPLANTATION**Seong Jae Yeo, Republic of Korea; Kim E.-S.; Jung M. K.; Kim S. K.; Lee H. S.; Lee J. S.; Lee S. W.; Lee Y.-J.; Han S.-Y.P0777 **AN AUSTRALIAN EXPERIENCE WITH ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) FOR WEIGHT LOSS**Graeme Rich, Australia; Gupta S.; Sud R.; Snazelle O.; Holtmann G.

P0778

**SURFACE IRREGULARITIES OCCURRING IN THE GASTRIC MUCOSA AFTER H. PYLORI ERADICATION MAKES IT DIFFICULT FOR ENDOSCOPIC DIAGNOSIS OF GASTRIC CANCER DETECTING.**Takuji Yamasaki, Japan; Chibai M.; Sakurai T.; Mitobe J.; Saruta M.; Sumiyama K.P0779 **COMBINED TREATMENT OF OVERWEIGHT WITH INTRA-GASTRIC BALLOON AND LIRAGLUTIDE AT HIGH DOSE: IS IT WORTH?**Ricardo Jose Fittipaldi-Fernandez, Brazil; Hoff A. C.

P0780

**PERCUTANEOUS ENDOSCOPIC GASTROSTOMY IN AMYOTROPHIC LATERAL SCLEROSIS WITH SEVERE VENTILATORY IMPAIRMENT**Rui Gaspar, Portugal; Coelho R.; Andrade P.; Gonçalves M.; Ramalho R.; Macedo G.**Endoscopy, colon**

P0781

**DIAGNOSTIC ACCURACY USING ARTIFICIAL INTELLIGENCE-ASSISTED ENDOCYTOLOGY FOR SESSILE SERRATED ADENOMA/POLYPS**Yushi Ogawa, Japan; Kudo S.; Mori Y.; Misawa M.; Takeda K.; Kataoka S.; Maeda Y.; Ichimasa K.; Ishigaki T.; Nakamura H.; Ogata N.; Kudo T.; Wakamura K.; Hayashi T.; Ishida F.; Inoue H.; Itoh H.; Oda M.; Mori K.

P0782

**A COMPARISON OF PERFORMANCE PARAMETERS FOR COLONOSCOPY FOR USING DIFFERENT ENDOSCOPY SYSTEMS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL**Cesare Hassan, Italy; Ratanachuek T.; Ge N.; Kashin S. V.; Neumann H.

P0783

**DIAGNOSTIC ABILITY OF BLUE LIGHT IMAGING FOR PREDICTING DEEP SUBMUCOSAL INVASION IN COL-ORECTAL LESIONS**Helmut Neumann, Germany; Grimminger P.; Rahman K. F.; Thieringer F.; Galle P. R.; Zimmermann T.; Tontini G. E.

P0784

**WITHDRAWN**

P0785

**EFFICACY AND SAFETY OF ETOMIDATE-MIDAZOLAM FOR SCREENING COLONOSCOPY IN ELDERLY: A PROSPECTIVE DOUBLE-BLINDED RANDOMIZED CONTROLLED STUDY**Lee J. M.; Choi S. J.; Jeon H. J.; Jang S.; Kim S. H.; Lee J. M.; Choi H. S.; Kim E. S.; Keum B.; Jeon Y. T.; Chun H. J.; Lee H. S.; Chang Duck Kim, Republic of Korea

P0786

**COMPARISON OF THE CLINICAL EFFICACY OF THE COLD SNARE POLYPECTOMY USING A THIN WIRE MINI-SNARE AND THICK WIRE MINI-SNARE FOR SMALL SIZE (5-8 MM) COLORECTAL POLYPS**Su Jung Han, Republic of Korea; Jung Y.; Huh K.-C.; Cho Y. S.; Chung I.-K.; Lee T. H.; Park S.-H.; Hwangbo Y.; Hong S. A.; Kim S.-J.

P0787

**USE OF WATER EXCHANGE (WE) FOR PERFORMANCE IMPROVEMENT TOWARDS ENHANCED ADENOMA DETECTION -- IS WE THERE YET?**Felix Leung, United States; Koo M.; Jia H.; Leung J.; Cadoni S.; Falt P.; Hsieh Y.-H.; Hu C.-T.; Pan Y.; Radaelli F.

P0788

**CAP-ASSISTED ENDOSCOPIC MUCOSAL RESECTION VERSUS ENDOSCOPIC SUBMUCOSAL DISSECTION FOR RECTAL NEUROENDOCRINE TUMORS: A MULTICENTER RETROSPECTIVE STUDY FROM CHINA**Yue Li, China; Liu Z.; Chen J.; Cheng B.; Li J.; Lin R.; Zhou L.; Chen Y.

P0789

**IMPROVED ENDOSCOPIC RESECTION OF LARGE FLAT LESIONS USING AN EXTERNAL ADDITIONAL WORKING CHANNEL (AWC)**Benjamin Walter, Germany; Schmidbaur S.; Hann A.; Meining A.

P0790

**CAN SERT SCORE PREDICT HISTOLOGICAL RECURRENCE IN PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION? COMPARATIVE STUDY WITH SMSA SCORE**João Carlos Silva, Portugal; Pinho R. T.; Silva A. P.; Ponte A.; Rodrigues J.; Sousa M.; Ribeiro Gomes A. C.; Carvalho J.

P0791

**CLINICAL OUTCOMES AND PATIENTS' SATISFACTION FOR NOVEL PATIENT REFERRAL SYSTEM CALLED 'SAME-DAY POLYPECTOMY'**Seung Yong Shin, Republic of Korea; Park J. J.; Park H.; Youn Y. H.; Kim J.-H.; Jung D. H.

P0792

**PHYSICIAN ADHERENCE TO SOCIETAL GUIDELINES FOLLOWING COLONOSCOPY WITH POLYPECTOMY**Jonathan Naftali, Israel; Half E.; Maza I.; Waterman M.; Yassin K.; Chermesh I.; Khamaysi I.; Yaccob A.; Brun R.; Saadi T.; Klein A.

P0793

**FACTORS INFLUENCING ACHIEVEMENT OF ADEQUATE BOWEL PREPARATION: ANALYSIS OF THE EUROPEAN COLONOSCOPY QUALITY INVESTIGATION GROUP (EQI) PROCEDURE QUESTIONNAIRE**Pedro Amaro, Portugal; Spada C.; Agrawal A.; Brink L.; Fischbach W.; Hüniger M.; Jover R.; Kinnunen U.; Koulaouzidis A.; Ono A.; Patai Á.; PetruzzIELLO L.; Toth E.; Curran V.; Riemann J. F.

P0794

**CLINICAL OUTCOME AFTER COLONOSCOPIC POLYPECTOMY OF PATIENTS TAKING DIRECT ORAL ANTICOAGULANTS: COMPARISON WITH CLOPIDOGREL**Gwang-Un Kim, Republic of Korea; Yang D.-H.; Kim J.; Oh E. H.; Ham N.; Song E. M.; Hwang S. W.; Park S. H.; Ye B. D.; Byeon J.-S.; Myung S.-J.; Yang S.-K.; Choe J.

P0795

**EFFECTIVENESS OF LIDOCAINE AS ANTISPASMODIC DRUGS DURING COLONOSCOPY: A MULTICENTER DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL**Hideki Mori, Japan; Nemoto D.; Suzuki S.; Katsuki S.; Iwaki T.; Aizawa M.; Takeuchi Y.; Uraoka T.; Matsuda T.; Fujita T.; Hewett D. G.; Togashi K.

P0796

**DEEP LEARNING FOR REAL-TIME AUTOMATED POLYP LOCALISATION IN COLONOSCOPY VIDEOS**Omer F. Ahmad, United Kingdom; Luengo I.; Herrera L.; Brandao P.; Li W.; Everson M.; Haidry R. J.; Vega R.; Seward E.; Vercauteren T.; Lovat L. B.

P0797

**USEFULNESS OF NBI MAGNIFYING ENDOSCOPY FOR DIAGNOSIS OF ADVANCED NEOPLASIA AMONG COL-ORECTAL LESIONS &LT; 10MM**Tatsuro Murano, Japan; Ikematsu H.; Shinmura K.; Ito R.; Kumahara K.; Sunakawa H.; Furue Y.; Sato D.; Minamide T.; Yamamoto Y.; Takashima K.; Yoda Y.; Hori K.; Oono Y.; Yano T.

P0798

**THE DIAGNOSTIC ARTIFICIAL INTELLIGENCE (AI) SYSTEM FOR DETECTION OF COLON POLYPS WITH HIGH EFFICIENCY OF DEEP LEARNING**Keisuke Hori, Japan; Ikematsu H.; Shinmura K.; Yoda Y.; Ohno Y.; Sakai Y.; Takemoto S.; Yokota H.; Yano T.

P0799

**A RANDOMISED CONTROLLED STUDY OF THE PREDICTION OF DIMINUTIVE/SMALL POLYP HISTOLOGY USING DIDACTIC VS. COMPUTER BASED SELF-LEARNING MODULE IN GASTROENTEROLOGY TRAINEES**Samuel Smith, United Kingdom; Saltzman J.; Shivaji U.; Lethebe B.; Bannaga A.; Kumar A.; McCulloch A.; Polewiczowska B.; Geh D.; Tahir F.; Baker G.; Fowler H.; O'Rourke J.; Qurashi M.; Widlak M. M.; Harvey P.; Lim P.; Khan S.; Gupta T.; Ghosh S.; Iacucci M.

P0800

**ENDOSCOPIC SUBMUCOSAL RESECTION (ESR) - INNOVATIVE METHOD AND INSTRUMENTS FOR RESECTION OF BIG LESIONS IN THE GIT**Klaus Metter, Germany; Farin G.; Bader A.; Faller M.; Haspel J.; Lubczyk V.; Riedl S.; Ruf E.; Grund K. E.

P0801

**MELANOSIS COLI: A HELPFUL CONTRAST EFFECT OR A HARMFUL PIGMENTATION?**Fadi Abu Baker, Israel; Mari A.; Feldman D.; Kopelman Y.

P0802

**THE PRESENCE OF A GASTROENTEROLOGY TRAINEE DURING COLORECTAL CANCER SCREENING COLONOSCOPY IMPROVES ADHERENCE TO QUALITY INDICATORS**Joana Rita Carvalho, Portugal; Brito M.; Noronha Ferreira C.; Gonçalves A. R.; Carrilho-Ribeiro L.; Velosa J.; Marinho R. T.

P0803

**COMPARISON OF NEWER COLONOSCOPY DEVICES WITH STANDARD FORWARD VIEWING (SFV) HIGH DEFINITION COLONOSCOPES IN DAILY PRACTICE**Martin Geyer, Switzerland; Leiner D.; Bannwart F.

P0804

**THE OBJECTIVE EVALUATION USING EYE TRACKING FOR VISIBILITY OF COLORECTAL LESIONS.**Kana Kumahara, Japan; Ikematsu H.; Sunakawa H.; Furue Y.; Ito R.; Satou D.; Minamide T.; Okamoto N.; Yamamoto Y.; Takashima K.; Nakajo K.; Murano T.; Shinmura K.; Yoda Y.; Hori K.; Oono Y.; Yano T.

P0805

**AN INTERNATIONAL SURVEY OF COLORECTAL POLYPECTOMY PRACTICE DEMONSTRATES ENCOURAGING ADHERENCE TO PUBLISHED GUIDANCE AND HIGHLIGHTS SPECIFIC AREAS FOR IMPROVEMENT**David James Tate, Australia; Desomer L.; Heitman S. J.; Forbes N.; Burgess N.; Awadie H.; De Looze D.; Anderson J.; Rex D.; Bourke M. J.

P0806

**DETERMINING THE MOST EFFECTIVE SURVEILLANCE SYSTEM AFTER AN ENDOSCOPIC POLYPECTOMY: A STUDY BASED ON THE LONG-TERM SURVEILLANCE OF 3,038 PATIENTS**Ryoichi Nozaki, Japan; Nakamura Y.; Yamada K.

P0807

**A NEW MODIFIED SIZE, MORPHOLOGY, SITE, ACCESS (SMSA) SCORE FOR IS A NOVEL RISK ASSESSMENT TOOL PREDICTING CRITICAL OUTCOMES OF ENDOSCOPIC MUCOSAL RESECTION (EMR)**Mayenaaz Sidhu, Australia; Tate D. J.; Desomer L.; Hourigan L.; Brown G.; Zanati S.; Moss A.; Singh R.; Raftopoulos S.; Williams S. J.; Lee E. Y. T.; Burgess N.; Bourke M. J.

P0808

**THE THERAPEUTIC OUTCOME OF ENDOSCOPIC SUB-MUCOSAL DISSECTION (ESD) FOR COLORECTAL LARGE PROTRUDING TUMORS**Tadateru Maehata, Japan; Ochiai Y.; Kiguchi Y.; Akimoto T.; Nakayama A.; Fujimoto A.; Goto O.; Kato M.; Yahagi N.

P0809

**THE TRACTION METHOD "RUBBER-CLIP-METHOD" CONTRIBUTES TO EFFECTIVE SUBMUCOSAL DISSECTION IN COLORECTAL ESD**Takuji Akamatsu, Japan; Nakatani Y.; Yamashita Y.

P0810

**EFFECTIVENESS OF DIGITAL QUALITY ASSURANCE SYSTEM IN COLONOSCOPY SCREENING FOR COLORECTAL CANCER – A RANDOMIZED HEALTH SERVICES STUDY**Marek Bugajski, Poland; Wieszczy P.; Pisera M.; Rupinski M.; Bretthauer M.; Hoff G.; Regula J.; Kaminski M. F.

P0811

**THE ROLE OF PAIN CATASTROPHIZING IN PAIN EXPERIENCE DURING ENDOSCOPIC PROCEDURES**Rossella Palma, Italy; Lauriola M.; Panetta C.; Raniolo M.; Foglia A.; La Spina G.; Cremona M.; Tomai M.; Pontone S.

P0812

**SAFETY AND EFFICACY OF THE FULL-THICKNESS RESECTION DEVICE (FTRD) IN THE COLORECTUM: A POOLED ANALYSIS OF PUBLISHED RESULTS**Andreas Wannhoff, Germany; Meier B.; Caca K.

P0813

**DOES POLYP DETECTION RATE CORRELATE WITH MEAN ADENOMA PER COLONOSCOPY?**Gabriela Vojtechová, Czech Republic; Suchanek S.; Ngo O.; Buckova B.; Grega T.; Voska M.; Májek O.; Zavoral M.

P0814

**IMPROVED COLORECTAL ADENOMA DETECTION RATE WITH LINKED COLOR IMAGING (LCI) TECHNOLOGY COMPARED TO WHITE LIGHT HIGH DEFINITION COLONOSCOPY: RESULTS OF A RANDOMIZED CONTROLLED TRIAL**Barbara Dorottya Lovász, Hungary; Szalai M.; Oczella L.; Dubravcsik Z.; Szepes A. Z.; Madácsy L.

P0815

**ENDOSCOPIC AND MOLECULAR CHARACTERISTICS DURING THE DEVELOPMENT OF TRADITIONAL SERRATED ADENOMA**Hironori Aoki, Japan; Yamamoto E.; Yamano H.-O.; Matsushita H.-O.; Yoshikawa K.; Harada E.; Tanaka Y.; Harada T.; Sugai T.; Suzuki H.

P0816

**PREDICTIVE FACTORS FOR REPEATING COLONOSCOPY IN OUTPATIENTS WITH INADEQUATE BOWEL PREPARATION.**Argyriou K.; Yap K.; Ho S.; Fateen W.; Budihal S.; Sansone S.; Ragunath K.; Adolfo Parra-Blanco, United Kingdom

P0817

**ENDOSCOPIC MUCOSAL RESECTION WITH ANCHORING OF THE SNARE TIP: MULTICENTER RETROSPECTIVE EVALUATION OF THE EFFECTIVENESS AND SAFETY.**Mathieu Pioche, France; Wallenhorst T.; Lepetit H.; Lépilliez V.; Rivory J.; Rostain F.; Bianchi L.; Jacques J.

P0818

**EFFICACY, SAFETY AND LONG-TERM OUTCOMES OF PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION FOR THE TREATMENT OF LARGE NON-PEDUNCULATED COLORECTAL POLYPS IN AN ENDOSCOPY REFERRAL CENTER.**Giancarla Fiori, Italy; Ravizza D.; Trovato C. M.; De Roberto G.; Bravi I.; Giunta M.; Crosta C.

P0819

**CLINICAL OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR COLORECTAL TUMORS ACCOMPANIED BY FIBROSIS IN THE SUBMUCOSAL LAYER**  
Yoshiro Tamegai, Japan; Okada K.; Osumi H.; Chino A.; Saito S.; Konishi T.; Fukunaga Y.; Muto T.

P0820 

**ENDOSCOPIC FEATURES OF RESPONSE TO NEOADJUVANT (CHEMO)RADIOTHERAPY FOR RECTAL CANCER: PRELIMINARY RESULTS.**  
van der Sande M. E.; Maas M.; Melenhorst J.; Breukink S. O.; Beets-Tan R. G. H.; Monique van Leerdam, The Netherlands; Beets G. L.

P0821

**GASTRIC ADENOMA OR EARLY GASTRIC CANCER IS AN IMPORTANT RISK FACTOR FOR COLORECTAL ADENOMA**  
Jun Lee, Republic of Korea; Kim S. J.

P0822 

**WHICH FACTORS ARE RELATED TO A RISK OF DEVELOPING A PERFORATION AFTER A COLONOSCOPY IN AN ORGANISED POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME? A NESTED CASE-CONTROL STUDY**  
Natale Imaz Ayo, Spain; Idigoras Rubio I.; Portillo Villares M. I.; Bilbao Iturribarria I.; Fernández Landa M. J.; Guierrez-Ibarluzea I.; Bujanda Fernández de Piérola L.; Arana-Arri E.

P0823

**ROLE OF FAECAL IMMUNOCHEMICAL TESTING IN THE DIAGNOSTIC WORKUP OF PATIENTS WITH IRON DEFICIENCY ANAEMIA.**  
Dalia Elena Morales Arráez, Spain; Hernández G.; Carrillo M.; Adrián Z.; Jimeno A. Z.; Quintero E.

### Endoscopy, ERCP

P0824

**ENDOSCOPIC TREATMENT OF BILE DUCT STONES IN PATIENTS WITH SURGICALLY ALTERED ANATOMY**  
Mitsuhiro Kida, Japan; Yamauchi H.; Miyata E.; Hasegawa R.; Kaneko T.; Okuwaki K.; Iwai T.; Imaizumi H.

P0825

**APPLICABILITY OF ASGE CRITERIA FOR ERCP IN CHOLECYSTECTOMIZED PATIENTS**  
Mafalda Sousa, Portugal; Pinho R. T.; Proença L.; Rodrigues J.; Silva J. C.; Gomes A. C.; Carvalho J.

P0826

**EFFICACY OF ETOMIDATE- VERSUS PROPOFOL-BASED SEDATION FOR ADVANCED ENDOSCOPIC PROCEDURE : A PROSPECTIVE, RANDOMIZED NON-INFERIORITY TRIAL**  
Su Jung Han, Republic of Korea; Lee T. H.; Yang J. K.; Cho Y. S.; Jung Y.; Chung I.-K.; Park S.-H.; Park S.; Kim S.-J.

P0827

**THE PERIAMPULLARY DIVERTICULUM: BOON OR BANE FOR THE ERCP ENDOSCOPIST?**  
Jing Liang Ho, Singapore; Seneviratna A.; Anastassiades C.; Yip C. H. B.

P0828

**UTILITY OF SPYGLASS® DS PERORAL CHOLANGIOSCOPY IN INDETERMINATE BILIARY LESIONS**  
Hyung Ku Chon, Republic of Korea; Kim T. H.

P0829

**COMPARISON OF ENDOSCOPIC SPHINCTEROTOMY, ENDOSCOPIC PAPILLARY LARGE BALLOON DILATION AND ENDOSCOPIC SPHINCTEROTOMY PLUS ENDOSCOPIC PAPILLARY LARGE BALLOON DILATION TREATMENT FOR REMOVAL OF LARGE BILE DUCT STONE.**  
Chung-Mou Kuo, Taiwan; Tai W.-C.; Wu K.-L.; Yao C.-C.; Lin C.-Y.

P0830

**EVALUATION OF THE SAFETY AND EFFICACY OF ENDOSCOPIC SPHINCTEROTOMY FOLLOWING ADDITIONAL BALLOON DILATION FOR THE MANAGEMENT OF COMMON BILE DUCT STONES**  
Shigeto Ishii, Japan; Fujisawa T.; Takahashi S.; Takasaki Y.; Suzuki A.; Tomishima K.; Kanazawa R.; Saito H.; Shiina S.; Isayama H.

P0831

**SAFETY AND EFFICACY OF NEEDLE KNIFE PAPILOTOMY AND NEEDLE KNIFE FISTULOTOMY IN PATIENTS 90 YEARS OF AGE AND OLDER.**  
Hiroyuki Hisai, Japan; Sakurai T.; Koshiba Y.; Watanabe K.; Ameda S.; Miyazaki E.

P0832 

**INITIAL EXPERIENCES WITH TRANSPANCREATIC PRECUT SPHINCTEROTOMY**  
Szilárd Gódi, Hungary; Pécsi D.; Pakodi F.; Szabó I.; Vincze A.

P0833

**IS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MORE RISKY AND COMPLICATED FOR THE ELDERLY? A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY**  
Hyunjik Lee, Republic of Korea; Cho C. M.; Heo J.; Jung M. K.; Kim T. N.; Kim K. H.; Cho K. B.; Lee Y. S.; Kim H. S.; Kim H. G.; Han J.; Lee D. W.

P0834

**EFFICACY OF DOUBLE-BALLOON ENDOSCOPY FOR THERAPEUTIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN PATIENTS WITH SURGICALLY ALTERED ANATOMY**  
Yuki Sumida, Japan; Yamaguchi A.; Kuwai T.; Konishi H.; Tao K.; Miura R.; Miyasako Y.; Kuroki K.; Tamaru Y.; Kouno H.; Kohno H.

P0835

**A NOVEL TECHNIQUE USING A LOOP-DEVICE FOR REPOSITIONING A NASOBILIARY CATHETER FROM MOUTH TO NOSTRIL IN ERCP**

Lee J. M.; [Hongsik Lee](#), Republic of Korea; Jang S.; Jeon H. J.; Choi S. J.; Lee J. M.; Kim S. H.; Choi H.-S.; Kim E.-S.; Keum B.; Jeon Y.-T.; Chun H. J.; Kim C. D.

P0836

**APPROPRIATE THERAPEUTIC STRATEGY FOR INITIAL ENDOSCOPIC DRAINAGE IN OBSTRUCTIVE JAUNDICE**

[Osamu Inatomi](#), Japan; Fujimoto T.; Mizuno R.; Owaki Y.; Bamba S.; Sugimoto M.; Andoh A.

P0837 **IMPACT OF PERIAMPULLARY DIVERTICULUM ON ERCP PERFORMANCE: A MATCHED CASE-CONTROL STUDY**

[Juan E Corral](#), United States; Mousa O. Y.; Kroener P. T.; Gomez V.; Lukens F.

P0838

**DEXMEDETOMIDINE IS SAFE AND REDUCES THE ADDITIONAL DOSE OF MIDAZOLAM FOR SEDATION DURING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN VERY ELDERLY PATIENTS**

[Ryo Mizuno](#), Japan; Inatomi O.; Owaki Y.; Shintani S.; Fujimoto T.; Bamba S.; Andoh A.

P0839 **TOTALLY-ENDOSCOPIC ENTERAL ANASTOMOSES: A NEW EFFECTIVE WAY TO CHANGE THE TREATMENT OF POSTSURGICAL LATE COMPLICATIONS OF HEPATICO-JEJUNOSTOMY**

Mutignani M.; Forti E.; Pugliese F.; Cintolo M.; Tringali A.; Ferrari G. C.; De Carlis L.; De Gasperi A.; Rampoldi A.; Paparozzi C.; [Lorenzo Dioscoridi](#), Italy

P0840

**NEEDLE-KNIFE FISTULOTOMY VERSUS STANDARD BILIARY SPHINCTEROTOMY FOR CHOLEDOCHOLITHIASIS: RECURRENCE OF COMMON BILE DUCT STONES**

[Livia Archibugi](#), Italy; Mariani A.; Traini M.; Petrone M. C.; Dabizzi E.; Rossi G.; Testoni S. G. G.; Testoni P. A.; Arcidiacono P. G.

P0841

**BILIARY METAL STENTS IN PATIENTS WITH MALIGNANT JAUNDICE AND CBD STRICTURE: A RETROSPECTIVE COHORT STUDY COMPARING UNCOVERED, PARTIALLY COVERED AND FULLY COVERED STENTS**

[Livia Archibugi](#), Italy; Mariani A.; Traini M.; Petrone M. C.; Dabizzi E.; Rossi G.; Testoni S. G. G.; Testoni P. A.; Arcidiacono P. G.

P0842

**CLINICAL OUTCOME OF THE RESECTION MARGIN POSITIVE OR UNCERTAIN CASES AFTER ENDOSCOPIC PAPILLECTOMY FOR AMPULLARY NEOPLASMS**

[Arata Sakai](#), Japan; Iemoto T.; Tanaka T.; Yamada Y.; Nakano R.; Fujigaki S.; Kobayashi T.; Shiomi H.; Masuda A.; Kodama Y.

**Endosonography**

P0843

**LOW NEGATIVE PRESSURE SUCTION YIELDS BETTER QUALITY SMEARS – PROSPECTIVE COMPARISON OF SLOW-PULL AND STANDARD SUCTION TECHNIQUES OF ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION**

[Renáta Bor](#), Hungary; Vasas B.; Fabian A.; Füredi Á.; Czakó L.; Farkas K.; Molnár T.; Hamar S.; Tiszlavicz L.; Kaizer L.; Szepes Z. G.

P0844

**CLINICAL UTILITY AND YIELD OF EUS IN PATIENTS WITH A PRIOR NON-DIAGNOSTIC MRCP; A TERTIARY CARE CENTRE EXPERIENCE.**

Bekkali N. L.-H.; [Fahd Rana](#), United Kingdom; Nayyar M.; Leeds J.; Oppong K.

P0845

**PREDICTING MALIGNANCY RISK IN GASTROINTESTINAL SUBEPITHELIAL TUMORS WITH CONTRAST-ENHANCED HARMONIC ENDOSCOPIC ULTRASOUND USING A PER-FUSION ANALYSIS SOFTWARE**

[Hyun Seok Lee](#), Republic of Korea; Cho C. M.; Kwon Y. H.; Nam S. Y.

P0846

**USEFULNESS OF PROCORE 20G NEEDLE FOR DIAGNOSIS OF PANCREATIC SOLID TUMOR**

[Shunsuke Watanabe](#), Japan; Toki M.; Goto T.; Yoshida T.; Ota H.; Ochiai K.; Gondo K.; Kurata I.; Nakamura K.; Yamaguchi Y.; Hisamatsu T.

P0847

**ENDOMETRIOSIS NODULE THICKNESS ON PRE-OPERATIVE RECTO-SIGMOID ENDOSCOPIC ULTRASONOGRAPHY PREDICTS THE NEED FOR BOWEL RESECTION VERSUS SHAVING TECHNIQUE**

[Victor Desplats](#), France; Moryoussef F.; D'Alessandro A.; du Cheyron J.; Romptaux M.; Chouillard E.; Roseau G.; Fauconnier A.; Vitte R.-L.

P0848

**ROLE OF CONTRAST- ENHANCED ENDOSCOPIC ULTRASOUND IN DIFFERENTIATION OF PANCREATIC CYSTS**

[Andrada Seicean](#), Romania; Olar M.-P.; Mosteanu E. O.; Rusu I.; Seicean R.



P0849

**ENDOSCOPIC ULTRASOUND GUIDED FINE-NEEDLE ASPIRATION OF RECTAL AND PERIRECTAL LESIONS**

Anna Fabian, Hungary; Bor R.; Vasas B.; Hamar S.; Tiszlavicz L.; Balint A.; Czako L.; Farkas K.; Milassin A.; Rutka M.; Szántó K.; Molnár T.; Szepes Z.

P0850

**ENDOSCOPIC ULTRASOUND-GUIDED BIOPSY OF SUBEPITHELIAL GASTROINTESTINAL LESIONS – JUST WET-IT**

Inês Pita, Portugal; Fernandes J.; Pimentel-Nunes P.; Dinis-Ribeiro M.; Bastos P.

P0851

**EXAMINATION OF THE USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY IN EARLY-STAGE STOMACH CANCERS**

Akira Kanamori, Japan; Tsuchida K.; Fukushi K.; Sakuma F.; Abe K.; Nagashima K.; Minaguchi T.; Tsuchida C.; Irisawa A.

P0852 **UTILITY OF LIVER AND SPLEEN EUS-ELASTOGRAPHY AS A DIAGNOSTIC TOOL FOR PREDICTING LIVER CIRRHOSIS AND PORTAL HYPERTENSION: A PROSPECTIVE CASE-CONTROL STUDY.**

Robles-Medranda C.; Valero M.; Puga-Tejada M.; Roberto Oleas, Ecuador; Autran-Nebel J.; De Britto S.; Ospina-Arboleda J.; Soria-Alcivar M.; Alvarado-Escobar H.; Del Valle R.; Pitanga Lukashok H.

P0853

**HIERARCHICAL ANALYSIS OF FACTORS ASSOCIATED WITH T STAGING OF GASTRIC CANCER BY ENDOSCOPIC ULTRASOUND: DECISION TREE METHOD**

Jung Kim, Republic of Korea; Chung H.; Kim S. G.; Kim H. J.; Choi J. H.; Han S. J.

P0854

**RANDOMIZED TRIAL COMPARING FNA AND FINE-NEEDLE BIOPSY FOR EUS-GUIDED SAMPLING OF SOLID TUMORS**

Ronghua Wang, China; Wang J.; Cheng B.

P0855

**NOVEL EUS-GUIDED IRREVERSIBLE ELECTROPORATION ABLATION OF PANCREAS: AN EXPERIMENTAL STUDY**

Lee J. M.; Chang Duck Kim, Republic of Korea; Jang S.; Han Jo J.; Choi S. J.; Lee J. M.; Kim S. H.; Choi H.-S.; Kim E.-S.; Keum B.; Jeon Y.-T.; Chun H. J.; Lee H.

P0856

**THE VALIDATION OF STRING SIGN IN THE DIFFERENTIAL DIAGNOSIS OF PANCREATIC CYSTS**

Ibrahim Hakki Köker, Turkey; Ünver N.; Malya F. Ü.; Biberici Keskin E.; İnce A. T.; Şentürk H.

P0857

**ENDOSCOPIC ULTRASOUND CORE TISSUE ACQUISITION: A SIGLE CENTER PROSPECTIVE STUDY**

Marianna Signoretti, Italy; Pizzicannella M.; Balassone V.; Covotta F.; Di Matteo F. M.

**Enteroscopy**

P0858

**SURVEILLANCE OF ALLOGRAFT REJECTION AFTER INTESTINAL TRANSPLANTATION USING MAGNIFYING ENDOSCOPY WITH NARROW BAND IMAGING**

Chen-Shuan Chung, Taiwan; Lee T.-H.; Lin C.-K.; Chen K.-C.; Chen Y.

P0859

**THE NEW INSERTION METHOD OF THE TRANS-NASAL ILEUS TUBE, THE ANTERIOR BALLOON METHOD, WAS APPLICABLE FOR THE SMALL BOWEL OBSTRUCTION: A RETROSPECTIVE CHART REVIEW OF THE 126 PATIENTS**

Daisuke Yamaguchi, Japan; Ikeda K.; Takeuchi Y.; Kinoshita R.; Fukuda H.; Morisaki T.; Ario K.; Tsunada S.; Furuta T.; Kusano M.; Fujimoto K.

P0860

**HYPERAMYLASAEMIA POST ANTEGRADE DOUBLE BALLOON ENTEROSCOPY – DOES INDOMETHACIN MAKE A DIFFERENCE?**

Stefania Chetcuti Zammit, United Kingdom; Raju S.; Ching H.-L.; Sanders D. S.; Sidhu R.

P0861

**NEED FOR ENTEROSCOPY IN LIVER TRANSPLANTED PATIENTS**

Pietro Soru, Italy; Bertè R.; Invernizzi F.; Orlando S.; Ferretti F.; Donato M. F.; Cantù P.; Vecchi M.; Elli L.

P0862 **ADENOMA DETECTION RATES IS ASSOCIATED WITH RESPECTIVE WITHDRAWAL TIME IN DIFFERENT COLON SEGMENTS.**

Yang Cheng, China; Qiang Z.; Min X.; Hui W.

**Capsule endoscopy**

P0863

**YIELD OF CAPSULE ENDOSCOPY IN OBSCURE GI BLEEDING – A COMPARATIVE STUDY BETWEEN PREMENOPAUSAL AND MENOPAUSAL WOMEN**

João Carlos Silva, Portugal; Pinho R.; Rodrigues A.; Ponte A.; Silva A. P.; Rodrigues J.; Sousa M.; Ribeiro Gomes A. C.; Carvalho J.

P0864

**IS PAN-ENTERIC VIDEO CAPSULE ENDOSCOPY A COST-EFFECTIVE OPTION FOR OPTIMIZATION OF CROHN'S DISEASE THERAPY IN ENGLAND?**

Rafael Torrejon Torres, Germany; McAlindon M.; Lobo A. J.; Blüher M.; Van Lent N.; Leonard C.; Saunders R.

P0865

**SURFACE MAPPING IN PLASTIC GASTRIC MODEL ASSISTED BY A ROBOTIC AUTOSCAN PROGRAM WITH A NEW MAGNETICALLY CONTROLLED GASTRIC CAPSULE ENDOSCOPY SYSTEM COMPARED TO MANUAL CONTROLLING**  
Szalai M.; Oczella L.; [Barbara Dorottya Lovász](#), Hungary; Madácsy L.

P0866

**SMALL BOWEL CAPSULE ENDOSCOPY (SBCE) IN THE ELDERLY. A MULTICENTRE PROSPECTIVE STUDY IN LOMBARDY REGION.**

Girelli C. M.; [Marco Soncini](#), Italy; Rondonotti E.

P0867

**DEVELOPMENTAL INNOVATIONS WHILE PRODUCING A NOVEL CAPSULE**

Lachter J.; Gluck N.; Moshkowitz M.; Half E.; Reines T.; Ringel Y.; Abu Freha N.; Levy M.; Shpak B.; [Nadir Arber](#), Israel

P0868

**SMALL BOWEL NEOPLASIA DETECTION IN LYNCH SYNDROME USING VIDEO CAPSULE ENDOSCOPY**

[Antonella Contaldo](#), Italy; Notaristefano C.; Zuppardo R. A.; Di Leo M.; Principi M. B.; Mannucci A.; Rizzi S.; Patricelli M. G.; Russo Raucchi A.; Testoni P. A.; Cavestro G. M.

P0869

**THE DIAGNOSTIC YIELD OF SMALL BOWEL CAPSULE ENDOSCOPY IN POSTSURGICAL CROHN'S DISEASE**

Viazis N.; [Christos Pontas](#), Greece; Chatzievangelinou C.; Tsoukali E.; Karampekos G.; Filippidis G.; Gkeros F.; Tziortziotis I.; Galanopoulos M.; Tsigaridas A.; Vraka M.; Varitimiadis L.; Mantzaris G.

P0870

**DEVELOPMENT OF QUALITY MEASURES FOR CAPSULE ENDOSCOPY REQUIRES A NOVEL APPROACH BASED ON A PERFORMANCE REVIEW OF A LARGE SINGLE CENTRE SERVICE**

[Olufemi Aoko](#), Ireland; Hanly M.; Varley R.; Fitzsimons A.; Syafiq Ismail M.; O'Connor A.; Breslin N.; Ryan B.; McNamara D.

### Biliary and pancreatic stenting

P0871

**LONG-TERM OUTCOME OF ENDOSCOPIC TREATMENT OF BILIARY STRICTURE FOLLOWING LIVING DONOR LIVER TRANSPLANTATION**

[Jong Kyun Lee](#), Republic of Korea

P0872

**EUS-ANTEGRADE BILIARY STENTING VERSUS PTBD FOR DISTAL MALIGNANT BILIARY OBSTRUCTION IN PATIENTS WITH SURGICALLY ALTERED ANATOMY**

[Takuji Iwashita](#), Japan; Uemura S.; Yoshida K.; Mita N.; Mukai T.; Shimizu M.

P0873

**THE USEFULNESS OF NEWLY MODIFIED NON-FLARED FULLY COVERED METAL STENT OF 12 MM-DIAMETER COMPARING WITH CONVENTIONAL STENT FOR PERI-AMPULLARY MALIGNANT BILIARY STRICTURES**

[Jong Ho Moon](#), Republic of Korea; Choi H. J.; Lee Y. N.; Lee H. W.; Lee T. H.; Cha S.-W.; Cho Y. D.; Park S.-H.

P0874

**DEVELOPMENT OF A NOVEL INTERNAL FISTULA TUBE FOR ENDOSCOPIC TRANSLUMINAL BILIARY DRAINAGE**

[Yukihiro Watanabe](#), Japan; Aikawa M.; Takase K.; Okada K.; Okamoto K.; Sakuramoto S.; Yamaguchi S.; Koyama I.

P0875

**EUS-GUIDED CHOLEDOCHODUODENOSTOMY USING A LUMEN APPOSING METAL STENT FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A RESTROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE**

[Andrea Anderloni](#), Italy; Fugazza A.; Auriemma F.; Carrara S.; Troncone E.; Di Leo M.; Maselli R.; Galtieri P. A.; Semeraro R.; Ferrara E. C.; Attardo S.; D'Amico F.; Repici A.

P0876

**ARE PLASTIC STENTS "EXPANDABLE" IN THE TREATMENT OF BILIARY STRICTURES AFTER ORTHOTOPIC LIVER TRANSPLANTATION? ✦**

[Vasile Sandru](#), Romania; Ilie M.; Plotogea O. M.; Diaconu C.; Ungureanu B.; Balan G.; Rosianu C.; Constantinescu G.

P0877

**LONG-TERM OUTCOME OF EUS-GUIDED GALLBLADDER DRAINAGE VS. PERCUTANEOUS GALLBLADDER DRAINAGE IN PATIENTS WHO ARE UNFIT FOR CHOLECYSTECTOMY: WHICH IS BETTER?**

[Seokjung Jo](#), Republic of Korea; Cho D. H.; Lee S. S.; Oh D.-W.; Song T.-J.; Park D. H.; Seo D.-W.; Lee S. K.; Kim M.-H.

P0878

**ENDOSCOPIC ULTRASOUND-GUIDED GALLBLADDER DRAINAGE VERSUS ENDOSCOPIC TRANSPAPILLARY GALLBLADDER DRAINAGE FOR ACUTE CHOLECYSTITIS IN HIGH-RISK SURGICAL PATIENTS: WHICH IS BETTER?**

[Seokjung Jo](#), Republic of Korea; Oh D.-W.; Song T.-J.; Park D. H.; Seo D.-W.; Lee S.; Kim M.-H.; Lee S. S.

## Poster Session

09:00 – 17:00

Hall X1

## Surgery II

## Oesophagus/stomach/duodenum

P0879

## THE THREE-YEAR EXPERIENCE OF ENDOSCOPIC TREATMENT OF THE ZENKER'S DIVERTICULUM

Shishin K.; [Ivan Nedoluzhko](#), Russian Federation; Pavlov I.; Kurushkina N.; Shumkina L.

P0880

## PREVALENCE OF PRECANCEROUS CONDITIONS AND LESIONS OF THE STOMACH IN CANDIDATES FOR BARIATRIC SURGERY

[Mónica Garrido](#), Portugal; Loureiro A.; Pedroto I.; Marcos-Pinto R.

P0881

## GASTRIC PRESSURE AND ESOPHAGEAL REFLUX EXPOSURE SUGGEST THAT OMEGA-LOOP BYPASS IS DIFFERENT FROM BILLROTH II.

[Salvatore Tolone](#), Italy; Savarino E.; Musella M.; Docimo L.

P0882

## LAPAROSCOPY AND ENDOSCOPY COOPERATIVE SURGERY FOR GASTRIC TUMOR.

[Hiroyuki Ozawa](#), Japan; Kawakubo H.; Mayanagi S.; Fukuda K.; Goto O.; Nakamura R.; Suda K.; Wada N.; Yahagi N.; Kitagawa Y.

P0883

## SHORT-TERM OUTCOMES OF LAPAROSCOPIC DISTAL GASTRECTOMY FOR GASTRIC CANCER AMONG ELDERLY PATIENTS DETERMINED USING COMORBIDITY PREDICTIVE FACTORS

[Shinya Otsuka](#), Japan; Hamano R.; Tsunemitsu Y.; Iwakawa K.; Inagaki M.; Iwagaki H.P0884 

## CLINICOPATHOLOGIC CHARACTERISTICS RELATED TO LYMPH NODE METASTASIS IN EARLY GASTRIC CANCER AFTER GASTRECTOMY

[Yihan Ma](#), China; Yang J.

P0885

## OPERATIVE MANAGEMENT OF PATIENTS WITH METASTATIC GASTROINTESTINAL STROMAL TUMORS: A POPULATION BASED RETROSPECTIVE STUDY.

Zheng W.; Hu W.; Hu M.; [Luyi Chen](#), China

## Hepatobiliary/pancreas/spleen

P0886

## BILE DUCT INJURY AFTER CHOLECYSTECTOMY: NEW CLASSIFICATION AND NOVEL APPROACH FOR THE MANAGEMENT IN EMERGENCY SITUATIONS. DATA OF 178 CASES.

[Pankaj N. Desai](#), India; Bhatt K.; Mangukiya D.; Kabrawala M.

P0887

## BRAUN ENTEROENTEROSTOMY AFTER PARTIAL PANCREATODUODENECTOMY AND CHILD RECONSTRUCTION DECREASES MORBIDITY, CLINICALLY RELEVANT PANCREATIC FISTULA, CLINICALLY RELEVANT DELAYED GASTRIC EMPTYING AND BILE LEAKS - A SYSTEMATIC REVIEW WITH META-ANALYSIS

[Stephan Schorn](#), Germany; Demir I. E.; Vogel T.; Schirren R.; Reim D.; Wilhelm D.; Friess H.; Ceyhan G. O.

P0888

## PREVENTION OF POSTOPERATIVE BILE-LEAKAGE BY A NEWLY DESIGNED TISSUE SEALANT PATCH

[Asmus Heumann](#), Germany; Bahar A.; Tooren M.; de Vries H.; Izbicki J. R.; Bockhorn M.

P0889

## SHORT TERM SURGICAL MORBIDITY AND MORTALITY OF DISTAL PANCREATECTOMY PERFORMED FOR BENIGN VS MALIGNANT DISEASES: A NSQIP ANALYSIS

[Fady Daniel](#), Lebanon; Tamim H.; Hosni M.; Mailhac A.; Jamali F.

P0890

## VALIDATION OF DAY 1 DRAIN FLUID AMYLASE LEVEL FOR PREDICTION OF CLINICALLY RELEVANT FISTULA FOLLOWING DISTAL PANCREATECTOMY USING THE NSQIP DATABASE

[Fady Daniel](#), Lebanon; Tamim H.; Hosni M.; Ibrahim F.; Mailhac A.; Jamali F.

P0891

## VALIDATION OF THE REVISED 2018 EUROPEAN GUIDELINE ON THE MANAGEMENT OF SURGICALLY REMOVED PANCREATIC CYSTIC NEOPLASMS WITH REGARD TO PATHOLOGICAL OUTCOME

[Nadine van Huijgevoort](#), The Netherlands; ten Bokkel-Huinink S.; Lekkerkerker S. J.; Somers I.; Del Chiaro M.; Busch O. R. C.; Fockens P.; Besselink M. G. H.; van Hooft J. E.

## Poster Session

09:00 – 17:00

Hall X1

## IBD II

## Basic/pathogenesis/pathology

P0892

## ENTEROBACTERIACEAE ARE ESSENTIAL FOR BENEFICIAL EFFECTS OF SACCHAROMYCES BOULARDII CNCM I-745 AND DELETERIOUS EFFECTS OF CANDIDA ALBICANS IN COLITIS

[Bruno Sovran](#), France; Planchais J.; Lamas B.; Natividad J. M.; Agus A.; Dupraz L.; Da Costa G.; Michel M.-L.; Langella P.; Richard M. L.; Sokol H.

P0893

**GUT INFLAMMATION DEMONSTRATES A CIRCADIAN RHYTHM AND THE CLOCK IS DISRUPTED IN A MURINE MODEL OF COLITIS**Tom Butler, United Kingdom; Dickson S.; Hand L.; Gibbs J.

P0894

**ADMINISTRATION OF IMM-124E AMELIORATES COLITIS**Spalinger M. R.; Atrott K.; Bähler K.; Melhem H.; Peres D. R.; Lalazar G.; Rogler G.; Michael Scharl, Switzerland; Frey-Wagner I.

P0895

**EPITHELIAL FERROPTOSIS IS A FEATURE OF CROHN'S DISEASE WHICH IS INDUCED BY WESTERN-DIET-DERIVED ARACHIDONIC ACID**Felix Grabherr, Austria; Mayr L.; Reitmeier I.; Gehmacher T.; Schwärzler J.; Gerner R. R.; Niederreiter L.; Koch R.; Zoller H.; Effenberger M.; Moschen A. R.; Ran Q.; Kaser A.; Tilg H.; Adolph T. E.

P0896

**LESION-SPECIFIC GENE EXPRESSION IN THE EPITHELIAL CELLS OF CROHN'S DISEASE BY COMPARING SMALL INTESTINAL ORGANOID FROM ACTIVE AND INACTIVE LESION IN THE SAME PATIENT.**Shuji Hibiya, Japan; Tsuchiya K.; Nishimura R.; Shirasaki T.; Watanabe S.; Katsukura N.; Okamoto R.; Nakamura T.; Watanabe M.

P0897

**WITHDRAWN**

P0898

**THE EFFECT OF NEW HERBAL PRESCRIPTION DERIVED FROM BOJANGGUNBI-TANG ON INFLAMMATORY BOWEL DISEASE**Ko S. J.; Kim J.; Nam S.; Jae Hong Lee, Republic of Korea; Lee B.; Bu Y.; Park J. W.

P0899

**UPON AIEC INFECTION, CROHN'S DISEASE-ASSOCIATED CIRCULATING MICRORNAs ARE TRANSFERRED BETWEEN HUMAN MACROPHAGES VIA THE EXOSOMAL SHUTTLE**Anaïs Larabi, France; Carriere J.; Dalmaso G.; Julien D.; Barnich N.; Nguyen H.

P0900

**CYR61 EXPRESSION IN INFLAMMATORY BOWEL DISEASE**Hyunsoo Kim, Republic of Korea; Park S.-Y.; Yoon J. H.; Lee S.P0901 **SUCCINATE INDUCES EMT THROUGH SUCNR1**Jesus Cosin-Roger, Spain; Asensi-Canto P.; Ortiz-Masia D.; Macias-Ceja D.; Gisbert-Ferrandiz L.; Salvador P.; Calatayud S.; Barrachina M. D.

P0902

**ECTOPIC EXPRESSION OF REG3A IN THE MICE DISTAL COLON IS MEDIATED BY INTERACTIONS BETWEEN NOTCH AND IL-22 SIGNALING PATHWAYS, AND PROMOTES TISSUE REPAIR BY THE AUGMENTATION OF EGFR SIGNALING**Fumiaki Ishibashi, Japan; Kuwabara K.; Kawamoto A.; Anzai S.; Takahashi J.; Nagata S.; Shimizu H.; Yui S.; Oshima S.; Tsuchiya K.; Nakamura T.; Watanabe M.; Okamoto R.

P0903

**1,25-(OH)2D3 STIMULATES NHE8 EXPRESSION VIA ERK1/2 SIGNALING PATHWAY IN DSS COLITIS MICE**Xiao Li, China; Geng C.; Lei X.; Wang C.

P0904

**ASSESSMENT OF AUTONOMIC FUNCTION IN INFLAMMATORY BOWEL DISEASE BY HEART RATE SPECTRAL ANALYSIS**Jingjing Ma, China; Zhao X.; Zhang H.

P0905

**CLASS-1-HISTONE DESACETYLASES AS A NEW THERAPEUTIC TARGET FOR THE CONTROL OF ADHERENT-INVASIVE E. COLI-INDUCED INTESTINAL INFLAMMATION.**Gimier E.; Nicolas Barnich, France; Denizot J.

P0906

**A PATHWAY TO UNDERSTAND COLITIS-ASSOCIATED CARCINOMA: GENE EXPRESSION ANALYSIS IN HUMAN COLON**Sehn M.; Danielle Cardoso da Silva, Germany; Elez Kurtaj S.; Siegmund B.; Kreis M.; Holmer C.; Hummel M.; Gröne J.; Schumann M.

P0907

**CB2 INHIBITOR PROMOTES FACTORS ASSOCIATED WITH MUCOSAL HEALING IN COLON EPITHELIAL CELLS OF IBD PATIENTS: AN EX-VIVO AND IN VITRO STUDY**Tartakover Matalon S.; Ringel Y.; Konikoff F.; Koltai H.; Lish I.; Timna Naftali, Israel

P0908

**LONGER DISEASE COURSE IS ASSOCIATED WITH REDUCED SYSTEMIC ANTI-INFLAMMATORY RESPONSE IN ULCERATIVE COLITIS PATIENTS**Vita Skuja, Latvia; Oppelt P.; Malina - Bambite J.; Putnina L.; Tropina E.; Rudzite D.; Lavrinovica E.; Oscepko A.; Krumina A.; Derovs A.; Lejnicks A.

P0909

**HYPERMETHYLATION PATTERNS IN DYSPLASIA IN INFLAMMATORY BOWEL DISEASE PATIENTS**Isadora Rosa, Portugal; Mata S.; Silva P.; Magro F.; Tavares Sousa M. H.; Barosa R.; Lago P.; Moleiro J.; Silva J. P.; Fonseca R.; Albuquerque C.; Dias Pereira A.

P0910

**DEVELOPMENT OF A CHRONIC DEXTRAN SULFATE SODIUM-INDUCED COLITIS MODEL IN THE NONHUMAN PRIMATE**Takahashi N.; Kitazawa C.; Awaga Y.; Itani Y.; [Ikuo Hayashi](#), United States; Takamatsu H.

P0911

**INCREASED ALVEOLAR NITRIC OXIDE CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SIGN OF SUBCLINICAL SMALL AIRWAY INFLAMMATION? ✦**[Adonis Protopapas](#), Greece; [Vradelis S.](#); [Karampitsakos T.](#); [Chatzimichael A.](#); [Paraskakis E.](#)

P0912

**LOW VITAMIN D RECEPTOR PROTEIN LEVELS IN MURINE AND HUMAN INTESTINAL FIBROSIS.**[Laura Gisbert Ferrándiz](#), Spain; [Salvador P.](#); [Macías-Ceja D. C.](#); [Cosín-Roger J.](#); [Ortiz-Masiá D.](#); [Navarro-Vicente F.](#); [Alós R.](#); [Calatayud S.](#); [Barrachina M. D.](#)

P0913

**CLINICAL ASPECTS AND PROGNOSIS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND AUTOIMMUNE LIVER DISEASE**[Henrique Carvalho Rocha](#), Brazil; [Vilela E. G.](#)P0914 **MEDIATORS OF APOPTOSIS IN CIRCULATING LYMPHOCYTES OF IBD PATIENTS ARE DECREASED AND BCL-2 IS AN ACCURATE MARKER OF IBD**[Katarzyna Neubauer](#), Poland; [Woźniak-Stolarska B.](#); [Krzystek-Korpacka M.](#)**Aetiology/epidemiology**

P0915

**DISEASE COURSE AND PROGNOSIS OF INCIDENT PATIENTS WITH MICROSCOPIC COLITIS - ONE YEAR FOLLOW-UP RESULTS. THE EUROPEAN PRO-MC COLLABORATION, A LINK AWARD PROJECT**[Verhaegh B. P.](#); [Wildt S.](#); [Münch A.](#); [Cebula W.](#); [Diac A.-R.](#); [Meisner S.](#); [Pedersen N.](#); [Fernández-Bañares F.](#); [Guagnozzi D.](#); [Lucendo A. J.](#); [Bohr J.](#); [Macaigne G.](#); [Tontini G. E.](#); [Kupcinskas J.](#); [Al-khalaf M.](#); [Penchev P.](#); [Miehlke S.](#); [Hjortswang H.](#); [Pierik M. J.](#); [Lars Kristian Munk](#), Denmark

P0916

**OPPORTUNISTIC INFECTIONS ARE MORE PREVALENT IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: A LARGE POPULATION BASED STUDY**[Sheriff M. Z.](#); [Mansoor E.](#); [Maneesh Dave](#), United States

P0917

**NON-CELIAC WHEAT SENSITIVITY AND CELIAC DISEASE IS STRONGLY AND INDEPENDENTLY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED STUDY OF 3542 RANDOMLY SELECTED SUBJECTS**[Potter M.](#); [Marjorie Walker](#), Australia; [Jones M. P.](#); [Koloski N.](#); [Keely S.](#); [Talley N. J.](#)

P0918

**LONGITUDINAL IMPACT OF IBS-TYPE SYMPTOMS ON DISEASE ACTIVITY, HEALTHCARE UTILISATION, PSYCHOLOGICAL HEALTH, AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE.**[David J Gracie](#), United Kingdom; [Hamlin P. J.](#); [Ford A. C.](#)

P0919

**EVIDENCE OF A BI-DIRECTIONAL EFFECT OF THE BRAIN-GUT AXIS IN INFLAMMATORY BOWEL DISEASE.**[David J Gracie](#), United Kingdom; [Hamlin P. J.](#); [Guthrie E. A.](#); [Ford A. C.](#)

P0920

**HOSPITALIZATION AND RE-HOSPITALIZATION IN INFLAMMATORY BOWEL DISEASE: REASONS FOR A GROWING REALITY**[Rui Gaspar](#), Portugal; [Andrade P.](#); [Nunes A. C.](#); [Magro F.](#); [Lopes S.](#); [Macedo G.](#)

P0921

**IS FATIGUE COMMON IN INFLAMMATORY BOWEL DISEASE AND IS IT A SEPARATE ENTITY?**[Katy Rebecca Morrison](#), United Kingdom; [Reynolds N.](#); [Todd J.](#); [Paterson J.](#); [Mowat C.](#); [Groome M.](#)

P0922

**PREVALENCE AND FEATURES OF SPONDYLOARTHRITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE**[Elena Belousova](#), Russian Federation; [Odintsova A.](#); [Abdulganieva D.](#); [Protopopov M.](#)

P0923

**FACTORS ASSOCIATED WITH GUT COLONIZATION AND DECOLONIZATION WITH EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING ENTEROBACTERIA IN ULCERATIVE COLITIS PATIENTS: PRELIMINARY STUDY RESULTS**[Vita Skuja](#), Latvia; [Bossmeyer F.](#); [Malina - Bambite J.](#); [Putnina L.](#); [Tropina E.](#); [Rudzite D.](#); [Lavrinovica E.](#); [Oscepkova A.](#); [Krumina A.](#); [Derovs A.](#); [Lejniaks A.](#)

P0924

**INCIDENCE AND DISEASE PRESENTATION OF ELDERLY-ONSET IBD IN A EUROPEAN POPULATION-BASED INCEPTION COHORT - AN ANALYSIS OF THE EPI-IBD 2010-2011 COHORTS**

Vicent Hernández Ramírez, Spain; Cadilla J. M.; Sebastian S.; Kaimakliotis I.; Cukovic Cavka S.; Dahlerup J. F.; Ladefoged K.; Kupcinskas L.; Turcan S.; Pedersen N.; Langholz E.; Thorsgaard N.; Andersen V.; Salupere R.; Belousova E. A.; Katsanos K. H.; Shonova O.; Fumery M.; Nielsen K. R.; Oksanen P.; Arebi N.; Bjornsson E. S.; Bailey Y.; D'Inca R.; Lakatos P. L.; Odes S.; Vegh Z.; Ellul P.; Goldis A.; Almer S.; Giannotta M.; Halfvarson J.; Duricova D.; Magro F.; Bell S.; Valpiani D.; Munkholm P.; Burisch J.

P0925

**USEFULNESS OF SYSTEMATIC LIVER BIOPSY DURING A SURGERY FOR INFLAMMATORY BOWEL DISEASE FOR THE DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS**  
Céline Miard, France; Desfourneaux V.; Turlin B.; Bendavid C.; Brochard C.; Siproudhis L.; Dewitte M.; Bouguen G.

**Diagnosis and monitoring**

P0926

**MARIA INDEX AT DIAGNOSIS AS A PREDICTOR OF DISABLING CROHN'S DISEASE**

Mafalda Sousa, Portugal; Castelo D.; Rodrigues J.; Silva J. C.; Ribeiro Gomes A. C.; Rodrigues A.; Carvalho J.

P0927

**DYSPLASIA SURVEILLANCE IN INFLAMMATORY BOWEL DISEASE - A COHORT STUDY**

Sofia Saraiva, Portugal; Rosa I.; Moleiro J.; Pereira Silva J.; Fonseca R.; Dias Pereira A.

P0928

**DISCRETE TERMINAL ILEAL ULCERS IN ULCERATIVE COLITIS PATIENTS: CLINICAL SIGNIFICANCE AND NATURAL COURSE**

Jae Seung Soh, Republic of Korea; Kim G.-U.; Kim K.-J.

P0929

**MAGNETIC RESONANCE ENTEROGRAPHY DEPLOYMENT IN AN INTERNATIONAL MULTICENTRE CLINICAL TRIAL OF VEDOLIZUMAB IN CROHN'S DISEASE: AN ANALYSIS OF TECHNICAL FEASIBILITY FROM THE VERIFY TRIAL**  
Jordi Rimola, Spain; Vas D.; Danese S.; Han C.; Yardi O.; Jones S.; Siegelman J.

P0930

**THE TORONTO IBD GLOBAL ENDOSCOPIC REPORTING (TIGER) SCORE: A SINGLE, EASY TO USE ENDOSCOPIC SCORE FOR ALL IBD PATIENTS**

Eran Zittan, Israel; Steinhart A. H.; Milgrom R.; Schwartz N.; Zelcer M.; Gralnek I. M.; Zelber-Sagi S.; Silverberg M. S.

P0931

**HISTOLOGICAL FEATURES OF ULCERATIVE COLITIS IN NON-OPERATED PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION**

Ponkratova N.; Alexey Okhlobystin, Russian Federation; Okhlobystina O.; Tertychnyy A.; Shifrin O.; Ivashkin V.

P0932

**COMPARISON OF BOWEL ULTRASONOGRAPHY AND MAGNETIC RESONANCE ENTEROGRAPHY FOR DETECTING ENDOSCOPIC BASED DISEASE ACTIVITY IN ILEOCO-LONIC CROHN'S DISEASE.**

Ilhami Yüksel, Turkey; Kilincalp S.; Coskun Y.; Akinci H.; Hamamci M.; Ekiz F.

P0933

**PLATELET INDICES IN THE COURSE OF INFLIXIMAB INDUCTION REGIMEN IN ULCERATIVE COLITIS PATIENTS - EXPERIENCE OF A SINGLE CENTRE - A PILOT STUDY**  
Agata Michalak, Poland; Cichoż-Lach H.; Kasztelan-Szczerbińska B.; Laskowska K.; Radwan P.

P0934

**DISEASE SEVERITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH CARDIOVASCULAR DISEASES.**

Aikaterini Mantaka, Greece; Tsoukali E.; Fragaki M.; Karmiris K.; Viazis N.; Mantzaris G.; Koutroubakis I.

P0935

**THE ROLE OF SERUM IL-17 AND IL-23 IN ASSESSING INFLAMMATORY BOWEL DISEASE SEVERITY**

Laura Alexandra Lucaciu, Romania; Ilies M.; Leucuta D.; Iuga C. A.; Seicean A.

P0936

**SYMPTOMS OF ANXIETY AND DEPRESSION IN INFLAMMATORY BOWEL DISEASE**

João Carlos Silva, Portugal; Machado A. S.; Silva A. P.; Rodrigues A.; Rodrigues J.; Sousa M.; Ribeiro Gomes A. C.; Carvalho J.

P0937

**QUALITY OF CARE AND OUTCOMES IN A TERTIARY HOSPITAL INFLAMMATORY BOWEL DISEASE (IBD) CENTER: MONITORING AND TREATMENT ALGORITHMS AT REFERRAL AND DURING FOLLOW-UP**

Restellini S.; Nene S.; Kohen R.; Lorant Gonczi, Hungary; Kürti Z.; Afif W.; Bessissow T.; Wild G.; Seidman E.; Bitton A.; Lakatos P.

P0938

**BENEFITS OF IMPLEMENTING A RAPID ACCESS CLINIC IN A HIGH VOLUME INFLAMMATORY BOWEL DISEASE CENTER: ACCESS, RESOURCE UTILIZATION AND OUTCOMES**

Sofia Nene, Canada; Kürti Z.; Morin I.; Bessissow T.; Afif W.; Wild G.; Seidman E.; Bitton A.; Lakatos P.

P0939

**FECAL CALPROTECTIN AS A SURROGATE MARKER FOR PREDICTING RELAPSE IN ADULTS WITH ULCERATIVE COLITIS: A META- ANALYSIS**Jiajia Li, China; Zhao X.; Zhang H.P0940 **GASTROINTESTINAL SYMPTOMS ARE COMMON IN U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS**Feldman S.; Fakharzadeh S.; Abell J.; Timothy Hoops, United States; Srivastava B.; Muser E.; Dungee D.; Quinn S.; Leone-Perkins M.; Kappelman M.

P0941

**THE ACCURACY OF A HOME PERFORMED FAECAL CALPROTECTIN TEST IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.**Tereza Lerchova, Czech Republic; Hradsky O.; Copova I.; Gonsorcikova L.; Potuznikova K.; Bronsky J.

P0942

**DOES FAECAL MICROBIAL DYSBIOSIS CORRELATES WITH DISEASE ACTIVITY MEASURES, FAECAL CALPROTECTIN AND SYMPTOM SCORES IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE**Dorit Ankersen, Denmark; Marker D.; Bech Johannesen T.; Iversen S.; Ulfsdotter Weimers M. P.; Burisch J.; Skytt Andersen P.; Paridaens K.; Casén C.; Munkholm P.

P0943

**DIAGNOSTIC YIELD IN THE VISUALIZATION OF CAPSULE ENDOSCOPY BY A TRAINED NURSE**Rodríguez de Miguel C.; Isis Karina Araujo Acuña, Spain; Escapa Llamazares M.; Romero Mascarell C.; Fernández-Esparrach M. G.; Ginès A.; Córdova H.; Sendino O.; del Manzano S.; Llach J.; Gómez Arbonés J.; González-Suárez B.

P0944

**HOW TO PREDICT THE RESPONSE TO THERAPY IN CROHN'S DISEASE? - WHEN CONTRAST-ENHANCED ULTRASOUND CAN MAKE A DIFFERENCE**Sara Monteiro, Portugal; Dias de Castro F.; Magalhães J.; Leite S.; Moreira M. J.; Cotter J.P0945 **THERAPEUTIC DRUG MONITORING OF ADALIMUMAB: A COMPARATIVE STUDY OF A NEW POINT-OF-CARE QUANTITATIVE TEST WITH THREE ESTABLISHED ELISA ASSAYS**Joana Afonso, Portugal; Rocha C.; Lago P.; Lourenço Vieira A.; Arroja B.; Dia C. C.; Magro F.

P0946

**FECAL CALPROTECTIN AND FECAL IMMUNOCHEMICAL TEST HAVE DIFFERENT ASSOCIATIONS WITH ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS**Hyung Wook Kim, Republic of Korea; Kang D.-H.; Choi C. W.; Park S. B.; Kim S.-J.; Nam H. S.; Ryu D. G.; Kim H. J.; Kwon B. J.; Yu J. S.

P0947

**AN OPEN LABEL PROSPECTIVE STUDY OF THE SOLUBLE SERUM MARKER ST2 (IL-33 RECEPTOR) IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: CLINICAL, ENDOSCOPIC AND HISTOLOGICAL RESULTS OF THE EVOLUTION STUDY**Fernando Magro, Portugal; Lopes S.; Silva M.; Portela F.; Branquinho D.; Correia L.; Fernandes S.; Cravo M.; Caldeira P.; Tavares Sousa H.; Patita M.; Cremers I.; Afonso J.; Redondo I.; Machado P.; Philip G.; Lopes J.; Carneiro F.

P0948

**CONTRAST-ENHANCED BOWEL ULTRASOUND IN PATIENTS WITH ULCERATIVE COLITIS**Larisa P. Orlova, Russian Federation; Bogdanova E. M.; Evgrafov P. G.; Shapina M. V.; Khalif I. L.; Veselov V. V.; Vardanyan A. V.

P0949

**CUTTING EDGE TECHNOLOGIES TO PREDICT TREATMENT RESPONDER AND NON-RESPONDER IN IBD PATIENTS**Matthias Breidert, Switzerland; Eftekhari P.

P0950

**SATISFACTION OF DEEP NURSE ADMINISTERED PROPOFOL SEDATION VERSUS MIDAZOLAM AND FENTANYL DURING COLONOSCOPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL**Jensen J. T.; Brynskov J.; Møller A. M.; Limschou A. C.; Konge L.; Peter Vilmann, Denmark

P0951

**LOW HAEMOGLOBIN DENSITY (LHD%) AS A NEW BIOMARKER FOR THE DETECTION OF IRON DEFICIENCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**Karima Farrag, Germany; Ademaj K.; Aksan A.; Leventi E.; Stein J.

P0952

**MONITORING OF SURROGATE MARKERS OF ATHEROSCLEROSIS IN A PROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE**Cilluffo M. G.; Barbara Scrivero, Italy; Tuttolomondo A.; Torres D.; Pinto A.; Camma C.; Cappello M.

P0953

**LONG-TERM OUTCOME OF TRANSMURAL HEALING VERSUS MUCOSAL HEALING IN CROHN'S DISEASE: THE TIME FOR A NEW TARGET**Castiglione F.; Nicola Imperatore, Italy; Testa A.; Nardone O. M.; Schettino M.; Opramolla A.; Pellegrini L.; Crispino F.; Caporaso N.; Rispo A.

P0954

**ADVANCED ENDOSCOPY FOR SURVEILLANCE OF COLONIC INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS**

Nicola Imperatore, Italy; Castiglione F.; Testa A.; De Palma G. D.; Caporaso N.; Rispo A.

P0955

**ROLE OF SERUM PROCALCITONIN FOR DIAGNOSIS OF CYTOMEGALOVIRUS REACTIVATION IN EXACERBATION OF ULCERATIVE COLITIS PATIENTS**Park S. B.; [Hyung Wook Kim](#), Republic of Korea; Kang D.-H.; Choi C. W.; Kim S.-J.; Nam H. S.; Ryu D. G.; Lee J. W.; Lee J. P.; Lee K. H.

P0956

**SYSTEMATIC REVIEW: PREDICTING THE DEVELOPMENT OF PSYCHOLOGICAL MORBIDITY IN INFLAMMATORY BOWEL DISEASE**

Anna Beatrix Hoogkamer, United Kingdom Brooks A.; Lobo A. J.; Rowse G.

P0957

**WITHDRAWN**

P0958

**ULTRASONOGRAPHIC FINDINGS ASSOCIATED WITH A HIGHER RISK OF SURGERY IN PATIENTS WITH STRICTURING CROHN'S DISEASE.**[Jose Luis Rueda Garcia](#), Spain; Suarez Ferrer C.; Poza Cordon J.; Martín Arranz E.; Jaquotot Herranz M.; Gómez Senent S.; Crivillén Anguita O.; Zarauza Soto Y.; Martín Arranz M. D.; Mora Sanz P.

P0959

**NBI FINDINGS IN MICROSCOPIC COLITIS AND UTILITY OF NBI GUIDANCE ON YIELD OF COLONIC BIOPSIES FOR ITS DIAGNOSIS**[Sidharth Shukla](#), India; Kochhar R.; Rana S.; Prasad K. K.; Dhaka N.; Malik S.; Berry N.; Sharma M.; Sinha S. K.

P0960

**THE PREVALENCE OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH HIDRADENITIS SUPPURATIVA**Lovas S.; Gáspár K.; Jenei A.; Kacska S.; Altörjay I. F.; Szegedi A.; Remenyik É.; [Karoly Palatka](#), Hungary**Treatment-medical**

P0961

**BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS**Lichtenstein G. R.; Tinsley A.; [Xavier Roblin](#), France; Hisamatsu T.; Vong C.; Tsuchiwata S.; Tsilkos K.; Zhang H.; Mukherjee A.; Su C.; Rubin D. T.

P0962

**EFFICACY AND SAFETY OF GASTRO-RESISTANT PHOSPHATIDYLCHOLINE (LT-02) FOR MAINTENANCE OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS INITIALLY REFRACTORY TO MESALAZINE: A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED STUDY (PCG-4)**[Axel Dignass](#), Germany; Stremmel W.; Bilianskyi L.; Horyński M.; Fellermann K.; Uebel P.; Armerding P.; Kühbacher T.; Stein J.; Kowalski M.; Avalueva E.; Bajbouj M.; Langhorst J.; Walczak P.; Olejnik O.; Heinemann H.; Müller R.; Greinwald R.; Reinisch W.

P0963

**REFLECT: A FRENCH NATIONWIDE PROSPECTIVE STUDY OF CT-P13 -INFLIXIMAB BIOSIMILAR USE IN REAL LIFE**Bouhnik Y.; [Stéphane Nancey](#), France

P0964

**REAL LIFE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AS INDUCTION THERAPY FOR KOREAN IBD PATIENTS IN WHOM ANTI-TNF TREATMENT FAILED: THE FIRST ASIAN PROSPECTIVE COHORT STUDY**[Jeongseok Kim](#), Republic of Korea; Ham N. S.; Oh E. H.; Song E. M.; Youn E. J.; Kwon E. J.; Cho Y. K.; Hwang S. W.; Park S. H.; Yang D.-H.; Byeon J.-S.; Myung S.-J.; Yang S.-K.; Ye B. D.

P0965

**IMPROVEMENT IN PHYSICIAN'S GLOBAL ASSESSMENT WITHIN 2 WEEKS IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB**Chiorean M.; Rubin D. T.; Löwenberg M.; [Javier P Gisbert](#), Spain; Tsilkos K.; Quirk D.; Salese L.; Zhang H.; Woodworth D. A.; Su C.

P0966

**IMMUNOLOGICAL CROSS-REACTIVITY OF ANTI-DRUG ANTIBODIES TO ADALIMUMAB AND ABP 501**[Mieke Jill Miller](#), United States; Starcevic Manning M.; Wala I.; Wang H.; Krishnan E.; Kaliyaperumal A.; Zhang N.; Mytych D.

P0967

**DEEP REMISSION AND MUCOSAL HEALING IN IBD PATIENTS UNDER IMMUNOSUPPRESSION WITH AZATHIOPRINE AND 6-MERCAPTOPYRIMIDINE**[João Carlos Silva](#), Portugal; Silva A. P.; Rodrigue A.; Fernandes S.; Rodrigues J.; Sousa M.; Ribeiro Gomes A. C.; Carvalho J.

P0968

**HIGH DOSE VITAMIN D DOES NOT PREVENT POSTOPERATIVE ENDOSCOPIC AND CLINICAL RECURRENCE IN CROHN'S DISEASE**[Jessica R. de Bruyn](#), The Netherlands; Bossuyt P.; Ferrante M.; West R. L.; Dijkstra G.; Witteman B. J.; Franchimont D.; van der Bilt J. D.; Tollens T.; Bemelman W. A.; D'Hoore A.; Duijvestein M.; D'Haens G. R.



P0969

**EVALUATING THE LONG TERM SAFETY AND EFFICACY OF ENDOSCOPIC DILATION TREATMENT OF PRIMARY AND SECONDARY DIGESTIVE STRICTURES IN CROHN'S DISEASE.**  
Mouillec A.; Grimaud J.-C.; Barthelet M.; Servajean C.; Benezech A.; Gonzalez J.-M.; Desjeux A.; Melanie Serrero, France

P0970

**ESTABLISHING PK EQUIVALENCE BETWEEN ADALIM-UMAB AND ABP 501 IN THE PRESENCE OF ANTI-DRUG ANTIBODIES USING POPULATION PK MODELLING**  
Doshi S.; Krishnan E.; Wang H.; Zhang N.; Vincent Chow, United States

P0971

**TIME COURSE OF THE INCIDENCE AND MAGNITUDE OF ANTI-DRUG ANTIBODIES TO ADALIMUMAB AND ABP 501 AND AMONG PATIENTS ON CONCOMITANT IMMUNOMODULATORY THERAPY**  
Mytych D.; Mieke Jill Miller, United States; Starcevic Manning M.; Wala I.; Wang H.; Zhang N.; Krishnan E.; Kaliyaperumal A.

P0972

**INJECTION SITE REACTIONS AND INJECTION SITE PAIN FOR THE ADALIMUMAB BIOSIMILAR ABP 501: RESULTS FROM TWO DOUBLE-BLIND RANDOMIZED CONTROLLED STUDIES**  
Krishnan E.; Zhang N.; Hui Wang, United States

P0973

**DEVELOPMENT OF ANTI-DRUG ANTIBODIES AMONG THOSE TREATED WITH ADALIMUMAB AND ABP 501 AND ITS IMPACT ON SERUM DRUG CONCENTRATION IN RANDOMISED**  
Vincent Chow, United States; Kaliyaperumal A.; Miller J.; Mytych D.; Starcevic Manning M.; Wala I.; Wang H.; Zhang N.; Krishnan E.

P0974

**EARLY DOSE OPTIMIZATION IN NONRESPONDERS TO GOLIMUMAB INDUCTION TREATMENT FOR ULCERATIVE COLITIS IS SUPPORTED BY PHARMACOKINETIC DATA THROUGH 1 YEAR.**  
Phillip G.; Marano C. W.; Adedokun O.; Melsheimer R.; Freddy Cornillie, United States

P0975

**REAL WORLD DATA ON THE USE OF 5 AMINOSALICYLIC ACID (5ASA) IN NON-FISTULATING, NON-STRICTURING CROHN'S DISEASE IN AN IBD TERTIARY CENTRE**  
Besher Mohamed, United Kingdom; Bloom S.; Tai C.

P0976

**PERSISTENCE OF BIOLOGIC THERAPY AND MAPPING OF SEQUENTIAL BIOLOGIC USE: RESULTS OF A SINGLE CENTRE COHORT WITH 841 PATIENTS TREATED OVER 18 YEARS**  
Jenkinson P.; Nikolas Plevris, United Kingdom; Chuah C. S.; Lyons M.; Rhys-Jones G.; Merchant L.; Arnott I.; Lees C.

P0977

**UNDETECTABLE FAECAL ANTI-TNF CONCENTRATIONS AFTER SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS**  
Anne Strik, The Netherlands; Berends S.; Rispens T.; de Vries A.; Lowenberg M.; Gecke K. B.; Mathôt R.; D'Haens G.

P0978

**EFFECTIVENESS AND SAFETY OF THE SWITCH FROM REMICADE® TO CT-P13 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**  
María Chaparro, Spain; Garre A.; Guerra Veloz M. F.; Vázquez J. M.; De Castro M. L.; Leo Carnerero E.; Rodríguez E.; Carbajo A. Y.; Riestra Menéndez S.; Jiménez I.; Calvet X.; Bujanda L.; Rivero M.; Gomollón F.; Benítez J. M.; Bermejo F.; Alcaide N.; Gutierrez Casbas A.; Mañosa M.; Iborra M.; Lorente Poyatos R.; Lamas M.; Barreiro de-Acosta M.; Kolle L.; Van Domselaar M.; Amo V.; Argüelles F.; Ramírez E.; Morell A.; Bernardo D.; Gisbert J. P.

P0979

**NEED FOR ADALIMUMAB DOSE OPTIMIZATION IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS**  
Olivares D.; Cristina Alba López, Spain; Cañas M.; Barraón A.; Colmenares M.; Rey Díaz-Rubio E.; Taxonera Samsó C.

P0980

**ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB**  
Sands B. E.; Long M. D.; Baidoo L.; Reinisch W.; Julian Panés, Spain; Nduaka C. I.; Soonasra A.; Pedersen R. D.; Lawendy N.; Chan G.; Friedman G. S.; Su C.

P0981

**LONG-TERM SAFETY IN THE OPEN-LABEL PERIOD OF A PHASE 2A STUDY OF BRAZIKUMAB, AN ANTIBODY AGAINST INTERLEUKIN-23**  
Bruce E. Sands, United States; Gasser Jr R. A.; Gommoll C.; Danese S.

P0982

**CLINICAL DECISION SUPPORT IMPROVES QUALITY OF CARE IN PATIENTS WITH ULCERATIVE COLITIS**  
Belinda Jackson, Australia; Begun J.; Gray K.; Liew D.; Knowles S.; De Cruz P.

P0983

**USTEKINUMAB IMPROVES PRODUCTIVITY AND REDUCES WORK LIMITATION OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THREE PHASE 3 CLINICAL TRIALS**  
Bruce E. Sands, United States; Han C.; Naessens D.; Gasink C.; Jacobstein D.; Gao L. L.; Feagan B. G.

P0984 

**SWITCH OF INFLIXIMAB ORIGINATOR TO BIOSIMILAR CT-P13 IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS IN A LARGE GERMAN IBD CENTER. A ONE YEAR, RANDOMIZED AND PROSPECTIVE TRIAL.**  
[Helene Röder](#), Germany; Schnitzler F.; Borchardt J.; Janelidze S.; Ochsenkühn T.

P0985

**RATIONALE AND PHASE 2 CLINICAL TRIAL DESIGN FOR PRV-6527, AN ORAL INHIBITOR OF THE CSF1RECEPTOR KINASE (CSF-1R) FOR CROHN'S DISEASE**  
[Gail Comer](#), United States; Moore B.; Manthey C.; Andre A.; Dunford P.; Ramos E.

P0986

**LONG TERM FOLLOW-UP OF PATIENTS WITH SEVERE, STEROID-RESISTANT ULCERATIVE COLITIS WHO RECEIVED INDUCTION THERAPY WITH CYCLOSPORINE AND WERE MAINTAINED WITH VEDOLIZUMAB**  
[Dino Tarabar](#), Serbia; El Jurdi K.; Yvellez O.; Milenkovic Z.; Petrovic S.; Subotic B.; Brocic T. P.; Brcerevic I.; Latinovic O.; Jocic T.; Rubin D. T.

P0987

**PROBIOTICS CAN IMPROVE THE INFLIXIMAB RESPONSE FOR PATIENTS WITH CROHN'S DISEASE**  
[Shi-Xue Dai](#), China; Sha W.

P0988

**ETROLIZUMAB TREATMENT MODULATES MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN'S DISEASE**  
 Sandborn W.; Panés J.; Fuh F.; Erickson R.; Jacob R.; Zhang W.; Tang M. T.; [Jacqueline McBride](#), United States

P0989

**EARLY INITIATION OF ADALIMUMAB SIGNIFICANTLY DIMINISHES ENDOSCOPIC POST-OPERATIVE CROHN'S DISEASE RECURRENCE, AND IS SUPERIOR TO IMMUNOMODULATORY THERAPY, REGARDLESS OF RISK STRATIFICATION. A RANDOMIZED, CONTROLLED STUDY.**  
[Erez Scapa](#), Israel; Fliss-Isakov N.; Tulchinsky H.; Yanai H.; White I.; Dotan I.; Maharshak N.

P0990

**EVALUATING EFFICACY, SAFETY AND PHARMACOKINETICS AFTER SWITCHING FROM INFLIXIMAB ORIGINATOR TO BIOSIMILAR CT-P13: RESULTS FROM A LARGE TERTIARY REFERRAL CENTER.**  
[Michiel Bronswijk](#), Belgium; Moens A.; Lenfant M.; Compennolle G.; Van Assche G.; Vermeire S.; Gils A.; Ferrante M.

P0991

**ANTI-TNF ALPHA THERAPY IN BIOLOGICS-NA&#970;VE ULCERATIVE COLITIS PATIENTS IN A PROSPECTIVE "REAL WORLD" STUDY IN GERMANY (BIOCOLITIS-REGISTRY)**  
[Bernd Bokemeyer](#), Germany; Atreya R.; Büning J.; Kühbacher T.; Maaser C.; Schmidt K.; Hartmann P.; Wiebe B.; Schreiber S.

P0992

**IMMUNOGENICITY AFTER TRANSITION FROM ADALIMUMAB TO ABP 501 IN PATIENTS WITH PLAQUE PSORIASIS**  
 Mytych D.; [Mieke Jill Miller](#), United States; Starcevic Manning M.; Wala I.; Zhang N.; Kaliyaperumal A.; Krishnan E.

P0993

**TIME COURSE OF THE INCIDENCE AND MAGNITUDE OF ANTI-DRUG ANTIBODIES TO ABP 501 AND ADALIMUMAB IN PSORIASIS PATIENTS TREATED FOR 16 WEEKS**  
 Mytych D.; [Mieke Jill Miller](#), United States; Starcevic Manning M.; Wala I.; Wang H.; Zhang N.; Kaliyaperumal A.; Krishnan E.

P0994

**GUT COLONIZATION WITH EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING ENTEROBACTERIA MIGHT BE ASSOCIATED WITH CIPROFLOXACIN RESISTANCE IN INFLAMMATORY BOWEL DISEASE PATIENTS: PRELIMINARY STUDY RESULTS**  
[Vita Skuja](#), Latvia; Rosberg A.; Malina - Bambite J.; Putnina L.; Tropina E.; Rudzite D.; Lavrinovica E.; Oscepko A.; Krumina A.; Derovs A.; Lejniaks A.

P0995

**PREDICTIVE ROLE OF ANTI-TNF TROUGH LEVELS IN THE OUTCOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN REMISSION**  
[María José Casanova](#), Spain; Chaparro M.; Gisbert J. P.

P0996

**CIPROFLOXACIN RESISTANCE IS HIGHER IN ULCERATIVE COLITIS PATIENTS WITH MORE SEVERE DISEASE ACTIVITY AND MORE EXACERBATIONS: PRELIMINARY STUDY RESULTS**  
[Vita Skuja](#), Latvia; Rosberg A.; Malina - Bambite J.; Putnina L.; Tropina E.; Rudzite D.; Lavrinovica E.; Oscepko A.; Krumina A.; Derovs A.; Lejniaks A.

P0997

**TREATMENT PERSISTENCE WITH IMMUNOSUPPRESSANT, AGENT-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT ANALYSIS IN GERMANY**  
 Wilke T.; Groth A.; Long G. H.; Tatro A. R.; Maywald U.; [Diana Sun](#), United States

P0998

**ORALLY-ADMINISTERED EMU OIL ATTENUATES CLINICAL INDICATORS OF DISEASE IN A MOUSE MODEL OF ACUTE CROHN'S DISEASE**  
[Suzanne Mashoutoub](#), Australia; Mitchell C.; Chartier L.; Trinder D.; Lawrance I.; Howarth G.

P0999

**LOW GOLIMUMAB TROUGH LEVELS AT WEEK 6 ARE ASSOCIATED WITH POOR CLINICAL, ENDOSCOPIC AND HISTOLOGICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS: PHARMACOKINETIC RESULTS OF THE EVOLUTION STUDY**

Fernando Magro, Portugal; Lopes S.; Silva M.; Portela F.; Branquinho D.; Correia L.; Fernandes S.; Cravo M.; Caldeira P.; Tavares Sousa H.; Patita M.; Cremers I.; Afonso J.; Redondo I.; Machado P.; Cornillie F.; Lopes J.; Carneiro F.

P1000

**RATE OF ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANY**

Wilke T.; Groth A.; Long G. H.; Tatro A. R.; Maywald U.; Diana Sun, United States

P1001

**ANTI-TNF USE IS ASSOCIATED WITH WORK PRODUCTIVITY LOSS IN IBD PATIENTS**

Sara van Gennep, The Netherlands; Evers S. W.; de Boer A. G. E. M.; de Boer N. K.; Rietdijk S.; Gielen M. E.; Gecke K. B.; Ponsoen C. Y.; Sluiter J. K.; D'Haens G. R.; Löwenberg M.

P1002

**REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB AND ANTI-TUMOUR NECROSIS FACTOR-ALPHA OVER 6 MONTHS IN ULCERATIVE COLITIS PATIENTS: A GERMAN RETROSPECTIVE CHART REVIEW**

Ulf Helwig, Germany; Mross M.; Schubert S.; Hartmann H.; Brandes A.; Kempf C.; Knop J.; Campbell-Hill S.; Ehehalt R.

## Poster Session

09:00 - 17:00

Hall Xi

Paediatric: Lower GI

**Paediatric and adolescent IBD**

P1003

**THE RELATIONSHIP BETWEEN INTESTINAL DYSBIOSIS AND INFLAMMATORY BOWEL DISEASE IN CHILDREN**

Oana Belej, Romania; Simedrea I.; Olariu L.; Marcovici T.; Pop M.; Marginean O.

P1004

**REMISSION INDUCTION IN CORTICOSTEROID NAÏVE CHILDREN AND ADOLESCENTS WITH ULCERATIVE COLITIS BY ADSORPTIVE LEUCOCYTAPHERESIS AFTER FAILURE OF FIRST-LINE MEDICATIONS**

Tomotaka Tanaka, Japan; Goishi H.; Iiboshi T.; Kajihara T.; Miura T.

P1005 **FAECAL CALPROTECTIN IN HEALTHY CHILDREN (0 TO 18 YEARS OLD) AND THE INFLUENCE OF AGE, GENDER AND ANTHROPOMETRY.**

Marta Velasco, Spain; Plata Fernández C.; Viada Bris J. F.; García Salido A.; Asensio J.; Muñoz Codoceo R. A.

P1006

**OUTCOME OF INFLAMMATORY BOWEL DISEASE IN CHILDREN WITH PRIMARY SCLEROSING CHOLANGITIS.**

Andrea Tenca, Finland; Niemi K.; Jaakkola T.; Färkkilä M. A.; Arola J.; Kolho K.-L.

P1007

**PLANNED TRANSITION OF ADOLESCENT INFLAMMATORY BOWEL DISEASE PATIENTS FROM PEDIATRIC TO ADULT CARE RESULTS IN HIGHER REMISSION RATES**

Sarlós P.; Otto Caroline, Hungary; Fehér D.; Farkas N.; Vincze A.; Tarnok A.

P1008

**EFFICACY AND SAFETY OF GRANULOMONOCYTAPHERESIS AS REMISSION INDUCTION THERAPY IN ULCERATIVE COLITIS PATIENTS INCLUDING ADOLESCENTS AND ELDERLY**

Toshihide Ohmori, Japan; Ohmori S.

P1009

**THE TRANSITIONAL PROCESS OF INFLAMMATORY BOWEL DISEASE FROM PEDIATRIC TO ADULT AGE**

Testa A.; Giannetti E.; Rispo A.; Rea M.; Miele E.; Opramolla A.; Nicola Imperatore, Italy; Di Luna I.; Nardone O. M.; Staiano A.; Castiglione F.

P1010

**EFFICACY AND DIAGNOSTIC ACCURACY OF FAECAL CALPROTECTIN IN CHILDREN IN PRIMARY CARE, A PROSPECTIVE PRIMARY CARE COHORT STUDY**

Walker G.; Mohamed Abdelrahim, United Kingdom; Moore L.; Heerasing N.; Hendy P.; Thomas A.; Hamilton B.; Bewshea C.; Goodhand J.; Calvert C.; Ahmad T.; Hart J.; Kennedy N. A.

**Paediatric functional lower bowel disorders INCLUDING recurrent abdominal pain**

P1011

**CARBOHYDRATES INTOLERANCE AND INTESTINAL DYSBIOSIS AMONG CHILDREN WITH RECURRENT ABDOMINAL PAIN**

Oana Belej, Romania; Simedrea I.; Olariu L.; Marcovici T.; Marginean O.

P1012

**WHOLE GUT TRANSIT MEASUREMENT USING NOVEL MAGNETIC RESONANCE IMAGING MINI-CAPSULES**

Kathryn Murray, United Kingdom; Hoad C.; Perkins A.; Gowland P.; Spiller R.; Harris R.; Devadason D.; Marciani L.



P1013

**RECURRENT ABDOMINAL PAIN AND PAIN-PREDOMINANT FUNCTIONAL GASTROINTESTINAL DISORDERS FROM BIRTH TO ADOLESCENCE - A PROSPECTIVE SWEDISH BIRTH COHORT STUDY**Jessica Sjölund, Sweden; Uusijärvi A.; Tornkvist N.; Kull I.; Bergström A.; Alm J.; Törnblom H.; Olen O.; Simren M.

P1014

**EFFECT OF DIETARY PATTERNS AND LIFESTYLE ON THE DEVELOPMENT OF CHILDHOOD CONSTIPATION: THE TOYAMA BIRTH COHORT STUDY**Masaaki Yamada, Japan; Sekine M.; Tatsuse T.

P1015

**IDENTIFYING PREDICTIVE FACTORS FOR THE RECURRENT OF PAEDIATRIC INTUSSUSCEPTION**Hyo-jeong Jang, Republic of Korea; Lee H. J.; Lee D. H.

P1016

**PSYCHO-GASTROENTEROLOGICAL PROFILE IN PAEDIATRIC OUTPATIENTS AFFECTED BY DISORDERS OF GUT-BRAIN INTERACTION**Giorgio V. Ilaria Venezia, Italy; Margiotta G.; Camardese G.; Gasbarrini A.; Gaetani E.**Poster Session**

09:00 - 17:00

Hall X1

**Other Lower GI Disorders II****Microbiology**

P1017

**A LINK BETWEEN STOOL FREQUENCY AND GUT MICROBIOTA**Hye-Jung Kwon, Republic of Korea; Lim J. H.; Lim S.; Park S. J.; Kim J. H.

P1018

**THE ROLE OF THE METABOLIC ACTIVITY OF THE INTESTINAL MICROFLORA IN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA RESISTANT TO CORTICOSTEROID THERAPY**Mikhail Abuzin, Russian Federation; Belmer S.; Donyush E.; Kondrashova Z.; Malkova O.P1019 **INHIBITORY EFFECT OF URSODEOXYCHOLIC ACID ON CLOSTRIDIUM DIFFICILE GERMINATION IS INSUFFICIENT TO PREVENT C. DIFFICILE COLITIS: A STUDY IN HAMSTERS AND HUMANS.**Palmieri L.-J.; Rainteau D.; Sokol H.; Beaugerie L.; Dior M.; Coffin B.; Bado A.; Humbert L.; Hoys S.; Janoir C.; Henri Duboc, France

P1020

**SIGNIFICANT DIFFERENCES IN THE GUT MICROBIOME OF PATIENTS WITH ACTIVE PSORIASIS**Nathaniel Aviv Cohen, Israel; Shapiro J.; Shalev V.; Koren O.; Uzan A.; Maharshak N.

P1021

**DIFFERENCE OF COLORECTAL CANCER MICROBIAL COMMUNITY A BY METAGENOMICS AND CULTURE-BASED METHODS**Dong Ho Lee, Republic of Korea; Lee Y. R.; Seol M. J.; Park Y. S.; Shin C. M.; Yoon H.; Kim N. Y.; Cho J. H.; Song D. J.; Kim K. M.**Lower GI malignant disease-epidemiology**

P1022

**A HEALTHY LIFESTYLE IS INVERSELY ASSOCIATED WITH BOTH PROXIMAL AND DISTAL COLORECTAL ADENOMAS**Naomi Fliss-Isakov, Israel; Kariv R.; Webb M.; Ivancovsky-Wajcman D.; Margalit D.; Zelber-Sagi S.P1023 **COMPARISON OF FIT-BASED COLORECTAL CANCER SCREENING PROGRAMMES**Toes-Zoutendijk E.; Portillo Villares M. I.; Hoeck S.; de Brabander I.; Perrin P.; Dubois C.; Monique van Leerdam, The Netherlands; Lansdorp-Vogelaar I.; Bardou M.

P1024

**IMPACT OF COLORECTAL CANCER SCREENING PROGRAMS ON SURGICAL PROCEDURES IN THE VENETO REGION (NORTHEAST ITALY)**Erik Rosa-Rizzotto, Italy; Caroli D.; Saia M.; Guido E.; De Lazzari F.

P1025

**ADDING FAMILY HISTORY OF COLORECTAL CANCER TO THE FIT-BASED SCREENING PROGRAM IN A DUTCH COLORECTAL CANCER SCREENING POPULATION SAMPLE**Victorine Roos, The Netherlands; Kallenberg F.; van der Vlugt M.; Bongers E.; Aalfs C.; Bossuyt P.; Dekker E.

P1026

**THE EPIDEMIOLOGY OF THE SERRATED POLYPOSIIS SYNDROME IN AN AUSTRALIAN SETTING - MORE COMMON THAN PREVIOUSLY APPRECIATED**David Prince, Australia; Keegan M.; Sundaralingham P.; Palfreeman S.; Kostalas S.**Lower GI malignant disease, pathogenesis**P1027 **CLINICOPATHOLOGICAL AND COMPREHENSIVE ANALYSIS BY NEXT GENERATION SEQUENCING (NGS) IN APPENDICEAL MUCINOUS TUMOR**Yuka Yanai, Japan; Saito T.; Hayashi T.; Akazawa Y.; Tsuyama S.; Yatagai N.; Tomita S.; Ogura K.; Matsumoto T.; Wada R.; Hirai S.; Yao T.

P1028

**EPITHELIAL TO MESENCHYMAL TRANSITION IN RESPONSE TO E. COLI-INDUCED SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE INDUCED CHEMOTHERAPEUTIC DRUG RESISTANCE**Thiphane Faïs, France; Cougnoux A.; Delmas J.; Barnich N.; Dalmasso G.; Bonnet R.

P1029

**FECAL INCONTINENCE IN CHRONICALLY CONSTIPATED WOMEN: CLINICAL FEATURE, MANOMETRIC MEASUREMENTS AND PELVIC FLOOR ANATOMICAL ANATOMICAL PATHOLOGIES**Dan Carter, Israel; Marady C.P1030 **INTEGRATIVE ANALYSIS OF GENE MUTATIONS AND DNA METHYLATION IN COLORECTAL SERRATED LESIONS**Takeshi Sawada, Japan; Nakanishi H.; Kaizaki Y.; Sasaki Y.; Yamamoto E.; Aoki H.; Eizuka M.; Takahashi N.; Hasatani K.; Kubota E.; Kataoka H.; Ota R.; Yanase Y.; Inagaki S.; Yamada S.; Minamoto T.; Suzuki H.; Sugai T.

P1031

**PREDICTION OF ADVANCED METACHRONOUS LESIONS IN COLONOSCOPIC SURVEILLANCE ACCORDING TO GENETIC PROFILE OF ADENOMATOUS AND SERRATED POLYPS**Oscar Murcia, Spain; Juárez-Quesada M.; Hernandez-Illan E.; Egoavil C.; Alustiza Fernandez M.; Giner-Calabuig M.; Rodríguez-soler M.; Alenda C.; García-Martínez A.; Aparicio Tormo J. R.; Ruiz-Gómez F.; Martínez J.; Casellas J. A.; Zapater P.; Soto J.-L.; Jover R.P1032 **EMILIN2, A MATRICELLULAR MOLECULE, IMPACTS ON MDSC RECRUITMENT AND MACROPHAGE POLARIZATION IN A MODEL OF COLORECTAL CARCINOGENESIS AND CORRELATES WITH IMMUNOSCORE IN CRC PATIENTS.**Eva Andreuzzi, Italy; Poletto E.; Pellicani R.; Polano M.; Tarticchio G.; Di Carlo E.; Cannizzaro R.; Colombatti A.; Mongiat M.P1033 **MOLECULAR CHARACTERISTICS OF THE DEPRESSED EARLY COLORECTAL CANCERS (DEPRESSED CRC)**Yuta Kouyama, Japan; Kudo S.; Kaga H.; Ogawa Y.; Kudo K.; Ichimasa K.; Miyachi H.; Ishida F.; Mimori K.P1034 **ANALYSIS OF METHYLATION FIELD DEFECT IN SERRATED POLYPOSIS SYNDROME**Eva Hernández-Illán, Spain; Lozano J. J.; Muñoz J.; Carballal S.; Cuatrecasas M.; Moreno L.; Diaz M.; Ocaña T.; Jung G.; Sánchez A.; Rivero L.; Castells A.; Pellisé M.; Balaguer F.**Lower GI malignant disease, diagnosis/histopathology**P1035 **COMPARISON OF IMMUNOPROFILING BETWEEN COLITIS-ASSOCIATED CANCER AND SPORADIC COLORECTAL CANCER**Jae Seung Soh, Republic of Korea; Jo S.; Lee H.; Song E. M.; Hwang S. W.; Park S. H.; Yang D.-H.; Ye B. D.; Byeon J.-S.; Yang S.-K.; Kim J. H.; Kim S.-Y.; Myung S.-J.

P1036

**CLINICOPATHOLOGIC FEATURES, MICROSATELLITE INSTABILITY STATUS AND CHARACTERISTIC MOLECULAR ALTERATIONS OF COLORECTAL SIGNET RING CELL CARCINOMAS.**Sun Mi Lee, Republic of Korea; Broaddus R.; Chen H.

P1037

**CLINICOPATHOLOGICAL DIFFERENCES BETWEEN RIGHT AND LEFT-SIDED T1 COLORECTAL CANCER: A SINGLE CENTER RETROSPECTIVE STUDY**Kenichi Mochizuki, Japan; Kudo S.; Ichimasa K.; Kouyama Y.; Sakurai T.; Matsuda S.; Yagawa Y.; Nakamura H.; Takeda K.; Ishigaki T.; Toyoshima N.; Mori Y.; Misawa M.; Ogata N.; Kudo T.; Hisayuki T.; Hayashi T.; Wakamura K.; Baba T.; Hidaka E.; Miyachi H.; Ishida F.P1038 **RISK FOR LYMPH NODE METASTASIS AND RECURRENT CANCER IN NON-PEDUNCULATED T1 COLORECTAL CARCINOMA STRATIFIED FOR CONSENSUS MOLECULAR SUBTYPES AND THE IMMUNOSCORE**Yara Backes, The Netherlands; Elias S. G.; Kranenburg O.; Trinh A.; Noe M.; Tuyenman J. B.; Van Lent A. U. G.; van Ginneken R.; Seldenrijk C.; Raicu M.; Milne A.; Boonstra J. J.; Groen J. N.; Schwartz M. P.; Wolfhagen F. H. J.; Geesing J. M. J.; ter Borg F.; Brosens L. A. A.; Van Bergeijk J. D.; Spanier B. W. M.; De Vos tot Nederveen Cappel W.; Kessels K.; Seerden T. C. J.; Vleggaar F. P.; Offerhaus G. J. A.; Siersema P. D.; Lacle M.; Moons L. M. G.P1039 **LIQUID BIOPSY IN COLORECTAL CANCER: DECIPHERING NOVEL NON-INVASIVE METHYLATION BIOMARKERS FOR COLORECTAL CANCER SCREENING IN SERUM CIRCULATING CELL-FREE DNA**Gallardo-Gómez M.; Planell N.; Morán S.; Páez de la Cadena M.; Martínez Zorzano V. S.; Rodríguez Berrocal F. J.; Rodríguez-Girondo M.; Labarga A.; Esteller M.; Joaquín Cubiella, Spain; Bujanda Fernández de Piérola L.; Castells A.; Balaguer F.; Jover R.; Gómez Cabero D.; De Chiara L.

P1040

**COLORECTAL CANCER AND EXPERIENCE IN TESTING FOR LYNCH SYNDROME IN A WEST LONDON HOSPITAL.**Anna Cavazza, United Kingdom; Radia C.; Harlow C.; Monahan K. J.

P1041

**SOX21 GENE PROMOTER METHYLATION ANALYSIS IN PERIPHERAL BLOOD MONONUCLEAR CELLS IS SENSITIVE PREDICTOR OF COLORECTAL CANCER**

Khodadoostan M.; Ahmadian M.; Salehi R.;

[Alireza Shavakhi](#), Iran; Saberi F.

P1042

**CORRELATION BETWEEN LONG-TERM FUNCTIONAL OUTCOME AND MR IMAGING PATTERNS OF RESPONSE IN CLINICAL COMPLETE RESPONDERS UNDERGOING WAIT-AND-SEE AFTER CHEMORADIOTHERAPY FOR RECTAL CANCER.**[Doenja M. J. Lambregts](#), The Netherlands; Maas M.;

Boellaard T. N.; Delli Pizzi A.; van der Sande M.;

Hupkens B. J. P.; Haak H. E.; Lahaye M. J.;

Beets-Tan R. G. H.; Beets G. L.

**Lower GI malignant disease, management**

P1043

**THE VALIDITY OF ENDOSCOPIC SUBMUCOSAL DISSECTION WITH SMALL-CALIBER ENDOSCOPE FOR THE LESIONS SPREADING TO APPENDIX ORIFICE**[Jun Tachikawa](#), Japan; Chiba H.; Arimoto J.; Ashikari K.;

Kuwabara H.; Nakaoka M.; Goto T.; Ohata K.

P1044

**THE PREDICTORS OF SEVERE SUBMUCOSAL FIBROSIS IN PATIENTS UNDERGOING COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION**[Keiichi Ashikari](#), Japan; Chiba H.; Tachikawa J.;

Arimoto J.; Kuwabara H.; Nakaoka M.; Nakajima A.

P1045

**USEFULNESS OF HYBRID ENDOSCOPIC SUBMUCOSAL DISSECTION USING MULTIFUNCTIONAL NEW DEVICE**[Jun Tachikawa](#), Japan; Chiba H.; Arimoto J.; Ashikari K.;

Kuwabara H.; Nakaoka M.; Goto T.; Ohata K.

P1046

**RECURRENT AND SECOND PRIMARY CANCERS AT THE ONE YEAR SURVEILLANCE COLONOSCOPY FOLLOWING CURATIVE COLORECTAL CANCER RESECTION**[Meta C. J. Van Lanschoot](#), The Netherlands;

van Leerdam M.; Lansdorp-Vogelaar I.; Doets S.;

Nagtegaal I. D.; van der Hulst R. W. M.; Meijer G. A.;

Dekker E.; van Berkel A.-M.

P1047

**ENDOSCOPIC RESECTION OF T1 COLORECTAL CANCER – INFLUENCE OF THE RISK FACTORS ON DECISION-MAKING AND PROGNOSIS**[Filipe Taveira](#), Portugal; Areia M.; Elvas L.; Alves S.;

Brito D.; Saraiva S.; Cadime A. T.

P1048

**BETTER RESULTS OF STOMA RATE AND ADVERSE EVENTS WHEN USING STENTS AS BRIDGE TO SURGERY FOR LEFT-SIDED MALIGNANT COLONIC OBSTRUCTION COMPARED WITH EMERGENCY SURGERY: A RETROSPECTIVE BICENTRIC STUDY**[Carmen Lara](#), Spain; Lavin I.; Caunedo A.;

Rodriguez-Téllez M.; Alcain G.

P1049

**STENT PLACEMENT AS BRIDGE TO SURGERY VERSUS EMERGENT SURGERY FOR MALIGNANT LEFT-SIDED COLONIC OBSTRUCTION**[Rui Morais](#), Portugal; Rodrigues-Pinto E.; Coelho C.;

Vilas Boas F.; Moutinho Ribeiro P.; Lopes S.;

Ramalho R.; Pereira P. R.; Macedo G.

P1050

**APOPTOSIS INDUCTION IN COLON CANCER CELL BY NEWLY DEVELOPED ENDOSCOPIC IRREVERSIBLE ELECTROPORATION ABLATION DEVICE**Jeen Y.-T.; Jang S.; Kim J. H.; [Sang Hoon Kim](#), Republic

of Korea; Han Jo J.; Choi S. J.; Lee J. M.; Kim S. H.;

Lee J. M.; Choi H.-S.; Kim E.-S.; Keum B.; Lee H.;

Chun H. J.; Kim C. D.

P1051

**EFFECT OF ORAL ANTICOAGULANTS AND NSAIDS ON THE ACCURACY OF FECAL IMMUNOCHEMICAL TESTS (FIT) WITHIN A COLORECTAL CANCER SCREENING PROGRAMME – A SYSTEMATIC REVIEW AND META-ANALYSIS**[S. A. V. Nieuwenburg](#), The Netherlands; Vuik F. E. R.;

Kruip M. J. H. A.; Spaander M. C. W.; Kuipers E. J.

P1052

**COMPARISON OF INCIDENCE AND SURVIVAL OUTCOMES IN MUCINOUS AND SIGNET-RING CELL COLORECTAL CANCERS WITH CLASSICAL ADENOCARCINOMA: A SEER ANALYSIS** ✦[Tahir Mehmood](#), Pakistan

P1053

**A SEER ANALYSIS OF INCREASING DISPARITIES IN AGE-RELATED CAUSE SPECIFIC SURVIVAL (CSS) AMONG PATIENTS WITH COLORECTAL CANCER**[Tahir Mehmood](#), Pakistan

P1054

**IMPACT OF OBESITY AND VISCERAL FAT DISTRIBUTION ON SURVIVAL AND PERITONEAL SEEDING METASTASIS OF STAGE III COLORECTAL CANCER**[Jung Won Park](#), Republic of Korea; Chang S. Y.; Park Y. H.;

Park S. J.; Cheon J. H.; Kim W. H.; Kim T. I.

P1055

**RISK OF RECURRENCE AND LYMPH NODE METASTASIS AFTER ENDOSCOPIC AND SURGICAL REMOVAL OF MALIGNANT COLORECTAL POLYPS: A COMPARATIVE STUDY**  
[Anna Fabian](#), Hungary; [Bor R.](#); [Szabó Ö.](#); [Rutka M.](#); [Vasas B.](#); [Andrási L.](#); [Balint A.](#); [Farkas K.](#); [Milassin Á.](#); [Szántó K.](#); [Molnár T.](#); [Szepes Z.](#)

P1056

**QUANTITATIVE FLUORESCENCE ENDOSCOPY: A NEW AND PROMISING TOOL TO PREDICT AND EVALUATE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER PATIENTS**  
[Tjalma J. J. J.](#); [S. J. de Jongh](#), The Netherlands; [Koller M.](#); [Linssen M. D.](#); [Hartmans E.](#); [Jorritsma-Smit A.](#); [Karrenbeld A.](#); [de Vries E. G. E.](#); [Kleibeuker J. H.](#); [Pennings J. P.](#); [Havenga K.](#); [Hemmer P. H. J.](#); [Hospers G. A. P.](#); [van Etten B.](#); [Ntziachristos V.](#); [van Dam G. M.](#); [Robinson D. J.](#); [Nagengast W. B.](#)

P1057

**WHICH IS THE REASON FOR WE NEED TO REPEAT COLONOSCOPIES IN COLORECTAL CANCER (CCR) SCREENING PROGRAM? ANALYSIS OF THE IMPACT OF ADDITIONAL COLONOSCOPIES IN THREE CONSECUTIVE ROUNDS**  
[Laura Carot](#), Spain; [Gonzalez M.](#); [Enriquez Marroquin C. F.](#); [Hernández C.](#); [Alvarez-Urturi C.](#); [Andreu Garcia M.](#); [Bessa Casserras X.](#)

P1058 

**ARTIFICIAL INTELLIGENCE CAN DETERMINE THE NEED FOR ADDITIONAL SURGERY AFTER ENDOSCOPIC RESECTION OF T1 COLORECTAL CANCER: ANALYSIS BASED ON BIG DATA FOR MACHINE LEARNING**  
[Katsuro Ichimasa](#), Japan; [Kudo S.](#); [Mori Y.](#); [Misawa M.](#); [Kouyama Y.](#); [Sakurai T.](#); [Yagawa Y.](#); [Matsudaira S.](#); [Nakamura H.](#); [Ishigaki T.](#); [Takeda K.](#); [Toyoshima N.](#); [Ogata N.](#); [Kudo T.](#); [Hayashi T.](#); [Wakamura K.](#); [Miyachi H.](#); [Ito H.](#); [Mori K.](#); [Ishida F.](#)

P1059

**LOCAL INJECTION OF A WATER JET AND MAGNIFIED ENDOSCOPIC OBSERVATION USING SPECIAL LIGHT ARE USEFUL FOR PREVENTING RESIDUAL LESIONS IN COLD POLYPECTOMY.**  
[Mitsunori Yasuda](#), Japan; [Naito Y.](#)

**IBS /Lower GI motility: Brain-gut and gut-brain axes, neuro-hormonal, neural-immune and visceral sensitivity**

P1060

**SYSTEMATIC REVIEW AND META-ANALYSIS: CONDITIONED PAIN MODULATION IN IRRITABLE BOWEL SYNDROME**  
[Ahmed Albusoda](#), United Kingdom; [Ruffle J.](#); [Friss K. A.](#); [Gysan M. R.](#); [Drewes A.](#); [Aziz Q.](#); [Farmer A. D.](#)

P1061

**ASSOCIATIONS BETWEEN SYMPTOMS AND GAS PRODUCTION DURING FODMAP BREATH TESTS IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS**  
[Clive Wilder-Smith](#), Switzerland; [Olesen S. S.](#); [Materna A.](#); [Drewes A.](#)

P1062

**FAECAL METABOLIC PHENOTYPING IN IRRITABLE BOWEL SYNDROME**  
[Zlatan Mujagic](#), The Netherlands; [Posma J. M.](#); [Jonkers D. M. A. E.](#); [Garcia-Perez I.](#); [Vork L.](#); [Weerts Z. Z. R. M.](#); [Holmes E.](#); [Nicholson J. K.](#); [Masclee A. A. M.](#)

P1063

**PROTEASE ACTIVATED RECEPTOR-2 INDUCES IMMUNE ACTIVATION AND VISCERAL HYPERSENSITIVITY IN POST-INFECTIOUS IRRITABLE BOWEL SYNDROME**  
[Du L.](#); [Long Y.](#); [Kim J. J.](#); [Chen B.](#); [Zhu Y.](#); [Dai N.](#); [Luyi Chen](#), China

P1064

**THE MODERATING IMPACT OF PAIN AETIOLOGY ON THERAPEUTIC CHANGE IN COGNITIVE-BEHAVIOURAL THERAPY FOR CHRONIC PAIN**  
[McNaughton D.](#); [Beath A.](#); [Hush J.](#); [Dear B.](#); [Michael Jones](#), Australia

P1065

**HOW THE PLACEBO EFFECT PLATEAUS: PREDICTORS OF THE SHAPE OF PLACEBO RESPONSE IN IBS-C**  
[Alissa Beath](#), Australia; [Ballou S.](#); [Lembo A. J.](#); [Jones M. P.](#)

### Irritable bowel syndrome: Epidemiology

P1066

**LACK OF EVIDENCE FOR A LINK BETWEEN INTESTINAL MAST CELLS, SYMPTOM PROFILE AND MUCOSAL BARRIER INTEGRITY IN IRRITABLE BOWEL SYNDROME**  
[Sofia Nordlander](#), Sweden; [Sundin J.](#); [Eutamène H.](#); [Theodorou V.](#); [Le Nevé B.](#); [Törnblom H.](#); [Simrén M.](#); [Öhman L.](#)

P1067

**SEXUAL DYSFUNCTION AND IMPACT OF IRRITABLE BOWEL SYNDROME IN PATIENTS AND SPOUSES**  
[Sabate J. M.](#); [Ducrotté P.](#); [Riviere P.](#); [Dapoigny M.](#); [Macaigne G.](#); [Mion F.](#); [Iglücki F.](#); [Bouchoucha M.](#); [Façon S.](#); [Blanchard A.](#); [Entremont A.](#); [Pauline Jouët](#), France

P1068

**ADHERENCE WITH LOW FODMAPS DIET IN IRRITABLE BOWEL SYNDROME: ARE EATING DISORDERS THE MISSING LINK?**  
[Mari A.](#); [Hosadurg D.](#); [Martin L.](#); [Valentina Passanati](#), United Kingdom; [Zarate Lopez N.](#); [Emmanuel A.](#)

P1069

**IRRITABLE BOWEL SYNDROME, CHRONIC FATIGUE AND PAIN IN A NORWEGIAN PRIMARY CARE POPULATION**  
[Knut-Arne Wensaas](#), Norway; [Litleskare S.](#); [Rortveit G.](#); [Emberland K. E.](#); [Waage S.](#); [Diaz E.](#); [Ruths S.](#); [Schei E.](#); [Fadnes L. T.](#); [Bjorvatn B.](#)

P1070

**THE SOCIOECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME IN A DUTCH POPULATION.**  
[Zsa Zsa Regina Maria Weerts](#), The Netherlands; [Keszthelyi D.](#); [Janssen D. J. P. A.](#); [Vork L.](#); [Essers B. A.](#); [Jonkers D. M.](#); [Masclée A.](#)

P1071

**STRONG EVIDENCE SOMATISATION MEASURES BASED ON SYMPTOM CHECKLISTS ARE MORE REFLECTIVE OF PSYCHOLOGICAL RATHER THAN PHYSICAL HEALTH: IMPORTANT CONSEQUENCES FOR GASTROENTEROLOGY RESEARCH AND PRACTICE**  
[Michael Jones](#), Australia; [Loxton D.](#); [Harris M.](#); [Beath A.](#); [Talley N. J.](#); [Koloski N.](#); [Ejova A.](#)

P1072

WITHDRAWN

P1073

**PREVALENCE AND IMPACT OF SELF-REPORTED VERSUS ROME IV CRITERIA-BASED IRRITABLE BOWEL SYMPTOMS IN THE GENERAL POPULATION**  
[Karen Van den Houte](#), Belgium; [Carbone F.](#); [Pannemans J.](#); [Corsetti M.](#); [Fischler B.](#); [Piessevaux H.](#); [Vanuytsel T.](#); [Tack J.](#)

**Irritable bowel syndrome: Classification and diagnosis**

P1074

**DOES BLINDING AFFECT THE OUTCOME OF FRUCTOSE BREATH TESTING IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS?**  
[Clive Wilder-Smith](#), Switzerland; [Olesen S. S.](#); [Materna A.](#); [Drewes A.](#)

P1075

**BLOATING IN A LARGE OUTPATIENT POPULATION: DISCHARGE OR INVESTIGATE?**  
[Catriona Zammit](#), Malta; [Ellul P.](#); [Vassallo M.](#)

**Irritable bowel syndrome: Treatment**

P1076

**EFFECTS OF ALOE BARBADENSIS MILL. EXTRACT ON SYMPTOMS AND FAECAL MICROBIOTA PROFILE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME**  
[Bani Ahluwalia](#), Sweden; [Böhn L.](#); [Störsrud S.](#); [Larsson F.](#); [Magnusson M. K.](#); [Simrén M.](#); [Öhman L.](#)

P1077

**EFFICACY AND SAFETY OF ELUXADOLINE IN IBS-D PATIENTS WHO REPORT INADEQUATE SYMPTOM CONTROL WITH PRIOR LOPERAMIDE USE: A PHASE 4, MULTICENTER, MULTINATIONAL, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY (RELIEF)**  
[Brenner D.](#); [Gutman C.](#); [Jo E.](#); [Steven Elmes](#), United States

P1078

**MULTIDISCIPLINARY SHARED MEDICAL APPOINTMENTS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS: PRELIMINARY RESULTS OF A NON-PHARMACOLOGICAL PILOT STUDY**  
[Marta Tejedor](#), Spain; [Alcalde D.](#); [Cruces C.](#); [Hernando E.](#); [López M. C.](#); [Briz R.](#); [Calvache A.](#); [Barranco R.](#); [Castillo L. A.](#); [Chico I.](#); [de Lucas M.](#); [Marruffo R.](#); [Rodríguez R.](#); [Delgado M.](#)

P1079

**HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: THE PATIENT'S PERCEPTION**  
[Anne-Sophie Donnet](#), United Kingdom; [Hasan S. S.](#); [Miller V.](#); [Whorwell P.](#)

P1080

**RANDOMIZED CLINICAL TRIAL: EFFECT OF BIO-25 ON MICROBIOTA COMPOSITION OF PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME**  
[Hod K.](#); [Dekel R.](#); [Nathaniel Aviv Cohen](#), Israel; [Sperber A.](#); [Ron Y.](#); [Boaz M.](#); [Berliner S.](#); [Maharshak N.](#)

P1081 

**STRUCTURED PATIENT GROUP EDUCATION VERSUS STRUCTURED PATIENT EDUCATION VIA THE INTERNET FOR PATIENTS WITH IBS: A RANDOMIZED, CONTROLLED TRIAL**  
[Perjohan Lindfors](#), Sweden; [Simrén M.](#); [Törnblom H.](#); [Ringström G.](#); [Störsrud S.](#); [Jerlstad P.](#); [Engstrand K.](#); [Ljotsson B.](#)

P1082

**USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY PATIENTS WITH ROMA IV CRITERIA FOR IRRITABLE BOWEL SYNDROME: A SINGLE-CENTER ITALIAN SURVEY**  
[Tiziana Larussa](#), Italy; [Rossi M.](#); [Suraci E.](#); [Marasco R.](#); [Imeneo M.](#); [Luzza F.](#)

**Ano-rectal disorders other than IBD or motility-related**

P1083

**THE MEANING OF BILE ACIDS AND VIOLATIONS OF MICROBIAL METABOLISM IN THE COLON IN THE PATHOGENIC MECHANISM OF DIARRHEA IN PATIENTS THAT SUSTAINED CHOLECYSTECTOMY OR RESECTION OF THE SMALL INTESTINE**  
[Svetlana Silvestrova](#), Russian Federation; [Indeykina L.](#); [Kuzmina T.](#); [Sabelnikova E.](#); [Parfenov A.](#)



P1084  
**PSYCHOLOGICAL MORBIDITY AND IMPACT ON THE QUALITY OF LIFE OF BENIGN ANORECTAL DISORDERS**  
Rui Morais, Portugal; Coelho R.; Santos A. L.; Costa-Moreira P.; Macedo G.

P1085  
**ANATOMICAL AND FUNCTIONAL FEATURES OF THE INTERNAL RECTAL PROLAPSE DETERMINED WITH 3D ENDORECTAL ULTRASONOGRAPHY AND HIGH RESOLUTION ANORECTAL MANOMETRY. AN OBSERVATIONAL CASE-CONTROL STUDY.**  
Salvatore Tolone, Italy; Brusciano L.; del Genio G.; Limongelli P.; Lanza Volpe M.; Terracciano G.; Gualtieri G.; Parisi S.; Docimo L.

P1086  
**FAECAL INCONTINENCE IN TYPE 2 DIABETICS: COMPARISON WITH NON DIABETIC HEALTHY INDIVIDUALS AND ANALYZE OF RELATED FACTORS.**  
João Xavier Jorge, Portugal; Fernandes L.; Panão E. A.; Costa Almeida C.; Delgado F. J.; Correia Coelho Á.

P1087  
**EFFECTS OF BIOFEEDBACK THERAPY ON CLINICAL AND MANOMETRIC PARAMETERS IN PELVIC FLOOR DYSFUNCTIONS**  
Lucia D'Alba, Italy; Neri M. C.; Corrado C.; Ribichini E.; Tassi A.; Zaccari P.; De Cesare A.; Di Paolo M. C.; Pallotta L.; Urgesi R.; Villotti G.; Vitale A.; Graziani M. G.

#### Poster Session

09:00 – 17:00 Hall X1  
**Oesophageal, Gastric and Duodenal Disorders II**

#### Immunity and inflammation (not *H. pylori*)

P1088  
**WITHDRAWN**

P1089  
**PREVALENCE OF AUTOIMMUNE GASTRITIS IN AUTOIMMUNE DISEASES: A POPULATION STUDY BASED ON A NON-INVASIVE TEST**  
 Di Mario F.; Silvia Speroni, Italy; Franceschi M.; Baldassarre G.; Antico A.; Panozzo M. P.; Rodriguez-Castro K.; Franzoni L.; Crafa P.; Miraglia C.; Rugge M.

P1090  
**GASTRIC FUNCTION MARKERS: BECAUSE ANTIBODIES ARE NOT ENOUGH IN THE EVALUATION OF AUTOIMMUNE GASTRITIS**  
 Rodriguez-Castro K.; Antico A.; Silvia Speroni, Italy; Franceschi M.; Baldassarre G.; Panozzo M. P.; Tursi A.; Brandimarte G.; Franzoni L.; Crafa P.; Miraglia C.; Nounne A.; Rugge M.; Di Mario F.

P1091  
**INCREASED DEEP INTRAEPITHELIAL LYMPHOCYTE INFILTRATION OF THE STOMACH CORPUS AS A CLUE OF AUTOIMMUNE ATROPHIC GASTRITIS**  
Marco Vincenzo Lenti, Italy; Vanoli A.; Giuffrida P.; Martino M.; Soriano S.; Pasini A.; Brachitta L. M.; Capuano F.; Arpa G.; Miceli E.; Staiani M.; Corazza G. R.; Di Sabatino A.


P1092  
**GASTRIC MUCOSAL DAMAGE INDUCED BY ETHANOL CAN BE IMPROVED BY CAFFEIC ACID IN RATS**  
Meltem Kolgazi, Turkey; Cilingir S.; Gemici M.; Yazar H.; Yilmaz O.; Ozer S.; Gulec-Suyen G.

#### Microbiology

P1093  
**WITHDRAWN**

P1094  
**GASTRIC MICROBIOTA ALTERATION FOLLOWING ERADICATION OF *H. PYLORI***  
Yuji Nadatani, Japan; Watanabe T.; Otani K.; Hosomi S.; Nagami Y.; Tanaka F.; Kamata N.; Taira K.; Yamagami H.; Tanigawa T.; Fujiwara Y.

P1095  
**HELICOBACTER PYLORI ANTIBODY AND PEPSINOGEN TESTING FOR PREDICTING GASTRIC MICROBIOME ABUNDANCE**  
Jae Gon Lee, Republic of Korea; Choi S.; Lee A.-R.; Eun C. S.; Han D. S.; Park C. H.

P1096   
**CHARACTERIZATION OF MUCOSAL AND FLUID MICROBIOME ACROSS STAGES OF GASTRIC CARCINOGENESIS**  
Cong He, China; Xia Z.; Xiao L.; Peng C.; Zhu Y.; Shu X.; Jia H.; Lu N.

P1097  
**COMPREHENSIVE ANALYSIS OF HISTOLOGICAL MICRORNAS OF PANCREATIC CANCER COLLECTED BY EUS-FNA**  
Kiyohito Kato, Japan; Kamada H.; Kobayashi K.; Masaki T.

P1098  
**ALTERATIONS IN GUT MICROBIOTA COMPOSITION DURING AGING**  
 Xu W.; Luyi Chen, China; Wang L.; Chen S.

## Upper GI and small intestinal bleeding

P1099

### COMPARISON OF RISK SCORING SYSTEMS FOR PATIENTS PRESENTING WITH ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGIB): AN ITALIAN MULTI-CENTRE PROSPECTIVE STUDY

Marmo R.; [Marco Soncini](#), Italy; Bennato R.; Cipolletta F.; Lucio O.; Parente F.; Lucio A.; Paterlini A.; Cesaro P.; Alessandra B.; Germana B.; de Franchis R.; Costamagna G.; Riccioni M. E.; Marmo C.; Tortora A.; Manno M.; Mangiafico S.; Conigliaro R. L.; Metrangolo S.; Merighi A.; Boarino V.; Segato S.; Imperiali G.; Bucci C.; Borgheresi P.; Baldassarre G.; Franceschi M.; Nucci A.; Ferraris L.; Zambelli A.; Londoni C.; Repici A.; Anderloni A.; De Matthaies M.; Triossi O.; Rotondano G.; Lamanda R.; Lauri A.; De Fanis C.; Di Giorgio P.; Pumpo R.; Andriulli A.; Bazzoli F.; Zagari R. M.; Buscarini E.; Cipolletta L.; Conte D.; Spinzi G.; Di Giulio E.; Balzano A.

P1100

### COMPARATIVE EFFICACY AND SAFETY OF INTERVENTIONS FOR PRIMARY PREVENTION OF VARICEAL BLEEDING: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Katsoula A.; [Paschalis Paschos](#), Greece; Malandris K.; Manolopoulos A.; Andreadis P.; Athanasiadou E.; Giouleme O.; Tsapas A.

P1101

### WITHDRAWN

P1102

### EFFECT OF GASTROPROTECTIVE AGENTS ON PREVENTING UPPER GASTROINTESTINAL BLEEDING IN PATIENTS RECEIVING DIRECT ORAL ANTICOAGULANTS: A RETROSPECTIVE MULTICENTER STUDY

[Hyun Lim](#), Republic of Korea

P1103 

### DEVELOPMENT OF A NEW SCORE TO PREDICT MORTALITY AND INTERVENTION IN UPPER GASTROINTESTINAL BLEEDING. THE HA(MA)SH SCORE

[Eduardo Redondo-Cerezo](#), Spain; Jiménez-Rosales R.; Vadillo-Calles F.; Ortega-Suazo E. J.; Valverde López F.; Martínez-Cara J.

P1104

### THE STATISTICAL COMPARISON OF ENDOSCOPIC PROCEDURE AND TRANSARTERIAL EMBOLIZATION FOR HEMORRHAGE CAUSED BY DUODENAL ULCER.

[Yuki Yonemoto](#), Japan; Fukami Y.; Hara H.; Mochida T.; Machida T.; Sugiyama Y.; Watanabe A.; Kaneshiro M.; Ikemiyagi H.; Yoshino K.; Sakita S.

P1105

### A RETROSPECTIVE SINGLE CENTRE REVIEW OF HEMO-SPRAY® IN GI BLEEDING.

[Erin Prentice](#), United Kingdom; Masegosa Ataz J.; Barron M.; Todd J.; Mowat C.; Groome M.

P1106

### IS TOPICAL TRANEXAMIC ACID EFFECTIVE IN UPPER GI BLEEDING?

[Mahsa Khodadoostan](#), Iran; Shahbazi A.; Shavakhi A.; Shavakhi A.

P1107

### CLINICAL COURSE AFTER HEMORRHAGE IN PATIENTS TAKING DOAC AND SIGNIFICANCE OF GASTROINTESTINAL BLEEDING

[Daisuke Yanagisawa](#), Japan; Abe K.; Osumi S.; Yamato H.; Maruyama K.; Nakamura N.; Miki A.; Okamura T.; Aoyagi H.; Isono A.; Kodashima S.; Yamamoto T.

P1108

### ENDOSCOPIC EXPLORATORY VARICES DEVASCULARIZATION FOR THE TREATMENT OF ACUTE ESOPHAGEAL VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS

[Lu Huang](#), China; Chen H. H.; Li G. Q.; Wang Z. G.; Qiong Y.; Wen C.

P1109

### EFFICACY AND SAFETY OF OCTREOTIDE FOR THE TREATMENT OF SEVERE RECURRENT GASTROINTESTINAL BLEEDING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: RESULTS OF A PROSPECTIVE PHASE II MULTICENTER CLINICAL TRIAL

[Karina Grooteman](#), The Netherlands; Kroon S.; Tenthof - van Noorden J.; Snijder R.; van Geenen E. J. M.; Mager J. J.; Drenth J. P. H.

P1110

### THE DETERMINATION OF NOVEL ANGIOGENIC FACTORS IN SMALL BOWEL ANGIODYSPLASIA

[Grainne Holleran](#), Ireland; Smith S.; McNamara D.

## Functional upper GI disorders: Basic

P1111

### ENHANCED EXPRESSION OF HUMAN HERPES SIMPLEX VIRUS 1 DERIVED MICRO RNA IN LOWER ESOPHAGEAL SPHINCTER MUSCLE USING BIOPSY SAMPLES UNDER PER-ORAL ENDOSCOPIC MYOTOMY

[Yuichiro Ikebuchi](#), Japan; Isomoto H.; Kanda T.; Sumi K.; Ikeda H.; Onimaru M.; Yoshida A.; Minami H.; Urabe S.; Nakao K.; Inoue H.

P1112

### JIANPILIQI FORMULA RESTORES DUODENAL MUCOSAL INTEGRITY AND SUPPRESSES LOW-GRADE INFLAMMATION IN A RAT MODEL OF FUNCTIONAL DYSPEPSIA

[Luqing Zhao Z'hao](#), China; Chang X.; Zhang S.

P1113

### MANOMETRICS CHARACTERISTICS OF OESOPHAGEAL MOTOR ACTIVITY IN TYPE 2 DIABETICS WITH COMPLAINTS OF CONSTIPATION: COMPARISON WITH DIABETICS WITHOUT CONSTIPATION.

[João Xavier Jorge](#), Portugal; Panão E. A.; Costa Almeida C.; Simões M. A.; Fernandes L.; Delgado F. J.

P1114

**IS THERE A ROLE OF INTERSTITIAL CELLS OF CAJAL FOR GASTRIC SLOW WAVE PATTERNS DURING GASTRIC ELECTRICAL STIMULATION**

Bora Keum, Republic of Korea; Jang S.; Han Jo J.; C hoi S. J.; Lee J. M.; Lee J. M.; Kim S. H.; Choi H.-S.; Kim E.-S.; Jeon Y.-T.; Lee H.; Chun H. J.; Kim C. D.

P1115 **HOW CAN WE MEASURE ACID SECRETION IN THE SINGLE PATIENT? A VALIDATED NON-INVASIVE SURROGATE TEST COMPARED WITH MAXIMAL ACID OUTPUT IN 600 PEOPLE**

Chiara Miraglia, Italy; Scida S.; Franceschi M.; Crafa P.; Barchi A.; Franzoni L.; Cannizzaro R.; Nouvenne A.; Scarpignato C.; Rugge M.; Di Mario F.

P1116

**INTERNATIONAL CONSENSUS CONFERENCE ON DUMPING SYNDROME DIAGNOSIS AND MANAGEMENT.**

Emidio Scarpellini, Italy; Arts J.; Karamanolis G.; Laurenus A.; Siquini W.; Suzuki H.; Ukleja A.; Van Beek A.; Vanhuysel T.; Tack J.; Dumping Syndrome Consensus Conference Research Group D.S.C.C.R.G.

P1117

**EFFICIENCY AND SAFETY OF ENDOSCOPIC DILATION OF THE PLUMMER-VINSON RING**

Mustapha Loutfi, Morocco; Chakkor A.; Salioun M.; Acharki M.; Kabbaj N.

P1118

**ENDOSCOPIC TREATMENT OF LARGE GASTRIC PHYTO-BEZOARS WITH A SIMPLE HANDMADE BEZOARATOME**

Toka B.; Ahmet Tarik Eminler, Turkey; Karacaer C.; Uslan M. I.; Koksal A. S.; Parlak E.

**Upper GI motility disorders: Clinical**P1119 **EFFECT OF INTRACOLONIC GAS ON GASTRIC TONE AND SATIETY IN PATIENTS WITH CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME AND DYSPEPTIC SYMPTOMS**

Caballero N.; Ingrid Marin, Spain; Benslaiman B.; Riu F.; Leal C.; Serra J.

P1120 **EVALUATION OF THE EFFECT OF ITRACONAZOLE, A POTENT CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF TAK-906, A PERIPHERALLY-SELECTIVE D<sub>2</sub>/D<sub>3</sub> DOPAMINE RECEPTOR ANTAGONIST**

Chunlin Chen, United States; Zhang W.; Bari M.; Baratta M.; Rosario M.

P1121

**SIGNIFICANT DECREASE IN INTEGRATED RELAXATION PRESSURE OF THE UPPER ESOPHAGEAL SPHINCTER FOLLOWING PNEUMATIC DILATION OF LOWER ESOPHAGEAL SPHINCTER FOR ACHALASIA**

Tamar Thurm, Israel; Deutsch (Mlynarsky) L.; Dekel R.; Ron Y.

P1122

**PER ORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA: TIME FOR CLINICAL PRACTICE GUIDELINES? A EUROPEAN MULTICENTER SURVEY**

Jean-Michel Gonzalez, France; Pioche M.; Jacques J.; Chabrun E.; Rivory J.; Wallenhorst T.; Leblanc S.; Rahmi G.; Vanbiervliet G.; Lepille V.; Branche J.; Privat J.; Chevaux J.-B.; Charachon A.; Bhandari P.; Albéniz Arbizu E.; Guarner Argente C.; Fedorov E. D.; Smirnov A.; Deviere J.; Seewald S.; Barthet M.; Vitton V.

P1123

**LONG-TERM EFFICACY OF PERORAL ENDOSCOPIC MYOTOMY FOR PATIENTS WITH ACHALASIA: A 4-YEAR FOLLOW-UP STUDY**

Chenghai He, China; Li M.; Ma C.; Ying X.; Lyu B.

P1124 **LONG BREAKS IN PERISTALTIC INTEGRITY SEEN IN FRAGMENTED AND FAILED SWALLOWS ON ESOPHAGEAL HIGH RESOLUTION MANOMETRY (HRM) PREDICT ABNORMAL REFLUX BURDEN BETTER THAN WEAK CONTRACTION VIGOR**

Arvind Rengarajan, United States; Rogers B.; Mauro A.; Ghisa M.; De Bortoli N.; Ribolsi M.; Penagini R.; Savarino E.; Gyawali C. P.

P1125

**COMBINED MULTICHANNEL INTRALUMINAL IMPEDANCE AND HIGH RESOLUTION MANOMETRY IMPROVES DETECTION OF CLINICALLY RELEVANT ESOPHAGOGASTRIC JUNCTION OUTFLOW OBSTRUCTION**

Tae-Se Kim, Republic of Korea; Song B. G.; Min Y. W.; Lee H.; Min B.-H.; Lee J. H.; Rhee P.-L.; Kim J. J.

P1126

**A SINGLE CENTER EXPERIENCE WITH PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA- TWO-YEAR FOLLOW-UP AND BEYOND +**

Zuzana Rabekova, Czech Republic; Vackova Z.; Lanska V.; Spicak J.; Stirand P.; Hucl T.; Kieslichova E.; Martinek J.

**Functional upper GI disorders: Clinical**

P1127

**COMPARISON OF BEHAVIORAL THERAPY AND STANDARDIZED DOCTOR'S INFORMATION IN REDUCING SYMPTOMS OF SUPRAGASTRIC BELCHING**

Punkkinen J.; Walamies M.; Haakana R.; Nyyssönen M.; Perttu Arkkila, Finland

P1128

**AGE AND MALE GENDER ARE ASSOCIATED WITH A DECLINE IN FUNCTIONAL GASTROINTESTINAL SYMPTOMS: 10 YEAR FOLLOW-UP OF THE KALIXANDA STUDY**

Jukka Ronkainen, Finland; Aro P.; Agr us L.; Andreasson A.; Walker M.; Talley N. J.

P1129

**DIFFERENT DYSREGULATION OF SYMPATHETIC AND PARASYMPATHETIC AUTONOMIC RESPONSE TO STRESS IN PATIENTS WITH FUNCTIONAL DYSPEPSIA**

Peter Lipt k, Slovakia; Mestanik M.; Banovcin P.; Hyrdel R.; Tonhajzerova I.

P1130

**MAST CELL ACTIVATION SYNDROME (MCAS) IN PATIENTS WITH RAPID ONSET OF FOOD INDUCED SYMPTOMS OF DYSPEPSIA, IBS, DIARRHOEA, NAUSEA OR VOMITING REACTS FAVOURABLY ON HISTAMINE 1 OR 2 BLOCKERS OR CROMOGLYCATE. AN OBSERVATIONAL STUDY.**

Marten Otten, The Netherlands; Akol H.; Oudkerk Pool M.; Tan T. G.; Schreuder T.

P1131

**OBSERVATIONAL STUDY OF FD/IBS OVERLAP SYNDROME CHARACTERISTICS AND EFFICACY OF TREATMENT**

Sergey Vyalov, Russian Federation

P1132

**SUICIDAL IDEATION IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS**

Michel Bouchoucha, France; Raynaud J.-J.; Bejou B.; Rompteaux P.; Sabate J.-M.; Benamouzig R.

P1133

**GENE POLYMORPHISM AND FUNCTIONAL DYSPEPSIA SUSCEPTIBILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Du L.; Chen B.; Zhang Y.; Dai N.; Luyi Chen, China

P1134

**PSYCHOLOGICAL FACTORS IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS: RELATION TO DYSPEPTIC SYMPTOMS AND GASTRIC DYSMOTILITY AS MEASURED WITH ULTRASOUND** ✨

Elisabeth Kjelsvik Steinsvik, Norway; Valeur J.; Hausken T.; Gilja O. H.

P1135 

**IMPACT OF ITOPRIDE AND DOMPERIDONE ON THE SENSITIVITY OF GASTRIC DISTENSION AND GASTRIC ACCOMMODATION IN HEALTHY VOLUNTEERS**

Karen Van den Houte, Belgium; Carbone F.; Pauwels A.; Vos R.; Vanuytsel T.; Tack J.

P1136

**NOT ONLY DUODENAL BUT ALSO JEJUNAL MUCOSAL INTEGRITY ARE IMPAIRED IN PATIENTS WITH FUNCTIONAL DYSPEPSIA. A STUDY USING SMALL BOWEL HRM/IMPEDANCE**

Kenichiro Nakagawa, United Kingdom; Yazaki E.; Aziz Q.; Sifrim D.

### Eosinophilic oesophagitis

P1137

**ALL AGES INCIDENCE AND PREVALENCE OF EOSINOPHILIC ESOPHAGITIS INCREASE CONTINUOUSLY IN CENTRAL SPAIN. A 12-YEAR POPULATION-BASED STUDY**

Arias Arias  .; Alfredo J Lucendo, Spain

P1138

**EOSINOPHILIC ESOPHAGITIS, AN ENIGMA? INCIDENCE AND CHARACTERISTICS IN ADULTS WITH DYSPHAGIA: A PROSPECTIVE OBSERVATIONAL STUDY**

Jaime Pereira Rodrigues, Portugal; Freitas T.; Wen X.; Sousa M.; Silva J. C.; Gomes C.; Sanches A.; Carvalho J.

P1139

**MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION ARE SIGNIFICANTLY REDUCED IN ACTIVE EOSINOPHILIC ESOPHAGITIS FOLLOWING 16 WEEKS OF TREATMENT WITH RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY**

Peter Gann, United States; Deaton R.; McMahon N.; Collins M. H.; Dellon E. S.; Hirano I.; Grimm M.; Woo A.; Karunaratne M.; Olson A.; Aranda R.; Opitck G. J.

P1140

**COMPREHENSIVE IMPEDANCE-PH ANALYSIS OF GAS-TROESOPHAGEAL REFLUX IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS.**

Frazzoni M.; Frazzoni L.; Tolone S.; Marsico M.; Marocchi M.; De Bortoli N.; Edoardo Savarino, Italy

P1141

**THERAPEUTIC MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS- A SURVEY AMONG GASTROENTEROLOGISTS IN GERMANY**

Stephan Miehke, Germany; von Arnim U.; Schlag C.; Frieling T.; Madisch A.; Loibl R.; Mainz D.; Labenz J.

P1142

**EOSINOPHILIC OESOPHAGITIS: THE EXPERIENCE FROM A UK DISTRICT GENERAL HOSPITAL**

Brenavan Natarajan, United Kingdom; Banerjee T.; Basavaraju K.

P1143

**FAECAL CALPROTECTIN AS A BIOMARKER OF GUT INFLAMMATION IS NOT A USEFUL TOOL FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH EOSINOPHILIC ESOPHAGITIS**

Marco Della Coletta, Italy; Ghisa M.; Tolone S.; De Bortoli N.; Bodini G.; Marabotto E.; Zentilin P.; Inferrera M.; Savarino V.; Savarino E.

**Reflux disease, diagnosis**P1144 **DO WE HAVE TO EXCLUDE EPIGASTRIC SYMPTOMS TO DIAGNOSE GERD?**

Mengyu Zhang, China; Tan N.; Chen M.; Xiao Y.

P1145

**NOVEL SYSTEM FOR IDENTIFICATION OF LOWER ESOPHAGEAL SPHINCTER WITH IMPEDANCE VARIATION STEP-UP METHOD: A FEASIBILITY STUDY.**

Aurelio Mauro, Italy; Franchina M.; Consonni D.; Penagini R.

P1146

**PSPW AND MNBI INCREASE THE DIAGNOSTIC YIELD OF IMPEDANCE-PH MONITORING AND ARE RELATED TO PPI RESPONSE IN GERD PATIENTS WITH ENT SYMPTOMS**

Mentore Ribolsi, Italy; Giordano A.; Biasutto D.; Cicala M.

P1147

**CORRELATION BETWEEN PERISTALTIC FUNCTION, ASSESSED BY HIGH RESOLUTION MANOMETRY, AND MUCOSAL INTEGRITY IN GERD PATIENTS**

Mentore Ribolsi, Italy; Giordano A.; Biasutto D.; Cicala M.

P1148 **ESOPHAGEAL HIGH RESOLUTION MANOMETRY CAN UNRAVEL THE MECHANISMS BY WHICH DIFFERENT BARIATRIC TECHNIQUES PRODUCE DIFFERENT REFLUX EXPOSURE**

Salvatore Tolone, Italy; Savarino E.; De Bortoli N.; Frazzoni M.; Frazzoni L.; Furnari M.; Martinucci I.; Parisi S.; Terracciano G.; Lanza Volpe M.; Savarino V.; Docimo L.

P1149

**ESOPHAGEAL DYSMOTILITY AND PREVALENCE OF EXPRESSION CD25 MARKER IN GERD PATIENTS.**

Anna Paraskheva, Russian Federation; Lyamina S.; Kalish S.; Storonova O.; Pirogov S.; Ponomarev A.; Sokolov K.; Rummyantseva D.; Trukhmanov A.; Malyshev I.; Maev I.; Ivashkin V.

P1150

**CARDIAC ARRHYTHMIA AND GERD IN CHILDREN.**

Tetiana Zimnytska, Ukraine; Golovko T.; Bulich I.

**Reflux disease, treatment**

P1151

**EFFECT OF ADVANCED DIAGNOSIS MODALITIES AND DISEASE PHENOTYPES ON PPI RESPONSE OF GASTRO-ESOPHAGEAL REFLUX DISEASE**

Nilay Danis, Turkey; Bor S.

P1152 **THE NEW P-CAB X482 WAS SAFE, TOLERABLE AND PROVIDED 24H INTRAGASTRIC CONTROL, AFTER SINGLE ORAL DOSES IN HEALTHY VOLUNTEERS**

Kjell Andersson, Switzerland; Unge P.

P1153

**HUMAN ESOPHAGEAL MUCOSA TOPICAL PROTECTION, IN VITRO EFFECT OF SULFATED POLYSACCHARIDE FROM MARINE ALGAE GRACILARIA CAUDATA**

Sales T.; Silva R.; Nicolau L. A.; Moreira R. L.; Nascimento R.; Barros F. C.; Alencar P.; Freitas A. L.; Santos A.; Nobre e Souza M. Â.; Sifrim D.; Marcellus Souza, Brazil

P1154

**A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAK-438 20 MG ONCE DAILY COMPARED TO LANSOPRAZOLE 30 MG ONCE DAILY IN PATIENTS WITH EROSIIVE ESOPHAGITIS: RESULTS FROM A CHINESE SUB-COHORT**

Minhu Chen, China; Dai N.; Fei G.; Chong C. F.; Funao N.; Zhang S.

P1155

**THE EFFICACY OF HANGESHASHINTO IN PATIENTS WITH PPI REFRACTORY GERD -RANDOMIZED, MULTICENTER EXPLORATORY STUDY-**

Toshihisa Takeuchi, Japan; Kojima Y.; Hongo H.; Murano M.; Inoue T.; Noguchi T.; Takeuchi N.; Higuchi K.

**Barrett's oesophagus: Basic**

P1156

**FARNESOID-X-RECEPTOR EXPRESSION HAS A PROTECTIVE FUNCTION AND EMERGES AS POTENTIAL TARGET TO PREVENT PROGRESSION FROM BARRETT ESOPHAGUS TO ADENOCARCINOMA**

Theresa Baumeister, Germany; Islam Sayin S.; I ngermann J.; Nuber A.; Fang H.-Y.; Stephens-Muench N.; Haller D.; Schmid R. M.; Wang T. C.; Quante M.

P1157

**APPLICATION OF A SELF-ASSEMBLING PEPTIDE MATRIX PREVENTS ESOPHAGEAL STRICTURE AFTER CIRCUMFERENTIAL ENDOSCOPIC SUBMUCOSAL DISSECTION IN A PIG MODEL**

Sarra Oumrani, France; Barret M.; Bordacahar B.; Beuvon F.; Batteux F.; Prat F.

P1158

**INHIBITORY EFFECT OF HYDROGEN SULFIDE ON BARRETT'S ESOPHAGUS METAPLASIA DEVELOPMENT**

Wierdak M.; Magierowska K.; Janmaat V.; Hubalewska-Mazgaj M.; Chmura A.; Bakalarz D.; Wójcik D.; Smits R.; Peppelenbosch M.; Brzozowski T.; [Marcin Magierowski](#), Poland

P1159

**IMPROVING BARRETT'S SURVEILLANCE PRACTICE THROUGH THE USE OF PRAGUE CLASSIFICATION OR LENGTH OF BARRETT'S OESOPHAGUS – A RETROSPECTIVE STUDY IN A DISTRICT GENERAL HOSPITAL**

Shivarajan A. A.; [Jason Stevenson](#), United Kingdom; Raja Shariff R.; Jafar W.; Kong C.

P1160

**MUCOSA-ASSOCIATED MICROBIOTA DIVERSITY SIGNIFICANTLY DIFFERS IN BARRETT'S ESOPHAGUS AND PROGRESSION TO ESOPHAGEAL ADENOCARCINOMA**

[Shajan Peter](#), United States; Wilcox C. M.; Pendegrift A.; Van der Pol W.; Kyanam Kabir Baig K. R.; Morrow C.; Mannon P.

**Barrett's oesophagus: Clinical**

P1161

**COMPUTER-AIDED DIAGNOSIS AND DEEP LEARNING IN THE EVALUATION OF EARLY BARRETT'S CANCER**

[Alanna Ebigbo](#), Germany; Mendel R.; Palm C.; Probst A.; Messmann H.

P1162 **THE IMPACT OF THE POLICY-PRACTICE GAP ON COST-EFFECTIVENESS OF BARRETT'S OESOPHAGUS MANAGEMENT**

[Amir-Houshang Omidvari](#), The Netherlands; Roumans C. A. M.; Kroep S.; de Jonge P.-J.; Spaander M. C. W.; Lansdorp-Vogelaar I.

P1163

**WITHDRAWN**

P1164

**THE LONG-TERM OUTCOME OF ENDOSCOPIC THERAPY IN ULTRA-SHORT BARRETT'S ESOPHAGUS WITH HIGH-GRADE DYSPLASIA AND EARLY ESOPHAGEAL CARCINOMA**

[Tomer Greener](#), Canada; Iwaya Y.; Shimamura Y.; Mosko J. D.; Kandel G.; Teshima C.; Kortan P. P.; May G. R.; Marcon N. E.

P1165

**HYBRID ARGON PLASMA COAGULATION IS SAFE AND EFFECTIVE FOR THE ABLATION OF DYSPLASTIC BARRETT'S OESOPHAGUS: INTERIM ANALYSIS OF A PROSPECTIVE STUDY**

Skacel E. P.; Baars J. E.; Tsoutsman T.; Manlapig Rubio M. J.; Bhate P.; Kench J.; Majumdar A.; Kaffes A.; [Payal Saxena](#), Australia

P1166

**WIDE-FIELD ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE TREATMENT OF BARRETT'S ESOPHAGUS NEOPLASIA (WF-ESD).**

Omae M.; Wang N.; [Francisco Baldaque Silva](#), Sweden

**Gastroduodenal neoplasia: Clinical**

P1167

**CLINICOPATHOLOGICAL FEATURES OF GASTRIC ADENOCARCINOMA OF THE FUNDIC GLAND TYPE ACCORDING TO COLOR AND MORPHOLOGICAL CLASSIFICATION**

[Atsushi Ikeda](#), Japan; Ueyama H.; Yao T.; Yatagai N.; Akazawa Y.; Komori H.; Izumi K.; Ueda K.; Matsumoto K.; Nagahara A.

P1168

**GASTRIC CANCER MORTALITY BY AGE, GENDER, AND BODY MASS INDEX**

Nam S. Y.; [Seong Woo Jeon](#), Republic of Korea; Lee H. S.; Kwon Y.-H.; Seo A.; Kim S. K.

P1169

**ENDOSCOPIC PREDICTION OF TUMOR INVASION DEPTH IN EARLY GASTRIC SIGNET RING CELL CARCINOMA**

[Hee Seok Moon](#), Republic of Korea; Kang S. H.; Sung J. K.; Jeong H. Y.

P1170

**CLINICAL SUBMUCOSAL INVASIVE GASTRIC CANCER: IS SURGERY THE ONLY OPTION?**

[Hyun Deok Lee](#), Republic of Korea; Chung H.; Kim S. G.; Kim J.; Jung H. C.

P1171

**THE CLINICAL CHARACTERISTICS AND THERAPEUTIC OUTCOMES OF NON AMPULLARY DUODENAL NEUROENDOCRINE TUMOR(NADNET) : MULTICENTER , RETROSPECTIVE STUDY**

[Gun Young Nam](#), Republic of Korea; Lee S.-W.; Sung J. K.; Cho Y. S.; Bang K.-B.; Kang S. H.; Kim K. B.; Kim S. H.; Moon H. S.; Song K.-H.; Kim S. M.; Chung I. K.; Lee D. S.; Jeong H. Y.; Youn S.-J.

P1172

**CLINICAL RISK FACTORS OF NON-CURATIVE RESECTION BY ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE PATIENTS WITH EXPANDED INDICATION OF INTESTINAL-TYPE EARLY GASTRIC CANCER (CT1), AN ANCILLARY ANALYSIS OF MULTI-INSTITUTIONAL, SINGLE-ARM, CONFIRMATORY TRIAL (JCOG0607).**

[Tomohiro Kadota](#), Japan; Hasuike N.; Ono H.; Boku N.; Mizusawa J.; Oda I.; Oyama T.; Fujisaki J.; Hirasawa K.; Morita Y.; Yoshio T.; Minashi K.; Takizawa K.; Nakamura K.; Muto M.

- P1173**  
**USEFULNESS OF LINKED COLOR IMAGING FOR RECOGNITION OF EARLY GASTRIC CANCER AND ADENOMA — COMPARISON WITH WHITE LIGHT & INDIGO CARMINE & BLUE LASER IMAGING—**  
Takeshi Yasuda, Japan; Nakahata Y.; Kurobe T.; Yasuda Y.; Omatsumi T.; Obora A.; Kojima T.; Yagi N.
- P1174**  
**PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE AND C-REACTIVE PROTEIN-TO-ALBUMIN RATIOS IN GASTRIC ADENOCARCINOMA**  
 Gamelas V.; João Silva, Portugal; Simões G.; Santos S.; Pavão Borges V.; Rocha M.; Carvalho D.; Esteves J.
- P1175**  
**DO AUTOIMMUNE COMORBIDITIES INCREASE THE RISK FOR NEUROENDOCRINE TUMOURS IN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS? RESULTS FROM AN ITALIAN DUAL-CENTRE STUDY**  
Marco Vincenzo Lenti, Italy; Miceli E.; Staiani M.; Pisati M.; Caccia Dominioni C.; Giuffrida P.; Cococchia S.; Di Stefano M.; Corazza G. R.; Magris R.; Maiero S.; De Re V.; Cannizzaro R.; Di Sabatino A.
- P1176**  
**THE ROLE OF BIOPSY IN DETERMINING TREATMENT STRATEGY IN EARLY GASTRIC CANCER**  
Yonsoo Kim, Republic of Korea; Kim J.-H.; Jung D. H.; Park J. J.; Yoon Y. H.; Park H.; Kwon I. G.; Choi S. H.
- P1177**  
**DEPTH DIAGNOSIS PERFORMANCE USING ENDOSCOPIC ULTRASOUND FOR EARLY GASTRIC CANCERS SUSPECTED FOR DEEP SUBMUCOSAL INVASION**  
Hiroyuki Takamaru, Japan; Yoshinaga S.; Oda I.; Abe S.; Nonaka S.; Suzuki H.; Katai H.; Sekine S.; Saito Y.
- P1178**  
**CHARACTERISTICS, RISK FACTORS AND SURVIVAL OF MISSED GASTRIC CANCER: A MULTICENTRIC COHORT STUDY**  
 Rodríguez de Santiago E.; Hernanz Ruiz N.; Luis Téllez, Sudan; Marcos Prieto H. M.; Jorge Turrión M. Á.; Barreiro Alonso E.; Sierra Morales M.; Nuñez Gómez L.; Jurado Jiménez A.; García Prada M.; Rodríguez Escaja C.; Foruny Olcina J. R.; González Martín J. Á.; Volpato Machado N.; Castaño García A.; Ríos Leon R.; Perez Valle I.; García García de Paredes A.; Peñas García B.; Albillos Martínez A.; Vazquez Sequeros E.
- P1179**  
**PRETREATMENT PREDICTIVE VALUE OF BLOOD NEUTROPHIL/LYMPHOCYTE RATIO IN RESECTABLE GASTRIC CANCER**  
 Borda A.; Ignacio Fernández-Urién, Spain; Vila J. J.; Albéniz E.; Zozaya J. M.; Guerra A.; Borda F.
- P1180**  
**YOUNG AGE AND RISK OF LYMPH NODE METASTASIS IN DIFFERENTIATED TYPE EARLY GASTRIC CANCER**  
 Lee H.; Song J. H.; Kim N. J.; Kim T.-S.; Min B.-H.; Lee J. H.; Jae J. Kim, Republic of Korea
- P1181**  
**PPI AND GASTRIC CANCER IN FUNCTIONAL DYSPEPSIA-BRIDGING THE GAP BETWEEN SCIENTIFIC EVIDENCE AND CLINICAL PRACTICE**  
Efrat Broide, Israel; Ein-Dor A.; Shirin H.; Leshno M.
- P1182**  
**GENDER- AND SITE-SPECIFIC EFFECT OF METABOLIC COMPONENTS ON DE NOVO GASTRIC CANCER: A NATIONAL POPULATION-BASED STUDY OF 5.49 MILLION KOREANS**  
Su Youn Nam, Republic of Korea; Jeon S. W.; Jeong J.; Lee W. K.
- P1183**  
**SARCOPENIA AS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL AND PERIOPERATIVE COMPLICATIONS IN PATIENTS WITH GASTRIC CANCER**  
 Koch C.; Reitz C.; Schreckenbach T.; Eichler K.; Al-Batran S.-E.; Goetze T.; Dux M.; Trojan J.; Irina Blumenstein, Germany
- Gastroduodenal neoplasia: Basic**
- P1184**  
**HOXC10 DIRECTLY REGULATED BY MIR129-5P CAN MODULATE WNT SIGNALING PATHWAY IN GASTRIC CANCER: CCND1 IS A CRUCIAL TARGET GENE.**  
Jiamin He, China; Lin R.; Chen L.; Chen S.
- P1185**  
**OVEREXPRESSION OF CD44V9 IN GASTRIC CANCER CELLS CONFERS RESISTANCE TO TRASTUZUMAB BY INDUCING ANTIOXIDANT ENZYMES**  
Hideki Mori, Japan; Matsuzaki J.; Tsugawa H.; Masaoka T.; Kanai T.; Suzuki H.
- P1186**  
**PLASMA AND MUCOSAL EXPRESSION OF MICRORNAS ALONG THE GASTRIC CARCINOGENESIS CASCADE**  
Inês Pita, Portugal; Libânio D.; Dias F.; Teixeira A. L.; Medeiros R.; Dinis-Ribeiro M.; Pimentel-Nunes P.
- P1187**  
**POLYMORPHISM -511C/T (RS16944) OF THE IL1B GENE AND LOW LEVEL OF PGI REPEATEDLY INCREASE GASTRIC CANCER RISK: SIBERIAN PROSPECTIVE CASE-CONTROL STUDY.**  
Anna Belkovets, Russian Federation; Kurilovich S. A.; Maksimov V.; Ragino Y.; Scherbakova L.

P1188 **GENETIC EVENTS AND CLONAL DIFFERENCES IN MULTI-  
PLE OCCURRENCE OF GASTRIC CANCER**Shinya Takaoka, Japan; Hirotsu Y.; Amemiya K.; Mochizuki H.; Kojima Y.; Omata M.**Poster Session**

09:00 – 17:00

Hall XI

**H. Pylori II****Epidemiology/natural history**

P1189

**RISK OF OVERALL MORTALITY AFTER HELICOBACTER  
PYLORI TREATMENT IN PATIENTS WITH HYPERTENSION**Young-Il Kim, Republic of Korea; Kim Y. A.; Lee J. W.; Kim H. J.; Kim S.-H.; Kim J. I.; Kim J. J.; Choi I. J.

P1190

**MIGRATORY AND SOCIAL PARAMETERS INFLUENCING  
RESISTANT HELICOBACTER PYLORI INFECTION  
IN SOUTHERN CHINA: A MUNICIPALITY-WIDE MULTI-  
CENTER PREVALENCE STUDY**Tao Lyu, China; Seto W.-K. W.; Ni L.; Guo J.; Mu P.; Li Y.; Yang Q.; Yu X.; Sun H.; Lyu Z.; Wu J.; Guo H.; Cheung K. S.; Leung W. K.

P1191

**PREVALENCE OF HISTOLOGIC ATROPHIC GASTRITIS  
AND INTESTINAL METAPLASIA IN THE CORPUS HAS DE-  
CREASED OVER 15 YEARS IN THE FEMALE IN KOREAN  
POPULATION**Young Jae Kwon, Republic of Korea; Kim N.; Baek S. M.; Lee H. S.; Lee J.; Yoon H.; Shin C.-M.; Park Y.-S.; Lee D. H.

P1192

**HELICOBACTER PYLORI INFECTION AND AUTOIMMUNE  
DISEASES: A POPULATION STUDY IN PRIMARY CARE  
SETTING**Di Mario F.; Silvia Speroni, Italy; Franceschi M.; Baldassarre G.; Antico A.; Panozzo M. P.; Rodriguez-Castro K.; Tursi A.; Brandimarte G.; Franzoni L.; Crafa P.; Miraglia C.; Nouvenne A.; Rugge M.

P1193

**NATURAL HISTORY OF GASTRIC ULCER IN A 25 YEARS  
FOLLOW-UP: ROLE OF HELICOBACTER PYLORI INFECTION  
AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS**Chiara Miraglia, Italy; Cavatorta O.; Franzoni L.; Crafa P.; Cannizzaro R.; Nouvenne A.; Speroni S.; Brandimarte G.; Tursi A.; Rugge M.; Franceschi M.; Di Mario F.

P1194

**HELICOBACTER PYLORI INFECTION AMONG PHYSICIANS  
OF DIFFERENT REGIONS OF RUSSIAN FEDERATION**Natalia Bakulina, Russian Federation; Simanenkov V.; Bakulin I.; Ilchishina T.

P1195

**IS HELICOBACTER PYLORI ERADICATION RELATED TO  
REFLUX ESOPHAGITIS? CORRELATION WITH GASTRIC  
ACID SECRETION**Di Mario F.; Serena Scida, Italy; Franceschi M.; Miraglia C.; Speroni S.; Rodriguez-Castro K.; Franzoni L.; Crafa P.; Cannizzaro R.; Tursi A.; Nouvenne A.; Brandimarte G.; Rugge M.; Scarpignato C.**Diagnosis**P1196 **OPTIMIZATION OF 13C UREA BREATH TEST THRESHOLD  
LEVELS FOR THE DETECTION OF HELICOBACTER PYLORI  
INFECTION IN A NATIONAL REFERRAL LABORATORY**Boltin D.; Belfer Gingold R.; Levi Z.; Dickman R.; Tsachi Tsadok Perets, Israel

P1197

**CLARITHROMYCIN RESISTANCE AND FEMALE GENDER  
AFFECT HELICOBACTER PYLORI ERADICATION FAILURE  
IN CHRONIC GASTRITIS**Seong Kon Lee, Republic of Korea; Chang Y.-W.

P1198

**A MOLECULAR DIAGNOSTIC TEST USING REVERSE  
BLOT HYBRIDIZATION ASSAY FOR IDENTIFICATION OF  
GENOMIC MUTATION RESPONSIBLE FOR ANTIBIOTICS  
RESISTANCE OF HELICOBACTER PYLORI**Kim Heeman, Republic of Korea; Kim J.; Wang H.-Y.; Lee H.

P1199

**EVALUATION OF THE RIDAGENE HELICOBACTER PYLORI  
REAL-TIME PCR ASSAY COMPARED TO CULTURE FOR  
THE DETECTION OF CLARITHROMYCIN RESISTANCE IN  
AN IRISH CENTRE**Brennan D.; Dwyer L.; Esmonde R.; Afzal Z.; Loughman E.; Douglas A. R.; O'Morain C.; McNamara D.; Sinead Smith, Ireland

P1200

**THE USEFULNESS OF LINKED COLOR IMAGING AND THE  
POTENTIAL OF AUTOMATIC DIAGNOSIS SYSTEM FOR  
DIAGNOSIS OF H. PYLORI INFECTION**Nobuaki Yagi, Japan; Yasuda T.; Nakahata Y.; Kurobe T.; Yasuda Y.; Omatsu T.; Obora A.; Kojima T.; Hiroyasu T.

P1201

**SPANISH PRIMARY CARE SURVEY ON THE MAN-  
AGEMENT OF H. PYLORI INFECTION: PERCEPTIONS,  
ACCESS TO INFORMATION AND CONTINUOUS MEDICAL  
EDUCATION.**Adrian Gerald McNicholl, Spain; Amador J.; Ricote Belinchon M.; Cañones-Garzón P. J.; Gene E.; Calvet Calvo X.; Gisbert J. P.



P1202

**EVALUATION OF CURIAN HPSA FLUOROMETRIC ASSAY. A NOVEL, RAPID IMMUNOASSAY FOR THE DETECTION OF HELICOBACTER PYLORI ANTIGENS IN HUMAN STOOL**  
Saracino I. M.; Pavoni M.; [Giulia Fiorini](#), Italy;  
Saccomanno L.; Bibbs D.; Vaira B.

### Treatment

P1203

**EFFICACY OF VONOPRAZAN-BASED THERAPY COMPARED TO PROTON PUMP INHIBITOR (PPI) IN *H. PYLORI* ERADICATION THERAPY**  
[Tomoyo Machida](#), Japan; Fukami Y.; Ishii R.; Hara H.; Mochida T.; Yonemoto Y.; Sugiyama Y.; Watanabe A.; Kaneshiro M.; Ikemiyagi H.; Yoshino K.; Sakita S.

P1204

**EFFICACIES OF DIFFERENT PROTON PUMP INHIBITOR-BASED 14-DAY BISMUTH-CONTAINING QUADRUPLE REGIMENS FOR THE INITIAL ERADICATION OF HELICOBACTER PYLORI IN THE SOUTHEAST COASTAL REGION OF CHINA: AN OPEN-LABEL, RANDOMIZED CLINICAL TRIAL**  
[Luyi Chen](#), China; He J.; Wang L.; Li A.; Chen S.

P1205

**APPARENT INTRACELLULAR HELICOBACTER PYLORI DETECTION BY IMMUNOHISTOCHEMISTRY AS INDEPENDENT RISK FACTOR FOR FAILURE OF FIRST-LINE ERADICATION THERAPY**  
[Andrea Beer](#), Austria; Hudler H.; Hader M.; Kundi M.; Hudler S.; Täuber V.; Gruber S.; Hirschl A.; Makristathis A.

P1206

**PAN-EUROPEAN REGISTRY ON *H. PYLORI* MAN-AGEMENT (HP-EUREG): IMPACT OF RESISTANCE ON EFFICACY.**  
[Adrian Gerald McNicholl](#), Spain; Perez Nyssen O.; Bordin D.; Tepe B.; Perez-Aisa A.; Dino V.; Caldas Álvarez M.; Bujanda Fernández de Piérola L.; Castro-Fernandez M.; Lerang F.; Leja M.; Rodrigo L.; Rokkas T.; Kupcinskas L.; Perez-Lasala J.; Virginius Jonaitis L.; Shvets O.; Gasbarrini A.; Simsek H.; Axon A.; Buzás G. M.; Machado J. C. L.; Niv Y.; Boyanova L.; Goldis A.; Lamy V.; Katicic M.; Przytulski K.; Beglinger C.; Venerito M.; Bytzer P.; Capelle L.; Milosavljevic T.; Veijola L.; Molina Infante J.; Vologzhanina L.; Fadeenko G.; Ariño I.; Fiorini G.; Ramas M.; García Donday M.; Megraud F.; O'Morain C.; Gisbert J. P.

P1207 

**META-ANALYSIS OF BISMUTH QUADRUPLE THERAPY IN SINGLE CAPSULE FOR THE ERADICATION OF HELICOBACTER PYLORI**  
[Olga Perez Nyssen](#), Spain; McNicholl A. G.; Gisbert J. P.

P1208 

**PAN-EUROPEAN REGISTRY ON *H. PYLORI* MAN-AGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 1,200 PATIENTS**  
[Adrian Gerald McNicholl](#), Spain; Perez Nyssen O.; Bordin D.; Tepe B.; Perez-Aisa A.; Dino V.; Caldas Álvarez M.; Bujanda Fernández de Piérola L.; Castro-Fernandez M.; Lerang F.; Leja M.; Rodrigo L.; Rokkas T.; Kupcinskas L.; Perez-Lasala J.; Jonaitis L.; Shvets O.; Gasbarrini A.; Simsek H.; Axon A.; Buzás G. M.; Machado J. C. L.; Niv Y.; Boyanova L.; Goldis A.; Lamy V.; Katicic M.; Przytulski K.; Beglinger C.; Venerito M.; Bytzer P.; Capelle L.; Milosavljevic T.; Veijola L.; Molina Infante J.; Vologzhanina L.; Fadeenko G.; Ariño I.; Fiorini G.; Ramas M.; García Donday M.; Megraud F.; O'Morain C.; Gisbert J. P.

P1209

**OUTCOMES OF FURAZOLIDONE-BASED QUADRUPLE THERAPY FOR HELICOBACTER PYLORI INFECTION AND PREDICTORS OF FAILED ERADICATION**  
[Yawen Zhang](#), China; Hu W.; Zheng W.; Du Q.; Kim J.; Kao J. Y.; Chen L.; Dai N.; Si J.

P1210

**CONCOMITANT VERSUS SEQUENTIAL THERAPY FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION: A TUNISIAN RANDOMIZED PROSPECTIVE STUDY**  
[Bochra Bouchabou](#), Tunisia; Medhioub M.; Khsiba A.; Hamzaoui M. L.; Mahmoudi M.; Azouz M. M.

P1211 

**SINGLE-CAPSULE BISMUTH-BASED QUADRUPLE THERAPY AS SECOND-LINE OR SALVAGE TREATMENT FOR HELICOBACTER PYLORI INFECTION: A NEW WINDOW OF OPPORTUNITY IN A SOUTH-EUROPEAN COUNTRY?**  
[Carina Leal](#), Portugal; Almeida N. P.; Correia C.; Branquinho D.; Fernandes A. I.; Calhau C.; Bastos I.; Tomé L.; Vasconcelos H.

P1212

**HIGH DOSE CLARITHROMYCIN WITH P-CAB PLUS AMOXICILLIN TRIPLE THERAPY REGIMEN IS MOST RECOMMENDED ON 1ST *H. PYLORI* ERADICATION REGIMEN: A MULTICENTER CENTER PROSPECTIVE CASE STUDY.**  
[Takuji Yamasaki](#), Japan; Chibai M.; Arai Y.; Nishio E.; Aizawa M.; Nakamura Y.; Saruta M.

P1213

**THE HELICOBACTER ERADICATION ASPIRIN TRIAL (HEAT): RECRUITMENT AND DEMOGRAPHICS OF THE RANDOMISED PATIENT POPULATION**  
Stevenson D. J.; [Jennifer Susan Dumbleton](#), United Kingdom; Avery A. J.; Coupland C.; Hobbs F. D. R.; Kendrick D.; Moore M. V.; Morris C.; Rubin G.; Smith M. D.; Hawkey C. J.

## Poster Session

09:00 – 17:00

Hall X1

## Small Intestinal II

## Small intestinal immunology, immunity and inflammation

P1214

## IMBALANCE OF TREG/TH17 IN RAT NSAID-INDUCED INTESTINAL INJURY

Wang M.; Lian L.; Chen Z.; Lv B.; [Li-Na Meng](#), China

P1215

## TERMINAL ILEITIS: WHEN IS IT NOT CROHN'S DISEASE?

[Stefania Chetcuti Zammit](#), United Kingdom;

Mcalindon M.; Hale M. F.; Sidhu R.

P1216

## H. PYLORI INFECTION MAY INDUCE SMALL INTESTINAL MUCOSAL INJURY

[Shinsuke Takagi](#), Japan; Mitsui K.; Fujimori S.; Omori J.; Nishimoto T.; Kataoka H.; Umeda T.; Tatsuguchi A.; Tanaka S.; Akimoto N.; Sato W.; Iwakiri K.

P1217

## EVIDENCE FOR IMMUNE ACTIVITY IN FUNCTIONAL DYSPEPSIA AND THE IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW

[Grace Burns](#), Australia; Carroll G.; Mathe A.; Horvat J.; Foster P.; Walker M.; Talley N. J.; Keely S.

## Small intestinal infections

P1218

## SYSTEMATIC REVIEW WITH META-ANALYSIS: PREVALENCE AND PREDICTORS OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN IRRITABLE BOWEL SYNDROME

Chen B.; Du L.; Zhang Y.; Dai N.; Su T.; Kim J. J.; [Binrui Chen](#), China

P1219

## BREATH TESTS FOR SMALL INTESTINAL BACTERIAL OVERGROWTH DIAGNOSIS: A SYSTEMATIC REVIEW WITH META-ANALYSIS

[Giuseppe Losurdo](#), Italy; Leandro G.; Principi M.; Barone M.; Ierardi E.; Di Leo A.

P1220

## THE CHANGING AND CHALLENGING FACE OF PROTON PUMP INHIBITORS –RELATED SMALL INTESTINAL BACTERIAL OVERGROWTH.

[Lucio Lombardo](#), Italy; Cresto A.; Giostra A.

## Coeliac disease (adult)

P1221

## SERUM REGENERATING ISLET-DERIVED 3-ALPHA PRE-DICTS THE EVOLUTION OF POTENTIAL COELIAC DISEASE INTO OVERT COELIAC DISEASE

[Paolo Giuffrida](#), Italy; Biagi F.; Schieppati A.; Marafini I.; Laudisi F.; Aronico N.; Monteleone G.; Corazza G. R.; Di Sabatino A.

P1222

## SCREENING FOR COELIAC DISEASE

[Line Lund Kårhus](#), Denmark; Skaaby T.; Madsen A. L.; Thuesen B. H.; Rumessen J.; Linneberg A.

P1223

## SERONEGATIVE COELIAC DISEASE: CLINICAL FEATURES AND PREVALENCE AMONG COELIAC PATIENTS

[Annalisa Schieppati](#), Italy; Marks L.; Maimaris S.; Porta P.; Biagi F.; Sanders D. S.

P1224

## ADULT COELIAC DISEASE REMISSION ASSESSMENT: DOES A D1 BIOPSY INCREASE THE DETECTION OF VILLOUS ATROPHY?

[Lauren Jade Marks](#), United Kingdom; Lau M.; Kurien M.; Hadjivassiliou M.; Mooney P.; Cross S.; Sanders D. S.

P1225

## EFFECTS OF BLINDED ACUTE AND SUB-ACUTE GLUTEN CHALLENGE ON EXTRA-INTESTINAL AND GASTRO-INTESTINAL SYMPTOMS IN NON-COELIAC GLUTEN SENSITIVITY VERSUS HEALTHY CONTROLS

[Julie Iven](#), Belgium; Geeraerts A.; Vanuytsel T.; Tack J.; Van Oudenhove L.; Biesiekierski J.

P1226

## IS SEROLOGY PREDICTIVE OF PERSISTING VILLOUS ATROPHY IN PATIENTS WITH ESTABLISHED COELIAC DISEASE?

[Lauren Jade Marks](#), United Kingdom; Lau M.; Kurien M.; Sanders D. S.; Hadjivassiliou M.

P1227

## BIOPSY AVOIDANCE STRATEGY IN ADULT COELIAC DISEASE

[Lauren Jade Marks](#), United Kingdom; Lau M.; Kurien M.; Cross S.; Egner W.; Hadjivassiliou M.; Rees M.; Rostami K.; Sargur R.; Swallow K.; Wild G.; Sanders D. S.

P1228

## HUMAN LEUCOCYTE ANTIGENS COELIAC HAPLOTYPES: FROM ETIOLOGICAL FACTORS TO DIAGNOSTIC APPROACHES

[Roxana Maxim](#), Romania; Plesa A.; Stanciu C.; Ciortescu I.; Cianga P.; Trifan A.-V.

P1229

## PERSISTENT VILLOUS ATROPHY AMONG ADULT CELIAC DISEASE PATIENTS ON A GLUTEN-FREE DIET: IS THERE A ROLE FOR SEROLOGY?

[Roxana Maxim](#), Romania; Plesa A.; Ciortescu I.; Mazilu B.; Stanciu C.; Oana Cristina S.; Trifan A.-V.

P1230

**HLA TYPING AND CELIAC DISEASE IN ROMANIANS**

Roxana Maxim, Romania; Plesa A.; Ciortescu I.; Stanciu C.; Cianga P.; Trifan A.-V.

P1231

**USEFULNESS OF DOUBLE-BALLOON ENTEROSCOPY FOR DIAGNOSIS OF MECKEL'S DIVERTICULUM**

Okubo Yuki, Japan

**Poster Session**

09:00 – 17:00

Hall XI

**Nutrition II****Obesity**

P1232

**ENDOSCOPIC GASTRIC MUCOSAL ABLATION (EGMA) FOR WEIGHT LOSS: THE FIRST HUMAN CASE REPORT**

Bingrong Liu, China; Liu D.; Zhao L.; Kong L.; Ahmed M. R.; Li D.; Song J.

P1233


**ALT REDUCTION IN GERIATRIC PATIENTS WHO HAVE UNDERGONE BARIATRIC SURGERY**

Sara Chalifoux, United States; Chaya Z.; Whitaker R.; Fujioka K.

P1234 **ORAL AND EXTRA-ORAL BITTER TASTE RECEPTOR EXPRESSION IN A MODEL OF ANTIBIOTIC-INDUCED DYSBIOSIS**

Martin Veysey, United Kingdom; Burns G.; Lucock M.; Keely S.; Beckett E.

P1235

**COMBINED USE OF LACTOBACILLUS AND BIFIDOBACTERIA PROBIOTIC STRAINS WITH NANOCERIA REDUCE CHOLESTEROL LEVEL IN OBESITY MOUSE MODEL** 

Bubnov R.; Lidiia Babenko, Ukraine; Mokrozub V.; Zholobak N.; Lazarenko L.; Spivak M.

P1236

**68GA-NODAGA-EXENDIN-4 PET/CT FOR IMAGING OF BETA CELLS IN PATIENTS AFTER ROUX-EN-Y GASTRIC BYPASS (RYGB) SURGERY**

Marti Boss, The Netherlands; Deden L. N.; Aarts E. O.; de Boer H.; Janssen I. M. C.; Brom M.; Berends F. J.; Gotthardt M.

P1237

**LIRAGLUTIDE TREATMENT IN OBESE DIABETIC PATIENTS MODULATES GAS PRODUCTION DURING LACTULOSE BREATH TEST: A NEW POTENTIAL TREATMENT TO MODULATE GUT MICROBIOTA**

Valentina Tesori, Italy; Sun A.; Moffa S.; Mezza T.; Santoro A.; Giaccari A.; Scaldaferrì F.; Cammarota G.; Gasbarrini A.

P1238

**ROLE OF DIETARY INTERVENTION IN CLINICAL IMPROVEMENT OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS**

Ahmed Zeid, Egypt; Darwish O.; Tayel D.; Abdel Moneim A.; Eid M.; Matrawy K.

P1239

**SAFETY AND EFFICACY OF ELIPSE BALLOON IN OBESE ADULT PATIENTS: A SINGLE-CENTER PILOT STUDY IN AN ITALIAN TERTIARY HOSPITAL.**

Riccardo Urgesi, Italy; Pagnini C.; Pallotta L.; D'Alba L.; Di Paolo M. C.; Vitale M. A.; De Cesare M. A.; Villotti G.; Graziani M. G.

P1240

**CHANGES IN THYROID HORMONE LEVELS IN OBESE EUTHYROID PATIENTS UNDERGOING BARIATRIC SURGERY**

Tânia Gago, Portugal; Vaz A.; Roseira J.; Cunha A. C.; Campelo P.; Guerreiro R.; Sousa D.; Guerreiro H.

**Nutrients and gut function**

P1241

**DIAGNOSIS OF LACTOSE MALABSORPTION BY THIRD GENERATION HYDROGEN BREATH TEST: TIME IMPLEMENTATION AND SAMPLES DATA REVIEW**

Filippo Scevola, Switzerland; Risch L.; Nydegger U.

P1242

**SINGLE DUODENAL MUCOSAL RESURFACING ELICITS IMPROVEMENTS IN GLYCAEMIC AND HEPATIC PARAMETERS IN TYPE 2 DIABETES MELLITUS: COMPLETE 1 YEAR RESULTS FROM THE FIRST PROSPECTIVE MULTI-CENTER STUDY**

Annieke C. G. van Baar, The Netherlands; Nieuwdoorp M.; Holleman F.; Deviere J.; Crenier L.; Haidry R. J.; Batterham R. L.; Hopkins D.; Rodríguez Grunert L.; Galvão Neto M.; Vignolo P.; Costamagna G.; Bergman J. J.

P1243

**DECIPHERING MICROBE-HOST COMMUNICATION BASED ON A DIETARY INTERVENTION WITH PARTIALLY HYDROLYZED GUAR GUM – THE PAGODA STUDY**

Simon Jakob Reider, Austria; Moosmang S.; Trgovec-Greif L.; Tragust J.; Tragust S.; Przysiecki N.; Sturm S.; Tilg H.; Stuppner H.; Rattei T.; Moschen A. R.

P1244

**MICRONUTRIENT STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**

Milica Stojkovic Lalosevic, Serbia; Pavlovic Markovic A.; Stankovic S.; Stojanovic M.; Kiurski S.; Stojkovic M.



P1245

**INFLUENCE OF INTRAGASTRIC AND INTRADUODENAL BITTER TASTANT ADMINISTRATION ON HUNGER RATINGS AND GUT PEPTIDE RELEASE IN HEALTHY CONTROLS**

Wout Verbeure, Belgium; Pussig B.; Tóth J.; Pauwels A.; Timmermans L.; Van Oudenhove L.; Depoortere I.; Tack J.; Deloosse E.

**Enteral and parenteral nutrition**

P1246

**VALIDATION OF SODIUM CONCENTRATION IN URINE USING POINT-OF-CARE TESTING; FEASIBILITY TO DETECT DEHYDRATION IN PATIENTS WITH AN ILEOSTOMY OR SHORT BOWEL**

Judith Beurskens Meijerink, The Netherlands; Buters Ambrosius N.; Oosting J.; de Grouw E.; Huisman- de Waal G. J.; van Berkel M.; Wanten G. J. A.

P1247

**PREVALENCE AND IMPACT OF MALNUTRITION IN A GASTROENTEROLOGY DEPARTMENT. MALNUTRITION IMPAIRS HOSPITAL OUTCOMES.**

Emanuele Rinninella, Italy; Cintoni M.; Basso L.; Egidi G.; Leone S.; Scialanga F.; Addolorato G.; Miggiano G. A. D.; Gasbarrini A.; Mele M. C.

P1248

**PERCUTANEOUS ENDOSCOPIC GASTROSTOMY: DEALING WITH THE ISSUE OF DISLODGMET**

Rui Magalhães, Portugal; Cúrdia Gonçalves T.; Pinto B.; Rosa B.; Marinho C.; Cotter J.

P1249

**A NUTRITION SUPPORT TEAM REDUCES INAPPROPRIATE GASTROSTOMY CASE SELECTION AND ALL-CAUSE 30-DAY MORTALITY**

Kirsty Donald, United Kingdom; Chatten K.; Burrows G.; McCann S.; Jafar W.

P1250

**COMPOSITION OF THE MICROBIOME IN PATIENTS WITH SHORT BOWEL SYNDROME**

Dóra Illés, Hungary; Schwab R.; Czakó L.

P1251

**RAPID DIAGNOSIS OF BLOODSTREAM INFECTIONS IN PATIENTS ON HOME PARENTERAL NUTRITION**

Yannick Wouters, The Netherlands; Dalloyaux D.; Roelofs H.; te Morsche R.; Wanten G. J. A.

**Poster Session**

09:00 – 17:00

Hall X2/X1

**Clinical Cases II****Liver/Biliary/Pancreas**

CC043

**CLINICAL CASE: PATIENT WITH ACERULOPLASMINEMIA PRESENTING WITH DIZZINESS, LANGUOR AND EPISODE OF PRESYNCOPE.**

Ivana Knezevic Stromar, Croatia; Jelakovic M.; Premuzic M.; Radic D.; Majerovic M.; Ostojic R.; Krznaric Z.

CC044

**HEPATOMEGALY AND PROTEINURIA - A RARE ASSOCIATION**

Ana Laranjo, Portugal; Carvalho M. M.; Rei A.; Mocanu I.; Ramos Pires S. I.; Veloso N.; Gonçalves L.; Godinho R.; Medeiros I.

CC045

**A RARE CASE OF SEVERE TRANSAMINASEMIA AND EXCESSIVE BILIRUBIN LEVELS PROVOKED BY HEPATITIS A VIRUS**

Maria Stafylidou, Greece; Gagalis A.; Paschos P.; Sarvani A.; Tzatzagou G.; Kalampakas A.

CC046

**HEPATITIS C VIRUS INFECTION: "BEYOND THE LIVER"**

Rui Castro, Portugal; Vilas A. P.; Borges Da Costa J.; Marinho R. T.

CC047

**COMPLETE RESPONSE ACHIEVED BY MULTIDISCIPLINARY TREATMENT MODALITIES AND ANAPHYLAXIS IN A HEPATOCELLULAR CARCINOMA PATIENT WITH RIGHT ATRIUM AND PULMONARY METASTASIS**

Dong Hyun Kim, Republic of Korea; Cho E.; Cho S. B.; Choi S. K.; Yu J.; Koh Y.-I.; Seo J. H.; Sim D. W.; Jun C. H.

CC048

**ONE HIT AT BIRTH, THREE CONCERNS IN YOUNG AGE: A RARE CASE OF EXTRA-HEPATIC PORTAL VEIN THROMBOSIS (EPVT) AND RELATED CONDITIONS.**

Francesco Auriemma, Italy; Guarino M.; Sessa A.; Cossiga V.; Mainenti P. P.; De Sio I.; La Mura V.; Caporaso N.; Morisco F.

CC049

**ASSOCIATION OF FAMILIAL ADENOMATOUS POLYPOSIS WITH NODULAR REGENERATIVE HYPERPLASIA**

Miguel Saraiva, Portugal; Dias E.; Cardoso H.; Liberal R.; Macedo G.

CC050

**BUDD–CHIARI SYNDROME – TWO CASES, TWO EVOLUTIONS**

Filipe de Sousa Damião, Portugal; Noronha Ferreira C.; Gonçalves A.; Mendes F.; Velosa J.; Tato Marinho R.

CC051

**A CASE REPORT OF ACUTE ACALCULOUS PANCREATITIS: THE DIAGNOSTIC AND THERAPEUTIC CHALLENGE**

Sonia Bernardo, Portugal; Palmela C.; Machado M. V.; Baldaia C.; Freitas C.; Noronha Ferreira C.; Carvalhana S.; Valente A.

CC052

**SEVERE ACUTE PANCREATITIS AFTER ENDOSCOPIC FOOD DISIMPACTATION: A CASE REPORT**

Luis Fernando Mayorga Ayala, Spain; Velasquez J. G.; Llerena R.; Maynard A.; Tasayco Huaman S.; Molero X.

CC053

**PANCREATIC PSEUDOCYST INTERNAL STENT MIGRATION: A CASE REPORT**

Ilenia Barbuscio, Italy; Fantin A.; Sciarrone S. S.; Ghisa M.; Sperti C.; Polese L.; Farinati F.

**Surgery/Endoscopy/Imaging**

CC054

**GASTRIC PERORAL ENDOSCOPIC MYOTOMY FOR THE TREATMENT OF POST-SURGICAL PYLORIC DYSFUNCTION: THE PERFECT THERAPY?**

Currais P.; Sofia Saraiva, Portugal; Barreiro P.; Marques I.; Casaca R.; Dias Pereira A.

CC055

**TRACHEAL INJURY AFTER FOREIGN BODY INGESTION**

Daniela Reis, Portugal; Verdelho Machado M.; Freitas C.; Baldaia C.; Valente A.; Velosa J.

CC056

**ENDOSCOPIC DIAGNOSIS AND THERAPY OF A 10 CM LARGE GASTRIC INFLAMMATORY FIBROID POLYP (VANEK TUMOR)**

Hubertus Heinrich Nietsch, Germany

CC057

**SUCCESSFUL SEALING OF A PERSISTENT GASTROCUTANEOUS FISTULA BY MEANS OF CYANOACRYLATE GLUE (GLUBRAN N-2®). A CASE-REPORT.**

Barzaghi F.; Girelli C. M.; Giordano Piero Bernasconi, Italy

CC058

**WITHDRAWN**

CC059

**FEASIBLE AND EFFICACY OF LAPAROSCOPIC-ASSISTED ENDOSCOPIC SUTURING CLOSURE OF FISTULA**

Xuan Li, China; Zhang G.

CC060

**ENDOSCOPIC CLOSURE OF LARGE SPONTANEOUS PERI-AMPULLARY DUODENAL DIVERTICULAR RETROPERITONEAL PERFORATION USING 3 PADLOCK CLIPS AFTER BILIARY STENT PLACEMENT.**

Javed Iqbal, United Kingdom; Todd J.; El-Sherif Y.; Tanwar S.

CC061

**GASTRITIS CYSTICA PROFUNDA - RARE CONDITION, MIMICKING GASTRIC MALIGNANT TUMOR**

Sergey Pirogov, Russian Federation; Perfileyev I.; Sukhin D.; Vodoleev A.; Sokolov V.; Belyakov M.

CC062

**SIMULTANEOUS TREATMENT OF POST DILATATION OESOPHAGEAL PERFORATION AND ACHALASIA USING TULIP BUNDLE AND TEMPORARY STENTING TECHNIQUES**

Anuj Bharat Vakharia, United Kingdom; Koshy R. M.; Taruka Jayasuriya P.; Thisarana Wijayaratne G.; Menon V.; Mannath J.; Vinnamala S.

CC063

**ENDOSCOPIC MANAGEMENT OF IATROGENIC ESOPHAGEAL PERFORATION DUE TO ATTEMPT TO REMOVE A LARGE UNKNOWN GASTRIC FOREIGN BODY. A CASE REPORT.**

Mohammad Taghi Ayoubi Khajekini, Italy; Leone N.; Castellino F.; Sansoe' G.; Framarin L.; Berrutti M.

CC064

**ENDOSCOPIC ULTRASOUND-GUIDED BILIARY DRAINAGE IN FAILURE OF ACCESS TO THE MAIN BILE DUCT WITH ERCP – AN EFFECTIVE SOLUTION IN CHALLENGING PATIENTS.**

Daniela Reis, Portugal; Carvalhana S.; Noronha Ferreira C.; Carrilho Ribeiro L.; Tato Marinho R.

CC065

**ANGIOTENSIN RECEPTOR BLOCKER INDUCED INTestinal ANGIOEDEMA**

Tianhong Wu, Australia; Kandpal H.; Hodgson R.

CC066

**TRANSGASTRIC DRAINAGE OF PERI-PANCREATIC COLLECTIONS IN PATIENTS WITH PANCREAS DIVISUM AND RECURRENT ACUTE PANCREATITIS**

Filipe de Sousa Damião, Portugal; Noronha Ferreira C.; Carvalhana S.; Moura M.; Rita Gonçalves A.; Araujo Correia L.; Carrilho Ribeiro L.; Tato Marinho R.

CC067

**ASPHYXIA CAUSED BY ESOPHAGIAL STENT**

Nigar Rustamova, Turks and Kaikos Islands; Onder F. O.

CC068

**ENDOSCOPIC STENTING OF MALIGNANT ILEOCECAL OBSTRUCTION: REPORT OF 5 CASES**

Alexandr Vodoleev, Russian Federation; Burdyukov M.; Duvanskiy V.; Pirogov S.; Karpova E. S.

CC069

**PARTIAL SPLENIC EMBOLIZATION USED FOR RESCUE TREATMENT OF ESOPHAGEAL VARICES BLEEDING**Vlad Pavel, Germany; Gößmann H.; Müller-Schilling M.; Schmid S. A.

CC070

**GASTROCOLIC FISTULIZATION AS A LATE COMPLICATION OF BILLROTH II GASTRECTOMY: AN UNEXPECTED CAUSE OF CHRONIC DIARRHEA**Miquel Marquès Camí, Spain; Malagelada Prats C.; Lobo Alvarez B.; Sellarès Nadal J.; Sihuay D.; Rios Vives M. A.; Abu-Suboh Abadía M.; Dot Bach J.; Armengol Miró J. R.

CC071

**VASCULAR STENT MIGRATION INTO DIGESTIVE TRACT AFTER TOTAL GASTRECTOMY – ENDOSCOPIC REMOVAL WITH INTERVENTIONAL RADIOLOGY ASSISTANCE: A CASE REPORT**Talita Sallum Mendonca, Brazil; Sztokfisz C. Z.; Pelosof A. G.; Calvalcanti A. C. B. S.; Seraphim A. M.; Taglieri E.; Micelli-Neto O.; Sampaio L. M.; Guerra J. G.; Zurstrassen C. E.; Lessa R. A.; Castro J. S. d. L.; Andrade E. R. A.; Takamoto A. H. R.**Lower GI**

CC072

**WERNICKE ENCEPHALOPATHY IN PATIENT WITH CROHN'S DISEASE AND SEVERE HYPOMAGNEAEMIA AND HYPOCALCAEMIA**Dinko Bekic, Croatia; Belosic Halle Z.; Luetic K.; Marusic M.; Maric N.; Budincevic H.

CC073

**VERY EARLY FMT APPLICATION IN ULCERATIVE COLITIS AND UNEXPECTED LONG-TERM REMISSION**Karakan T.; Ali Karatas, Turkey; Demirbaş Yüceldi S.; Gök Z.

CC074

**WET PERITONEAL TUBERCULOSIS**Mirza Faisal Anwar Baig, United Kingdom; Khan M. T.

CC075

**FECAL MICROBIOTA TRANSPLANTATION FOR PSEUDOMONAS COLITIS: A CLINICAL AND MICROBIOLOGICAL SUCCESS.**Brigida Barberio, Italy; Facchin S.; Savarino E. V.; D'inca R.; Zingone F.; Cola M.; Ghisa M.; Lorenzon G.; Rigo A.; Marinelli C.; Inferrera M.; Sturniolo G. C.

CC076

**INTESTINAL INVOLVEMENT IN WEGENER'S GRANULOMATOSIS MIMICKING AN INFLAMMATORY BOWEL DISEASE: A CASE REPORT**Filippo Pelizzaro, Italy; Ghisa M.; Barberio B.; Barbuscio I.; Della Coletta M.; Cocconcelli E.; Schiavon F.; Savarino E.; Farinati F.; Galeazzi F.**Upper GI**

CC077

**SEVERE HERPES SIMPLEX ESOPHAGITIS: AN UNCOMMON COMPLICATION FOLLOWING REACTIVATION OF HERPES SIMPLEX ENCEPHALITIS**Yu Jun Wong, Singapore; Loh J. T.; Chlebicki P. M.; Tan M. Y. D.

CC078

**A CASE REPORT OF SEVERE HAND - FOOT SKIN RESPONSE TO ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH APATINIB COMBINED WITH S-1**  
Yusheng Wang, China; Zhang C.; Song X.

CC079

**TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) FOR VARICES MANAGEMENT PRIOR TO EMR IN A PATIENT WITH INTRAMUCOSAL CARCINOMA SECONDARY TO BARRETT'S OESOPHAGUS. A CASE REPORT.**Priya Oka, United Kingdom; Sprakes M.; Vani D.

CC080

**NON-AMPULLARY DUODENAL SIGNET RING CELL CARCINOMA TREATED USING ENDOSCOPIC MUCOSAL RESECTION**Takeshi Okamoto, Japan; Nakamura K.; Fukuda K.; Suzuki K.

CC081

**GASTRIC MIXED ADENONEUROENDOCRINE CARCINOMA (MANEC): REPORT OF TWO CASES**Juliana Castro, Brazil; Pelosof A.; Mendonça T.; Taglieri E.; Seraphim A. M.; Micelli-Neto O.; Cabral J. G.; Sampaio L.; Takamoto A.; Andrade E.; Zitron C.

CC082

**GASTRIC KAPOSI'S SARCOMA AFTER LIVER TRANSPLANTATION**Baderaldeen Ahmed, Saudi Arabia; Abaalkhail F.; Hasan H.; Abdelhaleem M.; Alhamoudi W.; Elbeshbeshy H.; Elsiesty H.

CC083

**GASTRIC MALT LYMPHOMA ACCOMPANIED WITH INTESTINAL FOLLICULAR LYMPHOMA**Masao Yoshioka, Japan; Ito M.; Kaneto M.; Saito S.; Fujii M.; Ishiyama S.; Fujiwara A.; Nasu J.; Shiode J.; Yamamoto K.

CC084

**AN UNCOMMON CASE OF NEUROENDOCRINE TUMOR(NET) AT DUODENAL BULB AND DIFFICULTIES AND CHALLENGES THAT HAD TO BE ENCOUNTERED DURING DIAGNOSTIC PROCESS.**Maria Stafylidou, Greece; Gagalis A.; Vasiliou K.; Paschos P.; Tzatzagou G.; Kalampakas A.

## Poster Sessions by Day

Wednesday, October 24, 2018

## Poster Session

09:00 - 14:00

Hall X1

Liver and Biliary III

## Molecular biology, inflammation and fibrosis

P1252

**EFFECT OF ROSUVASTATIN ON HEPATIC STEATOSIS AND FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS : A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL**

Farshad Sheikhesmaeili, Iran; Naghshbandi N.; Parhizkar B.; Naghshbandi J.; Yousefinejad V.; Babahajian A.

P1253 

**MICRORNA-199A-3P PROMOTES THE ACTIVATION OF HEPATIC STELLATE CELLS AND LIVER FIBROSIS BY SUPPRESSING CAVEOLIN-2**

Yang X.; Wei R.; Men R.; Ma L.; Wen M.; Peng Y.; Yang L.; Xiaoli Fan, China

P1254 

**THE COMBINATION OF AN ANDROGEN, A BILE ACID AND AN EICOSANOID IS A PROMISING BIOMARKER FOR LIVER FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS**

Silke Schulze Pellengahr, Germany; Neuber S.; Wagner-Golbs A.; Christiansen N.; Schatz P.; Kamlage B.; Stickel F.; Hinrichsen H.; Schafmayer C.; von Schönfels W.; Montani M.; Röcken C.; Lerch M. M.; Berg T.; Datz C.; Brosch M.; Hampe J.

P1255 

**PLGA NANOPARTICLES BASED DELIVERY OF SRC KINASE SIGNALING PATHWAY INHIBITOR KX2-391 FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS**

Dhadhang Kurniawan, The Netherlands; Jajoriya A.; Dhawan G.; Mishra D.; Oosterhuis D.; Storm G.; Olinga P.; Mishra D. P.; Prakash J.; Bansal R.

P1256

**THERAPEUTIC INHIBITION OF SYK KINASE IN MACROPHAGES USING PLGA NANOPARTICLES FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS**

Dhadhang Kurniawan, The Netherlands; Jajoriya A.; Dhawan G.; Mishra D.; Storm G.; Mishra D. P.; Prakash J.; Bansal R.

P1257

**THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIAL GENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLIC STEATOHEPATITIS.**

Onal A.; Fatih Eren, Turkey; Yılmaz D.; Gocmen T.; Yılmaz Y.

## Microbiology

P1258

**THE RELATIONSHIP BETWEEN SMALL INTESTINAL BACTERIAL OVERGROWTH AND ENDOTOXEMIA LEVELS AND TLR2,TLR4 EXPRESSION IN PATIENTS WITH CIRRHOSIS**  
Ying Jie Ma, China; Gao X.; Zhou D.; Chen G.

P1259 

**MUCOSAL-ADHERENT ESCHERICHIA COLI NF73-1 ISOLATED FROM A PATIENT WITH NON-ALCOHOLIC STEATOHEPATITIS INDUCES LIVER INJURY IN HIGH FAT DIET MICE**

Song Y.; Jinde He, China; Wu N.; Wu Z.; Xu J.; Zhang Y.; Chi Y.; Liu Y.

## Metabolic/genetic disorders

P1260 

**DOES THE COFFEE VIA GUT-LIVER AXIS PLAY A BENEFICIAL EFFECT ON LIVER DAMAGE?**

Mazzone G.; Lembo V.; Vitaglione P.; Rossi A.; Valentina Cossiga, Italy; D'Argenio G.; Guido M.; Savoia M.; Caporaso N.; Morisco F.

P1261

**A NOVEL AUTOMATIC DIGITAL ALGORITHM THAT ACCURATELY QUANTIFIES STEATOSIS IN NAFLD ON HISTOPATHOLOGICAL WHOLE SLIDE IMAGES**

Isabelle Munsterman, The Netherlands; van Erp M.; Weijers G.; de Korte C.; Drenth J. P. H.; van der Laak J.; Tjwa E. T. T. L.

P1262 

**FATTY LIVER PROMOTES GAMMA-GLUTAMYL TRANSEPTIDASE ACTIVITY-INDUCED ARTERIAL PLAQUE FORMATION**

Kaori Kinoshita, Japan; Toshikuni N.; Tsuchishima M.; Tsutsumi M.

P1263 

**THE ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND MILD COGNITIVE IMPAIRMENT IN THE ELDERLY**

Deng Lihua, China; Jiaojiao L.; Yanan W.; Lingxia C.; Jie L.; Wang J.

P1264

**NONINVASIVE FIBROSIS SCORES (APRI, FIB 4 INDEX, BARD)-USEFUL TOOLS FOR EVALUATING FATTY LIVER DISEASE**

Simona Alina Popescu, Romania; Sporea I.; Gherhardt D.; Pienar C.; Braha A.; Sima A.; Sirlu R. L. D.; Danila M.; Silviu N.; Lupusoru R.; Foncea C. G.; Moga T.; Timar R.



P1265

**ENHANCED LIVER FIBROSIS (ELF) SCORE FOR NONINVASIVE DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS (NASH) WITH ADVANCED FIBROSIS.**Staufer K.; Marculescu R.; Obermayer-Pietsch B.; Stift J.; Lackner C.; Trauner M. H.; Rudolf Ernst Stauer, Austria

P1266

**THE ROLE OF CXCL10 FOR PREDICTING THE CARDIOVASCULAR RISK AND THE OCCURRENCE OF METABOLIC SYNDROME IN LIVER TRANSPLANT RECIPIENTS**Carmen-Cristina Ester, Romania; Cerban R.-C.; Iacob M. S.; Constantin G.; Pislaru L.; Grancea C.; Ruta S.; Gheorghe L. S.P1267 **UDCA IMPROVED INSULIN SENSITIVITY AND METABOLIC PARAMETERS IN NASH PATIENTS**Sergey Vyalov, Russian Federation

P1268

**NEW MARKERS FOR STEATOSIS ASSESSMENT IN NAFDL - THE IMPORTANCE OF METABOLOMICS**Dana Crisan, Romania; Suciu A.; Stefanescu H.; Romaniciuc F.; Socaciu C.; Grigorescu M.; Avram L.; Radu C.

P1269

**HEPATOMETABOLIC SYNDROME. NEW CRITERIAS FOR THE DEFINITION OF MS**Mihai Alexandru Munteanu, Romania; Brisc C.

P1270

**CLINICAL IMPACT OF COMORBIDITIES IN AN ITALIAN NAFLD COHORT**Miele L.; Antonio Liguori, Italy; Marrone G.; Ponziani F. R.; Spiniello L.; Tortora A.; Abbate V.; Ainora M. E.; Rinninella E.; De Matthaeis N.; Pizzolante F.; Biolato M.; Zocco M. A.; Riccardi L.; Mele M. C.; Siciliano M.; Addolorato G.; Pompili M.; Rapaccini G. L.; Gasbarrini A.; Grieco A.

P1271

**N-3 POLYUNSATURATED FATTY ACIDS IN NAFLD (A DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED STUDY)**Vaclav Smid, Czech Republic; Dvorak K.; Sedivy P.; Hajek M.; Hainer R.; Drobny M.; Vittek L.; Bruha R.**Hepatotoxicity/alcohol**

P1272

**HIGH-DENSITY LIPOPROTEIN LEVELS AND URIC ACID LEVELS MAY BE USEFUL TO DISTINGUISH ALCOHOLIC FATTY LIVER AND NONALCOHOLIC FATTY LIVER.**Akio Moriya, Japan; Iwasaki Y.; Kayashima E.; Mitsumune T.; Taniguchi H.; Ando M.

P1273

**GENDER DIFFERENCES IMPACT THE PD-1 AND PD-L1 EXPRESSION ON PERIPHERAL T AND B CELLS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE.**Beata Kasztelan-Szczerbinska, Poland; Adamczyk K.; Surdacka A.; Cichoz-Lach H.; Rolinski J.; Michalak A.; Onikijuk J.; Zygo B.; Szczerbinski M.

P1274

**SYSTEMIC UPREGULATION OF SELECTED CCL AND CXCL CHEMOKINES IN THE COURSE OF ALCOHOLIC LIVER DISEASE.**Beata Kasztelan-Szczerbinska, Poland; Onikijuk J.; Surdacka A.; Cichoz-Lach H.; Rolinski J.; Adamczyk K.; Michalak A.; Zygo B.; Szczerbinski M.; Wilczynska B.

P1275

**CALCULATION OF LILLE MODEL BETWEEN DAY 3 AND 4 CAN ACCURATELY PREDICT CORTICOSTEROID RESPONSE : A SINGLE CENTER RETROSPECTIVE STUDY.**Joana Carvão, Portugal; Magno Pereira V.; Oliveira A.; Sousa Andrade C.; Jasmins L.

P1276

**SIGNIFICANCE OF CIRCULATING MEDIATORS RELEASED FROM ACTIVATED NEUTROPHILS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE.**Beata Kasztelan-Szczerbinska, Poland; Zygo B.; Surdacka A.; Cichoz-Lach H.; Rolinski J.; Adamczyk K.; Michalak A.; Onikijuk J.; Szczerbinski M.; Wilczynska B.

P1277

**EVALUATION OF CYTOSTATIC-INDUCED LIVER INJURY RISK IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**Igor Skrypyuk, Ukraine; Maslova G.

P1278

**SAFETY ASSESSMENT IN THE HERBAL FIELD: COMMON PITFALLS**Olaf Kelber, Germany; Fink C.; Nieber K.; Kraft K.**Cirrhosis and complications: Clinical aspects**


P1279

**PREVALENCE AND PREDICTIVE FACTORS OF CIRRHOTIC CARDIOMYOPATHY IN A COHORT OF CIRRHOTIC PATIENTS**Dahmani W.; Aida Ben Slama, Tunisia; Slim M.; Jaziri H.; Limam M.; Aya H.; Elleuch N.; Brahem A.; Ajmi S.; Ksaa M.; Jmaa A.

P1280

**ASSESSMENT OF CARDIAC DYSFUNCTION IN CIRRHOSIS USING TISSUE-DOPPLER AND SPECKLE TRACKING ECHOCARDIOGRAPHY**Dahmani W.; Aida Ben Slama, Tunisia; Slim M.; Jaziri H.; Limam M.; Elleuch N.; Aya H.; Brahem A.; Ajmi S.; Ksaa M.; Jmaa A.



- P1281**  
**ENDOSCOPIC VARICEAL LIGATION FOLLOWED BY ARGON PLASMA COAGULATION AGAINST ENDOSCOPIC VARICEAL LIGATION ALONE: RESULTS OF 5,5-YEAR FOLLOW UP**  
Ahmed Kamal, Egypt; Abd Elmoety A. A.; Hamza Y.; Zeid A.
- P1282**  
**GLOMERULAR FILTRATION RATE BASED ON SERUM CREATININE IN DECOMPENSATED LIVER CIRRHOSIS - COMPARATIVE STUDY WITH THE "ROYAL FREE HOSPITAL" FORMULA**  
Pedro Costa-Moreira, Portugal; Gaspar R.; Andrade P.; Pereira P. R.; Morais R.; Silva M.; Coelho R.; Cardoso H.; Liberal R.; Lopes S.; Macedo G.
- P1283**  
**THE IMPACT OF BETA-BLOCKERS IN ADVANCED CIRRHOSIS**  
 Dorra T.; Zgoulli Rania, Tunisia; Norsaf B.; Khaou-Ouakaa A.; Meriam S.; Elloumi H.; Dalila G.; Kharrat J.
- P1284**  
**ACUTE-ON-CHRONIC LIVER FAILURE SCORE IN ACUTE DECOMPENSATED CIRRHOSIS: MEASUREMENT AND PROGNOSTIC VALUE**  
 Khedher S.; Nasreddine F.; Abdennebi C.; Ben Ismail K.; Khaled A.; Salem M.; El Jari K.; Zaimi Y.; Mouelhi L.; Yosra Said, Tunisia; Debbesh R.
- P1285**  
**THE NEW RECOMMENDED CRITERIA FOR SEPSIS ARE INAPPROPRIATE FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS**  
Petra Fischer, Romania; Grigoras C.-A.; Bugaru A.; Farcau O.; Pascalau S.; Benea A.; Stefanescu H.; Tantau M.; Ionescu D.; Procopet B. D.
- P1286**  
**LIMITED DIAGNOSTIC PERFORMANCE OF CONTROLLED ATTENUATION PARAMETER FOR ASSESSING HEPATIC STEATOSIS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE AND PORTAL HYPERTENSION**  
 Semmler G.; Stift J.; Scheiner B.; Paternostro R.; Schwabl P.; Pinter M.; Wöran K.; Stättermayer A. F.; Trauner M.; Reiberger T.; Mattias Mandorfer, Austria
- P1287**  
**THE VALUE OF ULTRASOUND BASED ELASTOGRAPHIC METHODS FOR RULING OUT THE PRESENCE OF ESOPHAGEAL VARICES IN LIVER CIRRHOTIC PATIENTS**  
Simona Alina Popescu, Romania; Sporea I.; Lupusoru R.; Stepan A.-M.; Sirli R. L. D.; Danila M.; Moga T.; Pienar C.; Mare R. G.; Bende F.; Foncea C. G.; Gherhardt D.; Miutescu B.
- P1288**  
**TRANSJUGULAR LIVER BIOPSY PERFORMED BY HEPATOLOGISTS TRAINED IN HEPATIC VENOUS PRESSURE GRADIENT MEASUREMENTS IS SAFE AND PROVIDES IMPORTANT DIAGNOSTIC AND PROGNOSTIC INFORMATION**  
 Semmler G.; Stift J.; Walzel C.; Mandorfer M.; Schwarzer R.; Schwabl P.; Paternostro R.; Bernhard Scheiner, Austria; Wöran K.; Pinter M.; Stättermayer A. F.; Trauner M.; Peck-Radosavljevic M.; Ferlitsch A.; Reiberger T.
- P1289**  
**DIAGNOSTIC ACCURACY OF BAVENO VI CRITERIA FOR SCREENING OF VARICES IN PATIENTS WITH COMPENSATED ADVANCED CHRONIC LIVER DISEASE - A META-ANALYSIS**  
Maria Stafylidou, Greece; Paschos P.; Katsoula A.; Malandris K.; Akriviadis E.; Haidich A.-B.; Tsapas A.
- P1290**  
**ABILITY OF MELD SCORE AND PLATELET COUNT FOR RULING-OUT HIGH-RISK VARICES IN COMPENSATED LIVER CIRRHOSIS PATIENTS**  
Nicolau Vallejo Senra, Spain; Molina-Pérez E.; Fernández-Castroagudín J.; Dominguez-Muñoz J. E.
- P1291**   
**NON-ALCOHOLIC FATTY LIVER DISEASE AFTER LIVER TRANSPLANTATION IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND CRYPTOGENIC CIRRHOSIS: THE IMPACT OF PRE-TRANSPLANT GRAFT STEATOSIS**  
Ahad Eshraghian, Iran; Nikeghbalain S.; Malek-Hosseini S. A.
- P1292**  
**GADOXETIC ACID ENHANCED MRI DISTINGUISHES ADVANCED CHRONIC LIVER DISEASE PATIENTS WITH IMPROVING LIVER FUNCTION AFTER SUSTAINED VIROLOGIC RESPONSE AND PATIENTS WITH PERSISTENT LIVER DAMAGE**  
Mattias Mandorfer, Austria; Haider L.; Güngören Z.; Reiberger T.; Bastati N.; Hodge J. C.; Chromy D.; Trauner M.; Herold C.; Peck-Radosavljevic M.; Ba-Ssalamah A.
- P1293**  
**THE CLINICAL DIFFERENCES BETWEEN CRYPTOGENIC CIRRHOSIS WITH CIRRHOSIS SECONDARY TO NON-ALCOHOLIC STEATOHEPATITIS AND AUTOIMMUNE HEPATITIS**  
Ahad Eshraghian, Iran; Nikeghbalain S.; Taghavi S. A.; Malek-Hosseini S. A.
- P1294**  
**HCV ERADICATION: A GAME-CHANGER IN THE RELATIONSHIP BETWEEN LIVER STIFFNESS AND PORTAL PRESSURE IN COMPENSATED ADVANCED LIVER DISEASE**  
 Sav R.; Oana Farcau, Romania; Fischer P.; Stancu O.; Horhat A.; Procopet B.; Radu C.; Sparchez Z. A.; Stefanescu H.

**Viral hepatitis C: Clinical aspects**P1295 

**NEW IFN FREE TREATMENT IMPROVES METABOLIC PROFILE IN HCV-RELATED LIVER TRANSPLANT RECIPIENTS**  
Junaïd Beig, New Zealand; Orr D.; Harrison B.; Gane E.

P1296

**NS5A AND NS5B RESISTANCE-ASSOCIATED SUBSTITUTIONS ARE ASSOCIATED WITH VIROLOGIC FAILURE IN HEPATITIS C VIRUS GENOTYPE 1 PATIENTS TREATED WITH SOFOSBUVIR AND LEDIPASVIR**

Seiichi Mawatari, Japan; Oda K.; Tabu K.; Ijuin S.; Kumagai K.; Tashima S.; Kasai A.; Tamai T.; Moriuchi A.; Ido A.

P1297

**SAFETY AND EFFICACY OF SOFOSBUVIR BASED REGIMENS IN TREATING HEPATITIS C VIRUS IN EGYPTIAN PATIENTS: REAL WORLD STUDY: SINGLE CENTER EXPERIENCE**

Mohamed Abbasy, Egypt; Abou Elela T.; Zakareya T.; Hendy O.; Al Haddad O. K.; Salman T.

P1298

**RIGHT TIMING FOR TRANSIENT ELASTOGRAPHY LEAD TO THE RIGHT FOLLOW UP AFTER HCV TREATMENT**

Laura Scribano, Italy; Caroli D.; Rosa-Rizzotto E.; Saia M.; Peraro L.; De Lazzari F.; Martines D.; Lobello S.

P1299

**HEPATITIS C VIRUS INFECTION: AN INSULAR REALITY**

Antonio Oliveira, Portugal; Carvão J.; Magno Pereira V.; Ladeira N.; Jasmins L.

P1300

**FIBROSCAN VS. FIBROMAX IN PATIENTS WITH HCV COMPENSATED LIVER CIRRHOSIS**

Roxana Lucia Denisa Sirlj, Romania; Lupusoru R.; Sporea I.; Lazar A.; Deleanu A.; Gheorghe L. S.; Iacob S.; Curescu M.; Brisc C.; Prelipcean C. C.; Popescu S. A.; Danila M.; Stanciu C.; Sandulescu L.; Trifan A.-V.

P1301

**RECURRENCE RATE OF HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH HCC AND VIRUS C COMPENSATED CIRRHOSIS TREATED WITH OMBITASVIR, PARITAPREVIR/R+DASABUVIR+RIBAVIRIN**

Irina Sandra, Romania; Preda C. M.; Fulger L.; Oproiu A.; Gavrilă D.; Diculescu M.; Dumitru R.; Vasilescu C.; Manuc M.

P1302

**LONG TERM FOLLOW UP OF CHRONIC HEPATITIS C PATIENTS: WILL SUSTAINED VIROLOGICAL RESPONSE BE ENOUGH TO PREVENT CIRRHOSIS IN THE LONG TERM?**

Coşkun Özer Demirtaş, Turkey; Suveran M.; Gürel S.

P1303

**DIAGNOSTIC PERFORMANCE EVALUATION OF RAPID DIAGNOSTIC ORIENTATION TEST IN THE DETECTION OF HEPATITIS C**

Naji Siham, Morocco; El-Mekkaoui A.; Khannoussi W.; Kharrasse G.; Ismaili Z.

**Immunology, autoimmune liver disease**

P1304

**PREDICTIVE FACTORS OF RESPONSE TO URSODESOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS**

Ons Gharbi, Tunisia; Kchir H.; Issaoui D.; Chaabouni H.; Maamouri N.

P1305

**COMBINATION THERAPY OF FENOFIBRATE AND URSODESOXYCHOLIC ACID IMPROVES THE PROGNOSIS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITH INCOMPLETE RESPONSE TO URSODESOXYCHOLIC ACID**

Marta Patita, Portugal; Liberal R.; Gaspar R.; Cardoso H.; Lopes S.; Macedo G.

P1306

**PREDICTIVE FACTORS OF URSODESOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS.**

Aida Ben Slama, Tunisia; Ksiao M.; Hamdi S.; Jaziri H.; Elleuch N.; Hammami A.; Jmaa A.

P1307

**LIPIDOMICS ANALYSES IN SERUM IDENTIFIED CANDIDATE BIOMARKERS FOR DISEASE PROGRESSION AND DEVELOPMENT OF PRIMARY SCLEROSING CHOLANGITIS AND BILIARY DYSPLASIA**

Vidya Velagapudi, Finland; Pessia A.; Arola J.; Boyd S.; Jokelainen K.; Färkkilä M. A.

P1308

**A STUDY ON PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) BASED ON A SURVEY**

Shu-Hei Okuyama, Japan; Kawamura N.; Hisamatsu T.

P1309

**WITHDRAWN**

**Liver neoplasia: Basic**

P1310

**UGT2B28 GENOMIC VARIATION IS ASSOCIATED WITH THE ONSET AGE OF ALCOHOLISM-ASSOCIATED HEPATOCELLULAR CARCINOMA**

Puo-Hsien Le, Taiwan; Liang K.-H.; Yeh C.-T.

- P1311**  
**METHYLATION OF MULTIPLE TUMOR SUPPRESSOR GENES(RUNT-RELATED TRANSCRIPTION FACTOR 3 (RUNX3), RAS ASSOCIATION DOMAIN FAMILY1 ISOFORM A(RASSF1A) AND E-CADHERIN ) IN HCV RELATED LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS.**  
Mahmoud El-Bendary, Egypt; Nour D.; Arafa M.; Neamatallah M. A.
- P1312**  
**THE ANTI-INFLAMMATORY RECEPTOR TREM2 HALTS THE GENERATION OF HCC IN MICE THROUGH THE INHIBITION OF LIVER INFLAMMATION AND HEPATOCYTE PROLIFERATIVE RESPONSES**  
Aitor Esparza, Spain; Labiano I.; Sharif O.; Oakley F.; Hijona E.; Jiménez-Agüero R.; O'Rourke C. J.; Andersen J. B.; Knapp S.; Mann D. A.; Bujanda L.; Banales J. M.; Perugorria M. J.
- P1313**  
**MUSASHI 2 CONTRIBUTES TO THE MAINTENANCE OF STEMNESS OF CD44V6+ LIVER CANCER STEM CELLS VIA NOTCH SIGNALING PATHWAY**  
 Cheng B.; Xijiu Wang, China; Wang R.
- P1314**  
**MICRORNA-195 INCREASES APOPTOSIS IN HEPATOCELLULAR CARCINOMA BY TARGETING THE KEY CELL CYCLE REGULATOR WEE1.**  
Yunan Zhang, China; An F.; Zhan Q.
- P1315**  
**THE RELATION BETWEEN MICRO-RNA GENE POLYMORPHISMS AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS**  
 Abdel-Samiee M.; Eljaky M. A.; Diab K. A.; Sheble N.; Allam M. M.; Zayed E.; Khalil F. O.; Abd-Elkreem M.; Othman W.; Khalaf F. A.; Eman Abdelsameea, Egypt
- P1316**  
**PERIOSTIN PROMOTES TUMORIGENESIS BY ACTIVATING EPITHELIAL-MESENCHYMAL TRANSITION IN LIVER CANCER.**  
Bo Hyun Kim, Republic of Korea; Lee S.D .; Lee J. H.; Lee I. J.; Koh S.-J.; Hong E. K.
- P1317**  
**TUMORSUPPRESSIVE MICRORNA EXPRESSION IN HEPATOCELLULAR CARCINOMA IS REGULATED BY P63 AND HCC THERAPEUTICS**  
Emily Ungermann, Germany; Aschenbrenner E.; Pollinger K.; Kunst C.; Müller-Schilling M.
- P1318**  
**P73 AND TIVANTINIB COOPERATE TO ORCHESTRATE EXPRESSION OF TUMORSUPPRESSIVE MICRORNAS IN HEPATOCELLULAR CARCINOMA**  
Lisa Kaser, Germany; Aschenbrenner E.; Pollinger K.; Kunst C.; Müller-Schilling M.
- Liver neoplasia: Clinical**
- P1319**  
**ASSOCIATION BETWEEN XRCC1 GENE POLYMORPHISM AND HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS**  
 Hamam O.; Abdel-Samiee M.; Helwa M.; Eman Abdelsameea, Egypt; Naguib M.; Zaghla H.; Soliman M.
- P1320**  
**1-HYDROXY PYRENE IN URINE AS A BIOLOGICAL MONITORING OF EXPOSURE TO POLYCYCLIC AROMATIC HYDROCARBONS MIGHT EXPLAIN WHY HEPATOCELLULAR CARCINOMA DEVELOPED AMONG SOME CASES OF CHRONIC ACTIVE VIRAL HEPATITIS**  
Raed Alazab, Egypt; Abdel Wahed A.; Motawea E.; Morsy S.; Elsayed A.
- P1321**  
**DIAGNOSTIC PERFORMANCE OF ALPHA- FETOPROTEIN, ALPHA-FETOPROTEIN-L3, PROTEIN INDUCED BY VITAMIN K ABSENCE, GLYPICAN 3 AND ITS COMBINATIONS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS ADMITTED IN A LARGE TRANSPLANT CENTER IN ROMANIA**  
Razvan-Claudiu Cerban, Romania; Ester C.-C.; Iacob M. S.; Paslaru L. L.; Constantin G.; Lita M.-C.; Pietreanu C.; Gheorghe L. S.
- P1322**  
**TALIN-1, OTHER THAN A POTENTIAL MARKER FOR HEPATOCELLULAR CARCINOMA DIAGNOSIS**  
 Aly Aboelfotoh O.; Mahmoud Foda E.; Mohamed Elghandour A.; Ghada Abdelrahman, Egypt; Mohamed Teama N.; Adel Ali R.
- P1323**  
**RADIOEMBOLIZATION WITH YTTRIUM-90 MICROSPHERES FOR INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: A SINGLE CENTRE REAL-LIFE EXPERIENCE**  
 Masotto A.; Massella A.; Bocus P.; Taddei G.; Oliboni E.; Lunardi G.; Cirillo M.; Salgarello M.; Boninsegna S.; Silvia Storato, Italy
- P1324**  
**RISK OF AGGRESSIVE/ADVANCED HEPATOCELLULAR CARCINOMA DEVELOPMENT AFTER DIRECT ACTING ANTIVIRAL THERAPY IN PATIENTS WITH HCV-RELATED CIRRHOSIS.**  
 Elessawy H.; Abdulhafiz E.; Heba Faheem, Egypt; Fahmy Y.; Elbastawisy S.; Hashish A.
- P1325**  
**WITHDRAWN**

P1326

**PREDICTIVE FACTORS FOR COMPLETE RESPONSE AND RECURRENCE AFTER TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA PATIENTS: A FIVE-YEAR EXPERIENCE**

Razvan-Claudiu Cerban, Romania; Ester C.-C.; Iacob M. S.; Grasu M.; Dumitru R.; Pietrareanu C.; Lita M.-C.; Constantin G.; Gheorghel L. S.

P1327 

**MONOFOCAL HEPATOCELLULAR CARCINOMA (HCC): SHOULD THE 5 CM CUT-OFF BE CONSIDERED AS FUNDAMENTAL? AN ANALYSIS OF THE ITA.LI.CA DATABASE**

Giulia Peserico, Italy; Penzo B.; Pelizzaro F.; Imondi A.; Sartori A.; vitale A.; Trevisani F.; Farinati F.

### Bile acids, transport, cholestasis, gallstones: Basic

P1328

**ANALYSIS OF THE BILIARY BACTERIAL COMMUNITIES IN CHOLEDOCHOLITHIASIS PATIENTS WITHOUT RECENT ANTIBIOTICS TREATMENT BASED ON 16S RRNA AMPLICON SEQUENCING**

Mengdie Shen, China; Ye F.; Zhang X.

P1329 

**FUNCTIONAL CHANGES OF PANETH CELL IN THE INTESTINAL EPITHELIUM OF MICE WITH OBSTRUCTIVE JAUNDICE AND AFTER INTERNAL AND EXTERNAL BILIARY DRAINAGE**

Xiaopeng Tian, China; Zhang Z.; Li W.

P1330

**EXPRESSION OF TLR4 IN DISTAL ILEUM OF MICE WITH OBSTRUCTIVE JAUNDICE AND ITS ROLE IN INTESTINAL MUCOSA BARRIER DAMAGE**

Xiaopeng Tian, China; Zhao H.; Li W.

P1331

**PREDICTING OUTCOMES OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS RECEIVING URSODESOXYCHOLIC ACID THERAPY USING THE GLOBE SCORE**

Aya Hammami, Tunisia; Hasnaoui B.; Elleuch N.; Ksiaa M.; Jaziri H.; Brahem A.; Ajmi S.; Ben Slama A.; Jmaa A.

### Biliary neoplasia: Basic

P1332

**EVALUATION OF THE POTENTIAL USE OF A SET OF MIRNAS IN INDETERMINATE BILIARY STRICTURES FOR EARLY DIAGNOSIS OF CHOLANGIOCARCINOMA.**

Ioannis Dimas, Greece; Gazouli M.; Vardas E.; Fragkaki M.; Velegraki M.; Voudoukis E.; Theodoropoulou A.; Paraskeva K. D.; Giannikaki E.; Paspatis G.

### Biliary neoplasia: Clinical

P1333

**A STUDY OF CORRELATION BETWEEN NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN CHOLANGIOCARCINOMA**

Monthira Maneerattanaporn, Thailand; Jiriyasin S.; Techawathanawanna S.

P1334

**SURVIVAL OF PATIENTS WITH DISTAL CHOLANGIOCARCINOMA: A POPULATION-BASED DUTCH COHORT**

Marin Strijker, The Netherlands; Belkouz A.; van der Geest L. G.; Busch O. R. C.; van Gulik T. M.; Verheij J.; Wilmink J. W.; Groot Koerkamp B.; Klümper H.-J.; Besselink M. G. H.

P1335

**ENDOSCOPIC SNARE PAPILLECTOMY (ESP) FOR AMPULLARY TUMOURS - SINGLE CENTER EXPERIENCE**

Amol Bapaye, India; Korrapati S. K.; Nemade P.; Mahadik M.; Dubale N. A.; Pujari R.; Bapaye J. A.

P1336

**THROMBOEMBOLISMS IN ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE ANALYSIS OF 174 CASES**

Kazunaga Ishigaki, Japan; Nakai Y.; Isayama H.; Saito K.; Takahara N.; Mizuno S.; Kogure H.; Tada M.; Koike K.

P1337

**PHOTODYNAMIC THERAPY OF PERIHILAR CHOLANGIOCARCINOMA - A RETROSPECTIVE COHORT ANALYSIS OVER A DECADE.**

Wilfried Obst, Germany; Canbay A. E.; Weigt J.

P1338

**TRENDS IN INCIDENCE, TREATMENT AND SURVIVAL OF GALLBLADDER CANCER; A NATION-WIDE COHORT STUDY.**

Elise de Savornin Lohman, The Netherlands; de Bitter T.; Verhoeven R.; van Laarhoven C.; Nagtegaal I. D.; Van der Post C.; de Reuver P.

### Poster Session

09:00 - 14:00

Hall X1

Pancreas III

### Pancreatitis, experimental

P1339

**FEASIBILITY OF A THREE-DIMENSIONAL SPHEROID CULTURE USING ENDOSCOPIC ULTRASOUND-GUIDED TISSUE SAMPLING IN PANCREATIC CANCER**

Chang-Min Cho, Republic of Korea; Nam S. Y.; Park J. Y.; Seo A. N.

P1340

**MAST CELL STABILIZERS AMELIORATE PAIN IN EXPERIMENTAL CHRONIC PANCREATITIS**

Sarah Klauss, Germany; Schorn S.; Friess H.; Ceyhan G. O.; Demir I. E.



P1341 

**DOPAMINE D<sub>2</sub> RECEPTOR SIGNALING CONTROLS INFLAMMATORY STATUS OF MACROPHAGES IN ACUTE PANCREATITIS THROUGH INHIBITION OF OXIDATIVE STRESS-INDUCED NF- $\kappa$ B AND INFLAMMASOME ACTIVATION**

Xingpeng Wang, China; Hu G.; Han X.; Wu J.; Li B.; Ye X.; Dai J.; Wu Z.; Ni J.; Chen C.

P1342

**FUNCTIONAL GENOMIC SCREENING DURING SOMATIC CELL REPROGRAMMING IDENTIFIES DKK3 AS A ROADBLOCK OF PANCREATIC REGENERATION**

Johann Gout, Germany; Breunig M.; Perkhofler L.; Seufferlein T.; Frappart P.-O.; Kleger A.

### Pancreatitis, acute

P1343 

**SMALLER PORTAL SYSTEM VEIN DIAMETERS PREDICT COMPLICATIONS AND OUTCOME IN ACUTE PANCREATITIS**

Geke Litjens, The Netherlands; Smeets X. J. N. M.; da Costa D. W.; Kievit W.; van Santvoort H. C.; Besselink M. G. H.; Fockens P.; Bruno M. J.; Kolkman J. J.; Drenth J. P. H.; Bollen T.; Geenen E. J. M.

P1344

**DIAGNOSTIC WORK-UP IN IDIOPATHIC ACUTE PANCREATITIS, A POST-HOC ANALYSIS OF A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT**

Nora Daphne Louise Hallensleben, The Netherlands; Umans D. S.; Bouwense S. A. W.; Verdonk R. C.; Besselink M. G. H.; van Hooft J. E.; Bruno M. J.

P1345

**DIFFERENCES BETWEEN THE OUTCOME OF RECURRENT ACUTE PANCREATITIS AND ACUTE PANCREATITIS**

Kochhar R.; Mallick B.; Sharma D. J.; Siddappa P. K.; Dhaka N.; Sarthak Malik, India; Dawra S.; Sinha S. K.; Muktesh G.; Yadav T. D.; Gupta V.

P1346

**DOES THE TIMING OF PERCUTANEOUS CATHETER DRAINAGE IMPACT OUTCOME IN PATIENTS WITH ACUTE FLUID COLLECTION IN PATIENTS WITH ACUTE PANCREATITIS.**

Bipadabhanjan Mallick, India; Dhaka N.; Gupta P.; Gulati A.; Malik S.; Sinha S. K.; Muktesh G.; Yadav T. D.; Gupta V.; Kochhar R.

P1347

**FACTORS AFFECTING OUTCOME AFTER PERCUTANEOUS CATHETER DRAINAGE OF FLUID COLLECTION IN PATIENTS WITH ACUTE PANCREATITIS**

Balaji Laxminarayanshetty Bellam, India; Muktesh G.; Dawra S.; Dhaka N.; Gupta P.; Sinha S. K.; Gupta V.; Yadav T. D.; Kochhar R.

P1348

**COMPARISON OF PROGNOSTIC SCORES IN THE CRITICALLY ILL PATIENT WITH SEVERE ACUTE PANCREATITIS**

Joana Carvão, Portugal; Nóbrega S.; Magno Pereira V.; Sousa Andrade C.; Pereira C.; Nóbrega J. J.; Jasmins L.

P1349

**ACUTE PANCREATITIS AS A RARE COMPLICATION OF HYDATID LIVER DISEASE. REPORT OF 16 CASES**

Omar Laalj, Morocco; Miry S.; Lahlali M.; Lamine Sejai A.; Abid H.; Elyousfi M.; Aqodad N.; Benajah D.-A.; El Abkari M.; Ibrahimy A.; Nada L.

P1350

**WHOLE-EXOME SEQUENCING TO IDENTIFY GENETIC RISK FACTORS FOR MULTIPLE-ORGAN FAILURE IN SEVERE ACUTE PANCREATITIS.**

Fons F. van den Berg, The Netherlands; Issa Y.; Besselink M. G. H.; Hennekam R. C.; Baas F.; Boermeester M. A.; van Santvoort H. C.

P1351

**PULMONARY FUNCTION IN THE EARLY PHASE OF ACUTE PANCREATITIS: A PROSPECTIVE COHORT STUDY**

Mikkel Werge, Denmark; Celiach T.; Merc A.-I.; Bisgaard T.; Feldager E.; Hansen E.; Schmidt P. N.; Novovic S.; Gluud L. L.

P1352

**DEVELOPMENT OF A SCORE TO DETERMINE THE RISK OF ACUTE BILIARY PANCREATITIS RELAPSE BEFORE CHOLECYSTECTOMY**

Daniel De la Iglesia-García, Spain; Mejuto R.; Lariño Noia J.; Calviño-Suárez C.; Mauriz-Barreiro V.; Monteserin-Ron L.; Cárdenas-Jaén K.; Rodríguez E.; Ureña-Campos R.; Iglesias-García J.; Dominguez-Muñoz J. E.

P1353

**WITHDRAWN**

P1354

**UTILITY OF ERCP IN ACUTE BILIARY PANCREATITIS**

Jamil K.; Su Su Latt, United Kingdom; Folkerts S.; Birdi S.

### Pancreatitis, chronic (including hereditary disorders)

P1355

**CLINICAL AND NUTRITIONAL FEATURES ARE PREDICTABLE FOR HOSPITALIZATION IN PATIENTS WITH CHRONIC PANCREATITIS: A COHORT STUDY.**

Serena Stigliano, Italy; Archibugi L.; Signoretti M.; Zerboni G.; Capurso G.

P1356

**OCTREOTIDE AMELIORATES PANCREATIC FATTY ACID SYNTHESIS AND  $\alpha$ -OXIDATION IN HIGH FAT DIET-INDUCED PANCREATIC STEATOSIS**

Can Gan, China; Chen Y.; Zhao C.; Tang S.; Tang C.; Liu R.

P1357

**PROSPECTIVE STUDY EVALUATING THE ENDOCRINE AND EXOCRINE PANCREATIC FUNCTIONS AFTER ENDOSCOPIC TREATMENT OF CHRONIC PANCREATITIS.**Shabneez Kautbally, Belgium; Perez Cuadrado-Robles E.; Hermans M.; Hubert C.; Moreels T.; Deprez P. H.

P1358

**THERAPEUTIC EFFICACY OF PANCREATIC ENZYME SUPPLEMENT AND CLINICAL CHARACTERISTICS IN EARLY CHRONIC PANCREATITIS**Ryo Mizuno, Japan; Owaki Y.; Inatomi O.; Bamba S.; Sugimoto M.; Andoh A.

P1359

**CLINICAL OUTCOME OF EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY COMBINED WITH ENDOSCOPIC TREATMENT FOR CHRONIC PANCREATITIS WITH PANCREATIC STONE**Ran Utsunomiya, Japan; Takigawa Y.; Tanaka K.; Nagai K.; Kobayashi Y.; Kin T.; Yane K.; Hayashi T.; Takahashi K.; Katanuma A.

P1360

**PANCREATIC EXOCRINE AND ENDOCRINE INSUFFICIENCY AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC PANCREATITIS (CP). A PROSPECTIVE, LONGITUDINAL COHORT STUDY**Daniel De la Iglesia-García, Spain; Vallejo Senra N.; López-López A.; Iglesias-García J.; Nieto-García L.; Dominguez-Muñoz J. E.

P1361

**OVERALL CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH CHRONIC PANCREATITIS AND EXOCRINE INSUFFICIENCY RECEIVING ENZYME REPLACEMENT THERAPY**Kovacheva-Slavova M.; Siminkovitch S.; Genov J.; Mitova R.; Golemanov B.; Gecov P.; Borislav Vladimirov, Bulgaria

P1362

**WITHDRAWN**

P1363

**THE COMMON TRUNCATION VARIANT P.W358X OF THE PNLI1PRP2 LIPASE IS NOT ASSOCIATED WITH CHRONIC PANCREATITIS**Pesei Z. G.; Nemeth B.; Eszter Hegyi, United States; Szentesi A.; Vincze A.; Kelemen D.; Hegyi P.; Sahin-Toth M.**Pancreatic cancer: Clinical**

P1364

**SERUM ALBUMIN LEVEL, PROGNOSTIC NUTRITIONAL INDEX, AND CA19-9 ARE TREATMENT-PREDICTIVE MARKERS FOR DISEASE CONTROL RATE IN PATIENTS WITH UNRESECTABLE PANCREATIC CANCER**Ailee Ikeda, Japan; Uchida D.; Horiguchi S.; Tomoda T.; Matsumoto K.; Kato H.; Okada H.

P1365

**DIAGNOSTIC ACCURACY OF CARCINOEMBRYONIC ANTIGEN IN DIFFERENTIATING MUCINOUS AND NON-MUCINOUS PANCREATIC CYSTIC NEOPLASMS: SYSTEMATIC REVIEW AND INDIVIDUAL PATIENT DATA META-ANALYSIS**Nadine van Huijgevoort, The Netherlands; Hoogenboom S. A.; Lekkerkerker S. J.; Topazian M.; Chandrasekhara V.; Morris-Stiff G.; Al-Haddad M.; Oppong K.; Khalid A.; Del Chiaro M.; Fockens P.; Besselink M. G. H.; van Hooft J. E.

P1366

**SCREENING TO DETECT PRECURSOR LESIONS OF PANCREATIC ADENOCARCINOMA IN HIGH-RISK INDIVIDUALS EXPERIENCED FROM RAMBAM HEALTH CARE CAMPUS**Lachter J.; Elizabeth Half, Israel; Khamaysi I.; Yassin K. A.P1367 **ASSOCIATION BETWEEN PROGRESSION OF LOW RISK IPMNS AND DIABETES MELLITUS**Christian Brooks, United States; Hu G.; Gausman V.; Schroppe B.; Sethi A.; Poneross J.; Gress F.; Gonda T.P1368 **PREDICTION OF LOCAL RESECTABILITY OF PANCREATIC DUCTAL ADENOCARCINOMA: ARTIFICIAL INTELLIGENCE BEATS HUMAN INTELLIGENCE?**Vd Putten J.; Janse M.; Geke Litjens, The Netherlands; Zinger S.; de With P. H. N.; Prokop W. M.; Hermans J. J.

P1369

**DOES ABO BLOOD TYPE INFLUENCE LONG TERM OUTCOMES OF PANCREATIC CANCER IN JAPANESE?**Yoshinori Tanaka, Japan; Kumagi T.; Terao T.; Kuroda T.; Yokota T.; Azemoto N.; Imamura Y.; Uesugi K.; Kisaka Y.; Shibata N.; Koizumi M.; Ohno Y.; Yukimoto A.; Tange K.; Nishiyama M.; Miyake T.; Miyata H.; Ishii H.; Hiasa Y.

P1370

**INFLAMMATION AND PROFILE OF IL-6,10 AND 17 INTERLEUKINS IN PATIENTS WITH CHRONIC PANCREATITIS AND PANCREATIC CANCER**Tantau A.; Alina Mandrutiu, Romania; Tantau M.; Tomuleasa C.

P1371

**WITHDRAWN**

P1372

**HETES IN PATIENTS WITH PANCREATIC CANCER: A PRELIMINARY REPORT.**Wojciech Blogowski, Poland; Bodnarczuk T.; Dolegowska K.; Deskur A.; Dolegowska B.; Starzynska T.

P1373

**SARCOPENIA AS A PREDICTOR OF COMPLICATIONS AFTER PANCREATIC RESECTIONS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA**Liudmyla Pererva, Ukraine; Kopchak V.; Khomyak I.; Duvalko A.; Davydenko N.; Kopchak K.

## Poster Session

09:00 – 14:00

Hall X1

## Endoscopy and Imaging III

## Endoscopy, upper GI

P1374

**ANALYSIS OF VOLUME ADJUSTMENT IMPACT, RESULTS AND COMPLICATIONS USING THE SPATZ BALLOON FOR EXCESS WEIGHT TREATMENT: A LARGE BRASILIAN EXPERIENCE IN FOUR HUGE CENTERS.**

Ricardo Jose Fittipaldi-Fernandez, Brazil; Hoff A. C.

P1375 

**A NOVEL TECHNIQUE FOR ENDOSCOPIC ENBLOC RESECTION FOR LESIONS UP TO 30 MM (EMR+)**

Benjamin Meier, Germany; Caca K.

P1376

**FEASIBILITY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL NEOPLASMS IN ELDERLY PATIENTS : A SINGLE CENTER, LARGE SCALE, RETROSPECTIVE STUDY**

Jin Hee Noh, Republic of Korea; Kim D. H.; Na H. K.; Ahn J. Y.; Jung K. W.; Lee J. H.; Choi K. D.; Song H. J.; Lee G. H.; Jung H.-Y.

P1377

**ENDOSCOPIC HAND-SUTURING FOR MUCOSAL DEFECTS AFTER GASTRIC ESD IN CASES WITH ANTITHROMBOTIC AGENTS: A CASE SERIES STUDY IN 8 PATIENTS**

Tepei Akimoto, Japan; Goto O.; Sasaki M.; Kiguchi Y.; Nakayama A.; Kato M.; Ochiai Y.; Maehata T.; Yahagi N.

P1378

**ENDOSCOPIC SUBMUCOSAL DISSECTION FOR GASTRIC INDEFINITE FOR NEOPLASIA :WHICH SHOULD BE RESECTED?**

Kim S.-J.; Kang D.-H.; Kim H. W.; Cheol Woong Choi, Republic of Korea; Park S. B.; Nam H. S.; Ryu D. G.; Lee J. W.; Lee J. P.; Lee K. H.

P1379 

**SAFETY AND EFFICACY OF SUBMUCOSAL TUNNELING ENDOSCOPIC SEPTUM DIVISION FOR EPIPHRENIC DIVERTICULUM**

Xuan Li, China; Zhang G.

P1380

**THE YIELD OF BIDIRECTIONAL ENDOSCOPY IN YOUNG MALES WITH IRON DEFICIENCY ANAEMIA**

Samantha Baillie, United Kingdom; McNair A.; Loganayagam A.

P1381

**NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER TREATED BY NEOADIUVANT CHEMOTHERAPY EVALUATED BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCL).**

Renato Cannizzaro, Italy; Magris R.; Fornasari M.; Pivetta E.; Maiero S.; Mongiat M.; De Re V.; Canzonieri V.; De Paoli A.; Buonadonna A.; Di Mario F.; Serraino D.; Belluco C.; Canton E.; Spessotto P.

P1382 

**FLUORESCENT ENDOSCOPY DURING ESOPHAGEAL CARCINOGENESIS IN A MOUSE MODEL**

Hsin-Yu Fang, Germany; Gorpas D.; Ingermann J.; Wein F.; Stangl S.; Ntziachristos V.; Multhoff G.; Schottelius M.; Quante M.

P1383

**ENDOSCOPIC VACUUM THERAPY FOR POSTOPERATIVE ESOPHAGEAL LEAK**

Taewan Kim, Republic of Korea; Min Y. W.; Lee H.; Min B.-H.; Kim H. K.; Choi Y. S.; Lee J. H.; Rhee P.-L.; Kim J. J.; Zo J. I.; Shim Y. M.

P1384 

**PER ORAL ENDOSCOPIC MYOTOMY USING TRIANGLE TIP KNIFE WITH OR WITHOUT WATER JET FUNCTION**

Philip Wai Yan Chiu, Hong Kong PRC; Wong V. W.; Wu J. C.; Ng E.; Lau J.

P1385

**UPPER GASTROINTESTINAL CAPSULE ENDOSCOPY AS AN ALTERNATIVE TO OESOPHAGOGASTRODUODENOSCOPY**

Foong Way David Tai, United Kingdom; Healy A.; Thurston V.; Sidhu R.; Mcalindon M.

P1386

**CLINICAL OUTCOMES OF ENDOSCOPIC RESECTION FOR NON-AMPULLARY DUODENAL LESIONS**

Hyun Seung Je, Republic of Korea; Jung K. W.; Park M. I.; Park S. J.; Moon W.; Kim S. E.; Kim J. H.

P1387

**OVER-THE-SCOPE CLIPS (OTSC) FOR THE TREATMENT OF STOMACH AND DUODENAL ULCERS WITH HIGH-RISK STIGMATA OF BLEEDING – ONE AND DONE?**

Stefan Gölder, Germany; Neuhaus L.; Stücker J.; Freuer D.; Braun G.; Ebigbo A.; Probst A.; Weber T.; Messmann H.

P1388

**SPORADIC NON-AMPULLARY DUODENAL LESIONS: TWO TERTIARY-CENTERS STUDY ON ENDOSCOPIC RESECTION EFFICACY AND RECURRENCE.**

Rossella Semeraro, Italy; Craviotto V.; Maselli R.; Alkandari A.; Varytimiadis L.; Galtieri A. P.; Fugazza A.; Anderloni A.; Carrara S.; Di Leo M.; Ferrara E. C.; Troncone E.; Attardo S.; Repici A.; Bhandari P.

P1389

**SAFETY OF ENDOSCOPIC FULL-THICKNESS RESECTION OF SUPEROEPITHELIAL TUMORS IN THE STOMACH AFTER PRIOR FULL-THICKNESS SUTURING**Andreas Wannhoff, Germany; Schmidt A.; Caca K.

P1390

**DELAYED REMOVAL INCREASED THE COMPLICATION OF SHARP FOREIGN BODY IN THE UPPER GASTROINTESTINAL TRACT: AN EXPERIENCE FROM MULTIPLE CENTERS IN CHINA**Liangjing Wang, China; Ma M.; Guo Y.

P1391

**ENDOSCOPIC MUCOSAL AUTOGRAFT FOR REVERSING THE REFRACTORY ESOPHAGEAL CAUSTIC STRICTURE: THE PRELIMINARY HUMAN EXPERIENCE**He K.; Lili Zhao, China; Wang X.; Liu L.; Fan Z.

P1392

**ENDOSCOPIC SCREENING FOR BIERMER'S DISEASE : EXPERIENCE OF A MOROCCAN ENDOSCOPY UNIT.**Ilham Azghari, Morocco; Salihoun M.; Acharki M.; Kabbaj N.

P1393

**PER-ORAL ENDOSCOPIC MYOTOMY FOR ESOPHAGEAL DIVERTICULA WITH OR WITHOUT ESOPHAGEAL MOTILITY DISORDERS.**Orlandini B.; Maximilien Barret, France; Guillaumot M.-A.; Chloe L.; Leblanc S.; Prat F.; Stanislas C.

P1394

**PERORAL ENDOSCOPIC MYOTOMY (POEM) IS EFFECTIVE IN TREATMENT OF NON CARDIAC CHEST PAIN CAUSED BY HYPERCONTRACTILE ESOPHAGEAL MOTILITY DISORDERS**David Albers, Germany; Frieling T.; Dakkak D.; Kuhlbusch-Zicklam R.; Toex U.; Gittinger M.; Schumacher B.

P1395

**NATIONAL TRENDS IN HEALTHCARE OUTCOMES AND UTILIZATION OF ENDOSCOPIC AND SURGICAL INTERVENTIONS IN PATIENTS HOSPITALIZED WITH OESOPHAGEAL FOREIGN BODY.**Malav Prafulkumar Parikh, United States; Gupta N. M.; Thind K.; Sarvepalli S.; Lopez R.; Thota P. N.; Sanaka M. R.

P1396

**WITHDRAWN**

P1397

**EFFECT OF VONOPRAZAN ON THE TREATMENT OF POST-ENDOSCOPIC SUBMUCOSAL DISSECTION ARTIFICIAL GASTRIC ULCER**Yukihiro Kusumoto, Japan; Yamada T.; Nakanishi R.; Nagahama S.; Kimura E.; Tanimoto T.; Ohnishi K.; Sueyoshi Y.; Yamaguchi T.; Matsumoto K.; Hirao M.; Hosui A.; Hiramatsu N.

P1398

**FLEXIBLE ENDOSCOPIC MYOTOMY IN ZENKER'S DIVERTICULUM: NO CORRELATION BETWEEN OUTCOME AND DIVERTICULUM SIZE OR PRETREATMENT AFTER COMPLETE SEPTOTOMY**David Albers, Germany; Dakkak D.; Schumacher B.

P1399

**TRANSORAL OUTLET REDUCTION FOR WEIGHT REGAIN AFTER GASTRIC BYPASS: ONE YEAR FOLLOW-UP.**Vincenzo Bove, Italy; Boskoski I.; Gibiino G.; Landi R.; Laterza L.; D'Aversa F.; Mangiola F.; Familiari P.; Tringali A.; Perri V.; Costamagna G.

P1400

**LONG-TERM OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR UNDIFFERENTIATED EARLY GASTRIC CANCER, BEYOND EXPANDED CRITERIA**Chang Beom Ryu, Republic of Korea; Bae J. Y.; Lee M. S.; Lim Y. S.

P1401

**EFFICACY OF G-POEM IN REFRACTORY GASTROPARASIS: A SYSTEMATIC REVIEW**Naveen Prasad Gopalakrishnan Ravikummar, United States; Kailasam K.; Ravindran A.; Sanaka M.

P1402

**FLEXIBLE ENDOSCOPY VESSEL-TISSUE SEALER ASSISTED FOR TREATMENT OF ZENKER DIVERTICULUM: AN EFFECTIVE AND SAFE PROCEDURE.**Alfaro E.; Cañameres P.; Carlos Sostres, Spain; Simón M. A.; Ducons J.

P1403

**PRIMARILY ENDOSCOPIC MANAGEMENT OF POST-SURGICAL FISTULAE IN THE UPPER GI TRACT IS AN EFFECTIVE AND SAFE THERAPEUTIC OPTION.**Freitas C.; Sonia Bernardo, Portugal; Ferreira C. N.; Seves I.; Freire R.; Russo P.; Mendez Santos S.; Lopes J.; Marques A.; Carrilho Ribeiro L.; Velosa J.; Marinho R. T.**Endoscopy, colon**

P1404

**SURVEILLANCE AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL COLORECTAL TUMORS**Taishi Okumura, Japan; Kudo S.; Hayashi T.; Kouyama Y.; Sakurai T.; Maeda Y.; Ogawa Y.; Ichimasa K.; Matsudaira S.; Nakamura H.; Yagawa Y.; Ishigaki T.; Toyoshima N.; Mori Y.; Misawa M.; Ogata N.; Kudo T.; Hisayuki T.; Wakamura K.; Ishida F.

P1405

**"DIAGNOSE-AND-LEAVE" STRATEGY FOR DIMINUTIVE LEFT COLORECTAL POLYPS**Carolina Palmela, Portugal; Costa Santos M. P.; Gouveia C.; Gomes C.; Nunes J.; Barjas E.; Torres J.; Cravo M.; Ferreira A. O.



P1406

**SHOULD WE ASK FOR AN ILEO-COLONOSCOPY IN ALL PATIENTS WITH SPONDYLOARTHROPATHY OR ONLY IN SYMPTOMATIC PATIENTS? \***

Zahra Bouhnoun, Morocco; Diallo F. D.; Nada L.; Hakima A.; Mounia E. Y.; Nourdin A.; Benajah D.-A.; Adil I.; El Abkari M.

P1407

**DO HYPERMOBILE JOINTS PREDICT A PAINFUL COLONOSCOPY?**

Abraham Beckers, The Netherlands; Vork L.; de Ridder R.; Aziz Q.; Masclee A.; Keszthelyi D.

P1408 **ROBOTIC FLEXIBLE ENDOSCOPY ALLOWING INTRA-LUMINAL SURGICAL TRIANGULATION FOR COMPLEX ENDOSCOPIC PROCEDURES: PRECLINICAL EXPERIENCE WITH 20 COLONIC ENDOSCOPIC MUCOSAL DISSECTIONS**

Pietro Mascagni, France; Fiorillo C.; Lim S. G.; Zanne P.; Nageotte F.; Zorn L.; Marescaux J.; De Mathelin M.; Dallemagne B.

P1409

**I-SCAN OPTICAL ENHANCEMENT IN COMBINATION WITH MAGNIFICATION ENDOSCOPY FOR THE IN VIVO ASSESSMENT OF HISTOLOGIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES**

Entcho Klenske, Germany; Atreya R.; Hartmann A.; Tontini G. E.; Neurath M.; Rath T.

P1410

**BARRIERS, BREAKTHROUGHS AND PREDICTORS OF SUCCESS IN IMPLEMENTING SPLIT REGIMEN OVER SINGLE DOSE (IMPROVES): A MULTICENTER STUDY USING A PLAN-DO-STUDY-ACT APPROACH**

Giuseppe Vanella, Italy; Hassan C.; De Bellis M.; Giardini M.; Grasso E.; Laterza F.; Tarantino O.; Di Giulio E.

P1411

**A PROSPECTIVE EVALUATION OF STUDY FOCUSED IMAGE ACQUISITION FOR COLORECTAL ENDOCYTOSCOPY**

Masashi Misawa, Japan; Kudo S.; Mori Y.; Kataoka S.; Nakamura H.; Ichimasa K.; Takeda K.; Yagawa Y.; Toyoshima N.; Kudo T.; Hayashi T.; Hisayuki T.; Wakamura K.; Inoue H.; Ishida F.

P1412

**OPTICAL CLASSIFICATION OF NEOPLASTIC COLORECTAL POLYPS – A COMPUTER ASSISTED APPROACH (THE COACH STUDY)**

Renner J.; Haller B.; Navarro-Avila F.; Saint-Hill-Febles Y.; Mateus D.; Ponchon T.; Poszler A.; Abdelhazef M.; Schmid R. M.; von Delius S.; Peter Klare, Germany

P1413

**EFFICACY AND SAFETY OF ENDOSCOPIC MUCOSAL RESECTION OF LARGE COLORECTAL LESIONS IN THE ELDERLY**

Verónica Pavão Borges, Portugal; Rocha M.; Simões G.; Mendez Santos S.; Gamelas V.; Silva M. J.; Russo P.; Capela T.; Pinto A.; Coimbra J.

P1414

**UNDERWATER ENDOSCOPIC MUCOSAL RESECTION (UEMR) FOR COLORECTAL (CR) LESIONS: A SYSTEMATIC REVIEW WITH META-ANALYSIS.**

Marco Spadaccini, Italy; Lamonaca L.; Frazzoni L.; Fuccio L.; Maselli R.; Galtieri P. A.; Di Leo M.; Craviotto V.; Ferdinando D.; Hassan C.; Repici A.

P1415

**WITHDRAWN**

P1416

**DOES ENDOSCOPIC SUBMUCOSAL DISSECTION REALLY DIFFER BETWEEN COLONIC AND RECTAL LESIONS? A WESTERN EXPERIENCE BY A SINGLE ENDOSCOPIST ON 505 PROCEDURES**

Fatih Aslan, Turkey; Kapran Y.; Ekinci N.; Arslan Yurtlu D.; Manici M.; Sengun B.; Agcaoglu O.; Unsal B.

P1417

**ENDOCYTOSCOPIC VASCULAR PATTERN OF COLORECTAL LESIONS IS USEFUL FOR PREDICTING PATHOLOGICAL DIAGNOSIS**

Shinei Kudo, Japan; Takashina Y.; Misawa M.; Kataoka S.; Nakamura H.; Maeda Y.; Matsudaira S.; Ichimasa K.; Toyoshima N.; Mori Y.; Kudo T.; Hisayuki T.; Ogata N.; Hayashi T.; Wakamura K.; Baba T.; Ishida F.; Inoue H.

P1418

**LONG-TERM OUTCOME AFTER ENDOSCOPIC MUCOSAL RESECTION (EMR) FOR COLORECTAL LESIONS**

Priya Oka, United Kingdom; Jalayeri Nia G.; Aldridge J.; Mangala Murugesan T.; Burke L.; Vani D.; Shah S.

P1419

**SCARE ENDOSCOPIC RESECTION FOR EARLY COLORECTAL CANCER IS IT AN ACCEPTABLE OPTION TO AVOID UNNECESSARY SURGERY AFTER A FIRST RESECTION WITH MICROSCOPICALLY POSITIVE DEEP MARGINS? : A MONOCENTRIC CASE SERIES OF A WESTERN CENTER.**

Dassetto C.; Ratone J. P.; Erwan Borjes, France; Caillol F.; Pesenti C.; Poizat F.; Meillat H.; de Chaisemartin C.; Lelong B.; Giovannini M.

P1420

**PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION OF COLORECTAL SUPERFICIAL LESIONS  $\geq 20$  MM IN SIZE: SHOULD WE TATTOO MORE?**

Pedro Marcos, Portugal; Eliseu L.; Leal C.; Vasconcelos H.

P1421

**LONG TERM OUTCOMES OF INITIALLY ENDOSCOPICALLY RESECTED MALIGNANT POLYPS WITHIN THE UK BOWEL CANCER SCREENING PROGRAMME**

Stavroula Pelitari, United Kingdom; Brookes M. J.; Ishaq S.; Shetty S.; Kumar A.; Veitch A.; McKaig B.; Mangalika M.; Muruganathan A.

P1422

**QUALITY ASSURANCE IN ENDOSCOPY: ABOVE AND BEYOND PROCEDURE RELATED PERFORMANCE**

Kutyla M.; Hourigan L.; O'Connor S. A.; Huelsen-Katz A.; Taylor A.; Shah A.; Garrad A.; Koloski N.; Gerald Holtmann, Australia

P1423

**DEVELOPMENT AND INITIAL VALIDATION OF A UNIVERSAL CLASSIFICATION FOR COLO-RECTAL POLYPS AND NEOPLASIA (UNICORN).**

Sneha John, Australia; Byeon J.-S.; Yang D.-H.; Yoshida N.; Hikichi T.; Bapaye A.; Cha J.-M.; Rerknimitr R.; Michida T.; Kim H. G.; Fujishiro M.

P1424

**A SIMPLIFIED TABLE MIXING VALIDATED DIAGNOSTIC CRITERIA IS EFFECTIVE TO IMPROVE CHARACTERIZATION OF COLORECTAL LESIONS BY FELLOWS: THE CONEECT CLASSIFICATION.**

Mathieu Pioche, France; Fabritius M.; Jacques J.; Gonzalez J.-M.; Dray X.; Coron E.; Branche J.; Lepage C.; Poincloux L.; Lepilliez V.; Saurin J. C.; Ponchon T.

P1425

**META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS SHOWS THAT ENDOCUFF INCREASES COLONOSCOPY ADENOMA DETECTION RATE.**

Konstantinos Triantafyllou, Greece; Gkolfakis P.; Tziatzios G.; Fuccio L.; Hassan C.

P1426

**COMPARISON OF ENDOSCOPIC SUBMUCOSAL DISSECTION USING THE POCKET CREATION METHOD AND THE CONVENTIONAL METHOD FOR COLORECTAL LESIONS**

Yuko Fujii, Japan; Nishimura M.

P1427

**LABEL-FREE MULTIPHOTON IMAGING AS A REAL-TIME DIAGNOSTIC TOOL FOR DISCRIMINATING COLORECTAL DISEASES**

He K.; Zhao L.; Liu L.; Wang X.; Zhining Fan, China

P1428

**TWO LITERS OF POLYETHYLENE GLYCOL (PEG) WITH 15 MG OF BISACODYL VERSUS 4 LITERS OF PEG FOR BOWEL PREPARATION TO COLONOSCOPY: PROSPECTIVE RANDOMIZED STUDY.**

Mohammed Oualgouh, Morocco; El-Mekkaoui A.; Abdelkrim Z.; Khannoussi W.; Kharrasse G.; Ismaili Z.

P1429

**WATER-AIDED COLONOSCOPY IS AS EFFECTIVE AS CONSCIOUS SEDATION IN CONTROLLING PAIN.**

Elisa Giambruno, Italy; Furnari M.; Zentilin P.; Brunacci M.; Parodi A.; Coccia G.

P1430

**SCREENING COLONOSCOPY IN YOUNGER ADULTS- WHEN SHOULD WE START?**

Daniela Penz, Austria; Waldmann E.; Gessl I.; Majcher B.; Szymanska A.; Asaturi A.; Hinterberger A.; Ferlitsch A.; Trauner M.; Ferlitsch M.

P1431

**USEFULNESS AND EFFICACY OF RETROFLEXION IN THE ASCENDING COLON DURING COLONOSCOPY FOR POLYP AND ADENOMA DETECTION**

Spyridon Michopoulos, Greece; Axiaris G.; Baxevanis P.; Stoupaki M.; Gagari V.; Leonidakis G.; Zampeli E.; Serafentinidis I.; Petraki K.; Sotiropoulou M.

P1432

**DOES THE ENDOSCOPIST'S GENDER INFLUENCE QUALITY PARAMETERS OF SCREENING COLONOSCOPY?**

Barbara Majcher, Austria; Penz D.; Waldmann E.; Hinterberger A.; Szymanska A.; Asaturi A.; Trauner M.; Ferlitsch M.

P1433

**UNDERWATER ENDOSCOPIC MUCOSAL RESECTION SHOWS TO BE MORE EFFECTIVE THAN EMR IN WORSE SCENARIOS WITH LESS ADVERSE EVENTS.**

Mónica Sánchez Alonso, Spain; Sobrino López A.; Uchima Koecklin H.; López Viedma B.; Domper Bardají F.; De la Santa Belda E.; Olivencia Palomar P.; Olmedo Camacho J.; Rodríguez Sánchez J.

P1434

**CHROMOENDOSCOPY WITH INDIGO CARMINE VERSUS ENDOCUFF FOR ADENOMA DETECTION RATE IN COLONOSCOPY: A RANDOMIZED CONTROLLED TRIAL.**

Fernandez Rivero J. A.; Gutierrez-Grobe Y.; Rojas-Mendoza F.; Oria-Hernandez J.; Nancy E. Aguilar-Olivos, Mexico

P1435

**"LEAVE-IN-SITU STRATEGY" FOR DIMINUTIVE COLORECTAL ADENOMAS**

Tomoyuki Kurata, Japan; Kudo S.; Maeda Y.; Mori Y.; Ogawa Y.; Minegishi Y.; Mochizuki K.; Misawa M.; Suzuki K.; Ichimasa K.; Takeda K.; Okumura T.; Kudo T.; Hayashi T.; Wakamura K.; Ishida F.

P1436

**WITHDRAWN**

P1437  
WITHDRAWN

P1438   
LONG TERM COLORECTAL CANCER INCIDENCE AND MORTALITY IN RELATION TO QUALITY OF A SINGLE NEGATIVE SCREENING COLONOSCOPY.

Robert Franczyk, Poland; Pilonis N.; Wieszczy P.; Didkowska J.; Wojciechowska U.; Pisera M.; Rupinski M.; Bugajski M.; Regula J.; Kaminski M.F.

P1439   
SEDOANALGESIA COMPLICATIONS DURING A COLONOSCOPY. WHICH FACTORS ARE INVOLVED?

Natale Imaz Ayo, Spain; Idigoras Rubio I.; Portillo Villares M. I.; Bilbao I.; Gutiérrez-Ibarluzea I.; Bujanda Fernández de Piérola L.; Arana-Arri E.

P1440  
IMPACT OF AN EDUCATIONAL INTERVENTION ON THE IMPROVEMENT OF QUALITY INDICATORS OF COLORECTAL CANCER SCREENING COLONOSCOPIES

Brito M.; Joana Rita Carvalho, Portugal; Ferreira C. N.; Gonçalves A. R.; Carrilho Ribeiro L.; Velosa J.; Marinho R. T.

P1441  
UTILITY OF 3D ENDOSCOPY IN MEASUREMENT OF COLON POLYP SIZE

Daisuke Kikuchi, Japan; Nomura K.; Kaise M.; Tanaka M.; Okamoto Y.; Iizuka T.; Hoteya S.

P1442  
SCREENING COLONOSCOPY: DOES THE ADR VARIATES WITHIN A TRAINING CENTER? AN EXPERIENCE AT A LATIN AMERICAN TRAINING CENTER

Giraud F.; Gustavo Javier Correa, Argentina; Martin Y.; Garbi M. L.; Perron N.; Carrica S. A.; Redondo A.; Oscar F.; Nestor C.; Baldoni F.; Tufare F.; Augusto V.

P1443  
WHO HAS MORE INCOMPLETE COLONOSCOPIES: SURGEONS, INTERNISTS OR GASTROENTEROLOGISTS?

Anna Hinterberger, Austria; Waldmann E.; Penz D.; Majcher B.; Asaturi A.; Szymanska A.; Trauner M.; Ferlitsch M.

P1444  
SECOND EVALUATION OF RIGHT COLON. DOES THE ADENOMA DETECTION RATE INCREASE?

Talani A.; Sciarretta M.; Yantorno M.; Gustavo Javier Correa, Argentina; Garavento L.; Martinez E.; Florencia G.; Villaverde A.; Tufare F.; Fernando B.

P1445  
DOUBLE BALLOON ASSISTED ESD VERSUS STANDARD ESD FOR SIGMOID LESIONS.

Momose K.; Kono Y.; Milsom J.; Sam Sharma, United States


## Endoscopy, ERCP

P1446  
DIAGNOSTIC YIELD OF SPYGLASSDS FOR BILIARY TRACT LESIONS

Yoshiharu Masaki, Japan; Ishigami K.; Ito A.; Shitani M.; Akutsu N.; Motoya M.; Sasaki S.; Nakase H.

P1447  
AMPULLARY RADIO FREQUENCY ABLATION : A NEW MINIMALLY INVASIVE APPROACH TO AVOID SURGERY ?

Pesenti C.; Caillol F.; Erwan Bories, France; Ratone J. P.; Poizat F.; Giovannini M.

P1448   
POST-ERCP PANCREATITIS (PEP): MINIMIZING ROLE OF PANCREATIC DUCT (PD) STENTING WITH NON-INVASIVE COMBINATION THERAPY IN DIFFICULT CASES ✦

Jing Liang Ho, Singapore; Chia C. T. W.; Chuah K. B.

P1449  
COMPARISON OF THE DIAGNOSTIC SENSITIVITY OF A NOVEL PERORAL CHOLANGIOSCOPY-GUIDED TARGET BIOPSY TO THAT OF CONVENTIONAL ENDOSCOPIC TRANSPAPILLARY FORCEPS BIOPSY IN PATIENTS WITH SUSPECTED BILE DUCT CANCER

Katsunori Sekine, Japan; Yasuda I.; Sato K.; Doi S.; Mabuchi M.; Takano Y.; Tsujikawa T.; Kuniyoshi N.; Iwashita T.; Miyazaki T.; Kawamoto M.; Takahashi M.

P1450  
ASSESSMENT OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) IN THE ELDERLY -IS ERCP REALLY SAFE IN THE ELDERLY?-

Chikako Shibata, Japan; Toda N.; Yamagami M.; Arai J.; Kurokawa K.; Kurosaki S.; Funato K.; Kondo M.; Takagi K.; Kojima K.; Ohki T.; Seki M.; Kato J.; Tagawa K.

P1451  
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY OF ACUTE CALCULOUS CHOLANGITIS IN PATIENTS WITH LIVER CIRRHOSIS

Dong S.-H.; Hyo Jung Ha, Republic of Korea; Oh C. H.; Lee S. K.

P1452  
RADIOFREQUENCY ABLATION (RFA) FOR INTRABILIARY EXTENSION OF ADENOMA OF THE PAPANILLA OF VATER: PRELIMINARY RESULTS

Tringali A.; Vincenzo Bove, Italy; Valerii G.; Landi R.; Perri V.; Boskoski I.; Familiari P.; Costamagna G.

P1453  
ASSOCIATION BETWEEN PREDICTIVE FACTORS AND RADIATION EXPOSURE DURING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY

Seok-Ho Dong, Republic of Korea; Oh C. H.; Ha H. J.; Lee S. K.

P1454

**ENDOSCOPIC RESECTION MAY BE CURATIVE FOR AMPULLARY CANCER? RESULTS OF A EUROPEAN MONOCENTRIC RETROSPECTIVE STUDY**Moullec A.; Erwan Bories, France; Ratone J.-P.; Caillol F.; Pesenti C.; Cador C.; Poizat F.; Ewald J.; Turrini O.; Giovannini M.

P1455

**ENDOSCOPIC SNARE PAPILLECTOMY: LONG TERM RESULTS IN 173 CONSECUTIVE PATIENTS.**Valerii G.; Tringali A.; Vincenzo Bove, Italy; Landi R.; Boskoski I.; Familiari P.; Perri V.; Costamagna G.

P1456

**ENDOSCOPIC OR COMBINED ENDOSCOPIC/PERCUTANEOUS MANAGEMENT IN COMPLEX BILE DUCT INJURIES.**Bouchard S.; Michael Fernandez Y Viesca, Belgium; Tan D.; Gupta T.; Bromberg L.; Arvanitakis M.; Eisendrath P.; Huberty V.; Le Moine O.; Lemmers A.; Deviere J.

P1457

**NATURAL HISTORY OF BILIARY CAST SYNDROME AFTER LIVER TRANSPLANTATION: A PROSPECTIVE CHOLANGIOGRAPHIC EVOLUTION STUDY.**Alia Hadeji, Belgium; Dept S.; Pezzullo M.; Le Moine O.; Deviere J.; Gustot T.; Moreno C.; Boon N.; Degre D.; Valerio L.; Lemmers A.

P1458

**HOLMIUM LASER LITHOTRIPSY TO TREAT DIFFICULT BILIARY AND PANCREATIC STONES USING PERORAL SINGLE OPERATOR CHOLANGIOPANCREATOSCOPY.**Nishmi Gunasingam, Australia; Craig P.

P1459

**BIOPSIES IN COMBINATION WITH BRUSH CYTOLOGY CAN IMPROVE THE CHARACTERIZATION OF MALIGNANT BILIARY STRICTURES DURING ERCP**Daniela Reis, Portugal; Noronha Ferreira C.; Freitas C.; Marques A.; Palma R.; Maldonado R.; Mendes de Almeida M.; Carrilho Ribeiro L.; Velosa J.; Tato Marinho R.

P1460

**ENDOSCOPIC MANAGEMENT OF BILE DUCT STONES IN PATIENTS WITH SURGICALLY ALTERED ANATOMY; EVALUATION OF NEWLY DEVELOPED SHORT TYPE DOUBLE BALLOON ENDOSCOPE**Masaaki Shimatani, Japan; Mitsuyama T.; Masuda M.; Tokuhara M.; Suzuki R.; Ito T.; Miyoshi H.; Ikeura T.; Takaoka M.; Okazaki, K.

P1461

**ENDOSCOPIC MANAGEMENT OF POST LIVER TRANSPLANT BILIARY ANASTOMOTIC STRICTURES: A RETROSPECTIVE ANALYSIS**Potts J.; Leonardo Henry Eusebi, United Kingdom; Greenham O.; Keane M.; Goodchild G.; Besherdas K.; Chapman M.; Johnson G.; Pereira S. P.; Webster G.; Thorburn D.

P1462

**BASKET VERSUS BALLOON EXTRACTION FOR CHOLEDOCHOLITHIASIS: A SINGLE CENTER PROSPECTIVE RANDOMIZED STUDY**Ekmektzoglou K.; Apostolopoulos P.; Dimopoulos K.; Tsiouris P.; Kalantzis C.; Erasmia Vlachou, Greece; Alexandrakis G.

P1463

**INCIDENCE AND RISK FACTORS OF POST-ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY PANCREATITIS (PEP) ACCORDING TO THE TYPE OF PROPHYLAXIS USED OVER TIME**Romina Ureña-Campos, Spain; Magallanes-Peláez N.; Álvarez-Pérez A.; De la Iglesia-García D.; Lariño Noia J.; Iglesias Canle J.; Iglesias-García J.; Dominguez-Muñoz J. E.**Endosonography**

P1464

**SAFETY AND EFFICACY OF EUS-GUIDED GALLBLADDER DRAINAGE (EUS-GBD) COMBINED WITH ERCP IN THE SAME SESSION.**Torres-Yuste R.; Garcia-Alonso F. J.; Cimavilla M.; Carbajo Lopez A. Y.; Mora Cuadrado N.; Penas-Herrero I.; Ramon Sanchez-Ocana, Spain; Sevilla-Ribota S.; De La Serna Higuera C.; Pérez-Miranda M.

P1465

**EUS ANATOMY OF THE PANCREATOBILIARY SYSTEM IN A SWINE MODEL: THE WISE EXPERIENCE.**Dario Ligresti, Italy; Kuo Y.-T.; Baraldo S.; Chavan R.; Keane M. G.; Selem S.; Seo D.-W.

P1466

**PREDICTIVE FACTORS FOR THE ASSESSMENT OF THE KI-67 INDEX IN PANCREATIC NEUROENDOCRINE TUMORS DIAGNOSED BY ENDOSCOPIC ULTRASONOGRAPHY**Verónica Pavão Borges, Portugal; Silva M. J.; Mascarenhas L.; Carvalho D.; Ramos G.

P1467

**WITHDRAWN**

P1468

**DIAGNOSIS AND OUTCOME OF MEDIASTINAL FOREGUT DUPLICATION CYSTS: THE ROLE OF EUS**Andrea Tenca, Finland; Färkkilä M. A.; Arkkila P.

P1469

**THE DIAGNOSTIC EFFICACY OF CONTRAST ENHANCED-ENDOSCOPIC ULTRASONOGRAPHY IN DIFFERENTIAL DIAGNOSIS OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) AND NON-GASTROINTESTINAL STROMAL TUMOR**Hyungkil Kim, Republic of Korea; Jang H.; Park J.-S.; Bang B. W.; Kwon G. S.; Shin Y.-W.

P1470

**SLOW-PULL TECHNIQUE FINE-NEEDLE BIOPSY WITH 20-GAUGE NEEDLE (SPUTNIQ-20G STUDY) VERSUS STANDARD SUCTION OF SOLID PANCREATIC LESIONS: A MULTICENTER RANDOMIZED TRIAL.**Roberto Di Mitri, Italy; Mocchiato F.; Antonini F.; Fabbri C.; Conte E.; Magro B.; Bonaccorso A.P1471 **DO WE NEED ENDOSCOPIC ULTRASONOGRAPHY IN THE WORKUP OF PATIENTS WITH ACHALASIA?**Sarra Oumrani, France; Barret M.; Roseau G.; Brieau B.; Leblanc S.; Prat F.; Chaussade S.

P1472

**EUS ELASTOGRAPHY STRAIN RATIO IN THE DIFFERENTIAL DIAGNOSIS OF GASTROINTESTINAL SUBEPITHELIAL LESIONS: RESULTS OF A MULTICENTER STUDY**Filippo Antonini, Italy; Fusaroli P.; Frazzoni L.; Belfiori V.; Auriemma F.; Rahal D.; Serrani M.; Lisotti A.; Giorgini S.; Fuccio L.; Repici A.; Macarri G.; Carrara S.

P1473

**THE IMPACT OF PANCREATIC NECROTIC CONTENTS IN FLUID COLLECTIONS ON TREATMENT STRATEGY AND SUBSEQUENT PANCREATIC DUCTAL ANATOMY**Jahangeer Basha, India; Lakhtakia S.; Pal P.; Chavan R.; Nabi Z.; Gupta R.; Ramchandani M.; Kalapala R.; Reddy D. N.

P1474

**A NEW 19 G ENDOSCOPIC ULTRASOUND CORE NEEDLE FOR THE HISTOLOGICAL DIAGNOSIS OF MESENCHYMAL TUMORS: A FEASIBILITY STUDY.**Gabriele Del conte, Italy; Collini P.; Pasquali S.; Margarotto A.; Masci E.

P1475

**DIRECT ENDOSCOPIC NECROSECTOMY IN SUPER-INFECTED FLUID COLLECTIONS IN NECROTIZING PANCREATITIS USING LUMEN-APPPOSING METAL STENTS: BETTER OUTCOME WITH EARLY INTERVENTION**David Albers, Germany; Meining A.; Seufferlein T.; Hann A.; Schumacher B.

P1476

**ADEQUACY AND DIAGNOSTIC YIELD OF A NOVEL CORE BIOPSY NEEDLE (SHARKCORE FNB NEEDLE) IN THE DIAGNOSIS OF SUBEPITHELIAL LESIONS: OUR SERIES**Ilenia Barbuscio, Italy; Fantin A.; Mescoli C.; Farinati F.

P1477

**CONNECT YOUR NEEDLE TO YOUR SMARTPHONE TO INCREASE EUS-FNA DIAGNOSTIC YIELD? ESGE RESEARCH GRANT 2016 PRELIMINARY RESULTS**Miruna-Maria Mitrut, Romania; Bocaniala A.; Tianu E.; Obrocea F.; Ciocirlan M.**Capsule endoscopy**

P1478

**THE PREVALENCE OF SMALL BOWEL AND COLONIC POLYPS IN PATIENTS WITH SPORADIC DUODENAL AND/OR AMPULLARY ADENOMAS – A PROSPECTIVE CASE CONTROL STUDY**Halim Awadie, Australia; Klein A.; Tate D. J.; Jideh B.; Bar-Yishay I.; Goodrick K.; Ahlenstiel G.; Bourke M. J.

P1479

**VIDEO CAPSULE ENDOSCOPY HAS A HIGHER DIAGNOSTIC YIELD WITH SIMILAR TECHNICAL SUCCESS IN “OLD-ELDERLY” COMPARED TO “YOUNG-ELDERLY” PATIENTS**Thurm T.; Gluck N.; Liat Deutsch (Mlynarsky), Israel

P1480

**THE COMPARISON OF THE EFFICIENCY OF COLON CAPSULE ENDOSCOPY AND OPTICAL COLONOSCOPY IN PATIENTS WITH POSITIVE IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST**Michal Voska, Czech Republic; Grega T.; Ngo O.; Buckova B.; Majek O.; Vojtechova G.; Tacheci I.; Benes M.; Bures J.; Spicak J.; Zavoral M.; Suchanek S.

P1481

**RISK OF SMALL BOWEL BLEEDING ASSOCIATED WITH USE OF ORAL ANTICOAGULANTS OR ANTIPLATELET AGENTS: A RETROSPECTIVE COHORT STUDY**Alessandro Mussetto, Italy; Garribba A. T.; Gasperoni S.; Cantoni F.; Triossi O.

P1482

**USE OF CHEWING GUM TO IMPROVE GASTRIC TRANSIT TIME IN CAPSULE ENDOSCOPY.**Catherina Gajardo Arias, Argentina; Bosch J.; Spallone L.; Figueredo R.; Garcia M. L.; Torrieri C.; Gomez V.; Bolino M. C.; Jean Marc D.; Caro L.; Cerisoli C.

P1483

**OMNI MODE REDUCES CAPSULE ENDOSCOPY READING TIME WHILST MAINTAINING ACCURACY.**Sabina Beg, United Kingdom; Wronska E.; Seitz U.; Ivanova E. V.; Fedorov E. D.; Araujo Acuña I. K.; Aabakken L.; Tari R.; Saurin J. C.; Rey J.-F.; Ragnunath K.P1484 **FEASIBILITY AND SAFETY OF ROBOTICALLY CONTROLLED MAGNETIC CAPSULE ENDOSCOPY IN THE VISUALIZATION OF UPPER GASTROINTESTINAL TRACT**Laszlo Andras Madacsy, Hungary; Lovasz B. D.; Zsobrak K.; Szalai M.; Oczella L.

P1485

**INVESTIGATING IRON-DEFICIENCY ANEMIA WITH SMALL BOWEL CAPSULE ENDOSCOPY: IS HAEMOGLOBIN A RELIABLE PREDICTOR OF POTENTIALLY BLEEDING LESIONS?**

Marta Freitas, Portugal; Magalhães R.; Rosa B. J. F.; Cotter J.

### Cross sectional imaging

P1486

**BULKING AND LAXATIVE EFFECTS OF KIWIFRUIT DIETARY SUPPLEMENTATION: NOVEL MRI IMAGING INSIGHTS**

Neele Dellschaft, United Kingdom; Wilkinson-Smith V.; Hoad C.; Marciari L.; Gowland P.; Spiller R.

P1487

**THE INCIDENTAL FINDING OF A BRANCH-DUCT INTRA-DUCTAL PAPILLARY MUCINOUS NEOPLASM LACKING COMPLEX FEATURES STILL REQUIRES ACTIVE LONG-TERM SURVEILLANCE.**

Trevor Tabone, Malta; Cortis K.; Azzopardi N.

P1488

**SIGNIFICANCE OF BOWEL WALL THICKENING ON EMERGENCY ROOM CT SCANS.**

Syed Adnan Mohiuddin, Qatar; Joseph J. A.; Chandra P.; Mushtaq K.; Al Kaabi S.

P1489

**FLUORESCENCE IMAGING OF EARLY CARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION BY TOPICALLY SPRAYING PROBE TARGETING DIPEPTIDYLPEPTIDASE-IV**

Keiko Yamamoto, Japan; Ohnishi S.; Mizushima T.; Kodaira J.; Ono M.; Hatanaka Y.; Hatanaka K.; Shimizu Y.; Urano Y.; Sakamoto N.

P1490 

**POST IMAGING COLORECTAL CANCER IN THE ENGLISH NATIONAL HEALTH SERVICE BOWEL CANCER SCREENING PROGRAMME**

Edmund Derbyshire, United Kingdom; Plumb A.; Nickerson C.; Wright S.; Moores B.; Morris E.; Valori R.; Rutter M. D.

P1491

**IN VIVO DIAGNOSIS OF FOOD ALLERGY WITH CONFOCAL ENDOMICROSCOPY**

Timo Rath, Germany; Atreya R.; Siebler J.; Neurath M. F.; Zopf Y.

P1492

**LABEL-FREE IMAGING FOR T STAGING OF GASTRIC CARCINOMA BY MULTIPHOTON MICROSCOPY**

He K.; Zhao L.; Liu L.; Zhining Fan, China

P1493

**DO WE UNDERESTIMATE THE ROLE OF HYPOTHALAMIC-PITUITARY-ADRENAL AXIS ACTIVATION BY GLP-1/ GLP-1 RECEPTOR AGONIST TREATMENT? FIRST DATA FROM GLP-1 RECEPTOR POSITRON EMISSION TOMOGRAPHY OF THE HUMAN PITUITARY**

Gotthardt M.; Marti Boss, The Netherlands; Deden L.; Booij J.; Brom M.

P1494

**SPATIO-TEMPORAL MAPPING OF GASTROINTESTINAL MOTILITY USING MRI AND COMPUTER POST-PROCESSING: A PROOF OF CONCEPT STUDY**

Alex Menys, United Kingdom; L Hoad C.; Spiller R.; Scott S. M.; Atkinson D.; Marciari L.; Taylor S.

### Enteral dilatation and stenting (oesophagus, stomach, duodenum, colon)

P1495

**SHORT- TERM AND LONG-TERM OUTCOMES OF SELF-EXPANDABLE METALLIC STENT PLACEMENT AS A BRIDGE TO SURGERY FOR MALIGNANT COLONIC OBSTRUCTION**

Yuki Miyasako, Japan; Sumida Y.; Takasago T.; Kuwai T.; Konishi H.; Tao K.; Miura R.; Kuroki K.; Tamaru Y.; Yamaguchi A.; Kouno H.; Kohno H.

P1496

**THE BOUGIECAP: A NEW METHOD FOR TREATMENT OF OESOPHAGEAL STRICTURES**

Benjamin Walter, Germany; Schmidbaur S.; Rahman I.; Hann A.; Duarte P.; Meining A.

P1497

**SHORT AND LONG-TERM RESULTS OF SELF-EXPANDABLE METAL STENTS FOR ACUTE MALIGNANT COLORECTAL OBSTRUCTION**

Rui Morais, Portugal; Coelho C.; Rodrigues-Pinto E.; Vilas Boas F.; Moutinho Ribeiro P.; Lopes S.; Pereira P. R.; Macedo G.

P1498

**TWO DECADES AFTER THE FIRST, WHAT ARE THE OUTCOMES OF DUODENAL STENTING: EXPERIENCE OF A FRENCH TERTIARY CENTER ABOUT 220 CASES.**

Ratone J.-P.; Fabrice Caillol, France; Zemmour C.; Bories E.; Pesenti C.; Lestelle V.; Hoibian S.; Godat S.; Proux A.; Capodano G.; Giovannini M.

P1499

**BARIATRIC ESOPHAGEAL STENTS AND ENDOSCOPIC SUTURING SYSTEM FOR ENDOSCOPIC MANAGEMENT OF POST-LAPAROSCOPIC SLEEVE GASTRECTOMY LEAKS: A SINGLE CENTER EXPERIENCE**

Edoardo Troncone, Italy; Anderloni A.; Maselli R.; Fugazza A.; Auriemma F.; Carrara S.; Ferrara E. C.; Galtieri P. A.; Semeraro R.; Attardo S.; Marinari G. M.; Repici A.

P1500

**ETIOLOGICAL SPECTRUM AND RESPONSE TO ENDOSCOPIC BALLOON DILATION IN PATIENTS WITH BENIGN GASTRIC OUTLET OBSTRUCTION**

Kochhar R.; Sarthak Malik, India; Gupta P.; Reddy Y.; Dhaka N.; Sinha S. K.; Mallick B.; Gupta V.

P1501

**DILATION OF BENIGN OESOPHAGEAL STRICTURE: LONGITUDINAL STUDY IN A MOROCCAN ENDOSCOPY UNIT**Iham Azghari, Morocco; Salihoun M.; Acharki M.; Kabbaj N.**Poster Session**

09:00 – 14:00

Hall X1

**Surgery III****Oesophagus/stomach/duodenum**

P1502

**A NOMOGRAM TO PREDICT LYMPH NODE METASTASIS IN PATIENTS WITH EARLY GASTRIC CANCER**Xuan Li, China; Zhang G.

P1503

**POPULATION BASED STUDY ON RISK FACTORS FOR TUMOR-POSITIVE RESECTION MARGINS IN PATIENTS WITH GASTRIC CANCER**Leonie R van der Werf, The Netherlands; Cords C.; van Berge Henegouwen M. I.; Lagarde S. M.; Wijnhoven B. P. L.P1504 **POSTOPERATIVE OUTCOMES OF THE DUTCH UPPER GASTROINTESTINAL CANCER AUDIT ACCORDING TO THE PLATFORM OF THE ESOPHAGEAL COMPLICATIONS CONSENSUS GROUP**Leonie R van der Werf, The Netherlands; Busweiler L. A. D.; van Sandick J.; van Berge Henegouwen M. I.; Wijnhoven B.P. L.

P1505

**NATIONWIDE OUTCOME OF GASTRECTOMY WITH EN-BLOC PARTIAL PANCREATECTOMY FOR GASTRIC CANCER**Leonie R van der Werf, The Netherlands; Eshuis W. J.; Draaisma W. A.; van Etten B.; Gisbertz S. S.; van der Harst E.; Liem M. S. L.; Lemmens V. E. P. P.; Wijnhoven B. P. L.; Besselink M. G. H.; van Berge Henegouwen M. I.

P1506

**ROOT-CAUSE ANALYSIS OF SERIOUS ADVERSE EVENTS AFTER SURGERY FOR GASTRIC CANCER**Bas P. L. Wijnhoven, The Netherlands; Cords C.; Damhuis R. A.; the PRISMAAG study group F.

P1507

**WITHDRAWN**

P1508

**THE IMPACT OF BODY POSITION ON GASTRIC EMPTYING AFTER PANCREATODUODENECTOMY**Emanuel Steiner, Austria; Breuer R.; Kazianka L.; Reiter B.; Holst J. J.; Miholic J.**Postoperative complications**

P1509

**GENETIC POLYMORPHISMS OF INTERFERON GAMMA (IFN- $\gamma$ ) IN MEXICAN-MESTIZO PATIENTS WITH ABDOMINAL SEPSIS** Jorge Luis de León Rendón, Mexico; Cuevas Covarrubias S. A.; González Huerta L. M.; Ángeles Martínez J.; Fonseca Camarillo G.; López Pérez R. Y.; Villanueva Herrero J. A.; Jiménez Bobadilla B.; Gracida Mancilla N. I.

P1510

**LONGSTANDING POSTOPERATIVE FLUID COLLECTION INFLUENCES RECURRENCE OF PANCREATOBILIARY MALIGNANCY**Youngjung Kim, Republic of Korea

P1511

**EFFICACY OF ENDOSCOPIC TREATMENT OF POST-SLEEVE GASTRECTOMY FISTULAS ACCORDING TO THE RADIOLOGICAL TYPE**Adrien Sportes, France; Airinei G.; Kamel R.; Raynaud J. J.; Sabate J. M.; Benamouzig R.

P1512

**EFFICACY OF ENDOSCOPIC VACUUM ASSISTED CLOSURE COMPARE WITH SELF-EXPANDABLE METALLIC STENT FOR POSTOPERATIVE ANASTOMOTIC LEAK OF GASTRIC CANCER**Soo In Choi, Republic of Korea; Park J. C.; Lee J. E.; Kim E. H.; Shin S. K.; Lee S. K.; Lee Y. C.P1513 **SURGICAL RESECTION FOR TREATMENT OF COLORECTAL POLYPS: A SINGLE CENTRE RETROSPECTIVE COHORT STUDY**Dianne Bosch, The Netherlands; Leicher L. W.; de Vos tot Nederveen Cappel W. H.; Vermeer N. C.; Peeters K. C.; van Westreenen H. L.**Laparoscopic techniques**

P1514

**WITHDRAWN**P1515 **NAVIGATION SURGERY FOR LATERAL LYMPH NODE DISSECTION USING THREE-DIMENSIONAL PELVIC MODEL PRODUCED BY 3D PRINTER**Daisuke Hojo, Japan; Murono K.; Emoto S.; Kaneko M.; Hiyoshi M.; Sasaki K.; Nishikawa T.; Shuno Y.; Tanaka T.; Hata K.; Kawai K.; Nozawa H.

P1516

**FEASIBILITY OF 2-TEAM TATME FOR LOWER RECTAL CANCER: SHORT-TERM OUTCOMES OF INITIAL TEN CASES**

Fuminori Teraishi, Japan; Kondo Y.; Toshima T.; Yano S.; Shigeyasu K.; Mori Y.; Kishimoto H.; Fujiwara T.

## Poster Session

09:00 – 14:00

Hall XI

IBD III

**Basic/pathogenesis/pathology**

P1517

**WNT2B INDUCES EPITHELIAL MESENCHYMAL TRANSITION: RELEVANCE IN FISTULA DEVELOPMENT IN CROHN'S DISEASE**

Macias-Ceja D. C.; Pedro Salvador Escribano, Spain; Alos R.; Navarro-Vicente F.; Gisbert Ferrándiz L.; Cosin-Roger J.; Calatayud S.; Barrachina M. D.; Ortiz-Masia D.

P1518

**THE BENEFICIAL USE OF STW 5 IN DSS INDUCED COLITIS IS PARTLY DUE TO AMELIORATING THE CHANGES IN GUT MICROBIOTA INDUCED BY DSS.**

Mohamed T. Khayyal, Egypt; Abdel-Tawab N. F.; Wadie W.; El-Sayed S.; Kelber O.; Abdel-Aziz H.

P1519

**RELATION OF CIRCULATING PROTEIN S (PROS1) WITH INFLAMMATORY BOWEL DISEASE (IBD) ACTIVITY, PATTERNS, AND C4-BINDING PROTEIN (C4BP)**

Alicia Sambuelli, Argentina; Chavero P.; de Larrañaga G.; Carrera Silva E. A.; Errasti A.; Tessone L.; Negreira S. M.; Gil A.; Huernos S. P.; Goncalves S.; Tirado P. R.; Rothlin C. V.

P1520

**ILEAL CHANGES IN PATIENTS WITH MICROSCOPIC COLITIS**

Sidharth Shukla, India; Kochhar R.; Rana S. V.; Prasad K. K.; Dhaka N.; Malik S.; Berry N.; Sharma M.; Sinha S. K.

P1521

**ORO-CECAL TRANSIT TIME AND LACTOSE INTOLERANCE IN PATIENTS WITH MICROSCOPIC COLITIS**

Sidharth Shukla, India; Kochhar R.; Rana S. V.; Prasad K. K.; Dhaka N.; Malik S.; Berry N.; Sharma M.; Sinha S. K.

P1522 **HIGH FAT DIET AGGRAVATES DEXTRAN SULFATE SODIUM (DSS)-INDUCED COLITIS THROUGH REGULATING IMMUNE RESPONSES OF GUT-ASSOCIATED LYMPHOID TISSUE**

Wu Z.; Yujing Chi, China; Zhang Y.; Song Y.; Xu J.; Liu Y.

P1523

**FUNGAL DYSBIOSIS FACILITATES NKP46- ILC3 IN INFLAMED MUCOSA OF UC PATIENTS THROUGH MEDIATION OF IL-23 PRODUCED BY DCS**

Jun Xu, China; Song Y.; Wu Z.; Zhang Y.; Li X.; Tan J.; Liu Y.

P1524

**WITHDRAWN**

P1525

**CD16 MACROPHAGES ACT AS A SOURCE OF PROINFLAMMATORY FACTORS PROMOTING INTESTINAL FIBROSIS**

Pedro Salvador Escribano, Spain; Cosin Roger J.; Gisbert Ferrándiz L.; Macias Ceja D. C.; Ortiz Masia D.; Calatayud S.; Barrachina D.

P1526

**PRESENCE OF ADHERENT-INVASIVE ESCHERICHIA COLI IN INFLAMMATORY BOWEL DISEASE IMPACTS THE EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION**

Xu Z.; Chevarin C.; Zuo T.; Zhang J.; Wong S.; Chan F. K. L.; Sung J. J. Y.; Yu J.; Barnich N.; Siew Chien Ng, Hong Kong PRC

P1527

**THE ASSOCIATION BETWEEN PERIANAL ABSCESS AND INFLAMMATORY BOWEL DISEASE WITH AN ANALYSIS OF PREDICTIVE VARIABLES: FINDINGS FROM THE THIN DATABASE**

Tom Thomas, United Kingdom; Singh Chandan J.; Harvey P.; Bhala N.; Nirantharakumar K.; Trudgill N.

P1528 **EXPLORING THE DIVERSITY OF MUTATIONAL LANDSCAPES IN IBD BY TISSUE PROFILING USING A TARGETED NEXT-GENERATION SEQUENCING (NGS) TUMOR PANEL**

Petra Minarikova, Czech Republic; Benesova L.; Belsanova B.; Semyakina A.; Kasalicky M.; Bortlík M.; Lukas M.; Zavoral M.; Minarik M.

P1529

**TOFACITINIB AND CYTOKINES OF THE JAK SIGNALING PATHWAY PROTECT AGAINST EXTRACELLULAR MATRIX (ECM) DESTRUCTION IN AN INTESTINAL EX VIVO MODEL.**

Martin Pehrsson, Denmark; Lindholm M.; Manon-Jensen T.; Krag A.; Karsdal M. A.; Kjeldsen J.; Bay-Jensen A.-C.; Mortensen J. H.

P1530

**ACTIVITY OF TRANSFORMING GROWTH FACTOR (TGF)  $\beta$ 1 AND BONE MORPHOGENIC PROTEIN (BMP) IN COLONIC EPITHELIUM ESCAPES THE INHIBITION OF SMALL MOTHERS AGAINST DECAPENTAPLEGIC (SMAD) 7 IN COLITIS-ASSOCIATED CANCER**

Pramodh Chitral Chandrasinghe, United Kingdom; Cereser B.; Moorghen M.; Del Bel Belluz L.; Al Bakir; I.; Hart A.; Stebbing J.; Warusavitarne J.

P1531

**AT BIOLOGIC ONSET THE GUT MICROBIAL PROFILE IN CROHN'S DISEASE PATIENTS IS SIMILAR TO THAT OF HEALTHY CONTROLS.**

Dario Sorrentino, United States; Kuballa A.; Geraci M.; Johnstone M.



P1532

**SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IS INCREASED IN BOTH CROHN'S DISEASE AND ULCERATIVE COLITIS: SYSTEMATIC REVIEW AND META-ANALYSIS**  
Ayesha Shah, Australia; Morrison M.; Burger D.; Martin N.; Rich J.; Ghasemi P.; Jones M. P.; Koloski N.; Walker M.; Talley N. J.; Holtmann G. J.

P1533

**THE EFFECTS OF ENTERIC GLIAL CELLS ON DENDRITIC CELL AND ITS POTENTIAL IMMUNOMODULATORY ROLES IN DEXTRAN SULPHATE SODIUM INDUCED COLITIS**  
Yu Huan, China

P1534 

**TARGETED ANALYSIS OF SERUM PROTEINS ENCODED AT KNOWN INFLAMMATORY BOWEL DISEASE RISK LOCI**  
 Drobin K.; Assadi G.; Hong M.-G.; Andersson E.; Fredolini C.; Forsström B.; Reznichenko A.; Akhter T.; Ek W.; Bonfiglio F.; Hansen M. B.; Sandberg K.; Greco D.; Repsilber D.; Schwenk J.; D'Amato M.; Jonas Halfvarson, Sweden

P1535

**INFLUENCE OF SMOKING ON THE MRNA EXPRESSION OF CYTOKINES IN MUCOSA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE**  
Zuzana Leskova, Slovakia; Krajcovicova A.; Soltys K.; Stuchlik S.; Sturdik I.; Koller T.; Jalali Y.; Hlavaty T.

P1536 

**SHALLOW WHOLE GENOME SEQUENCING PREDICTS THE FUTURE CANCER RISK OF LOW GRADE DYSPLASTIC LESIONS ARISING IN ULCERATIVE COLITIS**  
Ibrahim Al Bakir, United Kingdom; Curtius K.; Baker A.-M.; Clarke T. S. O.; Moorghen M.; Jansen M.; Rodriguez-Justo M.; Leedham S.; Hart A.; Graham T. A.

P1537

**ROLE OF FACTORS RELEASED FROM ADIPOSE TISSUE, CYTOKINES AND MYOKINES IN FORCED TREADMILL EXERCISE-INDUCED EXACERBATION OF EXPERIMENTAL COLITIS IN MICE FED STANDARD DIET AND DIET-INDUCED OBESITY. RELEVANCE OF PHYSICAL ACTIVITY TO THE COURSE OF IBD IN HUMANS**  
 Bilski J.; Surmiak M.; Mazur-Bialy A.; Magierowski M.; Wojcik D.; Hubalewska-Mazgaj M.; Ptak-Belowska A.; Magierowska K.; Thomas Brzozowski, Poland

P1538

**DIFFERENT METABONOMIC PROFILES BETWEEN CROHN'S PERIANAL FISTULA AND IDIOPATHIC (CRYPTOGLANDULAR) PERIANAL FISTULAS MAY OFFER CLUES TO UNDERLYING PATHOGENESIS.**  
Samuel Adegbola, United Kingdom; Sarafian M.; Sahnun K.; Tozer P.; Ding N.; Faiz O.; Warusavitarne J.; Hart A.; Holmes E.

P1539

**ASSOCIATION BETWEEN POLYMORPHISMS -318 C/T, 49 A/G OF CTLA-4 GENE AND POLYMORPHISM IVS 3 +17 T/C OF CD28 GENE AND CROHN'S DISEASE : A CONTROLLED STUDY**  
Monia Fekih, Tunisia; Hafi M.; El Araiedh A.; Serghini M.; Labidi A.; Ben Mustapha N.; Boubaker J.; Chaabane M.

### Aetiology/epidemiology

P1540

**CROHN'S DISEASE PHENOTYPE DIFFERS BY BODY MASS INDEX AT PRESENTATION**  
 Cooney J.; Aaron Bancel, United Kingdom; Rafiq S.; Woods A.; Braim D.; Stanton I.; Mendall M.

P1541

**FEMALE GENDER INCREASES THE RISK OF ANXIETY AND DEPRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDER ANTI-TNF&#945; THERAPY.**  
 Ferreiro-Iglesias R.; Manuel Barreiro-de Acosta, Spain; Calviño-Suárez C.; Baston Rey I.; Dominguez-Muñoz J. E.

P1542

**PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1**  
 Bergamschi G.; Paolo Giuffrida, Italy; D'incà R.; Aronico N.; Astegiano M.; Lenti M. V.; Fries W.; Ciacci C.; Cococcia S.; Rizzello F.; Bossa F.; Ghigliazza G.; Castiglione F.; Milla M.; Orlando A.; Principi M. B.; Nardelli S.; Scribano M. L.; Ricci C.; Mazzucco D.; Riegler G.; Bassotti G.; Buda A.; Neri M.; Bodini G.; Monica F.; Manca A.; Villa E.; Masotti M.; Comberlato M.; Sturniolo G. C.; Saibeni S.; Sidoli L.; Cannatelli R.; Neve V.; Rizzuto G.; Vernia P.; Pieraccini A.; Testa A.; Mengoli C.; Fontana R.; Valerii C.; Iovino P.; Pinto Vraca T.; Ponzio E.; Caccaro R.; Corazza G. R.; Di Sabatino A.

P1543

**THE IMPACT OF CROHN'S DISEASE ON PERIODONTAL STATUS – PRELIMINARY RESULTS FROM POLIBD STUDY**  
 Piatek D.; Korona-Glowniak I.; Sztembis J.; Jarmakiewicz S.; Malm A.; Kiela P. R.; Rafal Filip, Poland

P1544

**PREDICTING FACTORS OF PROXIMAL DISEASE EXTENT IN ULCERATIVE COLITIS IN THE BIOLOGIC ERA**  
Helena Martínez Lozano, Spain; Herrera Fajes J. L.; García García J.; Marín-Jiménez I.; Menchén L.

P1545

**THE ROLE OF SLEEP DISORDERS IN INFLAMMATORY BOWEL DISEASES (IBD) CLINICAL COURSE.**  
Marcin Sochał, Poland; Gabryelska A.; Krzywdzinska M.; Talar-Wojnarowska R.; Malecka Panas E.

P1546

**SELECTED CYTOKINES IN PERIODONTITIS IN PATIENTS WITH CROHN'S DISEASE - PRELIMINARY RESULTS FROM POLIBD STUDY**Piatek D.; Kiela P. R.; Sztembis J.; Jarmakiewicz S.; Korona-Glowniak I.; Malm A.; [Rafal Filip](#), Poland

P1547

**PREDICTIVE FACTORS OF BONE LOSS IN INFLAMMATORY BOWEL DISEASE**[Fadoua Errabie](#), Morocco; El-Mekkaoui A.; Khannoussi W.; Ismaili Z.; Kharrasse G.

P1548

**THE EPIDEMIOLOGICAL PROFILE OF INFLAMMATORY BOWEL DISEASE IN EASTERN REGION OF MOROCCO**[Fadoua Errabie](#), Morocco; El-Mekkaoui A.; Khannoussi W.; Ismaili Z.; Kharrasse G.

P1549

**PRESENCE OF GRANULOMAS IN INTESTINAL BIOPSIES FROM PATIENTS WITH CROHN'S DISEASE CORRELATES WITH DISTINCT DISEASE CHARACTERISTICS**[Nikoleta Perlepe](#), Greece; Siakavellas S.; Koureta E.; Delladetsima I.; Papatheodoridis G.; Bamias G.

P1550

**EPIDEMIOLOGY, INCIDENCE OF COLORECTAL CANCER, MORTALITY AND THE USE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS PATIENTS BETWEEN 2007-2016 IN HUNGARY**[Tamás Molnár](#), Hungary; Milassin Á.; Szántó K.; Takács P.; Gimesi-Országh J.; Kunovszki P.; Szamosi T.; Farkas K.**Genetics**

P1551

**NEXT GENERATION SEQUENCING DERIVED MIRNA SIGNATURES FOR ACTIVE ULCERATIVE COLITIS**[Vytautas Kiudelis](#), Lithuania; Juzenas S.; Skieveciene J.; Salteniene V.; Kupcinskas J.; Kiudelis G.; Jonaitis L.; Hemmrich-Stanisak G.; Du Z.; Hübenenthal M.; Franke A.; Kupcinskas L.P1552 **A COMBINATION OF CLINICAL, SEROLOGICAL AND GENETIC FACTORS PREDICTS COMPLICATED DISEASE COURSE IN PAEDIATRIC-ONSET CROHN'S DISEASE: RESULTS FROM A POPULATION-BASED STUDY**[Hélène Sarter](#), France; Savoye G.; Turck D.; Vasseur F.; Marot G.; Pariente B.; Colombel J.-F.; Gower-Rousseau C.; Fumery M.

P1553

**THE ROLE AND EXPRESSION OF MICRORNAS IN INFLAMMATORY BOWEL DISEASE**[Rogerio Saad-Hossne](#), Brazil; Sassaki L.; Baima J.; Pintor P.; Sibia C.**Diagnosis and monitoring**

P1554

**BOWEL PREPARATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.**[Alessandra Dell'Era](#), Italy; Grassi S.; Carmagnola S.; Molteni P.; Mezzina N.; Cassinotti A.; Massari A.; Maconi G.; Ardizzone S.

P1555

**UTILITY OF THIOPURINE METABOLITE TESTING IN INFLAMMATORY BOWEL DISEASE**[Ana Yaiza Carbajo](#), Spain; Barrio J.; García Alonso F. J.; Garrote J. A.; Cimavilla M.; Torres Yuste R.; Sánchez-Ocaña R.; Marinero M. A.; Atienza R.

P1556

**THE EVALUATION OF IL-33/ST2 LEVELS CAN PREDICT MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS.**[Loris Riccardo Lopetuso](#), Italy; Petito V.; Graziani C.; Pizarro T. T.; Armuzzi A.; Scaldaferrri F.; Gasbarrini A.

P1557

**CLINICAL AND COST EFFECTIVENESS OF THERAPEUTIC DRUG MONITORING (TDM) OF INFLIXIMAB IN ADULT INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS**[Sashiananthan Ganesanathan](#), United Kingdom; Hawthorne A. B.; Durai D.

P1558


**CLINICAL OUTCOMES OF CONCOMITANT PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW**Wu K.; [Nik Ding](#), Australia; Thompson A.

P1559

**PLATELET ACTIVATION BY ACTIVATED VON WILLEBRAND FACTOR IS A MARKER OF INTESTINAL WOUND HEALING IN PATIENTS WITH CROHN'S DISEASE**[Lasse Langholm](#), Denmark; Manon-Jensen T.; Sun S.; Mortensen J. H.; He Y.; Krag A.; Jensen M. D.; Bay-Jensen A.-C.; Kjeldsen J.; Karsdal M.P1560 **SERUM SIALIC-ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN (SIGLEC)-7 AS A FIBROGENIC BIOMARKER IN CROHN'S DISEASE**Di Sabatino A.; Mele D.; [Paolo Giuffrida](#), Italy; Ubezio C.; Aronico N.; Pasini A.; Cococcia S.; Lenti M. V.; Mengoli C.; Corazza G. R.; Mondelli M. U.; Varchetta S.

P1561

**BASEMENT MEMBRANE REMODELLING AS A BIOMARKER FOR MONITORING DISEASE ACTIVITY IN CROHN'S DISEASE PATIENTS - THE ROLE OF LAMININ.**[Majken Lindholm](#), Denmark; Di Sabatino A.; Mazza G.; Manon-Jensen T.; Giuffrida P.; Pinzani M.; Krag A.; Karsdal M. A.; Kjeldsen J.; Mortensen J. H.

- P1562  
**ASSOCIATION OF BODY COMPOSITION AND MUSCLE STRENGTH WITH DISEASE ACTIVITY IN PATIENTS WITH IBD**  
Ana Barišić, Croatia; Domislović V.; Karas I.; Ljubas Kelečić D.; Brinar M.; Vranešić Bender D.; Krznarić Ž.
- P1563   
**ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE**  
William J. Sandborn, United States; Lewis J.; Panés J.; Loftus; Jr E. V.; d'Haens G.; Yu Z.; Huang B.; Lacerda A. P.; Pangan A.; Feagan B. G.
- P1564  
**AGREEMENT BETWEEN ULTRASOUND ELASTICITY AND MAGNETIC RESONANCE IMAGING IN IDENTIFYING BOWEL WALL FIBROSIS IN PATIENTS WITH CROHN'S DISEASE.**  
Stefano Mazza, Italy; Forzenigo L. V.; Orlando S.; Coletta M.; Costantino A.; Vecchi M.; Fraquelli M.; Caprioli F.
- P1565  
**PREDICTORS AT ADMISSION OF COLECTOMY WITHIN ONE YEAR IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS**  
Le Baut G.; Julien Kirchgerner, France; Landman C.; Nion I.; Bourrier A.; Delattre C.; Martineau C.; Marteau P.; Sokol H.; Seksik P.; Viennot S.; Beaugerie L.; The Saint Antoine IBD network L.
- P1566  
**ROLE OF SERUM TREFOIL FACTOR 3 AS A BIOMARKER OF INTESTINAL INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE**  
Radislav Nakov, Bulgaria; Velikova T.; Nakov V.; Gerova V.; Tankova L.; Toumangelova-Yuzeir K.; Krasimirova E.; Ivanova-Todorova E.; Kundurzhiev T.; Kyurkchiev D.
- P1567  
**DETERMINATION OF ANORECTAL FUNCTION WITH HIGH RESOLUTION ANORECTAL MANOMETRY IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION**  
Salvatore Tolone, Italy; Lanza Volpe M.; Terracciano G.; Savarino E.; Bodini G.; Federico A.; Dallio M.; Loguercio C.; Savarino V.; Docimo L.; Gravina A. G.
- P1568  
**DREAM ANXIETY IN INFLAMMATORY BOWEL DISEASE** ✨  
Haluk Tarik Kani, Turkey; Sakalli Kani A.; Basgoze E.; Aksu C.; Kahraman M. M.; Alahdab Y. O.; Atug O.; Kuscü K.; Imeryüz N.
- P1569  
**CHARACTERIZATION OF IBD PATIENTS ADMITTED IN AN INTENSIVE CARE UNIT**  
Carolina Simões, Portugal; Fernandes S. R.; Machado M. V.; Freitas L. C. R.; Baldaia C.; Gonçalves A. R.; Moura dos Santos P.; Correia L.; Valente A. I.; Marinho R. T.
- P1570  
**METASTATIC VULVAR CROHN'S DISEASE: A RARE ENTITY**  
Nour Elleuch, Tunisia; Dahmani W.; Ben Slama A.; Aya H.; Jaziri H.; Brahem A.; Ajmi S.; Ksaa M.; Jmaa A.
- P1571  
**HIGH PREVALENCE OF UNTREATED AND UNDERTREATED VITAMIN D DEFICIENCY IN PATIENTS WITH IBD**  
Viktor Domislović, Croatia; Barišić A.; Brinar M.; Ljubas Kelecic D.; Karas I.; Vranešić Bender D.; Krznarić Ž.
- P1572  
**PREVALENCE AND FACTORS ASSOCIATED WITH SEXUAL DYSFUNCTION AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE** ✨  
Viktor Domislović, Croatia; Barišić A.; Brinar M.; Krznarić Ž.
- P1573  
**SEROLOGICAL ASSESSMENT OF TYPE XVI COLLAGEN REFLECTS INTESTINAL STRICTURES IN CROHN'S DISEASE PATIENTS**  
Joachim Høg Mortensen, Denmark; Lindholm M.; Di Sabatino A.; Giuffrida P.; Mazza G.; Pinzani M.; Karsdal M. A.; Manon-Jensen T.
- P1574  
**PREVALENCE AND PREDICTORS FACTORS FOR COMPLICATIONS IN ULCERATIVE COLITIS**  
Fadoua Errabie, Morocco; El-Mekkaoui A.; Khannoussi W.; Ismaili Z.; Kharrasse G.
- P1575  
**SERUM BIOMARKERS REFLECTING TISSUE-REMODELING CORRELATES WITH THE SIMPLE ENDOSCOPIC SCORE FOR CROHN'S DISEASE**  
Joachim Høg Mortensen, Denmark; Lindholm M.; Manon-Jensen T.; Karsdal M. A.; Agnholt J. S.; Grønbaek H.; Kirch Dige A.
- P1576  
**THE CONTROLLING NUTRITIONAL STATUS SCORE AS A METHOD OF NUTRITIONAL SCREENING AND PREDICTOR OF SEVERITY IN ULCERATIVE COLITIS.**  
Jorge Luis de León Rendón, Mexico; Gracida Mancilla N. I.; López Pérez R. Y.; Jiménez Bobadilla B.; Velázquez Aviña J.; Medoza Ramirez S.; Higuera de la Tijera F.; Villanueva Herrero J. A.

P1577

**ANALYSIS OF COSTS, USE OF HEALTH RESOURCES AND IMPACT ON WORK PRODUCTIVITY AND QUALITY OF LIFE IN ULCERATIVE COLITIS: A PROSPECTIVE SINGLE CENTER STUDY**Aiello A. F.; [Barbara Scrivo](#), Italy; Calvaruso V.; Cacioppo A.; Vitello A.; Cilluffo M. G.; Cappello M.

P1578

**FAECAL CALPROTECTIN AS SURROGATE MARKER OF TRANSMURAL HEALING ASSESSED USING MRI IN PATIENTS WITH CROHN'S DISEASE.**[Christophe Allimant](#), France; Messadeg L.; Minet Quinard R.; Goutte M.; Bouvier D.; Goutorbe F.; Pereira B.; Bommelaer G.; Hordonneau C.; Buisson A.

P1579

**FEATURES OF SMALL INTESTINE PERMEABILITY IN AUTOIMMUNE DISEASES OF THE DIGESTIVE SYSTEM: INFLAMMATORY BOWEL DISEASES AND AUTOIMMUNE LIVER DISEASES**Akberova D.; Abdulganieva D.; Mukhametova D.; [Alfiya Odintsova](#), Russian FederationP1580 **PATIENT-NEAR ADALIMUMAB TROUGH-LEVEL TESTING BY A NOVEL QUANTITATIVE RAPID TEST; THE QUANTUM BLUE ADALIMUMAB ASSAY.**Røseth A.; [Ida Lindsjøl](#), Norway

P1581

**SERUM ALBUMIN CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC DISEASE ACTIVITY IN NEWLY DIAGNOSED CROHN'S DISEASE PATIENTS**[Rune Gjerde](#), Norway; Carlsen A.; Karlsen L.; Tvedt-Gundersen E.; Aabakken L.; Omdal R.; Grimstad T.

P1582

**THE ACCURACY OF THREE DIFFERENT METHODS ON THERAPEUTIC DRUG MONITORING OF SB2**Magro F.; Rocha C.; Lourenço Vieira A.; Tavares Sousa M. H.; Rosa I.; Lopes S.; Carvalho J.; Dias C.; [Joana Afonso](#), PortugalP1583 **QUANTIFIED TERMINAL ILEAL MOTILITY DURING MR ENTEROGRAPHY AS A BIOMARKER OF CROHN'S DISEASE ACTIVITY: A PROSPECTIVE STUDY**[Alex Menys](#), United Kingdom; Puylaert C.; Tutein Nolthenius C.; Plumb A.; Makanyanga J.; Tielbeek J.; Brosens L.; Rodriguez-Justo M.; Atkinson D.; Bhatnagar G.; Vos F.; Stoker J.; Taylor S.

P1584

**SERUM CHITINASE 3-LIKE-1 IS A RELIABLE SURROGATE MARKER OF MUCOSAL HEALING AND AN EFFECTIVE TOOL TO PREDICT CLINICAL RELAPSE IN PATIENTS WITH CROHN'S DISEASE**[Elisa Sollelis](#), France; Vazeille E.; Hebuterne X.; Fumery M.; Pariente B.; Nancey S.; Seksik P.; Peyrin-Biroulet L.; Allez M.; Pereira B.; Barnich N.; Buisson A.

P1585

**CAPSULE ENDOSCOPY IN A TREAT TO TARGET APPROACH TO CROHN'S DISEASE PATIENTS**[Roxana Sadagurschi](#), Romania; Negreanu L.; Stemate A.; Goran L.; Babiuc R.P1586 **PERSONALISED CARE WITH THE TELEMEDICINE TOOL MYIBDCOACH IS COST-EFFECTIVE. A COST-UTILITY ANALYSIS OF THE MYIBDCOACH TRIAL.**[Marin de Jong](#), The Netherlands; Van Der Meulen - De Jong A.; Romberg-Camps M.; Becx M.; Maljaars J. P. W.; Cilissen M.; van Bodegraven A.; Mahmmod N.; Markus T.; Hameeteman W.; Dijkstra G.; Masclee A.; Boonen A.; Winkens B.; van Tubergen A.; Jonkers D. M.; Pierik M. J.

P1587

**WHAT DO IBD PATIENTS KNOW ABOUT DIET AND PREVENTIVE PRACTICES IN IBD?**[Juliana Costa](#), Portugal; Leal T.; Arroja B.; Gonçalves B.; Gonçalves R.; Soares J. B.

P1588

**DOES FECAL CALPROTECTIN BASED MONITORING HAVE AN IMPACT ON LONG-TERM OUTCOMES IN FINNISH ADULT PATIENTS WITH CROHN'S DISEASE: RETROSPECTIVE MULTI-CENTRE CHART REVIEW STUDY.**Hallinen T.; Jussila A.; [Clas-Göran af Björkesten](#), Finland; Kempainen H.; Soini E.; Mankinen P.; Valgardsson V. S.; Veckman V.; Nissinen R.; Naessens D.; Molander P.**Treatment-medical**

P1589

**REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB AND ANTI-TUMOUR NECROSIS FACTOR ALPHA TREATMENT OVER 6 MONTHS IN CROHN'S DISEASE PATIENTS: A GERMAN RETROSPECTIVE CHART REVIEW**[Ulf Helwig](#), Germany; Mross M.; Schubert S.; Hartmann H.; Brandes A.; Kempf C.; Knop J.; Campbell-Hill S.; Ehehalt R.

P1590

**THE SAFETY AND EFFICACY OF VEDOLIZUMAB IN THE ELDERLY – A RETROSPECTIVE ANALYSIS**[Nathaniel Aviv Cohen](#), Israel; Ron Y.; Fliss Isakov N.; Elashvili I.; Dotan I.; Maharshak N.

- P1591**  
**EAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKI-NUMAB FOR MODERATE-SEVERE CROHN'S DISEASE; A RETROSPECTIVE MULTICENTRE STUDY**  
Karima Farrag, Germany; Aksan A.; Rueter L.; Hausmann J.; Kubesch A.; Krause T.; Stein J.; Blumenstein I.
- P1592**  
**EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFlixIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY.**  
Sarah Fischer, Germany; Klenske E.; Schmitt H.; Vitali F.; Hirschmann S.; Koch F.; Ramming A.; Zundler S.; Krebs S.; Dörje F.; Nagore D.; Meyer S.; Uter W.; Neurath M.; Atreya R.
- P1593**  
**EVALUATION OF NEWLY REPORTED NUDT15 SNPS (EXON1 AND 3) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH THIOPURINES**  
Yuichiro Kojima, Japan; Hirotsu Y.; Omata W.; Sugimori M.; Takaoka S.; Mochizuki H.; Omata M.
- P1594**  
**THE PREOPERATIVE USE OF ANTI-TNF&#945;-ANTI-BODIES IN IBD PATIENTS UNDERGOING RESECTIVE ABDOMINAL SURGERY HAS NO INFLUENCE ON PERI- AND POSTOPERATIVE COMPLICATIONS**  
Isabel Braun, Germany; Heitland W.; Bader F.; Huber F.; Janelidze S.; Schnitzler F.; Ochsenkühn T.
- P1595**  
**PREDICTORS OF VEDOLIZUMAB RESPONSE TO INDUCTION: REAL LIFE EXPERIENCE**  
Maria Belvis Jiménez, Spain; Gutierrez Casbas A.; Vázquez Morón J. M.; García Sepulcro M.; Maldonado Perez B.; Sempere Robles L.; Laveda Cano R.; Pallares Manrique H.; Gómez E.; Castro Laria L.; Aargüelles Arias F.
- P1596**  
**LOWER RELAPSE RATES FOLLOWING A THERAPEUTIC DRUG MONITORING BASED STRATEGY FOR TNF ANTAGONIST DE-ESCALATION DURING INFLAMMATORY BOWEL DISEASE.**  
 Lucidarme C.; Petitcollin A.; Dewitte M.; Brochard C.; Siproudhis L.; Guillaume Bouguen, France
- P1597**  
**LONG-TERM EFFICACY OF VEDOLIZUMAB THERAPY ON CLINICAL AND ENDOSCOPIC ACTIVITY IN PATIENTS WITH ANTI-TUMOR NECROSIS FACTOR ALPHA RESISTANT INFLAMMATORY BOWEL DISEASE**  
Renáta Bor, Hungary; Szepes Z. G.; Matuz M.; Farkas K.; Fabian A.; Miheller P.; Palatka K.; Szamosi T.; Vincze A.; Lakner L. L.; Müllner K.; Papp M.; Szabone Dr Salamon Á.; Schäfer E.; Fülöpné Sarang K.; Nagy F.; Zsigmond F.; Banai J.; Szántó K.; Balint A.; Rutka M.; Milassin Á.; Molnár T.
- P1598**  
**LONG TERM PROGNOSIS OF CROHN'S DISEASE OF THE POUCH**  
Ibrahim Hatemi, Turkey; Ferhat Çelik A.; Gundogdu T.; Kepil N.
- P1599**  
**THE EFFECT OF PROBIOTIC LACTOBACILLUS CASEI ON MITOTIC AND APOPTOTIC ACTIVITY, HISTOPATHOLOGICAL SCORE AND MORPHOMETRIC PARAMETERS IN PORCINE EXPERIMENTAL INFLAMMATORY BOWEL DISEASE INDUCED BY DEXTRAN SODIUM SULFATE**  
Jan Bures, Czech Republic; Pejchal J.; Kohoutova D.; Kvetina J.; Radochova V.; Pavlik M.; Tichy A.; Rejchrt S.; Kopacova M.; Douda T.
- P1600**  
**AN INTRODUCTION TO LUCID; LIVING WITH ULCERATIVE COLITIS; IDENTIFYING THE SOCIOECONOMIC BURDEN IN EUROPE**  
 Rose A.; Lobo A. J.; Abounit S.; Avedano L.; Peyrin-Biroulet L.; Burisch J.; Fiorino G.; Hayee B.; Limdi J.; Sturm A.; Terry H.; Tucknott S.; Finnegan A.; Rosa Willock, United Kingdom
- P1601**  
**USE OF ANTI-TNF AGENTS FOR PRIMARY PREVENTION OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE: A NATIONWIDE, REAL-LIFE STUDY. RESULTS FROM THE SPANISH ENEIDA REGISTRY.**  
Eugeni Domènech, Spain; Canete F.; Mañosa M.; Casanova M. J.; González Sueyro R. C.; Barrío J.; Bermejo F.; Nos P.; Iglesias Flores E.; García Planella E.; Pérez Calle J. L.; Vicente Lidón R.; Rivero M.; Ramos L.; Vera M.; De Francisco R.; Torres A. M.; Benítez O.; Navarro Cortés P.; Taxonera C.; Hinojosa J.; Márquez Mosquera L.; Navarro Llavat M.; Ramírez de la Piscina P.; Gomollon García F.; Rodríguez Alonso L.; Núñez Alonso A.; Fernández Salazar L.; Almela P.; Ríos R.; De Castro L.; Clos parals A.; Eduard C.

P1602

**EVALUATION OF TREATMENT ADHERENCE AMONG INFLAMMATORY BOWEL DISEASE PATIENTS FROM ARGENTINA: A MULTICENTER STUDY**Lasa J.; Correa G.; Fuxman C.; Garbi L.; Linares M. E.; Lubrano P.; Olivera Sendra P. A.; [Astrid Rausch](#), Argentina; Toro M. A.; Yantorno M.; Zubiaurre I.

P1603

**INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH.**[Andrea Buda](#), Italy; Lorenzon G.; Barberio B.; Savarino E.; Zingone F.; D'inca R.

P1604

**RESCUE THERAPY WITH ANTI-TNF AGENTS FOR ESTABLISHED POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE. A MULTICENTRE, RETROSPECTIVE, NATIONWIDE STUDY.**[Eugeni Domènech](#), Spain; Cañete F.; Mañosa M.; Gonzalez Sueyro R. C.; Riestra Menéndez S.; Barreiro de Acosta M.; Nos P.; Iglesias Flores E.; Gutierrez Casbas A.; Ríos R.; Bujanda Fernández de Piérola L.; González Muñosa C.; Villoria A.; Casanova González M. J.; García Herola A.; Rodríguez-Lago I.; López Serrano P.; Ramírez de la Piscina P.; Navarro Llavat M.; Taxonera C.; Barrio J.; Ramos L.; Navarro P.; Benítez Leiva O.; Valls Gandía M.; Van Domselaar M.; Hernandez Camba A.; Verdejo Gil C.; Torrealba Medina L.; Sampedro González M.; Pajares Villarroya R.; Piqueras Cano M.; Martín-Arranz M. D.; Algaba García A.; Muñoz Villafranca C.; Arajol C.; Rivero Tirado M.; Delgado Guillena P. G.; Fernández Pordomingo A.; Camo Monterde P.; Sainz Arnau E.; Hinojosa J.; Clos Parals A.; Eduard C.

P1605

**STOPPING 5-AMINOSALICYLATES IN ULCERATIVE COLITIS PATIENTS STARTING BIOLOGIC THERAPY DOES NOT INCREASE THE RISK OF ADVERSE CLINICAL OUTCOMES**Ungaro R.; Limketkai B.; [Camilla Bjørn Jensen](#), Denmark; Allin K.; Colombel J.-F.; Jess T.

P1606

**TARGET CELLS OF VEDOLIZUMAB IN PERIPHERAL BLOOD AND GUT MUCOSAL CELLS FROM IBD PATIENTS.**[Michiel Dirk Voskuil](#), The Netherlands; Uniken Venema W. T. C.; Bangma A.; Jansen B. H.; Dijkstra G.; Weersma R. K.; Festen E. A. M.

P1607

**SYSTEMIC CYTOMEGALOVIRUS INFECTION IS A RELEVANT FACTOR AFFECTING SHORT AND LONG TERM OUTCOMES OF PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: AN 11-YEAR EXPERIENCE**Macaluso F. S.; Compagnoni S.; Renna S.; Maisano S.; Casà A.; Solina G.; Rizzo A. G.; La Seta F.; Ventimiglia M.; [Ambrogio Orlando](#), Italy; Cottone M.

P1608

**HIGH ANTI-TNF DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES.**Bodini G.; [Maria Giulia Demarzo](#), Italy; Saracco M.; Coppo C.; Baldissarro I.; Jain A.; Savarino E.; Savarino V.; Giannini E. G.

P1609

**EFFECTIVENESS AND SAFETY OF USTEKINUMAB 90 MG EVERY FOUR WEEKS IN CROHN'S DISEASE**[Mathurin Fumery](#), France; Peyrin-Biroulet L.; Nancey S.; Veyrard P.; Bouguen G.; Altwegg R.; Viennot S.; Laharie D.; Filippi J.; Buisson A.; Bozon A.; Brazier F.; Pouillon L.; Flourie B.; Siproudhis L.; Boivineau L.; Roblin X.; Treton X.

P1610

**RADIOLOGICAL OUTCOMES IN PERIANAL FISTULISING CROHN'S DISEASE TREATED WITH ANTI-TNFA THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS.**Lee T.; [Nik Ding](#), Australia

P1611

**GOLIMUMAB IMPROVES PATIENT-REPORTED WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH ULCERATIVE COLITIS: INTERIM RESULTS FROM A NON-INTERVENTIONAL TRIAL IN GERMANY**Teich N.; Grümmer H.; Jörgensen E.; Liceni T.; Holtkamp-Endemann F.; Cornillie F.; Hohenberger S.; [Tim Fischer](#), Germany

P1612

**DRUG-INDUCED TOXICITY AND IMMUNE-INFLAMMATORY DISORDERS OF HEPATO-PANCREATO-BILIARY SYSTEM IN IBD PATIENTS: A DIAGNOSTIC CHALLENGE**[Senka Marusic Dobric](#), Serbia; Lukic S.; Sokic Milutinovic A.; Jovanovic I.; Djuranovic S.; Milovanovic Alempijevic T.; Popovic D.

P1613

**EFFICACY AND SAFETY OF BIOSYMILAR INFLIXIMAB CT-P13 IN PATIENTS WITH CROHN'S DISEASE WHO WERE NAÏVE TO ANTI-TNF THERAPY: PRELIMINARY RESULTS FROM POLIBD STUDY**Pękala A.; Jarmakiewicz S.; Witas B.; [Rafal Filip](#), Poland

- P1614  
**DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY**  
Peter Bossuyt, Belgium; D'Haens G.; Panaccione R.; Sandborn W.; Reinisch W.; Travis S.; Schreiber S.; Armuzzi A.; Danese S.; Berg S.; Petersson J.; Maa J.-F.; Neimark E.; Colombel J.-F.
- P1615  
**ATTITUDES TOWARDS TREATMENT WITHDRAWAL IN IBD**  
Neil O'Morain, Ireland; O'Gorman S.; Doherty V.; Hanna C.; McNamara D.; Breslin N.; O'Connor A.; Ryan B.
- P1616  
**CLINICAL TRIAL: HIGH-DOSE VITAMIN D TREATMENT TO CROHN'S DISEASE PATIENTS WITH DISEASE ACTIVITY, A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND-ED STUDY (MIRVIDIC).**  
Mia Bendix, Denmark; Dige A.; Jørgensen S. P.; Dahlerup J. F.; Deleuran B.; Agnholt J.
- P1617   
**SECONDARY LOSS OF RESPONSE TO VEDOLIZUMAB: EXPERIENCE FROM A SINGLE UNIVERSITY CENTRE**  
Peter Lawrence Evans, United Kingdom; Tun G. S. Z.; Lee M. J.; Marshall L.; Wright A.; Brooks A. J.; Chew J.; Robinson K.; Hale M. F.; Lobo A. J.
- P1618  
**VEDOLIZUMAB TROUGH LEVELS DURING AND AFTER INDUCTION CORRELATE WITH CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE**  
Daniela Pugliese, Italy; Guidi L.; Panici Tonucci T.; Solitano V.; Felice C.; Privitera G.; Tulusso B.; Onori E.; Bertani L.; Costa F.; Papparella L. G.; Gremese E.; Papa A.; De Vitis I.; Gasbarrini A.; Rapaccini G. L.; Armuzzi A.
- P1619  
**TOLERANCE OF THIOPURINES IN PATIENTS WITH CHRONIC INFLAMMATORY BOWEL DISEASE (IBD)**  
Fadoua Errabie, Morocco; El-Mekkaoui A.; Khannoussi W.; Ismaili Z.; Kharrassa G.
- P1620  
**A MULTICENTER RANDOMIZED PROSPECTIVE STUDY ASSESSING THE EFFICACY OF SINERGIN IN INDUCTION AND MAINTAINING REMISSION IN MILD-MODERATE IBD**  
Simoa Monica Nicula, Romania; Dimitriu A.; Monica Lucia C.; Mateescu B. R.; Diculescu M.; Cristian G.; Gheorghe L. S.
- P1621  
**HIGHER ADALIMUMAB LEVELS DURING MAINTENANCE TREATMENT FOR CROHN'S ARE ASSOCIATED WITH DEEP REMISSION: RESULTS FROM A LARGE PROSPECTIVE CROSS-SECTIONAL COHORT**  
Nikolas Plevris, United Kingdom; Jenkinson P.; Lyons M.; Chuah C.; Rhys-Jones G.; Hall R.; Watson E.; Ho G.-T.; Din S.; Noble C.; Shand A.; Arnott I.; Lees C.
- P1622  
**INFLAMMATORY BOWEL DISEASE MANAGEMENT AND SEXUAL HEALTH ISSUES - DO EXPERTS IN THIS FIELD ADDRESS SEXUAL PROBLEMS IN ROUTINE PATIENT TREATMENT YET ? RESULTS OF THE IGLS-VIENNA-SEXMED-SURVEY ON EXPERTS IN IBD, BAD ISCHL, SEPTEMBER 2017**  
Lucia Ucsnik, Austria; Kottmel A.; Bitzer J.; Teleky B.; Högenauer C.
- P1623  
**WITHDRAWN**
- P1624  
**MULTIDISCIPLINARY TEAM CARE AT THE EMERGENCY DEPARTMENT CONTRIBUTES TO IMPROVED MANAGEMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES**  
Revital Barkan, Israel; Lelbovitzh H.; Goren I.; Aharoni Golan M.; Banai Eran H.; Perets T. T.; Adani E.; Shiber S.; Steiner H.; Drescher M. J.; Dotan I.; Yanai H.
- P1625  
**CHARACTERISTICS OF ANTI-TNF ALPHA THERAPY FOR ULCERATIVE COLITIS BETWEEN 2010-2016 IN HUNGARY**  
Anita Balint, Hungary; Farkas K.; Milassin Á.; Szántó K.; Takács P.; Gimesi-Országh J.; Kunovszki P.; Szamosi T.; Molnár T.
- P1626  
**VEDOLIZUMAB RESULTS IN REDUCED HOSPITALISATIONS AND STEROID USE AT 1 YEAR: RESULTS FROM THE SCOTTISH VEDOLIZUMAB COHORT**  
Nikolas Plevris, United Kingdom; Chuah C.; Jenkinson P.; Brennan P.; Allen R.; Lam W.; Shasi P.; Naismith G.; Arnott I.; Gaya D.; Mowat C.; Macdonald J.; Seenan J. P.; Churchhouse A.; Potts L.; Watson A.; Sengupta A.; Watts D.; Jafferbhoy H.; Groome M.; Lees C.
- P1627  
**AZATHIOPRINE INDUCES HYPERBILIRUBINEMIA IN INFLAMMATORY BOWEL DISEASE: A HOSPITAL BASED COHORT STUDY**  
Won Moon, Republic of Korea; Seo K. I.; Park S. J.; Park M. I.; Lee S. U.; Yun B. C.; Han B. H.; Park E. T.; Kim J. H.; Kim S. E.; Jung K.
- P1628  
**TARGETING DETECTION OF FISTULA TISSUE LEVELS OF ANTI-TNF - A POTENTIAL BIOMARKER OF TREATMENT RESPONSE?**  
Samuel Adegbola, United Kingdom; Sarafian M.; Sahnun K.; Pechlivanis A.; Phillips R. K.; Warusavitarne J.; Faiz O.; Haddow J.; Knowles C.; Tozer P.; Holmes E.; Hart A.

P1629

**USTEKINUMAB EFFICIENCY IN ASSOCIATION WITH SERUM LEVELS IN COMPLICATED REFRACTORY PATIENTS WITH CROHN'S DISEASE**

Martin Kolar, Czech Republic; Malickova K.; Bortlík M.; Pudilova K.; Duricova D.; Lukas M.; Machkova N.; Hrubá V.; Lukas M.

P1630

**POTENTIAL THERAPEUTIC EFFICACY OF CURCUMIN IN THE TREATMENT OF EXPERIMENTAL COLITIS. MODULATORY ROLE OF PROSTAGLANDINS, NITRIC OXIDE, HYPOXIA INDUCIBLE FACTOR-1ALPHA AND INTESTINAL MICROBIOTA**

Kwiecien S.; Wojcik D.; Sliwowski Z.; Magierowski M.; Surmiak M.; Magierowska K.; Hubalewska-Mazgaj M.; Targosz A.; Ptak-Belowska A.; Konturek P. C.; Thomas Brzozowski, Poland

P1631

**ACTIVE SUBSTANCES IN CHAMOMILE FLOWER AND COFFEE CHARCOAL EXTRACT CONTRIBUTE TO THE ANTISPASMODIC AND CYTOKINE/CHEMOKINE-INHIBITING ACTIVITY OF A TRADITIONAL HERBAL MEDICINE**

Weber L.; Hammoud D.; Goos K.-H.; Nieber K.; Arnhold J.; Cica Vissiennon, Germany

## Poster Session

09:00 – 14:00

Hall X1

Other Lower GI Disorders III

## Microbiology

P1632

**HUMAN MILK OLIGOSACCHARIDES IMPACT THE MICROBIOTA COMMUNITY AND ASSOCIATED BACTERIAL METABOLITES OF IBS PATIENTS**

Jackson F.; Suligoj T.; Louise Kristine Vigsnaes, Denmark; McConnell B.; Juge N.; Gibson G.

P1633

**DAY-TO-DAY VARIABILITY IN FECAL MICROBIAL RICHNESS AND ITS ASSOCIATION WITH STOOL CONSISTENCY: DO WE NEED MULTIPLE SAMPLE COLLECTION?**

Lisa Vork, The Netherlands; Penders J.; van Kuijk S.; Jalanka J.; Rajilic-Stojanovic M.; Bojic S.; Manichanh C.; Pozuelo M.; Masclee A.; Jonkers D.

P1634

WITHDRAWN

P1635 **CHANGES OF HUMAN GUT MICROBIOTA FUNCTIONAL POTENTIAL AFTER HELICOBACTER PYLORI ERADICATION THERAPY**

Dilyara Safina, Russian Federation; Markelova M.; Abdulkhakov S. R.; Grigoryeva T.; Boulygina E.; Malanin S.; Vasilyev I.; Siniagina M.; Abdulkhakov R.

P1636

**FECAL MICROBIAL ECOSYSTEM IS DISTINCT IN IRRITABLE BOWEL SYNDROME ACCORDING TO SUBTYPES**

Cesare Cremon, Italy; Guglielmetti S.; Gargari G.; Taverniti V.; Fiore W.; Barbaro M. R.; Bellacosa L.; Capelli E.; Stanghellini V.; Barbara G.

P1637

**CHARACTERIZATION OF GUT MICROBIOTA IN A COHORT OF NORMAL ITALIAN SUBJECTS; RESULTS FROM A CROSS-COUNTRY POPULATION STUDY**

Karlsson M. K.; Zullo A.; Peralta S.; Pace F.; Christina Casén, Papua New Guinea

## Lower GI bleeding

P1638

**A TEXT MINING TOOL TO DETECT THE MANAGEMENT OF ANTITHROMBOTICS BEFORE COLONOSCOPY – A ANALYSIS OF 656 PATIENTS**

Poon J.; Ching J. Y. L.; Lau A. Y. L.; Ho A. M. Y.; Lam T. Y. T.; Kyaw M. H.; Wu J. C. Y.; Francis Ka-leung Chan, Hong Kong PRC

P1639

**READMISSION OF GASTROINTESTINAL BLEEDING IN THE EMERGENCY DEPARTMENT**

Antonio Oliveira, Portugal; Carvão J.; Magno Pereira V.; Ladeira N.; Jasmins L.

P1640

**A NOVEL SCORING SYSTEM FOR LOWER GASTROINTESTINAL BLEEDING: A MULTI-CENTRE COMPARISON OF RISK ASSESSMENT TOOLS**

Samuel Smith, United Kingdom; Bazarova A.; Shivaji U.; Harvey P.; Slaney E.; McFarlane M.; Iqbal T.; Cooney R.; Bhala N.; Gkoutos G.; Ghosh S.; Iacucci M.

P1641

**OAKLAND SCORE IS NOT BETTER THAN HAEMOGLOBIN FOR PREDICTING OUTCOMES IN LOWER GASTROINTESTINAL BLEEDING**

Alba Lira, Spain; Machlab S.; Garcia Iglesias P.; Martínez-Bauer E.; Mármol C.; Gallach M.; Hernández L.; Brunet E.; Melcarne L.; Da Costa J.; Llibre G.; Puig-Divi V.; Junquera F.; Campo Fernandez R.; Calvet X.; Brullet E.

P1642

**THE USE OF NSAIDS, PAAS AND OACS IN HEMORRHAGE ASSOCIATED WITH DIVERTICULAR DISEASE**

Tânia Gago, Portugal; Ramos A.; Roseira J.; Cunha A. C.; Campelo P.; Guerreiro H.



**Lower GI malignant disease-epidemiology**

P1643  
**CAN METABOLIC AND LIFESTYLE RISK FACTORS PREDICT COLONIC ADENOMATOUS POLYPS?**  
Anthea Pisani, Malta; Azzopardi N.; Gatt K.; Santucci S.; Abdilla Y.; Barbara M. A.

P1644  
**HOW OLD IS OLD IN COLORECTAL CANCER**  
Lunpo Wu, China; Fu J.; Ruan H.; Wang L.

P1645  
**ENDOSCOPIC FINDINGS IN A COLORECTAL SCREENING PROGRAMME BELOW THE THRESHOLD OF 100 NG/ML (50-99 NG/ML)**  
Diana João Matias, Spain; Rodríguez Martín L.; Villar Lucas C.; Quiñones Castro R.; Díez Rodríguez R.; Jorquera Plaza F.; Vivas Alegre S.

P1646  
**COLORECTAL CANCER INCIDENCE AND MORTALITY REDUCTION IN THE CZECH REPUBLIC – EFFECT OF THE NATIONAL SCREENING PROGRAM?**  
Stepan Suchanek, Czech Republic; Ngo O.; Grega T.; Majek O.; Zavoral M.

P1647  
**RIGHT-SIDED LESIONS CHARACTERISTICS AND SURVIVAL IN A POPULATION BASED COLORECTAL SCREENING PROGRAMME**  
Eunate Arana-Arri, Spain; Imaz-Ayo N.; Idigoras Rubio I.; Bilbao Iturribarria I.; Gutierrez-Ibarluzea I.; García González J. M.; Portillo Villares M. I.


**Lower GI malignant disease, pathogenesis**

P1648  
**MITOTIC AND APOPTOTIC ACTIVITY IN SPORADIC COLORECTAL NEOPLASIA**  
Kohoutova D.; Pejchal J.; Jan Bures, Czech Republic


P1649  
**EXOGENOUS AND ENDOGENOUS ASSOCIATED FACTORS TO EARLY ONSET COLORECTAL CANCER**  
Zuppardo R. A.; Di Leo M.; Mannucci A.; Azzolini F.; Esposito D.; Fanti L.; Mazzoleni G.; Notaristefano C.; Edi V.; Patricelli M. G.; Russo Raucchi A.; Rosati R.; Testoni P. A.; Giulia Martina Cavestro, Italy

P1650  
**SLC25A22 MEDIATES EPIGENETIC REPROGRAMMING TO PROMOTE WNT/ $\beta$ -CATENIN SIGNALING AND CANCER STEMNESS IN KRAS-MUTANT COLORECTAL CANCER**  
Chi Chun Wong, Hong Kong PRC; Qian Y.; Li W.; Kang W.; Sung J. J. Y.; Yu J.


P1651  
**TRANSCRIPTION FACTORS ATF6 AND XBP1S OF THE UNFOLDED PROTEIN RESPONSE REDUCE COLORECTAL CANCER CELL PROLIFERATION AND STEMNESS THROUGH INTERACTION WITH PERK**  
Claudia Nanette Spaan, The Netherlands; Smit W. L.; Van Lidth De Jeude J. F.; Meijer B. J.; Muncan V.; van den Brink G. R.; Heijmans J.

P1652   
**KLOTHO SUPPRESSES SENESCENT MESENCHYMAL CELLS AND THE PROGRESSION OF COLORECTAL CANCER BY INHIBITING THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE VIA THE NF- $\kappa$ B PATHWAY**  
Liu Y.; Pan X.; Chen S.; Pan J.; Lin Z.; Su T.; Lai S.; Wu L.; Chen F.; Ge Q.; Chen L.; Ye S.; Liangjing Wang, China

P1653  
**S100P AS A NOVEL HYPOMETHYLATION TARGET IN SESILE SERRATED ADENOMA (SSA/P)-CANCER SEQUENCE: A GENOME-WIDE DNA METHYLATION ARRAY ANALYSIS**  
Tetsuji Takayama, Japan; Takahashi S.; Okamoto K.; Fujimoto S.; Nakagawa T.; Kagemoto K.; Okada Y.; Nakamura F.; Fujino Y.; Kitamura S.; Miyamoto H.; Sato Y.; Mugeruma N.

P1654   
**THE GUT MICROBIOTA INFLUENCES INTESTINAL EPITHELIAL PROLIFERATIVE POTENTIAL**  
John Parakalathil Thomas, United Kingdom; Parker A.; Divekar D.; Watson A.

P1655  
**MOLECULAR BIOLOGY ANALYSES USING NEXT-GENERATION SEQUENCING IN INFLAMMATORY BOWEL DISEASE'S PATIENTS WITH INTESTINAL CANCERS**  
Jean-Marc Gornet, France; Lehmann-Che J.; Hammoudi N.; Razafimahefa J.; Maillot M.; Poirot B.; Bertheau P.; Eveno C.; Lourenco N.; Allez M.; Aparicio T.

P1656   
**SCNN1B FUNCTIONS AS A TUMOR SUPPRESSOR IN COLORECTAL CANCER BY INHIBITING THE MEK-ERK PATHWAY**  
Qian Y.; Chi Chun Wong, Hong Kong PRC; Yu J.

**Lower GI malignant disease, diagnosis/histopathology**

P1657  
**DIAGNOSTIC AND PROGNOSTIC ROLE OF CIRCULATING CELL FREE DNA (CF DNA) IN DIFFERENT STAGES OF COLORECTAL CANCER**  
Mohamed Elnadry, Egypt

P1658  
**METACHRONOUS COLORECTAL CANCER IN A POPULATION BASED SCREENING PROGRAMME**  
Martínez-Indart L.; Idigoras Rubio I.; Portillo Villares M. I.; Bilbao Iturribarria I.; Imaz-Ayo N.; Bujanda Fernández de Piérola L.; Eunate Arana-Arri, Spain

P1659

**OVEREXPRESSION OF AT-RICH INTERACTIVE DOMAIN 3A CORRELATED WITH FAVORABLE PROGNOSIS IN PATIENTS WITH RESIDUAL RECTAL CANCER AFTER PRE-OPERATIVE CHEMORADIOTHERAPY**

An Na Seo, Republic of Korea; Yoon G.

P1660

**OPTICAL TECHNOLOGIES FOR ENDOSCOPIC REAL-TIME HISTOLOGICAL ASSESSMENT OF COLORECTAL POLYPS – A SYSTEMATIC REVIEW WITH META-ANALYSIS**

Sam Mason, United Kingdom; Poynter L.; Takats Z.; Darzi A.; Kinross J.

P1661

**AUTOMATED EXTRACTION OF ENDOSCOPIC ADENOMA DETECTION RATES FROM ENDOSCOPIC-PATHOLOGICAL DATA IS AS SENSITIVE AND SPECIFIC AS MANUAL EXTRACTION.**

Sebastian Zeki, United Kingdom

P1662

**DELAYING AND DRYING EFFECTS ON THE RESULTS OF GUIAIC FAECAL OCCULT BLOOD TESTING**

Andrew Field, United Kingdom; Morling J.; Chapman C.; Logan R.

P1663

**COMBINATION OF FAECAL OCCULT BLOOD TEST AND FAECAL CALPROTECTIN IS NOT AN EFFECTIVE STRATEGY TO AVOID NON PATHOLOGICAL COLONOSCOPIES IN A COLORECTAL CANCER SCREENING PROGRAM**

Gonzalo Hijos, Spain; Abril C.; Lorenzo M.; Navarro M.; Sostres C.; Lué A.; Chueca Lapuente E.; Arechavaleta S.; Gomollon F.; Lanas A.

P1664

**INCREASING THE CUT-OFF VALUES OF FIT IN POPULATION BASED COLORECTAL CANCER SCREENING IMPROVES FALSE POSITIVE RATES AND HEALTH RESOURCE UTILIZATION IN A NATIONAL PUBLIC HEALTH SERVICE**

Angel Lanas, Spain; Carrera P.; Navarro M.; Ferrandez A.; Cano M.

P1665

**LATE DIAGNOSIS OF COLORECTAL CANCER IN MOROCCO : WHAT REASONS BEHIND?**

Nada Lahmidani, Morocco; El Abkari M.; Ibrahim A.; Mellas N.; El Rhazi K.; Kharrasse G.; Afqir S.; Inrhaoun H.; Mrabti H.; Errihani H.

### Lower GI malignant disease, management

P1666

**THE EFFECT OF METFORMIN ON TUMOR RESPONSE OF NEO-ADJUVANT CCRT OF RECTAL CANCER**

Jung Min Kim, Republic of Korea; Park Y. H.; Park S. J.; Cheon J. H.; Kim W. H.; Kim T. I.

P1667

**LONG TERM RESULT OF “WATCH AND WAIT” WITH-OUT RADICAL SURGERY FOR COMPLETE CLINICAL RESPONSE OF RECTAL CANCER AFTER NEOADJUVANT CONCURRENT CHEMORADIATION THERAPY IN A SINGLE INSTITUTION IN TAIWAN**

C. W. Hsiao, Taiwan

P1668

**ACID-RESPONSIVE DRUG-COMPLEXED POLYPEPTIDE NANOPARTICLE EFFECTIVELY AND SAFELY TREATS COLORECTAL CANCER**

Qinglin Zhang, China; Zhan Q.; An F.; Xie Z.; Lin Y.

P1669

**DOES BRIDGE-TO-SURGERY STENT PLACEMENT PROVIDE BETTER ONCOLOGICAL OUTCOMES FOR OBSTRUCTIVE COLORECTAL TUMORS?**

Kunduz E.; Ibrahim Hakki Köker, Turkey; Yigman S.; Basaranoglu M.; Senturk H.

P1670

**ENDOSCOPIC FULL-THICKNESS RESECTION OF NEURO-ENDOCRINE TUMORS IN THE RECTUM – A SUBGROUP ANALYSIS OF THE GERMAN FTRD-REGISTRY**

Benjamin Meier, Germany; Caca K.

P1671

**RED BLOOD CELL DISTRIBUTION WIDTH INDEPENDENTLY PREDICTS SURVIVAL IN R0 RESECTED COLORECTAL CANCER**

Borda A.; Ignacio Fernández-Urién, Spain; Vila J. J.; Albéniz E.; Guerra A.; Zozaya J. M.; Borda F.

P1672

**SURVEILLANCE PROTOCOL FOR ABDOMINAL DESMOID TUMOURS IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP): EXPERIENCE OF A REGIONAL REFERRAL CENTRE**

Lupe Sanchez Mete, Italy; Mannisi E.; Martayan A.; Caterino M.; Ferraresi V.; Stigliano V.

P1673

**HIGH EXPRESSION OF LONG NON-CODING RNA LINK-A ASSOCIATES WITH POOR SURVIVAL IN PATIENTS WITH COLORECTAL CANCER**

Yanting Ye, China; Huang Z.; Gao J.; Zhao C.; Tang C.

P1674

**RISK OF METACHRONOUS ADVANCED NEOPLASIA IN PATIENTS WITH MULTIPLE DIMINUTIVE ADENOMAS**

Jung Yoon Kim, Republic of Korea; Lee S.-G.; Kim T. J.; Kim Y.-H.; Song J. H.; Kim E. R.

- P1675  
**ONCOLOGICAL RECURRENCE OUTCOMES AFTER STENTING AS BRIDGE TO SURGERY COMPARED TO EMERGENCY SURGERY FOR LEFT-SIDED MALIGNANT COLONIC OBSTRUCTION: RETROSPECTIVE BICENTRIC STUDY.**  
Carmen Lara Romero, Spain; Caunedo Alvarez Á.; Hergueta Delgado P.; Lavin Castejon I.; Camargo Camero R.; Romero Castro R.; Alcain Martínez G.
- P1676  
**EARLY- ONSET ENDOMETRIAL CANCER PATIENTS WITH OR WITHOUT FAMILY HISTORY ARE AT HIGH RISK FOR LYNCH SYNDROME**  
Lupe Sanchez Mete, Italy; Vocaturo G.; Martayan A.; Diodoro M.; Casini B.; Mannisi E.; Vizza E.; Stigliano V.
- P1677  
**STENT OR DECOMPRESSING COLOSTOMY AS BRIDGE-TO-SURGERY VERSUS ACUTE RESECTION IN OBSTRUCTED LEFT-SIDED COLON CANCER: A NATIONWIDE ANALYSIS OF 2587 PATIENTS**  
Joyce Valerie Veld, The Netherlands; Amelung F. J.; Van Halsema E. E.; Borstlap W. A. A.; Consten E. C. J.; Siersema P. D.; ter Borg F.; van der Zaag E.; Bemelman W. A.; Fockens P.; Tanis P. J.; van Hooft J. E.
- P1678  
**COLD SNARE PIECEMEAL ENDOSCOPIC MUCOSAL RESECTION (CSP-EMR) OF LARGE SESSILE COLONIC POLYPS  $\geq 20$  MM IS FEASIBLE, SAFE AND EFFECTIVE**  
Mangira D.; Karla Cameron, Australia; (Ja Hyuk) Koo B.; Moss A.
- P1679  
**BUTYRATE AS A RADIOSENSITIZER IN COLORECTAL CANCER PATIENTS DERIVED ORGANOID MODEL**  
Misun Park, Republic of Korea; Kwon J.; Kim Y.; Shin U. S.; Kim S. B.
- P1680  
**THE CHEMOPREVENTIVE EFFECT OF COMBINATION TREATMENT OF ASPIRIN AND METFORMIN FOR COLORECTAL CARCINOGENESIS**  
Takuma Higurashi, Japan; Matsuura T.; Kato S.; Nakajima A.
- P1681  
**COMPREHENSIVE TREATMENT DECISION SUPPORT OF GASTROINTESTINAL CANCERS BY AN ARTIFICIAL INTELLIGENCE-SUPPORTED SOFTWARE (MH GUIDE)**  
Kaduthanam S.; Huelsewig C.; Cubas Cordova M.; Stecker K.; Koch P.; Laib A.; Weber M.; Hettich S.; Stein M.; Brock S.; Matthias Löhr, Sweden
- P1682  
**LABORATORY PREDICTORS OF CLINICAL-PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN RECTAL CANCER**  
Tânia Gago, Portugal; Simão I.; Marreiros A.; Roseira J.; Cunha A. C.; Campelo P.; Caldeira P.; Guerreiro H.
- IBS /Lower GI motility: Brain-gut and gut-brain axes, neuro-hormonal, neural-immune and visceral sensitivity**
- P1683  
**THE RELATION OF SPHINGOLIPID IN THE CHANGE OF INTESTINAL BARRIER AS AGING, PRELIMINARY STUDY**  
Ji Hye Park, Republic of Korea; Kwon Y.-H.; Bae J.-S.
- P1684  
**CORRELATION OF RECTAL MOTILITY AND SENSITIVITY ABNORMALITIES WITH CLINICAL SYMPTOMS AND EMOTIONAL DISORDERS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME**  
Anatoly Ulyanin, Russian Federation; Storonova O.; Ivashkin V.; Poluektova E.; Shifrin O.; Trukhmanov A.
- P1685  
**RECTO-ANAL SENSORIAL AND MOTOR CHARACTERISTICS IN TYPE 2 DIABETICS WITH OR WITHOUT COMPLAINTS OF CONSTIPATION: A COMPARATIVE STUDY.**  
João Xavier Jorge, Portugal; Costa Almeida C.; Fernandes L.; Simões M. A.; Delgado F. J.
- P1686  
**NEURO-GLIAL MODULATION ASSOCIATED WITH PELVIC ORGANS CROSS-SENSITIZATION: EFFECT ON CHRONIC VISCERAL NOCICEPTION**  
Karim Atmani, France; Meleine M.; Illona B.; Guérin C.; Baron M.; Vaudry D.; Do Rego M. J.-C.; Déchelotte P.; Leroi A. M.; Gourcerol G.
- P1687  
**REPEATABILITY OF THE FRUCTOSE BREATH TEST IN FUNCTIONAL GASTROINTESTINAL DISORDERS**  
Clive Wilder-Smith, Switzerland; Olesen S. S.; Materna A.; Drewes A.
- P1688  
**DIETARY FODMAPS SUCH AS FRUCTO-OLIGOSACCHARIDES AND LACTOSE CAN INCREASE ABDOMINAL SENSITIVITY AND THE NUMBER OF MUCOSAL MASTOCYTES IN MICE; A STUDY ON UNDERLYING MECHANISMS.**  
Jasper Bernardus Johannes Kamphuis, France; Guiard B.; Yvon S.; Rivière P.; Tondereau V.; Eutamène H.; Theodorou V.
- IBS/Lower GI motility: Transmitters/signals/receptors/enteric nervous system**
- P1689   
**ADENOSINE A2B RECEPTOR REGULATES COLONIC FLUID SECRETION IN MICE**  
Teita Asano, Japan; Takenaga M.
- P1690  
**HYPERPLASIA OF ENTERIC GLIAL PROCESS TOWARD THE SENSORY NEURON AND INCREASED NETRIN-1 EXPRESSION IN THE COLONIC SUBMUCOSA IN A RAT MODEL OF VISCERAL HYPERSENSITIVITY**  
Fujikawa Yoshiko, Japan; Kazunari T.; Kazuhide H.

P1691

**ANO-RECTAL SENSORIAL AND MOTOR CHARACTERISTICS IN TYPE 2 DIABETICS WITH OR WITHOUT COMPLAINTS OF GASTRO-OESOPHAGEAL REFLUX: A COMPARATIVE STUDY.**

João Xavier Jorge, Portugal; Costa Almeida C.; Panão E. A.; Fernandes L.; Delgado F. J.; Simões M. A.

P1692

**ENHANCED CONNECTIONS OF SUBMUCOSAL GLIA AND NEURONAL OUTGROWTH TOWARD INTO THE MUCOSA IN ACCORDANCE WITH THE AXON GUIDANCE MOLECULES AND NEUROTROPHIC FACTOR MAY LEAD TO VISCERAL HYPERSENSITIVITY AFTER MILD IRRITATION WITH STRESS**

Fujikawa Yoshiko, Japan; Kazunari T.; Kazuhide H.

P1693

**MUCOSAL FEATURES AND MOLECULAR MECHANISMS UNDERLYING CHRONIC CONSTIPATION IN PATIENTS WITH PARKINSON'S DISEASE**

Fiorella Giancola, Italy; Torresan F.; Ioannou A.; Bianco F.; Gori A.; Sternini C.; Stanghellini V.; De Giorgio R.

### Lower GI motility disorders: Clinical

P1694

**A PROSPECTIVE EVALUATION OF GASTROINTESTINAL SYMPTOMS AND DYSMOTILITY IN SUBJECTS WITH AND WITHOUT HYPERMOBILITY SPECTRUM DISORDERS**

Lisa Vork, The Netherlands; Masclee A.; Beckers A.; Conchillo J.; Kruimel J.; Aziz Q.; Keszthelyi D.

P1695

**HISTOPATHOLOGIC SIGNS OF NEURON DEGENERATION IN INDIVIDUALS WITH GASTROINTESTINAL SYMPTOMS MAY BE FOUND IN CONVENTIONAL STAINING IN BOTH SUBMUCOSAL AND MYENTERIC NERVE PLEXA**

Bodil Ohlsson, Sweden; Englund E.

P1696

**MANAGING GASTROINTESTINAL MANIFESTATIONS IN PATIENTS WITH POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME - A UK DISTRICT GENERAL HOSPITAL EXPERIENCE**

Viral Sagar, United Kingdom; Nayagam J.; Asante M.

P1697

**COLONIC-TRANSIT TIME AS PREDICTOR OF OUTCOME OF COLONIC MANOMETRY IN PATIENTS WITH CHRONIC CONSTIPATION**

van Avesaat M.; Lisa Vork, The Netherlands; van Hoboken E.; Rinsma N.; Keszthelyi D.; Masclee A.

P1698

**GUT DYSBIOSIS IS A PROMINENT FEATURE OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION.**

Sacha Sidani, Canada; Giancola F.; De Palma G.; Stanghellini V.; Cogliandro R. F.; Collins S. M.; De Giorgio R.; Bercik P.

P1699

**SYSTEMATIC REVIEW AND META-ANALYSIS: PREVALENCE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN IRRITABLE BOWEL SYNDROME**

Ayesha Shah, Australia; Talley N. J.; Burger D.; Rich J.; Ghasemi P.; Jones M. P.; Kendall B.; Koloski N.; Walker M.; Morrison M.; Holtmann G. J.

P1700

**THE INFLUENCE OF THE DURATION OF THE DIABETES MELLITUS ON THE ANORECTAL FUNCTION.**

Malgorzata Reszczynska, Poland

P1701

**EVALUATION OF ANORECTAL FUNCTION IN DIABETES MELLITUS PATIENTS WITH DIABETES ENTEROPATHY SYMPTOMS.**

Malgorzata Reszczynska, Poland

### Irritable bowel syndrome: Treatment

P1702

**THE EFFECT OF PROBIOTIC ADMINISTRATION IMMEDIATELY AND ONE MONTH AFTER COLONOSCOPY IN DIARRHEA PREDOMINANT IBS PATIENTS**

Khodadoostanshahraki M.; Sara Shavakhi, Iran; Shavakhi A.

P1703

**A SMARTPHONE APPLICATION FOR SYMPTOM ASSESSMENT AND DATA COLLECTION IN MEDICAL TRIALS: EXAMPLE FROM AN IBS DRUG INTERVENTION TRIAL.**

Zsa Zsa Regina Maria Weerts, The Netherlands; Quanjel A. B. A.; Vork L.; Jonkers D. M.; Masclee A.; Keszthelyi D.

P1704

**ADHERENCE TO DIET LOW IN FERMENTABLE CARBOHYDRATES AND TRADITIONAL DIET FOR IRRITABLE BOWEL SYNDROME: WHAT ARE THE CHALLENGES AND OPPORTUNITIES?**

Egbert Clevers, Sweden; Tran M.; Van Oudenhove L.; Törnblom H.; Simrén M.

P1705

**EFFECTS OF ALKALINE-REDUCED DRINKING WATER ON IRRITABLE BOWEL SYNDROME WITH DIARRHEA: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY**

Dong Woo Shin, Republic of Korea; Yoon H.; Choi Y. J.; Shin C.-M.; Park Y. S.; Kim N.; Lee D.-H.

P1706

**FOCUSSED EDUCATION ON IBS IS A HELPFUL INTERVENTION TO REDUCE ANXIETY AND IMPROVE SYMPTOMS**

Valentina Passananti, United Kingdom; Zarate-Lopez N.; Mari A.; Perrin C.; Emmanuel A.

P1707

**INTESTINAL MICROBIOME IN IRRITABLE BOWEL SYNDROME BEFORE AND AFTER GUT-DIRECTED HYPNOTHERAPY**Peter J.; Fournier C.; Durdevic M.; Keip B.; Dejaco C.; Gabriele Moser, Austria**Diverticular disease**

P1708

**COLONIC DIVERTICULA: RISK FACTOR FOR COLORECTAL ADENOMAS?**Verónica Pavão Borges, Portugal; Mendez Santos S.; Vale Rodrigues R.; Capela T.; Silva M. J.; Vasconcelos Loureiro R.; Bernardes C.; Russo P.; Saiote J.

P1709

**ASSOCIATION BETWEEN COLONIC DIVERTICULA AND THE DETECTION OF ADENOMAS AND SERRATED POLYP SUBTYPES DURING SCREENING COLONOSCOPIES OF INDIVIDUALS WITH AN AVERAGE RISK FOR COLORECTAL CANCER.**Christoph Schramm, Germany; Kütting F.; Lang S.; Kasper P.; Chon S.-H.; Steffen H.-M.

P1710

**CHANGES IN ASSOCIATION BETWEEN INHIBITORY MOTOR NEURONS AND CALCITONIN GENE-RELATED PEPTIDE IN COLONIC DIVERTICULOSIS**Jaune Ieva Lukosiene, Lithuania; Pauza A. G.; Rysevaite K.; Kupcinskas J.; Saladzinskas Z.; Tamelis A.; Pauziene N.

P1711

**DIVERTICULAR DISEASE: REAL-LIFE PREVALENCE AND ASSOCIATED RISK FACTORS IN A HIGH-VOLUME ENDOSCOPIC UNIT**Kryssia Rodriguez-Castro, Italy; Baldassarre G.; Ferronato A.; Miraglia C.; Cambiè G.; Violi A.; Cuoco L.; Tursi A.; Cerofolini A.; Di Mario F.; Franceschi M.

P1712

**THE EFFICACY OF LACTOBACILLUS REUTERI 4659 IN REDUCING ABDOMINAL SYMPTOMS AND INFLAMMATORY BIOMARKERS IN ACUTE UNCOMPLICATED DIVERTICULATIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL**Petruzzello C.; Franceschi F.; Covino M.; Migneco A.; Veronica Ojetti, Italy

P1713

**MULTIDIMENSIONAL PROGNOSTIC INDEX PREDICTS MORTALITY IN HOSPITALIZED ELDERLY PATIENTS WITH DIVERTICULAR DISEASE**Nicola Aronico, Italy; Giuffrida P.; Pastorelli L.; Filippi E.; Musacchio C.; Fraternali G.; Bracchitta L. M.; Corazza G. R.; Vecchi M.; Pilotto A.; Di Sabatino A.**Poster Session**

09:00 – 14:00

Hall X1

**Oesophageal, Gastric and Duodenal Disorders III****Cell/molecular biology/pathology**

P1714

**EVALUATING GASTROINTESTINAL MORPHOLOGY AND ENTERIC NERVOUS SYSTEM VIABILITY IN THE DYSTONIA MUSCULORUM MOUSE MODEL OF HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE VI**  
Anisha Lynch-Godrej, Canada; De Repentigny Y.; Yaworski R.; Gagnon S.; Kothary R.P1715 **GASTROINTESTINAL BLEEDING AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION IS ASSOCIATED WITH A SHIFT TOWARD A PRO-ANGIOGENIC PHENOTYPE IN THE ANGIOPOIETIN AXIS**Edwards A.; Wilcox C. M.; Pamboukian S.; Mannon P.; Shajan Peter, United States

P1716

**WHOLE TRANSCRIPTOMIC ANALYSIS IN TURKISH PATIENTS WITH ACHALASIA.**Fatih Eren, Turkey; Celikel C.; Ozer A.; Batirel H.; Giral A.

P1717

**CIRCULAR RNA *009414* /MIR-30C-2-3P AXIS PROMOTES GASTRIC CANCER VIA BCL9/WNT/ $\beta$ -CATENIN SIGNALING PATHWAY**Xuan Li, China; Zhang G.

P1718

**ROLE OF HIGHLY DEREGULATED MICRORNAs IN GASTROINTESTINAL STROMAL TUMORS**Ugne Gyvyte, Lithuania; Juzenas S.; Gudoityte G.; Arstikyte J.; Kupcinskas J.; Skieceviciene J.; Kupcinskas L.

P1719

**GRANULOMATOUS GASTRITIS : CLINICAL AND PATHOLOGICAL FEATURES**Baklouti Raoua, Tunisia; Gueddiche A.; Aisseoui F.; Ben Amor S.; Ben Mansour W.; Bouhlel W.; Loghmeri H.; Safer L.**Immunity and inflammation (not *H. pylori*)**

P1720

**CHARACTERIZATION OF IMMUNE CELLS INFILTRATING THE CORPUS MUCOSA OF THE STOMACH IN AUTOIMMUNE ATROPHIC GASTRITIS**Giuffrida P.; Facciotti F.; Pasini A.; Marco Vincenzo Lenti, Italy; Martino M.; De Grazia F.; Miceli E.; Corazza G. R.; Caprioli F.; Di Sabatino A.

P1721

**EVALUATION OF A NEW ASSAY FOR THE QUANTITATIVE DETERMINATION OF CALPROTECTIN IN HUMAN FECES (CALIAGOLD)**Cesare Paparella, Italy; Barazzutti A.; Vespasiani F.; Longo G.; De Giorgio J.; Lucini R.

P1722

**SUSPICIOUS PATHOGENIC BACTERIA WITH HIGH AFFINITY BINDING WITH IGA IN THE STOMACH**Jinzhe Liu, China; Xue Y.; Zhou L.

P1723

**AUTOIMMUNE GASTRITIS: FREE RADICALS PRODUCTION BUT NOT OXIDATIVE STRESS-RELATED GENOMIC DAMAGE**Gemma Maddalo, Italy; Cardin R.; Favali A.; Orlando C.; Pilotto V.; Rugge M.; Fassan M.; Farinati F.

P1724

**THE IMPORTANCE OF EOSINOPENIA IN PREDICTION OF TREATMENT RESPONSE IN PATIENTS WITH CHOLANGITIS**  
Karacaer C.; Köksal A. S.; toka B.; Ahmet Tarik Eminler, Turkey; tozlu M.; Uslan M. I.**Upper GI and small intestinal bleeding**

P1725

**EFFICACY OF HEMOSPRAV AND ENDOCLOT IN THE TREATMENT OF GASTROINTESTINAL BLEEDING: RESULTS FROM A TERTIARY REFERRAL CENTER**Francesco Vitali, Germany; Naegel A.; Siebler J.; Neurath M.; Rath T.

P1726

**HEMOSPRAV USE IN ACUTE GASTROINTESTINAL BLEEDING- A 4 YEAR SINGLE CENTRE EXPERIENCE**Shivaji U. N.; Farique Leet, United Kingdom; Gupta T.; Harborne M.; Awasthi A.

P1727

**30- DAY MORTALITY OF ADMISSIONS TO INTENSIVE CARE UNIT WITH UPPER GASTROINTESTINAL BLEEDING**Junaïd Beig, New Zealand; Rajakrishnan V.; Stretton M.; Ow M.P1728 **REBLEEDING AND MORTALITY ARE HIGHER IN PATIENTS WITH GASTROINTESTINAL BLEEDING TREATED WITH ANTICOAGULANTS THAN ANTI-PLATELETS**Hosni M.; Rahal M.; Tamim H.; Sharara A.; Soweid A.; Daniel F.; Shaib Y.; Al Hashash J.; Mourad F.; Othman M.; Masri O.; Abou Fadel C.; Wehbe A.; Rckey D.; Kassem Barada, Lebanon

P1729

**ENDOSCOPIC RADIOFREQUENCY ABLATION IS AN EFFECTIVE THERAPY IN PATIENTS WITH SYMPTOMATIC ANAEMIA SECONDARY TO GASTRIC ANTRAL VASCULAR ECTASIA**Cormac Gerard Magee, United Kingdom; Lipman G.; Alzoubaidi D.; Everson M.; Sweis R.; Banks M.; Graham D.; Lovat L. B.; Murray C.; Haidry R. J.

P1730

**MANAGEMENT OF ANTIPLATELET AND ANTICOAGULANT THERAPY IN PATIENTS WITH NONVARICEAL UPPER GASTROINTESTINAL HEMORRHAGE.**Vogt C.; Allo G.; Bürger M.; Kasper P.; Chon S.-H.; Töx U.; Goeser T.; Steffen H.-M.; Christoph Schramm, Germany

P1731

**COFFEE GROUND VOMIT: DOES IT JUSTIFY AN URGENT ENDOSCOPY?**Aria Khani, United Kingdom; Maksunova Y.; Patel M.; Besherdas K.

P1732

**ORAL ANTICOAGULANTS AND UPPER GASTROINTESTINAL BLEEDING: POTENTIAL RISK FACTORS AND OUTCOMES - A SINGLE-CENTRE EXPERIENCE**Zane Straume, Latvia; Proskurina A.; Pokrotnieks J.; Kalejs O.; Lapina A.; Derovs A.

P1733

**GASTROINTESTINAL BLEEDING, A SERIOUS COMPLICATION OF PATIENTS WITH ACUTE CORONARY SYNDROME.**Aida Ben Slama, Tunisia; Ksaa M.; Hamdi S.; Jaziri H.; Aya H.; Elleuch N.; Jmaa A.

P1734

**ENDOSCOPIC APPLICATION OF HIGHLY MUCO-ADHESIVE POWDER (NEXPOWDER) FOR TREATMENT OF DIFFUSE OR REFRACTORY ACTIVE UPPER GASTROINTESTINAL BLEEDING (UGIB): PRELIMINARY RESULTS**

Don Haeng Lee, Republic of Korea; Bang B. W.; Hong S.-J.; Shin Y.-W.; Kim H.-K.; Kwon K. S.

P1735

**AORTO-OESOPHAGEAL FISTULA DETECTED BY UPPER DIGESTIVE ENDOSCOPY - CLINICAL PRESENTATION, ENDOSCOPIC ASPECTS AND PROGNOSIS OF A RARE ENTITY**Ismail M.; Ferreira C. N.; Luis Carrilho Ribeiro, Portugal; Velosa J.; Marinho R. T.

P1736

**EXPERIENCIE WITH N-BUTYL-2 CYANOACRYLATE GASTRIC VARIX INJECTION IN AN UNIVERSITY HOSPITAL OF LA PLATA, ARGENTINA**Leonart J. L.; Villaverde A.; Tufare F.; Martinez H.; Yantorno M.; Garavento L.; Guzman M.; Wallace V.; Chopita N.; Redondo A.; Gustavo Javier Correa, Argentina

P1737

**A RANDOMIZED TRIAL OF MONOPOLAR SOFT-MODE COAGULATION VERSUS HEMOCLIP FOR PEPTIC ULCER BLEEDING**Toka B.; [Ahmet Tarik Eminler](#), Turkey; Karacaer C.; Uslan M. I.; Koksal A. S.; Parlak E.**Upper GI nerve- gut and motility: Transmitters/signals/ receptors/enteric nervous system**

P1738

**SAFETY AND EFFICACY OF NALDEMEDINE IN THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CHRONIC NON-CANCER PAIN IN SUBJECTS WITH OR WITHOUT INADEQUATE RESPONSE TO LAXATIVES**[Jan Tack](#), Belgium; Hale M. E.; Yamada T.; Wild J.

P1739

**RNA SEQUENCING OF DUODENAL MUCOSA SAMPLES BEFORE AND AFTER FECAL MICROBIOTA TRANSPLANTATION DEMONSTRATES TRANSCRIPTOMIC CHANGES IN PATIENTS WITH IRRITABLE BOWEL SYNDROME-DIARRHEA**[Tarek Mazzawi](#), Norway; Eikrem Ø.; El-Salhy M.; Marti H.-P.; Arslan G.; Hausken T.

P1740

**ASSOCIATION BETWEEN INTERSTITIAL CELLS OF CAJAL AND ANTI-VINCULIN ANTIBODY IN HUMAN STOMACH**[Seung-Joo Nam](#), Republic of Korea; Kim J. H.; Lee S. H.; Kim T. S.; Lee M. J.; Park J. M.; Choi D. H.; Kang C. D.; Lee S. J.; Ryu Y.-J.; Park S. C.

P1741

**OVERALL SAFETY AND TOLERABILITY OF RELAMORELIN IN ADULTS WITH DIABETIC GASTROPARESIS: ANALYSIS OF PHASE 2A AND PHASE 2B TRIAL DATA**Camilleri M.; Lembo A. J.; McCallum R.; Tourkodimitris S.; Kemps L.; Miller M.; Bertelsen K.; Iacob A.; [Dominic Lawrance](#), United Kingdom

P1742

**COLD SENSATIONS AND HEARTBURN EVOKED BY ESOPHAGEAL INFUSION OF L-MENTHOL INDICATE EXPRESSION OF THE TRPM8 RECEPTOR IN ESOPHAGEAL C-FIBERS IN HUMANS.**[Peter Banovcin](#), Slovakia; Duricek M.; Liptak P.; Hyrdel R.; Kollarik M.**Upper GI motility disorders: Clinical**

P1743

**NEWLY DEVELOPED WIRELESS GASTROSTIMULATOR FOR MINIMALLY INVASIVE GASTRIC STIMULATION: A VIVO PILOT STUDY**[Eun-Sun Kim](#), Republic of Korea; Jang S.; Han Jo J.; Choi S. J.; Lee J. M.; Kim S. H.; Choi H.-S.; Keum B.; Jeon Y.-T.; Lee H.; Chun H. J.; Kim C. D.

P1744

**ESOPHAGO-GASTRIC JUNCTION OUTFLOW OBSTRUCTION: OUTCOMES OF 45 PATIENTS FROM A TERTIARY REFERRAL CENTRE**Mari A.; [Kalp Patel](#), United Kingdom; Martin H.; Raeburn A.; Sweis R.P1745 **ESOPHAGEAL APERISTALSIS IS UNDER INVESTIGATED IN THOSE WITHOUT ACHALASIA OR REFLUX**[Pierfrancesco Visaggi](#), Italy; Ibraheim H.; Wong T.; Dunn J.; Jafari J.; Zeki S.P1746 **RELATIONSHIP BETWEEN ESOPHAGEAL MOTILITY ABNORMALITIES AND SKIN INVOLVEMENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS: MULTIVARIATE ANALYSIS**[Shiko Kuribayashi](#), Japan; Motegi S.-I.; Hosaka H.; Sekiguchi A.; Hara K.; Shimoyama Y.; Kawamura O.; Kusano M.; Uraoka T.

P1747

**PER ORAL ENDOSCOPIC MYOTOMY IN ESOPHAGEAL MOTILITY DISORDERS: OUTCOMES IN OVER 700 PATIENTS**[Zaheer Nabi](#), India; Ramchandani M.; Chavan R.; Kalapala R.; Reddy D. N.

P1748

**ABNORMAL DISTENSIBILITY ON ESOPHAGEAL ENDOLUMINAL FUNCTIONAL LUMEN IMAGING PROBE (ENDO-FLIP) IDENTIFIES ESOPHAGEAL OUTFLOW OBSTRUCTION AND DIRECTS MANAGEMENT WHEN INTEGRATED RELAXATION PRESSURE (IRP) ON HIGH RESOLUTION MANOMETRY (HRM) IS NORMAL OR BORDERLINE**[Arvind Rengarajan](#), United States; Nix B.; Carlson D.; Gyawali C. P.

P1749

**FOOD RHEOLOGY AND NUTRITIONAL ASSESSMENT OF DIET IN ACHALASIC PATIENTS: AN OBSERVATIONAL STUDY**[Emanuela Ribichini](#), Italy; Cesarini A.; Rossi S.; Sacchi M. C.; Badiali D.

P1750

**PYLORIC DISTENSIBILITY MEASUREMENT PREDICTS SYMPTOMATIC RESPONSE TO INTRA-PYLORIC TOXIN BOTULINUM INJECTION**[Charlotte Desprez](#), France; Melchior C.; Leroi A. M.; Jacques J.; Gourcerol G.P1751 **PYLORIC DISTENSIBILITY MEASUREMENT AFTER GASTRIC SURGERY: WHICH SURGERY IS ASSOCIATED WITH PYLOROSPASM?**[Guillaume Gourcerol](#), France; Melchior C.; Philouze G.; Desprez C.; Zalar A.; Jacques J.; Leroi A. M.

**Functional upper GI disorders: Clinical**

P1752

**BENEFIT OF SMALL DOSE ANTIDEPRESSANTS FOR FUNCTIONAL DYSPEPSIA: EXPERIENCE FROM EASTERN CHINA**Du L.; Dai N.; Shen J.; [Luyi Chen](#), China

P1753

**INVESTIGATION OF AUTOIMMUNE GASTRITIS DIAGNOSED BY ENDOSCOPIC FINDINGS**[Maiko Kishino](#), Japan; Nakamura S.; Tokushige K.

P1754

**COMPARATIVE STUDY BETWEEN ROME 4 AND IV DIAGNOSTIC CRITERIA AMONG COLLEGE STUDENTS' FUNCTIONAL GASTROINTESTINAL DISORDERS EPIDEMIOLOGICAL INVESTIGATION IN CHINA**[Kejia Zhao](#), China; Li M.; Lu B.

P1755

**NORMAL MEAN NOCTURNAL BASELINE IMPEDANCE (MNBI) MAY DEFINE FUNCTIONAL HEARTBURN BETTER THAN ACID BASED METRICS ON PH-IMPEDANCE MONITORING**[Arvind Rengarajan](#), United States; Pomerat M.; Zerbib F.; Gyawali C. P.

P1756

**IMPROVEMENT OF MEAL-RELATED SYMPTOMS AND EPIGASTRIC PAIN IN PATIENTS WITH FUNCTIONAL DYSPEPSIA TREATED WITH ACOTIAMIDE WAS ASSOCIATED WITH ACYLATED GHRELIN LEVELS IN JAPAN**[Eriko Koizumi](#), Japan; Yamawaki H.; Agawa S.; Higuchi K.; Ikeda G.; Noda H.; Kodaka Y.; Ueki N.; Futagami S.; Iwakiri K.

P1757

**ASSESSMENT OF THIOL/DISULPHIDE HOMEOSTASIS IN PATIENTS WITH AUTOIMMUNE GASTRITIS**Kalkan Ç.; [Fatih Karakaya](#), Turkey; Boz S.; Nseselioglu S.; Erel Ö.; Kalkan E.; Soykan I.

P1758

**GASTRIC PH IN VIVO INFLUENCES LEVOTHYROXINE SODIUM TABLET REQUIREMENT IN HYPOTHYROID PATIENTS**[Giovanni Bruno](#), Italy; Virili C.; Porowska B.; Valvano M.; Zaccari P.; De Vito C.; Centanni M.; Severi C.

P1759

**QUANTITATIVE PCR AS A NOVEL APPROACH TO DETERMINE INFLUENCE OF DENSITY OF BACTERIAL COLONISATION ON HEALTH AND DISEASE**[Ayesha Shah](#), Australia; Shanahan E.; Berendsen E.; Macdonald G.; Rich J.; Ghasemi P.; Hansen T.; Koloski N.; Burger D.; Keely S.; Walker M.; Talley N.J.; Morrison M.; Holtmann G. J.

P1760

**STW 5 IS EFFECTIVE IN 10 FUNCTIONAL DYSPEPSIA SYMPTOMS**[Sabine Rabini](#), Germany; Wargenau M.; Stanghellini V.**Eosinophilic oesophagitis**

P1761

**ROUTINE OESOPHAGEAL BIOPSIES IN THE INVESTIGATION OF DYSPHAGIA: ARE THEY COST EFFECTIVE?**[Moeed Hassan Minto](#), United Kingdom; Neal D.

P1762

**VARIATION IN THE INVESTIGATION AND DIAGNOSIS OF EOSINOPHILIC OESOPHAGITIS IN DAILY CLINICAL PRACTICE**[Andreas V Hadjinicolaou](#), United Kingdom; Beg S.; Tun G. S. Z.; Warburton L.; Sansone S.; Riley S.; Ragnunath K.; Modolell I.

P1763

**BRAVO WIRELESS PH MONITORING CAN SAVE TIME WHEN INVESTIGATING PATIENTS WITH EOSINOPHILIC OESOPHAGITIS.**[Iona M Bell](#), United Kingdom; Zeki S. S.

P1764

**ESOPHAGEAL COMPLIANCE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS MEASURED BY ENDOFLIP BEFORE AND AFTER TREATMENT WITH TOPICAL BUDESONIDE.**[Sergio Casabona-Francis](#), Spain; Pérez-Fernández M. T.; Pérez-Romero M.; Sanz-García A.; Ortega-Rabbione G. J.; Fernández-Pacheco J.; Majano P. L.; Santander C.

P1765

**UNRESPONSIVE DYSPHAGIA TO PROTON PUMP INHIBITORS IN EOSINOPHILIC ESOPHAGITIS PATIENTS SUGGESTS TO START STEROID THERAPY WITHOUT THE NEED OF PERFORMING A SECOND UPPER ENDOSCOPY**[Marco Della Coletta](#), Italy; Frazzoni M.; Frazzoni L.; Ghisa M.; Marabotto E.; De Bortoli N.; Tolone S.; Furnari M.; Savarino V.; Savarino E.

P1766

**POOR CORRELATION BETWEEN ENDOSCOPIC FINDINGS, EOSINOPHILIC INFILTRATION AND REFLUX BURDEN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS**[Marco Della Coletta](#), Italy; Frazzoni M.; Frazzoni L.; Ghisa M.; Tolone S.; De Bortoli N.; Marabotto E.; Furnari M.; Savarino V.; Savarino E.**Reflux disease, epidemiology**

P1767

**COMPREHENSIVE ANALYSIS OF FACTORS DETERMINANT FOR EROSIVE REFLUX ESOPHAGITIS: SIGNIFICANCE OF DEMOGRAPHIC/LIFESTYLE FACTORS IS EMPHASIZED IN HELICOBACTER PYLORI-NONINFECTED SUBJECTS**[Hideaki Taniguchi](#), Japan; Iwasaki Y.; Aimi M.; Okada H.



- P1768  
**GASTRIC BYPASS SURGERY IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE: A POPULATION-BASED COHORT STUDY**  
Dag Holmberg, Sweden; Santoni G.; Xie S.; Lagergren J.
- P1769  
**WAIST CIRCUMFERENCES IS THE INDEPENDENT RISK FACTOR OF EROSIIVE ESOPHAGITIS : SINGLE-CENTER STUDY ON KOREAN NATIONAL CANCER SCREENING PROGRAM**  
YongKang Lee, Republic of Korea; Cho Y. S.; Hong J. H.; Shin S. Y.; Seo J. H.; Choi J.
- P1770  
**ALCOHOL CONSUMPTION AND THE RISK OF GASTRO-ESOPHAGEAL REFLUX DISEASE: A META-ANALYSIS**  
Jiaqi Pan, China; Cen L.; Chen W.; Yu C.; Li Y.; Shen Z.
- P1771  
**SMOKING AND ALCOHOL ARE ASSOCIATED WITH OESOPHAGEAL HYPOSENSITIVITY**  
Christian Lottrup, Denmark; Krarup A. L.; Ejstrup P.; McMahon B. P.; Drewes A. M.
- P1772  
**ASTHMA UNDER CONTROL IS INVERSELY RELATED WITH EROSIIVE ESOPHAGITIS AMONG HEALTHY ADULTS**  
Joo Hyun Lim, Republic of Korea; Lee D.-H.; Lee S. H.; Kim J. S.; Jung H. C.
- P1773  
**CLINICAL CHARACTERISTICS OF GASTROESOPHAGEAL REFLUX DISEASE IN SUBJECTS WITH SLEEP-DISORDERED BREATHING**  
Jung-Hwan Oh, Republic of Korea; Cho M.-J.
- P1774  
**MONITORING RISK FACTORS FOR THE ONSET OF ESOPHAGITIS IN A LONG 15 YEARS FOLLOW-UP**  
Di Mario F.; Serena Scida, Italy; Franceschi M.; Miraglia C.; Rodriguez-Castro K.; Franzoni L.; Crafa P.; Cannizzaro R.; Nouvenne A.; Tursi A.; Brandimarte G.; Rugge M.; Scarpignato C.
- Reflux disease, diagnosis**
- P1775  
**LARYNGEAL MUCOSAL IMPEDANCE VALUES; A NEW DIAGNOSTIC TOOL FOR LARYNGOPHARYNGEAL REFLUX DISEASE**  
Sezgin B.; Akyildiz S.; Serhat Bor, Turkey
- P1776  
**ON-THERAPY PARAMETERS RATHER THAN OFF-THERAPY IMPEDANCE-PH FEATURES BETTER IDENTIFY PATIENTS WITH NON-EROSIVE REFLUX DISEASE RESPONDING TO PROTON PUMP INHIBITOR THERAPY**  
Frazzoni M.; Frazzoni L.; Della Coletta M.; De Bortoli N.; Tolone S.; Savarino V.; Edoardo Savarino, Italy
- P1777  
**MULTICHANNEL IMPEDANCE MONITORING FOR DISTINGUISHING NON-EROSIVE OESOPHAGITIS WITH MINOR CHANGES ON ENDOSCOPY**  
Junko Fujino, Japan; Omari T.; Moore D.; Abu-Assi R.; Hammond P.; Couper R.
- P1778  
**THE CONSISTENCY OF LOS ANGELES CLASSIFICATION OF GASTROESOPHAGEAL REFLUX DISEASE ACCORDING TO THE INSERTION/WITHDRAWAL PHASES OF ESOPHAGO-GASTRODUODENOSCOPY**  
Seung-Joo Nam, Republic of Korea; Lee S. J.; Kang C. D.; Park S. C.; Park J. M.; Lee S. H.
- P1779  
**SYMPTOMS AND CLINICAL PRESENTATION ARE NOT PREDICTIVE OF ESOPHAGEAL REFLUX BURDEN IN OBESE PATIENTS EVALUATED FOR BARIATRIC SURGERY**  
Paul Hobbs, United States; Bennett M.; Gyawali C. P.
- P1780  
**HIGH PREVALENCE OF GERD IN PATIENS SYMPTOMATIC ON PPI: RESULTS OF THE BRAZILIAN LOST PATIENT (LOPA) STUDY**  
Caroline Tatim Saad, Brazil; Labenz J.; Attwood S.
- P1781  
**GERD PATIENTS ACROSS CULTURES HAVE SIMILAR CONCERNS: A COMPARISON OF „LOST“ GERD PATIENTS IN GERMANY AND BRAZIL**  
Caroline Tatim Saad, Brazil; Labenz J.
- Reflux disease, treatment**
- P1782  
**ENDOSCOPIC TRANSORAL FUNDOPLICATION WITH MUSE FOR GASTROESOPHAGEAL REFLUX DISEASE: RESULTS OF A SINGLE CENTER STUDY**  
Francesca D'Aversa, Italy; Familiari P.; Landi R.; Mangiola F.; Boskoski I.; Bove V.; Tringali A.; Perri V.; Attili F.; Gasbarrini A.; Costamagna G.
- P1783  
**ALGINATE AS ADD-ON FOR GORD WITH INSUFFICIENT PPI EFFECT: THE LOPA III TRIAL**  
Müller M.; Labenz G.; Borkenstein D.; Joachim Labenz, Germany
- P1784  
**EFFECTS OF DEXRABEPRAZOLE ON INTRAGASTRIC AND INTRAESOPHAGEAL ACIDITY IN GASTROESOPHAGEAL REFLUX DISEASE**  
Serhat Bor, Turkey; Bektas M.
- P1785  
**PROSPECTIVE, RANDOMIZED EX VIVO TRIAL TO ASSESS THE ANTI-REFLUX EFFECT OF ANTI-REFLUX MUCOSECTOMY IN PORCINE MODEL.**  
Xuan Li, China; Zhang G.

P1786

**ACUTE ADMINISTRATION OF FRUCTANS INCREASES THE NUMBER OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS IN HEALTH**

Hannelore Geysen, Belgium; Gielis E.; Deloose E.; Vanuytsel T.; Tack J.; Biesiekierski J. R.; Pauwels A.

**Oesophageal neoplasia: Clinical**

P1787

**RISK FACTORS FOR PATHOLOGICAL UPGRADING OF ESOPHAGEAL LOW-GRADE INTRAEPITHELIAL NEOPLASIA DIAGNOSED WITH ENDOSCOPIC FORCEPS BIOPSY**

Chen Yao, China; Wang Y.; Yang J.

P1788 **PLANNED SEMI-CIRCULAR ENDOSCOPIC SUBMUCOSAL DISSECTION FOR WIDESPREAD SUPERFICIAL ESOPHAGEAL CANCER**

Kazuya Yamaguchi, Japan; Kawada K.; Nakajima Y.; Tokairin Y.; Hoshino A.; Okada T.; Ryotokuji T.; Kume Y.; Ito T.

P1789

**THE MID-TERM OUTCOMES OF ENDOSCOPIC TREATMENT FOR SUPERFICIAL CERVICAL ESOPHAGEAL CANCER.**

Kenro Kawada, Japan; Nakajima Y.; Tokairin Y.; Hoshino A.; Okada T.; Ryotokuji T.; Kume Y.; Mora A.; Yamaguchi K.; Ito T.

P1790

**SURVIVAL RATES FOR PATIENTS WITH BARRETT'S HIGH-GRADE DYSPLASIA AND OESOPHAGEAL ADENOCARCINOMA WITH OR WITHOUT HUMAN PAPILLOMAVIRUS**

Shanmugarajah Rajendra, Australia; Xuan W.; Merrett N.; Sharma P.; Sharma P.; Pavey D.; Yang T.; D Santos L.; Sharaiha O.; Pande G.; Cosman P.; Wu X.; Wang B.

P1791

**THE MODIFIED GLASGOW PROGNOSTIC SCORE (MGPS) HAVE A PROGNOSTIC ROLE IN ESOPHAGEAL CANCER. (COMPARISON WITH PLASMA FIBRINOGEN AND SERUM ALBUMIN LEVELS (FA SCORE) AND NEUTROPHIL TO LYMPHOCYTE RATIO (NLR))**

Toshiki Yamashita, Japan

P1792

**OUTCOMES OF ESOPHAGECTOMY FOR PATIENTS AFTER NON-CURATIVE ENDOSCOPIC RESECTION OF EARLY ESOPHAGEAL CANCER**

Solène Dermine, France; Leconte M.; Leblanc S.; Douset B.; Berger A.; Rahmi G.; Pioche M.; Canard J.-M.; Lepilliez V.; Coriat R.; Stanislas C.; Prat F.; Barret M.

P1793

**ACCURACY OF ENDOSCOPIC TUMOR DEPTH PREDICTION IN SUPERFICIAL ESOPHAGEAL SQUAMOUS CARCINOMA**

Ji Young Choi, Republic of Korea; Jung H.-Y.; Ahn J. Y.; Bae S.-E.

P1794

**ARTIFICIAL INTELLIGENCE FOR AUTOMATED DETECTION OF EARLY OESOPHAGEAL SQUAMOUS CELL NEOPLASIA THROUGH CLASSIFICATION OF INTRAPAPILLARY CAPILLARY LOOPS**

Martin Everson, United Kingdom; Garcia Peraza Herrera L. C.; Li W. Q.; Muntion Luengo I.; Magee C.; Alzoubaidi D.; Ahmad O.; Graham D.; Banks M.; Vercauteren T.; Ourselin S.; Lovat L. B.; Wang H. P.; Wang W.-L.; Haidry R. J.

**Gastroduodenal neoplasia: Clinical**

P1795

**CHARACTERISTICS OF SYNCHRONOUS LESIONS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF GASTRIC EPITHELIAL NEOPLASIA**

Cheol Woong Choi, Republic of Korea; Kang D.-H.; Kim H. W.; Park S. B.; Kim S.-J.; Nam H. S.; Ryu D. G.; Lee K. H.; Lee J. W.; Lee J. P.

P1796

**TYPE AND TUMOR SIZE AFFECT CLINICAL OUTCOME IN GASTRIC NEUROENDOCRINE NEOPLASMS: A MULTI-CENTRE RETROSPECTIVE STUDY**

Maria Rinzivillo, Italy; Campana D.; Massironi S.; Faggiano A.; Lahner E.; Lamberti G.; Manuzzi L.; Zilli A.; Rossi R. E.; Guadagno E.; Pillozzi E.; Modica R.; Annibale B.; Panzuto F.

P1797

**CLINICAL OUTCOMES OF CASES DIAGNOSED AS NON-CURATIVE ENDOSCOPIC RESECTION OF EARLY GASTRIC CANCER AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION**

Nobue Ueki, Japan; Akimoto T.; Kirita K.; Koizumi E.; Agawa S.; Ikeda G.; Noda H.; Higuchi K.; Yamawaki H.; Kodaka Y.; Kawagoe T.; Futagami S.; Iwakiri K.

P1798

**WITHDRAWN**

P1799

**DECREASE OF SIGNET RING CELL GASTRIC CANCER IN JAPAN: A SINGLE INSTITUTE EXPERIENCE**

Dai Yoshimura, Japan; Ashizawa H.; Nakagomi K.; Takaoka S.; Hosoda K.; Suzuki Y.; Kojima Y.; Mochizuki H.; Omata M.

P1800

**DIAGNOSIS OF EARLY GASTRIC CANCER: A 17 YEARS SURVEY BASED ON SURGICAL SPECIMEN IN PARMA AREA**

Pellegrino Crafa, Italy; Cavatorta O.; Barchi A.; Capasso M.; Caruana P.; Mancini C.; Dell'Abate P.; Del Rio P.; Franzoni L.; Nouvenne A.; Franceschi M.; Miraglia C.; Cannizzaro R.; Cavestro G. M.; Ruggie M.; Di Mario F.

- P1801**  
**EFFECTIVE DIAGNOSTIC STRATEGY FOR GASTROINTESTINAL MALT LYMPHOMA FOCUSING ON TREE-LIKE APPEARANCE**  
Yuji Owaki, Japan; Inatomi O.; Mizuno R.; Murata M.; Otsuka T.; Sugimoto M.; Andoh A.
- P1802**  
**ENDOSCOPIC MANAGEMENT OF EARLY FOREGUT NEUROENDOCRINE TUMORS**  
Amol Bapaye, India; Korrapati S. K.; Nemade P.; Mahadik M.; Pujari R.; Bapaye J. A.; Date S.; Gadhikar H.
- P1803**   
**ENDOSCOPIC AND HISTOPATHOLOGICAL FINDINGS OF PATIENTS WITH GASTROINTESTINAL TRACT 18-FDG ACCUMULATION OF INCIDENTALLY FOUND ON PET/CT**  
Fatih Karakaya, Turkey; Soydal Ç.; Kartal A. Ç.; Karakaya M.; Kalkan Ç.; Soykan I.
- P1804**  
**PREVALENCE AND PROGNOSIS OF MISMATCH REPAIR DEFICIENCY IN OESOGASTRIC ADENOCARCINOMA**  
My Linh Tran Minh, France; Gardair C.; Lehmann-Che J.; Lambert J.; Mary F.; Goujon G.; Poté N.; Schischmanoff O.; Kaci R.; Theou-Anton N.; Cucherousset N.; Bertheau P.; Couvelard A.; Aparicio T.
- P1805**  
**ACCURACY OF A SERUM BIOMARKER TEST (GASTROPANEL®) FOR THE DIAGNOSIS OF MODERATE TO SEVERE ATROPHIC GASTRITIS IN PATIENTS WITH UNINVESTIGATED DYSPEPSIA**  
Fernando Macías García, Spain; Pérez-Suárez L.; Leal-López S.; Pérez-Becerra E.; Abdulkader-Nallib I.; Sipponen P.; Dominguez-Munoz J. E.
- P1806**  
**USEFULNESS OF UNDERWATER EMR FOR NON-AMPULLARY DUODENAL TUMOR**  
Akiko Takahashi, Japan; Oyama T.
- P1807**  
**OUTCOME OF ESD FOR ESOPHAGO-GASTRIC JUNCTIONAL ADENOCARCINOMA**  
Akiko Takahashi, Japan; Oyama T.
- P1808**  
**COMPARISON BETWEEN REDO ENDOSCOPIC TREATMENT AND SURGERY IN PATIENTS WITH RECURRENT GASTRIC NEOPLASMS**  
Sung Hyun Won, Republic of Korea; Kim D.; Gong E. J.; Choi K. D.; Song H.-J.; Lee G.-H.
- P1809**  
**EVALUATION OF GASTRIC POLYPS DETECTED BY ENDOSCOPY: WHAT IS THE CLINICAL SIGNIFICANCE?**  
Mónica Garrido, Portugal; Marcos-Pinto R.; Araújo T.; Pedroto I.
- P1810**  
**IMPACT OF PRE-NEOPLASTIC LESIONS AND TUMORS OF GI TRACT IN AFRICAN POPULATION IN PARMA AREA BASED ON PATHOLOGY RECORDS: RELATIONSHIP WITH RISK FACTORS AND HELICOBACTER PYLORI STATUS**  
Njike Yowoum J. P.; Crafa P.; Mario Capasso, Italy; Barchi A.; Masciangelo G.; Caruana P.; Mancini C.; Franzoni L.; Nouvenne A.; Miraglia C.; Cavatorta O.; Di Mario F.
- P1811**  
**ACCURACY OF LINEAR-ARRAY EUS FOR PREOPERATIVE STAGING OF GASTRIC CANCER.**  
Vincenzo Giorgio Mirante, Italy; De Nucci G.; Gabbani T.; Soriani P.; Deiana S.; Manes G.; Vecchi M.; Manno M.
- Gastroduodenal neoplasia: Basic**
- P1812**  
**CORRESPONDENCE BETWEEN GASTRIC FUNCTION MARKERS AND SEVERITY OF HISTOLOGICALLY ASSESSED GASTRIC INJURY: A PROSPECTIVE STUDY IN 144 CONSECUTIVE PATIENTS**  
 Di Mario F.; Silvia Speroni, Italy; Franceschi M.; Baldassarre G.; Antico A.; Panozzo M. P.; Rodriguez-Castro K.; Tursi A.; Brandimarte G.; Franzoni L.; Crafa P.; Miraglia C.; Nouvenne A.; Rugge M.
- P1813**  
**HYPERTHERMIA REGULATES BOTH SLC22A16 EXPRESSION AND ABCG2 EXPRESSION VIA ROS PRODUCTION TO ENHANCE THE CYTOTOXICITY OF DOXORUBICIN.**  
Hirofumi Matsui, Japan; Kurokawa H.
- P1814**  
**HOXB9 FUNCTIONS AS A POTENTIAL ONCOGENE AND IS NEGATIVELY REGULATED BY MIR-28-5P IN GASTRIC CARCINOGENESIS**  
 Kang W.; Zhou J.; Jinglin Zhang, Hong Kong PRC; Huang T.; Wong C. C.; Yu J.; Cheng A. S. L.; To K. F.
- P1815**  
**FUSOBACTERIUM NUCLEATUM IS FREQUENTLY DETECTED IN GASTRIC MUCOSA AND IS ASSOCIATED WITH WORSE PROGNOSIS IN DIFFUSE-TYPE GASTRIC CANCER PATIENTS**  
 Boehm E.; Langner C.; Kupcinskas J.; Steponaitiene R.; Urba M.; Skieceviciene J.; Canbay A.; Malfertheiner P.; Alexander Link, Germany
- P1816**  
**GASTRIC CANCER IN YOUNG ADULT: IT'S TIME TO SOUND THE ALARM!**  
Samira Miry, Morocco; Lahmidani N.; Abid H.; Aqodad N.; El Yousfi M.; Benajah D.; El Abkari M.; Ibrahimi A.

## Poster Session

09:00 – 14:00

Hall XI

*H. Pylori* III

## Pathogenesis: Microbial factors

P1817

**EVALUATION OF EPIYA PATTERN IN HELICOBACTER PYLORI CAGA AND ITS POSSIBLE RELATION WITH PEPTIC ULCER DISEASE AND GASTRIC CANCER IN EGYPTIAN PATIENTS.**

Fouad R.; Fathalah W.; Ghaith D.; Seif Elnasr M.; Walied El Hossary, Egypt

P1818

**PRIMARY RESISTANCE OF *H. PYLORI* TO ANTIMICROBIALS AGENTS IN A NORTHERN ITALIAN REGION: RESULTS FROM A PROSPECTIVE 5-YEARS STUDY**

Gatta L.; Scarpignato C.; Giulia Fiorini, Italy; Belsey J.; Maria Saracino I.; Ricci C.; Vaira B.

P1819 

**PAN-EUROPEAN REGISTRY ON *H. PYLORI* MANAGEMENT (HP-EUREG): BACTERIAL RESISTANCE OF 2,684 *H. PYLORI* ISOLATES**

Adrian Gerald McNicholl, Spain; Perez Nyssen O.; Bordin D.; Tepes B.; Perez-Aisa A.; Vaira D.; Caldas Álvarez M.; Bujanda Fernández de Piérola L.; Castro-Fernandez M.; Lerang F.; Leja M.; Rodrigo L.; Rokkas T.; Kupcinskas L.; Perez-Lasala J.; Jonaitis L.; Shvets O.; Gasbarrini A.; Simsek H.; Axon A.; Buzás G. M.; Machado J. C. L.; Niv Y.; Boyanova L.; Goldis A.; Lamy V.; Katicic M.; Przytulski K.; Beglinger C.; Venerito M.; Bytzer P.; Capelle L.; Milosavljevic T.; Veijola L.; Molina Infante J.; Vologzhanina L.; Fadeenko G.; Ariño I.; Fiorini G.; Ramas M.; G. Donday M.; Megraud F.; O'Morain C.; Perez Gisbert J.

P1820

**HELICOBACTER PYLORI HTRA IS NOT ASSOCIATED WITH CLINICOPATHOLOGICAL GASTRITIS PHENOTYPE OR VACA VIRULENCE FACTOR POLYMORPHISMS**

Alexander Link, Germany; Langner C.; Tammer I.; Haybaeck J.; Canbay A.; Malferteiner P.

## Treatment

P1821

**A QUICK FLOW CYTOMETRY PROTOCOL TO ASSESS HELICOBACTER PYLORI VIABILITY AND DENSITY.**

Alba C.; Alicia C. Marin, Spain; McNicholl A. G.; Montalban-Arques A.; García-Fresnadillo D.; Gisbert J. P.; Alarcón T.; Bernardo D.

P1822

**EFFICACY OF PYLERA VERSUS STANDARD THERAPY WITH ESOPEPRAZOLE AS THE FIRST LINE OF TREATMENT IN THE ERADICATION OF HELICOBACTER PYLORI. REAL LIFE STUDY.**

Alexander Flores Cucho, Spain; Valladolid Leon J. M.; Torrico Laguna A. M.; Rebollo J. M.; Blasco M.; Saenz-Dana M.; Pichiule M.; Quezada Pacheco R. H.; Caunedo-Álvarez A.

P1823

**SHORT-TERM AND LONG-TERM CHANGES OF GUT MICROBIOTA AND METABOLIC PARAMETERS AFTER HELICOBACTER PYLORI ERADICATION**

Jyh-Ming Liou, Taiwan; Chen C.-C.; Fang Y.-J.; Lin J.-T.; El-Omar E.; Wu M.-S.

P1824

**EFFECTIVENESS OF PYLERA AS FIRST LINE ERADICATION THERAPY FOR *H. PYLORI* INFECTIONS**

Teresa Romero García, Spain; Keco A.; Aviles M.; Llorca Fernández R.; Marques A.; Camara S.; Pabon M.; Lamas rojas E.; Rojas-Feria M.; Grande L.; Castro M.

P1825

**EFFICACY OF ORAL N-ACETYL CYSTEINE ON HELICOBACTER PYLORI ERADICATION IN ADDITION TO QUADRUPLE THERAPY REGIMEN**

Afshin Shafaghi, Iran; Mansour-Ghaneaee F.; Joukar F.; Manafi Afkham S.

P1826

**EFFECTS OF PROBIOTICS OR BROCCOLI SUPPLEMENTATION ON HELICOBACTER PYLORI ERADICATION WITH STANDARD CLARITHROMYCIN-BASED TRIPLE THERAPY**

Chang Y.-W.; Seong Kon Lee, Republic of Korea

P1827

**PYLERA AND SEQUENTIAL THERAPY FOR FIRST-LINE *H. PYLORI* ERADICATION: A CULTURE-BASED HEAD TO HEAD COMPARISON IN CLINICAL PRACTICE.**

Giulia Fiorini, Italy; Zullo A.; Saracino I. M.; Gatta L.; Pavoni M.; Dino V.

P1828

**FATE OF BENEFICIAL GUT MICROBIOTA AFTER *H. PYLORI* ERADICATION THERAPY: METAGENOMIC LANDSCAPE OF RESISTANCE MECHANISMS.**

Dilyara Khusnutdinova, Russian Federation; Malanin S.; Grigoryeva T.; Abdulkhakov S.; Vasilyev I.; Markelova M.; Boulygina E.; Siniagina M.; Abdulkhakov R.; Chernov V.; Chernova O.

P1829

**IS THE INTERVAL BETWEEN THE FIRST AND THE SECOND H.P. ERADICATION THERAPY RELEVANT FOR THE SUCCESS OF THE CURE? A COMPARISON BETWEEN ONE WEEK, ONE MONTH AND ONE YEAR.**

Di Mario F.; [Serena Scida](#), Italy; Tursi A.; Brandimarte G.; Franceschi M.; Crafa P.; Franzoni L.; Miraglia C.; Cavestro G. M.; Cannizzaro R.; Nouvenne A.; Scarpignato C.

P1830

**10-DAY VERSUS 14-DAY QUADRUPLE CONCOMITANT NON BISMUTH THERAPY FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION: RESULTS FROM A GREEK RANDOMIZED PROSPECTIVE STUDY.**

Apostolopoulos P.; Ekmektzoglou K.; [Erasmia Vlachou](#), Greece; Chounta E.; Dimopoulos K.; Theofanopoulos A.; Toumpelis K.; Kalantzis C.; Tsibouris P.; Alexandrakis G.

P1831

**EFFICACY AND SAFETY OF QUADRUPLE THERAPIES WITH AND WITHOUT BISMUTH IN THE ERADICATION OF HELICOBACTER PYLORI INFECTION. REAL LIFE STUDY**

[Roberto Henry Quezada Pacheco](#), Spain; Castillo Herrera L. A.; Flores Cucho A.; Adan Alonso M.; Gancedo Bringas P.; Delgado Galán M.

### ***H. pylori*-associated malignancy**

P1832

**PREDICTIVE FACTORS FOR REGRESSION OF LOW-GRADE GASTRIC MALT LYMPHOMA AFTER ANTI-HELICOBACTER PYLORI TREATMENT**

[Aya Hammami](#), Tunisia; Ben Slama A.; Hassine A.; Elleuch N.; Jaziri H.; Ajmi S.; Brahem A.; Ksaa M.; Jmaa A.

P1833 

**HELICOBACTER PYLORI CAGA PROMOTES EPITHELIAL MESENCHYMAL TRANSITION IN GASTRIC CARCINOGENESIS VIA TRIGGERING ONCOGENIC YAP PATHWAY**

[Nianshuang Li](#), China; Lu N.; Ge Z.; Fox J. G.; Feng Y.; Hu Y.; He C.; Xie C.; Ouyang Y.; Luo Z.

P1834 

**INTERACTION OF *H. PYLORI* WITH TOLL-LIKE RECEPTOR 2 -196 TO -174DEL POLYMORPHISM, IS ASSOCIATED WITH GASTRIC CANCER SUSCEPTIBILITY BUT NOT POOR PROGNOSIS IN CHINESE PATIENTS**

[Xiaoyong Wang](#), China; Wu J.

P1835

**A MULTI-INSTITUTIONAL PROSPECTIVE, OBSERVATIONAL STUDY ON THE RISK FACTORS FOR GASTRIC CANCER AFTER SUCCESSFUL H.PYLORI ERADICATION**

[Shun Takayama](#), Japan; Handa O.; Mukai R.; Majima A.; Inoue K.; Dohi O.; Yoshida N.; Kamada K.; Katada K.; Uchiyama K.; Ishikawa T.; Takagi T.; Konishi H.; Naito Y.; Ito Y.

P1836

**THE MANAGEMENT OF GASTRIC MALT LYMPHOMA**

Park B. S.; [Si-Hyung Lee](#), Republic of Korea; Cho J. H.; Kim S. B.; Kim K. O.; Kim K. H.; Jang B. I.; Kim T. N.

P1837

**INHIBITION OF MIR-20B REDUCES CELL VIABILITY AND COLONY FORMATION IN GASTRIC CANCER BY TARGETING PHOSPHATASE AND TENSIN HOMOLOG (PTEN) AND THIOREDOXIN-INTERACTING PROTEIN (TXNIP) GENES**

[Greta Streleckiene](#), Lithuania; Kupcinskas J.; Juzenas S.; Salteniene V.; Skieceviciene J.; Kiudelis G.; Jonaitis L.; Arstikyte J.; Leja M.; Langner C.; Franke S.; Malfetheriner P.; Link A.; Kupcinskas L.

P1838 

**HELICOBACTER PYLORI INFECTION AND THE INTERLEUKIN 8 -251 T&G;A POLYMORPHISM MIGHT BE A RISK FACTOR OF GASTRIC CANCER**

[Young-Woon Chang](#), Republic of Korea; Lee S. K.

P1839

**DETECTION OF LESIONS IN HELICOBACTER PYLORI GAS-TRITIS BEFORE AND AFTER ERADICATION BY EXPERT ENDOSCOPISTS**

[Alba Panarese](#), Italy; Shahini E.; Pesce F.; Giorgio P.; Caruso M. L.

### Poster Session

09:00 - 14:00

Hall X1

### Small Intestinal III

### **Coeliac disease (adult)**

P1840

**THE ROLE OF CAPSULE ENTEROSCOPY IN COELIAC DISEASE: RESULTS OF A PROSPECTIVE STUDY IN A TERTIARY REFERRAL CENTER**

[Francesca Ferretti](#), Italy; Orlando S.; Roncoroni L.; Vecchi M.; Elli L.

P1841

**METABOLIC ALTERATIONS IN CELIAC DISEASE OCCURRING AFTER GLUTEN-FREE DIET**

[Antonio Ciccone](#), Italy; Gabrieli D.; Cardinale R.; Di Ruscio M.; Vernia F.; Stefanelli G.; Necozone S.; Melideo D.; Frieri G.; Latella G.

P1842

**HISTOLOGIC RESPONSE TO BUDESONIDE IN PATIENTS WITH REFRACTORY CELIAC DISEASE TYPE 1 AND 2**

[Sherine Khater](#), France; Malamut G.; Cerf-Bensussan N.; Bruneau J.; Trinquand A.; Macintyre E.; Cellier C.

P1843

**CLADRIBINE THERAPY IN REFRACTORY CELIAC DISEASE TYPE II: A SINGLE CENTER EXPERIENCE**

Stefania Orlando, Italy; Gregorini A.I.; Ferla V.; Rossi F. G.; Pompa A.; Guidotti F.; Goldaniga M. C.; Valli V.; Cortelezzi A.; Ferretti F.; Vecchi M.; Baldini L.; Elli L.

P1844

**PERIPHERAL MONOCYTES IMPAIR THE BARRIER FUNCTION OF INTESTINAL EPITHELIAL CELLS: NEW INSIGHTS ON THE PATHOGENESIS OF CELIAC DISEASE.**

Deborah Delbue, Germany; Itzlinger A.; Jessen B.; Heldt C.; Branchi F.; Lissner D.; Schumann M.

P1845

**GENE EXPRESSION SIGNATURES DIFFERENTIATE NON-CELIAC GLUTEN SENSITIVITY FROM CELIAC DISEASE PATIENTS AND CONTROLS AND MAY POTENTIALLY CONTRIBUTE TO DISEASE DIAGNOSIS**

Konstantinos Efthymakis, Italy; Clemente E.; Sallèse M.; Neri M.

P1846

**CIRCULATING MICROVESICLE PATTERNS ARE DIFFERENT BETWEEN NON CELIAC GLUTEN SENSITIVITY PATIENTS AND HEALTHY CONTROLS**

Konstantinos Efthymakis, Italy; Bologna G.; Lanuti P.; Pipino C.; Milano A.; Laterza F.; Simeone P.; Bonitatibus A.; Insolita E.; Pandolfi A.; Marchisio M.; Miscia S.; Neri M.

P1847

**TOTAL ANNEXIN V+ CIRCULATING MICROVESICLES DIFFERENTIATE NON CELIAC GLUTEN SENSITIVITY FROM CELIAC DISEASE PATIENTS AND HEALTHY CONTROLS**

Konstantinos Efthymakis, Italy; Bologna G.; Lanuti P.; Pipino C.; Milano A.; Laterza F.; Simeone P.; Bonitatibus A.; Insolita E.; Pandolfi A.; Marchisio M.; Miscia S.; Neri M.

P1848

**DISTINCT MUCOSAL AND BLOOD MIRNA EXPRESSION PATTERNS MAY REPRESENT A RELIABLE MARKER FOR POSITIVE DISEASE DIAGNOSIS IN NON CELIAC GLUTEN SENSITIVITY**

Konstantinos Efthymakis, Italy; Clemente E.; Sallèse M.; Neri M.

P1849

**EFFECTS OF WATER LOAD TEST ON GASTRIC MOTILITY AND AUTONOMIC SYSTEM ACTIVITY IN PATIENTS WITH CELIAC DISEASE**

Furgala A.; Przybylska-Felus M.; Ciesielczyk K.; Gil K.; Mach T.; Małgorzata Zwolińska-Wcisło, Poland

P1850

**NON-CLASSICAL CLINICAL PRESENTATION OF CELIAC DISEASE IS MORE PREVALENT IN THE 21ST CENTURY: A SINGLE CENTER EXPERIENCE**

Judit Bajor, Hungary; Szakács Z.; Farkas N.; Hegyi P.; Vince A.

**Malabsorption syndromes and food enteropathies (adult)**

P1851

**DIFFERENCES IN SYMPTOMS AND GAS PRODUCTION FOLLOWING FRUCTOSE AND LACTOSE INGESTION IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS**

Clive Wilder-Smith, Switzerland; Olesen S. S.; Materna A.; Drewes A.

P1852

**NON-CELIAC GLUTEN SENSITIVITY DIAGNOSIS: COMPARISON BETWEEN IN-VIVO CHALLENGE ACCORDING TO "SALERNO EXPERTS' CRITERIA" AND GLUTEN ORAL MUCOSA PATCH TEST.**

Puce F.; Borghini R.; Marino M.; Casale R.; Donato G.; Rosato E.; Antonio Picarelli, Italy

P1853

**CLINICAL BENEFIT OF THE USE OF THE GAXILOSE TEST FOR HYPOLACTASIA DIAGNOSIS: A NON-INFERIORITY RANDOMIZED CONTROLLED CLINICAL TRIAL**

Monsalve-Hernando C.; Crespo L.; Ferreiro B.; Martín V.; Aldeguer X.; Opio V.; Fernández-Gil P. L.; Gaspar M. J.; Carmen Hermida, Spain

P1854

**SYSTEMATIC REVIEW WITH META-ANALYSIS: THE PREVALENCE OF BILE ACID MALABSORPTION AND THE RESPONSE TO CHOLESTYRAMINE IN PATIENTS WITH CHRONIC WATERY DIARRHOEA AND PRIOR CHOLECYSTECTOMY**

Laura Ruiz Campos, Spain; Fernández-Bañares F.

**Small intestinal bleeding**

P1855

**DIAGNOSTIC YIELD OF ENDOSCOPY IN CF-LVAD PATIENTS WITH GASTROINTESTINAL BLEEDING**

Asad Ali, United States; Tran H.; Rizvi O.; Adhaduk M.; Assouline Dayan Y.

P1856

**SMALL BOWEL GASTROINTESTINAL BLEEDING – CAN WE BLAME ANTICOAGULANTS?**

Stefania Chetcuti Zammit, United Kingdom; Mcalindon M.; Sidhu R.

P1857

**RHEMITT SCORE: THE BEGINNING OF A NEW ERA IN THE PREDICTION OF REBLEEDING!**

Rui Magalhães, Portugal; Cúrdia Gonçalves T.; Rosa B.; Moreira M. J.; Pinto B.; Cotter J.



P1858 **IMPACT OF THE TIMING OF CAPSULE ENDOSCOPY IN OVERT OBSCURE GASTROINTESTINAL BLEEDING ON YIELD AND REBLEEDING RATE - IS SOONER THAN 14 D ADVISABLE?**Ribeiro Gomes A. C.; Pinho R. T.; Rodrigues J.; Sousa M.; [João Carlos Silva](#), Portugal; Carvalho J.

P1859

**CYANOACRYLATE INJECTION THERAPY OF SMALL BOWEL VARICES (SBV) DURING DOUBLE-BALLOON ENTEROSCOPY (DBE): EXPERIENCE FROM TWO EUROPEAN CENTRES**Murino A.; May A.; [Nikolaos Lazaridis](#), United Kingdom; Koukias N.; Vlachou E.; Planche K.; Patch D.; Hayashi Y.; Despott E. J.

P1860

**IMPACT ON LONG-TERM SURVIVAL OF A POSITIVE VIDEO CAPSULE ENDOSCOPY AFTER A FIRST EPISODE OF OVERT OBSCURE GASTROINTESTINAL BLEEDING**[Rui Morais](#), Portugal; Andrade P.; Dias E.; Marques M.; Silva M.; Cardoso H.; Macedo G.

P1861

**IMPACT OF SMALL BOWEL BLEEDING PRESENTATION ON DIAGNOSTIC AND THERAPEUTIC PERFORMANCE OF BALLOON ASSISTED ENTEROSCOPY: A TERTIARY REFERRAL CENTER STUDY IN LATIN AMERICA**[Adriana Costa-Genzini](#), Brazil; Sulbaran M.; Yamashita E. T.; Kuboki Y. M.; Bergonso J. H.; Maia Minini D.; Cipriano Marchezini K.; Sousa Ferreira H.; Muniz Kawano R.; Kenro Takahashi W.; Nascimento M. H. A.

P1862

**TREATMENT OF CHRONIC STENOSING ENTERITIS: A CONDITION SIMILAR TO PROSTAGLANDIN-ASSOCIATED ENTEROPATHY**[May Min](#), United States; Hyatt B.; Marya N.; Cave D.**Vascular disorders**

P1863

**THE UTILITY OF CAPSULE ENDOSCOPY AND ENTEROSCOPY IN PATIENTS WITH HEREDITARY HAEMORRHAGIC TELANGIECTASIA.**[Stefania Chetcuti Zammit](#), United Kingdom; Sanders D. S.; Mcalindon M.; Sidhu R.**Poster Session**

09:00 – 14:00

Nutrition III

Hall X1

**Nutrients and gut function**

P1864

**WITHIN- AND BETWEEN SUBJECT VARIATION IN INTAKE OF FERMENTABLE OLIGO-, DI-, MONOSACCHARIDES AND POLYOLS (FODMAPS) AMONG PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)**Nybacka S.; [Stine Störsrud](#), Taiwan; Liljebo T.; Törnblom H.; Simrén M.; Winkvist A.

P1865

**INTAKE OF FERMENTABLE OLIGO-, DI-, MONOSACCHARIDES AND POLYOLS (FODMAPS) IN RELATION TO SYMPTOM SEVERITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)**Nybacka S.; [Stine Störsrud](#), Taiwan; Liljebo T.; Törnblom H.; Simrén M.; Winkvist A.P1866 **ASSESSING THE EFFECTS OF TWO PROBIOTIC FORMULATIONS ON CACO-2 CELL EPITHELIUM BARRIER MODEL**[Paola Palumbo](#), Italy; Lombardi F.; Cinque B.; Giuseppe S.; Kapaj A.; Cifone M. G.

P1867

**THE COMBINATION OF PEPPERMINT OIL AND CARAWAY OIL DOES NOT AFFECT GASTRIC FUNCTION, BUT INCREASES HUNGER RATINGS AND DECREASES SATIATION IN HEALTHY SUBJECTS.**[Imke Masuy](#), Belgium; Tackoen J.; Deloose E.; Van Oudenhove L.; Tack J.

P1868

**DIETARY FODMAPS CAN LEAD TO MICROBIAL PRODUCTION OF GLYCATION AGENTS, INCREASING MUCOSAL MASTOCYTES AND IMPACTING COLONIC MUCUS BARRIER FUNCTION.**[Jasper Bernardus Johannes Kamphuis](#), France; Yvon S.; Tondereau V.; Eutamène H.; Theodorou V.

P1869

**THERAPEUTIC RELEVANCE OF BODY MASS INDEX (BMI) CONTROL IN A POPULATION AFFECTED BY IRRITABLE BOWEL SYNDROME/BLADDER PAIN SYNDROME (IBS/BPS)**[Fabiana Lopalco](#), Italy; Milani A.; Cervigni M.; Gasbarrini A.; Gaetani E.**Enteral and parenteral nutrition**

P1870

**NO EVIDENCE FOR INCREASED RISK FOR CANDIDAEMIA IN THE PRESENCE OF POLYMORPHISMS IN THE CD58, LCE4A-CLORF68 AND TAGAP LOCI IN HOME PARENTERAL NUTRITION PATIENTS**[Yannick Wouters](#), The Netherlands; Roelofs H.; Wanten G.

P1871

**EFFICACY OF FORMULA DIETS IN PROMOTING WOUND HEALING AT THE SITE OF INTESTINAL ANASTOMOSIS**

Masayasu Aikawa, Japan; Watanabe Y.; Takase K.; Okada K.; Okamoto K.; Sato H.; Sakuramoto S.; Yamaguchi S.; Koyama I.

P1872

**EFFECT OF A POLYMERIC FEED RICH IN TGF- $\beta$  ON PATIENTS WITH IBD**

Afafe Taiymi, Morocco; Khannoussi W.; El-Mekkaoui A.; Ismaili Z.; Kharrasse G.

P1873

**AGE, ALBUMIN AND C-REACTIVE PROTEIN ARE USEFUL PREDICTORS OF 30-DAY MORTALITY IN PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBE INSERTION**

Carl Lane, United Kingdom; Corp A.; Subramanian V.; Rafferty H.

P1874

**WITHDRAWN**

P1875

**EXCLUSIVE ENTERAL NUTRITION IN ADULTS WITH ACTIVE CROHN'S DISEASE IS ASSOCIATED WITH DECREASED DISEASE ACTIVITY**

Tamar Pfeffer Gik, Israel; Yanai H.; Godny L.; Ron Y.; Maharshak N.; Dotan I.

P1876

**OUTCOMES FOLLOWING PERCUTANEOUS ENDOSCOPIC GASTROSTOMY INSERTION IN PATIENTS WITH LEARNING DISABILITY**

Harvey P.; Tom Thomas, United Kingdom; Chandan J.; Bhala N.; Nirantharakumar K.; Trudgill N.

P1877

**LOW CIRCULATING LEVELS OF CITRULLINE AND FGF19 PREDICT CHRONIC CHOLESTASIS AND POOR SURVIVAL IN ADULT PATIENTS WITH CHRONIC INTESTINAL FAILURE: DEVELOPMENT OF A MODEL FOR END-STAGE INTESTINAL FAILURE (MESIF RISK SCORE)**

Koelfat K.; Angelique Huijbers, The Netherlands; Schaap F.; van Kuijk S.; Winkens B.; Lenicek M.; Wanten G. J. A.; Olde Damink S.

**Poster Session**

09:00 - 14:00

Hall X2/X1

**Clinical Cases III****Liver/Biliary/Pancreas**

CC106

**GINSENG RELATED DRUG -INDUCED LIVER INJURY (DILI)**

Kyawzaw Lin, United States; Lin A. N.; Lin S.; Yoe L.; Reddy M.

CC107

**FATAL IRON TOXICITY FROM NON-ACCIDENTAL FERROUS SULPHATE INGESTION IN A YOUNG FEMALE**

Greco Mark Malijan, Philippines

CC108

**SUCCESSFUL TREATMENT OF COMBINED AUTOIMMUNE HEPATITIS AND CROHN'S COLITIS USING INFlixIMAB CONCOMITANT WITH MYCOPHENOLAT-MOFETIL (MMF): A CASE REPORT**

Karima Farrag, Germany; Teuber G.; Blumenstein I.; Stein J.

CC109

**NODULAR REGENERATIVE HYPERPLASIA INDUCED BY OXALIPLATIN-BASED CHEMOTHERAPY - CASE REPORT.**

Miguel Saraiva, Portugal; Dias E.; Cardoso H.; Macedo J.

CC110

**PORTAL HYPERTENSION RELATED TO RENDU-OSLER-WEBER DISEASE**

Marta Patita, Portugal; Nunes G.; Ramalho M.; Fonseca A. G.; Fonseca C.

CC111

**IDIOPATHIC PORTAL HYPERTENSION - A MISDIAGNOSED CONDITION**

Daniela Reis, Portugal; Cortez-Pinto J.; Verdelho Machado M.; Carvalhana S.; Noronha Ferreira C.; Freitas C.; Baldaia C.; Valente A.; Lackner K.; Cortez-Pinto H.

CC112

**A RARE CAUSE OF OBSTRUCTIVE JAUNDICE**

Ioan Cristian Nedelcu, Romania; Enache I. C.; Ilie M.; Ragea A. I.; Oprisanescu D.; Constantinescu G.

CC113

**A PATIENT WITH METACHRONOUS INVASIVE CARCINOMA OF THE PANCREATIC DUCT WITH A PREDOMINANTLY INTRADUCTAL GROWTH PATTERN**

Yoshihiro Hamada, Japan; Kato D.

CC114

**DIAGNOSTIC DIFFICULTIES IN DIFFERENTIATING BETWEEN RETROPERITONEAL NEUROENDOCRINE TUMOUR AND PARAGANGLIOMA - A CASE REPORT.**

Nina Blazevic, Croatia; Lonjak N.; Budimir I.; Zivkovic M.; Babic N.; Zovak M.; Pavic I.

CC115

**A CASE OF METASTATIC NET ASSOCIATED TO BILIARY AUTOIMMUNE DISEASE: IGG4-RELATED CHOLANGITIS CAN MIMIC MALIGNANT BILIARY STENOSIS**

Daniilo Pagliari, Italy; Rizzatti G.; Dal Lago A.; Brizi M. G.; Manfredi R.; Vellone M.; Schinzari G.; Rufini V.; Zocco M. A.; Perri V.; Attili F.; Costamagna G.; Gasbarrini A.; Giuliani F.





- CC116**  
**PANCREATIC ATYPICAL NEUROENDOCRINE TUMOUR AS A MIMICKER OF A PSEUDO-PAPILLARY SOLID NEOPLASIA**  
 Vítor Magno Pereira, Portugal; Moutinho Ribeiro P.; Vilas Boas F.; Morais R.; Gaspar R.; Lopes J.; Macedo G.
- Surgery/Endoscopy/Imaging**
- CC117**  
**BILHARZIAL POLYP MIMICKING CANCER COLON**  
 Albateo H.; Emara Elzanan M. H.; Mariam Salah Zaghloul, Egypt; Ahmed M. H.; Radwan M.; Seif A.; Elmoghazi M.; Elkashef W.
- CC118**  
**THERAPEUTIC COLONOSCOPIC RETROGRADE INSTILLATION OF GASTROGRAFFIN IN DISTAL INTESTINAL OBSTRUCTION SYNDROME IN CYSTIC FIBROSIS**  
Hein Myat Thu Htet, United Kingdom; Cheent K.; Highton A.
- CC119**  
**A MYTH IN COLONOSCOPY: CUSHION SIGN OR PILLOW SIGN**  
Kyawzaw Lin, United States; Lin A. N.; Hlaing P. P.; Linn S.; Reddy M.
- CC120**  
**ENDOSCOPIC TRANSECECAL APPENDECTOMY: A NOVEL OPTION FOR THE TREATMENT OF APPENDICEAL POLYPS**  
Bingrong Liu, China; Ye L.; Liu D.; Zhao L.; Kong L.; Mao X.; Huang Q.
- CC121**  
**A CASE OF GIANT PEDUNCULATED LEIOMYOMA OF THE SIGMOID COLON COME OUT FROM ANAL VERGE.**  
Takuji Yamasaki, Japan; Kamioka H.; Noguchi M.; Saruta M.; Sumiyama K.
- CC122**  
**SIGMOID PERFORATION CAUSED BY A MIGRATED PLASTIC BILIARY STENT**  
Pedro Marcos, Portugal; Martins C.; Eliseu L.; Capelão G.; Clara P.; Gonçalves C.; Vasconcelos H.
- CC123**  
**MULTIPLE FULL THICKNESS RESECTION IN COLONIC LESION TO AVOID SURGERY**  
Andrea Magarotto, Italy; Delconte G.; Masci E.
- CC124**  
**GIANT INFLAMMATORY FIBROID POLYP (VANEK'S TUMOR) OF THE TERMINAL ILEUM CAUSING ILEOCOLIC INTUSSUSCEPTION: AN ENDOSCOPIC FINDING**  
Joana Carvão, Portugal; Magno Pereira V.; Oliveira A.; Sousa Andrade C.; Ladeira N.; Cunha M. F.; Jasmins L.
- CC125**  
**ILEOCOLIC INTUSSUSCEPTION – MANIFESTATION OF INTESTINAL MANTLE CELL LYMPHOMA**  
Filipe de Sousa Damião, Portugal; Ismail M.; Noronha Ferreira C.; Xavier Brito L.; Carrilho Ribeiro L.; Tato Marinho R.; Velosa J.
- CC126**  
**MINIPROBE ENDOSCOPIC ULTRASONOGRAPHY IN THE DIAGNOSIS OF COLON HEMANGIOLYMPHANGIOMA**  
Sonia Bernardo, Portugal; Lima O.; Santos M.; Castro-Poças F.
- CC127**  
**PRIMARY EXTRA-RENAL PAPILLARY RENAL CELL CARCINOMA: AN UNIQUE DIAGNOSIS PERFORMED THROUGH ENDOSCOPIC ULTRASOUND.**  
Gonçalo Nunes, Portugal; Pinto Marques P.; Luz C.; Mendonça E.; Brito M. J.; Mansinho H.
- CC128**  
**A "DONUT" IN THE RECTUM - WHEN IT IS WHAT IT SEEMS!**  
Carolina Simões, Portugal; Carvalhana S.; Xavier Brito L.; Carrilho Ribeiro L.; Marinho R. T.
- CC129**  
**WHEN YOU LEAST EXPECT IT: A VERY RARE NEEDLE RUPTURE DURING A FINE NEEDLE BIOPSY.**  
Roberto Di Mitri, Italy; Magro B.; Mocciaro F.; Conte E.; Bonaccorso A.
- CC130**  
**A RARE ETIOLOGY OF BILIARY TRACT OBSTRUCTION**  
Vítor Magno Pereira, Portugal; Moutinho Ribeiro P.; Morais R.; Vilas Boas F.; Macedo G.
- CC131**  
**GASTRIC FUNDUS SPLENOSIS PRESENTING AS A STROMAL TUMOR AND DIAGNOSED BY ENDOSCOPIC ULTRASOUND-GUIDED SHARKCORE BIOPSY**  
Ilenia Barbuscio, Italy; Fantin A.; Savarino E. V.; Ghisa M.; Mescoli C.; Farinati F.
- CC132**  
**A TRICKY CASE OF PANCREATIC ARTERIOVENOUS MALFORMATION: THE ROLE OF ENDOSCOPIC ULTRASOUND IN THE DIAGNOSIS OF THIS RARE CONDITION**  
Ilenia Barbuscio, Italy; Fantin A.; Moletta L.; Ghisa M.; Sperti C.; Farinati F.
- CC133**  
**UPPER GASTROINTESTINAL TRACT SCHWANNOMAS- REPORT OF THREE CASES.**  
Kamran Mushtaq, Qatar; Sharma M.; ElBadri M.; Al Kaabi S.; Ahmad A.
- CC134**  
**THE REASONABLE SURGICAL TECHNIQUE FOR PREVENTION OF GASTRIC VOLVULUS COMPLICATED WITH PARAESOPHAGEAL HERNIA**  
Jiro Kimura, Japan; Mizokami K.; Kanzaki M.; Kubota T.
- Lower GI**
- CC135**  
**MESALAZINE-INDUCED MYOCARDITIS**  
Vaidotas Urbonas, Lithuania; Kilaite L.; Sudikiene R.

CC136

**RITUXIMAB TO THE RESCUE: A DIFFICULT CASE OF CHRONIC GASTROINTESTINAL BLEEDING DUE TO ANGIODYSPLASIA AND ACQUIRED VON WILLEBRAND SYNDROME (AVWS)**

James Hawken, United Kingdom; Knott A.; Clark A.; Fayyaz F.

CC137

**A RARE PRESENTATION OF BREAST CANCER**

Luísa Martins Figueiredo, Portugal; Horta D.; Martins A.; Reis J.

CC138

**PRIMARY LEIOMYOSARCOMA OF THE COLON**

Katarzyna Neubauer, Poland; Halon A.; Kempinski R.

### Upper GI

CC139

**A RARE CAUSE OF UPPER GI BLEEDING.**

Manuel Rocha, Portugal; Santos S.; Simões G.; Borges V.; Gamelas V.; Esteves J.; Coimbra J.

CC140

**"RECURRENT GASTROINTESTINAL BLEEDING OF UNKNOWN SOURCE IN AN 87 YEAR OLD: AN ATYPICAL CASE OF BLUE RUBBER BLEB NEVUS SYNDROME"**

Tom Thomas, United Kingdom; Bhalal N.; Iqbal T.; Boulton R.

CC141

**RECURRENT ULCER BLEED IN A PATIENT WITH HENOCCH-SCHONLEIN PURPURA (HSP) AND CYTOMEGALOVIRUS (CMV) INFECTION**

Jonathan Kuang, Sri Lanka; Yang J.

CC142

**BLUE RUBBER BLEB NEVUS SYNDROME: A RARE CASE OF CUTANEOUS LESIONS WITH MELENA AND ANEMIA IN A 16-YEAR OLD FEMALE**

Angelique Elga Lo, Philippines; Basco M.; Dizon M. C. A.

CC143

**HEMOSUCCUS PANCREATICUS**

Pedro Marcos, Portugal; Martins C.; Fernandes A.; Caldeira A.; Gil I.; Lopes B.; Amado C.; Pardal V.; Eliseu L.; Vasconcelos H.

CC144

**ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION AFTER BARIATRIC SURGERY: 2 CASES REPORT.**

Mariana Figueiredo Ferreira, Belgium; Braun E.; Van Gossum M.; Eisendrath P.

CC145

**EOSINOPHILLIA, DIARRHEA AND NEUROPATHY STRANGE TRIAD**

Eshak N.; Mohamed Hussein, Egypt; Elbanna A.; Abdelbary A.

CC146

**BEHCET VERSUS CROHN - A DIAGNOSTIC CHALLENGE**

Carolina Simões, Portugal; Gonçalves A. R.; Correia L.; Marinho R. T.

CC147

**MALPOSITION OF A NASOGASTRIC FEEDING TUBE**

Flávio Pereira, Portugal; Azevedo R.; Linhares M.; Pinto J.; Ribeiro H.; Tristan J.; Banhudo A.



## ESGE Learning Area

For all delegates of UEG Week whose focus is on endoscopy the ESGE Learning Area is without a doubt the first and best place to meet and mingle. Again this year, accomplished doctors and nurses will volunteer their time and expertise to support the ESGE mission: To promote good endoscopy, to show the basics as well as the latest developments, to support training and to offer small-group teaching activities to everyone with a real interest in the how and why of current endoscopy. The ESGE Learning Area provides a unique and ideal platform for live encounter and interaction among aspiring endoscopists and renowned experts in the field.

**Please come and be a part of it!**

For more programme details please see the UEG Week App.



## ESGE Learning Area

### Level 1

Saturday, October 20, 2018

	Hands-on Training Centre (L2)	E-Learning Stations (L3)
09:00		09:00 – 18:00 E-learning - Part I
10:00		- ESGE Days 2018: Live Demo - ESGE Days 2018: Scientific Programme Highlights - Endoscopic Ultrasonography Unit 1: The basics - Colonoscopy Unit 3: Polypectomy - Upper GI Unit 3: Variceal bleeding
11:00		- Colonoscopy Unit 1: The basics - POEM (Per-oral endoscopic myotomy) for esophageal achalasia (JGES)
12:00		- Magnifying endoscopic diagnosis of superficial Barrett's esophagus-related neoplasm (JGES) - Polyposis Syndrome / Genetic GI: Endoscopic Diagnosis and Management (ASGE)
13:00		- Troubleshooting Commonly Encountered Problems with Endoscope (ASGE)
14:00	14:00 – 15:30 ESGENA Workshop 4 - Upper GI Bleeding - ERCP - Colonoscopy	
15:00	ESGE Hands-on Training - Session 1 - Hemostasis/Upper GI Bleeding - EMR - Colonoscopy/Polypectomy - ERCP	
16:00	16:00 – 17:30 ESGENA Workshop 8 - Upper GI Bleeding - ERCP - Colonoscopy	
17:00	ESGE Hands-on Training - Session 2 - Hemostasis/Upper GI Bleeding - EMR - Colonoscopy/Polypectomy - ERCP	

Coffee Breaks: 10:30 – 11:00 and 15:30 – 16:00 | Lunch Break: 13:00 – 14:00

## Sunday, October 21, 2018

	Hands-on Training Centre (L2)	E-Learning Stations (L3)	ESGE Lecture Theatre (L3)
09:00		09:00 – 18:00 <b>E-learning - Part II</b> – ESGE Days 2018: Live Demo – ESGE Days 2018: Scientific Programme Highlights	
10:00		– Endoscopic Ultrasonography Unit 1: The basics – Colonoscopy Unit 3: Polypectomy – Upper GI Unit 3: Variceal bleeding – Colonoscopy Unit 1: The basics – POEM (Per-oral endoscopic myotomy) for esophageal achalasia (JGES)	10:30 – 11:00 <b>Endoscopy for GERD: what is there now and what is coming?</b> <i>Darina Kohoutová, Czech Republic</i> <i>Helmut Messmann, Germany</i>
11:00	11:00 – 12:30 <b>ESGENA Workshop 9</b> – Upper GI Bleeding – ERCP	– Magnifying endoscopic diagnosis of superficial Barrett's esophagus-related neoplasm (JGES) – Polyposis Syndrome / Genetic GI: Endoscopic Diagnosis and Management (ASGE) – Troubleshooting Commonly Encountered Problems with Endoscope (ASGE)	
12:00	<b>ESGE Hands-on Training - Session 3</b> – Hemostasis/Upper GI Bleeding – EMR – Colonoscopy/Polypectomy – ERCP		12:30 – 13:00 <b>Early colorectal neoplasia: when do I really need ESD?</b> <i>Michal Kaminski, Poland</i> <i>Michael Bourke, Australia</i>
13:00			
14:00	14:00 – 15:30 <b>ESGENA Workshop 10</b> – Colonoscopy		
15:00	<b>ESGE Hands-on Training - Session 4</b> – Hemostasis/Upper GI Bleeding – EMR – Colonoscopy/Polypectomy – ERCP		15:15 – 15:45 <b>EUS guided therapy of pancreatic lesions: a toy or a future?</b> <i>Istvan Hritz, Hungary</i> <i>Pierre Deprez, Belgium</i>
16:00	16:00 – 17:30 <b>ESGE Hands-on Training - Session 5</b> – Hemostasis/Upper GI Bleeding – EMR – Colonoscopy/Polypectomy – ERCP		
17:00			

Coffee Breaks: 10:30 – 11:00 and 15:30 – 16:00 | Lunch Break: 13:00 – 14:00

## Monday, October 22, 2018

	Hands-on Training Centre (L2)	E-Learning Stations (L3)	Open Simulator Training Area (L3)	ESGE Lecture Theatre (L3)
09:00		09:00 – 18:00 <b>E-learning – Part III</b> – ESGE Days 2018: Live Demo	09:00 – 18:00 <b>GI Endoscopy Simulator training – Part I</b>	
10:00	10:30 – 11:00 <b>ESGE Hands-on Training – Session 6</b> – EUS – FNA – Hemostasis/Upper GI Bleeding	– Endoscopic Ultrasonography Unit 1: The basics – Colonoscopy Unit 3: Polypectomy – Upper GI Unit 3: Variceal bleeding		10:30 – 11:00 <b>How do I find early cancer in the stomach?</b> <i>Miguel Areia, Portugal</i> <i>Krish Ragunath, United Kingdom</i>
11:00	– ERCP – Pediatric endoscopy - bleeding	– Colonoscopy Unit 1: The basics – POEM (Per-oral endoscopic myotomy) for esophageal achalasia (JGES)		11:30 – 12:00 <b>POEM and reflux: what to do?</b> <i>Mohan Ramchandani, India</i> <i>Marcel Tantau, Romania</i>
12:00		– Magnifying endoscopic diagnosis of superficial Barrett's esophagus-related neoplasm (JGES)		
13:00	12:30 – 14:00 <b>ESGE Hands-on Training – Session 7</b> – EUS – FNA – Hemostasis/Upper GI Bleeding	– Polyposis Syndrome / Genetic GI: Endoscopic Diagnosis and Management (ASGE) – Troubleshooting Commonly Encountered Problems with Endoscope (ASGE)		
14:00	– ERCP – Pediatric endoscopy - PEG			14:00 – 14:30 <b>Full thickness resection: how, when and to whom?</b> <i>Přemysl Falt, Czech Republic</i> <i>Alexander Meining, Germany</i>
15:00	14:30 – 16:00 <b>ESGE Hands-on Training – Session 8</b> – FNA – Colonoscopy/Polypectomy – EMR – Pediatric endoscopy - dilation			15:30 – 16:00 <b>Endoscopy in coeliac disease</b> <i>Alberto Murino, Italy</i> <i>Edward Despott, United Kingdom</i>
16:00				16:30 – 17:00 <b>Pancreatic cysts: which guideline do I choose?</b> <i>Tomas Hucil, Czech Republic</i> <i>Peter Vilmann, Denmark</i>
17:00				

Coffee Breaks: 10:00 – 10:30 and 15:30 – 15:45 | Lunch Break: 12:00 – 14:00

## Tuesday, October 23, 2018

	Hands-on Training Centre (L2)	E-Learning Stations (L3)	Open Simulator Training Area (L3)	ESGE Lecture Theatre (L3)
09:00		09:00 – 18:00 E-learning - Part IV – ESGE Days 2018: Live Demo – ESGE Days 2018: Scientific Programme Highlights – Endoscopic Ultrasonography Unit 1: The basics – Colonoscopy Unit 3: Polypectomy – Upper GI Unit 3: Variceal bleeding – Colonoscopy Unit 1: The basics	09:00 – 18:00 GI Endoscopy Simulator training - Part II	
10:00	09:30 – 11:00 ESGE Hands-on Training - Session 9 – Colonoscopy training – Clip treatment for bleeding, fistulae and perforations – Dysplastic Barrett's esophagus management – ESD			10:30 – 11:00 Prevention of ERCP pancreatitis: what to do to whom? <i>Tomislav Bokun, Croatia</i> <i>Stephen Pereira, United Kingdom</i>
11:00		– POEM (Per-oral endoscopic myotomy) for esophageal achalasia (JGES) – Magnifying endoscopic diagnosis of superficial Barrett's esophagus-related neoplasm (JGES) – Polyposis Syndrome / Genetic GI: Endoscopic Diagnosis and Management (ASGE) – Troubleshooting Commonly Encountered Problems with Endoscope (ASGE)		
12:00	11:30 – 13:00 ESGE Hands-on Training - Session 10 – Ablation – Resection/Hemostasis – Advanced Therapeutic Resection Techniques – EUS FNA/FNB & Axios			12:00 – 12:30 Early colorectal neoplasia: when do I need/not need histology and why? <i>Maria Pellisé, Spain</i> <i>Rodrigo Jover, Spain</i>
13:00				
14:00	14:00 – 15:30 ESGE Hands-on Training - Session 11 – EUS training – Clip treatment for bleeding, fistulae and perforations – POEM – Dysplastic Barrett's esophagus management			14:00 – 14:30 Diabetes mellitus: how do we treat it with endoscopy? <i>Mostafa Ibrahim, Belgium</i> <i>Jacques Devière, Belgium</i>
15:00				
16:00	16:00 – 17:30 ESGE Hands-on Training - Session 12 – Ablation – Resection/Hemostasis – RFA of the Biliary Tract & Biliary Metal Stent Placement – Advanced Therapeutic Resection Techniques			
17:00				

Coffee Breaks: 10:00 – 10:30 and 15:30 – 15:45 | Lunch Break: 12:00 – 14:00

## Wednesday, October 24, 2018

	Hands-on Training Centre (L2)	E-Learning Stations (L3)	Open Simulator Training Area (L3)	ESGE Lecture Theatre (L3)
09:00		09:00 – 14:00 E-learning – Part V – ESGE Days 2018 Live Demo – ESGE Days 2018: Scientific Programme Highlights	09:00 – 14:00 GI Endoscopy Simulator training – Part II	09:00 – 09:30 ERCP: when is time to go to EUS? <i>Ioannis Papanikolaou, Greece</i> <i>Manuel Pérez-Miranda, Spain</i>
10:00	09:30 – 11:00 ESGE Hands-on Training – Session 13 – Ablation – Resection/Hemostasis – Dysplastic Barrett's esophagus management – Cholangioscopy – Advanced Therapeutic Resection Techniques	– Endoscopic Ultrasonography Unit 1: The basics – Colonoscopy Unit 3: Polypectomy – Upper GI Unit 3: Variceal bleeding – Colonoscopy Unit 1: The basics – POEM (Per-oral endoscopic myotomy) for esophageal achalasia (JGES)		10:30 – 12:00 Latest ESGE guidelines <i>Cesare Hassan, Italy</i>  Endoscopic management of acute necrotizing pancreatitis <i>Marianna Arvanitakis, Belgium</i>
11:00	11:30 – 13:00 ESGE Hands-on Training – Session 14 – FNA – Clip treatment for bleeding, fistulae and perforations – Colonoscopy Training	– Magnifying endoscopic diagnosis of superficial Barrett's esophagus-related neoplasm (JGES) – Polyposis Syndrome/ Genetic GI: Endoscopic Diagnosis and Management (ASGE) – Troubleshooting Commonly Encountered Problems with Endoscope (ASGE)		Small bowel endoscopy <i>Emanuele Rondonotti, Italy</i> EUS guided sampling <i>Marcin Polkowski, Poland</i> Endoscopy in PSC <i>Lars Aabakken, Norway</i> Endoscopic polypectomy and EMR <i>Monika Ferlitsch, Austria</i>
12:00				
13:00				

Coffee Break: 10:00 – 10:30 | Lunch Break: 12:00 – 14:00

### Registration

There is limited availability of tickets for the training sessions from Saturday to Monday. Please go to the ESGE desk in the Learning Area and secure your ticket (starting on Saturday at 9:00). Participation will be on a first-come, first-served basis. To maintain a high standard of teaching each workstation is limited to a maximum of eight participants.

Endoscopic training on GI simulators is available on a walk-in basis throughout UEG Week as are the hands-on sessions on Tuesday and Wednesday.





## Ultrasound Learning Area

The Ultrasound Learning Area promotes the role of a major diagnostic and interventional tool in gastroenterology: Clinical ultrasonography in the hands of the gastroenterologist. It offers individual hands-on training, a basic and an advanced course on ultrasonography for the gastroenterologist, which are designed for both, the beginner and the experienced and lectures in abdominal ultrasonography in the topics Gastrointestinal US (GIUS), US in Pancreatic Diseases, Elastography & POCUS presented by expert gastroenterologists.

### Course directors

Dieter Nuernberg, Neuruppin, Germany  
Odd Helge Gilja, Bergen, Norway  
Ioan Sporea, Timisoara, Romania

### Faculty members & hands-on tutors

Klaus Dirks, Winnenden, Germany  
Mostafa Hassan ElShennawy, Egypt  
Vilmar Frauendorf, Neuruppin, Germany  
Christian Jenssen, Strausberg-Wriezen, Germany  
Giovanni Maconi, Milano, Italy  
Kim Nylund, Bergen, Norway  
Alina Popescu, Timisoara, Romania  
Adrian Saftoiu, Craiova, Romania  
Roxana Sirli, Timisoara, Romania  
Zeno Sparchez, Cluj, Romania  
Stefan Uebel, Berlin, Germany  
Jonas Valentinas, Vilnius, Lithuania

For more programme details please see the UEG Week App.



## Ultrasound Learning Area

Room L6, Level 1

### Programme Overview

#### Ultrasonography for the Gastroenterologist

	Saturday October 20, 2018	Sunday October 21, 2018	Monday October 22, 2018	Tuesday October 23, 2018	Wednesday October 24, 2018
09:00	09:00 – 10:30 Basic Course 1	09:00 – 10:30 Advanced Course 1	09:00 – 12:00 Hands-on Training C	09:00 – 12:00 Hands-on Training E	09:00 – 11:00 Elastography & Point of Care Ultrasound (POCUS)
10:00					
11:00	11:00 – 13:00 Basic Course 2	11:00 – 13:00 Advanced Course 2			11:00 – 14:00 Hands-on Training G
12:00					
13:00			13:00 – 15:00 Gastrointestinal US (GIUS)	13:00 – 15:00 US in pancreatic diseases	
14:00	14:00 – 16:00 Basic Course 3	14:00 – 16:00 Advanced Course 3			
15:00			15:00 – 18:00 Hands-on Training D	15:00 – 18:00 Hands-on Training F	
16:00	16:00 – 18:00 Hands-on Training A	16:00 – 18:00 Hands-on Training B			
17:00					

Saturday and Sunday | Coffee Breaks: 10:30 – 11:00 and 15:30 – 16:00 | Lunch Break: 13:00 – 14:00

Monday and Tuesday | Coffee Breaks: 10:00 – 10:30 and 15:30 – 15:45 | Lunch Break: 12:00 – 14:00

Wednesday | Coffee Break: 10:00 – 10:30 | Lunch Break: 12:00 – 14:00

Organised and supported by EFSUMB and BICUS



Supported by Hitachi Co., GE Co. and Bracco



GE Healthcare



## Surgical Learning Area

---

Welcome to the Surgical Learning Area!

The four surgical Societies, the EAES, the ESCP, The EDS and the EFISDS, representing the UEG Surgical block invite and welcome delegates to the Surgical Learning Area. This year we are delighted to have 5 different courses which include hands-on training, scenario and technique discussions, live surgery and new innovations. This year's new offering includes a trans oral ant reflux therapy course as well as laparoscopic liver surgery. Other courses are colorectal laparoscopic skills (LSS Grade 2), trans anal microsurgery and specific basic laparoscopic skills.

In addition to your registration as a UEG Week delegate we do require that participants register directly for the specific courses which are free of charge. Besides the specific courses there is the general education area with activities such as case-based discussions, meet the expert and video sessions. The purpose of the area is to broaden the awareness within the GI community for the surgical perspective within GI care and vice versa and attract attendees to gain a broader insight in surgical education and hands-on training procedures.

For more information on the courses see the UEG Week App!

### Faculty members

M. Adham, France  
A. Arezzo, Italy  
P. Ignatavicius, Lithuania  
J. Izbicki, Germany  
J. Jakimowicz, The Netherlands  
I. Jenkins, United Kingdom  
M. Morino, Italy  
H. Rosen, Austria  
A. Stearns, United Kingdom  
C. Thorn, United Kingdom  
R. van Hillegersberg, The Netherlands  
Y. Vashist, Switzerland  
N. Yassin, United Kingdom



## Surgical Learning Area

### Level 1

Saturday, October 20, 2018

	General Area		Room L4
09:00		09:00 – 18:00 Information desk, running videos	09:00 – 18:00 Course one: Laparoscopic surgical skills grade 2 colorectal surgery hands-on
10:00			
11:00			
12:00			
13:00			
14:00	14:00 – 15:00 EDS Basic laparoscopic surgical skills – Session 1		
15:00			
16:00			
17:00			

Coffee Breaks: 10:30 – 11:00 and 15:30 – 16:00 | Lunch Break: 13:00 – 14:00

## Sunday, October 21, 2018

	General Area		Room L4	Room L5
09:00	09:00 – 13:00 EDS Basic laparoscopic surgical skills course – Session 2	09:00 – 18:00 Information desk, running videos	09:00 – 15:30 Course one: Laparoscopic surgical skills grade 2 col-orectal surgery hands-on	09:00 – 10:00 TEO/TEM Theory and discussion
10:00				
11:00				10:30 – 18:00 TEO/TEM hands-on instruction
12:00				
13:00				
14:00	14:00 – 18:00 EDS Basic laparoscopic surgical skills course – Session 3			
15:00				
16:00				
17:00				

Coffee Breaks: 10:30 – 11:00 and 15:30 – 16:00 | Lunch Break: 13:00 – 14:00

## Surgical Learning Area

### Level 1

Monday, October 22, 2018

	General Area			Room L4	Room L5
09:00	09:00 – 13:00 EDS Basic laparoscopic surgical skills course – Session 4	09:00 – 13:00 Transoral ant reflux therapy course – Session 1	09:00 – 18:00 Information desk, running videos	09:00 – 18:00 Course two: Laparoscopic surgical skills grade 2 colorectal surgery hands-on	09:00 – 10:00 TEO/TEM Theory and discussion
10:00					
11:00					10:30 – 18:00 TEO/TEM hands-on instruction
12:00					
13:00	14:00 – 18:00 EDS Basic laparoscopic surgical skills course – Session 5				
14:00					
15:00					
16:00					
17:00					

Coffee Breaks: 10:00 – 10:30 and 15:30 – 15:45 | Lunch Break: 12:00 – 14:00

The Surgical Learning Area is run courtesy of:



And kindly supported by:



## Tuesday, October 23, 2018

	General Area			Room L4	Room L5
09:00	09:00 – 13:00 EDS Basic laparoscopic surgical skills course – Session 6	09:00 – 13:00 Transoral ant reflux therapy course – Session 2	09:00 – 18:00 Information desk, running videos	09:00 – 15:30 Course two: Laparoscopic surgical skills grade 2 colorectal surgery hands-on	09:00 – 15:30 TEO/TEM hands-on instruction
10:00					
11:00					
12:00					
13:00	14:00 – 18:00 EDS Basic laparoscopic surgical skills course – Session 7				
14:00					
15:00					
16:00					
17:00					

Coffee Breaks: 10:00 – 10:30 and 15:30 – 15:45 | Lunch Break: 12:00 – 14:00

## Wednesday, October 24, 2018

	General Area	Room L4	Room L5
09:00	09:00 – 13:00 EDS Basic laparoscopic surgical skills course – Session 8	09:00 – 12:00 LSS colorectal course	09:00 – 12:00 TEO/TEM hands-on instruction
10:00			
11:00			
12:00			

Coffee Break: 10:00 – 10:30 | Lunch Break: 12:00 – 14:00

**Evidence Based  
Medicine Course**



## Evidence Based Medicine Course

Saturday and Sunday, October 20–21, 2018

**Please note that this meeting takes place outside of the core scientific programme and attendance is by invitation only.**

This course, designed for clinicians in gastroenterology of all ages, from all career levels, aims to teach Evidence Based Medicine (EBM) principles and how they can be applied in daily clinical work.

The course combines interdisciplinary clinical cases with questions of diagnosis and therapy, and identifies opportunities to integrate EBM into clinical practice. Delegates will be guided by tutors and stimulated with short input lectures, they will work in break-out groups and discuss the results achieved.

### Faculty

Alexander Ford (Leeds, United Kingdom)  
Sanjiv Mahadeva (Kuala Lumpur, Malaysia)  
Leonardo Eusebi (Bologna, Italy)  
Gavin Johnson (London, United Kingdom)  
John Kane (Leeds, United Kingdom)  
Anne Lund Krarup (Aalborg, Denmark)  
Björn Lindkvist (Gothenburg, Sweden)  
Andre Mihaljevic (Heidelberg, Germany)

## Programme Overview

### Module A

**Clinical questions: From clinical practice to answerable questions**

Exercises based on patient histories

### Module B

**Search literature databases: From the question to potentially relevant evidence**

Interactive lecture and hands-on computer exercise

### Module C

**Design your study: From papers to critically appraised new knowledge**

Group work and interactive lectures

### Module D

**EBM transfer: From critically appraised new knowledge to changed practice**

**From learning to teaching EBM skills**

Group work, theory input and video analysis

Apply in February for the upcoming Evidence Base Medicine Course, taking place at UEG Week Barcelona 2019!

**Application deadline: July 12, 2019**



The UEG Evidence Based Medicine Course 2018, Vienna, Austria, 20/10/2018-21/10/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



**ESGENA**

European Society of Gastroenterology  
and Endoscopy Nurses and Associates

## 22<sup>nd</sup> ESGENA Conference

Hosted by the Austrian Society of Endoscopy Nurses and  
Associates (IVEPA)



In Conjunction with the 26<sup>th</sup> United European  
Gastroenterology Week



For more programme details please see the UEG Week  
App or [ueg.eu/week/esgena](http://ueg.eu/week/esgena)



## 22<sup>nd</sup> ESGENA Conference

### Word of Welcome

Dear colleagues,

On behalf of ESGENA, the Austrian Society of Endoscopy Nurses and Associates (IVEPA) it is our great pleasure to invite you to the 22<sup>nd</sup> ESGENA Conference which will be held during the 26<sup>th</sup> United European Gastroenterology Week, October 20–22, 2018 in Vienna, Austria.

Why should you attend the ESGENA Conference? The ESGENA conference is a unique venue for meeting colleagues from different countries and expanding your professional network. The relaxed atmosphere supports collegial exchange and helps to overcome language barriers. The ESGENA conference includes state-of-the-art lectures, free papers & posters, lunch sessions, workshops with hands-on training and live transmissions. Last breaking news about new trends and developments as well as presentations about interesting projects and studies in Gastroenterology and Endoscopy ensure a truly global context. The exchange with nurses from all over the world combined with the opportunity to attend the medical programme of the UEG Week ensures that the ESGENA conference will be an exceptional educational event.

Following past meetings in 2008, 2014 and 2016, this is the fourth time that the medical and nursing community of Gastroenterology and Endoscopy will meet in Vienna. The city on the Danube is known not only for the Prater, the Hofburg and delicious pastries, but also for great experiences with and without adrenalin factor.

Enjoy the extraordinary Austrian hospitality, combined with the multicultural atmosphere of an international meeting.

We hope to welcome you to the 22<sup>nd</sup> ESGENA Conference and 26<sup>th</sup> UEG Week in October 2018 in Vienna

Marjon de Pater  
President of ESGENA

Dagmar Zrzavy  
President of IVEPA

## Programme Overview

Saturday, October 20, 2018

	Room E2	Room M	Room L7	Room L8	Room 1.61/1.62	ESGE Learning Area
09:00						
10:00						
11:00						
12:00	11:30 – 13:00 ESGENA Opening Session Quality makes the difference					
13:00	<b>13:00 – 14:00 Lunch Break</b>					
14:00		14:00 – 15:30 Special Bronchoscopy Session I	14:00 – 15:30 Workshop 1 Electrosurgery in Endoscopy: How to make it safe and effective?  Olympus	14:00 – 15:30 Workshop 2 The nurse's role in tissue resection and infection prevention  Boston	14:00 – 15:30 Workshop 3 Health and Safety in Endoscope Reprocessing  Dr Weigert	14:00 – 15:30 Workshop 4 Hands-on training on biosimulators: Upper GI Bleeding ERCP Colonoscopy
15:00	<b>15:30 – 16:00 Coffee Break</b>					
16:00		16:00 – 17:30 Special Bronchoscopy Session II  Olympus	16:00 – 17:30 Workshop 5 More than nice to know – Damage prevention & correct endoscope handling  Olympus	16:00 – 17:30 Workshop 6 Electrosurgery – Prevention of complication  Erbe	16:00 – 17:30 Workshop 7 The influence of endoscopes reprocessing on successful infection prevention – a risk assessment of the individual processing steps Cantel	16:00 – 17:30 Workshop 8 Hands-on training on biosimulators: Upper GI Bleeding ERCP Colonoscopy
17:00						

Sunday, October 21, 2018

	Room G	Room K	Poster Area	ESGE Learning Area
09:00	09:00 – 10:30 Session 1 Abstract-based	09:00 – 10:30 Session 2 Quality starts with building and reconstruction		
10:00	10:30 – 11:00 Coffee Break		10:30 – 11:00 Poster Exhibition I	
11:00	11:00 – 12:30 Session 3 Education	11:00 – 12:30 Session 4 Management – safety first		11:00-12:30 Workshop 9 Hands-on training on Bio simulators: Upper GI Bleeding ERCP
12:00	12:30 – 15:00 Lunch Session 1 GE Endoscopy	12:30 – 15:00 Lunch Session 2 Hygiene & Infection control		
13:00	13:00 – 14:00 Lunch Break		13:30 – 15:00 Poster Exhibition II	
14:00	12:30 – 15:00 Lunch Session 1 GE Endoscopy	12:30 – 15:00 Lunch Session 2 Hygiene & Infection control		14:00 – 15:30 Workshop 10 Hands-on training on bio simulators: ERCP Colonoscopy
15:00	15:00 – 16:30 Session 5 Hygiene – points of discussion	15:00 – 16:30 Session 6 IBD		
16:00	16:30 – 17:00 Coffee Break			
17:00	17:00 – 18:00 Present & Future in GI Endoscopy ESGENA Free Paper and Poster Award			
18:00	18:00 – 19:00 ESGENA Annual General Assembly			

## **Common Interest Group Meetings**

Common Interest Group - meetings organized by medical associations to discuss topics of interest. These meetings are open to all UEG Week delegates.

## Common Interest Group Meetings

### Sunday, October 21, 2018

08:00 – 10:00 Room L8  
**FMT and Stool Banking**  
 EHMSG

FMT is a novel therapy in gastroenterology. For safe application, careful donor selection and screening, and standardized processing and storage of FMT suspension is mandatory. Stool banking will ensure availability, enable quality assurance, and increase cost-effectiveness of FMT. This meeting will address indications, implementation, standardization and quality assurance of FMT.

10:00 – 12:00 Room 1.86  
**Healthy Stomach Initiative**  
 HSI

One of the annual group of interest meeting among global GI specialists with the aim to bring the latest knowledge to medical professionals and awareness to the general, global population on stomach health, preventive care and treatment options.

13:30 – 16:30 Room N2  
**Common interest group meeting on coeliac disease**  
 European Society for Study of Coeliac Disease

The common interest group meeting on coeliac disease is arranged by the European Society for Study of Coeliac Disease. The meeting is open to all interested in coeliac disease. This year's program is focused on ongoing European multi-center studies. The meeting will end with a business meeting for members.

14:00 – 15:30 Room L7  
**Diagnosis and management of autoimmune hepatitis: the basics and beyond**  
 IAIHG

This interactive common interest group meeting will address the basics and pitfalls in the diagnosis and treatment of autoimmune hepatitis, its variant syndromes and special populations.

### Monday, October 22, 2018

18:00 – 19:30 Room N2  
**Getting closer to 2030: Where do we stand? (Towards elimination of Viral Hepatitis on a global level)**  
 WGO

WGO's 2018 WDHD theme is Viral Hepatitis B&C, Lifting the Global Burden. This session explores where efforts stand currently to eliminate viral hepatitis globally. Experts will present on the diagnosis and management of viral hepatitis B&C and the challenges to eliminating viral hepatitis on a global scale.

### Tuesday, October 23, 2018

18:00 – 19:30 Room L7  
**Underwater colonoscopy - New frontiers**  
 Global under water group

World lead investigators on underwater colonoscopy to discuss ongoing studies for peer to peer support and collaboration. Aim to finalize a Delphi process on water aided colonoscopy and this will be ideal forum. Organizing Committee – Saud Ishaq, Sergio Cadoni, Toshio Kuwai, Uedo Noriya, Leonardo Frazzoni, Felix Leung, Chris Mulder.





## Business Meetings

Please note that attendance is by invitation only.

<b>UEG</b>	<b>Friday, October 19, 2018</b>	
15:00 – 18:30	Council Meeting	Hotel Hilton Vienna
	<b>Saturday, October 20, 2018</b>	
09:30 – 12:30	Journal Management Board Meeting	UEG Meeting Room 1
14:00 – 17:00	Public Affairs Committee Meeting	UEG Meeting Room 1
15:00 – 16:45	Standards & Guidelines Task Force meeting	UEG Meeting Room 2
17:00 – 18:30	National Societies Committee Meeting	UEG Meeting Room 2
	<b>Sunday, October 21, 2018</b>	
08:00 – 11:00	E-learning Team Meeting	UEG Meeting Room 2
12:30 – 14:15	Journal Editorial Board Meeting	UEG Meeting Room 1
13:00 – 15:00	National Societies Forum Meeting	Room F1
13:30 – 16:00	Scientific Committee – PGT Taskforce Meeting	UEG Meeting Room 3
16:00 – 19:00	Meeting of Members	Room F1
	<b>Monday, October 22, 2018</b>	
12:15 – 13:45	Research Board Meeting	UEG Meeting Room 1
16:00 – 18:00	Scientific Committee 2019 – Group Coordinators' Meeting	UEG Meeting Room 2
17:00 – 18:30	Equality & Diversity Task Force Meeting	UEG Meeting Room 1
	<b>Tuesday, October 23, 2018</b>	
17:15 – 18:00	Meeting with Friends of YTG	Room 2.15
	<b>Wednesday, October 24, 2018</b>	
08:00 – 10:00	Young Talent Group Meeting	UEG Meeting Room 2
10:30 – 11:45	Industry Debrief Meeting	Room 1.86
<b>EAGEN</b>	<b>Saturday, October 20, 2018</b>	
13:00 -18:00	Board Meeting	Room 2.17
<b>EPC</b>	<b>Sunday, October 21, 2018</b>	
11:30 – 13:30	Council Meeting	Room 2.17
<b>IAPWG</b>	<b>Sunday, October 21, 2018</b>	
14:00 – 18:00	Consensus Group Meeting	Room 2.17
<b>Guideline IgG4-related GI diseases</b>		
	<b>Sunday, October 21, 2018</b>	
15:00 – 18:00	European Guideline on IgG4-related GI diseases UEG and SGF evidence-based recommendations	Room 2.31
<b>ESDO</b>	<b>Tuesday, October 23, 2018</b>	
18:00 – 19:30	General Assembly	Room 2.17
<b>BRAINFOOD</b>	<b>Wednesday, October 24, 2018</b>	
09:00 – 16:00	Planning Meeting for the European Training Network Application	Room 2.15



### UEG Press Briefing

Monday, October 22, 2018

12:15 – 13:30

Room 1.86

## **Industry Sponsored Symposia**

The programme of industry sponsored symposia is not affiliated with UEG and as of September 12, 2018.

## Industry Sponsored Symposia

Sunday, October 21, 2018

### Industry Sponsored Symposium

16:15 - 17:45

Room E1

**From promise to practice: setting a course towards improved IBD management**  
(Pfizer)

Chair: Remo Panaccione, Canada

#### Welcome and introduction

Remo Panaccione, Canada

#### Interview 1: Personalised medicine: putting the 'I' in IBD

Fraser Cummings, United Kingdom

#### Interview 2: Therapeutic drug monitoring (TDM): where are we now and where are we going?

Niels Vande Castele, USA

#### Interview 3: The biosimilars opportunity: has practice lived up to promise?

James Lindsay, United Kingdom

#### Audience Q&A/discussion

### Industry Sponsored Symposium

18:00 - 19:30

Room F2

**Practical insights into the day-to-day management of Crohn's disease**  
(Janssen)

Chairs: Silvio Danese, Italy

Ailsa Hart, United Kingdom

#### Welcome and introduction

Ailsa Hart, United Kingdom

#### New biologicals for CD: positioning anti-IL-12/23 therapy in current treatment algorithms

Silvio Danese, Italy

#### Day-to-day management of Crohn's disease: practical insights

Willem Bemelman, The Netherlands

Silvio Danese, Italy

Iris Dotan, Israel

Ailsa Hart, United Kingdom

#### Close of meeting

Silvio Danese, Italy

### Industry Sponsored Symposium

18:00 - 19:30

Room E1

**Working together to improve the quality of patient care in IBD**  
(Pfizer)

Chair: Alessandro Armuzzi, Italy



#### Welcome and introduction

Alessandro Armuzzi, Italy

#### The patient perspective: Learnings from the UC Narrative

Luisa Avedano, Belgium

Rasheed C., Canada

#### The physician perspective: Bridging the communication gap between patients and physicians

Alessandro Armuzzi, Italy

#### The nurse perspective: Meeting both clinical and patient needs

Anna Karoliina Ylanne, Finland

#### The psychologist perspective: Understanding the psychosocial impact of IBD

Lyndsay Hughes, United Kingdom

#### Building a multidisciplinary team to improve the quality of patient care

Stefan Schreiber, Germany

#### Panel discussion with audience Q&A

## Industry Sponsored Symposia Monday, October 22, 2018

### Industry Sponsored Symposium

18:00 - 19:30 Room D  
**Shared Decision-making in Ulcerative Colitis: Balancing Benefits and Risks to Optimise Outcomes**  
 (Takeda Pharmaceuticals International AG)  
 Chair: Geert D'Haens, The Netherlands



#### Welcome and Introduction

Geert D'Haens, The Netherlands

#### Shared Decision-making in Ulcerative Colitis: Why and How?

Gil Y. Melmed, USA

#### Assessing Safety of Biologics in a Patient-Empowered Treatment Model

Benjamin Pariente, France

#### Ensuring Rapid and Sustained Efficacy in a Patient-Empowered Treatment Model

Geert D'Haens, The Netherlands

#### Conclusion: Shared Decision-making to Empower Patients

Geert D'Haens, The Netherlands

#### Panel Discussion/Q&A

All

### Industry Sponsored Symposium

07:00 - 08:00 Room F2  
**Earlier Introduction of Biologics in IBD: Does It Make Sense?**  
 (Celltrion Healthcare)  
 Chair: Stefan Schreiber, Germany



#### Opening Remarks

Stefan Schreiber, Germany

#### Exploring Opportunities of Earlier Introduction of Biologics

Iris Dotan, Israel

#### Growing Impact of Earlier Introduction of Biologics in Pediatric IBD

Lissy de Ridder, The Netherlands

#### Clinical Evidence of CT-P13 SC Formulation

Stefan Schreiber, Germany

#### Panel Discussion

All

### Industry Sponsored Symposium

17:45 - 19:15 Room B  
**Are we ready to change the course of IBD?**  
 (AbbVie)  
 Chair: Remo Panaccione, Canada



#### Welcome and introduction

Remo Panaccione, Canada

#### Assessing the course: Understanding progression in IBD

Laurent Peyrin-Biroulet, France

#### Navigating outcomes: Optimising treatment of IBD

Jean-Frédéric Colombel, USA

#### Breaking down barriers: A patient case of treat to target

Remo Panaccione, Canada

#### Looking beyond IBD: Effecting change in patients' lives

Eduard Louis, Belgium

#### Concluding remarks and close

Remo Panaccione, Canada

### Industry Sponsored Symposium

17:45 - 19:15 Room F2  
**A worldwide perspective on diagnosis and management of diverticular disease: understanding similarities and differences**  
 (ALFASIGMA S.p.A)  
 Chair: Fermin Mearin, Spain



**Introduction to the regional patient case approach**  
 Fermin Mearin, Spain

**The European perspective**  
 Giovanni Barbara, Italy

**The Asian perspective**  
 Kok Ann Gwee, Singapore

**The North American perspective**  
 Neil H. Stollman, USA

**Global perspective in colonic diverticular disease and future directions**  
 All

### Industry Sponsored Symposium

17:45 - 19:15 Room E1  
**Advanced Imaging in Endoscopy and Therapeutic Techniques**  
 (FUJIFILM Europe GmbH)  
 Chairs: Alessandro Repici, Italy  
 Prateek Sharma, USA



**Tips and tricks for advanced polyp resection**  
 Alessandro Repici, Italy

**LCI can improve the adenoma detection rate**  
 Franco Radaelli, Italy

**How to make Barrett's imaging easier?**  
 Jacques Bergman, The Netherlands

**Round Table discussion: How to get trained on the new BASIC Classification model**  
 Lead by Cesare Hassan, Italy

### Industry Sponsored Symposium

17:45 - 19:15 Room D  
**Tofacitinib in UC: From clinical evidence to clinical practice – a 'choose your own' symposium**  
 (Pfizer)  
 Chair: Silvio Danese, Italy



**Welcome and introductions**  
 Silvio Danese, Italy

**New approaches to modulating cytokine signalling**  
 Silvio Danese, Italy

**Evidence of efficacy: Tofacitinib pivotal studies**  
 Geert D'Haens, The Netherlands

**Tofacitinib safety: Data from clinical studies and the real world**  
 Iris Dotan, Israel

**Tofacitinib: Choose your own topics**  
 Presentation of three key topics based on audience voting

**Panel discussion with audience Q&A**

### Industry Sponsored Symposium

17:45 - 19:15 Room C  
**Mucosal Healing in Crohn's Disease: Lessons From Theory to Practice**  
 (Takeda Pharmaceuticals International AG)  
 Chair: Peter Irving, United Kingdom



**Introduction to Mucosal Healing: Evolution of Treatment Goals**  
 Peter Irving, United Kingdom

**Critical Appraisal: Aiming for Mucosal Healing in Clinical Practice**

**Theory: Why Should We Target Mucosal Healing?**  
 Charlie Lees, United Kingdom

**Applying Theory to Practice: What Every Clinician Needs to Know**  
 Filip Baert, Belgium

**Panel Discussion/Q&A**  
 All

**Is Mucosal Healing an Attainable Target? Insights from Clinical Trials and the Real World**  
 Peter Irving, United Kingdom

**Panel Discussion/Q&A**  
 All

## Industry Sponsored Symposia

### Tuesday, October 23, 2018

#### Industry Sponsored Symposium

07:00 – 08:00 Room F2  
**Therapeutic Drug Monitoring in IBD: The Value of Biosimilar Infliximab**  
 (Celltrion Healthcare)  
 Chair: Walter Reinisch, Austria



#### Advancing the Role of Therapeutic Drug Monitoring in IBD Treatment

Walter Reinisch, Austria

#### Immunogenicity of Biosimilar: Letting the Immune System be the Judge on Similarity

Shomron Ben-Horin, Israel

#### Clinical Evidence of Therapeutic Drug Monitoring: PANTS

Nick Kennedy, United Kingdom

#### Panel Discussion

All

#### Industry Sponsored Symposium

07:00 – 08:00 Room M  
**Ablation of Barrett's esophagus with HybridAPC**  
 (Erbe Elektromedizin GmbH)  
 Chairs: Horst Neuhaus, Germany  
 Prateek Sharma, USA

#### Role and overview of thermal methods in the treatment of Barrett's disease

Andrea May, Germany

#### Rationale of Hybrid APC and first clinical proof of principle

Hendrik Manner, Germany

#### European Multicenter cohort study of HybridAPC in Barrett's disease

Thomas Rösch, Germany

#### HybridAPC: Initial US experience and RCT status

Prateek Sharma, USA

#### Industry Sponsored Symposium

17:45 – 19:15 Room B  
**Sequencing success: Optimising IBD therapies with a treat-to-target approach?**  
 (AbbVie)  
 Chair: Geert D'Haens, The Netherlands



#### Welcome and Introduction

Geert D'Haens, The Netherlands

#### IBD pathogenic pathways – Is there cross-talk and compensation?

Geert D'Haens, The Netherlands

#### Biologic sequencing in IBD – What's the evidence?

Tim Raine, United Kingdom

#### Therapeutic options in IBD – T2T in clinical practice

Gert Van Assche, Belgium

#### A tight-control approach in IBD – An interactive case study

All

#### Q&A

All

#### Close

#### Industry Sponsored Symposium

17:45 – 19:15 Room G  
**The emerging treatment landscape of IBD: role of innovator biologics and biosimilars**  
 (Amgen Europe GmbH)  
 Chair: Walter Reinisch, Austria



#### Welcome and introduction

Walter Reinisch, Austria

#### Preparing for the next era in the management of inflammatory bowel disease

Jean-Frédéric Colombel, USA

#### Upcoming biosimilars in the spotlight: what to consider when selecting

Walter Reinisch, Austria

#### Alleviating patient concerns about biosimilars: challenges and opportunities

Alessandro Armuzzi, Italy

#### Panel discussion

All

#### Closing remarks

Walter Reinisch, Austria

### Industry Sponsored Symposium

17:45 – 19:15 Room C

#### Eosinophilic Esophagitis – State of the Art (Dr. Falk Pharma GmbH)

Chairs: Alex Straumann, Switzerland  
Stephen E. Attwood, United Kingdom

Scientific Organizers: Stephan Miehke, Germany  
Arjan J. Bredenoord,  
The Netherlands

#### Welcome

Alex Straumann, Switzerland

#### Epidemiology & Pathogenesis

Arjan J. Bredenoord, The Netherlands

#### Diagnosis and Monitoring

Alain Schoepfer, Switzerland

#### Dietary Treatment

Alfredo J. Lucendo, Spain

#### Medical Therapy (Steroids, PPIs, biologics)

Stephan Miehke, Germany

#### Future Perspectives and needs in EoE

Javier Molina-Infante, Spain

#### Farewell

Stephen E. Attwood, United Kingdom

### Industry Sponsored Symposium

17:45 – 19:15 Room E1

#### Anti-TNFs in IBD – A Patient-Centric Interdisciplinary Approach

(Samsung Bioepis/Biogen)  
Chair: Laurent Peyrin-Biroulet, France



#### Introduction to the expanding treatment armamentarium of gastroenterologists in IBD

Laurent Peyrin-Biroulet, France

#### Discussion

Faculty and Audience

#### An effective ‘Target-to-Treat’ approach with anti-TNF inhibitors in IBD

Silvio Danese, Italy

#### Discussion

Faculty and Audience

#### Patient-centric pre-switch scenarios in daily clinical practice: TDM, predictors and patients’ needs

Raja Atreya, Germany

#### Discussion

Faculty and Audience

#### Implementing gain share models: A clinical and economical evaluation

Fraser Cummings, United Kingdom

#### Discussion

Faculty and Audience

#### Staying connected with the patient: Post-switch follow-up in daily clinical practice

Kay Greveson, United Kingdom

#### Discussion

Faculty and Audience

#### Wrap-up

Laurent Peyrin-Biroulet, France





## Congress Information

### Registration

On-site Registration does not necessarily entitle the participants to receive all congress material. Registration will be handled upon a first-come, first-served basis, priority will be given to pre-registered delegates.

### Congress Language

The official language of UEG Week is English. No simultaneous translation will be provided.

### Name Badges

Participants are requested to wear their name badge at all times during the congress. The colours of the name badges have the following significance:

- Delegate of UEG Week
- Faculty, Officers, Organisers of UEG Week
- Delegate of Postgraduate Teaching Programme
- Delegate of UEG Week and Postgraduate Teaching Programme
- Exhibitor & Delegate of UEG Week
- Delegate of ESGENA
- Exhibitor
- Press
- Congress Staff
- Guest/Common Interest Group/Business Meeting

YGN Young GI Network

P/NP Prescriber/Non-Prescriber

In case the badge is being scanned at exhibition booths or during an Industry Sponsored Symposium the delegate gives his/her consent that his/her personal data, comprising full name, address (institute/company, department, address) and email address is being passed on to UEG sponsors/exhibitors listed on the website [ueg.eu](http://ueg.eu) for the purpose of providing marketing and information material relating to the field of digestive health as well as information on scientific events.

### How to get around

We ask all of our visitors to think of the environment and use public transport wherever possible.

### Public Transportation Ticket

The congress badge serves as a public transportation ticket if it includes the logo of the public transportation

company Wiener Linien alongside the validity date. All registered UEG Week and Fellow in Training delegates are entitled to use the public transportation system free of charge from Monday through to Wednesday, October 22–24. ESGENA delegates may use the public transportation ticket free of charge from Saturday through to Monday, October 20–22. Vienna's public transportation system includes bus, Straßenbahn (tram), U-Bahn (underground) and S-Bahn (express city train). However, transportation to/from the airport using the CAT train, or S-Bahn (rail city train) once the city boundaries are left, requires the purchase of a separate ticket.

Please see page 291 for a Metro Map of Vienna.

Kindly note that the congress badge only serves as a public transportation ticket if shown in conjunction with a valid ID (passport) in case of ticket checks.

### How to get from the city centre to the venue

The fastest way to get from the city centre to the ACV is the underground line U1 (red) with direction 'Leopoldau'. Get off the U1 at 'Kaisermühlen - VIC' and take exit 'Schüttaustrasse' (Austria Center Vienna is also indicated).

### How to get to the airport

Vienna International Airport - VIE is easily accessible from the ACV by public transportation and by taxi. The trip by taxi takes approx. 25 minutes, by public transportation approx. 50 minutes.

The fastest way is the airport bus VAL 3 which takes you hourly and directly from/to Kaisermühlen - VIC in 40 min. One-way ticket EUR 8, return ticket EUR 13.

Alternatively, you can take the underground line U1 (red) from the station 'Kaisermühlen - VIC' with direction 'Reumannplatz'. Change at 'Schwedenplatz' and take the underground line U4 (green) with direction 'Hütteldorf'. Get off the train at 'Landstrasse - Wien Mitte' and take the City Airport Train or the S-Bahn (S7). The City Airport Train operates every 30 minutes, S7 every hour.

### Taxi

A taxi stand is located close to the ACV next to the underground station 'Kaisermühlen - VIC'. Taxis can be called day and night at the telephone numbers:

+43 1 401 00, +43 1 601 60 or +43 1 313 00

### Abstracts

The abstracts of UEG Week Vienna 2018 will be available online in the Library on the UEG Education website.

### Congress News and Website

The UEG Week website, UEG Week App and our social media channels will provide an overview of sessions and data presented each day and “what not to miss” the following day along with hot topics and snapshots of the congress. For more information, visit the UEG Week website ([ueg.eu/week](http://ueg.eu/week)).

### Live streaming of Sessions



Be part of UEG Week and view 50% of all sessions wherever you are! UEG will connect everyone to its annual meeting via live stream on the UEG Week Live website. Lean back and get updated on relevant GI and liver topics free of charge, and connect with the community via the UEG Week Social Wall. Simply sign in to myUEG. For more information, please visit [live.ueg.eu](http://live.ueg.eu).

### UEG Week 2018 App

Get the UEG Week 2018 App for your smartphone and experience the congress at your fingertips! Send questions during sessions via the Q&A tool or quickly find your way through the most up-to-date congress schedule. Cast your vote in interactive sessions via the app. Have a look at floor plans and browse the exhibition and company profiles.

The app is free of charge for iPhone/iPad and Android smartphone users.

The UEG Week 2018 App is available at:



### Programme Changes

UEG cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

### Meet UEG

Find out more about the work we do at the UEG Booth in the Entrance Foyer.



#### Opening Hours

Friday	October 19	14:00 – 18:00
Saturday	October 20	07:30 – 18:00
Sunday	October 21	07:30 – 18:00
Monday	October 22	07:00 – 18:00
Tuesday	October 23	07:00 – 18:00
Wednesday	October 24	07:00 – 16:00

### UEG Members Village

Meet representatives of UEG’s Member Societies in the Entrance Foyer.

### Patient Organisations & other Associations

Interact with representatives from patient organisations and other related associations in our Association & Future Events Area on level 1.

### UEG Young GI Lounge

Join the Young GI Network in the Young GI Lounge on Level 0. For more info please see page 21.

### Speakers Centre

The Speakers Centre is located in Foyer E on Level 0. It is equipped with PCs where speakers can work on their slides. Speakers are asked to hand in their CD-ROM or USB stick, containing the PowerPoint Presentation (IBM format or compatible, no multisession) or video preferably one day before, but at the latest 3 hours prior to the presentation. The slides will be transferred to the central congress server and will be available afterwards on a special congress notebook in the session room. The use of personal notebooks is not allowed. Technical staff will be happy to assist.



#### Opening Hours

Friday	October 19	14:00 – 18:00
Saturday	October 20	07:30 – 18:00
Sunday	October 21	07:30 – 18:00
Monday	October 22	07:00 – 18:00
Tuesday	October 23	07:00 – 18:00
Wednesday	October 24	07:00 – 14:00

### Internet Centre and WiFi

2 Internet Centres with several terminals are located in Foyer E on Level 0 and in the Hands-on Area on Level 1. WiFi is available throughout the venue.

**UEGWiFi by Pfizer**

**Password: uegweek18**

### Poster Exhibition

Posters are displayed from Monday, October 22 until Wednesday, October 24 in the scientific centre in Hall X1. The posters are changed daily and are at display during the following times:



Monday	October 22	09:00 – 17:00
Tuesday	October 23	09:00 – 17:00
Wednesday	October 24	09:00 – 14:00

The poster presenters are asked to put up and remove their poster on the day of presentation according to the schedule below:

**Hanging:** On the day of display 08:00 – 09:00.

**Removal:** On the day of display 17:00 – 17:30 (Mon-Tue) and 14:00 – 14:30 (Wed).

Posters that have not been removed by the respective time will be disposed of. Poster material to put up the poster is available at the poster service desk in the poster exhibition area.

If you have submitted a poster for printing through the CTI Poster Printing Service, please pick up your poster at the poster service desk in the poster area:



Monday	October 22	08:00 – 17:30
Tuesday	October 23	08:00 – 17:30
Wednesday	October 24	08:00 – 14:30

### E-Posters

E-Posters will be available in the scientific centre in Hall X1. All poster presenters have been invited to upload their poster prior to UEG Week. All uploaded E-Posters can be searched for and viewed electronically on the 4 terminals in the poster area during the above mentioned times.

### Technical Exhibition

UEG Week is accompanied by a major technical exhibition taking place in Halls X2, X3, X4, X5 on Levels –2 and 0. This provides an excellent opportunity for physicians, pharmacists, pharmacy assistants, nurse practitioners, physician assistants to interact with the industry and familiarise themselves with the latest advances in technology and pharmacology.

For further information and floor plans please see the list of exhibitors on page 295 and following, in the UEG Week 2018 App as well as on the UEG website [ueg.eu/week](http://ueg.eu/week).

Please note that according to the EU Directive 2001/83/EC promotional material related to prescription-only medicines must be distributed or provided exclusively to healthcare professionals who are authorised to prescribe or dispense them.



#### Opening Hours

Monday	October 22	09:00 – 17:30
Tuesday	October 23	09:00 – 17:30
Wednesday	October 24	09:00 – 14:00

### Press Centre

The Press Centre is located in Foyer F on Level 0. It is open from 08:00 – 18:00 (Sun-Tue, October 21-23) and 08:00 – 16:00 (Wed, October 24).

**All press/media representatives are invited to attend the press briefing in Room 1.86:**

#### Press Briefings

Monday October 22 12:15 – 13:30

Local and international speakers will be available to answer questions.

The Press Centre is managed by the press agency Spink. The agency's staff is pleased to provide more detailed information related to press activities during UEG Week.

### Silent Room

There is a room set apart for prayer. It is a quiet place, where delegates may withdraw to seek divine strength and guidance. The silent room is located in Room 0.81 on Level 0.

### Coffee Breaks and Lunch

Lunch and coffee are not included in the registration fee. UEG offers a certain amount of catering during the breaks on a first-come, first-served basis.

### PGT Programme and ESGENA Conference (Sat–Sun)



#### PGT Catering

**Saturday, October 20 and Sunday, October 21 (Foyer A, B, C)**

Coffee Break 10:30 – 11:00

Lunch 13:00 – 14:00



#### ESGENA Catering

**Saturday, October 20 (Foyer M)**

Coffee Break 10:30 – 11:00 // 15:30 – 16:00

Lunch 13:00 – 14:00

**Sunday, October 21 (Foyer G)**

Coffee Break 10:30 – 11:00 // 16:30 – 17:00

Lunch 13:00 – 14:00

### UEG Week Catering (Mon–Wed)



**Monday, October 22 and Tuesday, October 23 (Halls X2 – X5)**

Coffee Break 10:00 – 10:30 // 15:30 – 15:45

Lunch 12:00 – 14:00

**Wednesday, October 24 (Halls X2 – X5)**

Coffee Break 10:00 – 10:30

Lunch 12:00 – 14:00

Throughout the venue there will be water dispensers and catering kiosks to buy refreshments and snacks.

### Networking Areas

The perfect meeting point to network with colleagues are our designated networking areas in the exhibition area in Halls X2 – X5 or at the UEG Booth in the Entrance Foyer where we provide charging stations for your mobile devices. The Live Endoscopy will also be transmitted to the networking areas on Tuesday.

Congress delegates below 40 are also invited to meet other young fellows in the Young GI Lounge on Level 0, where they can form new collaborations, surf the net, charge their devices and join our social media activities!

### Cloakroom

The cloakroom is located in Foyer F in back of Level 0 and can be used free of charge from Saturday, October 20 through Wednesday, October 24. Participants can also store their luggage there.

### Emergency and First Aid

In case of emergency please contact the staff at the registration counters in the Entrance Foyer. The attentive staff will be pleased to help.

### Car Park

The Austria Center Vienna provides covered, secure parking for delegates. The parking fee of € 3 per hour or € 10 per day is not included in the registration fee.

**Opening hours:** Monday to Friday: 07:30 – 20:00.

### Smoking

The ACV is a non-smoking venue. Smoking is prohibited within the congress venue.

### Photos, Filming and Recording of Scientific Sessions



It is strictly forbidden to film, take photos or record any oral or poster presentation of UEG Week without the consent of the organiser (including smart phones, mobile devices, etc).

Please note that numerous sessions will be recorded and published at [ueg.eu/education/library](http://ueg.eu/education/library) immediately after the congress and will be available for all congress delegates. This archive will also include all abstracts, E-Posters and the Syllabus of the Postgraduate Teaching Programme.


### Insurance / Liability

UEG does not accept any liability for damages and/or losses of any kind which may be incurred by the congress participants, during either the official activities or official UEG networking events. Delegates attend the congress at their own risk. Participants are advised to take out insurance against loss, accidents or damage that could be incurred during the congress.

### Safety

As in all major cities and congress venues, people should always keep an eye on their personal belongings.

Please be aware of pickpocketing and bag-snatching and make sure to take off your name badge and congress bag when you go sightseeing in downtown Vienna. Wearing the name and bag identifies you as a tourist which might attract pickpockets.



## Acknowledgements

(as of September 6, 2018; in alphabetical order)

UEG gratefully acknowledges the support of the following companies:

### Premium Partners

AbbVie		Olympus Europa SE & Co. KG	
Amgen Europe GmbH		Pfizer	
FUJIFILM Europe GmbH		Takeda Pharmaceuticals International AG	
Janssen			

### Major Partners

ALFASIGMA S.p.A		MEDTRONIC	
Celltrion Healthcare		Norgine	
Gilead Sciences		PENTAX EUROPE GmbH	

### General Sponsors and Exhibitors

3-D Matrix	BÜHLMANN Laboratories AG
3D Systems Simbionix	CALPRO AS
Allergan	Cantel
Alton (Shanghai) Medical Instruments Co., Ltd	CapsoVision, Inc.
amg International GmbH	CASEN RECORDATI S.L
Ankon Medical Technologies	CBC Group
Anrei Medical (Hangzhou) Co., Ltd.	Celgene Corporation
Apollo Endosurgery	Changzhou Dahua Group/Citec
Arc Medical Design	Changzhou JiuHong Instrument Co., Ltd
Bayer Consumer Health	Choyang Medical Industry Ltd.
BCM Co., Ltd	Cook Medical
Beijing Huaco Healthcare Technologies Co., Ltd.	Creo Medical Ltd.
BIOCODEX	Diversatek Healthcare
Biocrates Life Sciences AG	Dr. Falk Pharma GmbH
BioGaia	Eli Lilly and Company
Biogen Intl. GmbH	ELLA-CS, s.r.o.
Boston Scientific International	EMED SP. Z O. O. SP. K.

## General Sponsors and Exhibitors

ENDALIS	NET New Electronic Technology GmbH
EndoAid Ltd.	NEXTBIOMEDICAL Co.,Ltd.
EndoClot Plus, Inc.	NIKKISO
Endoscopic Ultrasound Journal editorial office	NISO Biomed
Endoscopy / ESGE - Thieme	Noventure
Endoss	Ovesco Endoscopy AG
Endotics	Oxford University Press
Erbe Elektromedizin GmbH	Peter Pflugbeil GmbH
Eurospital	Probiotics International Ltd
Exalenz	R-Biopharm AG
Finemedix Co., Ltd	Reckitt Benckiser
Fischer ANalysen Instrumente GmbH	Richen Medical Science
GE Healthcare	Robarts Clinical Trials
Genetic Analysis AS	Roche
Hangzhou AGS MedTech Co., Ltd.	Rogaska Donat Mg
IMMUNDIAGNOSTIK AG	S&G Biotech INC.
INFAL GMBH	SAGE Publishing
Insitumed GmbH	Samsung Bioepis Co., Ltd.
IntroMedic Co., Ltd.	Sandoz International GmbH
invendo medical GmbH	SHANGHAI ANQING MEDICAL INSTRUMENT CO., LTD
Jiangsu ATE Medical Technology Co., Ltd	Shangxian Minimal Invasive Inc.
Jiangsu Kangjin Medical Instrument Co., Ltd.	SHENZHEN ZHONGHE HEADWAY BIO-SCI & TECH CO., LTD
Jinshan Science & Technology	Shionogi Ltd.
Karger Publishers	Shire
KARL STORZ SE & CO. KG	SMART Medical Systems Ltd.
LA LETTRE DE L'HEPATO-GASTROENTEROLOGUE	SOFAR SPA
Laborie	SOLUSCOPE
Leo Medical Co., Ltd.	SonoScape Medical Corp.
Leufen Medical GmbH	Standard Sci-Tech Inc.
Life Partners Europe	STEELCO SPA
Lumendi	SUMITOMO BAKELITE CO., LTD.
M.I. Tech Co., Ltd.	Surgical Science
Mauna Kea Technologies	Taewoong Medical
Medify	The Standard Co., Ltd
Medi-Globe GmbH/ Endo-Flex GmbH	Tillotts Pharma AG
MEDITALIA S.A.S.	US Endoscopy
Mednova Medical	W. L. Gore & Associates
medwork GmbH	Wassenburg Medical B.V.
Micro-Tech-Europe GmbH	Wego Group
Mirai Medical	Wiley
MSD (Merck & Company, Inc.)	WILSON INSTRUMENTS (SHA) CO., LTD
MTW-Endoskopie	Wisepress Medical Bookshop
Mylan GmbH	Zeon Medical Inc.



**UEG thanks its long-term partners for their continuous support!**

# List of Exhibitors and Exhibition Floor Plans

---

## Technical Exhibition

UEG Week is accompanied by a major technical exhibition taking place in Halls X2, X3, X4, X5 on Levels -2 and 0.



### Opening Hours

Monday	October 22	09:00 - 17:30
Tuesday	October 23	09:00 - 17:30
Wednesday	October 24	09:00 - 14:00



## List of Exhibitors

(as of September 6, 2018; in alphabetical order)

Premium Partners	Booth No.	General Exhibitors	Booth No.
AbbVie	X5/20	Celgene Corporation	X4/4
AbbVie	X5/34	Changzhou Dahua Group/Citec	X5/47
Amgen Europe GmbH	X2/10	Changzhou JiuHong Instrument Co., Ltd	X4/8
FUJIFILM Europe GmbH	X5/37	Choyang Medical Industry Ltd.	X4/23
Janssen	X4/1	Cook Medical	X2/24
Janssen	X4/2	Creo Medical Limited	X3/14
Janssen	X4/3	Diversatek Healthcare	X3/9
OLYMPUS Europa SE & Co. KG	X3/6	Dr. Falk Pharma GmbH	X2/18
Pfizer (Inflammation)	X5/3	Eli Lilly and Company	X4/20
Pfizer (Biosimilars)	X5/4	ELLA-CS, s.r.o.	X2/29
Pfizer (Pipeline)	X5/19	EMED SP. Z O. O. SP. K.	X3/16
Takeda Pharmaceuticals International AG	X3/7	ENDALIS	X4/28
Takeda Pharmaceuticals International AG	X2/27	EndoAid Ltd.	X5/28
<b>Major Partners</b>	<b>Booth No.</b>	EndoClot Plus, Inc.	X5/27
ALFASIGMA S.p.A	X2/14	Endoscopic Ultrasound Journal editorial office	X4/13a
Celltrion Healthcare	X5/10	Endoscopy / ESGE - Thieme	X5/30
Gilead Sciences	X5/32	Endoss	X5/43
MEDTRONIC	X2/11	Endotics	X5/38
Norgine	X2/13	Erbe Elektromedizin GmbH	X2/15
PENTAX Europe GmbH	X3/3	Eurospital	X5/24
<b>General Exhibitors</b>	<b>Booth No.</b>	Exalenz	X5/12
3-D Matrix	X5/18	Finemedix Co., Ltd	X3/18
3D Systems Symbionix	X5/8	Fischer ANalysen Instrumente GmbH	X5/29
Alton (Shanghai) Medical Instruments Co., Ltd	X3/10	GE Healthcare	X5/6
amg International GmbH	X5/41	Genetic Analysis AS	X3/11
ANKON Medical Technologies	X5/5	Hangzhou AGS MedTech Co., Ltd.	X2/16
Anrei Medical (Hangzhou) Co., Ltd.	X4/21	HITACHI Medical Systems / PENTAX Europe GmbH	X3/3
Apollo Endosurgery	X3/12	IMMUNDIAGNOSTIK AG	X5/16
Arc Medical Design	X4/25	INFAI GmbH	X4/34
BCM Co., Ltd	X4/17	Insitumed GmbH	X2/9
Beijing Huaco Healthcare Technologies Co., Ltd.	X3/2e	IntroMedic Co., Ltd.	X2/30
BIOCODEX	X2/23	invendo medical GmbH	X3/17
BioGaia	X5/7	Jiangsu ATE Medical Technology Co., Ltd	X5/26
Biogen Intl. GmbH	X3/5	Jiangsu Kangjin Medical Instrument Co., Ltd.	X4/33
Biocrates Life Sciences AG	X3/2a	Jinshan Science & Technology	X2/28
Boston Scientific International	X2/19	Karger Publishers	X4/10
BÜHLMANN Laboratories AG	X5/36	KARL STORZ SE & CO. KG	X4/16
CALPRO AS	X4/18	LA LETTRE DE L'HEPATO-GASTROENTEROLOGUE	X5/35
Cantel	X3/2	Laborie	X5/31
CapsoVision, Inc.	X5/39	Leo Medical Co., Ltd.	X5/23
CASEN RECORDATI S.L.	X2/5	Leufen Medical GmbH	X4/7
CBC Group	X2/2	Life Partners Europe	X5/42
		Lumendi	X5/15
		M.I. Tech Co., Ltd.	X4/22

General Exhibitors	Booth No.	General Exhibitors	Booth No.
Mauna Kea Technologies	X4/32	Wassenburg Medical B.V.	X5/11
Medify	X5/14	Wego Group	X3/2b
Medi-Globe GmbH/ Endo-Flex GmbH	X2/25	Wiley	X4/12
MEDITALIA S.A.S.	X5/40	WILSON INSTRUMENTS (SHA) CO., LTD	X2/6
Mednova Medical	X3/2d	Wisepress Medical Bookshop	X4/11
medwork GmbH	X3/8	Zeon Medical Inc.	X4/19
Micro-Tech Europe GmbH	X2/26		
Mirai Medical	X4/24	<b>Members Village - Level 0</b>	<b>Booth No.</b>
MSD (Merck & Company, Inc.)	X2/20	EAES	MV0/7
MTW-Endoskopie	X2/32	EAGEN	MV0/15
Mylan GmbH	X4/5	EASL	MV0/1
NET New Electronic Technology GmbH	X5/45	ECCO	MV0/16
NEXTBIOMEDICAL Co.,Ltd.	X4/6	EDS	MV0/3
NIKKISO	X2/8	EFISDS	MV0/6
NISO Biomed	X5/33	EHMSG	MV0/12
Noventure	X3/20	EPC	MV0/10
Ovesco Endoscopy AG	X3/15	ESCP	MV0/8
Oxford University Press	X4/13	ESDO	MV0/4
Peter Pflugbeil GmbH	X5/25	ESGAR	MV0/14
Probiotics International Ltd	X4/27	ESGE	MV0/17
R-Biopharm AG	X2/3	ESNM	MV0/5
Reckitt Benckiser	X4/29	ESP	MV0/2
Richen Medical Science	X2/1	ESPCG	MV0/11
Robarts Clinical Trials	X2/4	ESPEN	MV0/9
Roche	X2/12	ESPGHAN	MV0/13
Rogaska Donat Mg	X3/2c		
S&G Biotech INC.	X4/30	<b>Association &amp; Future Events Area - Level 1</b>	<b>Booth No.</b>
SAGE Publishing	X4/9	EGEUS - European Group for	
Sandoz International GmbH	X2/22	Endoscopic UltraSonography	AFA1/14
SHANGHAI ANQING MEDICAL INSTRUMENT CO., LTD	X4/14	Egypt Gastro Hep Congress	AFA1/13
Shangxian Minimal Invasive Inc.	X5/13	Endo Live Roma 2019	AFA1/6
SHENZHEN ZHONGHE HEADWAY		Euro-Eus 2019	AFA1/15
BIO-SCI & TECH CO., LTD	X5/9	European Section and Board of	
Shionogi Ltd.	X5/22	Gastroenterology and Hepatology (ESBGH)	AFA1/11
Shire	X5/1	GEEW	AFA1/7
Shire	X5/2	International Foundation	
SMART Medical Systems Ltd.	X3/1	for Gastrointestinal Disorders	AFA1/12
SOFAR SPA	X2/7	Journal Gastrointestinal and Liver Diseases	AFA1/16
SOLUSCOPE	X3/19	The Rome Foundation	AFA1/4
SonoScape Medical Corp.	X3/4	Turkish Society of Gastroenterology	AFA1/5
Standard Sci-Tech Inc.	X2/31	World Endoscopy Organization - WEO	AFA1/10
STEELCO SPA	X5/21	World Gastroenterology Organisation - WGO	AFA1/904
SUMITOMO BAKELITE CO., LTD.	X5/17		
Surgical Science	X5/46	<b>Patient Organisations - Level 1</b>	<b>Booth No.</b>
Taewoong Medical	X2/21	Association of European Coeliac Societies (AOECS)	AFA1/3
The Standard Co., Ltd	X4/15	EuropaColon/Digestive Cancers Europe	AFA1/2
US Endoscopy	X2/17	European Federation of Crohn's and	
W. L. Gore & Associates	X5/44	Ulcerative Colitis Associations (EFCCA)	AFA1/1


**Scientific Centre  
Hall X1**



**Exhibition  
Hall X2**




**Exhibition  
Hall X3**



Level  
**-2**

■ Premium Partners / Major Partners    ■ General Exhibitors

Level **0**





## Letter of Thanks



Dear Colleagues,

On behalf of the UEG Scientific Committee, I would like to take this opportunity to thank you most sincerely for your contribution as an abstract reviewer for the original programme of UEG Week Vienna 2018. The abstract reviewing process has been again very important this year with a number of innovations introduced to improve especially the poster abstract presentations.

I know just how much time and effort reviewing abstracts takes, but without your expertise we would not have the quality that I believe we have achieved in the free paper and poster sessions, and UEG Week would not be the top international digestive diseases meeting that it has become today.

Thank you!

We received a number of **3,170 abstracts** in total for UEG Week 2018. In total, **2,214 abstracts** were accepted, giving an **acceptance rate of 69,84%**. **337 abstracts** will be delivered as **oral presentations** and **1,877** as **posters**. I am even more pleased to tell you that standards have again reached a very high level and we can expect to be exposed to most interesting research and great presentations.

This high volume and high standard confirm that UEG Week is the most important forum at which to present your best research.

We have received **88 video cases** and **254 clinical cases** which were formally evaluated by the Scientific Committee for presentation in Vienna. As in previous years, late breaking abstracts have been scored by the Scientific Committee for presentation in Vienna. The quality of reviewing this year was excellent, but if you have any further (positive or negative) comments, please do let us know! Finally, but most importantly, thanks to all investigators both within and outside Europe who have submitted their research to the meeting, and who are clearly contributing to making UEG Week Vienna 2018 such a great success!

A handwritten signature in blue ink, appearing to read 'Herbert Tilg'.

Herbert Tilg  
Chair of the UEG Scientific Committee

## List of Reviewers

### A

Aabakken, Lars  
 Acalovschi, Monica  
 Adamina, Michel  
 Adar, Tomer  
 Aden, Konrad  
 Adham, Mustapha  
 Adolph, Timon Erik  
 Aghemo, Alessio  
 Agréus, Lars  
 Albano, Emanuele  
 Allez, Matthieu  
 Almasio, Piero Luigi  
 Almeida, Raquel  
 Annibale, Bruno  
 Arber, Nadir  
 Ardizzone, Sandro  
 Arlt, Alexander  
 Arvanitakis, Marianna  
 Atherton, John  
 Aziz, Qasim  
 Azpiroz, Fernando

### B

Baert, Filip  
 Bahr, Matthias J.  
 Balaguer, Francesc  
 Bañales, Jesús M.  
 Barbara, Giovanni  
 Barbu, Sorin Traian  
 Barthet, Marc  
 Bazzoli, Franco  
 Beaugerie, Laurent  
 Beglinger, Christoph  
 Beldi, Guido  
 Bemelman, Willem A.  
 Benamouzig, Robert  
 Bergman, Jacques J.  
 Bergquist, Annika  
 Bernink, Jochem Huib Jan  
 Besselink, Marc G.H.  
 Bhandari, Pradeep  
 Biancone, Livia  
 Binder, Henry J.  
 Binek, Janek  
 Bisschops, Raf  
 Blero, Daniel  
 Boeckstaens, Guy E.

Boermeester, Marja A.  
 Bokun, Tomislav  
 Bor, Serhat  
 Bories, Erwan  
 Bornschein, Jan  
 Bouhnik, Yoram  
 Bourreille, Arnaud  
 Bredenoord, Arjan  
 Brigidi, Patrizia  
 Bruno, Marco J.  
 Bures, Jan  
 Burisch, Johan  
 Burra, Patrizia  
 Buscarini, Elisabetta  
 Bytzer, Peter

### C

Caprioli, Flavio  
 Capurso, Gabriele  
 Cardenas, Andres  
 Carneiro, Fatima  
 Carter, Ross  
 Caseiro Alves, Filipe  
 Castiella Eguzkiza,  
 Agustin  
 Castro, Rui  
 Cellier, Christophe  
 Cenac, Nicolas  
 Chmiela, Magdalena  
 Cholongitas, Evangelos  
 Colombel, Jean-Frederic  
 Copaescu, Catalin  
 Corsetti, Maura  
 Cortez-Pinto, Helena  
 Cortot, Antoine  
 Costamagna, Guido  
 Cottone, Mario  
 Cravo, Marilia  
 Craxi, Antonio  
 Cremers, Isabelle  
 Crippa, Stefano  
 Csepregi, Antal

### D

Danese, Silvio  
 de Boer, K.H.N. (Nanne)  
 de Franchis, Roberto  
 De Giorgio, Roberto

de Knecht, Robert J.  
 De Palma, Giovanni D.  
 Dejaco, Clemens  
 Dekker, Evelien  
 Delhaye, Myriam  
 de-Madaria, Enrique  
 Depoortere, Inge  
 Deprez, Pierre Henri  
 Deviere, Jacques  
 D'Haese, Jan Goesta  
 di Pietro, Massimiliano  
 Dignass, Axel  
 Dinis-Ribeiro, Mario  
 Dolak, Werner  
 Dolinsek, Jernej  
 Dorta, Gian  
 Dotan, Iris  
 Drenth, Joost P.H.  
 Drewes, Asbjørn  
 Dupont, Christophe  
 Duran, Rafael

### E

Eisendrath, Pierre  
 Eliakim, Abraham (Rami)  
 Ensari, Arzu  
 Esmat, Gamal  
 Eutamene, Helene

### F

Färkkilä, Martti A.  
 Farmer, Adam Donald  
 Farre, Ricard  
 Ferenci, Peter  
 Ferrante, Marc  
 Ferreira, Rui M.  
 Ferreiro-Iglesias, Rocio  
 Fichna, Jakub  
 Fiorucci, Stefano  
 Fitzgerald, Rebecca Clare  
 Floreani, Annarosa  
 Fockens, Paul  
 Ford, Alexander Charles  
 Fox, Mark  
 Francoz, Claire  
 Friess, Helmut  
 Froehlich, Florian  
 Fujishiro, Mitsuhiro

### G

Gangl, Alfred  
 Gasbarrini, Antonio  
 Gemilyan, Manik  
 Ghaneh, Paula  
 Ghia, Jean-Eric  
 Giangregorio,  
 Francesco  
 Gionchetti, Paolo  
 Giovannini, Marc  
 Gisbert, Javier  
 Gisbertz, Suzanne S.  
 Gloor, Beat  
 Goetz, Martin  
 Gomes de Sousa, Rita  
 Gordon, Harriet  
 Gottrand, Frederic  
 Graziadei, Ivo  
 Grgurevic, Ivica  
 Grønbaek, Henning  
 Grundy, David

### H

Haboubi, Najib  
 Haddad, Fouad  
 Hahnloser, Dieter  
 Halfvarson, Jonas  
 Hammad, Essam  
 Hammer, Heinz Florian  
 Handra-Luca, Adriana  
 Hassan, Cesare  
 Havre, Roald Flesland  
 Hegyi, Peter  
 Heicie, Frank  
 Heinrich, Henriette  
 Hellström, Per Martin  
 Helmberger, Thomas  
 Herszényi, László  
 Hofer, Harald  
 Hoffman, Arthur  
 Hojsak, Iva  
 Holleran, Grainne  
 Hov, Johannes Roksund  
 Hovde, Øistein  
 Huberty, Vincent  
 Huibregtse, Inge L.  
 Hunyady, Bela  
 Hytiroglou, Prodromos

**I**

Iacopini, Giampaolo  
Ianiro, Gianluca  
Ibrahim, Mostafa  
Ilan, Yaron  
Ilie, Madalina  
Isajevs, Sergejs

**J**

Jackson, Simon  
Jenkins, Ian  
Jonkers, Daisy Mae

**K**

Kelly, Paul  
Keshav, Satish  
Keszthelyi, Daniel  
Kida, Mitsuhiko  
Kim, Won Ho  
Kleger, Alexander  
Knowles, Charles H.  
Kobara, Hideki  
Koletzko, Sibylle  
Kolho, Kaija-Leena  
Koning, Frits  
Kramer, Ludwig  
Krishnadath, Kausilia K.  
Kupcinskas, Limas  
Kurppa, Kalle

**L**

Lackner, Karoline  
Laghi, Andrea  
Laharie, David  
Lakatos, Peter László  
Lamarque, Dominique  
Langner, Cord  
Laukkarinen, Johanna  
Lee, James C.  
Leedham, Simon  
Leicester, Roger  
Leja, Marcis  
Lemmers, Arnaud  
Leroi, Anne Marie  
Lévy, Philippe  
Lewis, Michael  
Liberal, Rodrigo  
Lindberg, Greger  
Lindley, Keith  
Lindsay, James  
Löhr, Matthias  
Lomer, Miranda  
Lopes, Ana Isabel  
Louis, Edouard

Louis, Hubert  
Lügering, Andreas  
Lugli, Alessandro  
Lundin, Knut E.A.  
Luzza, Francesco

**M**

Maaroots, Heidi-Ingrid  
Maaser, Christian  
Machado, Jose Carlos L.  
Magro, Fernando  
Maillard, Michel  
Makrithatis, Athanasios  
Malagelada, Carolina  
Malagelada, Juan Ramon  
Manns, Michael  
Manolakopoulos, Spilios  
Mantzaris, Gerassimos  
Marinho, Rui Tato  
Marquardt, Jens Uwe  
Marteau, Philippe  
Marti-Bonmati, Luis  
Martinek, Jan  
Mascee, Ad  
Matos, Celso  
Mcalindon, Mark  
McColl, Kenneth E.L.  
McLaughlin, John  
Megraud, Francis  
Meier, Peter  
Meining, Alexander  
Meisner, Soren  
Menu, Yves  
Michetti, Pierre  
Michl, Patrick  
Mikolasevic, Ivana  
Milashka, Mariana  
Milosavljevic, Tomica  
Mion, Francois  
Moeller, Soeren  
Mönkemüller, Klaus  
Moreels, Tom  
Morino, Mario  
Moschen, Alexander R.  
Mulder, Chris J.J.  
Muñoz-Navas, Miguel  
Musso, Alessandro  
Myrelid, Pär

**N**

Nakajima, Takeshi  
Nakov, Radislav  
Nardone, Gerardo  
Naylor, Gregory

Neesse, Albrecht  
Ness-Jensen, Eivind  
Neuberger, James  
Neufert, Clemens  
Neunlist, Michel  
Ng, Siew Chien  
Nielsen, Ole Haagen  
Nowakowska-Dulawa, Ewa

**O**

Odes, Shmuel  
Ohlsson, Bodil  
Öhman, Lena  
Okolicsanyi, Lajos  
Oliveira, Carla  
Oliveira, Claudia  
O'Morain, Colm  
Öresland, Tom

**P**

Pace, Fabio  
Papadopoulou, Alexandra  
Papanikolaou, Ioannis  
Papatheodoridis, Georgios  
Pár, Alajos  
Paradis, Valerie  
Parola, Maurizio  
Pech, Oliver  
Peck-Radosavljevic, Markus  
Pedersen, Natalia  
Penagini, Roberto  
Pereira, Stephen  
Pérez-Miranda, Manuel  
Péron, Jean-Marie  
Petrosillo, Nicola  
Pohl, Daniel  
Pokrotnieks, Juris  
Prifti, Skerdi  
Püspök, Andreas

**Q**

Quante, Michael  
Quintero Carrion, Enrique

**R**

Ragunath, Krish  
Rajilic-Stojanovic, Mirjana  
Rakoncay, Zoltan  
Ramadori, Giuliano  
Rebours, Vinciane  
Reenaers, Catherine  
Reeves, Helen  
Regula, Jaroslav

Reif, Shimon  
Ricart Gomez, Elena  
Ricciardiello, Luigi  
Riis, Lene Buhl  
Risio, Mauro  
Rodrigues, Cecília Maria Pereira  
Rodríguez-Lago, Iago  
Roeb, Elke  
Rogler, Gerhard  
Rokas, Theodore  
Roman, Sabine  
Romano, Marco  
Ronkainen, Jukka  
Rooman, Ilse  
Rösch, Thomas  
Rosendahl, Jonas  
Rubin, Gregory  
Rudler, Marika  
Ruemmele, Frank  
Rugge, Massimo  
Russo, Francesco Paolo  
Ruszniewski, Philippe

**S**

Salaga, Maciej  
Salkic, Nermin  
Salupere, Riina  
Santos, Javier  
Sarnelli, Giovanni  
Savarino, Edoardo  
Savarino, Vincenzo  
Scharl, Michael  
Schemann, Michael  
Schneditz, Georg  
Schöfl, Rainer  
Schölmerich, Jürgen  
Schoon, Erik Jan  
Schreiber, Stefan  
Schrumpf, Erik  
Seewald, Stefan  
Seifert, Bohumil  
Sekiguchi, Masau  
Serag Zakaria, Khaled  
Serra, Jordi  
Seufferlein, Thomas  
Shamir, Raanan  
Sheridan, James P.  
Shetty, Shishir  
Shimosegawa, Tooru  
Shirin, Haim  
Siegmond, Britta  
Siersema, Peter D.  
Sifrim, Daniel



Simrén, Magnus  
Singh, Baljit  
Socha, Piotr  
Sokol, Harry  
Sookoian, Silvia  
Spada, Cristiano  
Spiller, Robin  
Spinelli, Antonino  
Sporea, Ioan  
Staiano, Annamaria  
Stallmach, Andreas  
Stanghellini, Vincenzo  
Stauber, Rudolf  
Stengel, Andreas  
Stieger, Bruno  
Stoyanova, Daniela  
Sung, Joseph Jao Yiu

**T**

Tack, Jan  
Tacke, Frank  
Tamori, Akihiro  
Tanis, Pieter  
Taylor, Stuart  
Thapar, Nikhil  
Thorlacius, Henrik

Tilg, Herbert  
Tiniakos, Dina  
Tomazic, Ales  
Törnblom, Hans  
Torres, Joana  
Tözün, Nurdan  
Trauner, Michael  
Trifan, Anca-Victorita  
Troncone, Riccardo  
Trovato, Cristina Maria  
Trukhmanov, Alexander  
Tsochatzis, Emmanuel  
Tulassay, Zsolt  
Turner, Dan  
Tutuian, Radu

**U**

Uranues, Selman  
Uraoka, Toshio  
Urbonas, Vaidotas

**V**

Vaira, Bernardino  
Valantinas, Jonas  
van Berge Henegouwen,  
Mark Ivo

van de Graaf, Stan  
van der Woude, C. Janneke  
van Eijck, Casper H.J.  
van Herwaarden, Yasmijn  
Van Hoetegem, Philippe  
Van Kemseke, Catherine  
van Leerdam, Monique  
Van Oudenhove, Lukas  
Veereman, Gigi  
Verdelho Moutinho  
Machado, Mariana  
Luisa  
Veres, Gabor  
Vermeire, Severine  
Vilmann, Peter  
Vinter-Jensen, Lars  
Vlachogiannakos, John  
Vogel, Arndt  
Vogel, Wolfgang  
von Hahn, Thomas

**W**

Walker, Marjorie  
Watson, Alastair  
Weersma, Rinse K.  
Welsch, Christoph

Wilder-Smith, Clive  
Wittenburg, Henning  
Wolthuis, Albert

**Y**

Yamaoka, Yoshio  
Yao, Kenshi

**Z**

Zachou, Kalliopi  
Zaninotto, Giovanni  
Zeissig, Sebastian  
Zelinkova, Zuzana  
Zerbib, Frank  
Zins, Marc

The graphic features a dark grey background with an orange wavy line that starts from the bottom left and moves towards the top right. Along this line are four icons representing different awards: a microscope, a star on a pedestal, a virus/cell, and a book with a ribbon. Text labels for each award are placed next to their respective icons. The UEG Research logo is in the top left, and a call to action is in the bottom left.

**UNITED EUROPEAN GASTROENTEROLOGY**  
**ueg research**

**We support your research career every step of the way**

**Research Prize**

**Research Career Development Award**

**Rising Star Award**

**Research Fellowship**

Find out more, visit [ueg.eu/awards-grants](http://ueg.eu/awards-grants)

## **Index of Authors and Co-Authors**

## Index of Authors and Co-Authors

<b>A</b>			
Aabakken, L. ....	36, 39, 55, 67, 84, 91, 224, 231		
Aalbers, A. ....	137		
Aalfs, C. ....	191		
Aargüelles Arias, F. ....	232		
Aarts, E. O. ....	206		
Abaalkhail, F. ....	209		
Abad, A. ....	49		
Abassi, Z. ....	127		
Abbasy, M. ....	213		
Abbey, Y. ....	124		
Abd El Khalik, A. ....	170		
Abd El Maksoud, M. ....	125, 170		
Abd El-Ghany, M. ....	135		
Abd El-Maksoud, M. ....	168		
Abd El-Razek, A. ....	168		
Abd Elmoety, A. A. ....	212		
Abd Elsamee, A. ....	123		
Abd-Elkreem, M. ....	214		
Abd-Elsalam, S. ....	64, 122, 125, 129		
Abdel Moneim, A. ....	206		
Abdel Wahed, A. ....	214		
Abdel-Aziz, H. ....	227		
Abdel-malek, M. O. ....	123		
Abdel-Samiee, M. ....	214		
Abdel-Tawab, N. F. ....	227		
Abdel-Wahab, M. ....	169		
Abdelaal, A. ....	162		
Abdelattati, E. A. ....	120, 122, 124		
AbdelAziz, M. ....	170		
Abdelbary, A. ....	253		
Abdelhafez, M. ....	220		
Abdelhaleem, M. ....	209		
Abdelkrim, Z. ....	221		
Abdelli, M. N. ....	168		
Abdelrahim, M. ....	190		
Abdelrahman, G. ....	214		
Abdelrazek, A. ....	162		
Abdelsameea, E. ....	165, 214		
Abdelsamiae, E. ....	152		
Abdennebi, C. ....	212		
Abdilla, Y. ....	126, 236		
Abdo, M. ....	162		
Abdulganieva, D. ....	184, 231		
Abdulhafiz, E. ....	123, 214		
Abdulkader-Nalib, I. ....	246		
Abdulkader, I. ....	134		
Abdulkareem, L. O. ....	168		
Abdulkhakov, R. ....	58, 74, 101, 235, 247		
Abdulkhakov, S. ....	58, 74, 101, 235, 247		
Abdulkhakov, S. R. ....	58, 74, 235		
Abe, K. ....	128, 180, 197		
Abe, S. ....	130, 202		
Abe, Y. ....	129, 148		
Abell, J. ....	186		
Abid, H. ....	69, 216, 246		
Abiko, S. ....	155		
Abo-El-Enein, A. ....	169		
Abou Ali, E. ....	135		
Abou Elela, T. ....	213		
Abou Fadel, C. ....	242		
Abounit, S. ....	232		
Abreu, C. ....	162		
Abreu, I. ....	121		
Abreu, S. ....	147		
Abril, C. ....	237		
Abrudan, C. ....	120		
Abu-Assi, R. ....	244		
Abu Baker, F. ....	176		
Abu-El-Haija, M. ....	65		
Abu Freha, N. ....	181		
Abuzin, M. ....	191		
Accomando, S. ....	61		
Aceituno, M. ....	159		
Acevedo, J. ....	49		
Acharki, M. ....	198, 219, 226		
Achkar, M. ....	130		
Acosta-Crow, A. ....	154		
Adachi, T. ....	138, 172		
Adair, R. ....	56		
Adam, R. ....	38		
Adamczyk, K. ....	211		
Adan Alonso, M. ....	248		
Addolorato, G. ....	162, 207, 211		
Adedokun, O. ....	188		
Adegbola, S. ....	228, 234		
Adel Ali, R. ....	214		
Ademaj, K. ....	186		
Aden, K. ....	96		
Adeniran, A. ....	134		
Adhaduk, M. ....	249		
Adil, I. ....	220		
Admyre, C. ....	142		
Adolph, T. E. ....	70, 183		
Adrian, Z. ....	131, 178		
Advani, R. ....	135		
af Björkesten, C.-G. ....	231		
Affif, W. ....	185		
Afonso, J. ....	186, 190, 231		
Afonso, M. B. ....	59, 76, 166		
Afzal, Z. ....	203		
Agawa, S. ....	243, 245		
Aghemo, A. ....	40, 56, 68, 79, 123		
Agnholt, J. ....	230, 234		
Agrawal, A. ....	175-176		
Agréus, L. ....	199		
Aguilar-Gama, V. ....	148		
Aguilar-Olivos, N. E. ....	221		
Aguilera Castro, L. ....	71		
Agus, A. ....	182		
Agwa, S. ....	123		
Aharon-Kaspi, S. ....	148		
Aharoni Golan, M. ....	234		
Ahluwalia, B. ....	195		
Ahmad, A. ....	252		
Ahmad, O. F. ....	176		
Ahmad, T. ....	190		
Ahmadi, V. ....	167		
Ahmadian, M. ....	193		
Ahmed Ali, U. ....	46		
Ahmed, B. ....	209		
Ahmed, M. H. ....	252		
Ahmed, M. R. ....	206		
Ahmed, T. ....	121		
Ahn, J. Y. ....	218, 245		
Aiello, A. F. ....	231		
Aihara, Y. ....	174		
Aikawa, M. ....	181, 251		
Aimi, M. ....	158, 243		
Ainora, M. E. ....	167, 211		
Airinei, G. ....	226		
Aissaoui, M. ....	123		
Aissat, Y. ....	123		
Aisseoui, F. ....	240		
Aizawa, D. ....	151		
Aizawa, M. ....	176, 204		
Ajdarkosh, H. ....	123		
Ajmi, S. ....	125, 211, 215, 230, 248		
Akagi, Y. ....	155		
Akamatsu, N. ....	158		
Akamatsu, T. ....	177		
Akarsu, M. ....	156		
Akasaka, R. ....	156		
Akazawa, Y. ....	129, 156-157, 191, 201		
Akberova, D. ....	231		
Akhter, T. ....	228		
Akimoto, N. ....	160, 162, 205		
Akimoto, T. ....	82, 130, 149, 156, 177, 218, 245		
Akinci, H. ....	185		
Akizue, N. ....	52, 80, 153, 174		
Akkaoui, A. ....	114		
Akkuratova, I. ....	171		
Akl, E. ....	152		
Akol, H. ....	199		
Akriavidis, E. ....	168, 212		
Aksan, A. ....	186, 232		
Aksenov, P. ....	157		
Aksu, C. ....	230		
Akutsu, N. ....	222		
Akyildiz, S. ....	244		
Al-Akkad, W. ....	57		
Al-Azzawi, Y. ....	124, 132		
Al Bakir, I. ....	151, 228		
Al-Batran, S.-E. ....	202		
Al-Drainy, B. ....	169		
Al Haddad, O. ....	165, 213		
Al Haddad, O. K. ....	213		
Al Hajjar, N. ....	120		
Al-Hasani, H. ....	110, 167		
Al Hashash, J. ....	241		
Al-Kaab, A. ....	94		
Al Kaabi, S. ....	225, 252		
Al-khalaf, M. ....	184		
Al Nabhani, Z. ....	100		
Ala, A. ....	124, 170		
Aladrén B., S. ....	49, 144		
Alahdad, Y. O. ....	230		
Alaimo, G. ....	58		
Alakkari, A. ....	140		
Alarcón, O. ....	131		
Alazab, R. ....	214		
Alba, C. ....	93, 143, 188, 247		
Alba López, C. ....	188		
Albano, E. ....	48		
Albano, F. ....	136		
Albatee, H. ....	252		
Albazaz, R. ....	40, 92, 101		
Albéniz, E. ....	202, 237		
Albéniz Arbizu, E. ....	95, 198		
Albéniz-Arbizu, E. ....	131		
Alberelli, M. A. ....	58		
Albers, D. ....	219, 224		
Albert, J. ....	38, 109-110		
Albillos Martínez, A. ....	71, 202		
Alblas, M. ....	92		
Albrektsen, G. ....	142		
Albuquerque, C. ....	130, 147, 183		
Albusoda, A. ....	95, 194		
Alcaide, N. ....	188		
Alcain, G. ....	193		
Alcaín, G. ....	49, 93		
Alcalá, L. G. ....	162		
Alcalde, D. ....	195		

Aldeguer, X.....	49, 93, 148-149, 249	Altamimi, K.....	140	Anderloni, A.....	181, 197, 218, 225	Aoki, Y.....	131
Alderlieste, Y.....	149	Altonbary, A.....	135	Anders, M.....	62	Aoko, O.....	130, 181
Aldridge, J.....	220	Altorjay, I. F.....	134, 187	Andersen, J. B.....	214	Aoun, R.....	152
Alencar, P.....	200	Altwegg, R.....	61, 233	Andersen, T.....	100	Aoyagi, H.....	197
Alenda, C.....	192	Alustiza, J. M.....	121	Andersen, V.....	48, 185	Aoyama, K.....	88, 133, 158
Alessandra, B.....	197	Alustiza Fernandez, M.....	96, 192	Anderson, J.....	80, 177	Aparicio, J. R.....	172
Alexandrakis, G.....	223, 248	Alvarado-Escobar, H.....	51-52, 154, 180	Andersson, E.....	228	Aparicio Tormo, J. R.....	192
Alexandrino, G.....	64, 134, 168	Álvarez-Delgado, A.....	131	Andersson, K.....	200	Apostolopoulos, P.....	223, 248
Alexiev, A.....	114	Álvarez Herrero, L.....	148	Ando, M.....	211	Appenrodt, B.....	79, 102, 150
Alexopoulou, A.....	168	Álvarez-Pérez, A.....	223	Andoh, A.....	179, 217, 246	Aqodad, N.....	69, 216, 246
Alfaro Perez, I. J.....	141	Álvarez Sanchez, M. V.....	95	Andrade, E.....	209	Arafa, M.....	100, 214
Alfaro, E.....	219	Álvarez-Urturi, C.....	94, 194	Andrade, G.....	123	Arai, J.....	152, 222
Algaba, A.....	93, 143	Alvaro, D.....	100, 166	Andrade, P.....	145, 170, 172, 175, 184, 212, 250	Arai, M.....	52, 80, 153, 174
Algaba García, A.....	233	Alves, J.....	121, 123	Andrade, R.....	96	Arai, Y.....	204
Alghobashy, Y.....	124	Alves, R.....	163	Andrási, L.....	194	Arajol, C.....	93, 233
Algül, H.....	68, 89, 103, 173	Alves, S.....	193	André, A.....	189	Aral, M.....	162
Alhamoudi, W.....	209	Alves, V. A. F.....	157	Andreadis, P.....	197	Arana-Arri, E.....	178, 222, 236
Alhelbawy, M.....	124	Alvisi, M.....	128	Andreasson, A.....	199	Aranda, R.....	69, 98, 199
Ali, A.....	62, 249	Alvisi, P.....	140	Andreazzo, P.....	150	Arasaradnam, R.....	87, 94, 140
Ali, G.....	159	Aly Aboelfotoh, O.....	214	Andresen, V.....	47, 87, 103, 110	Arau, B.....	159
Ali El-Feky, M.....	139	Alzoubaidi, D.....	62, 83, 241, 245	Andreu Garcia, M.....	94, 194	Araujo, I.....	158
Ali Khan, M.....	133	Amador, J.....	74, 203	Andreuzzi, E.....	192	Araújo, T.....	134, 246
Alieva, I.....	58	Amalou, K.....	168	Andriulli, A.....	197	Araujo Acuña, I. K.....	186, 224
Alieva, N.....	162	Amano, H.....	125	Andrianjafy, C.....	149	Araujo Correia, L.....	164, 208
Alishah, S. H.....	121-122	Amano, N.....	156	Ang, D.....	153	Arber, N.....	181
Alkandari, A.....	81, 218	Amano, Y.....	128, 134, 157	Ang, T.-L.....	153	Arbune, M.....	169
Alkhatieb, Z.....	124	Amara, J.....	130	Ángeles Martínez, J.....	226	Archibugi, L.....	172, 179, 216
Allam, M.....	124, 214	Amaral, A. J.....	59	Angeletti, S.....	92, 129-130	Arcidiacono, P. G.....	134, 172, 179
Allam, M. M.....	214	Amaro, P.....	176	Angeli, P.....	167	Ardengh, J. C.....	133
Allam, N.....	124, 152	Ameda, S.....	178	Angelogiannopoulou, N.....	134	Ardizzone, S.....	160, 229
Allegretta, L.....	100, 150	Amelung, F. J.....	238	Angriman, I.....	138	Arebi, N.....	48, 185
Allen, M.....	114	Amemiya, K.....	52, 203	Angrisman, L.....	36, 154, 161	Arechavaleta, S.....	237
Allen, R.....	234	Amieva-Balmori, M.....	149	Ankersen, D.....	139, 186	Aref, W.....	129, 163
Allez, M.....	35, 46-47, 59, 75-76, 84, 86, 91, 98, 231, 236	Amil Dias, J.....	55, 93, 102	Annibale, B.....	92, 129, 150, 245	Areia, M.....	74, 80, 84, 87, 193
Allimant, C.....	231	Amin, M. A.....	122	Annicchiarico, B. E.....	167	Arena, U.....	124
Allin, K.....	233	Amiot, A.....	61	Anunziata, M. L.....	100, 150, 157	Arends, J.....	77
Allo, G.....	241	Amiot, X.....	135-136	Ansari, N.....	135	Argüelles-Arias, F.....	49
Alm, J.....	191	Amjahdi, A.....	114	Ansell, J.....	150	Argüelles, F.....	49, 188
Almeida, N. P.....	204	Amlani, B.....	151	Anthony, D.....	50	Argyriou, K.....	177
Almeida, V.....	163	Amo, V.....	188	Antico, A.....	92, 196, 203, 246	Arias Arias, Á.....	199
Almela, P.....	49, 93, 232	Amoedo, J.....	148-149	Antonelli, G.....	130	Arias García, L.....	193
Almer, S.....	185	Amorena, E.....	158	Antonelli, M.....	162	Arieira, A.....	49, 71, 121-122, 136, 166
Alonso, C.....	148	Amorós Tenorio, A.....	152	Antonenko, A.....	120	Arihiro, K.....	53
Alonso, I.....	131	Amorós-Tenorio, A.....	131	Antonini, F.....	224	Arimoto, J.....	132, 193
Alonso Lopez, S.....	167	Amoruso, A.....	160	Antonov, K.....	114, 162	Ariño, I.....	98, 204, 247
Alonso-Cotoner, C.....	162	Amouri, A.....	159	Antunes, M. T.....	171	Ario, K.....	180
Alos, R.....	86, 184, 227	An, F.....	214, 237	Antypas, P.....	52	Arkila, P.....	198, 223
Alric, L.....	71	An, J.....	139	Anzai, H.....	148	Armengol Debeir, L.....	71
Alsabaawy, M.....	124	Anand, A.....	82, 155	Anzai, S.....	57, 183	Armengol Miró, J. R.....	209
Alsebaey, A.....	124	Anastasi, N.....	69	Aoki, H.....	147, 177, 192	Armerding, P.....	80, 187
		Anastassiades, C.....	178				

Armsisen, A.....	151	Attili, F.....	72, 134, 244, 251	Badr, M.....	122	Bañales, J. M.....	55, 63, 86, 91, 99, 214
Armuzzi, A.....	61, 139-142, 229, 234	Attwood, S.....	62, 244	Bae, J. Y.....	174, 219	Banares, R.....	56, 78, 83, 102
Arndtz, K.....	171	Auge Fradera, J. M.....	147	Bae, J.-S.....	238	Bancil, A.....	228
Arnelo, U.....	56, 92, 127	Augusto, V.....	222	Bae, S.-E.....	245	Banerjee, A.....	144
Arnhold, J.....	235	Auricchio, R.....	64, 161	Baeg, M. K.....	146	Banerjee, R.....	143
Arnold, F.....	50, 172	Auremma, F.....	181, 205, 224-225	Baek, S. M.....	157, 203	Banerjee, T.....	199
Arnott, I.....	188, 234	Aust, D.....	68	Baert, F.....	78, 97	Bang, B. W.....	224, 241
Aro, P.....	199	Autran-Nebel, J.....	51, 180	Bafutto, M.....	51, 100	Bang, C. S.....	133, 149
Arola, J.....	59, 76, 190, 213	Avallone, E. V.....	145	Bagheri Lankarani, K.....	169	Bang, J. Y.....	56, 99
Aronico, N.....	205, 228-229, 240	Avalueva, E.....	187	Bahar, A.....	182	Bang, K.-B.....	201
Arpa, G.....	196	Avedano, L.....	232	Bahí, A.....	148-149	Bang, S.....	136
Arribas-Anta, J.....	131	Averna, A.....	58	Bahlouli, W.....	161	Bangma, A.....	233
Arrizabalaga, B.....	121	Avery, A. J.....	204	Bai, Y.....	61	Banhudo, A.....	122, 163, 167, 253
Arroja, B.....	186, 231	Aviles, M.....	247	Baicus, C.....	168	Banks, M.....	62, 153, 241, 245
Arroyo, M.....	49	Awadie, H.....	80, 85, 177, 224	Baidoo, L.....	188	Bannaga, A.....	176
Arslan Yurtlu, D.....	220	Awaga, Y.....	184	Baig, M. F. A.....	209	Bannwart, F.....	177
Arslan, G.....	242	Awasthi, A.....	241	Baik, G. H.....	133, 149	Banovcin, P.....	69, 199, 242
Arstikyte, J.....	240, 248	Axiaris, G.....	221	Bailey, Y.....	185	Bansal, R.....	55, 210
Arts, J.....	71, 198	Axon, A.....	98, 204, 247	Baillie, S.....	218	Bapaye, A.....	215, 221, 246
Arvanitakis, M.....	35, 37, 39, 54, 62, 68, 72, 84-85, 92, 103, 223	Aya, H.....	211, 230, 241	Baima, J.....	229	Bapaye, J. A.....	215, 246
Arvola, T.....	161	Ayari, M.....	162	Bair, M.-J.....	165	Bar-Yishay, I.....	224
Arzani, D.....	58	Ayoub, F.....	131	Bajaj, G.....	75	Barada, K.....	152, 241
Asada, Y.....	133	Ayoubi Khajekini, M. T.....	208	Bajbouj, M.....	187	Baraldo, S.....	223
Asai, Y.....	136, 171	Ayuk, F.....	58	Bajor, J.....	126-127, 145, 162, 171, 249	Barastegui, R.....	141
Asano, T.....	238	Ayyildiz, T.....	164	Bak, V.....	145	Baratta, M.....	198
Asante, M.....	239	Azemoto, N.....	173, 217	Bakalarz, D.....	201	Barazzutti, A.....	241
Asaturi, A.....	221-222	Azevedo, R.....	122, 130, 163, 167, 253	Baker, A.-M.....	228	Barbara, G.....	38, 51-52, 72, 103, 150, 235
Aschenbrenner, E.....	122, 214	Azghari, I.....	219, 226	Baker, G.....	176	Barbara, M. A.....	236
Asensi-Canto, P.....	71, 183	Aziz, Q.....	95, 194, 199, 220, 239	Bakker, M.....	53, 85	Barbaro, F.....	78
Asensio, J.....	190	Azmat, R.....	122	Bakó, K.....	65	Barbaro, M. R.....	52, 72, 235
Asensio, T.....	69	Azouz, M. M.....	204	Bakulin, I.....	120, 203	Barberan Bernardos, A.....	50
Ashaye, A.....	144	Azpíroz, F.....	57, 96	Bakulina, N.....	120, 203	Barberio, B.....	146, 209, 233
Ashikari, K.....	132, 193	Azuma, K.....	123	Bal, K.....	123	Barbuscio, I.....	208-209, 224, 252
Ashizawa, H.....	125, 245	Azuma, M.....	89, 129	Balachandran, A.....	50	Barchi, A.....	198, 245-246
Ashorov, O.....	159	Azzolini, F.....	236	Balaguer, F.....	62, 95, 115, 192	Bardini, R.....	138
Ashoush, O.....	129, 164	Azzopardi, N.....	225, 236	Balan, G.....	181	Bardou, M.....	95, 191
Aslan, F.....	220	<b>B</b>		Balassone, V.....	180	Bargo, D.....	61, 142
Aslan, N.....	140	Ba-Ssalamah, A.....	40, 212	Baldaia, C.....	144, 208, 230, 251	Bari, M.....	198
Aslanian, H.....	56, 134	Baars, J.....	137, 201	Baldaque Silva, F.....	201	Barisic, A.....	110
Assadi, G.....	228	Baas, F.....	216	Baldaque-Silva, F.....	134	Barišić, A.....	230
Asselah, H.....	125	Baba, T.....	131, 192, 220	Baldassarre, G.....	92, 196-197, 203, 240, 246	Barjas, E.....	219
Assouline Dayan, Y.....	249	Babahajian, A.....	210	Baldi, F.....	150	Barkan, R.....	234
Assouline-Dayan, Y.....	69, 98	Babenko, L.....	206	Baldini, L.....	249	Barkaszi-Szabó, Z.....	162
Astegiano, M.....	150, 160, 228	Babic, N.....	251	Baldissarro, I.....	233	Barkov, A.....	156
Asthana, A. K.....	140	Babiuc, R.....	231	Baldoni, F.....	222	Barla, G.....	168
Ates, F.....	140	Bäbler, K.....	143, 183	Balint, A.....	145, 180, 194, 232, 234	Barnard, G.....	124
Athanasiadou, E.....	197	Bac, D. J.....	149	Ballo, S.....	194	Barnier-Rasmussen, N.....	76
Atienza, R.....	229	Bachmann, O.....	141-142	Balogh, M.....	162	Barnhoorn, M.....	57
Atkinson, D.....	225, 231	Backes, Y.....	148-149, 192	Balzano, A.....	197	Barnich, N.....	70, 86, 139, 183, 192, 227, 231
Atmani, K.....	161, 238	Badawi, R.....	64	Bamba, S.....	134, 179, 217	Baroiu, L.....	169
Atreya, R.....	70, 76, 78, 102, 189, 220, 225, 232	Badcock, N.....	72	Bambas, G.....	229	Baroiu, N.....	169
Attrott, K.....	183	Bader, A.....	176	Bamias, G.....	139	Baron, M.....	238
Attaran-Bandarabadi, M.....	142	Bader, F.....	232	Bana e Costa, T.....	124	Barone, M.....	158, 160, 205
Attardo, S.....	181, 218, 225	Badiali, D.....	153, 242	Banales, J.....	166	Barosa, R.....	183
		Bado, A.....	191			Barr, H.....	62

Barrachina, M. D. ....	71, 86, 183-184, 227	Baur, N. ....	166	Beltran, B. ....	49	Bergman, J. J. ....	48, 62-63, 73, 82, 88, 98, 102, 154-155, 206
Barrajón, A. ....	188	Baxevanis, P. ....	221	Belvis Jiménez, M. ....	125, 232	Bergson, J. H. ....	250
Barranco, R. ....	195	Bay-jensen, A.-C. ....	227, 229	Belyakov, M. ....	208	Bergström, A. ....	191
Barrault, C. ....	56	Bazarova, A. ....	235	Bemelman, W. A. ....	36, 55, 59, 86, 102, 137, 142, 145-146, 187, 238	Berliba, E. ....	97, 142
Barreiro, P. ....	134, 208	Bazin, C. ....	149	Ben Abbes, M. ....	166	Berliner, S. ....	195
Barreiro Alonso, E. ....	202	Bazzoli, F. ....	197	Ben Abdallah, H. ....	168	Bermejo, F. ....	49, 93, 188, 232
Barreiro de Acosta, M. ....	233	Beath, A. ....	150, 194-195	Ben Abdelwahed, M. ....	168	Bernardo, D. ....	49, 64, 70, 93, 188, 247
Barreiro de-Acosta, M. ....	49, 93, 144, 188, 288	Beau, P. ....	71	Ben Amor, S. ....	240	Bernardo, S. ....	122, 144, 163, 208, 219, 252
Barrenetxea, Z. ....	148	Beaugerie, L. ....	84, 144, 191, 230	Ben Hemo, D. ....	127	Bernasconi, G. P. ....	208
Barresi, L. ....	99, 103	Becchetti, C. ....	99, 169	Ben-Horin, S. ....	85	Berner-Hansen, M. ....	139
Barret, M. ....	200, 219, 224, 245	Becerro, I. ....	52	Ben Ismail, K. ....	212	Berni, E. ....	122
Barriás, S. ....	164	Bech Johannesen, T. ....	186	Ben Mansour, W. ....	240	Bernstein, C. N. ....	70
Barrichello, S. ....	110	Becher, B. ....	71	Ben Mustapha, N. ....	228	Berrutti, M. ....	208
Barrio, J. ....	49, 69, 93, 229, 232-233	Beck, Y. ....	163	Ben Slama, A. ....	125, 211, 213, 215, 230, 241, 248	Berry, N. ....	187, 227
Barroca, H. ....	172	Becker, A. ....	57, 71, 81	Ben Slimane, B. ....	168	Bertani, L. ....	234
Barron, M. ....	197	Beckers, A. ....	220, 239	Benajah, D.-A. ....	69, 216, 246, 220	Bertels, R. ....	180
Barros, F. C. ....	200	Beckett, E. ....	206	Benamouzig, R. ....	199, 226	Bertelsen, K. ....	242
Barroso, E. ....	169	Beckman, E. ....	74	Bendavid, C. ....	185	Bertheau, P. ....	236, 246
Barros-García, P. ....	160	Becq, A. ....	47, 71, 135	Bende, F. ....	212	Bertino, G. ....	58
Bartell, N. ....	174	Becx, M. ....	231	Bender, D. ....	230	Bertolami, C. ....	61
Barthel, C. ....	142	Beer, A. ....	125, 204	Bendix, M. ....	234	Bertoletti, F. ....	143
Barthet, M. ....	80, 98, 103, 136, 188, 198	Beets-Tan, R. ....	54, 137, 178, 193	Bendtsen, F. ....	49	Berzin, T. M. ....	47
Bartneck, M. ....	55	Beets, G. L. ....	54, 65, 178, 193	Benea, A. ....	212	Besheer, T. ....	123, 125, 168, 170
Bartolacci, V. ....	58	Beg, S. ....	224, 243	Benech, N. ....	141	Besherdas, K. ....	223, 241
Bartzaghi, F. ....	208	Beglinger, C. ....	88, 98, 204, 247	Benes, M. ....	161, 224	Bessa, X. ....	94, 147
Basaranoglu, M. ....	237	Beguinet, F. ....	166	Benesova, L. ....	227	Bessa Casserras, X. ....	194
Basavaraju, K. ....	199	Begun, J. ....	188	Benezech, A. ....	188	Besselink, M. G. H. ....	46, 54, 68, 82, 84-85, 182, 215-217, 226
Basco, M. ....	253	Beig, J. ....	213, 241	Bengi, G. ....	156	Bessissow, T. ....	185
Basford, P. J. ....	62	Bejoui, B. ....	199	Bengis, P. ....	135	Betrissey, B. ....	51
Basgoze, E. ....	230	Bekic, D. ....	209	Benítez, J. M. ....	144	Bettenworth, D. ....	144
Basha, J. ....	224	Bekkali, N. ....	127, 179	Benítez Leiva, O. ....	232	Beuten, U. ....	36-37
Bassel, M. ....	143	Bektas, A. ....	164	Benjira, R. ....	233	Beurskens Meijerink, J. ....	207
Bassett, P. ....	62	Bektas, M. ....	244	Benkirane, A. ....	164	Beuvon, F. ....	200
Bassi, C. ....	49, 82	Bekthari, A. ....	50	Bennato, R. ....	197	Bewshea, C. ....	190
Basso, L. ....	207	Belala, Z. ....	125	Bennett, M. ....	244	Beyer, G. ....	172
Bassotti, G. ....	100, 228	Belardi, F. ....	153	Benslaiman, B. ....	150, 198	Beyna, T. ....	53, 60, 62, 85, 94
Bastani, N. ....	212	Belei, O. ....	190	Bento-Miranda, M. ....	121	Bezobchuk, S. ....	40
Bastiaansen, B. A. J. ....	73	Belfer Gingold, R. ....	203	Benz, E. ....	131	Bhala, N. ....	227, 235, 251, 253
Baston Rey, I. ....	228	Belfiori, V. ....	224	Ber, Y. ....	49	Bhandari, B. R. ....	142
Bastos, I. ....	204	Belghanem, F. ....	168	Berard, L. ....	144	Bhandari, P. ....	39, 41, 62, 67, 72, 78, 80-81, 85, 133, 151, 198, 218
Bastos, P. ....	180	Belghazi, K. ....	155	Berardi, G. ....	130	Bharadwaj, S. ....	47
Basyte - Bacevice, V. ....	121	Belhadjimbrouk, E. ....	162	Bercik, P. ....	70, 103, 239	Bhate, P. ....	137, 201
Batista Pires, C. ....	129	Belkouz, A. ....	215	Beregova, T. ....	120	Bhatia, V. ....	171
Batrel, H. ....	240	Belkovets, A. ....	202	Berends, F. J. ....	206	Bhatnagar, G. ....	231
Battaglia, A. ....	138	Bell, I. ....	243	Berends, S. ....	188	Bhatt, K. ....	133, 135, 182
Batterham, R. L. ....	206	Bell, S. ....	185	Berendsen, E. ....	243	Bhattacharya, U. ....	127
Batteux, F. ....	200	Bellaguarda, E. ....	61	Berg, S. ....	234	Bi, Y.-W. ....	65
Bauer, C. ....	99	Bellam, B. L. ....	216	Berg, T. ....	210	Biagi, F. ....	205
Bauer, D. ....	125	Bellanger, J. ....	132	Bergamschi, G. ....	228	Bialek, A. ....	129
Bauer, M. P. ....	75	Bellido Muñoz, F. ....	125	Berganza, J. ....	148	Bialek, J. ....	129
Baumann-Durchschein, F. ....	75	Belluodo, N. ....	61	Berger, A. ....	173, 245	Bian, S. ....	142
Baumeister, T. ....	82, 155, 200	Belluco, C. ....	218	Berger, A. W. ....	173		
Baumeler, S. ....	150	Belmer, S. ....	191	Berger, A.-E. ....	75		
Baumstarck, K. ....	149	Belmonte, L. ....	161				
		Belosic Halle, Z. ....	209				
		Belousova, E. ....	48, 184-185				
		Belsanova, B. ....	227				
		Belsey, J. ....	159, 247				

Bianchi, D. ....	128	Boaz, M. ....	195	Boone, J. H. ....	141	Boulygina, E. ....	74, 235, 247
Bianchi, E. T. ....	51	Bobusoglu, O. ....	140	Boonen, A. ....	231	Bourke, M. J. ....	37, 47, 62, 80, 85, 91, 93, 177, 224
Bianchi, L. ....	177	Bocaniala, A. ....	224	Boonstra, J. J. ....	148-149, 192	Bourrille, A. ....	141
Biasco, F. ....	239	Bocca, C. ....	48	Bor, R. ....	145, 179-180, 194, 232	Bourrier, J. ....	144, 230
Bianco, M. A. ....	100, 150	Boccagni, P. ....	169	Bor, S. ....	200, 244	Boursier, J. ....	48, 58
Biancone, L. ....	140-141, 160	Bock, S. ....	150	Borda, A. ....	202, 237	Bousnina, O. ....	166
Biasiolo, A. ....	167	Böck, S. ....	172	Borda, F. ....	202, 237	Bousseloub, A. ....	168
Biasutto, D. ....	200	Bockhorn, M. ....	82, 182	Bordacahar, B. ....	200	Boutaleb, A. F. ....	123
Bibani, N. ....	171	Bocus, P. ....	214	Bordin, D. ....	98, 204, 247	Bouvier, D. ....	139, 231
Bibbs, D. ....	204	Bod, B. ....	171	Borg, C.-M. ....	36	Bouvier, M. ....	149
Bibeau, F. ....	37, 54, 63	Bödi, P. ....	65, 162	Borg, F. ....	148-149, 192, 238	Bouvy, N. ....	60, 101, 114
Biberci Keskin, E. ....	172, 180	Bodini, G. ....	168, 200, 228, 230, 233	Borges, V. ....	202, 253	Bouwense, S. A. W. ....	216
Biel, C. ....	57	Bodiou, J. ....	136	Borges Da Costa, J. ....	207	Bove, V. ....	78, 89, 91, 219, 222-223, 244
Bielasik, A. ....	129	Bødker, M. B. ....	136	Borgheresi, P. ....	197	Bown, S. ....	153
Biermann, K. ....	83, 134	Bodnarczuk, T. ....	217	Borghini, R. ....	249	Boyanova, L. ....	98, 204, 247
Biesiekierski, J. ....	205, 245	Boeckstaens, G. E. ....	76, 81, 103	Bories, E. ....	62, 68, 92, 134-136, 220, 222-223, 225	Boyd, S. ....	59, 76, 213
Bilbao, I. ....	222	Boeger, C. ....	96	Borkenstein, D. ....	244	Boz, S. ....	243
Bilbao Iturrigarria, I. ....	178, 236	Boehm, E. ....	246	Borovicka, J. ....	150	Bozhychko, M. ....	126
Bilhim, T. ....	124	Boehm, V. ....	71	Borstlap, W. A. A. ....	137, 238	Bozkurt, H. S. ....	57, 164
Bilianskyi, L. ....	187	Boellaard, T. N. ....	193	Bortlik, M. ....	227, 235	Bozon, A. ....	233
Billiauw, L. ....	71	Boermeester, M. A. ....	46, 85, 89, 216	Borup, C. ....	100	Brachitta, L. M. ....	196
Bilski, J. ....	228	Boeva, I. ....	157	Bos, D. ....	173	Braha, A. ....	210
Bindslev, N. ....	139	Bogdanova, E. M. ....	186	Bosari, S. ....	138, 160	Braham, A. ....	211, 215, 230, 248
Bing, L. ....	60, 91	Boghaert, E. ....	147	Bosca-Watts, M. M. ....	143	Braim, D. ....	228
Binienda, A. ....	138	Bogie, R. M. M. ....	53, 85	Bosch, D. ....	226	Branche, J. ....	198, 221
Biolato, M. ....	58, 211	Böhn, L. ....	195	Bosch, J. ....	224	Branchi, F. ....	64, 249
Biondo, S. ....	38, 65, 78	Bohr, J. ....	184	Boschard, C. ....	136	Brandao, P. ....	176
Birchler, M. ....	75	Boisseau, N. ....	70	Boschetti, E. ....	57	Brandes, A. ....	190, 231
Birdi, S. ....	216	Boivin, L. ....	61, 233	Boschetti, G. ....	75	Brandimarte, G. ....	100, 145, 150, 196, 203, 244, 246, 248
Bischoff, S. ....	103	Bojic, S. ....	235	Bosco, D. ....	166	Branquinho, D. ....	186, 190, 204
Bisgaard, T. ....	216	Bojovic, K. ....	122	Boskoski, I. ....	78, 89, 91, 219, 222-223, 244	Braun, E. ....	253
Bisschops, R. ....	41, 71, 74, 88, 102, 155	Bokemeyer, A. ....	144	Bosman, A. ....	149	Braun, G. ....	36, 114, 218
Bisseling, T. ....	149	Bokemeyer, B. ....	189	Bosque López, M. J. ....	164	Braun, I. ....	232
Bittner, K. ....	174	Boku, N. ....	201	Boss, M. ....	173, 206, 225	Bravi, I. ....	177
Bitton, A. ....	185	Bolado Concejo, F. ....	158	Bossa, F. ....	228	Brazier, F. ....	93, 233
Bitzer, J. ....	234	Boland, K. ....	142	Bosshardt, C. ....	92	Brcerevic, I. ....	189
Biviano, I. ....	153	Boldys, H. ....	175	Bossmeyer, F. ....	184	Bredenoord, A. ....	53, 55, 60, 86, 111
Bizid, S. ....	168	Böle-Feysoyt, C. ....	161	Bossuyt, P. ....	138, 187, 191, 234	Breidert, M. ....	186
Bjørn Jensen, C. ....	233	Bolino, M. C. ....	224	Botti, F. ....	63	Brennan, D. ....	203
Bjornsson, E. S. ....	185	Bollas, I. ....	110	Bouali, M. R. ....	168	Brennan, K. ....	75
Bjorvatn, B. ....	195	Bollen, T. ....	46, 85, 216	Bouchabou, B. ....	100, 168, 204	Brennan, P. ....	164, 234
Blackwell, C. ....	50	Bologna, G. ....	249	Bouchard, S. ....	223	Brenner, D. ....	100, 195
Blanchard, A. ....	194	Boltin, D. ....	159, 163, 203	Bouchelouche, P. ....	100	Breslin, N. ....	130, 140, 181, 234
Blas, J. ....	160	Bommelaer, G. ....	139, 231	Bouchoucha, M. ....	194, 199	Bressler, B. ....	143
Blas, L. ....	160	Bonaccorso, A. ....	91, 163, 224, 252	Boudabbous, M. ....	159	Bretthauer, M. ....	177
Blasco, M. ....	247	Bonfiglio, F. ....	228	Boughoula, K. ....	168	Breuer, R. ....	126, 226
Blazevic, N. ....	251	Bongers, E. ....	191	Bougouen, G. ....	185, 232-233	Breukink, S. O. ....	53, 178
Bleiker, E. M. A. ....	172	Boninsegna, S. ....	214	Bouguerra, C. ....	169	Breunig, M. ....	57, 216
Blesl, A. ....	75	Bonitatibus, A. ....	249	Bouhlei, W. ....	240	Brezgin, A. G. ....	162
Blogowski, W. ....	217	Bonnart, C. ....	71-72	Bouhnik, Y. ....	71, 75, 97, 187	Brieau, B. ....	224
Bloom, S. ....	145, 188	Bonnet, R. ....	70, 192	Bouhoun, Z. ....	220	Bril, L. ....	139
Blount, K. ....	75	Bonsing, B. A. ....	57	Boulette, I. ....	161	Brinar, M. ....	230
Bluff, D. ....	61, 142	Booi, J. ....	225	Boulton, R. ....	253		
Blüher, M. ....	126, 180	Boon, M. ....	162				
Blumberg, R. S. ....	70	Boon, N. ....	92, 223				
Blumenstein, I. ....	202, 232, 251						
Boal Carvalho, P. ....	136						
Boarino, V. ....	197						

Brink, L. ....	176	Brzozowski, T. ....	201, 228, 235	Butter, M. ....	143	Camardese, G. ....	191
Brinkman, D. ....	84	Bu, Y. ....	183	Butturini, G. ....	49	Camargo Camero, R. ....	238
Brisac, C. ....	211, 213	Bubán, T. ....	145	Buzás, G. M. ....	98, 204, 247	Cambiè, G. ....	150, 240
Brischoux, S. ....	132	Bubnov, R. ....	206	Byeon, J.-S. ....	176, 187, 192, 221	Cameron, K. ....	238
Brito, C. ....	147	Bucalau, A.-M. ....	174	Byrne, M. ....	85	Camilleri, M. ....	242
Brito, D. ....	193	Bucci, C. ....	197	Bytzer, P. ....	98, 146, 204, 247	Camma, C. ....	58, 186
Brito, J. ....	141	Buckova, B. ....	177, 224			Cammarota, G. ....	75, 139, 146, 206
Brito, M. ....	176, 222, 252	Bucobo, J. C. ....	134	<b>C</b>		Camo Monterde, P. ....	233
Brito Casillas, Y. ....	152	Bucsics, T. ....	65, 98	Caballero, N. ....	150, 198	Campana, D. ....	245
Briz, R. ....	195	Buda, A. ....	142, 228, 233	Cabibbo, G. ....	58	Campanale, M. ....	72
Brizi, M. G. ....	251	Budihal, S. ....	177	Cabral, J. G. ....	164, 209	Campani, C. ....	124
Broadus, R. ....	192	Budimir, I. ....	251	Cabriada, J. L. ....	49, 93, 144	Campbell, N. ....	140
Brochard, C. ....	185, 232	Budincevic, H. ....	209	Cabriada Nuño, J. L. ....	144	Campbell-Hill, S. ....	143, 190, 231
Brocic, T. P. ....	189	Budnik, H. C. ....	37, 58, 88, 96	Caca, K. ....	73, 177, 218-219, 237	Campelo, P. ....	150, 206, 235, 258
Brock, S. ....	50, 238	Budzinskiy, S. ....	136	Caccaro, R. ....	228	Campillo, A. ....	138
Broeders, L. ....	137	Bugajski, M. ....	53, 81, 87, 129, 177, 222	Caccia Dominioni, C. ....	153, 202	Campo, N. ....	58
Broers, C. ....	153	Bugariu, A. ....	212	Cacciola, I. ....	58	Campo, R. ....	87, 110
Broet, P. ....	75	Buggenhout, A. ....	174	Cachanado, M. ....	144	Campo Fernandez, R. ....	69, 235
Broide, E. ....	89, 202	Bugianesi, E. ....	48, 109	Cacioppo, A. ....	231	Camus, M. ....	135
Brom, M. ....	173, 206, 225	Buisson, A. ....	75, 86, 139, 231, 233	Cacopardo, B. ....	58	Cañamares, P. ....	219
Bromberg, L. ....	223	Buitinga, M. ....	173	Cadena Herrera, M. L. ....	125	Canard, J.-M. ....	245
Bronkhorst, P. ....	173	Bujanda, L. ....	49, 55, 166, 188, 214	Cadime, A. T. ....	193	Cañas, M. ....	188
Bronsky, J. ....	186	Bujanda Fernández de Piérola, L. ....	86, 98-99, 148, 178, 192, 204, 222, 233, 236, 247	Cadiot, G. ....	61, 75	Canavese, G. ....	160
Bronswijk, M. ....	189	Bulajic, M. ....	161	Cadoni, S. ....	175	Canbay, A. ....	246-247
Brookes, M. J. ....	221	Bulich, I. ....	200	Cador, C. ....	223	Canbay, A. E. ....	215
Brooks, A. ....	187, 234	Bulois, P. ....	141	Caenepeel, P. ....	71	Canena, J. ....	134, 163
Brooks, C. ....	92, 217	Büning, J. ....	189	Caetano, C. ....	145	Canete, F. ....	232-233
Brosch, M. ....	210	Buonadonna, A. ....	218	Cahen, D. L. ....	40, 85, 92, 103, 134, 172	Cañete-Ruiz, Á. ....	131
Brosens, L. A. A. ....	192	Burdyukov, M. ....	208	Cai, Y. ....	158	Cani, P. ....	70
Brosolo, P. ....	157	Bures, J. ....	153, 224, 232, 236	Caillol, F. ....	92, 135-136, 220, 222-223, 225	Cannatelli, R. ....	228
BROUTIER, L. ....	63, 111	Burger, D. ....	228, 239, 243	Cairo, G. ....	160	Cannavo, M. ....	58
Brouwers, A. ....	173	Bürger, M. ....	241	Calabrese, E. ....	140-141	Cannito, S. ....	48
Brown, G. ....	80, 177	Burgess, N. ....	80, 85, 177	Calabrò, A. ....	160	Cannizzaro, M. ....	58
Browne, P. ....	52, 144	Burisch, J. ....	48-49, 70, 84, 95, 117, 139, 185-186, 232	Calatayud, S. ....	71, 86, 183-184, 227	Cannizzaro, R. ....	160, 192, 198, 202-203, 218, 244-245, 248
Bruce, S. ....	51	Burke, L. ....	220	Caldas Álvarez, M. ....	98, 204, 247	Cano, F. ....	151
Bruha, R. ....	211	Burns, G. ....	95, 205-206	Caldeira, A. ....	122, 163, 167, 253	Cano, M. ....	233, 237
Brullet, E. ....	69, 110, 235	Buron, A. ....	94, 147	Caldeira, P. ....	186, 190, 238	Cañones-Garzón, P. J. ....	74, 203
Brummer, R. ....	52, 89	Burr, N. ....	53, 56, 93, 100	Calhau, C. ....	204	Canton, E. ....	218
Brummer, R. J. ....	52, 89	Burra, P. ....	40, 77, 79, 169	Calle Gómez, A. R. ....	152	Cantoni, F. ....	224
Brun, R. ....	176	Burrello, C. ....	63, 138	Calvache, A. ....	195	Cantù, P. ....	180
Brunacci, M. ....	221	Burrows, G. ....	207	Calvalcanti, A. C. B. S. ....	209	Canzonieri, V. ....	160, 218
Bruneau, J. ....	98, 248	Burton, H. ....	151	Calvaruso, V. ....	58, 231	Cao, X. ....	70, 144
Brunelle, S. ....	135	Buscaglia, J. ....	56, 134	Calvert, C. ....	190	Capasso, M. ....	245-246
Brunet, E. ....	69, 110, 235	Buscarini, E. ....	49, 111, 197	Calvet, X. ....	49, 93, 188, 235	Capela, T. ....	163, 220, 240
Brunet, J. ....	149	Busch, O. R. C. ....	46, 82, 84, 182, 215	Calvo Calvo, X. ....	69, 74, 203	Capelão, G. ....	252
Brunkwall, L. ....	51	Buschens, C. J. ....	60, 78, 86, 142, 145-146	Calviño-Suárez, C. ....	216, 228	Capelínha, A. ....	110
Bruno, G. ....	243	Busweiler, L. A. D. ....	226	Calvo-Lerma, J. ....	162	Capellà, G. ....	149
Bruno, M. J. ....	46, 49, 58, 80, 82-83, 85, 92, 95, 101, 128, 134, 158, 172, 216	Buters Ambrosius, N. ....	207	Cama, R. ....	144-145	Capelle, L. ....	98, 204, 247
Bruno, S. ....	123	Butler, T. ....	183	Camara, S. ....	247	Capelli, E. ....	52, 72, 235
Brusciano, L. ....	196			Camara de Castro Oliveira, L. ....	100	Capelli, M. ....	157
Brusilovskaya, K. ....	125			Cámara-Hijón, C. ....	160	Capezzuto, E. ....	150
Bruzzese, D. ....	125					Caplan, A. I. ....	63
Bruzzi, S. ....	48					Capodano, G. ....	226
Bruzzone, L. ....	58					Caporaso, N. ....	125, 166, 186-187, 207, 210
Brynskov, J. ....	186						



Cappelleri, J. ....	61, 142, 144	Carter, D. ....	192	Castro-Poças, F. ....	163, 252	Chambrier, C. ....	71
Cappello, M. ....	61, 186, 231	Carter, R. ....	67, 72	Castro Poceiro, J. ....	141	Chan, A. T. ....	54
Caprioli, F. ....	63, 138, 230, 240	Caruana, P. ....	245-246	Cataldi, F. ....	86, 97, 142-144	Chan, F. K.-I. ....	69, 235
Capuano, F. ....	196	Caruso, M. L. ....	248	Caterino, M. ....	237	Chan, F. K.-I. ....	69, 227, 235
Capurso, G. ....	49, 92, 172, 216	Carvalho, S. ....	121-122, 208, 251-252	Cauda, R. ....	146	Chan, G. ....	145, 188
Caputo, C. ....	161, 170	Carvalho, C. ....	54	Caunedo, A. ....	193	Chan, M. W. Y. ....	151
Carabotti, M. ....	92, 150	Carvalho, D. ....	202, 223	Caunedo Alvarez, Á. ....	125, 238	Chandan, J. ....	227, 251
Carapelle, M. ....	52	Carvalho, J. ....	110, 123, 132, 134, 163, 169, 176, 178, 180, 185, 187, 199, 231, 250	Caunedo-Álvarez, A. ....	247	Chande, N. ....	143
Carbajo, A. Y. ....	93, 188, 229	Carvalho, P. B. ....	71	Cavasi, A. ....	120	Chandra, P. ....	225
Carbajo López, A. Y. ....	52	Carvalho, R. ....	64, 168	Cavatorta, O. ....	203, 245-246	Chandrasekhara, V. ....	217
Carballal, S. ....	95, 192	Carvalho, S. D. ....	114	Cavazza, A. ....	192	Chandrasinghe, P. C. ....	227
Carbone, A. ....	153	Carvão, J. ....	110, 121, 123, 167, 211, 213, 216, 235, 252	Cave, D. ....	250	Chanez, B. ....	135
Carbone, F. ....	195, 199	Casà, A. ....	233	Cavestro, G. M. ....	49, 181, 236, 245, 248	Chang, C.-C. ....	147
Carbonnel, F. ....	54, 75, 89, 93, 106	Casabona-Francés, S. ....	69, 153, 243	Cavlina, M. ....	110	Chang, D.-K. ....	144
Card, T. R. ....	157	Casaca, R. ....	130, 208	Cazacu, I. ....	65, 171	Chang, K. ....	134
Cárdenas-Jaén, K. ....	126, 172, 216	Casadei, R. ....	128, 172	Cazals-Hatem, D. ....	71, 86	Chang, L. ....	38, 75, 96, 103
Cardin, R. ....	241	Casale, R. ....	249	Cazzato, M. ....	129	Chang, S. K. ....	131
Cardinale, R. ....	248	Casanova, M. J. ....	49, 70, 144, 189, 232	Cea Soriano, L. ....	50	Chang, S. Y. ....	193
Cardoso, H. ....	121, 162, 207, 212-213, 250-251	Casanova González, M. J. ....	64, 144, 233	Cea-Calvo, L. ....	140	Chang, T.-S. ....	151
Cardoso, M. ....	121	Casellas, F. ....	101, 140	Ceausu, E. ....	168	Chang, X. ....	197
Cardoso da Silva, D. ....	183	Casellas, J. A. ....	172, 192	Ceballos, D. ....	144	Chang, Y.-F. ....	147
Carelli, V. ....	57	Casén, C. ....	186, 235	Cebula, W. ....	184	Chang, Y.-L. ....	151
Carey, F. ....	164	Casini, B. ....	238	Cecconello, I. ....	51, 157	Chang, Y.-W. ....	203, 247-248
Carlsen, A. ....	231	Casper, M. ....	150	Ceci, V. ....	52	Chanpong, A. ....	163
Carlson, D. ....	242	Cassieri, C. ....	145, 150	Cedola, F. ....	141	Chanteloup, E. ....	75
Carmagnola, S. ....	229	Cassinotti, A. ....	229	Celiah, T. ....	216	Chao, C.-Y. ....	72
Carneiro, C. ....	141	Cassoni, P. ....	160	Celik, M. M. ....	168	Chaparro, M. ....	49, 64, 70, 86, 93, 144, 188-189
Carneiro, F. ....	37, 162, 172, 186, 190	Castaño, M. ....	64	Celikel, C. ....	240	Chapman, C. ....	237
Caro, L. ....	224	Castaño García, A. ....	202	Cellier, C. ....	98, 132, 248	Charachon, A. ....	198
Caroli, A. ....	150	Castelijin, D. A. R. ....	64	Celler, L. ....	124, 244	Chari, S. T. ....	54, 101, 103
Caroli, D. ....	146, 150, 168, 170, 191, 213	Castellino, F. ....	208	Cenac, N. ....	72	Charnley, R. ....	127
Caroline, O. ....	190	Castells, A. ....	147-149, 192	Cenacchi, G. ....	57	Charpentier, C. ....	139
Caronna, R. ....	160	Castells, X. ....	147	Cenin, D. ....	95	Charro, M. ....	49
Carot, L. ....	94, 147, 194	Castello, D. ....	185	Cerban, R.-C. ....	211, 214-215	Chartier, L. ....	189
Carpino, G. ....	100, 166	Castiella, A. ....	121	Cereatti, F. ....	52	Chastier, A. ....	168
Carrara, S. ....	49, 59, 103, 172, 181, 218, 224-225	Castier, Y. ....	71	Cereser, B. ....	227	Chattelieu, G. ....	132
Carrasco, A. ....	159	Castiglione, F. ....	140, 186-187, 190, 228	Cerf-Bensussan, N. ....	81, 98, 248	Chatten, K. ....	207
Carrera, P. ....	237	Castillo, L. A. ....	195	Ceriani, R. ....	123	Chatzievangelinou, C. ....	181
Carrera-Lasfuentes, P. ....	50	Castillo Herrera, L. A. ....	248	Cerisoli, C. ....	224	Chatzimichael, A. ....	184
Carrera Silva, E. A. ....	227	Castro, F. D. ....	145	Cernotova, V. ....	126	Chau, C. ....	164
Carrica, S. A. ....	222	Castro, J. ....	164, 209	Cerofolini, A. ....	240	Chaussade, S. ....	132, 224
Carrier, P. ....	132	Castro, M. ....	72, 188, 247	Cersosimo, G. ....	161	Chausse, P. ....	70
Carriere, J. ....	183	Castro, R. ....	59, 130, 166, 207, 236, 238	Cervantes, A. ....	126-127	Chavan, R. ....	137, 150, 153, 223-224, 242
Carrillo, M. ....	178	Castro, R. E. ....	59, 166	Cervignini, M. ....	250	Chavanelle, V. ....	70
Carrilho Ribeiro, L. ....	208, 219, 222-223, 241, 252	Castro-Fernandez, M. ....	98, 204, 247	Cervinskiene, J. ....	146	Chavero, P. ....	227
Carrilho-Ribeiro, L. ....	176	Castro Laria, L. ....	232	Cesarini, A. ....	242	Chaves, P. ....	130, 147
Carrington, E. ....	38, 61, 87			Cesna, V. ....	151	Chaya, Z. ....	206
Carroccio, A. ....	61			Ceyhan, G. O. ....	82, 89, 127, 182, 215	Chayama, K. ....	53, 147
Carroll, G. ....	205			Cha, S.-W. ....	181	Cheent, K. ....	252
Carroll, I. ....	63			Chaabane, M. ....	228	Chemaly, M. ....	130
Carroll, N. ....	163			Chaabouni, H. ....	213	Chen, B. ....	142, 194, 199, 205
Cartabellotta, F. ....	58			Chaber-Ciopinska, A. ....	129	Chen, C. ....	198, 216
				Chabrun, E. ....	198	Chen, C.-C. ....	74, 247
				Chaen, T. ....	131	Chen, C.-W. ....	147
				Chakkor, A. ....	198	Chen, F. ....	236
				Chalifoux, S. ....	206	Chen, G. ....	210
						Chen, H. ....	192, 197

Chen, H. H.....	197	Chinda, D.....	158-159	Choi, S. K.....	169, 207	Cintolo, M.....	179
Chen, H.-L.....	165	Ching, H.-L.....	180	Choi, Y. H.....	136	Cintoni, M.....	207
Chen, J.....	155, 175	Ching, J.....	69, 235	Choi, Y. J.....	239	Ciocirlan, M.....	124, 224
Chen, K.-C.....	180	Ching, J. Y. L.....	235	Choi, Y. S.....	218	Ciocirlan, M.....	124
Chen, L.....	74, 98, 152, 182, 194, 196, 199, 202, 204, 236, 243	Chino, A.....	132-133, 178	Cholet, F.....	135-136	Ciortescu, I.....	205-206
Chen, M.....	142, 200	Chiorean, M.....	86, 140, 187	Cholongitas, E.....	168	Cipolletta, F.....	197
Chen, Q.....	159	Chirica, M.....	72	Chon, H. K.....	110, 135, 178	Cipolletta, L.....	197
Chen, S.....	74, 96, 196, 202, 204, 236	Chiu, C.-M.....	121	Chon, S.-H.....	240-241	Cirillo, M.....	214
Chen, T.....	130	Chiu, C.-T.....	147, 152	Chonan, A.....	133	Citrano, M.....	61
Chen, W.....	124, 244	Chiu, P. W. Y.....	94, 218	Chong, C. F.....	200	Ciurea, T.....	172
Chen, W.-M.....	151	Chiu, Y.-L.....	121	Chopita, N.....	241	Claes, I.....	162
Chen, W.-Y.....	147	Chlebicki, P. M.....	209	Chou, C. J.....	51	Clara, P.....	252
Chen, Y.....	159, 175, 180, 216	Chloe, L.....	219	Chouillard, E.....	179	Clark, A.....	253
Chen, Y.-C.....	151	Chmelova, K.....	169	Chounta, E.....	248	Clarke, T. S. O.....	228
Chen, Y.-H.....	151	Chmura, A.....	201	Chow, V.....	188	Claro, I.....	130, 147
Chen, Y.-W.....	153	Cho, C. M.....	128, 178-179	Chowers, Y.....	67, 74-75, 112	Claudia Canofari, C. C.....	141
Chen, Z.....	205	Cho, C.-M.....	215	Christensen, A. H.....	52, 144	Clayton, J.....	131, 161
Cheng, A. S. L.....	58, 246	Cho, D. H.....	181	Christensen, E.....	120	Clelia, M.....	133
Cheng, B.....	169, 172, 175, 180, 214	Cho, E.....	128, 169, 207	Christiansen, N.....	210	Clemente, E.....	249
Cheng, C.-C.....	147	Cho, J.....	63, 69, 125, 127, 156, 174, 191, 248	Christopher, B.....	140	Clevers, E.....	239
Cheng, C.-H.....	165	Cho, J. H.....	96, 125, 156, 191, 248	Chromy, D.....	167, 212	Clifford, G.....	53
Cheng, H. R.....	53, 85	Cho, J. Y.....	69	Chtourou, L.....	159	Clos-Garcia, M.....	148
Cheng, H.-C.....	147	Cho, K. B.....	178	Chu, C.-Y.....	165	Clos Parals, A.....	232-233
Cheng, W.-C.....	147	Cho, K.-B.....	173	Chu, M. A.....	151	Closa, D.....	126
Cheng, Y.....	180	Cho, M.-J.....	244	Chu, Y.....	60	Cnossen, W. R.....	121
Cheon, J. H.....	143, 146, 193, 237	Cho, M.-L.....	140	Chuah, C.....	188, 234	Coccia, G.....	221
Cheong, P. K.....	69	Cho, S. B.....	169, 207	Chuah, C. S.....	188	Cocco, A.....	140
Cheong, W.-K.....	131	Cho, S.-J.....	174	Chuah, K. B.....	164, 222	Cocconcelli, E.....	209
Cheraitia, S.....	125	Cho, T.....	133	Chuah, S.-K.....	159	Cocconcia, S.....	153, 202, 228-229
Chermesh, I.....	176	Cho, Y. D.....	181	Chun, H.....	130, 136, 175, 179-180, 193, 198, 242	Coëffier, M.....	161
Chernin, E.....	142	Cho, Y. K.....	187	Chun, H. J.....	130, 175, 179-180, 193, 198, 242	Coelho, C.....	193, 225
Chernov, V.....	247	Cho, Y. S.....	175, 178, 201, 244	Chun, H.-J.....	174	Coelho, M.....	130
Chernova, O.....	247	Cho, Y.-S.....	140, 149, 156	Chung, C.-S.....	121, 180	Coelho, R.....	175, 196, 212
Chesher, C.....	159	Choe, J.....	176	Chung, H.....	92, 129, 180, 201	Coffin, B.....	41, 61, 98, 191
Chetcuti Zammit, S.....	160, 180, 205, 249-250	Choi, A.....	52	Chung, I. K.....	201	Cogliandro, R. F.....	239
Cheung, K. S.....	98, 152, 203	Choi, C. W.....	186-187, 218, 245	Chung, I.-K.....	175, 178	Cohen, N. A.....	146, 191, 195, 231
Cheung, R.....	143	Choi, C. H.....	131	Chung, M. J.....	136	Coilly, A.....	77, 83, 96
Cheungpasitporn, W.....	170	Choi, C. W.....	186-187, 218, 245	Churchhouse, A.....	234	Coimbra, É.....	124
Chevarin, C.....	227	Choi, H. J.....	69, 125, 181	Ciacci, C.....	42, 78, 154, 160-161, 170, 228	Coimbra, J.....	163, 220, 253
Chevau, J.-B.....	141, 198	Choi, H. S.....	175	Cianga, P.....	205-206	Cola, M.....	146, 209
Chi, Y.....	166, 210, 227	Choi, H.-S.....	130, 174, 179-180, 193, 198, 242	Ciardi, A.....	160	Colas, C.....	132
Chia, C. T. W.....	222	Choi, I. J.....	174, 203	Cicala, M.....	200	Cold, F.....	144
Chiam, D.....	147	Choi, J.....	128, 173, 180, 244	Ciccantelli, B.....	153	Colecchia, A.....	128
Chiang, M.-K.....	151	Choi, J. H.....	128, 173, 180	Ciccone, A.....	248	Colell, L.....	95
Chiaroni, G.....	47, 87, 100	Choi, J. Y.....	245	Cichoż-Lach, H.....	211	Coletta, M.....	154, 209, 230, 244
Chiba, H.....	132, 193	Choi, J.-H.....	69	Cichoż-Lach, H.....	124, 167, 185	Collini, P.....	224
Chibai, M.....	175, 204	Choi, K.....	147, 218, 246	Cicu, A. S.....	150	Collins, J.....	163
Chico, I.....	195	Choi, K. D.....	218, 246	Ciesielczyk, K.....	249	Collins, M.....	69, 98, 199
Chien, H.....	131	Choi, M. S.....	50	Cifone, M. G.....	250	Collins, M. H.....	98, 199
Chikhi, Y.....	125	Choi, M.-G.....	140, 149, 156	Cilingir, S.....	196	Collins, S.....	239
Chikugo, K.....	134	Choi, S.....	130, 169, 174-175, 179-180, 193, 196, 202, 207, 242	Cilissen, M.....	231	Collins, S. M.....	239
Chikugo, T.....	134	Choi, S. H.....	202	Cillo, U.....	169	Colmenares, M.....	188
Chimenti, M. S.....	141	Choi, S. I.....	226	Cilluffo, M. G.....	186, 231	Colombatti, A.....	192
		Choi, S. J.....	130, 174-175, 179-180, 193, 242	Cinavilla, M.....	52, 56, 223, 229	Colombel, J.-F.....	61, 63, 75, 97, 142-143, 145, 229, 233-234
				Cinque, B.....	250	Colombo, C.....	162
						Colombo, M.....	123
						Colucci, R.....	150

Colussi, D.....	95, 110	Correia, C.....	204	Craig, P.....	223	<b>D</b>	
Combaret, L.....	70	Correia, L.....	144, 164, 186, 190, 208, 230, 253	Craviotto, V.....	218, 220	D'Alba, L.....	100, 196, 206
Comberlato, M.....	228	Correia, M.....	124	Cravo, M.....	130, 186, 190, 219	D'Alessandro, A.....	179
Combes, G.....	171	Correia Coelho, Á.....	196	Craxi, A.....	58	D'Amato, M.....	148, 228
Comer, G.....	189	Correia-Sousa, J.....	145, 163-164	Cremers, I.....	83, 186, 190	D'Ambra, G.....	130
Cominelli, F.....	63	Corroero Aguilár, F. J.....	152	Cremon, C.....	52, 72, 150, 235	D'Amico, F.....	181
Comley, R.....	142	Corsetti, M.....	195	Cremona, M.....	177	D'Angelo, R.....	57
Compagnoni, S.....	233	Cortegoso Valdivia, P.....	160	Crenier, L.....	206	D'Argenio, G.....	166, 210
Compennolle, G.....	74, 189	Cortelezzi, A.....	249	Crespi, M.....	168	D'Armiesto, F. P.....	160
Concepción, P.....	158	Cortés, X.....	140	Crespo, L.....	249	D'Aversa, F.....	91, 219, 244
Conchillo, J.....	239	Cortés-Pérez, H.....	131	Crespo, P.....	162	D'Haens, G.....	36, 79, 81, 86, 91, 97, 138, 142, 144, 187-188, 190, 234
Conde-García, B.....	131	Cortésí, L.....	153	Cresto, A.....	205	D'Haens, G. R.....	86, 187, 190
Condon, M.....	141	Cortez-Pinto, H.....	51, 59, 94, 96, 121-122, 166, 251	Cribiù, F. M.....	63, 138	d'Haens, G.....	230
Conigliaro, P.....	141	Cortez-Pinto, J.....	147	Crippa, S.....	49, 92	D'Haese, J.....	172
Conigliaro, R. L.....	100, 150, 197	Cortis, K.....	245	Crisan, D.....	120, 211	D'Hoore, A.....	39, 46, 60, 187
Conner, M. E.....	70	Cosin-Roger, J.....	71, 86, 183-184, 227	Crisan, L.....	167	D'Inca, R.....	48, 142, 146, 185, 209, 233
Consonni, D.....	200	Coskun, Y.....	185	Crispano, F.....	186	D'Incà, R.....	140, 160, 228
Constantin, A.....	114	Cosman, P.....	245	Crispino, P.....	145	da Costa, D. W.....	216
Constantin, G.....	211, 214-215	Coss-Adame, E.....	149	Cristian, G.....	234	Da Costa, G.....	182
Constantinescu, G.....	181, 251	Cossiga, V.....	166, 207, 210	Cristino, A.....	122	Da Costa, J.....	69, 207, 235
Consten, E. C. J.....	238	Costa, D.....	121, 216	Critchlow, T.....	138	Da Costa Martins, B.....	138
Contaldo, A.....	136, 181	Costa, F.....	234	Crivillén Anguita, O.....	187	Da Massa Carrara, P.....	157
Conte, D.....	197	Costa, I.....	57, 134	Croagh, D.....	65	Dabizzi, V.....	179
Conte, E.....	91, 163, 224, 252	Costa, J.....	69, 114, 124, 162, 207, 231, 235	Croitoru, K.....	142	Dadduzio, V.....	170
Contente, L. F.....	141, 150	Costa, M. N.....	64, 168	Crooks, C.....	157	Daguenel, A.....	144
Conti, L.....	92, 129	Costa, R.....	57	Cros, J.....	128	Dahan, M.....	132
Conway, P.....	122	Costa Almeida, C.....	196-197, 238-239	Cross, S.....	205	Dahl, E. E.....	120
Cooney, A.....	131	Costa-Genzini, A.....	250	Crosta, C.....	177	Dahlerup, J. F.....	48, 185, 234
Cooney, J.....	228	Costa-Moreira, P.....	145, 196, 212	Crowley, C.....	57	Dahmani, W.....	211, 230
Cooney, R.....	138, 235	Costa Santos, M. P.....	219	Cruces, C.....	195	Dai, N.....	194, 199-200, 204-205, 243
Cooper, B.....	160	Costamagna, G.....	89, 91, 197, 206, 219, 222-223, 244, 251	Csoszanszki, N.....	162	Dai, S.-X.....	189
Copescu, C.....	114	Costantini, D.....	100, 166	Csupor, D.....	126	Dakkak, D.....	219
Copova, I.....	186	Costantino, A.....	230	Cuatrecasas, M.....	95, 192	Dal Lago, A.....	251
Coppo, C.....	233	Costeira, F.....	114	Cubas Cordova, M.....	238	Dallek, G.....	55, 79, 168
Coppo, P.....	160	Costello-Goldring, E.....	63, 99	Cubiella, J.....	46, 147-148, 192	Dallemagne, B.....	220
Coppola, C.....	170	Cotter, I.....	139	Cucherousset, N.....	246	Dalio, M.....	121, 138, 230
Coppola, L.....	160	Cotter, J.....	49, 71, 121-122, 136, 145, 166-167, 186, 207, 225, 249	Cuevas Covarrubias, S. A.....	226	Dalloyaux, D.....	207
Coppola, N.....	125	Cottone, M.....	61, 233	Cunha, A. C.....	150, 206, 235, 238	Dalmasso, G.....	183, 192
Corazza, G. R.....	57, 153, 160, 196, 202, 205, 228-229, 240	Cougnoux, A.....	192	Cunha, M. F.....	252	Dalton, H.....	50, 98
Corazzari, E. S.....	145, 153	Coumaros, D.....	141	Cuomo, R.....	150	Daly, M. J.....	46
Corcos, O.....	71	Couper, R.....	244	Cúrdia Gonçalves, T.....	49, 71, 122, 145, 166-167, 207, 249	Dambrauskas, Z.....	151
Cordeiro, A. M.....	163	Coupland, C.....	204	Curescu, M.....	213	Damery, S.....	171
Cordero Ruiz, P.....	125	Coutinho, L. M. d. A.....	51	Currais, P.....	130, 208	Damhuis, R. A.....	226
Córdova, H.....	186	Couvelard, A.....	246	Curran, V.....	176	Damiani, A.....	150
Cordova Guevara, H.....	158	Covington, J.....	94, 140	Currie, C. J.....	122	Dan, Y. Y.....	131
Cords, C.....	226	Covino, M.....	240	Curti, M.....	57	Danese, S.....	67, 75, 79, 93, 97, 100, 102, 142-143, 185, 188, 234
Coriat, R.....	245	Covotta, F.....	180	Curtius, K.....	228	Dang, H.....	149
Cornelius, C.....	129	Crafa, P.....	150, 196, 198, 203, 244-246, 248	Curvers, W.....	88, 155	Daniel, F.....	182, 241
Cornillie, F.....	143, 145, 188, 190, 233	Crai, S.....	171	Cvancarova, M.....	140	Danila, M.....	124, 210, 212-213
Coron, E.....	60, 73, 132, 221			Czako, L.....	53, 56, 127, 134, 171, 179-180, 207	Danilov, D.....	154
Corona, M.....	52					Danis, N.....	61, 200
Corp, A.....	251						
Corrado, C.....	196						
Corral, J.....	172, 179						
Correa, G.....	233						
Correa, G. J.....	222, 241						

Danne, C.....	81	de Jonge, P.-J.....	201	Debbeche, R.....	162, 169	Delvaux, M.....	135-136
Dannemann, A.....	126	de Jongh, S. J.....	137, 194	Debbesh, R.....	212	Demarzo, M. G.....	168, 233
Dao, V. H.....	153	De Juan, M.-D.....	121	Debita, M.....	169	Demcsák, A.....	65
Daperno, M.....	140	de Korte, C.....	210	Debourdeau, A.....	136	Demengeot, J.....	140
Dapigny, M.....	194	de la Barreda, R.....	131	Decaens, T.....	40, 79, 99	Demetter, P.....	174
Darwish, O.....	206	De la Iglesia-García, D.....	216-217, 223	Dechelotte, P.....	161	Demir, B.....	123
Darzi, A.....	237	De la Peña-García, J.....	131	Déchelotte, P.....	238	Demir, I. E.....	82, 89, 127, 182, 215
Das, A.....	172	de la Riva, S.....	69	Dechêne, A.....	140	Demir, M.....	168
Dassetto, C.....	220	De la Santa Belda, E.....	221	Decka, R.....	126	Demirtaş, C.....	213
Dassopoulos, T.....	54	De La Serna Higuera, C.....	52, 56, 223	Decollogny, A.....	140	Demmak, H.....	136
Datz, C.....	210	De La Torre, V.....	50	Decsi, T.....	65	Demuth, D.....	143
Daum, S.....	64, 173	de Larrañaga, G.....	227	Deden, L.....	206, 225	Denadai-Souza, A.....	71
Dave, M.....	63, 184	De Lazzari, F.....	146, 150, 168, 191, 213	Deden, L. N.....	206	Deng, Y.-F.....	151
Davi, A.....	58	De Leo, L.....	161-162	Degasperi, S.....	138	Denizot, J.....	183
Davydenko, N.....	217	De Leo, P.....	58	Degre, D.....	92, 223	Denzer, S.....	58
Dawra, S.....	216	de León Rendón, J. L.....	226, 230	Deiana, S.....	246	Denzer, U. W.....	92
Dawsey, S.....	155	de Lima-Karagiannis, A.....	42	Deisenhammer, F.....	75	Depoortere, I.....	207
De Angelis, C. G.....	160	De Looze, D.....	53, 98, 177	Dejaco, C.....	94, 240	Deprez, P. H.....	37, 52, 67, 72, 78, 217
De Bastiani, M.....	159	de Lucas, M.....	195	Dejong, C. H.....	46, 85	Dekker, E.....	41, 47, 53, 67, 74, 87, 149, 191, 193
De Bastiani, R.....	159	de Lusignan, S.....	124, 170	Del Bel Belluz, L.....	227	Del Cerro, M. J.....	71
De Bellis, M.....	220	de Madaria, E.....	172	Del Chiaro, M.....	40, 50, 56, 85, 92, 127, 182, 217	Del conte, G.....	224
de Bitter, T.....	215	De Mathelin, M.....	220	Del Rio, P.....	245	Del Favero, G.....	150
de Boeck, K.....	162	De Mattheais, N.....	163, 211	del Genio, G.....	196	del Manzano, S.....	186
de Boer, A. G. E. M.....	190	De Mattheias, M.....	197	Del Pozo-García, A. J.....	131	Del Rio, P.....	245
de Boer, H.....	206	De Medici, A.....	150	Del Valle, R.....	51-52, 154, 180	Delattre, C.....	230
de Boer, N. K.....	190	de Mestier, L.....	128	Delatue, C.....	230	Delbue, D.....	249
De Bortoli, N.....	69, 154, 198-200, 243-244	de Moura, E. T. H.....	51	Delconte, G.....	252	Delconte, G.....	252
de Brabander, I.....	191	De Nitto, D.....	145	Delcros, G.....	70	Deleanu, A.....	213
De Britto, S.....	51, 180	de Nucci, G.....	246	Deleuran, B.....	234	Deleuran, B.....	234
De Bruyn, J. R.....	187	De Palma, G.....	187, 239	Delgado, A. A. d. A.....	51	Delgado, F. J.....	196-197, 238-239
De Caestecker, J.....	62	De Palma, G. D.....	187	Delgado, M.....	195	Delgado, R.....	131
De Carlis, L.....	179	De Paoli, A.....	218	Delgado Galán, M.....	248	Delgado Guillena, P. G.....	233
De Castro, L.....	49, 93, 232	De Pretis, G.....	150	Della Coletta, M.....	154, 200, 209, 243-244	Dell’Era, A.....	229
De Castro, M. L.....	188	de Quadros, L. G.....	110	Della Valle, N.....	150	Della Valle, N.....	150
De Cesare, A.....	196	De Re, V.....	202, 218	Delladetsima, I.....	229	Delli Pizzi, A.....	193
De Cesare, M. A.....	206	De Repentigny, Y.....	240	Dellon, E.....	69, 98, 199	Dellon, E. S.....	199
de Chaisemartin, C.....	220	de Ridder, R.....	53, 85, 220	Dellschaft, N.....	225	Delmas, J.....	192
De Chiara, L.....	192	De Roberto, G.....	177	Deloose, E.....	207, 245, 250	Deloese, E.....	207, 245, 250
De Colibus, P.....	150	De Salvo, C.....	70	Deltedesco, E.....	75	Delvaux, M.....	135-136
De Coppi, P.....	57, 137	de Savornin Lohman, E.....	215			Demarzo, M. G.....	168, 233
De Cristofaro, E.....	140	De Sio, I.....	207			Demcsák, A.....	65
De Cruz, P.....	188	de Sousa Damião, F.....	164, 208, 252			Demengeot, J.....	140
De Fanis, C.....	197	De Vitis, I.....	234			Demetter, P.....	174
De Felici, I.....	140	De Vito, C.....	243			Demir, B.....	123
de Franchis, R.....	197	De Vos tot Nederveen Cappel, W.....	148-149, 192, 226			Demir, I. E.....	82, 89, 127, 182, 215
de Francisco, R.....	93, 232	de Vries, A.....	188			Demir, M.....	168
De Gasperi, A.....	179	de Vries, E. G. E.....	137, 194			Demirtaş, C.....	213
De Giorgio, J.....	241	de Vries, H.....	182			Demmak, H.....	136
De Giorgio, R.....	57, 102, 106, 239	de With, P.....	88, 155, 217			Demuth, D.....	143
De Grazia, F.....	240	de With, P. H. N.....	217			Denadai-Souza, A.....	71
De Gregorio, M.....	127	de-Madaria, E.....	54, 65, 126			Deng, Y.-F.....	151
de Groof, J.....	88, 155	Dear, B.....	194			Denizot, J.....	183
de Grouw, E.....	207	Deaton, R.....	199			Denzer, U.....	58
De Hertogh, G.....	143					Denzer, U. W.....	92
de Jong, D.....	141					Depoortere, I.....	207
de Jong, J. J.....	125					Deprez, P. H.....	37, 52, 67, 72, 78, 217
de Jong, M.....	231					Dekker, E.....	41, 47, 53, 67, 74, 87, 149, 191, 193

Di Fusco, D.....	64, 138	Dignass, A.....	46, 54-55, 72, 80, 187	Donat, E.....	151	Duburque, C.....	135-136
Di Giacomo, A.....	58	Dijkgraaf, M. G. W.....	46, 84	Donatelli, G.....	52	Ducons, J.....	219
Di Giorgio, P.....	197	Dijkstra, G.....	57, 187, 231, 233	Donato, G.....	249	Ducrotté, P.....	161, 194
Di Giulio, E.....	129-130, 172, 197, 220	Dimas, I.....	215	Donato, M. F.....	180	Dueñas-Sadornil, C.....	160
Di Grazia, A.....	64, 138	Dimitriu, A.....	234	Donato, P.....	163	Dufour, J.-F.....	40, 48, 68, 79, 94
Di Leo, A.....	136, 158, 160, 205	Dimitropoulos, K.....	223, 248	Donday, M. G.....	98, 247	Duijvestein, M.....	57, 142, 187
Di Leo, M.....	181, 218, 220, 236	Din, S.....	234	Dong, S.-H.....	222	Dulai, P. S.....	143
Di Lorenzo, F.....	58	Dinallo, V.....	64, 138	Dong, Y.....	110	Dulbecco, P.....	58
Di Luna, I.....	190	Ding, H.....	124	Donnarumma, L.....	125	Dumay, A.....	49
Di Marco, M. C.....	172	Ding, N.....	228-229, 233	Donnet, A.-S.....	195	Dumbleton, J. S.....	204
Di Marco, V.....	58	Dinis-Ribeiro, M.....	36, 39, 59, 77-78, 87, 92, 95, 97, 130, 180, 202	Donyush, E.....	191	Dumitrascu, D. L.....	94
Di Mario, F.....	92, 100, 150, 196, 198, 203, 218, 240, 244-246, 248	Dino, P.....	52	Dörje, F.....	232	Dumitru, R.....	213, 215
Di Martino, L.....	70	Dino, V.....	204, 247	Dorra, T.....	212	Dunford, P.....	189
Di Marzo, V.....	138	Diodoro, M.....	238	Doshi, S.....	188	Dungee, D.....	186
Di Matteo, F. M.....	180	Dior, M.....	191	Dot Bach, J.....	209	Dunn, J.....	62, 242
Di Matteo, S.....	100, 166	Dioscoridi, L.....	179	Dotan, I.....	63, 72, 78, 102, 117, 163, 189, 231, 234, 251	Dupraz, L.....	182
Di Mitri, R.....	61, 91, 140, 163, 224, 252	Discepolo, V.....	161	Dou, L.....	155	Durai, D.....	229
Di Paolo, M. C.....	196, 206	Divekar, D.....	236	Douadi, C.....	139	Durante, M.....	97, 142
di Pietro, M.....	48, 62, 82, 98, 102	Dizon, M. C. A.....	253	Douda, T.....	153, 232	Durdevic, M.....	240
Di Rosolini, A.....	58	Džuranovic, S.....	233	Doudinskaya, E.....	161	Duricova, D.....	48, 185, 235
Di Ruscio, M.....	248	Do, A.....	95	Douglas, A. R.....	139, 203	Duvalco, A.....	217
Di Sabatino, A.....	57, 153, 160, 196, 202, 205, 228-230, 240	Doan, T.....	142	Dousset, B.....	245	Duvanskiy, V.....	208
Di Stefano, M.....	58, 202	Dobos, G. J.....	140-141	Draaisma, W. A.....	226	Düx, M.....	202
Dia, C. C.....	186	Dobszai, D.....	126, 171	Drăgănescu, M.....	169	Dvorak, K.....	211
Diab, K. A.....	214	Docimo, L.....	182, 196, 200, 230	Draganov, P.....	56, 131, 135	Dvorchchenko, K. O.....	120
Diac, A.-R.....	184	Dodmani, M.....	123	Dragoni, G.....	124	Dwyer, L.....	203
Diaconu, C.....	181	Doets, S.....	193	Drastich, P.....	161	Dyson, J.....	37, 77, 99
Diallo, F. D.....	220	Doghri, I.....	166	Dray, X.....	57, 135-136, 144, 221	Dzhantukhanova, S.....	137
Diamantopoulou, G.....	146	Dogliioni, C.....	134	Drenth, J. P. H.....	57, 77, 96, 121, 125, 166, 170, 197, 210, 216	East, J. E.....	97, 114
Diano, N.....	121	Doherty, V.....	234	Drescher, M. J.....	234	Eberth, J.....	151
Dias de Castro, F.....	49, 122, 136, 166, 186	Dohi, O.....	248	Dresen, E.....	65, 91	Ebigbo, A.....	201, 218
Dias Pereira, A.....	130, 147, 183, 185, 208	Dohmen, K.....	123	Drewes, A.....	47, 101, 136, 194-195, 238, 244, 249	Ebrahim, M.....	120
Dias, C.....	231	Doi, A.....	130, 152	Drewes, A. M.....	136, 244	Edelman, K.....	69
Dias, E.....	173, 207, 250-251	Doi, S.....	222	Drobin, K.....	228	Edi, V.....	236
Dias, F.....	202	Dokmak, S.....	128	Drobne, D.....	74, 144	Edir, A.....	71-72
Díaz Jiménez, J. A.....	152	Dokoska, S.....	164	Drobny, M.....	211	Eduard, C.....	232-233
Díaz-Ondina, M.....	148	Dolak, W.....	65	Drobný, E.....	144	Edwards, A.....	240
Díaz-Tasende, J.....	131	Dolegowska, B.....	217	Drozdo, V.....	156	Efat, A.....	124
Diaz, E.....	195	Dolegowska, K.....	217	Drummond, S.....	161	Effenberger, M.....	183
Diaz, M.....	147, 192	Dolezel, R.....	155	Drury, M.....	126	Eftekhari, P.....	186
Dib, N.....	61	Dolinsek, J.....	161-162	Dryden, G.....	143	Efthymakis, K.....	249
DiBonaventura, M.....	61, 142, 144	Dolz-Abadía, C.....	131	Drozdov, V.....	179	Egan, L.....	41, 46
Dickman, R.....	151, 159, 203	Domènech, E.....	49, 93, 232-233	Drummond, S.....	161	Egidi, G.....	207
Dickson, S.....	183	Domínguez, E.....	49, 93, 232-233	Drury, M.....	126	Egner, W.....	205
Diculescu, M.....	42, 54, 61, 124, 168, 213, 234	Domínguez-Cajal, M.....	49	Dryden, G.....	143	Egoavil, C.....	192
Didden, P.....	148-149	Dominguez-Munoz, J. E.....	101, 126, 246	Dryden, G.....	179	Eguchi, S.....	130
Didkowska, J.....	222	Dominguez-Munoz, J. E.....	126, 212, 216-217, 223, 228	Duan, L.....	70, 72, 144	Eguchi, T.....	126
Diez Rodríguez, R.....	236	Domislović, V.....	230	Duarte, P.....	225	Ehehalt, R.....	190, 231
Dige, A.....	230, 234	Domper Bardají, F.....	221	Dubale, N. A.....	215	Ehken, H.....	62
		Donald, K.....	207	Dubois, C.....	191	Ehsan, N.....	165
				Dubois, C.....	191	Eichler, K.....	202
				Dubravcsik, Z.....	177	Eid, M.....	206
						Eigenbauer, E.....	166
						Eikrem, Ø.....	242
						Ein-Dor, A.....	202

Eisendrath, P. ....	36, 92, 99, 223, 253	Elgendy, W. ....	165	Eros, A. ....	145	Fagerström, N. ....	56
Eissa, N. ....	70	Elhammady, D. ....	123	Eröss, B. ....	126-127, 130, 145	Faggiano, A. ....	245
Eizaguirre, E. ....	166	Eliakim, R. ....	39, 61, 114	Errabie, F. ....	229-230, 234	Faheem, H. ....	214
Eizuka, M. ....	156, 192	Elias, S. G. ....	148-149, 192	Errasti, A. ....	227	Fahmy, Y. ....	214
Ejova, A. ....	72, 195	Elisei, W. ....	100, 150	Errico, S. ....	121	Fahrbach, K. ....	144
Ejstrud, P. ....	244	Eliseu, L. ....	162, 220, 252-253	Errihani, H. ....	237	Fahrenkrog-Petersen, L. ....	126
Ek, W. ....	228	Eljaky, M. A. ....	214	Esaka, N. ....	133	Faït, T. ....	192
Ekinci, N. ....	220	Eljeri, K. ....	162	Esaki, M. ....	60, 129	Faiss, S. ....	62
Ekiz, F. ....	185	Elkashef, W. ....	168, 252	Escapa Llamazares, M. ....	186	Faiz, O. ....	228, 234
Ekmektzoglu, K. ....	223, 248	Ell, C. ....	62	Eshak, N. ....	253	Fakharzadeh, S. ....	186
Ekoff, H. ....	151	Elleuch, N. ....	125, 211, 213, 215, 230, 241, 248	Eshraghian, A. ....	167, 212	Falcão, A. C. G. M. ....	51
El Abkari, M. ....	69, 216, 220, 237, 246	Elli, L. ....	160, 180, 248-249	Eshuis, W. J. ....	226	Falcón-Pérez, J. M. ....	148
El-Amir, M. ....	139	Eloumi, H. ....	171, 212	Eskandere, D. ....	135	Falconi, M. ....	49, 92
El Araiedh, A. ....	228	Ellul, P. ....	48, 185, 195	Esmat, G. ....	123	Faleschini, G. ....	161
El-Bendary, M. ....	100, 123, 168-170, 214	Elmes, S. ....	195	Esmonde, R. ....	203	Faller, M. ....	176
El Fouly, A. ....	162	Elmokadem, A. ....	170	Esparza, A. ....	214	Falt, P. ....	175
El-Gilany, A.-H. ....	168	Elmorsy, A. ....	170	Esparza-Baquer, A. ....	55	Familiari, P. ....	73, 83, 91, 219, 222-223, 244
El Hossary, W. ....	247	Elnadry, M. ....	236	Espírito Santo, V. ....	147	Fan, H.-Z. ....	165
El Jari, K. ....	212	Elsabagh, A. ....	164	Esposito, D. ....	236	Fan, X. ....	124, 165, 210
El Jeri, K. ....	169	Elsayed, A. ....	214	Esposito, I. ....	85, 94, 99	Fan, Z. ....	219, 221, 225
El Jurdi, K. ....	189	Elsayed, E. ....	168	Essers, B. A. ....	195	Fang, H.-Y. ....	82, 98, 155, 200, 218
El Koti, I. ....	164	Elshaarawy, O. ....	124, 152	Esmann, J. J. ....	141	Fang, J. ....	83, 154
El-Majzoub, N. ....	152	Elshahawy, H. ....	168	Esteller, M. ....	192	Fang, Y.-J. ....	247
El Mazny, A. ....	129	Elshayeb, E. ....	122	Ester, C.-C. ....	211, 214-215	Fangmann, L. ....	89
El-Mekkaoui, A. ....	213, 221, 229-230, 234, 251	Elvas, L. ....	193	Esteve, M. ....	49, 93, 144, 159	Fantín, A. ....	208, 224, 252
El Nakadi, I. ....	174	Elyousfi, M. ....	216	Esteves, J. ....	202, 253	Fantoni, M. ....	146
El-Omar, E. ....	74, 247	Emara Elzanan, M. H. ....	100, 252	Estévez-Pérez, L. ....	126	Farag, A. ....	129, 163-164
El Rhazi, K. ....	237	Emberland, K. E. ....	195	Etrích, T. J. ....	173	Farag, I. ....	120
El Samanoudy, A. ....	170	Eminler, A. T. ....	198, 241-242	Eun, C. ....	143, 196	Farah, K. ....	95, 173
El sayed, E. Y. ....	125	Emmanuel, A. ....	149-150, 194, 239	Eun, C. S. ....	196	Farcau, O. ....	212
El-Salhy, M. ....	242	Emoto, S. ....	130, 226	Eusebi, L. H. ....	92, 223	Faria, G. ....	121, 213
El-Sayed, M. ....	139	Empananza, J. I. ....	121	Eutamène, H. ....	194, 238, 250	Faria, M. G. ....	110, 167
El-Sayed, S. ....	227	Enache, I. C. ....	251	Evans, L. ....	69, 98	Farias, G. F. A. ....	51
El-shafae, M. M. ....	169	Enck, P. ....	81	Evans, M. ....	138	Farid, K. ....	100, 170
El-Sherif, Y. ....	208	Endo, M. ....	156	Evans, P. L. ....	234	Farin, G. ....	176
El-Shirbeny, H. ....	129	Endo, Y. ....	94, 133, 158	Eveno, C. ....	236	Farin, H. ....	57, 76
El Yousfi, M. ....	246	Endoh, B. ....	134	Everett, S. ....	56	Farinati, F. ....	170, 208-209, 215, 224, 241, 252
El Zorkany, K. ....	120	Engberg, J. ....	146	Evers, S. W. ....	190	Farkas, K. ....	61, 145, 179-180, 194, 229, 232, 234
Elalfy, H. ....	123, 125, 168, 170	Engbersen, M. ....	137	Everson, M. ....	62, 83, 153, 176, 241, 245	Farkas, N. ....	127, 145, 171, 190, 249
Elashvili, I. ....	231	Engelhardt, B. ....	143	Evgrafov, P. G. ....	186	Färkkilä, M. A. ....	50, 59, 76, 84, 213
ElBadri, M. ....	252	Engelhardt, J. ....	59	Ewald, J. ....	223	Färkkilä, M. A. ....	190, 223
Elbanna, A. ....	253	Englund, E. ....	239	Eweeda, K. M. ....	162	Farmazon, A. ....	166
Elbastawisy, S. ....	214	Engstrand, K. ....	195	Ezzeldin, I. B. ....	164	Farmer, A. D. ....	51, 60, 95-96, 108, 194
Elbeshbeshy, H. ....	209	Engstrand, L. ....	50	Fabbri, C. ....	224	Farrag, K. ....	186, 232, 251
Elefsiniotis, I. ....	168	Ennaifer, R. ....	100, 168	Fabian, A. ....	145, 179-180, 194, 232	Farraís, S. ....	160
Elegezy, M. ....	170	Enriquez Marroquin, C. F. ....	194	Fabiani, B. ....	160	Farrant, M. ....	124
Elekes, G. ....	145	Entremont, A. ....	194	Fabritius, M. ....	221	Farre, R. ....	49, 94
Elemshtay, W. ....	168	Epping-Stippel, L. ....	149	Facchin, S. ....	142, 146, 209	Farrell, J. J. ....	134
Elessawy, H. ....	123, 214	Eppink, J. J. ....	125	Facchia, M. ....	163	Fateen, W. ....	177
Elezkurtaj, S. ....	183	Epstein, M. ....	143, 148	Facciotti, F. ....	63, 138, 240	Fathalah, W. ....	247
Elferink, M. A. G. ....	149	Ercoli, G. ....	63, 138	Façon, S. ....	194	Fathy, W. ....	120
Elfert, A. ....	64	Eren, F. ....	210, 240	Fadeenko, G. ....	98, 204, 247	Fattahi, M. R. ....	167
Elgebaly, A. ....	122, 125	Erickson, R. ....	189	Fadeeva, N. ....	142		
		Erickson, U. ....	51	Fadnes, L. T. ....	195		
		Erler, N. ....	134				

Fauconnier, A. ....	179	Fernández-Moro, C. ....	134	Finnegan, A. ....	232	Foruny Olcina, J. R. ....	202
Faulkner-Jones, A. ....	57	Fernández-Pacheco, J. ....	243	Fiocca, F. ....	52	Forzenigo, L. V. ....	230
Favali, A. ....	241	Fernandez-Pereira, L. ....	160	Fiocca, R. ....	160	Fossati, M. ....	138
Fawzi Tolba, M. ....	122	Fernández Pordomingo, A. ....	233	Fiore, W. ....	235	Fossmark, R. ....	142
Fayoud, M. ....	129	Fernandez Rivero, J. A. ....	221	Fiorella, S. ....	150	Foster, P. ....	95, 205
Fayyaz, F. ....	253	Fernandez Rodriguez, C. ....	167	Fiori, G. ....	177	Fouad, M. H. A. ....	125
Fazio, V. ....	58	Fernández Rosaenz, H. ....	144	Fiorillo, C. ....	89, 220	Fouad, R. ....	247
Feagan, B. G. ....	75, 97, 138, 142, 188, 230	Fernández Salazar, L. ....	49, 232	Fiorini, G. ....	74, 98, 159, 204, 247	Fournier, C. ....	240
Febbraro, I. ....	140	Fernández-Salazar, L. ....	49, 93	Fiorino, G. ....	232	Fournier, N. ....	140
Fedderson, U. R. ....	139	Fernandez-Tome, S. ....	64, 70	Fischbach, W. ....	151, 176	Fowler, H. ....	176
Federico, A. ....	121, 138, 230	Fernández-Urién, I. ....	202, 237	Fischer, P. ....	212	Fox, J. G. ....	98, 248
Fedorov, E. ....	136, 154, 198, 224	Fernandez Y Viesca, M. ....	223	Fischer, S. ....	232	Fox, M. ....	41, 71, 153
Fehér, B. ....	65	Fernando, B. ....	222	Fischer, T. ....	233	Fracasso, P. ....	140
Fehér, D. ....	190	Ferracane, C. ....	61	Fischler, B. ....	195	Fraga, J. ....	163
Fehér, E. ....	171	Ferrández, A. ....	237	Fittipaldi-Fernandez, R. J. ....	175, 218	Fragaki, M. ....	185
Fei, G. ....	200	Ferrándiz, Y. ....	86, 184, 227	Fitzke, H. E. ....	95	Fragkaki, M. ....	60, 215
Feistritzer, C. ....	70	Ferrante, M. ....	39, 67, 73, 97, 142-143, 187, 189	Fitzsimons, A. ....	181	Fraile, M. ....	64, 167
Fekih, M. ....	228	Ferrara, E. C. ....	181, 218, 225	Fliss -Isakov, N. ....	148	Framarin, L. ....	208
Feldager, E. ....	216	Ferrarese, A. ....	169	Fliss Isakov, N. ....	48, 231	Franceschi, F. ....	139, 240
Feldman, D. ....	176	Ferraresi, V. ....	237	Flisiak, R. ....	40	Franceschi, M. ....	92, 100, 150, 196-198, 203, 240, 244-246, 248
Feldman, S. ....	186	Ferrari, G. C. ....	179	Fliss Isakov, N. ....	48, 231	Franchimont, D. ....	36, 187
Felice, C. ....	71, 234	Ferraris, L. ....	197	Fliss-Isakov, N. ....	189, 191	Franchina, M. ....	200
Felipe-Silva, A. ....	157	Ferreira, A. O. ....	219	Floreani, A. ....	83, 91	Franchioni, E. ....	136
Fellermann, K. ....	80, 187	Ferreira, C. N. ....	219, 222, 241	Florena, A. M. ....	160	Francisco, I. ....	147
Feng, Y. ....	248	Ferreira, D. ....	145	Florent, C. ....	135	Francisconi, C. ....	51
Ferdinando, D. ....	220	Ferreira, J. M. ....	163	Flores Cucho, A. ....	247-248	Franco, L. M. ....	64, 167
Ferenci, P. ....	121, 167	Ferreira, P. ....	164	Flourie, B. ....	75, 233	Franco, M. ....	129
Ferenci, T. ....	145	Ferreira, S. ....	130	Fociani, P. ....	160	Franczyk, R. ....	222
Ferguson, J. ....	171	Ferreira-Nossa, H. C. ....	160	Fockens, P. ....	36, 46, 51, 54, 77, 85, 182, 216-217, 238	Franke, A. ....	229
Ferhat Çelik, A. ....	232	Ferreiro, B. ....	249	Foda, E. ....	123, 214	Franke, S. ....	248
Ferkolj, I. ....	74, 144	Ferreiro-Iglesias, R. ....	228	Fogg, C. ....	62	Frankova, S. ....	169
Ferla, V. ....	249	Ferrer, C. ....	159, 187	Foglia, A. ....	177	Franz, E. ....	138
Ferlitsch, A. ....	65, 121, 167, 212, 221	Ferrer, J. A. ....	167	Foglia, B. ....	48	Franzoni, L. ....	150, 196, 198, 203, 244-246, 248
Ferlitsch, M. ....	41, 53, 67, 87, 221-222	Ferrero, S. ....	160	Földes, I. ....	145	Frappart, P.-O. ....	50, 57, 172, 216
Fernades, S. ....	169, 187	Ferretti, F. ....	180, 248-249	Földi, M. ....	65, 171	Fraternale, G. ....	240
Fernandes, A. ....	169, 204, 253	Ferrini, L. ....	150	Folgado Alberto, S. ....	168	Frauen, R. C. ....	58
Fernandes, A. I. ....	204	Ferronato, A. ....	92, 240	Folkerts, S. ....	216	Frazzoni, L. ....	133, 154, 199-200, 220, 224, 243-244
Fernandes, C. ....	173	Ferrusquia, J. ....	167	Follo, M. ....	58	Frazzoni, M. ....	154, 199-200, 243-244
Fernandes, J. ....	180	Festa, S. ....	140	Foncea, C. G. ....	210, 212	Fredolini, C. ....	228
Fernandes, L. ....	196-197, 238-239	Festi, D. ....	72, 128	Fong, S. S. ....	131	Freire, R. ....	130, 219
Fernandes, S. ....	123, 144, 164, 171, 186, 190, 230	Fetche, S. N. ....	136	Fonseca, A. G. ....	251	Freitag, A. ....	144
Fernandes, S. R. ....	164, 171, 230	Fibbe, W. E. ....	57	Fonseca, C. ....	251	Freitag, T. L. ....	64
Fernandez, C. ....	167	Fichna, J. ....	138	Fonseca, J. ....	134	Freitas, A. L. ....	200
Fernandez, I. ....	167	Fichtner, D. ....	142	Fonseca, R. ....	147, 183, 185	Freitas, C. ....	208, 219, 223, 251
Fernández-Bañares, F. ....	87, 159, 184, 249	Field, A. ....	237	Fonseca Camarillo, G. ....	226	Freitas, L. C. R. ....	230
Fernández-Castroagudín, J. ....	212	Figueiredo, L. M. ....	64, 168, 253	Fontana, R. ....	228	Freitas, M. ....	225
Fernández-Esparrach, M. G. ....	158, 186	Figueiredo, N. ....	54	Forbes, N. ....	177	Freitas, S. ....	121
Fernández-Gil, P. L. ....	249	Figueiredo, R. ....	224	Forde, J. ....	131, 135	Freitas, T. ....	132, 134, 199
Fernández Landa, M. J. ....	178	Figueiredo Ferreira, M. ....	253	Fornasari, M. ....	218	Frenguelli, L. ....	57
		Figura, G. V. ....	165	Fornés, V. ....	162	Fresneda, D. ....	160
		Filip, R. ....	137, 161, 228-229, 233	Forstner, B. ....	166	Freuer, D. ....	218
		Filipe, B. ....	130, 147	Forti, E. ....	179	Frey-Wagner, I. ....	183
		Filippi, E. ....	240	Forti, G. ....	150	Fridman, W. H. ....	87
		Filippi, J. ....	61, 75, 233				
		Filippidis, G. ....	181				
		Fink, C. ....	211				

Friedman, A. B.....140	Fukuma, Y.....148	Gallego-Gómez, R.....126	García Planella, E.....232
Friedman, G. S.....97, 145, 188	Fukumoto, T.....135	Galli, G.....92, 129	García-Planella, E.....49, 93
Frieling, T.....199, 219	Fukunaga, S.....129	Gallmeier, E.....173	García Prada, M.....202
Frieling, C.....173	Fukunaga, Y.....132, 178	Galloway, G.....72	García-Puig, R.....159
Frieri, G.....248	Fukushi, K.....128, 180	Galtieri, A. P.....218	García-Rayado, G.....126
Fries, W.....61, 140, 228	Fukuzawa, M.....131	Galtieri, P. A.....81, 181, 220, 225	García-Rodríguez, L. A.....50
Friess, H.....59, 82, 89, 127, 165-166, 182, 215	Fulger, L.....213	Galtieri, P. A.....181, 220, 225	García-Rodríguez, A.....158
Friger, M.....142	Fülöpné Sarang, K.....232	Gamao Neto, M.....206	García Salido, A.....190
Frigerio, I.....49	Fumery, M.....48, 61, 86, 93, 139, 185, 229, 231, 233	Gama-Carvalho, M.....59	García-Sánchez, V.....49, 93
Friss, K. A.....194	Fumihiko, H.....160	Gambato, M.....169	García Sepulcre, M. F.....49
Frödin, J.-E.....50	Funao, N.....200	Gameel, A.....135	García-Sepulcre, M. F.....49, 93, 140
Frøkjær, J. B.....136	Funaro, B.....167	Gamelas, V.....202, 220, 253	García-Sepulcre, M. F.....232
Fruillon, L.....49	Funato, K.....152, 222	Gan, C.....121, 165, 172, 216	García-Tsao, G.....54, 76
Fruzio, A.....150	Füredi, Á.....179	Gan, T.....156	Garcovich, M.....167
Fu, J.....236	Furgala, A.....249	Ganal-Vonarburg, S.....70	Gardair, C.....86, 246
Fu, Q.....166	Furlan, D.....160	Gancedo Bringas, P.....248	Garg, M.....173
Fu, T.....124	Furnari, M.....62, 69, 168, 200, 221, 243	Ganda Mall, J.-P.....89	Gargari, G.....235
Fuccio, L.....87, 133, 220-221, 224	Furudoi, A.....53	Gane, E.....213	Gargouri, D.....171
Fuchs, E.-M.....65	Furue, Y.....176-177	Ganesanathan, S.....229	Garrad, A.....221
Fuduli, G.....58	Furusyo, N.....123	Gann, P.....199	Garre, A.....49, 93, 188
Fugazza, A.....181, 218, 225	Furuta, T.....180	Gao, H.....159	Garríba, A. T.....224
Fuh, F.....189	Furutani, K.....129	Gao, J.....121, 165, 237	Garrido, E.....71
Fuhler, G.....58, 82, 158	Fusai, G.....57	Gao, L. L.....80, 188	Garrido, M.....121, 182, 246
Fujie, M.....153	Fusaroli, P.....224	Gao, X.....142, 210	Garrido Lestache, E.....71
Fujigaki, S.....127, 135, 179	Fuschi, D.....52, 72	Garavaglia, F.....138	Garriga, M.....162
Fujii, M.....133, 209	Fushida, S.....157	Garavento, L.....222, 241	Garrote, J. A.....229
Fujii, Y.....125, 128, 170, 221	Futagami, S.....243, 245	Garbi, L.....233	Gasbarrini, A.....51, 58, 60, 70, 75, 88, 98, 138-139, 141, 146,
Fujiki, S.....81, 173	Fuxman, C.....233	Garbi, M. L.....222	159, 162-163, 167, 191, 204, 206-207,
Fujimori, S.....160, 162, 205		Garçes, S.....140	211, 229, 234, 244, 247, 250-251
Fujimoto, A.....82, 177	<b>G</b>	Garcés Duran, R.....158	Gasbarrini, G.....167
Fujimoto, K.....180	Gabbani, T.....246	García, J. J.....158	Gasink, C.....80, 97, 188
Fujimoto, S.....236	Gabbard, S.....60, 153	García, L.....93	Gáspár, K.....187
Fujimoto, T.....179	Gabrieli, D.....248	García, M. L.....167, 242	Gaspar, M. J.....249
Fujimoto, Y.....174	Gabryelska, A.....228	García Alonso, F. J.....229	Gaspar, R.....121, 170, 172-173, 175, 184, 212-213, 252
Fujino, J.....244	Gadeke, L.....62	García-Alonso, F. J.....52, 56, 223	Gasparri, L.....92
Fujino, Y.....236	Gadhikar, H.....246	García-Caballero, T.....126	Gasperoni, S.....224
Fujioka, K.....206	Gaemers, I.....138	García Cano, J.....133	Gasser Al-Azab, G.....124
Fujisaki, J.....58, 88, 133, 201	Gaetani, E.....139, 191, 250	García Caparrós, C.....164	Gasser Jr, R. A.....188
Fujisawa, T.....178	Gagalís, A.....207, 209	García Cedillo, M. F.....149	Gatchalian, L.....151
Fujishiro, M.....88, 158, 175, 221	Gagari, V.....221	García Donday, M.....204	Gatt, K.....236
Fujita, M.....136, 171	Gagnon, S.....240	García-Esquinas, E.....144	Gatta, L.....159, 247
Fujita, T.....163, 176	Gago, T.....150, 206, 235, 238	García-Fresnadillo, D.....247	Gaudio, E.....100, 166
Fujita, Y.....173	Gaidhane, M.....52, 133-135	García García de Paredes, A.....202	Gaudioso, G.....160
Fujiwara, T.....227	Gajardo Arias, C.....224	García García, J.....228	Gault, N.....71
Fujiwara, Y.....129, 134, 196	Gajdán, L.....171	García-Gil, J.....148-149	Gausman, V.....92, 217
Fukami, Y.....197, 204	Gallang, R. L.....114	García González, J. M.....236	Gavrila, D.....213
Fukayama, M.....130	Galanopoulos, M.....181	García Herola, A.....49, 233	Gawel, K.....129
Fuks, D.....38	Galatola, M.....161	García-Herola, A.....49	Gaya, D.....234
Fukuda, H.....61, 180	Galeazzi, F.....209	García-Iglesias, P.....69	Gazouli, M.....215
Fukuda, K.....131, 146, 173, 182, 209	Gallach, M.....69, 110, 235	García-López, S.....49, 93	Ge, N.....175
Fukuda, M.....148	Gallagher, C.....139, 141	García-Martínez, A.....192	Ge, Q.....236
Fukuda, S.....131, 158-159	Gallardo-Gómez, M.....192	García-Mateo, S.....50	Ge, Z.....248
Fukuda, T.....138	Galle, P. R.....79, 107, 150, 175	García-Morales, T.....131	Ge, Z.-Z.....149
Fukuhara, S.....56	Gallejo, M.....141	García-Nimo, L.....148	
Fukuhara, T.....76, 122		García-Nimo, L.....148	
		García-Pérez, I.....194	
		García Peraza Herrera, L. C.....245	



Gea Rodríguez, F. ....	71	Giannakopoulos, A. ....	160	Gisbert Ferrándiz, L. ....	71, 86, 183-184, 227	Gómez Senent, S. ....	187
Gecse, K. B. ....	142, 188, 190	Giannelis, P. ....	147	Gisbertz, S. S. ....	37, 48, 72, 83, 226	Gommoll, C. ....	188
Gede, N. ....	126, 171	Giannelli, E. ....	190	Gittering, M. ....	219	Gomollon, F. ....	237
Geenen, E. J. M. ....	197, 216	Gianniki, E. ....	215	Giuffrè, M. R. ....	63	Gomollón, F. ....	49, 144, 188
Geeraerts, A. ....	205	Giannini, E. G. ....	124, 168, 233	Giuffrida, P. ....	57, 160, 196, 202, 205, 228-230, 240	Gomollon Garcia, F. ....	232
Geesing, J. M. J. ....	148, 192	Giannone, A. G. ....	160	Giuliante, F. ....	100, 251	Gomollón Garcia, F. ....	144
Geginat, J. ....	63	Giannotta, M. ....	48, 185	Giunta, M. ....	177	Gonçalves, A. ....	144, 164, 176, 208, 222, 230, 253
Geh, D. ....	176	Giardini, M. ....	220	Giuseppe, S. ....	250	Gonçalves, B. ....	231
Gehmacher, T. ....	70, 183	Giardino, A. ....	49	Gjerde, R. ....	231	Gonçalves, C. ....	252
Geissler, M. ....	173	Gibbs, J. ....	183	Gjoko, D. ....	164	Gonçalves, G. ....	121
Gemici, M. ....	196	Gibiino, G. ....	91, 219	Gkeros, F. ....	181	Gonçalves, L. ....	207
Genda, T. ....	156	Gibson, G. ....	235	Gkolfakis, P. ....	221	Gonçalves, M. ....	175
Gene, E. ....	74, 203	Gibson, P. R. ....	140	Gkoutos, G. ....	235	Gonçalves, R. ....	114, 231
Geng, C. ....	161, 172, 183	Gielens, E. ....	245	Glanemann, M. ....	150	Gonçalves, S. ....	227
Genius, J. ....	142	Giestas, S. ....	134	Glasinovic, E. ....	69	Goncz, L. ....	185
Genov, J. ....	217	Gigante, G. ....	61, 142	Gleizes, A. ....	75	Gonda, T. ....	92, 135, 172, 217
Genova, S. ....	61	Gijsbers, K. M. ....	149	Glerup, P. ....	159	Gonda, T. A. ....	92, 135, 172
Gensollen, T. ....	70	Gil, A. ....	227	Glickman, J. ....	70	Gondo, K. ....	179
Georgieva, Z. ....	157	Gil, I. ....	253	Gluck, N. ....	148, 181, 224	Gong, E. J. ....	246
Geraci, M. ....	227	Gil, K. ....	249	Glud, L. L. ....	216	Goni, E. ....	172
Gerada, J. ....	126	Gilbert, P. ....	148	Gnant, M. ....	166	Gonsorcikova, L. ....	186
Geramizadeh, B. ....	169	Gilad, O. ....	148	Gnocen, T. ....	210	Gonzalez, J.-M. ....	136, 188, 198, 221
Gerard, R. ....	135-136	Giles, B. ....	163	Godat, S. ....	225	Gonzalez, M. ....	194
Gerardi, S. ....	139	Gilja, O. H. ....	77, 199	Godfrey, E. ....	65	Gonzalez, Y. ....	131
Géraud, C. ....	165	Gillespie, W. ....	132	Gódi, S. ....	126-127, 134, 171, 178	Gonzalez-Cordero, P. L. ....	52, 56, 160
Gerding, D. ....	75	Gilletta, C. ....	61	Godinho, R. ....	207	Gonzalez-Dieguez, L. ....	64, 167
Gergaud, O. ....	49	Gim, S. ....	140	Godny, L. ....	251	González Huerta, L. M. ....	226
German Jørgensen, S. P. ....	100	Gimeno, A. Z. ....	178	Goesser, T. ....	150, 241	González Martín, J. Á. ....	202
Germana', B. ....	150, 197	Gimeno Garcia, A. Z. ....	131	Goetz, M. ....	163	Gonzalez Mendez, A. ....	167
Germani, G. ....	169	Gimesi-Országh, J. ....	229, 234	Goetze, T. ....	202	González Muñoz, C. ....	233
Germer, R. R. ....	70, 183	Gimier, E. ....	183	Góg, C. ....	126	Gonzalez Suarez, B. ....	158
Gerova, V. ....	230	Ginard, D. ....	144	Goggins, M. ....	92, 99	González Suárez, B. ....	186
Gervain, J. ....	171	Giner, A. ....	141	Goh, M. J. ....	150	Gonzalez Suyo, R. C. ....	232-233
Gessl, I. ....	65, 221	Giner-Calabuig, M. ....	192	Goichon, A. ....	161	Goodchild, G. ....	223
Gesuale, C. ....	140	Gines, A. ....	158, 186	Goikotxea-Rodero, U. ....	131	Goodhand, J. ....	190
Gevers, T. J. G. ....	166	Gingold-Belfer, R. ....	163	Goishi, H. ....	143, 190	Goodman, W. ....	70
Geyer, M. ....	177	Giordano, A. ....	200	Gök, Z. ....	101, 209	Goodrick, K. ....	224
Geysen, H. ....	153, 245	Giorgini, S. ....	224	Gold, M. ....	129	Goor, H. V. ....	46, 85
Ghait, R. S. A. ....	125	Giorgio, F. ....	158	Gölder, S. ....	218	Goorhuis, A. ....	75
Ghailh, D. ....	247	Giorgio, P. ....	197, 248	Góldis, A. ....	48, 98, 185, 204, 247	Goos, K.-H. ....	235
Ghairbi, O. ....	168, 213	Giorgio, V. ....	58, 191	Golemanov, B. ....	217	Gopalakrishnan Ravikumar, N. P. ....	219
Ghasemi, P. ....	158, 228, 239, 243	Giouleme, O. ....	197	Gollo, C. ....	89	Goran, L. ....	231
Ghazizadeh, S. ....	50	Giovannis, P. ....	170	Golob, S. ....	144	Gordon, C. ....	62
Ghazy, M. S. ....	162	Giovannenze, F. ....	146	Golovko, T. ....	200	Gore-Booth, J. ....	67
Gheonea, D.-I. ....	172	Giovannini, M. ....	67, 72, 78, 92, 134-136, 220, 222-223, 225	Gomaa, A. ....	124, 152	Gorelick, K. J. ....	97, 144
Gheorghe, L. S. ....	211, 213-215, 234	Giral, A. ....	240	Gomes, A. C. ....	123, 163, 169, 176, 178, 180, 185, 187, 250	Goren, I. ....	164, 234
Gherhardt, D. ....	210, 212	Girardi, B. ....	158	Gomes, C. ....	121, 132, 134, 199, 219	Gori, A. ....	57, 239
Gherib, I. ....	123	Giraud, F. ....	222	Gómez, E. ....	93, 232	Gori, M. C. ....	153
Ghia, J.-E. ....	70	Girelli, C. M. ....	181, 208	Gomez, V. ....	179, 224	Gorkiewicz, G. ....	75
Ghigliazza, G. ....	228	Gisbert, J. P. ....	49, 64, 70, 74, 86, 93, 98, 144, 188-189,	Gómez Arbonés, J. ....	186	Gornet, J.-M. ....	61, 236
Ghisa, M. ....	69, 146, 198, 200, 208-209, 243, 252		203-204, 247	Gómez Cabero, D. ....	192	Gorpas, D. ....	218
Ghiuchici, A. M. ....	124					Götsmann, H. ....	209
Ghosh, S. ....	79-80, 86, 97, 138, 142-143, 176, 235					Gotink, A. W. ....	155
Giaccari, A. ....	206					Goto, O. ....	82, 177, 182, 218
Giambruno, E. ....	221						
Giancola, F. ....	239						

Goto, T. ....	132, 179, 193	Gress, T. M. ....	68, 85, 103	Gulati, A. ....	216	Hader, M. ....	204
Gotoda, T. ....	60, 159	Grieco, A. ....	58, 211	Gulbinas, A. ....	151	Haderer, M. ....	122
Gotthardt, M. ....	173, 206, 225	Griesmann, H. ....	173	Gulec-Suyen, G. ....	196	Hadithi, M. ....	46
Gottier, C. ....	71, 143	Grigoras, C.-A. ....	212	Gullo, I. ....	162	Hadjivassiliou, M. ....	205
Gottrand, F. ....	55, 95	Grigorescu, M. ....	120, 211	Gulturk, I. ....	123	Haendchen Bento, L. ....	129
Gotzeva, A. ....	169	Grigoryeva, T. ....	58, 74, 101, 235, 247	Gunasekera, A. V. ....	124	Hafif, M. ....	228
Goujon, G. ....	246	Grillo, F. ....	160	Gunasingam, N. ....	223	Häfner, M. ....	56
Goulis, I. ....	168	Grimaud, J.-C. ....	61, 188	Gundogdu, T. ....	232	Hägendorn, R. ....	126
Gourcerol, G. ....	78, 98, 113, 238, 242	Grimm, M. ....	199	Güngören, Z. ....	212	Hahnloser, D. ....	40, 47, 53, 59
Gourlain, H. ....	169	Grimminger, P. ....	175	Günther, S. ....	52, 144	Haider, G. ....	121
Goury, A. ....	169	Gröchenig, H. P. ....	75	Guo, C.-G. ....	152	Haider, L. ....	212
Gout, J. ....	50, 172, 216	Groen, J. N. ....	148, 192	Guo, H. ....	203	Haidich, A.-B. ....	212
Goutorbe, F. ....	231	Grønbaek, H. ....	230	Guo, H.-L. ....	65	Haidry, R. J. ....	62, 83, 153, 155, 176, 206, 241, 245
Goutte, M. ....	139, 231	Gröne, J. ....	183	Guo, J. ....	203	Hainer, R. ....	211
Gouveia, C. ....	130, 219	Grønlund, D. ....	136	Guo, Q. ....	142	Hajdune Dr. Varga, M. M. ....	126
Goverde, A. ....	95	Groome, M. ....	164, 184, 197, 234	Guo, T. ....	163	Hajek, M. ....	211
Gow, I. F. ....	161	Groot Koerkamp, B. ....	82, 215	Guo, Y. ....	219	Hajek, P. ....	69
Gower-Rousseau, C. ....	139, 229	Grooteman, K. ....	197	Gupta, A. ....	82, 153	Hakim, H. ....	135
Gowland, P. ....	190, 225	Grootjans, J. ....	70	Gupta, N. M. ....	60, 153, 219	Hakim, A. ....	220
Grabherr, F. ....	70, 183	Große Perdekamp, M. ....	58	Gupta, P. ....	216, 226	Hakkinen, M. ....	172
Gracida Mancilla, N. I. ....	226, 230	Groth, A. ....	189-190	Gupta, R. ....	224	Halász, A. ....	127, 171
Gracie, D. J. ....	184	Gruber, M. ....	41	Gupta, S. ....	69, 98, 175	Hale, M. E. ....	242
Graffeo, M. ....	128	Gruber, S. ....	204	Gupta, T. ....	176, 223, 241	Hale, M. F. ....	205, 234
Graham, D. ....	62, 83, 153, 241, 245	Grümmer, H. ....	233	Gürel, S. ....	216, 226	Half, E. ....	176, 181, 217
Graham, T. A. ....	228	Grund, K. E. ....	176	Gustafsson-Liljefors, M. ....	50	Halfvarson, J. ....	48, 185, 228
Gralnek, I. ....	36, 40, 55, 69, 72, 98, 185	Grunddal, K. V. ....	139	Gustot, T. ....	92, 223	Halkjær, S. I. ....	52, 144
Grancea, C. ....	211	Grünhage, F. ....	150	Guthrie, E. A. ....	184	Hall, A. ....	57
Grande, L. ....	247	Grywalska, E. ....	124	Guthrie, I. ....	65, 162	Hall, R. ....	234
Grassi, F. ....	153	Guadagno, E. ....	245	Gutiérrez, A. ....	49	Hallensleben, N. D. L. ....	216
Grassi, S. ....	229	Guagnozzi, D. ....	69, 184	Gutierrez Casbas, A. ....	49, 93, 188, 232-233	Haller, B. ....	220
Grasso, A. ....	58	Gualtieri, G. ....	196	Gutierrez Garcia, M. L. ....	167	Haller, D. ....	46, 56, 63, 70, 88, 98, 200
Grasso, E. ....	220	Guardiola, J. ....	49, 93, 148-149	Gutierrez-Grobe, Y. ....	221	Hallinen, T. ....	231
Grasso, V. ....	128	Guardiola Arévalo, A. ....	69	Gutierrez-Ibarluzea, I. ....	222, 236	Halon, A. ....	253
Grasu, M. ....	215	Guarino, M. ....	125, 207	Gutierrez-Stampa, M. Á. ....	148	Halonen, J. ....	148, 161
Grau, J. ....	147	Guarner Argente, C. ....	198	Gutman, C. ....	195	Ham, N. ....	176, 187
Gravina, A. G. ....	138, 230	Guarner-Argente, C. ....	131	Guz, M. ....	167	Hamada, T. ....	68
Gravis, G. ....	135	Guarneri, L. ....	58	Guz, W. ....	137	Hamada, Y. ....	128, 251
Graviss, E. ....	64	Guarracino, M. ....	125	Guzman, M. ....	241	Hamam, O. ....	214
Gray, K. ....	188	Gudoityte, G. ....	240	Gyawali, C. P. ....	69, 94, 198, 242-244	Hamamci, M. ....	185
Gray, M. ....	72, 89	Gueddiche, A. ....	240	Gyimesi, J. ....	64, 161-162	Hamamoto, R. ....	132
Graziani, C. ....	138-139, 141, 229	Guérin, C. ....	238	Gyökeres, T. ....	134	Hamano, R. ....	182
Graziani, M. G. ....	100, 150, 196, 206	Guerra, A. ....	202, 237	Gyömbér, Z. ....	126-127	Hamar, S. ....	179-180
Grecco, E. ....	110	Guerra, J. G. ....	209	Gyöngyi, Z. ....	126	Hamdi, S. ....	213, 241
Greco, D. ....	228	Guerra Veloz, M. F. ....	188	Gysan, M. R. ....	194	Hamed, M. ....	135
Greco, L. ....	96, 161	Guerreiro, H. ....	150, 206, 235, 238	Gyvyte, U. ....	240	Hameeteman, W. ....	231
Green, A. ....	69	Guerreiro, R. ....	206			Hamidi Ghalehjegh, S. ....	85
Green, S. ....	62, 80	Guerrero, L. ....	89	<b>H</b>		Hamidouche, N. ....	123
Greenberg, D. ....	142	Guglielmetti, S. ....	235	Ha, H. J. ....	222	Hamilton, B. ....	190
Greenberg, S. A. ....	146	Gui, X. ....	138	Ha, S. M. ....	110, 167	Hamlin, P. J. ....	184
Greener, T. ....	142, 201	Guiard, B. ....	238	Haak, H. E. ....	193	Hammami, A. ....	125, 213, 215, 248
Greenham, O. ....	223	Guidi, L. ....	140, 234	Haakana, R. ....	198	Hammel, P. ....	128
Greenup, A.-J. ....	143	Guido, E. ....	191	Haal, S. ....	77	Hammer, J. ....	94
Grega, T. ....	177, 224, 236	Guidotti, F. ....	249	Haas, S. L. ....	127	Hammond, P. ....	244
Greinwald, R. ....	80, 187	Guillamot, M.-A. ....	219	Hacein-Bey, S. ....	75	Hammoud, D. ....	235
Gremese, E. ....	234	Gujda, G. ....	52	Haddow, J. ....	234	Hammoudi, N. ....	236

Hamshaw, L. ....	129	Hasan, H. ....	209	He, C. ....	139, 158, 196, 198, 248	Hernández-Illán, E. ....	192
Hamvas, J. ....	126-127, 171	Hasan, M. ....	56, 99, 122	He, J. ....	47, 74, 202, 204, 210	Hernández Ramírez, V. ....	48, 185
Hamza, Y. ....	212	Hasan, S. S. ....	195	He, K. ....	219, 221, 225	Hernández Villalba, L. ....	49
Hamzaoui, M. L. ....	204	Hasatani, K. ....	192	He, S. ....	155	Hernando, E. ....	195
Han Jo, J. ....	180, 193, 198, 242	Hasegawa, R. ....	135, 178	He, Y. ....	229	Hernanz Ruiz, N. ....	202
Han, C. ....	185, 188	Hasegawa, S. ....	161	Healy, A. ....	218	Herold, C. ....	212
Han, D. S. ....	196	Hashash, J. ....	152, 241	Hebuterne, X. ....	75, 144, 231	Herrera, L. ....	176, 245, 248
Han, J. ....	152, 178, 180, 193, 198, 242	Hashimoto, K. ....	61	Hedström, A. ....	127	Herrera de Guise, C. ....	101
Han, J.-H. ....	125	Hashimoto, M. ....	170	Heeman, K. ....	203	Herrera Fajes, J. L. ....	228
Han, S. J. ....	175, 178, 180	Hashimoto, S. ....	153	Heerasing, N. ....	190	Herreros de Tejada, A. ....	131
Han, S.-Y. ....	175	Hashish, A. ....	214	Hegade, V. ....	56	Herrmann, K. ....	140-141
Han, X. ....	216	Hasnaoui, B. ....	215	Hegazy, A. ....	123	Heruti, I. ....	151
Han, Z. ....	61, 70, 144	Haspel, J. ....	176	Hegyi, E. ....	50, 217	Hervas, D. ....	151
Hanada, H. ....	114	Hassan, C. ....	36, 53, 87, 97, 109, 130-131, 133, 148, 175, 220-221	Hegyi, P. ....	40, 54, 59, 65, 67, 73, 89, 126-127, 130, 134, 145, 171, 217, 249	Hetta, H. F. ....	123
Hanaauer, S. ....	80, 97	Hassan, M. ....	172	Heimann, A. ....	134	Hettich, S. ....	238
Hand, L. ....	183	Hassan, M. S. ....	162	Heindl, M. ....	126	Heuchel, R. L. ....	50
Handa, O. ....	248	Hassan, Z. ....	121	Heinemann, H. ....	80, 187	Heumann, A. ....	182
Hanly, M. ....	181	Hassan-Zahraee, M. ....	86	Heinemann, V. ....	172	Hewett, D. G. ....	176
Hann, A. ....	176, 224-225	Hassany, M. ....	125	Heinrich, H. ....	41, 61, 83, 100	Hiasa, Y. ....	173, 217
Hanna, C. ....	234	Hasselblatt, P. ....	58, 80	Heitland, W. ....	232	Hibiya, S. ....	71, 183
Hanna, G. ....	37	Hassine, A. ....	248	Heitman, S. J. ....	177	Hidaka, E. ....	131, 192
Hansen, E. ....	216	Hassler, S. ....	75	Heitmann, M. ....	120	Hidalgo-Sastre, A. ....	126
Hansen, L. ....	52, 144	Hassuike, N. ....	201	Hela, G. ....	159	Hidekazu, K. ....	174
Hansen, M. B. ....	120, 228	Hata, K. ....	130, 226	Helal, A. ....	124	Hiemori, A. ....	133
Hansi, N. ....	58	Hatamori, H. ....	133	Heldt, C. ....	64, 249	Higashi, N. ....	123
Hanzel, J. ....	144	Hatanaka, Y. ....	225	Heller, S. ....	57	Higashino, K. ....	174
Hanzel, J. ....	74	Hatemi, I. ....	123, 232	Helwa, M. ....	214	Higashiyama, M. ....	53
Hao, J. ....	127	Hauser, G. ....	172	Helwig, U. ....	190, 231	Higgins, B. ....	62
Hao, L. ....	65	Hausken, T. ....	199, 242	Hemmer, P. H. J. ....	137, 194	Highton, A. ....	252
Hara, H. ....	57, 197, 204	Hausmann, J. ....	232	Hemrich-Stanisak, G. ....	229	Higuchi, K. ....	200, 243, 245
Hara, K. ....	242	Hausmann, M. ....	71	Hendy, O. ....	213	Higuera, R. ....	143
Harada, E. ....	177	Haveman, J. W. ....	46	Hendy, P. ....	190	Higurashi, T. ....	238
Harada, H. ....	128, 134, 157	Havenga, K. ....	137, 194	Hennekam, R. C. ....	216	Hijona, E. ....	55, 214
Harada, N. ....	133	Hawes, R. ....	56, 99	Henriques, M. ....	162	Hijos, G. ....	237
Harada, T. ....	114, 177	Hawken, L. ....	253	Henry, H. ....	51	Hiki, N. ....	132
Harada, Y. ....	157	Hawkey, C. J. ....	204	Heo, C. M. ....	144	Hikichi, T. ....	170, 221
Harai, S. ....	125	Hawthorne, A. B. ....	229	Heo, J. ....	178	Hilkemeijer, T. R. H. ....	128
Harbi, R. ....	125	Hayasaka, K. ....	128, 134, 157	Hepburn, T. ....	53	Hiller, J. ....	58
Harborne, M. ....	241	Hayashi, I. ....	184	Hergueta Delgado, P. ....	238	Hiltunen, P. ....	162
Hardi, R. ....	143	Hayashi, J. ....	123	Hering, L. ....	71	Hincelin-Mery, A. ....	75
Hardwick, J. C. H. ....	149	Hayashi, K. ....	153	Hermans, M. ....	217	Hingorani, A. ....	63
Harlow, C. ....	192	Hayashi, R. ....	147	Hermida, C. ....	249	Hino, H. ....	155
Harris, M. ....	195	Hayashi, S. ....	85, 174	Hermus, L. ....	137	Hinojosa, J. ....	49, 232-233
Harris, R. ....	190	Hayashi, T. ....	127, 131-133, 157, 173, 175, 191-192, 194, 217, 219-221	Hernandez, A. ....	131	Hinrichsen, H. ....	210
Harrison, B. ....	213	Hayashi, Y. ....	60-61, 91, 160, 250	Hernandez, C. ....	147	Hinterberger, A. ....	87, 221-222
Hart, A. ....	59, 63, 78, 227-228, 234	Haybaeck, J. ....	247	Hernández, C. ....	194	Hiraga, Y. ....	53
Hart, J. ....	190	Hayee, B. ....	81, 232	Hernandez, D. ....	131	Hirai, F. ....	143
Hartleb, M. ....	175	Hayee, B. R. ....	168	Hernández, G. ....	178	Hirai, R. ....	152
Hartmann, A. ....	220	Hazan, R. ....	151	Hernández, L. ....	49, 69, 235	Hirai, S. ....	191
Hartmann, D. ....	59, 126, 165-166	Hazelton, W. D. ....	62	Hernandez, M. ....	131	Hiramatsu, N. ....	219
Hartmann, H. ....	190, 231	Hazen, W. L. ....	148	Hernandez Camba, A. ....	233	Hiramamine, Y. ....	170
Hartmann, P. ....	189	Hazewinkel, Y. ....	41	Hernandez-Illan, E. ....	192	Hirano, D. ....	147
Hartmans, E. ....	194	He, A. ....	144			Hirano, I. ....	54, 69, 98, 199
Haruhiro, H. ....	174					Hirano, K. ....	68
Harvey, P. ....	176, 227, 235, 251					Hirao, M. ....	219
Hasak, S. ....	94					Hiraoka, Y. ....	61

Hiroaki, K. ....	160	Holzmann, B. ....	126, 166	Hrubá, V. ....	235	Hünger, M. ....	176
Hirotsuda, A. ....	60	Hommel, D. W. ....	57	Hruz, P. ....	46	Huo, J. ....	147
Hirotsu, Y. ....	52, 203, 232	Hompes, R. ....	146	Hsiang, J. C. ....	69	Huorka, M. ....	126
Hiroyasu, T. ....	203	Honarvar, B. ....	169	Hsiao, C. W. ....	237	Hupkens, B. J. P. ....	193
Hirschfield, G. ....	123, 171	Hong, E. K. ....	214	Hsieh, P. ....	131	Hur, C. ....	62
Hirschi, A. ....	204	Hong, J. H. ....	244	Hsieh, Y.-H. ....	175	Hüser, N. ....	59, 126, 165-166
Hirschmann, S. ....	232	Hong, M.-G. ....	228	Hsu, M.-H. ....	155	Hush, J. ....	194
Hisai, H. ....	178	Hong, S. A. ....	175	Hsu, W.-T. ....	151	Hussein, H. ....	70
Hisamatsu, T. ....	179, 187, 213	Hong, S. P. ....	69	Htet, H. M. T. ....	252	Hussein, M. ....	253
Hisayuki, T. ....	131, 133, 192, 219-220	Hong, S.-J. ....	241	Hu, C.-T. ....	175	Hutfless, S. ....	143
Histace, A. ....	135-136	Hong, S.-N. ....	144	Hu, G. ....	216-217	Huyck, S. ....	143
Hiyoshi, M. ....	226	Hongo, H. ....	200	Hu, J. ....	143	Hwang, S. W. ....	176, 187, 192
Hjortswang, H. ....	184	Hongtao, N. ....	110	Hu, L.-H. ....	65	Hwangbo, Y. ....	175
Hlaing, P. P. ....	252	Honjo, M. ....	171	Hu, M. ....	80, 182	Hyatt, B. ....	250
Hlavaty, T. ....	126, 228	Honkoop, P. ....	172	Hu, W. ....	182, 204	Hyoju, S. ....	89
Ho, A. M. Y. ....	235	Hoogenboom, S. A. ....	217	Hu, Y. ....	136, 158, 248	Hyrdel, R. ....	69, 199, 242
Ho, A.-S. ....	147	Hoogkamer, A. B. ....	187	Huan, Y. ....	228	Hyun, J. J. ....	69
Ho, G.-T. ....	234	Hoops, T. ....	186	Huang, B. ....	74, 79, 142-143, 230	I	
Ho, J. J. ....	178, 222	Hopkins, D. ....	206	Huang, H.-T. ....	159	Iacob, A. ....	242
Ho, S. ....	56, 135, 177	Hordonneau, C. ....	231	Huang, J. ....	61, 83	Iacob, M. S. ....	211, 214-215
Hoad, C. ....	190, 225	Horhat, A. ....	212	Huang, J.-Y. ....	153	Iacobello, C. ....	58
Hobbs, F. D. R. ....	204	Hori, K. ....	88, 149, 176-177	Huang, L. ....	136, 197	Iacucci, M. ....	138, 176, 235
Hobbs, P. ....	244	Hori, T. ....	80	Huang, P. ....	165	Iancu, A. V. ....	169
Hockenjos, B. ....	58	Horie, Y. ....	88, 133	Huang, R. ....	63	Ianiró, G. ....	75, 88, 106, 139, 146
Hocquet, A. ....	40	Horiguchi, S. ....	217	Huang, S. ....	128, 163	Iannicelli, E. ....	49
Hod, K. ....	195	Horii, T. ....	60	Huang, T. ....	147, 151, 246	Iannone, A. ....	136, 158, 160
Hodge, J. C. ....	212	Horise, Y. ....	136	Huang, Y. ....	82, 129	Ianosí, G. ....	166
Hodgson, R. ....	208	Horiuchi, M. ....	170	Huang, Z. ....	237	Ianosí, S. ....	166
Hoeck, S. ....	191	Horiuchi, Y. ....	58	Hubalewska-Mazgaj, M. ....	201, 228, 235	Iborra, M. ....	93, 143, 188
Hoff, A. C. ....	175, 218	Hornung, B. V. H. ....	75	Hübenthal, M. ....	229	Ibraheim, H. ....	242
Hoff, G. ....	177	Horta, D. ....	64, 134, 253	Huber, F. ....	232	Ibrahim, F. ....	182
Hoffman, A. ....	129	Horta Sangenis, D. ....	159	Hubert, C. ....	52, 217	Ibrahim, M. ....	36, 41, 59, 99
Hoffman, S. ....	63	Horvat, J. ....	205	Huberty, V. ....	36, 83, 174, 223	Ibrahim, S. ....	64, 141
Hoffmeister, A. ....	126-127	Horváth, Á. ....	162	Hucl, T. ....	36, 56, 72, 91, 102, 161, 198	Ibrahim, W. ....	123
Hofker, S. ....	85	Horváth, E. ....	65	Hudler, H. ....	204	Ibrahimi, A. ....	69, 216, 237, 246
Högenauer, C. ....	75, 89, 101, 234	Horvatits, T. ....	58	Hudler, S. ....	204	Ichida, K. ....	131
Hohenberger, S. ....	233	Horyňski, M. ....	187	Hudson, M. ....	77, 122	Ichijima, R. ....	60, 130
Hohwieler, M. ....	57	Hosadurg, D. ....	194	Huelsen-Katz, A. ....	221	Ichiki, Y. ....	123
Hoischen, A. ....	121	Hosaka, H. ....	242	Huelsewig, C. ....	50, 238	Ichimasa, K. ....	131-133, 159, 175, 192, 194, 219-221
Høivik, M. L. ....	140	Hoshino, A. ....	245	Huernos, S. P. ....	227	Ide, D. ....	133
Hojo, D. ....	226	Hoskin, B. ....	61, 142	Huggett, M. ....	56	Idigoras Rubio, I. ....	178, 222, 236
Hojo, M. ....	129, 156-157	Hosni, M. ....	182, 241	Hugot, J.-P. ....	49, 139	Ido, A. ....	59, 170, 213
Hold, G. L. ....	70	Hosoda, K. ....	125, 245	Huguet, A. ....	71	Iemoto, T. ....	179
Holleman, F. ....	206	Hosoda, Y. ....	133, 167	Huguet-Malavés, J. M. ....	49	Ierardi, E. ....	136, 158, 160, 205
Holleman, R. A. ....	85	Hosomi, S. ....	70, 129, 134, 196	Huh, C. W. ....	152	Iglesias Canle, J. ....	223
Hollenbach, M. ....	126-127	Hosoya, A. ....	138	Huh, K.-C. ....	175	Iglesias Flores, E. ....	93, 232-233
Holleran, G. ....	61, 70, 139, 197	Hospers, G. A. P. ....	137, 194	Huhtala, H. ....	161	Iglesias-García, J. ....	103, 108, 134, 216-217, 223
Holm, O. ....	120	Hosui, A. ....	219	Hui, W. ....	180	Iglicki, I. ....	194
Holmberg, D. ....	244	Hoteit, B. ....	130	Huijbers, A. ....	251	liboshi, T. ....	143, 190
Holmer, C. ....	183	Hotta, K. ....	132, 151	Huisman- de Waal, G. J. ....	207	Iijima, K. ....	156
Holmes, E. ....	194, 228, 234	Hou, H. ....	70, 144	Hull, M. A. ....	53, 93	Iino, T. ....	137
Holst, J. J. ....	226	Houghton, L. ....	38, 49, 96, 103	Hulst, J. ....	162	Iizuka, M. ....	145
Holster, S. ....	52	Houist, G. ....	135	Humbert, L. ....	191	Iizuka, T. ....	222
Holtkamp-Endemann, F. ....	233	Hourigan, L. ....	80, 177, 221	Hummel, M. ....	183		
Holtmann, G. ....	72, 95, 158, 175, 221, 228, 239, 243	Hovde, Ø. ....	78	Humphries, A. ....	110		
		Howaldt, S. ....	93, 141				
		Howarth, G. ....	189				
		Hovs, S. ....	191				
		Hradsky, O. ....	186				

Ijuin, S. ....	59, 213	Ionescu, D. ....	160, 212	Ito, T. ....	174, 223, 245	Jairath, V. ....	98, 138, 143
Ikarashi, S. ....	153	Ionescu, D. F. ....	160	Ito, Y. ....	68, 248	Jajoriya, A. ....	210
Ikebuchi, Y. ....	170, 197	Iovino, P. ....	100, 154, 161, 170, 228	Itoh, F. ....	156	Jalali, Y. ....	126, 228
Ikeda, A. ....	129, 156-157, 201, 217	Iqbal, J. ....	163, 208	Itoh, H. ....	132-133, 175	Jalanka, J. ....	235
Ikeda, G. ....	243, 245	Iqbal, K. ....	121	Itoh, T. ....	174	Jalayeri Nia, G. ....	220
Ikeda, H. ....	197	Iqbal, T. ....	235, 253	Itoi, T. ....	56, 131, 136, 171	Jamal, S. ....	164
Ikeda, K. ....	180	Irie, H. ....	170	Itokawa, Y. ....	134	Jamali, F. ....	182
Ikehara, H. ....	60	Irisawa, A. ....	128, 180	Itzlinger, A. ....	64, 249	James, K. ....	140
Ikematsu, H. ....	88, 132, 149, 176-177	Irving, P. ....	141	Iuga, C. A. ....	185	Jamet, P. ....	160
Ikemiyagi, H. ....	197, 204	Isaksson, S. ....	138-139	Ivancovsky-Wajcman, D. ....	48, 191	Jamil, K. ....	216
Ikeura, T. ....	89, 223	Isayama, H. ....	68, 178, 215	Ivanov, A. N. ....	162	Janelidze, S. ....	93, 189, 232
Ikeya, T. ....	131, 146, 173	Iseki, H. ....	136	Ivanova, E. V. ....	224	Jang, B. I. ....	125, 248
Ikezawa, K. ....	134	Ishaq, S. ....	80, 133, 221	Ivanova, L. A. ....	123	Jang, H. ....	224
Ikuta, S. ....	136	Ishbaq, F. ....	57, 66, 183	Ivanova-Todorova, E. ....	230	Jang, H.-J. ....	191
Ila, V. ....	65	Ishida, E. ....	174	Ivashkin, V. ....	65, 154, 167, 185, 200, 238	Jang, S. ....	69, 130, 174-175, 179-180, 193, 198, 242
Ilan, N. ....	127	Ishida, F. ....	131-133, 175, 192, 194, 219-221	Iven, J. ....	205	Jang, S. H. ....	174
Ilchishina, T. ....	203	Ishida, K. ....	146	Iversen, S. ....	186	Jankowski, J. ....	62
Ilie, M. ....	50, 108, 115, 181, 251	Ishida, T. ....	114, 143	Iwabuchi, M. ....	94, 148	Janmaat, V. ....	82, 201
Ilies, M. ....	185	Ishido, K. ....	129	Iwagaki, H. ....	182	Janoir, C. ....	191
Illés, A. ....	127, 171	Ishigaki, K. ....	215	Iwai, T. ....	135, 178	Janse, M. ....	217
Illés, D. ....	171, 207	Ishigaki, N. ....	114	Iwakawa, K. ....	182	Jansen, B. H. ....	233
Illona, B. ....	238	Ishigaki, T. ....	175, 192, 194, 219	Iwaki, T. ....	176	Jansen, M. ....	62, 228
Imai, K. ....	151	Ishigami, K. ....	222	Iwakiri, K. ....	160, 162, 205, 243, 245	Jansen, P. L. M. ....	83
Imaizumi, H. ....	135, 178	Ishiguro, M. ....	173	Iwamoto, H. ....	133	Janssen, D. J. P. A. ....	195
Imamura, T. ....	134	Ishiguro, Y. ....	145	Iwamuro, M. ....	155	Janssen, I. M. C. ....	206
Imamura, Y. ....	170, 173, 217	Ishihara, R. ....	158, 174	Iwao, Y. ....	147	Januszewicz, W. ....	129
Imaz Ayo, N. ....	178, 222, 236	Ishihara, S. ....	88, 158	Iwasaki, E. ....	56	Jaquotot Herranz, M. ....	187
Imeneo, M. ....	195	Ishii, H. ....	173, 217	Iwasaki, M. ....	128	Jarmakiewicz, S. ....	228-229, 233
Imeryüz, N. ....	230	Ishii, R. ....	204	Iwasaki, Y. ....	158, 211, 243	Jarzbaski, A. ....	129
Imondi, A. ....	170, 215	Ishii, S. ....	178	Iwase, H. ....	133	Jasinski, L. ....	110, 121, 123, 167, 211, 213, 216, 235, 252
Impagnatiello, M. ....	146	Ishikawa, H. ....	57, 158	Iwashita, T. ....	68, 99, 181, 222	Jasper, D. ....	42
Imperatore, N. ....	186-187, 190	Ishikawa, K. ....	52, 80, 153, 174	Iwata, K. ....	99	Jauskaitiene, A. ....	151
Imperiali, G. ....	197	Ishikawa, M. ....	120, 155	Iwata, M. ....	174	Jaziri, H. ....	125, 211, 213, 215, 230, 241, 248
Inaba, T. ....	155	Ishikawa, S. ....	152	Iwaya, Y. ....	201	Je, H. S. ....	218
Inadomi, J. ....	62	Ishikawa, T. ....	248	Izawa, N. ....	128	Jean Marc, D. ....	224
Inagaki, M. ....	182	Ishikawa-Kakiya, Y. ....	134	Izbéki, F. ....	126-127, 171	Jeen, Y. T. ....	130, 175
Inagaki, S. ....	192	Ishiwatari, H. ....	151	Izbicki, J. ....	82, 182	Jeen, Y.-T. ....	174, 179-180, 193, 198, 242
Inatomi, O. ....	134, 179, 217, 246	Ishiyama, A. ....	151	Izquierdo-Martín, A. ....	160	Jelakovic, M. ....	207
İnce, A. T. ....	180	Ishiyama, S. ....	508	Izumi, K. ....	129, 156-157, 201	Jendoubi, N. ....	166
Indeykina, L. ....	195	Islam Sayin, S. ....	98, 200	Izumi, M. ....	136	Jenei, A. ....	187
Inferreira, M. ....	146, 200, 209	Ismail, M. ....	130, 181, 241, 252	Jafar, W. ....	201, 207	Jenkins, I. ....	35, 42, 47, 54, 84
Ingermann, J. ....	82, 98, 155, 218	Ismail, S. ....	141	Jacob, C. E. ....	157	Jenkinson, P. ....	188, 234
Inghilleri, M. ....	153	Ismaili, Z. ....	213, 221, 229-230, 234, 251	Jacob, P. ....	135	Jensen, J. T. ....	186
Ingravalle, F. ....	141	Isomoto, H. ....	170, 197	Jacob, R. ....	189	Jensen, T. S. R. ....	139
Inokuma, T. ....	170	Isono, A. ....	197	Jacobstein, D. ....	80, 97, 188	Jeon, H. J. ....	174-175, 179
Inoue, H. ....	73, 93, 132-133, 161, 175, 197, 220	Israeli, E. ....	146	Jacques, J. ....	48, 73, 82, 102, 132, 177, 198, 221, 242	Jeon, S. ....	98, 202
Inoue, K. ....	248	Issa, Y. ....	46, 216	Jafari, J. ....	242	Jeon, S. R. ....	151
Inoue, N. ....	147	Issaoui, D. ....	213	Jafferhoy, H. ....	234	Jeon, S. W. ....	98, 201-202
Inoue, T. ....	139, 200	Itani, Y. ....	184	Jain, A. ....	233	Jeon, Y. ....	121
Inrhaoun, H. ....	237	Itkonen, O. ....	172	Jakkola, T. ....	190	Jeong, E. J. ....	69
Inserra, G. ....	61	Ito, A. ....	141, 145, 222	Jablaoui, A. ....	159	Jeong, H. Y. ....	156, 201
Insolia, E. ....	249	Ito, H. ....	132, 194	Jackson, B. ....	188	Jeong, J. ....	202
Invernizzi, F. ....	180	Ito, K. ....	125, 128, 157, 170	Jackson, F. ....	235		
Ioannidou, P. ....	168	Ito, M. ....	149, 209	Jacob, C. E. ....	157		
Ioannou, A. ....	239	Ito, R. ....	176-177	Jacob, P. ....	135		
		Ito, S. ....	85, 151	Jacob, R. ....	189		
				Jacobstein, D. ....	80, 97, 188		
				Jacques, J. ....	48, 73, 82, 102, 132, 177, 198, 221, 242		
				Jafari, W. ....	201, 207		
				Jafari, J. ....	242		
				Jafferhoy, H. ....	234		
				Jain, A. ....	233		

Jeong, S. ....	69, 125, 136, 146	Jørgensen, S. P. ....	100, 234	Kaise, M. ....	222	Kang, H. ....	136
Jeong, S. H. ....	146	Jorquera Plaza, F. ....	236	Kaizaki, Y. ....	192	Kang, J. ....	136
Jerlstad, P. ....	195	Jorritsma-Smit, A. ....	137, 194	Kaizer, L. ....	179	Kang, S. H. ....	156, 201
Jess, T. ....	41, 84, 233	Jose, N. ....	138	Kajihara, T. ....	143, 190	Kang, W. ....	50, 58, 147, 151, 236, 246
Jessen, B. ....	249	Joseph, J. A. ....	225	Kajiwara, E. ....	123	Kani, H. T. ....	230
Jeyaparakash, V. ....	167	Jouët, F. ....	194	Kaku, H. ....	133	Kanmura, S. ....	170
Jeyarajah, J. ....	138	Joukar, F. ....	247	Kakugawa, Y. ....	47	Kanno, Y. ....	125, 128, 157, 170
Jha, A. ....	128	Jouve, E. ....	61	Kakushima, N. ....	151	Kano, T. ....	76, 122
Jha, L. ....	69	Jovanovic, I. ....	233	Kalabic, J. ....	97, 142	Kansara, J. ....	140
Ji, Y. ....	159	Jover, R. ....	176, 192	Kalafateli, M. ....	146	Kant, T. ....	110
Jia, H. ....	175, 196	Jovic, J. ....	122	Kalampakas, A. ....	207, 209	Kanzaki, H. ....	155
Jia, X. ....	121, 165, 172	Jovicic, I. ....	141	Kalantzis, C. ....	223, 248	Kanzaki, M. ....	252
Jiamin, H. ....	96, 202	Joyce, H. ....	144-145	Kalapala, R. ....	224, 242	Kao, J. Y. ....	204
Jiang, W. ....	167	Jr, E. V. ....	143, 230	Kale, A. ....	123	Kapaj, A. ....	250
Jiaojiao, L. ....	210	Juárez-Quesada, M. ....	192	Kalejs, O. ....	50, 241	Kapatais, A. ....	168
Jideh, B. ....	224	Juette, H. ....	141	Kalish, S. ....	154, 200	Kapizioni, C. ....	96, 147
Jie, L. ....	210	Juge, N. ....	235	Kaliyaperumal, A. ....	187-189	Kappelman, M. ....	186
Jimenez, A. ....	131	Juhas, S. ....	155	Kalkan, Ç. ....	243, 246	Kapran, Y. ....	220
Jiménez, I. ....	188	Juhász, F. ....	65	Kalkan, E. ....	243	Kara, B. ....	57
Jiménez, M. ....	125	Juliá, B. ....	140	Kallel, L. ....	166	Karabulut, E. ....	123
Jimenez-Agüero, R. ....	55, 88, 99, 166	Julien, D. ....	183	Kallel, R. ....	159, 171	Karacaer, C. ....	198, 241-242
Jiménez-Agüero, R. ....	214	Jun, C. H. ....	169, 207	Kallenberg, F. ....	191	Karagiannakis, D. ....	168
Jiménez Bobadilla, B. ....	226, 230	Jung, D. H. ....	148, 152, 156, 176, 202	Kamada, H. ....	196	Karagyozov, P. ....	157
Jiménez-Rosales, R. ....	50, 152, 197	Jung, G. ....	192	Kamada, K. ....	248	Karakan, T. ....	101, 209
Jin, H. ....	127, 163	Jung, H. C. ....	92, 129, 201, 244	Kamal, A. ....	212	Karakaya, F. ....	243, 246
Jindal, A. ....	64	Jung, H. I. ....	173	Kamal, M. ....	122	Karakaya, M. ....	246
Jinnai, H. ....	128	Jung, H.-Y. ....	218, 245	Kamata, N. ....	134, 196	Karamanolis, G. ....	198
Jiriyasin, S. ....	215	Jung, K. ....	234	Kambayashi, H. ....	141	Karampekos, G. ....	181
Jmaa, A. ....	125, 211, 213, 215, 230, 241, 248	Jung, K. W. ....	218	Kamieniarz, L. ....	144-145	Karampitsakos, T. ....	184
Jo, E. ....	195	Jung, M. K. ....	175, 178	Kamilova, O. ....	162	Karanikas, G. ....	126
Jo, J. H. ....	136	Jung, Y. ....	151, 175, 178	Kaminska, E. K. ....	172	Karaoulani, T. ....	168
Jo, S. ....	181, 192	Jung, Y. S. ....	147	Kaminski, M. F. ....	53, 67, 74, 81, 95, 129, 177	Karas, I. ....	230
Joanne Manlapig Rubio, M. ....	137	Jüngst, C. ....	150	Kamlage, B. ....	210	Karatapanis, S. ....	168
João Matias, D. ....	236	Junji, K. ....	174	Kamm, M. A. ....	47, 68, 78, 88	Karataş, A. ....	209
Jochum, W. ....	150	Junquera, F. ....	69, 110, 235	Kammphuis, J. B. J. ....	238, 250	Kärhus, L. L. ....	205
Jocic, T. ....	189	Jurado Jiménez, A. ....	202	Kamps, A. ....	172	Karim, M. ....	50
John, S. ....	50, 221	Jussila, A. ....	231	Kanai, T. ....	56, 80, 202	Kariv, R. ....	48, 148, 191
Johnson, G. ....	223	Juzenas, S. ....	229, 240, 248	Kanamor, A. ....	126, 128, 180	Karlsen, L. ....	231
Johnstone, M. ....	227	<b>K</b>		Kanao, H. ....	53	Karlsen, T. H. ....	46, 76, 99
Jokelainen, K. ....	59, 76, 213	Kaán, K. ....	65	Kanata, R. ....	136	Karlsson, M. K. ....	235
Joly, F. ....	36, 71, 103	Kabakchiev, B. ....	142	Kanatani, T. ....	152	Karmiris, K. ....	185
Jonaitis, L. ....	98, 150, 204, 229, 247-248	Kabbaj, N. ....	198, 219, 226	Kanazawa, R. ....	178	Karpińska, K. ....	129
Jonefjäll, B. ....	138	Kabravala, M. ....	128, 135, 182	Kanda, T. ....	197	Karpova, E. S. ....	208
Jones, C. ....	75	Kaci, R. ....	246	Kandel, G. ....	201	Karpova, R. ....	166
Jones, D. ....	77	Kacska, S. ....	187	Kandler, J. ....	62	Karrenbeld, A. ....	137, 194
Jones, M. ....	72, 150, 158, 184, 194-195, 228, 239	Kadenczki, O. ....	65, 162	Kandpal, H. ....	208	Karsdal, M. ....	227, 229-230
Jones, M. P. ....	150, 158, 184, 194, 228, 239	Kadota, T. ....	201	Kane, J. ....	129	Karstensen, J. G. ....	95
Jones, S. ....	75, 185	Kaduthanam, S. ....	50, 238	Kaneke, M. ....	130, 226	Kartal, A. Ç. ....	246
Jonkers, D. ....	194-195, 231, 235, 239	Kaffes, A. ....	137, 147, 201	Kaneke, T. ....	135, 178	Karumaratne, M. ....	199
Joossens, M. ....	51, 88	Kaga, H. ....	192	Kanemitsu, Y. ....	156	Kasai, A. ....	59, 213
Jorge Turrión, M. Á. ....	202	Kagemoto, K. ....	236	Kanesaka, T. ....	174	Kasalicky, M. ....	227
Jørgensen, E. ....	233	Kagramanova, A. ....	142	Kaneshiro, M. ....	197, 204	Kaser, A. ....	46, 70, 76, 81, 97, 183
		Kahaleh, M. ....	52, 133-135	Kanetaka, K. ....	130	Kaser, L. ....	214
		Kahraman, M. M. ....	230	Kaneto, M. ....	209	Kashin, S. ....	175
		Kaibysheva, V. ....	154	Kang, C. D. ....	242, 244	Kashin, S. V. ....	59, 74, 88, 129, 175
		Kailasam, K. ....	219	Kang, D.-H. ....	136, 186-187, 218, 245	Kashiwagi, K. ....	147
		Kaimakiotis, I. ....	48, 185				

Kashtanova, D. ....	161	Kawata, N. ....	151	Keum, B. ....	130, 174-175, 179-180, 193, 198, 242	Kim, D. ....	58, 133, 169, 218, 246
Kasper, P. ....	240-241	Kawata, S. ....	170	Kezzoula, D. ....	168	Kim, D. H. ....	169, 207, 218
Kassir, N. ....	144	Kawauchi, K. ....	174	Khalaf, F. A. ....	214	Kim, D. J. ....	133
Kasztelan-Szczerbińska, B. ....	211, 124, 167, 185	Kawazoe, A. ....	149	Khaled, A. ....	212	Kim, D.-U. ....	69
Kata, D. ....	145	Kawecki, A. ....	129	Khalid, A. ....	217	Kim, E. H. ....	157, 226
Katada, C. ....	129	Kaya, B. ....	46	Khalid, J. M. ....	143	Kim, E. R. ....	144, 237
Katada, K. ....	248	Kayahara, T. ....	152	Khalif, I. L. ....	186	Kim, E. S. ....	130, 175
Katagiri, T. ....	136	Kayashima, E. ....	211	Khalifa, A. ....	145	Kim, E.-S. ....	173-175, 179-180, 193, 198, 242
Katai, H. ....	202	Kayhan, C. ....	144	Khalife, S. ....	130	Kim, G. ....	136
Katanuma, A. ....	127, 173, 217	Kaymazli, M. ....	164	Khalil, F. O. ....	214	Kim, G.-U. ....	176, 185
Kataoka, H. ....	192, 205	Kazakova, D. ....	166	Khamaysi, I. ....	127, 176, 217	Kim, H. ....	125, 143, 151, 169, 178, 180, 183, 186, 203, 218, 221, 224, 245
Kataoka, S. ....	132-133, 175, 220	Kazama, S. ....	148	Khan, M. T. ....	209	Kim, H. G. ....	125, 151, 178, 221
Katicic, M. ....	98, 204, 247	Kazianka, L. ....	126, 226	Khan, S. ....	176	Kim, H. J. ....	92, 180, 186, 203
Katkevičute, E. ....	71	Kazu, H. ....	174	Khani, A. ....	241	Kim, H. K. ....	218
Kato, D. ....	128, 251	Kazuhide, H. ....	72, 238-239	Khanna, R. ....	138	Kim, H. S. ....	169, 178
Kato, H. ....	217	Kazunari, T. ....	72, 238-239	Khanna, S. ....	75	Kim, H. W. ....	186-187, 218, 245
Kato, J. ....	152, 222	Kchaou-Ouakaa, A. ....	171, 212	Khannoussi, W. ....	68, 98, 213, 221, 229-230, 234, 251	Kim, H.-K. ....	241
Kato, K. ....	196	Kchir, H. ....	213	Kharrasse, G. ....	213, 221, 229-230, 234, 237, 251	Kim, J. ....	92, 97, 126, 128-129, 131, 138, 140, 146, 149, 152, 154, 174, 176, 180, 183, 187, 191-194, 198, 201, 203-205, 218, 234, 242, 244
Kato, M. ....	82, 123, 130, 156, 177, 218	Keane, M. ....	223	Kharrat, J. ....	171, 212	Kim, J. G. ....	154
Kato, N. ....	52, 80, 153, 174	Keane, M. G. ....	223	Khater, S. ....	98, 248	Kim, J. H. ....	130, 138, 156, 174, 191-193, 218, 234, 242
Kato, R. ....	137	Keco, A. ....	247	Khayyal, M. T. ....	227	Kim, J. I. ....	203
Kato, S. ....	238	Kedia, P. ....	133-135	Khedher, S. ....	169, 212	Kim, J. J. ....	194, 198, 202-203, 205, 218
Kato, T. ....	129	Kee, K. M. ....	69	Kherat, N. ....	125	Kim, J. L. ....	129
Katsanos, K. H. ....	48, 185	Keegan, M. ....	56, 191	Khodadoostan, M. ....	193, 197	Kim, J. M. ....	146, 237
Katsoula, A. ....	197, 212	Keely, S. ....	95, 184, 205-206, 243	Khodadoostanshahraki, M. ....	239	Kim, J. S. ....	97, 152, 156, 244
Katsoulis, M. ....	63	Kegasawa, T. ....	134	Khokhlova, O. N. ....	123	Kim, J. U. ....	126
Katsube, T. ....	76, 122	Keil, C. ....	141	Khomyak, I. ....	217	Kim, J. W. ....	131
Katsuki, S. ....	136, 176	Keip, B. ....	240	Khor, A. ....	154	Kim, J. Y. ....	237
Katsukura, N. ....	71, 183	Keita, B. A. ....	136	Khorrami, S. ....	49	Kim, J.-H. ....	156, 176, 202
Katsuyama, Y. ....	128, 134, 157	Kelber, O. ....	211, 227	Khorshid, M. ....	76	Kim, J.-O. ....	151
Katzarov, K. ....	169	Kelemen, D. ....	217	Khsiba, A. ....	204	Kim, K. ....	96, 125, 140, 178, 191, 201, 248
Kaukinen, K. ....	161-162	Kelep, J. ....	42, 75, 78, 98	Khullar, V. ....	135	Kim, K. B. ....	201
Kaul, V. ....	174	Kellow, J. ....	150	Khusnutdinova, D. ....	247	Kim, K. H. ....	125, 178, 248
Kautbally, S. ....	217	Kelly, C. ....	124, 170	Kida, M. ....	89, 135, 178	Kim, K. M. ....	96, 191
Kawachi, H. ....	58, 130	Kempeneers, M. A. ....	46	Kiel, P. R. ....	228-229	Kim, K. O. ....	125, 140, 248
Kawada, T. ....	245	Kempf, C. ....	190, 231	Kieslichova, E. ....	198	Kim, K.-J. ....	185
Kawagoe, T. ....	245	Kempinski, R. ....	253	Kiesslich, R. ....	129	Kim, K.-P. ....	50
Kawaguchi, K. ....	170	Kempainen, E. ....	172	Kievit, L. ....	48	Kim, M. ....	85
Kawaguti, F. S. ....	129, 138	Kempainen, H. ....	231	Kievit, W. ....	166, 216	Kim, M.-H. ....	69, 181
Kawahara, Y. ....	137, 155	Kemps, L. ....	242	Kiguchi, Y. ....	82, 130, 156, 177, 218	Kim, N. ....	147, 157, 191, 202-203, 239
Kawahira, H. ....	130	Ken, K. ....	174	Kikuchi, A. ....	153	Kim, N. H. ....	147
Kawai, D. ....	81, 173	Kench, J. ....	201	Kikuchi, D. ....	222	Kim, N. J. ....	202
Kawai, K. ....	130, 226	Kendrick, D. ....	204	Kikuchi, E. ....	174	Kim, N. Y. ....	191
Kawai, T. ....	131	Kennedy, N. A. ....	190	Kilaite, L. ....	252		
Kawakami, T. ....	134	Kenro Takahashi, W. ....	250	Kilincalp, S. ....	185		
Kawakami, Y. ....	125, 128, 170	Keohane, J. ....	131	Kim, B. ....	174		
Kawakubo, H. ....	182	Kepil, N. ....	232	Kim, B. H. ....	214		
Kawakubo, K. ....	120	Kerdsirichairat, T. ....	56	Kim, B. J. ....	131, 154		
Kawamoto, A. ....	57, 183	Kerever, S. ....	132	Kim, C. D. ....	130, 174-175, 179-180, 193, 198, 242		
Kawamoto, M. ....	222	Kerkhof, M. ....	148	Kim, C. G. ....	174		
Kawamura, N. ....	213	Kern, M. ....	126				
Kawanishi, K. ....	150	Kessels, K. ....	148-149, 192				
Kawano, A. ....	123	Keswani, R. ....	56				
Kawano, S. ....	137, 155	Keszthelyi, D. ....	72, 195, 220, 239				
Kawasaki, K. ....	146, 156	Ketikoglou, I. ....	168				
Kawashima, Y. ....	148	Keulemans, Y. C. A. ....	46				
		Keulen, E. ....	53, 85				

Kim, S. B.....	125, 238, 248	Kitagawa, Y. ....	131, 182	Koch, C.....	202	Koloski, N. A.....	72
Kim, S. E. ....	218, 234	Kitajima, M. ....	148	Koch, F. ....	232	Koltai, H. ....	183
Kim, S. G.....	92, 129, 180, 201	Kitamura, S. ....	236	Koch, P. ....	238	Komaç, Ö. ....	156
Kim, S. H. ....	130, 174-175, 179-180, 193, 198, 201, 242	Kitano, M. ....	134, 150	Koch, R. ....	183	Komagome, M. ....	163
Kim, S. J. ....	178	Kitano, Y.....	133	Kochhar, R.....	187, 216, 226-227	Komori, H.....	129, 156-157, 201
Kim, S. K. ....	147, 175, 201	Kitazawa, C.....	184	Kockelmann, F. ....	142	Kondo, Y. ....	222
Kim, S. M. ....	201	Kittner, J. ....	150	Koda, H. ....	170	Kondou, M. ....	152
Kim, S. W. ....	144	Kiudelis, G. ....	150, 229, 248	Kodaira, J. ....	225	Kondrackiene, J. ....	121
Kim, S.-H. ....	203	Kiudelis, V. ....	229	Kodaka, Y. ....	243, 245	Kondrashova, Z. ....	191
Kim, S.-J. ....	131, 175, 178, 186-187, 218, 245	Kiurski, S. ....	141, 206	Kodama, Y. ....	127, 135, 179	Kondratiuk, N. ....	156
Kim, S.-O. ....	50, 69	Kiyokawa, H. ....	156	Kodashima, S. ....	197	Kong, C. ....	62, 201
Kim, S.-Y. ....	192	Kjærgaard, S. ....	139	Koelfat, K. ....	251	Kong, C. Y. ....	62
Kim, T. ....	110, 128, 135, 146, 178, 193, 218, 237, 242, 248	Kjeldsen, J. ....	227, 229	Kogure, H. ....	68, 134, 215	Kong, L. ....	206, 252
Kim, T. H. ....	110, 128, 135, 178	Kladovikova, O. ....	154	Kogure, R. ....	163	Konge, L. ....	186
Kim, T. I. ....	146, 193, 237	Klare, P. ....	220	Koh, C. ....	131	König, A. ....	173
Kim, T. J. ....	144, 237	Klauss, S. ....	89, 215	Koh, D. H. ....	125, 136	König, J. ....	52, 100
Kim, T. N. ....	125, 178, 248	Kleger, A. ....	50, 57, 68, 82, 89, 99, 172, 216	Koh, K. C. ....	50	Königshofer, P. ....	98, 125
Kim, T. S. ....	242	Kleibeuker, J. H. ....	194	Koh, S.-J. ....	138, 214	Konikoff, F. ....	79, 183
Kim, T.-S. ....	198, 202	Klein, A. ....	136, 176, 224	Koh, Y. ....	137	Konikoff, T. ....	163
Kim, W. H. ....	69, 146, 193, 237	Klekotka, P. ....	142	Koh, Y.-I. ....	207	Konishi, H. ....	133, 178, 225, 248
Kim, Y. ....	96, 146, 202-203, 226, 238	Klemenak, M. ....	161-162	Kohen, R. ....	185	Konishi, T. ....	178
Kim, Y. A. ....	203	Klenske, E. ....	220, 232	Kohla, M. ....	124	Konishi, Y. ....	136
Kim, Y. J. ....	146	Klerys, C. ....	160	Kohlwes, E. ....	150	Konno, N. ....	170
Kim, Y.-H. ....	143-144, 237	Klimek, M. ....	128	Kohno, H. ....	133, 178, 225	Kono, S. ....	131
Kim, Y.-I. ....	174, 203	Klopocka, M. ....	144	Kohoutova, D. ....	232, 236	Kono, Y. ....	222
Kim, Y.-T. ....	136	Klöpöck, N. ....	126	Koike, K. ....	68, 134, 175, 215	Konstantakis, C. ....	146
Kimura, A. ....	139	Klümper, H.-J. ....	215	Koike, Y. ....	157	Konturek, P. C. ....	235
Kimura, C. ....	138	Klyueva, K. ....	137	Koizumi, A. ....	82	Koo, M. ....	175
Kimura, E. ....	219	Kment, M. ....	174	Koizumi, E. ....	243, 245	Kooyker, A. ....	87
Kimura, J. ....	252	Knabe, M. ....	41, 62	Koizumi, M. ....	173, 217	Kopacova, M. ....	153, 232
Kimura, S. ....	149	Knapp, D. ....	51	Koizumi, W. ....	89, 129	Kopchak, K. ....	217
Kim, T. ....	127, 173, 217	Knapp, S. ....	214	Koizumi, Y. ....	134	Kopchak, V. ....	217
Kinaneh, S. ....	127	Knezevic Ivanovski, T. ....	140	Kojic, D. ....	141	Kopelman, Y. ....	176
Kinnunen, U. ....	176	Knezevic Stromar, I. ....	207	Kojima, H. ....	171	Kordes, M. ....	50
Kinoshita, J. ....	157	Knezevic Usaj, S. ....	140	Kojima, K. ....	152, 222	Koren, O. ....	191
Kinoshita, K. ....	210	Knipe, H. ....	127	Kojima, T. ....	202-203	Korneeva, I. ....	142
Kinoshita, R. ....	180	Knittel, T. ....	142	Kojima, Y. ....	125, 138, 200, 203, 232, 245	Kornowski, A. ....	151
Kinoshita, Y. ....	149	Knop, J. ....	190, 231	Kok, N. ....	137	Korona-Glowniak, I. ....	228-229
Kinross, J. ....	237	Knördel, J. ....	155	Köker, I. H. ....	172, 180, 237	Korotkevich, A. ....	146, 157
Kinugasa, H. ....	137	Knott, A. ....	253	Koksal, A. S. ....	198, 241-242	Korpela, T. ....	172
Kiprian, D. ....	129	Knowles, C. ....	234	Kolacek, S. ....	64	Korponay-Szabo, I. R. ....	64, 161-162
Kirchgesner, J. ....	144, 230	Knowles, S. ....	140, 188	Kolar, M. ....	235	Korrapati, S. K. ....	215, 246
Kirchner, T. ....	172	Knyazev, O. ....	142	Koletzko, B. ....	161-162	Kortan, P. P. ....	201
Kirita, K. ....	245	Ko, K. H. ....	136	Koletzko, S. ....	60, 64, 79, 93, 97, 161-162	Kortt, N. ....	137
Kis, I. ....	162	Ko, S. H. ....	146	Kolgazi, M. ....	196	Korytko, I. ....	52
Kisaka, Y. ....	173, 217	Ko, S. J. ....	183	Kolho, K.-L. ....	93, 95, 97, 190	Koshiba, Y. ....	178
Kishida, Y. ....	151	Kobayashi, K. ....	129-130, 196	Kolkman, J. J. ....	216	Koshita, S. ....	125, 128, 170
Kishimoto, S. ....	136	Kobayashi, S. ....	130	Kolkman, M. ....	166	Koshy, R. M. ....	208
Kishine, K. ....	148	Kobayashi, T. ....	127, 135, 179	Kollar, M. ....	155, 174	Koskinas, J. ....	168
Kishino, M. ....	243	Kobayashi, Y. ....	61, 127, 160, 173, 217	Kollarik, M. ....	69, 242	Kostalas, S. ....	191
Kiss, S. ....	65	Kobe, D. ....	174	Kolle, L. ....	188	Kothari, S. ....	174
Kitadai, Y. ....	74, 147	Kocazybek, B. ....	123	Koller, M. ....	137, 194	Kothari, T. ....	174
		Koch, A. ....	128, 140-141, 149, 155	Koller, T. ....	126, 228	Kothary, R. ....	240
		Koch, A. D. ....	128, 149, 155	Koltsi, N. ....	72, 95, 158, 184, 195, 221, 228, 239, 243	Kotieva, A. ....	136
		Koch, A. K. ....	140-141			Kotvskaya, Y. ....	161
						Kottmel, A. ....	234
						Kouihal, W. ....	125



Koukias, N.....	91, 250	Kroon, S.....	197	Kupcinskas, J.....	58, 121, 150, 184, 229, 240, 246, 248	Kwon, Y. J.....	157, 203
Koukoufiki, A.....	168	Kruger, S.....	172	Kurata, T.....	221	Kwon, Y.-H.....	98, 201, 238
Koulaouzidis, A.....	176	Kruimel, J.....	239	Kurata, T.....	179	Kyanam Kabir Baig, K. R.....	201
Koulentaki, M.....	168	Kruip, M. J. H. A.....	193	Kurata, T.....	221	Kyaw, M. H.....	69, 235
Koulias, E.....	168	Krumina, A.....	183-184, 189	Kure, T.....	170	Kylänpää, L.....	62, 84, 172
Koumoutsos, I.....	141	Krupka, N.....	70	Kurent, T.....	74, 144	Kyurkchiev, D.....	230
Kouno, H.....	133, 178, 225	Krzaczek, M.....	161	Kurguzova, D.....	156		
Koureta, E.....	229	Krznaric, Z.....	83, 110, 157, 207	Kuribayashi, S.....	242	<b>L</b>	
Kourikou, A.....	168	Krznarić, Ž.....	230	Kurien, M.....	160, 205	L'Huillier, C.....	161
Kourkoulis, P.....	147	Krzystek-Korpacka, M.....	184	Kurilovich, S. A.....	202	La Cruz, A.....	49
Koutoufaris, G.....	147	Krzywdzinska, M.....	228	Kurniawan, D.....	210	La Mura, V.....	207
Koutroubakis, I.....	185	Ksiaa, M.....	125, 211, 213, 215, 230, 241, 248	Kurobe, T.....	202-203	La Rocca, L.....	58
Koutsoumpas, A.....	144-145	Kuang, J.....	253	Kuroda, K.....	133	La Seta, F.....	233
Kouyama, Y.....	131, 159, 192, 194, 219	Kuballa, A.....	227	Kuroda, T.....	173, 217	La Spina, G.....	177
Kovacheva-Slavova, M.....	217	Kubesch, A.....	232	Kurokawa, H.....	246	Laalaj, O.....	69, 216
Kovács, G.....	127	Kubo, A.....	158	Kurokawa, K.....	152, 222	Labardi, M.....	157
Kowalik, A.....	124	Kubo, T.....	174	Kuroki, K.....	133, 178, 225	Labarga, A.....	192
Kovács, J. B.....	162	Kuboki, Y. M.....	250	Kurosaki, S.....	152, 221	Labat, L.....	169
Kowalski, M.....	187	Kubota, E.....	192	Kurosawa, T.....	171	Labenz, G.....	244
Koyama, F.....	164	Kubota, T.....	252	Kurppa, K.....	102, 161-162	Labenz, J.....	199, 244
Koyama, I.....	181, 251	Kuchiba, A.....	132	Kürti, Z.....	185	Labiano, I.....	55, 214
Koyama, R.....	134	Kück, M.....	142	Kurumi, H.....	170	Labidi, A.....	228
Koyama, Y.....	131	Kudo, K.....	192	Kurushkina, N.....	137, 182	Lacerda, A.....	86, 97, 142-143, 230
Koyanagi, T.....	123	Kudo, S.....	131-133, 159, 175, 192, 194, 219-221	Kusano, C.....	60	Lacerda, A. P.....	97, 143, 230
Koynarski, V.....	157	Kudo, T.....	131-133, 155, 175, 192, 194, 219-221	Kusano, M.....	180, 242	Lachter, J.....	181, 217
Kozakai, F.....	125, 128, 170	Kudo, Y.....	159	Kuscu, K.....	130	Lackner, C.....	211
Kozbial, K.....	167	Kudryavtseva, A.....	154	Kusumoto, K.....	234	Lackner, K.....	251
Kozelj, M.....	144	Kühbacher, T.....	80, 86, 187, 189	Kusumoto, Y.....	219	Lackovic, A.....	172
Koželj, M.....	74	Kuhlbusch-Zicklam, R.....	219	Kusunose, H.....	125, 128, 170	Lacle, M.....	148-149, 192
Kozikopoulou, D.....	168	Kuijper, E.....	75	Kutsumi, H.....	127, 135	Lacle, M. M.....	148-149
Kraft, K.....	211	Kuipers, E. J.....	53, 58, 82, 87, 95, 158, 193	Kütting, F.....	240	Lacy, B.....	43, 47, 87, 96
Krag, A.....	227, 229	Kukulska, M.....	139	Küttner-Magalhães, R.....	164	Lada, S.....	145
Krajcivova, J.....	174	Kulkarni, A.....	173	Kutyla, M.....	221	Ladefoged, K.....	185
Krajcovicova, A.....	126, 228	Kull, I.....	191	Kutz, M.....	158	Ladeira, N.....	213, 235, 252
Krall, K.....	56, 99	Kumagai, K.....	59, 170, 213	Kuvaev, R.....	129	Lagarde, S. M.....	226
Kranenburg, O.....	192	Kumagi, T.....	173, 217	Kuwabara, H.....	132, 193	Lage, P.....	130, 147
Kranidioti, H.....	168	Kumahara, K.....	176-177	Kuwabara, K.....	57, 183	Lagergren, J.....	80, 155, 244
Krärup, A. L.....	244	Kumar, A.....	176, 221	Kuwai, T.....	53, 133, 178, 225	Lages, J.....	121
Krasnov, G.....	154	Kume, Y.....	245	Kuwatani, M.....	120	Laghi, A.....	49
Krasnykh, L.....	156	Kump, P. K.....	73, 75, 110	Kuzmina, T.....	195	Laghi, L.....	49, 96
Kraszewska, E.....	129	Kumpulainen, P.....	172	Kvetina, J.....	153, 232	Laginestra, A.....	160
Kraszewski, A.....	65	Kunchev, M.....	169	Kwan, V.....	65	Lago, P.....	145, 183, 186
Krause, T.....	232	Kundi, M.....	204	Kwacien, S.....	235	Lagoussis, P.....	157
Krauss, T.....	82	Kundurzhiev, T.....	230	Kwon, B. J.....	186	Laharie, D.....	36, 39, 47, 61, 139, 233
Krawczyk, M.....	86, 99, 150	Kunduz, E.....	237	Kwon, C.-I.....	69, 136	Lahat, A.....	54
Kraynova, E.....	129	Kunihiro, M.....	53	Kwon, G. S.....	224	Lahaye, M.....	137, 193
Krebs, S.....	232	Kuniyoshi, N.....	222	Kwon, H.-J.....	191	Lahaye, M. J.....	193
Kreidlova, M.....	169	Kunovszki, P.....	229, 234	Kwon, I. G.....	202	Lahcene, M.....	125
Kreis, M.....	183	Kunst, C.....	122, 214	Kwon, J.....	140, 238	Lahlali, M.....	69, 216
Kremer, M.....	150	Künzli, H. T.....	154	Kwon, J. Y.....	140	Lahmidani, N.....	237, 246
Krencnik, T.....	161-162	Kroep, S.....	159, 178	Kwon, K. S.....	241	Lahner, E.....	92, 129, 245
Kresovic, A.....	172	Kröger, S.....	161	Kwon, Y. H.....	179	Lai, M.....	150
Krishnan, E.....	187-189					Lai, S.....	236
Kristensen, V. A.....	140, 160					Laiglesia, M.....	158
Krizko, M.....	145					Laine, L.....	50, 98
Kroener, P. T.....	179					Lakatos, P.....	48, 185

Lakatos, P. L. ....	185	Larghi, A. ....	72, 134	Lecca, P. G. ....	145, 150	Lee, S. ....	50, 69, 85-86, 98, 125, 136, 142-144, 173, 175, 181, 183, 222, 226, 234, 242, 244, 248
Lake, L. ....	144-145	Lariño Noia, J. ....	216, 223	Lecleire, S. ....	135-136	Lee, S. D. ....	144
Lakhtakia, S. ....	224	Larsson, F. ....	195	Lecomte, T. ....	132	Lee, S. E. ....	131
Lakner, L. L. ....	232	Larussa, T. ....	195	Lecomte, M. ....	245	Lee, S. G. ....	143
Lalande, V. ....	144	Lasa, J. ....	233	Lee, A.-R. ....	196	Lee, S. H. ....	125, 136, 242, 244
Lalazar, G. ....	183	Lashen, S. A. ....	169	Lee, B. ....	183	Lee, S. J. ....	85, 242, 244
Lam, K. L. Y. ....	69	Laskowska, K. ....	185	Lee, B.-I. ....	140, 149, 156	Lee, S. K. ....	50, 69, 181, 203, 222, 226, 247-248
Lam, T. Y. T. ....	235	Laskowski, J. ....	97, 142	Lee, C. ....	153	Lee, S. M. ....	192
Lam, W. ....	234	Lasson, A. ....	138	Lee, C.-T. ....	155	Lee, S. S. ....	50, 69, 181
Lama, S. ....	121	Lásztity, N. ....	65	Lee, D. H. ....	96, 156, 191, 203, 241	Lee, S. U. ....	234
Lamanda, R. ....	197	Latchford, A. ....	62, 95	Lee, D. S. ....	201	Lee, S. W. ....	98, 175
Lamarque, D. ....	141	Latella, G. ....	100, 150, 160, 248	Lee, D. W. ....	178	Lee, S. Y. ....	85, 143, 173
Lamas rojas, E. ....	247	Laterza, F. ....	220, 249	Lee, D.-H. ....	157, 239, 244	Lee, S.-G. ....	237
Lamas, B. ....	182	Laterza, L. ....	139, 219	Lee, E. ....	129, 177	Lee, S.-H. ....	125, 248
Lamas, M. ....	188	Latinovic, O. ....	189	Lee, E. Y. T. ....	177	Lee, S.-W. ....	201
Lambert, J. ....	246	Latt, S. S. ....	216	Lee, G. H. ....	218	Lee, T. ....	69, 125, 175, 178, 181, 233
Lamberti, G. ....	245	Lau, A. Y. L. ....	235	Lee, G.-H. ....	246	Lee, T. H. ....	69, 175, 178, 181
Lambin, T. ....	61	Lau, J. ....	218	Lee, H. ....	98, 130, 136, 148, 157, 173-175, 178-181, 191-193, 198, 201-203, 218, 242	Lee, T. Y. ....	125
Lambrechts, D. M. ....	137	Lau, M. ....	205	Lee, H. D. ....	201	Lee, T.-H. ....	180
Lambrechts, D. M. J. ....	193	Lauber, C. L. ....	51	Lee, H. H. ....	149	Lee, W. K. ....	202
Lamine Sejai, A. ....	69, 216	Laudanno, O. ....	89	Lee, H. J. ....	148, 173, 191	Lee, W.-J. ....	86, 97, 142-143
Lammert, F. ....	86, 99-100, 121, 150	Laudisi, F. ....	64, 138, 205	Lee, H. S. ....	98, 130, 136, 157, 175, 201, 203	Lee, Y. ....	96, 173-174, 178, 181, 191, 226
Lamonaca, L. ....	123, 200	Lauenstein, T. ....	140	Lee, H. W. ....	181	Lee, Y. J. ....	173
Lampach, D. ....	125	Laukkarinen, J. ....	89	Lee, H.-H. ....	140, 149	Lee, Y. K. ....	244
Lampichler, K. ....	125	Laurenus, A. ....	198	Lee, I. J. ....	214	Lee, Y. N. ....	181
Lamy, V. ....	98, 204, 247	Laurent-Puig, P. ....	63, 87	Lee, I.-S. ....	125	Lee, Y. R. ....	96, 191, 226
Lan, Y. ....	154	Lauri, A. ....	197	Lee, J. ....	50, 86, 125, 130-131, 143, 157, 173-175, 178-180, 187, 193, 198, 202-203, 214, 218, 226, 242, 245	Lee, Y. S. ....	178
Lanas, A. ....	50, 237	Lauriola, M. ....	177	Lee, J. C. ....	68, 78, 85, 102	Lee, Y.-K. ....	165
Lanas Gimeno, A. ....	153	Laursen, S. B. ....	50, 98	Lee, J. E. ....	226	Lee, Y.-L. ....	173
Landi, F. ....	141	Lavigne, J. ....	144	Lee, J. G. ....	157, 196	Lee, Y.-N. ....	69
Landi, R. ....	78, 91, 219, 222-223, 244	Lavin, I. ....	193	Lee, J. H. ....	50, 143, 183, 198, 202, 214, 218	Leedham, S. ....	228
Landman, C. ....	144, 230	Lavin Castejon, I. ....	238	Lee, J. K. ....	125, 181	Leeds, J. ....	127, 179
Lane, C. ....	251	Lavrinovica, E. ....	183-184, 189	Lee, J. M. ....	130, 174-175, 179-180, 193, 198, 240, 242	Leenhardt, R. ....	135-136
Lange, S. ....	71, 143, 240	Lawendy, N. ....	79, 97, 145, 188	Lee, J. P. ....	187, 218, 245	Leens, C. ....	188, 234
Langella, P. ....	182	Ławniczak, M. ....	129	Lee, J. S. ....	175	Leet, F. ....	241
Langers, A. M. J. ....	149	Lawrance, D. ....	242	Lee, J. W. ....	187, 203, 218, 245	Lefor, A. ....	61, 160
Langholm, L. ....	229	Lawrance, I. ....	189	Lee, J. Y. ....	173-174	Legall, G. ....	144
Langholz, E. ....	48, 185	Layec, S. ....	71	Lee, J.-H. ....	174	Legros, R. ....	132
Langhorst, J. ....	80, 140-141, 187	Lazar, A. ....	213	Lee, K. ....	187, 218, 245	Lehmann-Che, J. ....	236, 246
Langner, C. ....	55, 58, 77, 88, 97, 115, 246-248	Lazarenko, L. ....	206	Lee, K. H. ....	187, 218, 245	Lei, X. ....	161, 172, 183
Lansdorp-Vogelaar, I. ....	62, 83, 87, 95, 191, 193, 201	Lazarescu, A. M. ....	171	Lee, K.-M. ....	143	Leibovitzh, H. ....	234
Lanska, V. ....	198	Lazaridis, N. ....	91, 250	Lee, M. ....	151, 174, 219, 234, 242	Leicher, L. W. ....	226
Lanuti, P. ....	249	Lazarotto, T. ....	74	Lee, M. J. ....	234, 242	Leiner, D. ....	177
Lanza Volpe, M. ....	196, 200, 230	Le Baut, G. ....	230	Lee, M. S. ....	151, 174, 219	Leitão, C. ....	122, 163, 167
Lapina, A. ....	50, 241	Le Bourhis, L. ....	46, 86	Lee, M.-Y. ....	153	Leite, S. ....	121, 123, 167, 169, 186
Lapitz, A. ....	86, 99	Le Moine, O. ....	92, 223			Leja, M. ....	51, 59, 77, 80, 88, 95, 98, 204, 247-248
Laplanche, J.-L. ....	169	Le Mouel, J. P. ....	93, 135-136			Lejniaks, A. ....	183-184, 189
Lappalainen, M. ....	50	Le Nevé, B. ....	194			Lekkerkerker, S. J. ....	182, 217
Lara, C. ....	125, 193, 238	Le, P.-H. ....	152, 213			Leliveld, L. ....	128
Lara, J. ....	131	Leal, C. ....	162, 198, 204, 220				
Lara Romero, C. ....	125, 238	Leal, T. ....	231				
Larabi, A. ....	183	Leal-López, S. ....	126, 246				
Laranjo, A. ....	124, 169, 207	Leal Téllez, J. ....	152				
Laredo De La Torre, V. ....	50	Leandri, C. ....	135-136				
		Leandro, G. ....	205				
		Leblanc, S. ....	198, 219, 224, 245				

Lelong, B.....	220	Li, J.....	152, 158, 175	Lima, O.....	252	Liu, R.....	216
Lemaire, M. A.....	136	Li, J.-N.....	154	Limam, M.....	211	Liu, S.....	61
Lembo, A. J.....	194, 242	Li, K.....	144	Limdi, J.....	232	Liu, W.....	159
Lembo, V.....	166, 210	Li, L.....	47	Limenitakis, J.....	70	Liu, X.....	47, 155
Lemmens, V. E. P. P.....	226	Li, M.....	148, 198, 243	Limketkai, B.....	61, 233	Liu, Y.....	65, 70, 144, 148, 155, 166, 210, 227, 236
Lemmers, A.....	38, 47, 92, 99, 174, 223	Li, N.....	248	Limongelli, P.....	196	Liu, Z.....	142, 154, 175
Lenfant, M.....	189	Li, Q.....	130	Limschou, A. C.....	186	Livat Yonnet, S.....	132
Lenicek, M.....	251	Li, R.....	142	Lin, A. N.....	110, 251-252	Livovsky, D.....	146
Lennon, A. M.....	85	Li, T.-S.....	139	Lin, C.-K.....	121, 180	Ljotssón, B.....	43, 195
Lenti, M. V.....	153, 160, 196, 202, 228-229, 240	Li, W.....	155, 176, 215, 236, 245	Lin, C.-Y.....	159, 178	Ljubas-Kelecic, D.....	110, 230
Lenz Tolentino, L. H.....	129, 138	Li, W. Q.....	245	Lin, F.....	134	Llach Vila, J.....	158
Leo Carnerero, E.....	188	Li, X.....	114, 139, 161, 172, 183, 208, 218, 226-227, 240, 244	Lin, I.-T.....	165	Llach, J.....	95, 186
Leon, H.....	158	Li, X.-B.....	149	Lin, J.....	128	Llaó, J.....	49, 93
Leonard, C.....	180	Li, X.-Y.....	158	Lin, J.-H.....	65	Lleo, A.....	55, 83, 103, 116
Leonart, J. L.....	241	Li, Y.....	47, 124, 139-141, 169, 175, 203, 244	Lin, J.-T.....	74, 247	Leo De Valda, A.....	123
Leone, A.....	166	Li, Z.....	70	Lin, K.....	110, 251-252	Llerena, R.....	208
Leone, N.....	208	Li, Z.-S.....	65	Lin, R.....	175, 202	Llibre, G.....	69, 235
Leone, S.....	207	Lian, L.....	205	Lin, S.....	157, 251	Llorca Fernández, R.....	247
Leone-Perkins, M.....	186	Liang, C.-M.....	159	Lin, W.-R.....	147	Llorente Barrio, M.....	93
Leonidakis, G.....	221	Liang, K.-H.....	213	Lin, Z.....	236	Lo, A. E.....	114, 253
Leontyev, A.....	146	Liang, R.....	164	Linares, M. E.....	233	Lo, B.....	49, 52
Lepage, C.....	221	Liang, X.....	159	Lindfors, K.....	162	Loadman, P. M.....	53
Lepetit, H.....	177	Liao, J.....	152	Lindfors, P.....	195	Lobello, S.....	168, 170, 213
Lepillez, V.....	198	Liao, P.-N.....	147	Lindholm, M.....	227, 229-230	Lobo, A. J.....	180, 187, 232, 234
Lepilliez, V.....	177, 221, 245	Liao, W.....	139	Lindley, K. J.....	163	Lobo Alvarez, B.....	209
Leppkes, M.....	63, 81	Liao, Z.....	65	Lindsjö, I.....	231	Löfberg, R.....	142
Lerang, F.....	98, 204, 247	Liauw, M. X. W.....	110	Lindström, O.....	172	Loftus Jr., E. V.....	86, 143, 145, 230
Lerch, M. M.....	53-54, 67, 73, 172, 210	Libânio, D.....	134, 202	Linxia, C.....	210	Logan, R.....	53, 237
Lerchova, T.....	186	Libânio Monteiro, D.....	81	Linhares, M.....	122, 163, 167, 253	Loganayagam, A.....	218
Leroi, A. M.....	238, 242	Liberal, R.....	55, 66, 121, 173, 207, 212-213	Link, A.....	58, 246-248	Logue, J.....	127
Leroy, V.....	36, 42, 48, 59, 68, 103	Lica, K.....	174	Linn, S.....	252	Loguercio, C.....	121, 138, 230
Leroyer, A.....	139	Licata, A.....	58	Linneberg, A.....	205	Loh, J. T.....	209
Leshno, M.....	202	Liceni, T.....	233	Linsse, M. D.....	137, 194	Lohan, C.....	144
Leskova, Z.....	126, 228	Lichtenstein, G. R.....	145, 187	Liou, J.-M.....	74, 247	Lohr, J.-M.....	127
Lessa, R. A.....	209	Lichtenstein, L.....	151	Lipman, G.....	241	Löhr, M.....	50, 101, 103, 126, 238
Lestelle, V.....	225	Lieberman, D.....	54, 87	Liptak, P.....	242	Lohse, A.....	36, 58
Letamendi, G.....	121	Lieffernickx, C.....	55	Lipták, P.....	199	Lohse, A. W.....	58
Lethebe, B.....	176	Liew, D.....	188	Lira, A.....	69, 235	Loibl, R.....	199
Leucuta, D.....	185	Ligresti, D.....	56, 223	Lish, I.....	79, 183	Lombardi, F.....	250
Leung, F.....	175	Liguori, A.....	58, 211	Lishchinskaya, A.....	142	Lombardi, G.....	170
Leung, J.....	175	Lihua, D.....	210	Lisi, D.....	150	Lombardo, L.....	205
Leung, W. K.....	98, 152, 203	Lijfering, W. M.....	149	Lissner, D.....	55, 93, 249	Lombardo, V.....	160
Leventi, E.....	186	Liljebo, T.....	250	Lita, M.-C.....	214-215	Loncaric, A.....	172
Levi, Z.....	203	Lim, C.-H.....	149, 156	Litjens, G.....	216-217	Londoni, C.....	197
Levine, A.....	93, 97	Lim, H.....	197, 244	Littlekare, S.....	195	Long, G. H.....	189-190
Levit, R.....	161	Lim, J. H.....	191, 244	Liu, B.....	175, 206, 252	Long, M. D.....	188
Levy, M.....	181	Lim, K.-H.....	147	Liu, D.....	147, 163, 166, 206, 252	Long, X.....	159
Lévy, P.....	85, 128	Lim, K.-W.....	147	Liu, F.....	154-155	Long, Y.....	194
Lewis, J.....	230	Lim, L. L.....	153	Liu, G.....	144	Longcroft-Wheaton, G.....	62, 85
Li, A.....	61-62, 204	Lim, P.....	176	Liu, H.....	83	Longo, G.....	241
Li, B.....	216	Lim, S.....	191, 220	Liu, J.....	47, 157, 241	Lonjak, N.....	251
Li, C.....	135-136, 151, 166	Lim, S. G.....	220	Liu, J.-P.....	158	Lopalco, F.....	250
Li, D.....	159, 206	Lim, S. J.....	100	Liu, K.....	137	Lopes, B.....	253
Li, G. Q.....	197	Lim, Y. S.....	219	Liu, L.....	219, 221, 225	Lopes, J.....	172, 186, 190, 219, 252
Li, H.....	58, 60, 147, 151						

Lopes, L. ....	134	Lu, L. ....	127, 133, 163	Maa, J.-F. ....	234	Magalhães, R. ....	71, 166,
Lopes, S. ....	145, 172, 184, 186,	Lu, M. ....	166	Maamouri, N. ....	213	207, 225, 249	
	190, 193, 212-213,	Lu, N. ....	155, 196, 248	Maas, M. ....	178, 193	Magallanes-Peláez, N. ....	223
	225, 231	Lu, N.-H. ....	158	Maaser, C. ....	36, 55, 112, 189	Magalon, J. ....	61
Lopetuso, L. R. ....	70, 75, 138-139,	Lu, Q. ....	174	Mabuchi, M. ....	222	Magarotto, A. ....	224, 252
	150, 159, 229	Lu, W. ....	133, 163	Maccaigne, G. ....	184, 194	Magee, C. ....	83, 245
López, M. C. ....	195	Lubczyk, V. ....	176	Macaluso, F. S. ....	61, 233	Magee, C. G. ....	62, 241
Lopez, R. ....	60, 144,	Lucaciú, L. A. ....	185	Macarie, M. ....	126-127	Mager, J. J. ....	197
	153, 219	Lucas, J. ....	61, 142	Macarri, G. ....	224	Maggiori, L. ....	71
Lopez de Hierro, M. ....	152	Luce, M. ....	142	Macciomei, M. C. ....	160	Magierowska, K. ....	201, 228, 235
López-López, A. ....	217	Lucejko, M. ....	40, 112	Maccioni, A. ....	160	Magierowski, M. ....	82, 201,
López Pérez, R. Y. ....	226, 230	Lucendo, A. J. ....	49, 69, 93, 184	MacConell, L. ....	50, 77, 123	228, 235	
López San-Román, A. ....	93	Luciano, L. ....	149	Macdonald, G. ....	243	Maglio, M. ....	161
Lopez-San Roman, A. ....	49	Lucidarme, C. ....	232	Macdonald, J. ....	234	Magnano, A. ....	61
López Serrano, P. ....	93, 233	Lucille Hayman Manzur, L. ....	163	Macedo, G. ....	110, 121, 145, 153,	Magno Pereira, V. ....	110, 121, 123,
López Vicente, J. ....	95	Lucini, R. ....	241		162, 170, 172-173,		167, 211, 213,
López Viedma, B. ....	221	Lucio, A. ....	197		175, 184, 193, 196,		216, 235, 252
Lord, R. ....	129	Lucio, O. ....	197		207, 212-213,		
Lorenceau-Savale, C. ....	132	Lacock, M. ....	206		225, 250-252	Magnusson, M. K. ....	138-139, 195
Lorente, R. ....	49, 93	Luê, A. ....	237	Macedo, M. ....	160	Magome, S. ....	160
Lorente Poyatos, R. ....	49, 144, 188	Luebeck, G. ....	62	Mach, T. ....	249	Magri, G. ....	61
Lorenz, J. ....	126-127	Luengo, I. ....	176, 245	Machado, A. S. ....	185	Magris, R. ....	202, 218
Lorenzo, M. ....	237	Luetic, K. ....	209	Machado, J. C. L. ....	98, 204, 247	Magro, B. ....	91, 163, 224, 252
Lorenzo, G. ....	146, 209, 233	Luinetti, O. ....	160	Machado, M. V. ....	208, 230	Magro, F. ....	48, 183-186,
Losurdo, G. ....	136, 158, 160, 205	Luis, E. ....	110	Machado, P. ....	186, 190		190, 231
Lotfy, M. ....	164	Lukas, M. ....	227, 235	Machida, T. ....	197, 204	Maguire, R. ....	50
Lotttrup, C. ....	244	Lukens, F. ....	179	Machlab, S. ....	69, 110, 235	Mahadik, M. ....	215, 246
Loubaris, K. ....	164	Lukic, S. ....	233	Macia, F. ....	147	Mahajan, U. M. ....	172
Loughnan, E. ....	203	Lukosiene, J. I. ....	150, 240	Macias-Ceja, D. C. ....	71, 86,	Maharshak, N. ....	63, 146, 189, 191,
Louis, E. ....	36, 61, 75, 79,	Lunkov, V. ....	65, 167		183-184, 227		195, 231, 251
	86, 89, 97, 115,	Luo, X. ....	61, 76, 167	Macías García, F. ....	246	Maher, T. ....	65
	143-144	Luo, Y. ....	142	Macintyre, E. ....	248	Mahfouz, M. ....	123
Louis, H. ....	69, 73	Luo, Z. ....	248	Mackiewicz, A. ....	80	Mahiou, H. ....	123
Loundou, A. ....	149	Lupascu, A. ....	167	MacMahon, F. ....	141	Mahmod, N. ....	231
Lounes, F. ....	125	Lupusoru, R. ....	124, 210,	Maconi, G. ....	100, 150, 229	Mahmoud Foda, E. ....	214
Loureiro, A. ....	182		212-213	Macpherson, A. ....	70	Mahmoudi, M. ....	204
Loureiro, R. ....	130, 240	Lütgehetmann, M. ....	58	Macutkiewicz, C. ....	56	Maia Minini, D. ....	250
Lourenço, L. ....	134	Luthra, P. ....	100	Madácsy, L. ....	177, 181	Maia, L. ....	121, 163
Lourenço, L. C. C. ....	64	Luz, C. ....	252	Madacsy, L. A. ....	224	Maiero, S. ....	202, 218
Lourenco, N. ....	236	Luzza, F. ....	195	Madacsy, T. ....	89, 145	Mailhac, A. ....	182
Lourenço Vieira, A. ....	186, 231	Lv, B. ....	71, 138, 158-159,	Madalinski, M. ....	132	Maillard, F. ....	70
Loustaud-Ratti, V. ....	132		174, 205	Madarama, A. ....	131	Maillet, M. ....	236
Loutfi, M. ....	198	Lyamina, S. ....	154, 200	Maddalo, G. ....	170, 241	Maimaris, S. ....	205
Louvet, A. ....	56, 96	Lymberopoulos, D. ....	168	Madisch, A. ....	199	Mainenti, P. P. ....	207
Lovas, S. ....	145, 187	Lynch-Godrei, A. ....	240	Madl, C. ....	65	Mainz, D. ....	199
Lovász, B. D. ....	177, 181, 224	Lyons, M. ....	188, 234	Madonia, S. ....	58	Maio, R. ....	130
Lovat, L. ....	153,	Lyu, B. ....	136, 198	Madrigal, R. ....	49, 93	Maire, F. ....	128
Lovat, L. B. ....	62, 83, 176,	Lyu, T. ....	203	Madrigal, R. E. ....	49	Maisano, S. ....	233
	241, 245	Lyu, Z. ....	203	Madsen, A. L. ....	205	Maisonnette, P. ....	127
Lovati, G. ....	63			Maeda, Y. ....	132-133, 175,	Majcher, B. ....	87, 221-222
Lovera, M. ....	128	<b>M</b>			219-221	Majek, O. ....	95, 177, 224, 236
Lowenberg, M. ....	141, 188	Ma, C. ....	198	Maehara, O. ....	166	Majerovic, M. ....	207
Löwenberg, M. ....	187, 190	Ma, H. ....	174	Maehata, T. ....	82, 130, 156,	Majima, A. ....	158, 248
Loxton, D. ....	195	Ma, J. ....	183		177, 218	Majumdar, A. ....	137, 147, 201
Lozano, J. J. ....	192	Ma, L. ....	210	Maekawa, A. ....	174	Makanyanga, J. ....	231
Lu, B. ....	243	Ma, M. ....	219	Maev, I. ....	154, 200	Makashova, V. V. ....	123
Lu, C.-K. ....	151	Ma, S. ....	127	Maevskaya, M. ....	65, 167	Maki, A. ....	163
Lu, H. ....	159	Ma, W. ....	124, 167	Magalhães, J. ....	71, 121-122,	Makris, K. ....	147
Lu, J. ....	157	Ma, Y. ....	182, 210		145, 166-167, 186	Makrithathis, A. ....	204
						Maksimov, V. ....	202

Maksunova, Y.....	241	Mangiavillano, B.....	68, 92, 101	Mari, A.....	149-150, 153, 176, 194, 239, 242	Martin, P.....	144
Malagelada, C.....	57	Mangiola, F.....	91, 219, 244	Maria, N.....	75	Martin, S. W.....	144
Malagelada Prats, C.....	209	Mangira, D.....	238	Maria Saracino, I.....	247	Martín, V.....	249
Malagón, M.....	148-149	Mangualde, J.....	130	Mariani, A.....	172, 179	Martin, Y.....	222
Malamut, G.....	81, 89, 98, 102, 106, 141, 248	Mangukiya, D.....	133, 135, 182	Maric, N.....	209	Martín Arranz, E.....	187
Malandris, K.....	197, 212	Manić, M.....	220	Marier, J. F.....	144	Martín Arranz, M. D.....	187
Malanin, S.....	58, 74, 235, 247	Mankinen, P.....	231	Marijnen, C. A. M.....	337	Martín-Arranz, M. D.....	49, 233
Malcolm, A.....	150	Mann, D. A.....	55, 214	Marin, A. C.....	64, 247	Martín-Holgado, D.....	160
Maldonado, R.....	223	Mannath, J.....	62, 208	Marin, I.....	150, 198	Martinek, J.....	155, 174, 198
Maldonado Perez, B.....	232	Manner, H.....	62, 129	Marin, J. J.....	86, 99	Martines, H.....	58
Malecka Panas, E.....	228	Manning, J.....	148	Marín-Gabriel, J. C.....	131	Martínez, A.....	71, 202
Malek-Hosseini, S. A.....	212	Mannisi, E.....	237-238	Marín-Jiménez, I.....	140, 228	Martínez, E.....	222
Malekhosseini, S. A.....	169	Manno, M.....	197, 246	Marinari, G. M.....	225	Martínez, H.....	241
Malekzadeh, R.....	80	Mannon, P.....	201, 240	Marinelli, C.....	146, 209	Martínez, I.....	148
Maletesta, L.....	75	Manns, M.....	51, 77, 83, 96, 141-142	Marinero, M. A.....	229	Martínez, J.....	192
Maléth, J.....	59, 89, 145	Mannucci, A.....	181, 236	Marinho, C.....	121-122, 166-167, 207	Martínez, R. J.....	62, 87, 96, 102
Malfatti, F.....	58	Mannucci, P. M.....	153	Marinho, R. T.....	122, 164, 171, 176, 207, 219, 222, 230, 241,	Martínez-Acitores, D.....	158
Malfratherner, P.....	58, 60, 79, 86, 115, 246-248	Mano, Y.....	94, 148	Marino, M.....	161, 249	Martínez-Ares, D.....	134
Malgerud, L.....	50	Manolakopoulos, S.....	168	Mark, E. B.....	136	Martínez-Bauer, E.....	69, 87, 110, 235
Malickova, K.....	235	Manolopoulos, A.....	197	Markelova, M.....	74, 101, 235, 247	Martínez-Becerra, J.....	160
Malijan, G. M.....	251	Manon-Jensen, T.....	227, 229-230	Marker, D.....	186	Martínez-Cara, J. G.....	152
Malik, H.....	124	Mañosa, M.....	49, 93, 188, 232-233	Markovic Denic, L.....	122	Martínez-Cara, J.....	50, 152, 197
Malik, S.....	187, 216, 226-227	Mansinho, H.....	252	Marks, L.....	205	Martínez-Indart, L.....	236
Malina - Bambite, J.....	183-184, 189	Mansoor, E.....	184	Marks, L. J.....	205	Martínez-Lozano, H.....	228
Malinowski, M.....	150	Mansour-Ghanaei, F.....	247	Markus, T.....	231	Martínez-Montiel, M. P.....	49
Malissin, I.....	169	Manlaka, A.....	185	Marmo, C.....	157, 197	Martínez-Montiel, P.....	49, 143
Malizia, G.....	58	Manthey, C.....	189	Marmo, R.....	98, 133, 150, 157, 197	Martínez-Zorzano, V. S.....	192
Maljaars, J. P. W.....	57, 231	Mantzaris, G.....	181, 185	Marmol, C.....	69, 235	Martini, A.....	167
Malkova, O.....	191	Manuc, M.....	124, 168, 213	Marmor, S.....	134	Martino, M.....	160, 196, 240
Mallet, M.....	110	Manvar, A.....	56, 135	Marocchi, M.....	199	Martins, A.....	64, 168, 253
Mallik, B.....	216, 226	Manzano, M. L.....	167	Marot, G.....	229	Martins, B.....	129, 138
Malm, A.....	228-229	Mão Ferro, S.....	130	Marques, A.....	219, 223, 247	Martins, C.....	252-253
Maluf-Filho, F.....	129, 138, 157	Mao, X.....	252	Marques, I.....	208	Martinsen, T. C.....	142
Maluskova, J.....	174	Marabotto, E.....	168, 200, 243	Marques, M.....	250	Martinucci, I.....	200
Malya, F. U.....	172, 180	Marady, C.....	192	Marques, V.....	166	Martone, A. M.....	141
Malyshev, I.....	154, 200	Marafatto, F.....	167	Marquês Camí, M.....	209	Martorano, M.....	138
Manabe, N.....	137	Marafini, I.....	64, 138, 205	Márquez, L.....	49	Maruoka, D.....	52, 80, 153, 174
Manafi Afkham, S.....	247	Marano, C. W.....	143, 188	Márquez Mosquera, L.....	93, 232	Marusawa, H.....	50
Manca, A.....	228	Marasco, G.....	72, 128	Marra, F.....	51, 63, 124	Marusic, M.....	172, 209
Manceñido, N.....	143	Marasco, R.....	195	Marreiros, A.....	141, 238	Marusic Dobric, S.....	233
Mancini, C.....	245-246	Marcelino, P.....	169	Marrone, G.....	58, 211	Maruyama, H.....	134
Mandelli, E. D.....	150	Marcellan, E.....	138	Marruffo, R.....	195	Maruyama, K.....	197
Mandile, R.....	161	Marchisio, M.....	249	Marshall, L.....	234	Mary, F.....	246
Mandorfer, M.....	65, 121, 125, 166-167, 212	Marciani, L.....	190, 225	Marsico, M.....	199	Marya, N.....	250
Mandrutiu, A.....	217	Marcon, N. E.....	201	Márta, K.....	65, 126-127, 130, 171	Marziani, M.....	37, 55, 63, 86, 91, 99, 103
Maneerattanaporn, M.....	215	Marcos, N.....	93	Martayan, A.....	237-238	Marzouk, O.....	129
Manes, G.....	246	Marcos, P.....	162, 220, 252-253	MartEAU, P.....	86, 135, 144, 230	Mas-de-Xaxars, T.....	148
Manesis, E.....	168	Marcos-Pinto, R.....	182, 246	Marti, H.-P.....	242	Masahiro, I.....	133
Manfredi, R.....	251	Marcos Prieto, H. M.....	202	Marti, L.....	150	Masaki, T.....	196
Mang, T.....	78	Marcovici, T.....	190	Martin, L.....	194	Masaki, Y.....	222
Mangala Murugesan, T.....	220	Marculescu, R.....	211	Martin, H.....	160, 242	Masamune, K.....	136
Mangalika, M.....	221	Mare, R. G.....	124, 212	Martin, L.....	194	Masamunt, J.....	141
Manganelli, C.....	139	Margalit, D.....	191	Martín, L.....	228	Masaoka, T.....	202
Mangiafico, S.....	197	Marginean, O.....	190	Martini, N.....	228	Mascagni, P.....	220
		Margiotta, G.....	191			Mascarenhas, L.....	223
						Mascareño, I.....	131
						Masci, E.....	224, 252

Masciangelo, G.....	246	Matsuzaki, J.....	202	Mearin, L.....	64	Merighi, A.....	157, 197
Masclee, A.....	53, 85, 194-195, 220, 231, 235, 239	Matute, J.....	70	Meczker, Á.....	126	Merino, O.....	49
Masegosa Ataz, J.....	197	Matuz, M.....	126, 232	Medeiros, I.....	207	Merino, X.....	162
Maselli, R.....	81, 181, 218, 220, 225	Matyasiak Budnik, T.....	37, 58, 88, 96, 160	Medeiros, R.....	202	Merkle, J.....	57
Mashtoub, S.....	189	Matzel, K.....	61	Medhioub, M.....	204	Merle, L.....	132
Masip, E.....	151, 162	Maurano, A.....	150	Medoza Ramirez, S.....	230	Merrett, N.....	245
Maslova, G.....	211	Mauriz-Barreiro, V.....	216	Medvedev, Y.....	120	Merta, D.....	169
Mason, N.....	122	Mauro, A.....	69, 198, 200	Mégarbane, B.....	169	Mescoli, C.....	160, 224, 252
Mason, S.....	237	Maurus, C.....	150	Megraud, F.....	60, 74, 79, 98, 204, 247	Mesli, F.....	135-136
Masotti, M.....	228	Mavroudis, G.....	139	Mehmood, M. H.....	121	Mesquita, M.....	147
Masotto, A.....	214	Mawatari, S.....	59, 170, 213	Mehmood, T.....	193	Messadeg, L.....	231
Masri, O.....	241	Maxim, R.....	205-206	Mehta, A.....	143	Messmann, H.....	47, 65, 67, 80, 84, 201, 218
Massella, A.....	214	May, A.....	39, 41, 62, 101, 250	Meier, B.....	177, 218, 237	Mestanik, M.....	199
Massironi, S.....	245	May, G. R.....	201	Meijer, B. J.....	236	Metrangolo, S.....	197
Masu, K.....	125, 128, 170	Mayanagi, S.....	182	Meijer, G. A.....	53, 193	Metter, K.....	176
Masucci, L.....	75, 138, 146	Mayerle, J.....	40, 46, 67, 99, 172	Meining, A.....	72, 83, 88, 103, 155, 176, 224-225	Metz, A.....	127
Masuda, A.....	127, 135, 179	Maynard, A.....	208	Meisner, S.....	37, 53, 65, 184	Meulen, L. W. T.....	53, 85
Masuda, M.....	223	Mayorga Ayala, L. F.....	208	Mejuto, R.....	216	Meyer, S.....	232
Masuy, I.....	250	Mayr, L.....	70, 183	Mekky, M. A.....	123	Meyer-Gerspach, A. C.....	88
Mata, S.....	147, 183	Maywald, U.....	189-190	Mekushinov, K.....	169	Mezei, Z. A.....	145
Mata-Romero, P.....	160	Maza, I.....	136, 176	Melcarne, L.....	69, 235	Mezza, T.....	206
Mateescu, B. R.....	234	Mazlu, B.....	205	Melchior, C.....	242	Mezzina, N.....	229
Materna, A.....	194-195, 238, 249	Mazor, Y.....	150	Mele, D.....	229	Miard, C.....	185
Mateus Dias, A.....	163	Mazumdar, S.....	123	Mele, M. C.....	141, 207, 211	Miceli, E.....	153, 196, 202, 240
Mateus, D.....	220	Mazur-Bialy, A.....	228	Meleine, M.....	238	Micelli-Neto, O.....	209
Mathe, A.....	95, 205	Mazza, G.....	57, 229-230	Melenhorst, J.....	54, 178	Michalak, A.....	124, 167, 185, 211
Mathôt, R.....	188	Mazza, S.....	230	Melideo, D.....	248	Michalopoulos, G.....	147
Mathou, N.....	134	Mazzawi, T.....	242	Mellas, N.....	237	Michel, M.....	127
Matono, S.....	155, 174	Mazzola, G.....	58	Mello, E. S.....	157	Michel, M.-L.....	182
Matos, C.....	85, 92	Mazzoleni, G.....	236	Melsher, R.....	188	Michetti, P.....	143
Matoso, P.....	140	Mazzone, G.....	166, 210	Melzer, E.....	146	Michida, T.....	174, 221
Mátrai, P.....	126-127, 130	Mazzucco, D.....	228	Men, R.....	124, 165, 210	Michiyo, T.....	174
Matrawy, K.....	206	McAlindon, M.....	180, 205, 218, 249-250	Mena, R.....	93	Michl, P.....	127, 173
Matsubara, S.....	163	McBride, J.....	189	Menacho, M.....	49	Michopoulos, S.....	221
Matsubayashi, H.....	151	McCallum, R.....	242	Menchén, L.....	228	Miehlke, S.....	68, 184, 199
Matsuda, K.....	58, 155	McCann, C.....	137	Mendel, R.....	201	Miele, C.....	166
Matsuda, T.....	47, 133, 176	McCann, S.....	207	Mendes, F.....	208	Miele, E.....	161, 190
Matsudaira, S.....	131, 192, 194, 219-220	McCluskey, J. T.....	161	Mendes Santos, S.....	121, 219-220, 240	Miele, L.....	58, 211
Matsueda, K.....	130, 152, 155	McConnell, B.....	235	Mendonça, E.....	252	Miggiano, G. A. D.....	207
Matsui, H.....	246	Mccord, M.....	62	Mendonça, T.....	164, 209	Migliora, P.....	160
Matsumoto, K.....	80, 126, 129, 156-157, 170, 201, 217, 219	McCulloch, A.....	176	Mendonça, T. S.....	209	Migneco, A.....	240
Matsumoto, M.....	47	McFarlane, M.....	87, 235	Mendoza, I.....	49	Miheller, P.....	232
Matsumoto, R.....	130	McKinney, E. F.....	81	Meng, L.-N.....	71, 138, 158-159, 205	Miholic, J.....	126, 226
Matsumoto, T.....	131, 146, 156, 191	McKoy, K.....	70	Mengoli, C.....	228-229	Miki, A.....	197
Matsumura, T.....	52, 80, 153, 174	McMahon, B. P.....	244	Menon, V.....	208	Miki, K.....	123
Matsunaka, T.....	158	McMahon, N.....	199	Menshaw, A.....	122, 125	Mikkola, K.....	173
Matsunami, Y.....	171	McNair, A.....	218	Mensi, A.....	169	Mikó, A.....	126-127, 171
Matsuo, H.....	174	McNamara, D.....	130, 139-141, 181, 197, 203, 234	Menshawy, A.....	141	Mikoviny Kajzrlíkova, I.....	132
Matsuo, K.....	88, 158	McNaughton, D.....	194	Mentella, M. C.....	141	Milani, A.....	250
Matsuo, Y.....	156	McNicholl, A. G.....	74, 98, 203-204, 247	Menys, A.....	225, 231	Milano, A.....	157, 249
Matsushita, H.-O.....	177	McPherson, S.....	103, 115	Merc, A.-I.....	216	Milassin, Á.....	145, 180, 194, 229, 232, 234
Matsuura, N.....	174	McStay, M.....	160	Mercanoglu, B.....	82	Milckiewicz, M.....	55
Matsuura, T.....	238	Mearín, F.....	43, 49, 75, 86	Merchant, L.....	188	Milenkovic, Z.....	189
Matsuyama, M.....	136			Meriam, S.....	171, 212	Milgrom, R.....	185

Milioni, K. ....	147	Mitchell, C. ....	189	Mohammed El Sayed Ahmed, A. ....	125, 170	Mora Sanz, P. ....	187
Milkiewicz, P. ....	55, 86	Mitiche, A. ....	123	Mohess, X. ....	139	Morais, R. ....	153, 162, 173, 193, 196, 212, 225, 250, 252
Milla, M. ....	228	Mitobe, J. ....	175	Mohiuddin, S. A. ....	225	Morales Alvarado, V. J. ....	49
Miller, J. ....	188	Mitova, R. ....	217	Mokrozub, V. ....	206	Morales Arráez, D. E. ....	178
Miller, M. J. ....	187-189	Mitova, V. ....	157	Molander, P. ....	231	Morán, S. ....	192
Miller, S. ....	64	Mitre, M. ....	173	Moleiro, J. ....	183, 185	Morando, F. ....	125
Miller, S. D. ....	64	Mitruţ, M.-M. ....	224	Molendijk, I. ....	57	Moreau, R. ....	46, 79, 102
Miller, V. ....	195	Mitsui, H. ....	129	Molero, X. ....	67, 208	Moreels, T. ....	52, 217
Millman, J. ....	135	Mitsui, K. ....	160, 162, 205	Moletta, L. ....	252	Moreira, L. ....	95
Milluzzo, S. M. ....	128	Mitsui, T. ....	163	Molina Infante, J. ....	55, 98, 103, 160, 204, 247	Moreira, M. ....	49, 71, 136, 145, 186, 249
Milne, A. ....	192	Mitsumune, T. ....	211	Molina-Pérez, E. ....	212	Moreira, M. J. ....	49, 71, 136, 145, 186, 249
Milosavljevic, T. ....	98, 122-123, 204, 247	Mitsuyama, T. ....	223	Møller, A. M. ....	186	Moreira, R. L. ....	200
Milovanovic, T. ....	122-123	Miura, K. ....	81, 173	Molnár, T. ....	145, 179-180, 194, 229, 232, 234	Morella, A. ....	188
Milovanovic Alempijevic, T. ....	233	Miura, R. ....	133, 178, 225	Molteni, P. ....	229	Morello, E. ....	48
Milsom, J. ....	222	Miura, T. ....	143, 190	Mommersteeg, M. ....	58, 158	Moreno, C. ....	56, 78, 83, 92, 223
Mimidis, K. ....	168	Miura, Y. ....	61, 125	Momose, K. ....	222	Moreno, L. ....	95, 192
Mimori, K. ....	192	Miutescu, B. ....	212	Monahan, K. J. ....	151, 192	Moreno-Monteagudo, J. A. ....	64, 70
Min, B.-H. ....	198, 202, 218	Miyachi, H. ....	159, 192, 194	Mongiat, M. ....	192, 218	Morgado, S. ....	147
Min, M. ....	250	Miyahara, H. ....	170	Monica Lucia, C. ....	234	Mori, A. ....	85
Min, T. ....	175	Miyake, M. ....	130	Monica, F. ....	228	Mori, H. ....	174, 176, 202
Min, X. ....	180	Miyake, T. ....	173, 217	Mönkemüller, K. ....	54, 108	Mori, K. ....	89, 132-133, 175, 194
Min, Y. W. ....	198, 218	Miyamoto, H. ....	236	Monsalve-Hernando, C. ....	249	Mori, N. ....	155
Minaguchi, T. ....	128, 180	Miyamoto, K. ....	125, 128	Montalban-Arques, A. ....	247	Mori, Y. ....	131-133, 175, 192, 194, 219-221, 227
Minami, H. ....	73, 197	Miyamoto, S. ....	120, 155	Montani, M. ....	210	Morikawa, T. ....	130
Minami, K. ....	56	Miyamoto, S. ....	120, 155	Montasser, I. F. ....	162	Morimoto, Y. ....	152
Minami, M. ....	152	Miyasako, Y. ....	133, 178, 225	Monteiro, S. ....	71, 121, 136, 167, 186	Morin, I. ....	185
Minamide, T. ....	149, 176-177	Miyata, E. ....	135, 178	Monteleone, G. ....	64, 138, 160, 205	Morino, M. ....	36, 77, 97, 101
Minamoto, T. ....	192	Miyata, H. ....	173, 217	Monteleone, I. ....	64, 138	Morisaki, T. ....	180
Minarik, M. ....	227	Miyata, Y. ....	163	Monteserin-Ron, L. ....	216	Morisawa, T. ....	158
Minarikova, P. ....	227	Miyazaki, E. ....	178	Montgomery, A. ....	53	Morisco, F. ....	42, 125, 166, 207, 210
Minashi, K. ....	201	Miyazaki, H. ....	133	Montil, M. ....	144	Morise, T. ....	131
Minatsuki, C. ....	175	Miyazaki, T. ....	222	Montineri, A. ....	58	Morita, C. ....	123
Minegishi, Y. ....	132-133, 231	Mizokami, K. ....	252	Moon, H. S. ....	156, 201	Morita, M. ....	158
Minet Quinard, R. ....	139, 231	Mizumoto, Y. ....	134	Moon, J. H. ....	69, 125, 181	Morita, Y. ....	201
Mínguez, B. ....	162	Mizuno, K.-I. ....	153	Moon, J. P. ....	136	Moriuchi, A. ....	59, 170, 213
Mínguez, M. ....	49, 93	Mizuno, M. ....	130, 152	Moon, S.-H. ....	125, 128	Moriya, A. ....	211
Minni, F. ....	128	Mizuno, R. ....	179, 217, 246	Mooney, P. ....	205	Morling, J. ....	237
Minto, M. H. ....	243	Mizuno, S. ....	68, 134, 215	Moons, L. M. G. ....	148-149, 192	Moro, C. ....	50
Mion, F. ....	194	Mizusawa, J. ....	201	Moore, B. ....	189	Morris, A. J. ....	62
Miquel, M. ....	110	Mizushima, T. ....	155, 225	Moore, D. ....	244	Morris, C. ....	204
Miquel-Cusachs, O. ....	148	Mnif, L. ....	159	Moore, L. ....	190	Morris, E. ....	53, 87, 93, 225
Miraglia, C. ....	92, 150, 196, 198, 203, 240, 244-246, 248	Mocanu, I. ....	207	Moore, M. V. ....	204	Morris-Stiff, G. ....	217
Miranda-Soberanis, V. ....	127	Mocciaro, F. ....	61, 91, 140, 163, 224, 252	Moores, B. ....	87, 225	Morrison, K. R. ....	184
Mirante, V. G. ....	246	Mochida, K. ....	131	Moorghen, M. ....	227-228	Morrison, M. ....	95, 228, 239, 243
Mirra, P. ....	166	Mochida, T. ....	197, 204	Moosmang, S. ....	206	Morrissey, S. ....	173
Miry, S. ....	216, 246	Mochizuki, H. ....	52, 125, 203, 232, 245	Mora, A. ....	245	Morrow, C. ....	201
Misawa, M. ....	131-133, 175, 192, 194, 219-221	Mochizuki, K. ....	131-132, 192, 221	Mora, N. ....	52	Morsche, R. H. M. ....	121
Miscia, S. ....	249	Mochizuki, K. ....	131-132, 192, 221	Moraes, L. ....	138	Morschedy, A. ....	129
Miscioscia, A. ....	153	Mohamed, A. ....	123	Mora Cuadrado, N. ....	223	Morsy, S. ....	214
Mishra, D. ....	210	Mohamed, B. ....	100, 188	Mora-Gutiérrez, I. ....	64		
Mishra, D. P. ....	210	Mohamed, G. ....	168				
Misra, R. ....	162	Mohamed Elghandour, A. ....	214				
Mita, N. ....	99, 181	Mohamed Teama, N. ....	214				
		Mohammed, N. ....	129				

Mortensen, J. H. ....	227, 229-230	Müller, R. ....	80, 187	Myung, S.-J. ....	176, 187, 192	Nakajima, T. ....	130
Moryoussef, F. ....	179	Müller-Schilling, M. ....	78, 122, 209, 214	Myung, Y. S. ....	146	Nakajima, Y. ....	245
Moschen, A. R. ....	51, 63, 70, 81, 183, 206	Müllner, K. ....	232			Nakamaru, K. ....	89
Mosdósi, B. ....	65	Muncan, V. ....	236	<b>N</b>		Nakamoto, Y. ....	156
Moser, G. ....	240	Münch, A. ....	68, 143, 184	Na, H. K. ....	218	Nakamura, F. ....	236
Moshkowitz, M. ....	181	Münch, T. ....	98	Nabi, Z. ....	137, 150, 153, 224, 242	Nakamura, H. ....	131-133, 166, 175, 192, 194, 219-220
Mosko, J. D. ....	201	Munck, L. K. ....	100, 184	Nabil, T. ....	159	Nakamura, J. ....	170
Mosoni, C. ....	162	Munda, P. ....	167	Nada, L. ....	69, 216, 220	Nakamura, K. ....	131, 138, 146-147, 173, 179, 201, 209
Mosquera, M. ....	140	Mundet, L. ....	100	Nadatan, Y. ....	196	Nakamura, N. ....	197
Moss, A. ....	80, 177, 238	Mundre, P. ....	129	Naegel, A. ....	241	Nakamura, R. ....	182
Mössner, J. ....	126-127	Mundt, B. ....	82	Naegeli, A. ....	142	Nakamura, S. ....	74, 141, 146, 156, 243
Mosteanu, E. O. ....	179	Muniraj, T. ....	56	Naemattalah, M. ....	169	Nakamura, T. ....	57, 183
Moszbacher, D. ....	65	Muniz Kawano, R. ....	250	Naessens, D. ....	188, 231	Nakamura, Y. ....	177, 204
Mota-Reyes, C. ....	82	Munkholm, P. ....	48, 139, 185-186	Naftali, J. ....	176	Nakamuta, M. ....	123
Motawea, E. ....	214	Muñoz, C. ....	49	Naftali, T. ....	79, 183	Nakanishi, H. ....	192
Motegi, S.-I. ....	242	Muñoz, E. ....	49	Nagahama, S. ....	219	Nakanishi, K. ....	146
Mothey, M. ....	175	Muñoz, J. ....	192	Nagahara, A. ....	80, 129, 156-157, 201	Nakanishi, R. ....	219
Motokawa, Y. ....	174	Muñoz, R. ....	56, 167	Nagai, K. ....	127, 173, 217	Nakano, K. ....	131
Motoya, M. ....	222	Muñoz Codocéo, R. A. ....	190	Nagaishi, T. ....	138-139	Nakano, R. ....	127, 135, 179
Motoya, S. ....	79-80	Muñoz-Jurado, G. ....	154	Nagamatsu, S. ....	174	Nakao, K. ....	172, 197
Motta, J. P. ....	71-72	Muñoz Villafraña, C. ....	49, 233	Nagami, Y. ....	129, 134, 196	Nakaoka, M. ....	132, 193
Mouelhi, L. ....	162, 212	Munsterman, I. ....	170, 210	Nagao, K. ....	133	Nakase, H. ....	222
Moullec, A. ....	188, 223	Munteanu, M. A. ....	211	Nagaoka, I. ....	148	Nakashima, H. ....	130
Moum, B. ....	140	Muntion Luengo, I. ....	245	Nagasaka, T. ....	128	Nakatani, A. ....	174
Mounia, E. Y. ....	220	Murabayashi, T. ....	125, 128, 170	Nagashima, K. ....	128, 180	Nakatani, T. ....	148
Mountford, G. ....	72	Muragaki, Y. ....	136	Nagata, S. ....	53, 57, 183	Nakatani, Y. ....	177
Moura, E. G. H. ....	110	Murakami, D. ....	128, 134, 157	Nagata, Y. ....	130	Nakayama, A. ....	82, 130, 156, 177, 218
Moura, M. ....	208	Murakami, M. ....	89	Nagayasu, K. ....	148	Nakazawa, A. ....	163
Moura dos Santos, P. ....	144, 230	Murakami, T. ....	80, 127	Nagengast, W. B. ....	63, 137, 194	Nakmouche, M. ....	123
Mourad, F. ....	241	Murano, M. ....	200	Nageotte, F. ....	220	Nakov, R. ....	83, 230
Mouri, H. ....	130, 152	Murano, T. ....	176-177	Naghshbandi, J. ....	210	Nakov, V. ....	230
Mousa, N. H. ....	169	Murasugi, S. ....	141, 145	Naghshbandi, N. ....	210	Nam, G. Y. ....	201
Mousa, O. ....	170, 179	Murata, A. ....	156	Nagore, D. ....	232	Nam, H. S. ....	186-187, 218, 245
Mousa, O. Y. ....	179	Murata, M. ....	246	Nagtegaal, I. D. ....	54, 87, 193, 215	Nam, S. ....	179, 183, 201, 215
Mousa, W. ....	122	Murcia, O. ....	96, 192	Naguib, M. ....	214	Nam, S. Y. ....	98, 179, 201-202, 215
Moussaide, G. ....	173	Murino, A. ....	39, 91, 115, 250	Nagy, A. ....	65	Nam, S.-J. ....	242, 244
Moutinho Ribeiro, P. ....	172-173, 193, 225, 252	Murono, K. ....	130, 226	Nagy, F. ....	145, 232	Nancey, S. ....	75, 86, 141, 187, 231, 233
Mowat, C. ....	184, 197, 234	Murphy, A. ....	141	Nahas, C. S. R. ....	138	Nantes, O. ....	143
Mozdiak, E. ....	87	Murphy, D. ....	122	Nahas, S. C. ....	138	Naoki, M. ....	174
Mpellou, A. ....	168	Murray, C. ....	54, 57, 241	Nahon, P. ....	102	Napolitano, D. ....	139
Mrabti, H. ....	237	Murray, K. ....	190	Nahon, S. ....	61	Narayanasmay, R. ....	62
Mross, M. ....	190, 231	Murri, R. ....	146	Naismith, G. ....	234	Nardelli, S. ....	228
Mu, P. ....	203	Murthy, S. ....	60, 153	Naito, Y. ....	194, 248	Nardis, P. G. ....	52
Muckenhuber, M. ....	166	Murugananthan, A. ....	221	Nájera Muñoz, R. ....	56	Nardone, G. ....	100, 150
Música-Aguinaga, F. ....	131	Musacchio, C. ....	240	Nakadoi, K. ....	53	Nardone, O. M. ....	186, 190
Muguruma, N. ....	236	Musala, C. ....	174	Nakagawa, K. ....	199	Naruse, T. ....	139
Mujagic, Z. ....	194	Musella, M. ....	182	Nakagawa, S. ....	158-159	Nascimento, M. H. A. ....	250
Mukai, R. ....	248	Muser, E. ....	186	Nakagawa, T. ....	52, 80, 153, 174, 236	Nascimento, R. ....	200
Mukai, S. ....	171	Mushtaq, K. ....	225, 252	Nakagawa, W. ....	164	Nasi, A. ....	51
Mukai, T. ....	68, 99, 181	Mussetto, A. ....	224	Nakagomi, K. ....	125, 245	Nasreddine, F. ....	212
Mukhametova, D. ....	231	Mutafchiyski, V. ....	169	Nakahara, R. ....	128, 134, 157	Nasu, J. ....	209
Mukherjee, A. ....	187	Mutignani, M. ....	179	Nakahata, Y. ....	202-203	Natarajan, B. ....	199
Mukhtar, A. ....	162	Muto, M. ....	201	Nakahira, A. ....	81		
Muktesh, G. ....	216	Muto, T. ....	132, 178	Nakahori, M. ....	133		
Mulder, C. J. J. ....	64, 81	Mylopoulou, T. ....	168	Nakai, Y. ....	68, 134, 215		
Muller, M. ....	128	Myrelid, P. ....	73	Nakajima, A. ....	149, 193, 238		
Müller, M. ....	244	Mytych, D. ....	187-189				



Natarajan, D.....	137	Ngu, J. H. ....	50, 98	Nobis, S. ....	161	Nyuzuki, S. ....	174
Natividad, J. M. ....	182	Nguyen, D. ....	64	Noble, C. ....	234	Nyssönen, M. ....	198
Naval, M. ....	151	Nguyen, G. C. ....	142	Nobre e Souza, M. Â. ....	200		
Navaneethan, U. ....	56, 99	Nguyen, H. ....	183	Nóbrega, J. J. ....	216	<b>O</b>	
Navarro, M. ....	149, 237	Nguyen, N. ....	65	Nóbrega, S. ....	216	O'Connel Franscichetto,	
Navarro, P. ....	93, 233	Nguyen, N. N. ....	126	Noda, H. ....	243, 245	E. ....	171
Navarro-Avila, F. ....	220	Nguyen, Q. N. ....	134	Noda, T. ....	158	O'Connell, P. R. ....	47, 62, 97
Navarro Cortés, P. ....	232	Ni, J. ....	216	Noda, Y. ....	125, 128, 170	O'Connor, A. ....	130, 140-141,
Navarro Llavat, M. ....	49, 232-233	Ni, L. ....	203	Noe, M. ....	192	181, 234	
Navarro-Llavat, M. ....	49, 93	Nicholson, J. K. ....	194	Nogales-Rincón, Ó. ....	131	O'Connor, S. A. ....	221
Navarro-Vicente, F. ....	86, 184, 227	Nickerson, C. ....	87, 225	Noguchi, M. ....	252	O'Gorman, S. ....	234
Navas Lopez, V. M. ....	49	Nicolas, D. ....	131	Noguchi, T. ....	200	O'Morain, C. ....	46, 98,
Navascues, C. A. ....	167	Nicolau, L. A. ....	200	Noh, J. H. ....	218	203-204, 247	
Navez, J. ....	52	Nicolucci, C. ....	121	Nomura, H. ....	123	O'Morain, N. ....	41, 234
Nawel, B. ....	100, 168	Nicola, S. M. ....	234	Nomura, K. ....	222	O'Rourke, J. ....	176
Nayagam, J. ....	239	Nie, D. ....	82, 129	Nonaka, S. ....	202	Oakley, F. ....	214
Nayak, S. ....	144	Nieber, K. ....	211, 235	Nordlander, S. ....	194	Oana Cristina, S. ....	205
Nayar, M. ....	127, 179	Niechcial, A. ....	143	Normann, A. ....	166	Obada, M. ....	165
Nduaka, C. I. ....	79, 145, 188	Niederreiter, L. ....	70, 183	Noronha Ferreira, C. ....	164, 176,	Obata, T. ....	81
Ndububa, D. A. ....	168	Nielsen, K. R. ....	48, 185	208, 223,		Obermayer-Pietsch, B. ....	211
Neagoe, C. D. ....	166	Niemi, K. ....	190	251-252		Obialo, N. ....	143
Neal, D. ....	243	Niemiec, M. ....	129	Norsaf, B. ....	212	Obora, A. ....	202-203
Neamatallah, M. A. ....	123, 214	Nieminen, U. ....	50	Norton, C. ....	61	Obrocea, F. ....	224
Nedelcu, I. C. ....	251	Niess, J. H. ....	46	Norton, R. ....	50	Obst, W. ....	215
Nedoluzhko, I. ....	137, 182	Nielfeld, L. ....	173	Nos Mateu, P. ....	144	Ócal, S. ....	122
Negreanu, L. ....	231	Nieto-García, L. ....	217	Nos, P. ....	49, 93, 144,	Ocaña, T. ....	95, 192
Negro, F. ....	55, 68	Nieto, J. ....	52, 135	232-233		Occhigrossi, G. ....	140
Neimark, E. ....	234	Nietsch, H. H. ....	110, 208	Not, T. ....	55, 161-162	Ochiai, K. ....	179
Nemade, P. ....	215, 246	Nieuwdorp, M. ....	206	Notaristefano, C. ....	181, 236	Ochiai, T. ....	81, 131, 148
Nemes, É. ....	162	Nieuwenburg, S. A. V. ....	95, 193	Nour, D. ....	214	Ochiai, Y. ....	82, 130, 156,
Nemeth, B. ....	126, 217	Nieuwenhuis, V. ....	46, 85	Nourdin, A. ....	220	177, 218	
Nemoto, D. ....	176	Nigro, C. ....	166	Nouvenne, A. ....	150, 196, 198,	Ochsenkuehn, T. ....	141
Nene, S. ....	185	Niimi, K. ....	175	203, 244-246, 248		Ochsenkühn, T. ....	93, 189, 232
Neri, A. ....	63	Nikaki, K. ....	153	Novak, G. ....	74, 138, 144	Oczella, L. ....	177, 181, 224
Neri, B. ....	140-141	Nikeghbalain, S. ....	212	Novák, J. ....	171	Oda, I. ....	74, 130, 201-202
Neri, M. ....	100, 196, 228, 249	Nikeghbalian, S. ....	169, 212	Novella Durán, M. T. ....	49	Oda, K. ....	59, 80, 170, 213
Neri, M. C. ....	100, 196	Nikolic, V. ....	122-123	Novikov, A. ....	133	Oda, M. ....	132-133, 175
Nesi, G. ....	160	Nikuseva Martic, T. ....	157	Novo, E. ....	48, 167	Odes, S. ....	48, 142, 185
Nestor, C. ....	222	Nilsson, P. ....	51	Novovic, S. ....	216	Odintsova, A. ....	101, 184, 231
Neto, M. G. ....	110	Ninomiya, R. ....	163	Nozaki, R. ....	177	Odysseos, G. ....	126
Neubauer, K. ....	184, 253	Ninomiya, Y. ....	147	Nozawa, H. ....	130, 226	Offerhaus, G. J. A. ....	148-149, 192
Neuber, S. ....	210	Nion-Larmurier, I. ....	135-136, 144	Nseselioglu, S. ....	243	Ogata, N. ....	131-132, 175, 192,
Neuhaus, H. ....	59, 62, 72, 85,	Nion, I. ....	230	Nsibi, S. ....	162	194, 219-220	
88, 93, 97, 155		Nirantharakumar, K. ....	227, 251	Ntetskas, G. ....	168	Ogata, S. ....	146
Neuhaus, L. ....	218	Nishikawa, T. ....	130, 226	Ntouli, V. ....	147	Ogawa, C. ....	158
Neumann, H. ....	150, 157, 175	Nishimoto, T. ....	160, 162, 205	Ntziachristos, V. ....	137, 194, 218	Ogawa, E. ....	123
Neurath, M. ....	46, 67, 220,	Nishimura, K. ....	148	Nuber, A. ....	200	Ogawa, M. ....	132
225, 232, 241		Nishimura, M. ....	221	Nucci, A. ....	197	Ogawa, T. ....	125, 128, 170
Neurath, M. F. ....	225	Nishimura, N. ....	130, 152	Nuernberg, D. ....	77	Ogawa, Y. ....	132, 159, 175,
Neuweiler, J. ....	124	Nishimura, R. ....	71, 183	Nunes, A. C. ....	184	192, 219, 221	
Neuymina, T. ....	121, 166	Nishio, E. ....	204	Nunes, G. ....	114, 140, 251-252	Ogura, K. ....	191
Neve, V. ....	228	Nishiyama, M. ....	173, 217	Nunes, J. ....	219	Oh, C. H. ....	222
Nevens, F. ....	166	Nissinen, R. ....	231	Núñez Alonso, A. ....	232	Oh, D.-W. ....	181
Nevi, L. ....	100, 166	Nissinen, S. I. ....	172	Núñez Gómez, L. ....	202	Oh, E. H. ....	176, 187
Nezu, Y. ....	138	Nitsche, U. ....	106	Nuutila, P. ....	173	Oh, J.-H. ....	244
Ng, D. ....	69	Niv, Y. ....	98, 159, 204, 247	Nuzzo, A. ....	71, 169	Oh, S. Y. ....	148
Ng, E. ....	218	Nix, B. ....	94, 242	Nybacka, S. ....	250	Ohara, M. ....	120, 166
Ng, S. C. ....	69, 82, 227	Nizzoli, G. ....	63	Nydegger, U. ....	206	ohata, K. ....	193
Ngo, O. ....	95, 177, 224, 236	Nobili, A. ....	153	Nylund, K. ....	77	Ohira, H. ....	170

Ohira, T. ....	157	Olivares, D. ....	143, 188	Oria-Hernandez, J. ....	221	Rourselin, S. ....	245
Ohki, T. ....	222	Olivari, N. ....	128	Orlandi, A. ....	160	Ouyang, Y. ....	248
Ohkoshi, S. ....	57	Oliveira, A. ....	110, 121, 123, 167, 211, 213, 235, 252	Orlandini, B. ....	219	Overbeek, K. A. ....	92, 172
Ohlsson, B. ....	51, 239	Oliveira, A. M. ....	64	Orlando, A. ....	61, 140, 228, 233	Overwater, A. ....	63, 154
Öhman, L. ....	138-139, 194-195	Oliveira, C. ....	88	Orlando, C. ....	241	Ow, M. ....	241
Ohmiya, T. ....	161	Oliveira, E. C. ....	100	Orlando, R. ....	61	Owaki, Y. ....	179, 217, 246
Ohmori, S. ....	190	Oliver, L. ....	148-149	Orlando, S. ....	180, 230, 248-249	Oyama, M. ....	174
Ohmori, T. ....	145, 190	Olivera Sendra, P. A. ....	233	Orlova, L. P. ....	186	Oyama, T. ....	155, 201, 246
Ohnishi, S. ....	120, 155, 166, 225	Olmedo Camacho, J. ....	221	Orlmann, S. ....	172	Ozaka, M. ....	136
Ohnita, K. ....	172	Olsavszky, V. ....	165	Orr, D. ....	213	Ozawa, E. ....	172
Ohno, Y. ....	88, 173, 176, 217	Olsen, A. R. ....	146	Orr, J. ....	122	Ozawa, H. ....	182
Ohta, H. ....	136	Olsen, M. ....	124	Ortega-Moreno, L. ....	64, 70	Ozawa, T. ....	88, 158
Ohta, T. ....	157	Olson, A. ....	69, 98, 199	Ortega-Rabbione, G. J. ....	243	Özer Etik, D. ....	122
Ohta, Y. ....	52	Omae, M. ....	201	Ortega-Suazo, E. J. ....	152, 197	Ozer, A. ....	240
Ohtsuka, K. ....	132, 148	Omari, T. ....	244	Ortiz-Fernández-Sordo, J. ....	62	Ozer, S. ....	196
Ohtsuru, S. ....	50	Omata, M. ....	52, 125, 203, 232, 245	Ortiz-Masia, D. ....	86, 227	Özög, İ. ....	137
Ohya, T. R. ....	133	Omata, W. ....	232	Ortiz-Masia, D. ....	71, 183-184, 227	<b>P</b>	
Oikawa, M. ....	128	Omatsu, T. ....	202-203	Oscar, F. ....	222	Pace, F. ....	150, 235
Oikonomopoulou, M. ....	168	Omdal, R. ....	231	Oscepkova, A. ....	183-184, 189	Pachofszky, T. ....	65
Oishi, H. ....	137	Omidvari, A.-H. ....	62, 201	Oshima, S. ....	57, 71, 183	Padolecchia, E. ....	128
Ojetti, V. ....	139, 240	Ominami, M. ....	129	Osmane, R. ....	123	Páez de la Cadena, M. ....	192
Oka, P. ....	209, 220	Omori, J. ....	160, 205	Ospina-Arboleda, J. ....	51-52, 154, 180	Pagliari, D. ....	251
Oka, S. ....	53, 147	Omori, T. ....	141, 145	Öst, Å. ....	142	Pagnini, C. ....	206
Okada, A. ....	126	Omorogbe, J. ....	130	Östapchenko, L. I. ....	120	Pai, R. ....	138
Okada, H. ....	137, 155, 158, 161, 217, 243	Omura, A. ....	158	Østergaard, L. R. ....	136	Paiella, S. ....	49
Okada, K. ....	178, 181, 251	Onal, A. ....	210	Osterman, M. T. ....	145	Paik, S. W. ....	50
Okada, M. ....	61, 160	Onali, S. ....	141	Ostiz, M. ....	158	Paik, W. H. ....	69, 136
Okada, S. ....	130	Onder, F. O. ....	208	Östman, A. ....	50	Paik, Y.-H. ....	50
Okada, T. ....	128, 245	Onesti, E. ....	153	Ostojic, R. ....	207	Pajares, R. ....	49, 93
Okamoto, A. ....	136	Ong, E. H. D. ....	131	Osumi, H. ....	58, 178	Pajares Villarroja, R. ....	49, 233
Okamoto, K. ....	181, 236, 251	Onikujuk, J. ....	211	Osumi, S. ....	197	Pakarinen, M. ....	71, 95, 117
Okamoto, N. ....	177	Onimaru, M. ....	197	Ota, A. ....	149	Pakodi, F. ....	134, 178
Okamoto, R. ....	57, 71, 183	Ono, A. ....	176	Ota, H. ....	133, 179	Pal, P. ....	224
Okamoto, T. ....	89, 131, 173, 209	Ono, H. ....	151, 201	Ota, R. ....	192	Palacios, R. S. ....	63
Okamoto, Y. ....	137, 222	Ono, M. ....	175, 225	Ota, T. ....	133	Palatka, K. ....	145, 187, 232
Okamura, T. ....	197	Ono, S. ....	155	Otake, Y. ....	47	Palazzo, M. ....	38, 40, 92, 101, 107
Okanobu, H. ....	53	Onori, E. ....	234	Otani, K. ....	129, 134, 196	Palcevski, G. ....	161-162
Okazaki, K. ....	89	Onoyama, T. ....	170	Otazua, P. ....	121	Palfreeman, S. ....	191
Okhlobystin, A. ....	185	Ooi, J. L. S. ....	153	Otero-Alen, B. ....	126	Paliy, I. ....	156
Okhlobystina, O. ....	185	Ooijevaar, R. ....	75	Otero, Y. ....	70	Pallagi, P. ....	59, 89
Okimoto, K. ....	52, 80, 153, 174	Ooki, T. ....	152	Othman, A. A. ....	143	Pallardy, M. ....	75
Oksala, N. ....	172	Oomori, J. ....	162	Othman, M. ....	241	Pallares Manrique, H. ....	232
Oksanen, P. ....	48, 185	Oono, Y. ....	149, 176-177	Othman, W. ....	214	Pallone, F. ....	140
Okubo, M. ....	129	Oosten, L. E. M. ....	57	Otle, A. ....	101	Pallotta, L. ....	150, 196, 206
Okumura, T. ....	219, 221	Oosterhuis, D. ....	210	Otsuka, F. ....	137	Pallotta, N. ....	153
Okuwaki, K. ....	135, 178	Oosting, J. ....	207	Otsuka, S. ....	182	Palma, R. ....	177, 223
Okuyama, S.-H. ....	213	Opiteck, G. ....	69, 98, 199	Otsuka, T. ....	163, 246	Palmela, C. ....	208, 219
Okuzono, T. ....	133	Opiteck, G. J. ....	98, 199	Otte, A. ....	141	Palmer, S. C. ....	158
Olaisen, M. ....	142	Oppelt, P. ....	183	Otten, M. ....	199	Palmieri, L.-J. ....	191
Olar, M.-P. ....	179	Oppong, K. ....	127, 179, 217	Ottóffy, M. ....	171	Palumbo, P. ....	250
Olariu, L. ....	190	Opramolla, A. ....	186, 190	Oualgouh, M. ....	221	Pamboukian, S. ....	240
Olavarria, A. ....	71	Oprisanescu, D. ....	251	Ouchchane, L. ....	139	Pan, J. ....	124, 236, 244
Olde Damink, S. ....	251	Oproiu, A. ....	168, 213	Oudkerk Pool, M. ....	199	Pan, W. ....	47
Oleas, R. ....	51-52, 154, 180	Ordás Jimenez, I. ....	39, 141	Ouldgougam, R. ....	125	Pan, X. ....	236
Olen, O. ....	191	Orellana, R. ....	110	Oumrani, S. ....	135, 200, 224	Pan, Y. ....	175
Olesen, S. S. ....	194-195, 238, 249	Orho-Melander, M. ....	51			Pana, M. ....	62
Oleynik, O. ....	187						
Oliboni, E. ....	214						

Panaccione, R.....	97, 234	Parisinis, C.....	63	Pastorino, R.....	58	Pellis�, M.....	95, 192
Pan�o, E. A.....	196-197, 239	Park, A.....	143	Patai, �.....	134, 176	Pellis� Urquiza, M.....	37, 47, 95
Panarese, A.....	248	Park, B. S.....	248	Patel, C.....	135	Peloso, A.....	209
Pand�, G.....	245	Park, C. H.....	60, 128, 157, 169, 196	Patel, K.....	132, 153, 242	Peloso, A. G.....	209
Pandolfi, A.....	249	Park, D. H.....	50, 69, 181	Patel, M.....	241	Penagini, R.....	69, 198, 200
Pandolfino, J.....	38	Park, D. I.....	144, 147	Patel, P.....	80, 110	Pe�as Garc�a, B.....	502
Pan�s, J.....	39, 46, 55, 67, 79, 86, 97, 141, 143, 188-189, 230	Park, E. H.....	159	Patel, R.....	63, 97	Pe�as-Herrero, I.....	52, 56
Panetta, C.....	177	Park, E. T.....	234	Patelrini, A.....	197	Penck, R.....	77, 123
Pang, A.....	151	Park, H.....	136, 156, 176, 202	Paternostro, R.....	121, 167, 212	Penchev, P.....	184
Pangan, A.....	230	Park, J. C.....	226	Paterson, J.....	184	Pendgraft, A.....	201
Panic, N.....	161	Park, J. H.....	147, 238	Patita, M.....	140, 170, 186, 190, 213, 251	Penders, J.....	235
Panicci Tonucci, T.....	234	Park, J. J.....	156, 176, 202	Patricelli, M. G.....	181, 236	Pendharkar, S.....	126-127
Panikkar, M.....	175	Park, J. M.....	156, 242, 244	Pattou, F.....	173	Peng, C.....	196
Panis, Y.....	71	Park, J. W.....	183, 193	Paugam-Burtz, C.....	71	Peng, S.....	124
Panjawatnanan, P.....	170	Park, J. Y.....	136, 154, 215	Paul, S.....	75	Penman, I.....	62
Pannemans, J.....	195	Park, J.-S.....	140, 224	Pauliat, E.....	132	Penna, A.....	100, 150
Pannu, D.....	56	Park, K. S.....	173	Paulli, M.....	160	Pennacchi, C. M. P. S.....	129
Panozzo, M. P.....	92, 196, 203, 246	Park, M.....	218, 234, 238	Pauwels, A.....	153, 199, 207, 245	Pennings, J. P.....	194
Panzuto, F.....	245	Park, M. I.....	218, 234	Pauza, A. G.....	240	Penttil�, A.....	172
Paoluzi, P.....	145	Park, S.....	130, 136, 146, 157, 169, 176, 178, 186-187, 191-193, 218, 234, 237, 242, 244-245	Pauziene, N.....	150, 240	Penz, D.....	87, 221-222
Papa, A.....	100, 139, 150, 234	Park, S. B.....	186-187, 218, 245	Pav�o Borges, V.....	163, 202, 220, 223, 240	Penzo, B.....	215
Papa, V.....	57	Park, S. C.....	242, 244	Pavel, V.....	209	Peppelenbosch, M.....	58, 82, 158, 201
Papadopoulos, N.....	168	Park, S. H.....	176, 187, 192	Pavey, D.....	245	Peralta, S.....	235
Papageorgiou, M.-V.....	168	Park, S. J.....	146, 191, 193, 218, 234, 237	Pavlik, M.....	232	Peraro, L.....	213
Papakonstantinou, F.....	168	Park, S. W.....	136, 157	Pavlov, I.....	182	Perbtani, Y.....	56
Papanikolaou, I.....	38, 68, 112	Park, S. Y.....	169	Pavlovic Markovic, A.....	123, 141, 206	Perdigoto, R.....	169
Paparella, C.....	241	Park, S.-H.....	69, 175, 178, 181	Pavoni, M.....	74, 204, 247	Pereira, B.....	231
Paparozzi, C.....	179	Park, S.-Y.....	183	Payeras Cap�, M. A.....	164	Pereira, C.....	216
Papastergiou, V.....	134, 168	Park, T. Y.....	133	Paz, K.....	146	Pereira, E.....	122, 163, 167
Papatheodoridis, G.....	168, 229	Park, Y. H.....	146, 193, 237	Pazos, Y.....	126	Pereira, F.....	121-122, 163, 167, 253
Papi, C.....	140, 160	Park, Y. S.....	96, 191, 239	Pearson, C.....	53	Pereira, G.....	164
Papp, M.....	48, 79, 103, 171, 232	Park, Y.-S.....	157, 203	Pecere, S.....	72	Pereira, H.....	132
Papparella, L. G.....	234	Parker, A.....	236	Pech, O.....	48, 62, 73, 88, 92, 102, 155	Pereira, M. A.....	157
Paranandi, B.....	56	Parlak, E.....	198, 242	Pechlivanis, A.....	234	Pereira, P. R.....	173, 193, 212, 225
Paraskakis, E.....	184	Parmeggiani, F.....	150	Peck-Radosavljevic, M.....	65, 69, 78-79, 167, 212	Pereira, S.....	54
Paraskeva, K. D.....	134, 215	Parodi, A.....	221	P�csi, D.....	126-127, 130, 134, 178	Pereira, S. P.....	223
Paraskevova, A.....	154, 200	Parola, M.....	48, 167	Pedersen, N.....	48, 184-185	Pereira de Campos Carvalho, P. J.....	51
Pardak, P.....	161	Paroni, M.....	63	Pedersen, R. D.....	188	Pereira Silva, J.....	185
Pardal, J.....	162	Paroni Sterbini, F.....	75	Pedroto, I.....	145, 163-164, 182, 246	Perell�, A.....	69
Pardal, V.....	253	Parry, J.....	171	Peeters, K.....	57	Perera, N.....	137
Pareja, M. J.....	166	Parvaiz, A.....	54	Peeters, K. C.....	149, 226	Pererva, L.....	217
Parekh, N.....	143	Pascalau, S.....	212	Pehtrrson, M.....	227	Peres, D. R.....	183
Parello, A.....	113	Paschos, P.....	197, 207, 209, 212	Peine, S.....	58	Perets, T. T.....	159, 203, 234
Parente, F.....	197	Pasina, L.....	153	Peixoto, A.....	89, 153	Perez, K.....	46
Pares, A.....	123	Pasini, A.....	196, 229, 240	Pejchal, J.....	232, 236	Perez-A�sa, A.....	98, 204, 247
Pares, O.....	54	Paskauskas, S.....	151	Pe�ala, A.....	137, 233	Perez-Becerra, E.....	246
Parfenov, A.....	142, 195	Paslaru, L. L.....	214	Pelitari, S.....	221	P�rez Calle, J. L.....	49, 93, 232
Parhizkar, B.....	210	Paspatis, G.....	72, 215	Pelizzaro, F.....	170, 209, 215	P�rez-Calle, J. L.....	49, 143
Paridaens, K.....	186	Pasquali, S.....	224	Pellegrini, L.....	186	P�rez-Cami�a, J.....	126
Pariante, B.....	61, 86, 139, 229, 231	Passananti, V.....	150, 239	Pellicani, R.....	192	P�rez-Cormenzana, M.....	148
Parihar, V.....	131	Passanati, V.....	149, 194	Pellise, M.....	147	Perez Cuadrado-Robles, E.....	52, 117
Parikh, M. P.....	60, 153, 219	Pastorelli, D.....	170			Perez-Cuadrado-Robles, E.....	88
Parisi, S.....	196, 200	Pastorelli, L.....	157, 240			Perez Fern�ndez, T.....	153

Perez Gisbert, J.....	247	Petita, S. ....	58	Pioche, M.....	52, 92, 113, 141, 177, 198, 221, 245	Pollinger, K. ....	122, 214
Perez-Lasala, J.....	98, 204, 247	Peyrin-Biroulet, L. ....	61, 86, 93, 143, 145,	Pipino, C. ....	249	Polo, B. ....	151
Pérez-Miranda, M.....	52, 56, 80, 101, 223		231-233	Piqueras Cano, M. ....	233	Polster, A. ....	138
Perez Nyssen, O.....	98, 204, 247	Pezzilli, R. ....	49	Piqueras, M.....	49, 93	Poluektov, Y. ....	166
Pérez-Romero, M. ....	243	Pezzotti, P. ....	153	Pirici, D. ....	172	Poluektova, E. ....	238
Pérez-Suárez, L. ....	246	Pezzullo, M. ....	92, 223	Pirogov, S.....	200, 208	Polywka, S. ....	58
Perez Valle, I. ....	202	Pfeffer Gik, T.....	251	Pirogova, I.....	121, 166	Pomerat, M. ....	243
Perfetti, V. ....	160	Pfeffer-Gik, T.....	93	Pironi, L. ....	57	Pompa, A. ....	249
Perfilyev, I. ....	208	Pfisterer, N. ....	65	Pirrotta, E. ....	159	Pompili, M. ....	163, 167, 211
Pericleous, M. ....	124, 170	Phelip, J. M. ....	75	Pisani, A. ....	83, 236	Ponchon, T. ....	37, 73, 78, 84, 220-221
Perin, S. ....	137	Philandrianos, C.....	61	Pisati, M.....	153, 202	Poneros, J. ....	217
Perini, B.....	142	Philip, G.....	143, 145, 186, 188	Pischke, S.....	58	Ponkratova, N.....	185
Perkhofer, L. ....	50, 172, 216	Phillips, A. ....	38, 68, 77	Piscitelli, F. ....	138	Ponomarev, A.....	154, 200
Perkins, A.....	190	Phillips, N. ....	65	Piselli, P. ....	169	Ponsoien, C. Y.....	67, 86, 99, 146, 190
Perlemuter, G. ....	94	Phillips, R. K. ....	234	Pisera, M.....	177, 222	Pontas, C.....	181
Perlepe, N. ....	229	Philouze, G.....	242	Pislaru, L.....	211	Ponte, A. ....	169, 176, 180
Perretta, S.....	89	Piano, S. ....	64, 76, 83	Pistone, M. T. ....	139	Ponte, A. ....	169, 176, 180
Perrí, V.....	67, 91, 219, 222-223, 244, 251	Piatek, D. ....	228-229	Pita, I. ....	180, 202	Pontisso, P.....	167
		Pica, R. ....	140, 145	Pitanga-Lukashok, H.....	51-52, 154, 180	Pontone, S.....	150, 177
Perricone, R. ....	141	Picardo, S.....	143	Pittet, V.....	140	Ponziani, F. R. ....	163, 167, 211
Perrin, C.....	239	Picarelli, A. ....	249	Piva, R. ....	161	Ponzo, E.....	228
Perrin, P.....	191	Picchio, M. ....	100, 150	Pivetta, E.....	218	Poon, J. ....	235
Perrod, G. ....	132	Picci, A. ....	161	Pizarro, T. T. ....	70, 229	Pop, C. S. ....	168
Perron, N. ....	222	Pienar, C. ....	210, 212	Pizzacannella, M. ....	180	Pop, M. ....	190
Perrot, V.....	151	Pieraccini, A. ....	228	Pizzoferrato, M. ....	139, 141	Popescu, A. ....	124
Perrotta, T. A. ....	154	Pierik, M. J. ....	184, 231	Pizzolante, F. ....	163, 211	Popescu, C. ....	168
Persichella, A. ....	160	Piescik-Lech, M.....	64	Pizzolant, J. ....	182	Popescu, I. ....	172
Persico, M. ....	125	Piessevaux, H. ....	195	Planche, K.....	250	Popescu, M. ....	166
Personeni, N. ....	123	Pietrabissa, A. ....	57	Planell, N. ....	192	Popescu, S. A. ....	124, 210, 212-213
Perticone, F. ....	153	Pietraruenu, C. ....	214-215	Plastaras, L.....	61	Popov, R.....	169
Perugorria, M.....	55, 86, 99, 214	Pietro, O.....	135	Plata Fernández, C. ....	190	Popovic, D.....	122, 233
Pesce, F. ....	248	Pignot, G.....	135			Popp, A. ....	162
Pesce, M.....	150	Pigo, F.....	150	Plesa, A.....	205-206	Porcari, S. ....	61
Pesei, Z. G.....	217	Pileri, S. ....	160	Plevris, N. ....	188, 234	Poropat, G. ....	172
Pesenti, C.....	92, 135-136, 220, 222-223, 225	Pilonis, N. ....	222	Plotogea, O. M.....	181	Porowska, B. ....	243
		Pilotto, A. ....	240	Plumb, A.....	47, 61, 225, 231	Porres, J. ....	160
Peserico, G. ....	170, 215	Pilotto, V. ....	241	Plusnin, R. ....	146	Porretti, L. ....	63
Pessia, A. ....	59, 76, 213	Pilozzi, E. ....	130, 245	Pockros, P.....	50	Porta, P.....	205
Pessorusso, F. C. S. ....	157	Pimentel Nunes, P. ....	39, 59, 77, 84, 92, 117, 130	Poddar, U. ....	146, 171	Portela, F. ....	186, 190
Petalidis, I.....	168	Pimentel-Nunes, P.....	180, 202	Podesser, B. K. ....	125	Portelli, V. ....	58
Peter, J. ....	240	Pin Vieito, N. ....	147-148	Podmanicky, D.....	145	Portillo Villares, M. I.....	178, 191, 222, 236
Peter, S. ....	201, 240	Pineda, M. ....	149	Poen, A. C. ....	46		
Peterova, E.....	153	Pinese, E.....	161	Poetter-Lang, S.....	99, 116	Posch, A. ....	75
Petersen, A. ....	52, 144	Pineton de Chambrun, G.....	61	Pohl, D.....	47, 98	Poscia, A. ....	139
Peterson, J. ....	234	Pinho, R.....	132, 134, 163, 176, 178, 180, 250	Pohl, H.....	46, 102	Posma, J. M.....	194
Petitcollin, A.....	232			Poincloux, L. ....	221	Post, Z. ....	149
Petito, V. ....	138-139, 141, 229	Piñol, V. ....	148-149	Poirot, B.....	236	Poszler, A. ....	220
Petraki, K. ....	221	Pintar, S.....	152	Poizat, F. ....	134, 220, 222-223	Potter, M. ....	184
Petrauskas, D.....	121	Pinter, M.....	212	Pokrotnieks, J. ....	50, 241	Potts, J. ....	223
Petrenkiene, V. ....	121	Pinto, A. ....	186, 220	Polano, M. ....	192	Potts, L. ....	234
Petritsch, W. ....	75	Pinto, B.....	166, 207, 249	Polese, L. ....	208	Potuznikova, K. ....	186
Petrone, M. C. ....	38, 80, 99, 134, 179	Pinto, J.....	122, 163, 167, 253	Poletto, E. ....	192	Pouillon, L.....	93, 233
Petrov, M.....	126-127	Pinto Marques, P. ....	114, 252	Polewiczowska, B. ....	176	Poullnot, F. ....	71
Petrovic, S. ....	189	Pinto Vraca, T. ....	228	Poley, J. W. ....	46, 62, 80, 84, 134	Poulsen, S. S. ....	139
Petruziello, L. ....	67	Pintor, P. ....	229	Polkowski, M.....	103, 172	Pouw, R. ....	155
Petruziello, C. ....	240	Pinzani, M.....	51, 57, 79, 229-230	Pollák, É.....	162	Poyatos, R. ....	49, 144, 188
Petruziello, L.....	176			Poller, D. ....	62	Poynter, L. ....	237
						Poza Cordon, J. ....	187

Pozuelo, M. ....	235	Pyatakova, A. ....	137	Rahman, F. ....	171	Rath, T. ....	220, 225, 241
Pozzi Mucelli, R. ....	56	Pylypenko, S. ....	120	Rahman, I. ....	80, 225	Ratone, J. P. ....	92, 135-136, 220, 222-223, 225
Prabhu, A. ....	56	<b>Q</b>		Rahman, K. F. ....	150, 175	Rattei, T. ....	206
Prakash, J. ....	55, 210	Qarage, L. ....	153	Rahmi, G. ....	132, 135-136, 198, 245	Rausch, A. ....	233
Pranzo, G. ....	150	Qi, J. ....	147-148	Raicu, G. M. ....	63, 154	Rauws, E. A. J. ....	46
Prasad, K. K. ....	187, 227	Qian, Y. ....	236	Raicu, M. ....	192	Ravaioli, F. ....	128
Prasad, K. N. ....	162	Qiang, Z. ....	180	Raimondo, G. ....	58	Raynandran, A. ....	219
Prasad, V. ....	173	Qiong, Y. ....	197	Raimundo, M. ....	122	Ravizza, D. ....	177
Prat, F. ....	48, 200, 219, 224, 245	Quadarella, A. ....	167	Raine, T. ....	48, 57, 74, 96	Raymond, P. ....	58, 170
Pratschke, J. ....	63	Quader, F. ....	69	Rainer, F. ....	75	Raynaud, J. J. ....	226
Preda, C. M. ....	71, 168, 213	Quanjel, A. B. A. ....	239	Rainio, M. ....	172	Raynaud, J.-J. ....	199
Prelipcean, C. C. ....	213	Quante, M. ....	82, 98, 155, 200, 218	Rainteau, D. ....	100, 191	Razafimahefa, J. ....	236
Premuzic, M. ....	207	Quaranta, G. ....	75, 138	Raja Shariff, R. ....	201	Rckey, D. ....	241
Prentice, E. ....	197	Quarta, S. ....	167	Raja, S. ....	60, 153	Rea, M. ....	190
Prestileo, T. ....	58	Queiroz, N. S. F. ....	51	Rajabalan, A. ....	174	Rebillard, E. ....	136
Pricci, M. ....	158	Quezada Pacheco, R. H. ....	247-248	Rajakrishnan, V. ....	241	Rebollo, J. M. ....	247
Prieto, R. J. ....	151	Quigley, E. M. ....	57	Rajar, P. ....	144	Rebours, V. ....	40, 66, 73, 128
Prince, D. ....	191	Quilliot, D. ....	71	Rajendra, S. ....	154, 245	Reddy, D. N. ....	137, 150, 153, 224, 242
Principi, M. ....	136, 158, 160, 181, 205	Quinn, S. ....	186	Rajilic-Stojanovic, M. ....	70, 76, 235	Reddy, M. ....	110, 251-252
Principi, M. B. ....	181, 228	Quiñones Castro, R. ....	236	Raju, S. ....	180	Reddy, Y. ....	226
Privat, J. ....	136, 198	Quintero, E. ....	56, 131, 178	Rakonczay, Z. J. ....	59, 89	Redero, L. ....	64
Privitera, A. C. ....	61	Quintero Carrion, E. ....	53	Ramada, J. ....	134	Ramadan, N. ....	222, 241
Privitera, G. ....	234	Quirk, D. ....	79, 187	Ramallo, M. ....	251	Redondo, I. ....	186, 190
Probst, A. ....	201, 218	Qurashi, M. ....	176	Ramalho, R. ....	175, 193	Redondo-Cerezo, E. ....	50, 152, 197
Proca, D. ....	168	<b>R</b>		Ramas, M. ....	98, 204, 247	Reenaers, C. ....	78
Procopet, B. ....	212	R-Lyons, R. ....	140	Ramavath, N. N. ....	48	Rees, C. J. ....	53
Prodigalidad, P. A. ....	114	Raafat, D. ....	168	Ramchandani, M. ....	153, 224, 242	Rees, M. ....	205
Proença, L. ....	178	Rabekova, Z. ....	198	Rameil, S. ....	142	Reeves, H. ....	40, 94, 102
Prokofiev, A. ....	156	Rabiner, E. A. ....	142	Ramió-Pujol, S. ....	148-149	Reggiani Bonetti, L. ....	160
Prokop, W. M. ....	217	Rabini, S. ....	243	Ramírez, E. ....	188	Regis, G. ....	164
Proskurina, A. ....	50, 241	Radaelli, F. ....	151, 175	Ramírez de la Piscina, P. ....	49, 232-233	Regula, J. ....	62, 67, 97, 100, 129, 151, 177, 222
Protic-Nedeljkovic, M. ....	140	Raderer, M. ....	78	Ramírez-de la Piscina, P. ....	49	Rehfeld, J. ....	126
Protopapas, A. ....	184	Radia, C. ....	192	Ramirez Maldonado, E. ....	171	Rei, A. ....	124, 207
Protopopov, M. ....	184	Radic, D. ....	207	Ramos Pires, S. I. ....	207	Reiberger, T. ....	65, 98, 125, 166-167, 212
Prott, G. ....	150	Radochova, V. ....	153, 232	Ramos-Zabala, F. ....	131	Reichert, M. ....	100, 150
Proux, A. ....	225	Radu, C. ....	120, 211-212	Ramos, A. ....	235	Reider, S. J. ....	206
Przybylska-Felus, M. ....	249	Radulescu, G. ....	143	Ramos, E. ....	189	Reijntjes, M. ....	146
Przysiecki, N. ....	206	Radulovic, K. ....	46	Ramos, G. ....	163, 223	Reim, D. ....	182
Przyluski, K. ....	98, 204, 247	Radwan, M. ....	252	Ramos, L. ....	49, 232-233	Reimao, S. ....	136
Ptak-Belowska, A. ....	228, 235	Radwan, P. ....	185	Ramos, M. F. K. P. ....	157	Reinacher-Schick, A. ....	173
Puce, F. ....	249	Rady, M. ....	124	Rampoldi, A. ....	179	Reines, T. ....	181
Pudilova, K. ....	235	Raeburn, A. ....	149, 242	Ran, Q. ....	70, 183	Reinisch, W. ....	80, 85, 97, 144-145, 187-188, 234
Puga-Tejada, M. ....	51-52, 154, 180	Raeisi Shahraki, H. ....	169	Rana, F. ....	127, 179	Reis, D. ....	208, 223, 251
Pugliese, A. ....	57	Rafael, M. A. ....	64	Rana, N. ....	70	Reis, J. ....	64, 134, 253
Pugliese, A. ....	234	Rafferty, H. ....	251	Rana, S. ....	187, 227	Reiter, B. ....	226
Pugliese, F. ....	179	Rafiq, S. ....	228	Rando, M. M. ....	162	Reitmeier, I. ....	183
Puig-Divi, V. ....	69, 110, 235	Raftopoulos, S. ....	80, 177	Rangelova, E. ....	56	Reitz, C. ....	202
Pujals, M. ....	87	Ragab, M. ....	135	Rania, Z. ....	100, 168, 212	Reizis, A. R. ....	123
Pujari, R. ....	215, 246	Ragea, A. I. ....	251	Raniolo, M. ....	177	Rejchrt, S. ....	153, 232
Pukkala, E. ....	50	Ragino, Y. ....	202	Rantanen, T. ....	172	Rekab, R. ....	168
Pumpo, R. ....	197	Ragunath, K. ....	62, 73, 98, 102, 177, 224, 243	Rashed, L. A. ....	169	Rembacken, B. ....	54, 57, 71, 129
Pungpapong, S. ....	170	Rahal, D. ....	224	Rashed, L. A. ....	169	Rassam, P. ....	130
Punkkinen, J. ....	198	Rahal, M. ....	241	Rashid, S. ....	120	Ratanachuek, T. ....	175
Pussig, B. ....	207	Rahamat-Langendoen, J. ....	170	Rassam, P. ....	130		
Putnina, L. ....	183-184, 189	Rahier, J. F. ....	55				
Puylaert, C. ....	231						

Remes-Troche, J. M.....	149	Riegler, G.....	140, 228	Robles-Medranda, C.....	51-52, 154, 180	Roelofs, H.....	57, 207, 250
Ren, J.....	142	Riemann, J. F.....	176	Roblin, X.....	75, 187, 233	Roepman, R.....	121
Rengarajan, A.....	198, 242-243	Riera, J.....	49	Roca, M.....	151, 162	Rogai, F.....	140
Renna, S.....	61, 140, 233	Riestra, S.....	49	Rocha, A.....	145	Rogers, B.....	198
Renner, J.....	220	Riestra Menéndez, S.....	93, 144, 188, 233	Rocha, C.....	186, 231	Rogler, G.....	36, 67, 71-72, 183
Repici, A.....	37, 67, 72, 78, 81, 92, 130, 181, 197, 218, 220, 224-225	Rietdijk, S.....	190	Rocha, H. C.....	184	Rohof, W.....	42
Repo, M.....	162	Riezzo, G.....	158	Rocha, M.....	145, 163-164, 202, 220, 253	Rohr-Udilova, N.....	125
Repšilber, D.....	52, 228	Rigo, A.....	146, 209	Röcken, C.....	210	Roine, A.....	172
Rerknimitr, R.....	221	Riley, S.....	243	Rockey, D.....	152	Rojas-Feria, M.....	247
Rescigno, M.....	63	Rimassa, L.....	123	Röder, H.....	189	Rojas-Mendoza, F.....	221
Restellini, S.....	185	Rimola, J.....	75, 141, 185	Rodinò, S.....	100, 150	Rokkas, T.....	98, 204, 247
Reszczyńska, M.....	239	Rimondi, A.....	157	Rodondi, P.-Y.....	140	Rolinski, J.....	211
Retamero Orta, M. D.....	49	Rinaldi, R.....	57	Rodrigo, L.....	98, 204, 247	Roliński, J.....	124
Reumkens, A.....	53, 85	Rinaldi, G.....	134	Rodríguez, A.....	187	Rolland, C.....	71-72
Reuterwall, M. H.....	56	Ringel, Y.....	51, 79, 136, 181, 183	Rodríguez, A.....	110, 180, 185	Rolo, R.....	114
Revilla Marti, P.....	50	Ringel-Kulka, T.....	51	Rodríguez, C. M. P.....	59, 166	Rolski, W.....	129
Rew, J. S.....	169	Ringström, G.....	195	Rodríguez, C. M. P.....	110, 123, 163, 169, 176, 178, 180, 185, 187, 250	Romain, O.....	135-136
Rewisha, E.....	124, 152	Rinninella, E.....	207, 211	Rodríguez, J.....	132, 134, 199	Román, M. B.....	148
Rex, D.....	85, 177	Rinsma, N.....	239	Rodríguez, J. P.....	132, 134, 199	Roman, S.....	43, 53, 58, 60, 102
Rey, J. W.....	129	Rinzivillo, M.....	245	Rodríguez, M.....	86	Romanciu, F.....	211
Rey, J.-F.....	224	Rios Leon, R.....	202	Rodríguez, P.....	59, 130, 147	Romańczyk, M.....	175
Rey Díaz-Rubio, E.....	188	Rios Vives, M. A.....	209	Rodríguez, P. M.....	59	Romańczyk, T.....	175
Reygosa, C.....	131	Ríos, R.....	232-233	Rodríguez, P. M.....	59	Romano, C.....	61
Reynolds, N.....	184	Riquelme Pérez, A. J.....	51	Rodríguez, P. M.....	59	Romberg-Camps, M.....	231
Reznichenko, A.....	228	Risch, L.....	206	Rodríguez-Pinto, E.....	173, 193, 225	Rombouts, K.....	57
Rhee, P.-L.....	198, 218	Rispens, T.....	188	Rodríguez, C.....	49, 144	Romeo, S.....	141
Rhimi, M.....	159	Rispo, A.....	186-187, 190	Rodríguez, E.....	216, 188	Romera, R.....	160
Rhys-Jones, G.....	188, 234	Rita Gonçalves, A.....	208	Rodríguez, E.....	216, 188	Romero, A.....	160
Ribaldone, D.....	160	Riu, F.....	198	Rodríguez, G. E.....	49	Romero, P.....	49
Ribeiro, H.....	122, 163, 167, 253	Rivera, M.....	153	Rodríguez, M.....	64, 167	Romero, R.....	131
Ribeiro, U.....	129, 138, 157	Rivero, L.....	192	Rodríguez, M.....	195, 236	Romero, R.....	49
Ribeiro Gomes, A. C.....	123, 163, 169, 176, 180, 185, 187, 250	Rivero, M.....	49, 93, 144, 188, 232	Rodríguez, S.....	160	Romero Castro, R.....	238
Ribes Koninckx, C.....	64, 151	Rivero Sánchez, L.....	95	Rodríguez, S.....	160	Romero García, T.....	247
Ribes-Koninckx, E.....	162	Rivero Tirado, M.....	49, 233	Rodríguez, S.....	160	Romero Mascarell, C.....	186
Ribichini, E.....	196, 242	Rivière, P.....	143, 194	Rodríguez, S.....	160	Romero Vazquez, J.....	125
Ribolsi, M.....	198, 200	Rivière, P.....	238	Rodríguez, S.....	160	Rommel, N.....	53, 70, 113
Ricart, E.....	49	Rivory, J.....	141, 177, 198	Rodríguez, S.....	160	Rompoteaux, M.....	179
Ricart Gomez, E.....	49, 93, 141	Riznik, P.....	161-162	Rodríguez, S.....	160	Rompoteaux, P.....	199
Riccardi, L.....	157, 163, 167, 211	Rizvi, O.....	249	Rodríguez, S.....	160	Ron, Y.....	195, 198, 231, 251
Ricci, C.....	128, 159, 172, 228, 247	Rizza, S.....	160	Rodríguez, S.....	160	Roncoroni, L.....	160, 248
Ricciardelli, C.....	150	Rizzatti, G.....	139, 141, 251	Rodríguez, S.....	160	Rondonotti, E.....	181
Ricciardiello, L.....	66, 79, 96	Rizzello, F.....	228	Rodríguez, S.....	160	Ronkainen, J.....	199
Riccioni, M.....	67	Rizzo, A.....	160	Rodríguez, S.....	160	Ronot, M.....	71
Riccioni, M. E.....	197	Rizzo, A. G.....	233	Rodríguez, S.....	160	Rooman, I.....	68
Rich, G.....	175	Rizzo, G.....	142	Rodríguez, S.....	160	Roos, V.....	191
Rich, J.....	158, 228, 239, 243	Rizzo, G. L.....	150	Rodríguez, S.....	160	Roque Ramos, L.....	140
Richard, M. L.....	182	Rizzuto, G.....	61, 228	Rodríguez, S.....	160	Rortveit, G.....	195
Richard, V.....	132	Robbins, A.....	140	Rodríguez, S.....	160	Rosa, B.....	71, 136, 166, 207, 225, 249
Richmond, E.....	62	Robert, M.....	134	Rodríguez, S.....	160	Rosa, I.....	130, 147, 183, 185, 231
Ricote Belinchon, M.....	74, 203	Robinson, A. M.....	142	Rodríguez, S.....	160	Rosa-Rizzotto, E.....	146, 150, 168, 170, 191, 213
Rieder, F.....	144	Robinson, D. J.....	194	Rodríguez, S.....	160	Rosario, M.....	198
Riedl, F.....	65	Robinson, K.....	234	Rodríguez, S.....	160	Rosati, R.....	236
Riedl, S.....	176	Robledo, P.....	144	Rodríguez, S.....	160	Rosberg, A.....	189
		Robledo Andrés, P.....	144	Rodríguez, S.....	160	Rösch, T.....	62

Rose, A. ....	100, 232	Ruskone - Fourmestaux, A. ....	160	Safroneeva, E. ....	69, 98	Salem, O. E. ....	114
Roseau, G. ....	179, 224	Russell, W. ....	139, 159	Saftoiu, A. ....	67, 77, 99, 114, 172	Salem, S. ....	169
Roseira, J. ....	141, 150, 206, 235, 238	Russello, M. ....	58	Safwat, E. ....	164	Salemme, M. ....	160
Rosendahl, J. ....	73, 116, 127	Russo, F. ....	158	Sagami, R. ....	128, 134, 157	Sales, T. ....	200
Rosenstiel, P. ....	51, 81, 96	Russo, F. P. ....	169	Sagar, V. ....	239	Salese, L. ....	61, 142, 187
Røseth, A. ....	231	Russo, P. ....	219-220, 240	Sagawa, T. ....	136	Salgado, M. ....	145
Rosianu, C. ....	181	Russo Raucci, A. ....	181, 236	Sağol, Ö. ....	156	Salgarello, M. ....	214
Roskams, T. ....	134	Rustamova, N. ....	208	Sahin, M. ....	140	Salihoum, M. ....	198, 219, 226
Rosón-Rodríguez, P. J. ....	131	Rustemovic, N. ....	157	Sahin-Toth, M. ....	50, 73, 217	Sallese, M. ....	249
Ross, P. ....	65	Rusu, I. ....	179	Sahm, V. ....	82	Sallinen, V. ....	126
Rossi, A. ....	140, 166, 210	Ruszkiewicz, A. ....	134	Sahnun, K. ....	228, 234	Sallun, R. A. A. ....	51
Rossi, F. G. ....	249	Ruths, S. ....	195	Saia, M. ....	146, 150, 168, 170, 191, 213	Salman, T. ....	165, 213
Rossi, G. ....	179	Rutka, M. ....	145, 180, 194, 232	Saibeni, S. ....	228	Saló, J. ....	148
Rossi, M. ....	195	Rutter, M. D. ....	47, 53, 74, 87, 93, 225	Said, Y. ....	162, 169, 212	Salomone Megna, A. ....	125
Rossi, R. E. ....	245	Ruvoletto, M. ....	167	Saiganov, S. ....	120	Salteniene, V. ....	229, 248
Rossi, S. ....	242	Ruzzarin, A. ....	169	Saint-Hill-Febles, Y. ....	220	Saltzman, J. ....	176
Rossitti, P. ....	161	Ryan, B. ....	130, 139-141, 181, 234	Sainz Arnau, E. ....	233	Salupere, R. ....	48, 185
Rosso, C. ....	48	Rybczynski, M. ....	58	Saiote, J. ....	240	Salvador, E. ....	121
Rostain, F. ....	177	Rydell, N. ....	151	Saisho, K. ....	155, 174	Salvador P. ....	71, 183-184
Rostami, K. ....	205	Rym, K. ....	171	Saitis, A. ....	168	Salvador Escribano, P. ....	86, 227
Roth, W. ....	150	Ryotokuji, T. ....	245	Saito, H. ....	88, 133, 178	Salvatori, F. M. ....	52
Rothenberg, M. ....	69	Ryozawa, S. ....	68	Saito, I. ....	175	Salvia, R. ....	49, 82
Rothlin, C. V. ....	227	Rysevaite, K. ....	240	Saito, K. ....	153, 215	Samaan, M. ....	141
Rotondano, G. ....	197	Ryu, C. B. ....	174, 219	Saito, S. ....	132-133, 178, 209	Samah, E. ....	132
Rotti, G. P. ....	59	Ryu, D. G. ....	186-187, 218, 245	Saito, T. ....	68, 157, 191	Sambuelli, A. ....	227
Rouanet, E. ....	124	Ryu, J. K. ....	136	Saito, Y. ....	47, 130, 132, 202	Sammarco, A. ....	170
Roumans, C. A. M. ....	83, 201	Ryu, Y.-J. ....	242	Sakae, H. ....	137	Samonakis, D. ....	168
Rousseau, A. ....	144	<b>S</b>		Sakaguchi, Y. ....	175	Sampaio, L. M. ....	209
Rousset, P. ....	71-72	Saad-Hossne, R. ....	229	Sakai, A. ....	127, 135, 179	Sampaziotis, F. ....	46
Rovedatti, L. ....	160	Saad, C. T. ....	244	Sakai, P. ....	51	Sampedro González, M. ....	233
Rowse, G. ....	187	Saad, H. M. ....	114	Sakai, T. ....	125, 128, 170	Sampietro, G. M. ....	160
Roy, M. ....	49	Saadeh, L. M. ....	138	Sakai, Y. ....	88, 176	San Juan Acosta, M. ....	152
Røyset, E. S. ....	142	Saadi, R. ....	130	Sakaki, N. ....	130	Sanaka, M. ....	60, 153, 219
Rozner, G. ....	148	Saadi, T. ....	176	Sakalinskiene, J. ....	146	Sanches, A. ....	199
Ruan, H. ....	236	Sabate, J. M. ....	194, 226	Sakalli Kani, A. ....	230	Sánchez, V. ....	192
Rubenstein, J. H. ....	62	Sabate, J.-M. ....	199	Sakamori, R. ....	134	Sánchez, V. ....	95
Rubin, D. ....	144	Sabatier, F. ....	61	Sakamoto, H. ....	61, 148, 160	Sánchez Alonso, M. ....	221
Rubin, D. T. ....	79, 187, 189	Sabelnikova, E. ....	195	Sakamoto, N. ....	80, 120, 155, 166, 225	Sanchez-Carriel, M. ....	154
Rubin, G. ....	50, 204	Saberi, F. ....	193	Sakamoto, T. ....	130, 132	Sanchez-Mete, L. ....	237-238
Rubio, S. ....	143	Sabet, J. ....	89	Sakata, Y. ....	81	Sanchez-Ocana, R. ....	52, 56, 223
Rudzite, D. ....	183-184, 189	Sabry, M. ....	169	Sakita, S. ....	197, 204	Sánchez-Temprano, A. ....	126
Rueda García, J. L. ....	187	Sacchi, M. C. ....	242	Sakuma, F. ....	128, 180	Sánchez-Yagüe, A. ....	131
Rueffer, A. ....	141	Saccomanno, L. ....	74, 204	Sakurai, T. ....	131, 159, 175, 178, 192, 194, 219	Sandberg, K. ....	228
Rueter, L. ....	232	Sacher-Huvelin, S. ....	135-136	Sakuramoto, S. ....	181, 251	Sandborn, W. ....	189, 234
Ruf, E. ....	176	Sadafumi, A. ....	174	Sakuyama, N. ....	148	Sandborn, W. J. ....	75, 79, 86, 97, 138, 142, 144, 230
Ruffa, A. ....	140-141	Sadagurschi, R. ....	231	Saladzinskas, Z. ....	240	Sanders, D. S. ....	160, 180, 205, 250
Ruffle, J. ....	95, 194	Saenz-Dana, M. ....	247	Salaga, M. ....	138	Sandler, J. G. ....	162
Rufini, V. ....	251	Safarikia, S. ....	100, 166	Salahi, H. ....	169	Sandra, I. ....	168, 213
Rugge, M. ....	92, 160, 196, 198, 203, 241, 244-246	Safarnezhad Tameshkel, F. ....	123	Salameh, E. ....	161	Sandri, G. ....	160
Ruiz, P. ....	125, 159	Safarpour, A. R. ....	167	Salas, A. ....	46, 63, 76	Sandrieser, L. ....	65
Ruiz Campos, L. ....	159, 249	Safatle-Ribeiro, A. V. ....	129	Salazar, L. ....	49, 232	Sandru, V. ....	94, 181
Ruiz-Gómez, F. ....	192	Safer, L. ....	240	Salcedo, M. T. ....	162	Sands, B. ....	63, 97, 188
Rumessen, J. ....	100, 205	Safin, A. ....	58	Saleh, S. ....	123	Sands, B. E. ....	97, 188
Rumyantseva, D. ....	154, 200	Safina, D. ....	58, 74, 235	Salehi, R. ....	193	Sanduleanu-Dascalescu, S. ....	53, 85
Rupinski, M. ....	177, 222			Salem, N. ....	135		
Rupnik, M. ....	152						

Sandulescu, L.....	213	Sato, D.....	176	Schatz, P.....	210	Schwab, P.....	64-65, 98, 125, 167, 212
Sandvik, A. K.....	142	Sato, H.....	153, 251	Schei, E.....	195	Schwalber, A.....	81
Sangro, B.....	40	Sato, J.....	151	Scheiner, B.....	65, 166-167, 212	Schwartz, D.....	48, 142
Sanguinetti, M.....	75, 138, 146	Sato, K.....	94, 134, 222	Schempf, U.....	163	Schwartz, M. P.....	148, 192
Sanna, G.....	159	Sato, S.....	156	Scherbakova, L.....	202	Schwartz, N.....	185
Sano, T.....	136	Sato, T.....	148	Scherm, S.....	122	Schwarzer, R.....	212
Sansoe', G.....	208	Sato, W.....	160, 205	Schettino, M.....	186	Schwarzler, J.....	70, 183
Sansone, S.....	177, 243	Sato, Y.....	134, 156, 170, 236	Schiavoni, E.....	139	Schwenk, J.....	228
Santander, C.....	64, 69-70, 243	Satoh, T.....	123	Schiepatti, A.....	205	Scialanga, F.....	207
Santander Vaquero, C.....	153	Satoshi, S.....	134, 157	Schiffino, L.....	150	Sciarretta, M.....	222
Santeusanio, G.....	160	Satou, D.....	177	Schina, M.....	168	Sciarrone, S. S.....	169, 208
Santiago, I.....	54	Satsangi, J.....	47	Schirren, R.....	182	Scida, S.....	198, 203, 244, 248
Santini, D.....	160	Sattianayagam, P.....	110	Schirrmeister, W.....	58	Scifo, G.....	58
Santo, E.....	134	Saunders, R.....	180	Schischmanoff, O.....	246	Scomparin, R.....	129
Santoni, A.....	61	Saurin, J. C.....	132, 135-136, 141, 221, 224	Schlag, C.....	199	Scott, C.....	81
Santoni, G.....	244	Sauvanet, A.....	128	Schledzewski, K.....	165	Scott, S. M.....	225
Santonicola, A.....	154, 161, 170	Sauvanet, P.....	70	Schlösser, S.....	122	Scribani, M.....	58
Santorio, A.....	206	Sav, R.....	212	Schmid, P.....	150	Scribano, L.....	168, 213
Santos, A.....	110, 145, 162, 196, 200	Savarino, E.....	41, 48, 60, 69, 150, 154, 182, 198-200, 230, 233, 243-244	Schmid, R. M.....	82, 126, 155, 200, 220	Scribano, M. L.....	140, 228
Santos, A. A.....	59	Saveljeva, S.....	70	Schmid, S. A.....	209	Scrivo, B.....	186, 231
Santos, A. L.....	110, 145, 162, 196	Savoia, M.....	210	Schmidbauer, S.....	176, 225	Searle, G.....	142
Santos, C.....	121	Savoye, G.....	84, 139, 229	Schmidt, A.....	89, 219	Sebastian, S.....	48, 185
Santos, L. D.....	245	Sawada, M.....	136	Schmidt, K.....	189	Sebepos-Rogers, G. M.....	151
Santos, M.....	145, 219, 252	Sawada, N.....	131	Schmitt, H.....	232	Seddik, H.....	164
Santos, S.....	121, 202, 219-220, 240, 253	Sawada, T.....	192	Schmitt-Graeff, A.....	58	Sedivy, P.....	211
Santos-Laso, A.....	166	Sawai, T.....	128	Schneglbberger, S.....	166	Seenan, J. P.....	234
Santos Nunes, L.....	64	Sawai, Y.....	158	Schneider, S.....	71	Seerden, F.....	149
Santucci, S.....	236	Sawatzki, M.....	124	Schnitzler, F.....	93, 189, 232	Seerden, T. C. J.....	148, 192
Sanyal, A.....	50	Saxena, P.....	137, 147, 201	Schoepfer, A.....	55, 69, 98, 101, 140	Seewald, S.....	84, 198
Sanz-García, A.....	243	Sayed, H. A.....	123	Schoeters, P.....	143	Segateli, V.....	138
Saoula, H.....	123	Sayed Hasan, M.....	122	Schöniger-Hekele, M.....	65	Segato, S.....	197
Saparapan Marques, C. F.....	138	Sbлатtero, D.....	161-162	Schoon, E. J.....	63, 88, 154-155, 172	Seguy, D.....	71
Saracco, M.....	233	Scaccianoce, G.....	150	Schor, S.....	182, 215	Sehn, M.....	183
Saracino, I. M.....	74, 159, 204, 247	Scaioli, E.....	72	Schorn, S.....	182, 215	Seibold, F.....	140
Sarafian, M.....	228, 234	Scaldeferri, F.....	70, 100, 138-139, 141, 150, 206, 229	Schottelius, M.....	218	Seicean, A.....	179, 185
Saraiva, M.....	173, 207, 251	Scalisi, I.....	58	Schramm, C.....	150, 240-241	Seicean, R.....	179
Saraiva, S.....	130, 169, 185, 193, 208	Scapa, E.....	134, 189	Schrauven, R. W. M.....	148-149	Seidler, U.....	152
Saray, A.....	172	Scarpa, M.....	138	Schrekenbach, T.....	202	Seidman, E.....	185
Sargur, R.....	205	Scarpellini, E.....	198	Schreiber, S.....	70, 76, 79, 85, 96-97, 130, 143-144, 189, 234	Seif Elnasr, M.....	247
Sarid, O.....	142	Scarpignato, C.....	150, 159, 198, 203, 244, 247-248	Schreuder, T.....	199	Seif, A.....	252
Sarin, S.....	64	Scarpulla, G.....	61	Schroeder, D.....	141	Seif, M.....	125
Saríos, P.....	127, 145, 171, 190	Scevola, F.....	206	Schrope, B.....	217	Seifi, V.....	169
Šarnelytė, J.....	122	Schaap, F.....	251	Schubert, L.....	71	Seitz, U.....	224
Sarter, H.....	139, 229	Schachschal, G.....	62	Schubert, S.....	190, 231	Sekharan, A.....	150
Sartori, A.....	170, 215	Schäfer, E.....	232	Schuchmann, M.....	122	Seki, M.....	152, 222
Saruta, M.....	133, 175, 204, 252	Schafmayer, C.....	210	Schulien, I.....	58	Sekigawa, K.....	129
Sarvani, A.....	207	Scharf, M.....	72	Schulz, A.....	150	Sekiguchi, A.....	242
Sarvepalli, S.....	60, 153, 219	Scharfiter, M.....	72	Schulz, C.....	37	Sekiguchi, M.....	47, 130
Sasahira, N.....	136	Scharl, M.....	71, 143, 183	Schulze, S.....	166	Sekine, A.....	222
Sasaki, K.....	110, 130, 226	Schattenberg, J.....	150	Schulze Pellengahr, S.....	210	Sekine, K.....	222
Sasaki, M.....	82, 218			Schumacher, B.....	219, 224	Sekine, S.....	191
Sasaki, T.....	136, 149			Schumann, M.....	64, 81, 183, 249	Sekine, S.....	202
Sasaki, Y.....	192			Schuppan, D.....	77, 81, 102	Seksik, P.....	46, 61, 75, 86, 144, 230-231
Sasanuma, S.....	132			Schwab, R.....	207	Seldenrijk, C.....	192
Sassaki, L.....	229					Seldenrijk, C. A.....	63, 154
						Selem, S.....	223
						Selema, P.....	143



Sellarès Nadal, J.....	209	Sezgin, B.....	244	Shibata, N.....	173, 217	Shpak, B.....	181
Semela, D.....	124	Sgambato, A.....	138-139	Shibata, T.....	132	Shringarpure, R.....	50
Semeraro, C.....	150	Sha, J.....	110	Shibatoge, M.....	158	Shu, X.....	196
Semeraro, R.....	92, 181, 218, 225	Sha, W.....	189	Shiber, S.....	234	Shukla, S.....	187, 227
Semmler, G.....	212	Shackelton, L.....	138	Shibolet, O.....	48	Shuleshova, A.....	154
Sempere Robles, L.....	93, 232	Shafaghi, A.....	247	Shibuya, H.....	60	Shumkina, L.....	137, 182
Semyakina, A.....	227	Shafayat, A.....	53	Shichijo, S.....	88, 158, 174	Shuno, Y.....	226
Sen Sarma, M.....	146, 162, 171	Shah, A.....	50, 158, 221, 228, 239, 243	Shiffman, M.....	177, 123	Shvets, O.....	98, 204, 247
Sendino, O.....	186	Shah, S.....	133-134, 220	Shifrin, O.....	185, 238	Si, J.....	204
Sendino Garcia, O.....	158	Shahbazi, A.....	197	Shigematsu, H.....	123	Siakavellas, S.....	229
Sendra, P.....	164, 233	Shahini, E.....	248	Shigemori, K.....	158	Sibia, C.....	229
Seneviratna, A.....	178	Shaib, Y.....	241	Shigeyasu, K.....	227	Sicília Aladrén, B.....	49, 144
Sengun, B.....	220	Shalaby, S.....	169	Shiina, S.....	178	Sicília, B.....	93, 144
Sengupta, A.....	234	Shalev, Y.....	191	Shim, C. S.....	125	Siciliano, M.....	167, 211
Sengupta, S.....	131	Shaleve, V.....	88	Shim, J. H.....	69	Sidani, S.....	239
Senkerikova, R.....	169	Shamsaefar, A.....	169	Shim, Y. M.....	218	Siddappa, P. K.....	216
Seno, H.....	50	Shanahan, E.....	95, 243	Shimada, T.....	157	Siddiqui, A.....	56
Senturk, H.....	172, 180, 237	Shanahan, F.....	70, 103	Shimada, Y.....	156	Siddiqui, H. A. B.....	122
Senzolo, M.....	169	Shand, A.....	234	Shimamoto, F.....	53	Sidhu, M.....	80, 85, 91, 177
Seo, A.....	201, 215	Shannon, B.....	75	Shimamura, Y.....	201	Sidhu, R.....	160, 180, 205, 218, 249-250
Seo, A. N.....	215, 237	Shapina, M. V.....	186	Shimatani, M.....	223	Sidoli, L.....	228
Seo, D. W.....	128	Shapiro, D.....	50, 77, 123	Shimizu, H.....	57, 183	Siebler, J.....	225, 241
Seo, D.-W.....	50, 69, 125, 181, 223	Shapiro, J.....	191	Shimizu, K.....	146	Sief, S.....	135
Seo, J. H.....	169, 207, 244	Shapovaliantc, S.....	154	Shimizu, M.....	99, 181	Siegelman, J.....	75, 185
Seo, K. I.....	234	Shapovalianz, S.....	136	Shimizu, R.....	76	Siegmund, B.....	36, 55, 64, 85, 91, 183
Seoane-Mosteiro, C.....	126	Sharaiha, O.....	245	Shimizu, Y.....	155, 225	Sierra-Ausin, M.....	143
Seol, M. J.....	96, 191	Sharar, A.....	241	Shimoda, S.....	123	Sierra Morales, M.....	202
Seow, H.....	139	Sharif, O.....	55, 214	Shimodate, Y.....	130, 152	Siersema, P. D.....	37, 77, 94, 148-149, 192, 238
Sequeira, C.....	150	Sharma, D. J.....	216	Shimoyama, T.....	158-159	Sifrim, A.....	57
Serafentiniadis, I.....	221	Sharma, M.....	69-70, 187, 227, 252	Shimoyama, Y.....	242	Sifrim, D.....	69, 153, 199-200
Seraphim, A. M.....	209	Sharma, P.....	48, 62, 73, 245	Shin, C. M.....	191	Signoretti, M.....	49, 52, 180, 216
Serebrova, S.....	156	Sharma, S.....	222	Shin, C.-M.....	96, 157, 203, 239	Siguairo, O.....	167
Serebrovskaya, L. V.....	123	Sharrack, N.....	175	Shin, D. W.....	156, 239	Sihag, S.....	130
Sergeev, I.....	79, 136	Shater, M.....	164	Shin, G.-Y.....	156	Siham, N.....	213
Serghini, M.....	228	Shaun Russell, W.....	159	Shin, S.....	133, 226, 244	Sihuay, D.....	209
Serghiou, S.....	63	Shava, U.....	137	Shin, S. K.....	226	Sikafi, R.....	110
Sergienko, R.....	142	Shavakhi, A.....	193, 197, 239	Shin, S. P.....	133	Silano, M.....	160
Serra, C.....	128	Shavakhi, S.....	239	Shin, S. Y.....	146, 176, 244	Silkueniene, G.....	151
Serra, J.....	47, 98, 150, 198	Sheble, N.....	214	Shin, U. S.....	238	Silva Fernandes, J.....	134
Serra-Pagès, M.....	148-149	Shekhar, C.....	76	Shin, Y.-W.....	224, 241	Silva, A. P.....	123, 169, 176, 180, 185, 187
Serraino, D.....	169, 218	Shelton, J.....	53	Shinagawa, T.....	130	Silva, J.....	202
Serrano, M.....	148-149	Shen, J.....	243	Shinbo, K.....	149	Silva, J. C.....	110, 123, 132, 134, 163, 169, 176, 178, 180, 185, 187, 199, 250
Serrero, M.....	61, 188	Shen, M.....	71, 138, 158, 215	Shinmura, K.....	88, 149, 176-177	Silva, M.....	110, 186, 190, 212, 250
Servajejan, C.....	188	Shen, X.-Z.....	154	Shinozaki, S.....	61, 160	Silva, M. J.....	163, 220, 223, 240
Sese, E.....	49	Shen, Y.....	124	Shintani, S.....	179	Silva, P.....	183
Sesê, E.....	49, 93	Sheriff, M. Z.....	184	Shiode, J.....	209	Silva, R.....	82, 153, 200
Sessa, A.....	207	Sheron, N.....	56	Shiomi, H.....	127, 135, 179	Silverberg, M. S.....	75, 142, 185
Sessa, F.....	160	Shestak, I.....	146	Shiozawa, S.....	155	Silvestrova, S.....	195
Sestito, L.....	162	Shetty, S.....	221	Shiraishi, R.....	114	Silviu, N.....	124, 210
Sethi, A.....	135, 217	Sheu, B.-S.....	147	Shirasaka, D.....	133	Sim, D. W.....	207
Seufferlein, T.....	57, 88, 99, 110, 173, 216, 224	Shi, Q.....	128	Shirasaki, T.....	71, 183		
Sevastianos, V.....	168	Shiba, M.....	129, 134	Shirin, H.....	89, 202		
Sever, N.....	74	Shibamoto, A.....	174	Shishin, K.....	137, 182		
Severi, C.....	243	Shibata, C.....	152, 222	Shitani, M.....	222		
Seves, I.....	219	Shibata, J.....	88	Shivaji, U.....	176, 235, 241		
Sevilla-Ribota, S.....	52, 56, 223			Shivaji, U. N.....	138, 241		
Seward, E.....	176			Shivarajan, A. A.....	201		
				Shiwaku, H.....	73, 161		
				Shonova, O.....	185		

Sima, A. ....	124, 210	Smith, A. ....	53, 56, 93	Sonnenberg, S. ....	127	Spiniello, L. ....	211
Simanankov, V. ....	203	Smith, M. D. ....	204	Sood, R. ....	129	Spinzi, G. ....	157, 197
Simão, A. L. ....	59	Smith, S. ....	94, 138, 176, 197, 203, 235	Soonasra, A. ....	97, 188	Spivak, E. ....	161, 171
Simão, I. ....	238	Smith, S. C. L. ....	138	Sopheno Falco, J. ....	131	Spivak, M. ....	206
Simbrunner, B. ....	125	Smits, R. ....	82, 201	Soria-Alcivar, M. ....	51-52, 154, 180	Sporea, I. ....	124, 210, 212-213
Simedrea, I. ....	190	Smolynchuk, E. ....	156	Soriani, P. ....	246	Sportes, A. ....	226
Siminkovitch, S. ....	217	Smoot Malecha, E. ....	77, 123	Soriano, J. ....	142	Sprakes, M. ....	209
Simões, C. ....	121-122, 164, 230, 252-253	Smout, A. ....	49, 60	Soriano, S. ....	196	Sprange, K. ....	53
Simões, G. ....	202, 220, 253	Smrekar, N. ....	74, 144	Soriano-Gabarró, M. ....	50	Sprinzl, M. ....	150
Simões, M. A. ....	197, 238-239	Smtih, J. ....	136	Sorrentino, D. ....	227	Squadrito, G. ....	58
Simon-shane, C. ....	135	Snazelle, O. ....	175	Soru, P. ....	180	Sremac, M. ....	157
Simon, M. ....	75	Snijder, R. ....	197	Sostres, C. ....	219, 237	Srivastava, A. ....	146, 162, 171
Simón, M. A. ....	219	So, H. ....	50	Sostres Homedes, C. ....	50	Srivastava, B. ....	186
Simon, T. ....	144	So, I. T. ....	173	Sotiropoulou, M. ....	221	Stabuc, B. ....	74, 138, 144
Simonelli, C. ....	75, 146	So, K. ....	143	Soto, J.-L. ....	192	Staettermayer, A. F. ....	167
Simonova, M. ....	169	Soares, J. B. ....	114, 231	Soto, N. ....	140	Stafylidou, M. ....	207, 209, 212
Simrén, M. ....	43, 49, 76, 86, 103, 138-139, 191, 194-195, 239, 250	Sobrinho López, A. ....	221	Soub Defeu, W. ....	92	Staiani, M. ....	196, 202
Simsek, H. ....	98, 204, 247	Socaciu, C. ....	120, 211	Sousa, C. ....	121	Staiano, A. ....	93, 190
Sina, C. ....	101	Sochal, M. ....	228	Sousa, D. ....	206	Staiano, L. ....	170
Sinakos, E. ....	168	Sofue, K. ....	127	Sousa, M. ....	110, 121, 123, 132, 134, 163, 169, 176, 178, 180, 183, 185, 187, 199, 231, 250	Stampori, M. ....	168
Singh, J. ....	137	Sofuni, A. ....	136, 171	Sousa, R. ....	122, 167	Stanciu, C. ....	205-206, 213
Singh, R. ....	80, 126-127, 177	Soh, J. S. ....	185, 192	Sousa, X. ....	169	Stancu, O. ....	212
Singh, S. K. ....	171	Sohn, C. I. ....	147	Sousa Andrade, C. ....	110, 167, 211, 216, 252	Stanghellini, V. ....	38, 52, 57, 72, 78, 86, 235, 239, 243
Sinha, S. K. ....	187, 216, 226-227	Sohn, K. M. ....	121	Sousa Ferreira, H. ....	250	Stangl, S. ....	218
Singh Chandan, J. ....	227	Soini, E. ....	231	Souza, X. ....	164	Stanislas, C. ....	219, 245
Sinagina, M. ....	74, 235, 247	Sokic Milutinovic, A. ....	233	Souza Moura, M. ....	153, 200	Stankovic, S. ....	141, 206
Sinn, D. H. ....	50	Sokol, H. ....	70, 86, 100, 144, 182, 191, 230	Souza, M. ....	153, 200	Stanley, A. J. ....	50
Sipponen, P. ....	246	Sokolov, K. ....	200	Souza, T. F. ....	110	Stanton, I. ....	228
Siproudhis, L. ....	185, 232-233	Sokolov, V. ....	208	Sovran, B. ....	182	Starcevic Manning, M. ....	187-189
Siquini, W. ....	198	Solcia, E. ....	160	Soweid, A. ....	241	Starkov, Y. ....	137
Siringo, S. ....	61	Solina, G. ....	160, 233	Soydal, Ç. ....	246	Starostin, B. ....	158
Sirli, R. L. D. ....	124, 210, 212-213	Solińska, A. ....	137	Soykan, I. ....	243, 246	Starzynska, T. ....	217
Sirvent, P. ....	70	Solitano, V. ....	234	Spaan, C. N. ....	236	Stassen, L. ....	53
Sjölund, J. ....	191	Solito, S. ....	161	Spaander, M. C. W. ....	58, 77, 80, 82-83, 87, 95, 151, 158, 193, 201	Stattermayer, A. F. ....	212
Skaaby, T. ....	205	Sollelis, E. ....	231	Spada, C. ....	39, 67, 72, 78, 102, 128, 176	Staubert, R. E. ....	211
Skacel, E. P. ....	201	Soltys, K. ....	228	Spadaccini, M. ....	220	Staudacher, H. ....	43, 88, 96
Skarbalieni, J. ....	139	Somani, P. ....	69-70	Spaho, L. ....	124	Staufner, K. ....	211
Skiećeviciene, J. ....	121, 229, 240, 246, 248	Somers, I. ....	182	Spalinger, M. R. ....	71, 143, 183	Stebbing, J. ....	227
Skok, P. ....	152	Sommerer, I. ....	126-127	Spallone, L. ....	224	Stecker, K. ....	50, 238
Skordilis, K. ....	138	Soncini, M. ....	157, 181, 197	Spanier, B. W. M. ....	148, 192	Stefanelli, G. ....	248
Skroubis, G. ....	146	Song, B. G. ....	198	Sparchez, Z. A. ....	212	Stefanescu, H. ....	120, 211-212
Skrypnik, I. ....	211	Song, D. J. ....	96, 156, 191	Sperber, A. ....	195	Steffen, H.-M. ....	240-241
Skuja, V. ....	183-184, 189	Song, E. M. ....	176, 187, 192	Sperling, J. ....	169	Steiger, K. ....	126
Skytt Andersen, P. ....	186	Song, H. J. ....	218	Sperling, F. ....	173	Stein, A. ....	136
Slaney, E. ....	235	Song, H.-J. ....	246	Speroni, S. ....	196, 203, 246	Stein, D. ....	143
Slangen, R. ....	149	Song, J. ....	206	Sperti, C. ....	208, 252	Stein, J. ....	80, 186-187, 232, 251
Slim, M. ....	211	Song, J. H. ....	202, 237	Spessotto, P. ....	218	Steiner, H. ....	82
Sliwowski, Z. ....	235	Song, K.-H. ....	201	Spicak, J. ....	161, 169, 174, 198, 224	Steinert, R. E. ....	161
Slinim-Nevo, V. ....	142	Song, S. Y. ....	136	Spigset, O. ....	142	Steinhart, A. H. ....	142, 185
Sluiter, J. K. ....	190	Song, T. ....	69	Spiller, R. ....	38, 190, 225	Steinsvik, E. K. ....	199
Smart, H. ....	62	Song, T. J. ....	69	Spina, L. ....	140, 157	Stella, D. ....	127
Smeets, X. J. N. M. ....	216	Song, T.-J. ....	181	Spinelli, A. ....	91, 111	Stellingwerf, M. ....	146
Smid, V. ....	211	Song, X. ....	209	Sonne, K. ....	159	Stemate, A. ....	231
Smirnov, A. ....	198	Song, Y. ....	47, 143, 159, 210, 227				
Smit, W. L. ....	236	Soni, M. ....	143				

Stenman, U.-H. ....	172	Su, F. ....	137	Sundin, J. ....	138, 194	Sztembis, J. ....	228-229
Stepan, A.-M. ....	212	Su, T. ....	96, 205, 236	Sung, J. J. Y. ....	227, 236	Sztofksiz, C. Z. ....	209
Stephan, B. ....	124	Su, W. ....	165	Sung, J. K. ....	156, 201	Szymanska, A. ....	221-222
Stephens-Muench, N. ....	200	Su, Y.-C. ....	153	Supper, P. ....	125		
Steponaitiene, R. ....	246	Suarez-Farinas, M. ....	63	Suraci, E. ....	195	<b>T</b>	
Sternini, C. ....	57, 239	Suarez Ferrer, C. ....	187	Surdacka, A. ....	211	Taavela, J. ....	162
Stevens, T. ....	86, 138, 142	Subotic, B. ....	189	Surlin, V. ....	172	Taberna-Arana, L. ....	133
Stevenson, D. J. ....	204	Subramaniam, S. ....	62, 81, 85	Surmiak, M. ....	228, 235	Tabone, T. ....	225
Stevenson, J. ....	201	Subramanian, V. ....	93, 251	Sutti, S. ....	48	Taborelli, M. ....	169
Stift, J. ....	125, 211-212	Sucena, M. ....	121	Sutton, R. ....	68, 73	Tabu, K. ....	59, 213
Stigliano, S. ....	216	Suchanek, S. ....	95, 151, 177, 224, 236	Suveran, M. ....	213	Tacheci, I. ....	153
Stigliano, V. ....	237-238	Suciu, A. ....	120, 211	Suzuki, A. ....	134, 178	Tachikawa, J. ....	132, 193
Stimac, D. ....	172	Sud, R. ....	175	Suzuki, H. ....	147, 177, 192, 198, 202	Tack, J. ....	43, 49, 71, 78, 153, 195, 198-199, 205, 207, 242, 245, 250
Stirand, P. ....	198	Suda, G. ....	166	Suzuki, K. ....	132-133, 159, 209, 221	Tacke, F. ....	51, 55, 78, 94
Stiuso, P. ....	121	Suda, K. ....	163, 182	Suzuki, R. ....	170, 223	Tackoen, J. ....	250
Stodtmann, S. ....	143	Suda, T. ....	134	Suzuki, S. ....	60, 66, 176	Tada, M. ....	134, 215
Stojanovic, M. ....	206	Sudikiene, R. ....	252	Suzuki, T. ....	134	Tada, T. ....	88, 133, 158
Stojkovic, M. ....	141, 206	Suehiro, S. ....	128	Suzuki, Y. ....	80, 125, 245	Taddei, G. ....	214
Stojkovic Lalosevic, M. ....	123, 141, 206	Suen, B. Y. ....	69	Svegl, P. ....	144	Tag-Adeen, M. ....	139, 172
Stoker, J. ....	53, 231	Sueyoshi, H. ....	134	Svistunov, A. ....	156	Tagawa, K. ....	152, 222
Stoklosa, T. ....	137	Sueyoshi, Y. ....	219	Svorcan, P. ....	140	Tagawa, T. ....	130
Stolfi, C. ....	138	Sugai, T. ....	146, 156, 177, 192	Svrcek, M. ....	54, 87	Taghavi, S. A. ....	212
Storato, S. ....	214	Sugano, K. ....	74, 79	Swager, A.-F. ....	155	Taglieri, E. ....	209
Storm, G. ....	210	Sugahara, Y. ....	137	Swahn, F. ....	62, 116	Taharouchet, B. ....	125
Storonova, O. ....	154, 200, 238	Sugimori, M. ....	232	Swallow, K. ....	205	Taher, H. ....	127
Störsrud, S. ....	195, 250	Sugimori, S. ....	81	Swartz, A. ....	151	Tahir, F. ....	176
Stöß, C. ....	166	Sugimoto, A. ....	131	Sweis, R. ....	153, 241-242	Tai, C. ....	100, 188
Stotzer, P.-O. ....	138	Sugimoto, M. ....	170, 179, 217, 246	Sy, M. L. ....	151	Tai, F. W. D. ....	218
Stoupaki, M. ....	221	Sugimura, M. ....	94, 148	Syafiq Ismail, M. ....	181	Tai, W.-C. ....	159, 178
Straathof, J. W. A. ....	53, 85	Sugino, T. ....	151	Syed, A. ....	65, 95, 173	Tai, Y. ....	121, 165
Strahilevitz, J. ....	146	Sugino, Y. ....	147	Szabo, F. ....	65	Taida, T. ....	52
Strand, D. ....	56	Sugiura, R. ....	120	Szabo, G. ....	124	Tailleur, A. ....	132
Straub, B. ....	48	Sugiyama, T. ....	74	Szabó, I. ....	171, 178	Taira, K. ....	129, 134, 196
Straumann, A. ....	69, 98	Sugiyama, Y. ....	197, 204	Szabó, Ö. ....	194	Taiymi, A. ....	251
Straume, Z. ....	50, 241	Sugizaki, K. ....	74	Szabone Dr Salamon, Á. ....	232	Tajiri, H. ....	73, 81
Strayer, S. ....	151	Suguro, M. ....	131	Szachniewicz, M. ....	55	Takabatake, H. ....	152
Streit, A. ....	75	Suk, K. T. ....	133	Szakács, Z. ....	130, 249	Takács, P. ....	229, 234
Streleckiene, G. ....	248	Sukhin, D. ....	208	Szakó, L. ....	126, 130	Takács, T. ....	126-127, 171
Stremmel, W. ....	80, 187	Sukovas, A. ....	151	Szalai, M. ....	177, 181, 224	Takada, K. ....	151
Stretton, M. ....	241	Sulbaran, M. ....	250	Szamosi, T. ....	229, 232, 234	Takagi, K. ....	152, 222
Strid, H. ....	138-139	Suligoj, T. ....	235	Szántó, K. ....	145, 180, 194, 229, 232, 234	Takagi, S. ....	160, 205
Strijker, M. ....	215	Sultan, A. M. ....	169	Szcerbinski, M. ....	211	Takagi, T. ....	170, 248
Strik, A. ....	188	Sümeği, J. ....	171	Szegedi, A. ....	187	Takahara, N. ....	134, 215
Strippoli, G. F. M. ....	158	Sumi, K. ....	197	Szely, N. ....	75	Takahashi, A. ....	155, 246
Strömbeck, A. ....	138	Sumida, Y. ....	133, 172, 178, 225	Szentesi, A. ....	65, 126-127, 134, 171, 217	Takahashi, J. ....	57, 183
Stroppa, I. ....	150	Sumiyama, K. ....	175, 252	Szentkereszty, Z. ....	126	Takahashi, K. ....	123, 127, 133, 153, 159, 173, 217
Struyvenberg, M. R. ....	155	Sumskiene, J. ....	121	Szepes, A. ....	127	Takahashi, M. ....	222
Stuchlík, S. ....	228	Sun, A. ....	206	Szepes, A. Z. ....	177	Takahashi, N. ....	184, 192
Stückle, J. ....	218	Sun, D. ....	189-190	Szepes, Z. ....	126-127, 134, 145, 171, 179-180, 194, 232	Takahashi, S. ....	138, 178, 236
Stueker, D. ....	163	Sun, H. ....	203	Sun, S. ....	129	Takai, A. ....	50
Stupakov, P. ....	82	Sun, Y. ....	206	Sun, Y. ....	159	Takamaru, H. ....	130, 132, 202
Stuppner, H. ....	206	Suna, N. ....	122	Sunada, K. ....	61, 160	Takamatsu, H. ....	184
Sturdik, I. ....	126, 228	Sunada, K. ....	61, 160	Sunaka, K. ....	176-177	Takamoto, A. ....	209
Sturm, A. ....	85, 232	Sunakawa, H. ....	176-177	Sundaralingham, P. ....	191	Takano, K. ....	136
Sturm, S. ....	206	Sundaram, S. ....	123	Sundaram, S. ....	123	Takano, Y. ....	222
Sturmiolo, G. C. ....	146, 209, 228			Szűjártó, A. L. ....	145	Takaoka, M. ....	223
Su, C. ....	79, 97, 145, 187-188						

Takaoka, S.....	125, 129, 203, 232, 245	Tanabe, S.....	89, 129	Tavares de Sousa, H.....	141, 150	Theocharis, S.....	134
Takasago, T.....	225	Tanaka, F.....	129, 134, 196	Tavares Sousa, H.....	186, 190	Theodorou, V.....	194, 238, 250
Takasaki, Y.....	178	Tanaka, K.....	127, 134, 173-174, 217	Tavares Sousa, M. H.....	183, 231	Theofanopoulou, A.....	248
Takase, K.....	181, 251	Tanaka, M.....	149, 157, 222	Taveira, F.....	193	Theou-Anton, N.....	246
Takashima, K.....	176-177	Tanaka, R.....	171	Taverniti, V.....	235	Thieringer, F.....	150, 175
Takashina, Y.....	220	Tanaka, S.....	53, 133, 147, 155, 160, 205	Taxonera Samso, C.....	188	Thijs, W. J.....	46
Takasu, A.....	131, 146, 173	Tanaka, T.....	127, 130, 135, 143, 155, 174, 179, 190, 226	Taxonera, C.....	49, 93, 143, 232-233	Thimme, R.....	58
Takasumi, M.....	170	Tanaka, Y.....	127, 130, 135, 143, 155, 174, 179, 190, 226	Taylor, D.....	206	Thind, K.....	219
Takatori, Y.....	167	Tanaka, Y.....	121, 165, 172, 216, 237	Taylor, A.....	221	Thisarana Wijayaratne, G.....	208
Takats, Z.....	237	Tang, C.....	121, 165, 172, 216, 237	Taylor, S.....	84, 102, 225, 231	Thomas, A.....	190
Takatsuki, M.....	130	Tang, M. T.....	189	te Morsche, R.....	207	Thomas, J. P.....	236
Takayama, S.....	248	Tang, S.....	121, 165, 172, 216	te Morsche, R. H. M.....	121	Thomas, M.....	68, 85, 103
Takayama, T.....	236	Tang, T. J.....	149	Techathuvanana, K.....	59	Thomas, T.....	227, 251, 253
Takeda, H.....	50	Tange, K.....	173, 217	Techawathanawanna, S.....	215	Thomas-Gibson, S.....	39, 80
Takeda, K.....	132-133, 175, 192, 194, 220-221	Tanigawa, T.....	129, 134, 196	Tegtbur, U.....	142	Thomas-Salom, G.....	131
Takeda, Y.....	170	Taniguchi, H.....	158, 211, 243	Teich, N.....	233	Thomassin, J.....	135
Takehara, T.....	134	Taniguchi, Y.....	170	Teixeira, A.....	163	Thome, M.....	89
Takei, K.....	81, 173	Tanikawa, C.....	58	Teixeira, A. L.....	121	Thomopoulos, K.....	146
Takemoto, K.....	81, 173	Tanimoto, T.....	88, 133, 219	Teixeira, V.....	202	Thompson, A.....	229
Takemoto, S.....	88, 176	Tanis, P.....	137, 146, 238	Tejedor, J.....	56	Thorburn, D.....	223
Takenaga, M.....	238	Tanis, P. J.....	137, 238	Tejedor, M.....	195	Thorkildsen, C.....	139
Takenaka, R.....	81, 155, 173	Tankova, L.....	230	Tél, B.....	65	Thorpe, A. J.....	97, 145
Takeuchi, N.....	200	Tannapel, A.....	141, 173	Teleky, B.....	234	Thorpe, S.....	62
Takeuchi, T.....	200	Tantau, A.....	217	Telese, A.....	57, 91	Thorsgaard, N.....	185
Takeuchi, Y.....	174, 176, 180	Tantau, M.....	53, 68, 120, 212, 217	Teller, S.....	82, 89, 127	Thota, P. N.....	60, 153, 219
Takezawa, R.....	130	Tanudisastro, M. P.....	147	Télez, L.....	71, 202	Thuesen, B. H.....	205
Takezawa, T.....	61, 160	Tanwar, S.....	163, 208	Télez, L.....	71, 202	Thunga, C. K.....	146
Takigawa, Y.....	127, 173, 217	Tao, K.....	133, 178, 225	ten Bokkel-Huinink, S.....	182	Thurm, T.....	198, 224
Takahara, H.....	139	Tarabar, D.....	97, 144, 189	Tenca, A.....	190, 223	Thurston, V.....	218
Takiyama, H.....	130, 158	Tarallo, M.....	61, 142	Tenthof - van Noorden, J.....	197	Tian, D. A.....	152
Takizawa, K.....	151, 201	Tarantino, I.....	52-53	Tepe, B.....	204	Tian, T.....	165
Talani, A.....	222	Targan, S.....	97	Tepes, B.....	65, 67, 98, 247	Tian, X.....	215
Talar-Wojnarowska, R.....	228	Targosz, A.....	235	Ter Borg, F.....	148-149, 192, 238	Tianu, E.....	224
Talkhan, M.....	125, 162, 164	Tari, A.....	74	Terai, S.....	153	Tielbeek, J.....	231
Talley, N. J.....	72, 95, 158, 184, 195, 199, 205, 228, 239	Tari, R.....	224	Teraishi, F.....	227	Tiele, A.....	140
Tamai, T.....	59, 213	Tarli, C.....	162	Terán-Lantarón, A.....	131	Tilg, H.....	35, 46, 70, 96, 183, 206
Tamaki, H.....	158	Tarnasky, P.....	133, 135	Terao, T.....	173, 217	Timar, R.....	124, 210
Taman, S.....	168	Tarnok, A.....	190	Terhaar Sive Droste, J. S.....	148	Timmer, R.....	46, 85
Tamaru, Y.....	53, 133, 178, 225	Tartakover Matalon, S.....	183	Terracciano, G.....	196, 200, 230	Timmermans, L.....	207
Tamburrino, D.....	57	Tarticchio, G.....	192	Terry, H.....	232	Tinozzi, F. P.....	57
Tamegai, Y.....	132, 178	Taruka Jayasuriya, P.....	208	Tertychnyy, A.....	185	Tinsley, A.....	187
Tamelis, A.....	150, 240	Tasayco Huaman, S.....	208	Terveer, E. M.....	75	Tirado, P. R.....	227
Tamim, H.....	182, 241	Tashima, S.....	59, 213	Teshima, C.....	201	Tishkov, I.....	157
Tammer, I.....	247	Tassi, A.....	196	Tesori, V.....	206	Tishlavicz, L.....	179-180
Tamura, T.....	53, 134, 174	Tate, D. J.....	80, 85, 91, 177, 224	Tessolini, J.....	75, 142	Tjalma, J. J. J.....	137, 194
Tan, A. C.....	46	Tato Marinho, R.....	164, 208, 223, 252	Tessone, L.....	227	Tjwa, E. T. T. L.....	170, 210
Tan, D.....	223	Tatsoy, A.....	189-190	Testa, A.....	140, 186-187, 190, 228	Tkacheva, O.....	161
Tan, J.....	139, 227	Tatsuguchi, A.....	160, 205	Testoni, P. A.....	179, 181, 236	To, K. F.....	58, 147, 151, 246
Tan, M. Y. D.....	209	Tatsumi, N.....	174	Testoni, S. G. G.....	179	Tobin, A. M.....	141
Tan, N.....	200	Tatsumi, T.....	134	Tetsuya, N.....	71	Toda, N.....	152, 222
Tan, T. G.....	199	Tatsuse, T.....	191	Teuber, G.....	251	Todd, J.....	184, 197, 208
Tan, W.....	53	Täuber, V.....	204	Thabut, D.....	35, 40, 79, 102, 109	Todoerti, K.....	63
Tan, Y.....	147, 163			Thakkar, S.....	65, 95, 173	Toes-Zoutendijk, E.....	87, 191
Tan, Y.-Y.....	163			Thapar, N.....	55, 137	Toex, U.....	219
				Thayalasekaran, S.....	81, 85, 133	Togashi, K.....	176
				Theocharis, G.....	146	Togawa, O.....	68
						Toka, B.....	198, 241-242

Tokairin, Y. ....	245	Toyonaga, H. ....	170	Tsigaridas, A. ....	181	<b>U</b>	
Toki, M. ....	179	Toyoshima, N. ....	131-133, 192, 194, 219-220	Tsilkos, K. ....	187	Ubezio, C. ....	229
Tokodi, I. ....	65, 162	Toyoshima, O. ....	58	Tsochatzis, E. ....	59, 66	Ubierto, V. ....	158
Tokuhara, M. ....	223	Toyoshima-Kawabata, Y. ....	138	Tsolias, C. ....	146, 168	Uc, A. ....	59
Tokushige, K. ....	141, 145, 243	Tozer, P. ....	228, 234	Tsoukali, E. ....	181, 185	Ucar, E. ....	168
Tollens, T. ....	187	tozlu, M. ....	241	Tsoutsman, T. ....	137, 201	Uchida, D. ....	217
Tolone, S. ....	69, 101, 106, 154, 182, 196, 199-200, 230, 243-244	Trad, D. ....	171	Tsuchida, C. ....	180	Uchida, K. ....	89, 131
Tomai, M. ....	177	Tragust, J. ....	206	Tsuchida, K. ....	128, 180	Uchima Koecklin, H. ....	221
Tomé, L. ....	204	Tragust, S. ....	206	Tsuchida, T. ....	58	Uchiyama, K. ....	248
Tomishima, K. ....	156, 178	Traini, M. ....	179	Tsuchishima, M. ....	210	Ucsnik, L. ....	234
Tomita, S. ....	191	Tran, H. ....	249	Tsuchiwata, S. ....	187	Udd, M. ....	172
Tomita, Y. ....	158	Tran, M. ....	239	Tsuchiya, K. ....	57, 71, 183	Uebel, P. ....	130, 187
Tomoda, T. ....	217	Tran Minh, M. L. ....	246	Tsuchiya, T. ....	171	Ueda, K. ....	129, 156-157, 201
Tomuleasa, C. ....	217	Trang, C. ....	75	Tsuda, K. ....	133	Ueda, Y. ....	50
Tondereau, V. ....	238, 250	Trapero Martinez, A. M. ....	49	Tsuda, M. ....	155	Uedo, N. ....	174
Tondi, P. ....	167	Trauner, M. ....	48, 55, 63, 65, 77, 87, 91, 98, 121, 125, 166-167, 211-212, 221-222	Tsugawa, H. ....	202	Uejima, M. ....	174
Tonelli, F. ....	160	Traversa, G. ....	140	Tsugawa, N. ....	138	Ueki, N. ....	243, 245
Tong, H. ....	121	Travis, S. ....	143, 234	Tsugeno, H. ....	81, 173	Uemura, S. ....	99, 181
Tongtawe, T. ....	158	Trreiber, G. ....	58	Tsuji, S. ....	56	Ueno, M. ....	152
Tonhajzerova, I. ....	199	Tretton, X. ....	86, 233	Tsuji, Y. ....	126, 175	Uesugi, K. ....	173, 217
Tonozuka, R. ....	171	Trevisani, F. ....	124, 215	Tsujimae, M. ....	126	Uesugi, N. ....	156
Tontini, G. E. ....	157, 175, 184, 220	Trgovec-Greif, L. ....	206	Tsunada, S. ....	180	Ueyama, H. ....	80, 129, 156-157, 201
Tooren, M. ....	182	Triantafyllou, K. ....	221	Tsunemitsu, Y. ....	182	Ufimtceva, I. ....	166
Topalova, A. ....	162	Triantopoulou, C. ....	134	Tsutsumi, M. ....	210	Uhl, W. ....	173
Topazian, M. ....	217	Triantos, C. ....	146, 168	Tsuyama, S. ....	157, 191	Uhunmwangho, A. O. ....	168
Tops, S. ....	74	Tribich, S. ....	144-145	Tsuzura, H. ....	156	Ujihara, T. ....	128, 134, 157
Tora, I. ....	177	Trifan, A.-V. ....	205-206, 213	Tsvetaeva, E. ....	167	Ukai, K. ....	94, 148
Törnblom, H. ....	138, 191, 194-195, 239, 250	Triggianese, P. ....	141	Tu, Q. ....	172	Ukleja, A. ....	198
Tornkvist, N. ....	191	Trinder, D. ....	189	Tucillo, C. ....	138	Ulfssdotter Weimers, M. P. ....	186
Toro, M. A. ....	233	Tringali, A. ....	38, 62, 67, 91, 179, 219, 222-223, 244	Tucknott, S. ....	232	Ullah, S. ....	175
Torok, I. ....	126, 171	Trinh, A. ....	192	Tufare, F. ....	222, 241	Ulyanin, A. ....	238
Torrealba, L. ....	148	Trinquand, A. ....	248	Tugnoli, V. ....	57	Umans, D. S. ....	216
Torrealba Medina, L. ....	233	Triossi, O. ....	197, 224	Tulchinsky, H. ....	63, 189	Umeda, T. ....	160, 205
Torrejon Torres, R. ....	180	Tripathi, P. R. ....	146	Tumova, E. ....	153	Umemura, K. ....	145
Torrella Cortés, E. ....	144	Tristán, E. ....	159	Tun, G. S. Z. ....	234, 243	Umemura, S. ....	136
Torrella Cortes, E. A. ....	144	Tristan, J. ....	163, 167, 253	Tunemi, M. ....	128	Umutlu, L. ....	140-141
Torres, A. M. ....	232	Tristan Barros, J. ....	122	Turato, C. ....	167	Ungaro, R. ....	233
Torres, D. ....	186	Trojan, J. ....	202	Turcan, S. ....	48, 185	Unge, P. ....	200
Torres-Yuste, R. ....	52, 223, 229	Trombetta, E. ....	63	Turck, D. ....	229	Unger, L. ....	166
Torresan, F. ....	157, 239	Troncone, E. ....	181, 218, 225	Turello, G. ....	74	Ungermann, E. ....	214
Torrieri, C. ....	224	Troncone, R. ....	64, 161	Turlin, B. ....	185	Ungprasert, P. ....	170
Tortora, A. ....	197, 211	Tropina, E. ....	183-184, 189	Turnava, L. ....	159	Ungureanu, B. ....	172, 181
Toshikuni, N. ....	210	Trovatello, A. ....	61	Turrini, O. ....	223	Uniken Venema, W. T. C. ....	233
Toshima, T. ....	227	Trovato, C. M. ....	177	Tursi, A. ....	78, 89, 100, 150, 196, 203, 240, 244, 246, 248	Unruh, O. ....	141
Tóth, A. ....	65	Trudgill, N. ....	62, 227, 251	Tutein Nolthenius, C. ....	53, 231	Unsal, B. ....	220
Toth, E. ....	176	Trukhmanov, A. ....	154, 200, 238	Tuttle, J. ....	97, 142	Ünver, N. ....	180
Toth, J. ....	126	Trovatello, A. ....	61	Tuttolomondo, A. ....	186	Urabe, M. ....	134
Tóth, J. ....	207	Trovato, C. M. ....	177	Tutuian, R. ....	60, 101	Urabe, S. ....	197
Touchefeu, Y. ....	37, 65, 96	Trugust, J. ....	206	Tuyman, J. B. ....	192	Urabe, Y. ....	147
Touibi, Y. ....	164	Tsukhmanov, A. ....	154, 200, 238	Tüzün Ince, A. ....	127, 172	Urano, Y. ....	225
Toumangelova-Yuzeir, K. ....	230	Tsapatkiewicz, A. ....	137	Tvedt-Gundersen, E. ....	231	Uraoka, T. ....	82, 176, 242
Tourkodimitris, S. ....	242	Tsapaki, V. ....	134	Tveito, K. ....	160	Urba, M. ....	246
Toya, Y. ....	146, 156	Tsapas, A. ....	197, 212	Tyberg, A. ....	52, 133-135	Urbonvas, V. ....	146, 252
Toyama, H. ....	135	Tschurtschenthaler, M. ....	96	Tzatzagou, G. ....	207, 209	Ureña-Campos, R. ....	216, 223
Toyokawa, T. ....	133, 155	Tse, Y. K. ....	69	Tziatzios, G. ....	221	Urgesi, R. ....	150, 196, 206
		Tsibouris, P. ....	223, 248	Tziortziotis, I. ....	181	Urreta, I. ....	121
						Urushibara, F. ....	132
						Usai, P. ....	160

Uslan, M. I. ....	198, 241-242	Van de Ven, S. E. M. ....	128	van Laarhoven, H. W. M. ....	94	Vas, D. ....	185
Usui, S. ....	167	van de Wetering, A. J. P. ....	53, 85	Van Laethem, J.-L. ....	174	Vasapolli, R. ....	58
Uter, W. ....	232	van Delden, O. ....	56	Van Lanschot, M. C. J. ....	193	Vasas, B. ....	179-180, 194
Uto, H. ....	59, 170	van den Akker-van Marle, M. E. ....	149	van Leerdam, M. ....	87, 178, 191, 193	Vasconcelos, H. ....	162, 204, 220, 252-253
Utsunomiya, R. ....	127, 173, 217	van den Berg, F. F. ....	89, 216	van Lelyveld, N. ....	149	Vasconcelos Loureiro, R. ....	240
Uusijärvi, A. ....	191	van den Blink, A. ....	148	van Lent, A. U. ....	148, 192	Vasilenko, G. ....	156
Uzan, A. ....	191	van den Brink, G. R. ....	138, 236	van Lent, A. U. G. ....	192	Vasilescu, C. ....	213
<b>V</b>		Van den Houde, K. ....	195, 199	Van Lent, N. ....	180	Vasilioiu, K. ....	209
Vackova, Z. ....	155, 174, 198	van der Bilt, J. D. ....	187	Van Lidth De Jeude, J. F. ....	236	Vasilyev, I. ....	74, 235, 247
Vadala di Prampero, S. F. ....	161	van der Ende, K. ....	121	Van Limbergen, J. ....	101	Vassallo, M. ....	195
Vadillo-Calles, F. ....	50, 152, 197	van der Geest, L. G. ....	215	van Milligen de Wit, A. W. ....	149	Vassallo, R. ....	61, 100, 150
Vafaeimanesh, J. ....	123	van der Harst, E. ....	85, 226	van Munster, S. ....	63, 98, 155	Vasseur, F. ....	229
Vaira, B. ....	74, 204, 247	van der Hulst, R. W. M. ....	193	Van Oudenhove, L. ....	43, 72, 88, 95, 205, 207	Vasseur, P. ....	135
Vaira, D. ....	98, 159, 247	van der Kraan, J. ....	149	van Sandick, J. ....	226	Vassiliadis, T. ....	168
Vaira, V. ....	160	van der Laak, J. ....	210	Van Riet, P. ....	92, 134, 172	Vatn, M. H. ....	140
Vakharia, A. B. ....	208	van der Lely, L. ....	143	Van Riet, P. A. ....	92, 172	Vaudry, D. ....	238
Valantiene, I. ....	121	van der Merwe, S. ....	134	van Roessel, S. ....	82	Vavassori, S. ....	157
Valantinas, J. ....	122	Van der Meulen - De Jong, A. ....	57, 231	van Santvoort, H. C. ....	42, 46, 67, 85, 216	Vavricka, S. ....	42, 115
Vale Rodrigues, R. ....	240	van der Meulen, K. E. ....	154	van Santvoort, H. C. ....	42, 46, 67, 85, 216	Vaya, M. J. ....	151
Valente, A. ....	144, 208, 251	Van der Pol, W. ....	201	van Spijk, A. ....	121	Vaz, A. ....	206
Valente, A. I. ....	230	Van der Post, C. ....	215	Van Stappen, T. ....	142	Vazeille, E. ....	70, 139, 231
Valente, R. ....	56, 92, 127	Van der Putten, J. ....	88, 155	Van Tubergen, A. ....	231	Vázquez, J. M. ....	188
Valerii, C. ....	228	van der Sande, M. ....	54, 178, 193	Van Tubergen, A. ....	231	Vázquez Morón, J. M. ....	232
Valerii, G. ....	222-223	van der Sommen, F. ....	88, 155	Van Viegen, T. ....	138	Vazquez Sequeiros, E. ....	202
Valerio, L. ....	223	van der Slugt, M. ....	191	Van Westreenen, E. ....	149	Vd Putten, J. ....	217
Valero, M. ....	51, 154, 180	Van der Waaij, L. ....	172	Van Westreenen, E. L. ....	137	Vecchi, M. ....	63, 140, 157, 160, 180, 230, 240, 246, 248-249
Valeur, J. ....	160, 199	van der Werf, L. R. ....	94	van Westreenen, H. L. ....	226	Veckman, V. ....	231
Valkov, I. ....	114, 162	van der Woude, C. J. ....	42, 57, 97	Vanacore, D. ....	121	Veenendaal, R. A. ....	57
Valladolid Leon, J. M. ....	247	van der Zaag, E. ....	238	Vanbiervliet, G. ....	39, 135-136, 198	Veenstra, R. ....	149
Valle, C. ....	64, 167	van der Zwaan, S. M. S. ....	149	Vande Castele, N. ....	138	Veereman, G. ....	78, 97, 101
Vallejo Senra, N. ....	212, 217	van Dieren, S. ....	84, 145	Vanden Berghe, P. ....	56	Vega, R. ....	176
Valli, V. ....	249	van Dijk, M. ....	170	Vandeputte, D. ....	88	Vege, S. S. ....	54, 80, 92, 103
Valls Gandía, M. ....	233	Van Domselaar, M. ....	49, 188, 233	Vanella, G. ....	92, 172, 220	Vegh, Z. ....	48, 185
Valori, R. ....	53, 87, 93, 225	Van Duijvendijk, P. ....	46, 85	Vanhuytsel, T. ....	198	Veijola, L. ....	98, 204, 247
Valpiani, D. ....	48, 185	Van Dullemen, H. ....	46	Vani, D. ....	209, 220	Veitch, A. ....	62, 221
Valvano, M. ....	243	van Eden, H. ....	137	Vanner, S. ....	72	Velagapudi, V. ....	59, 76, 213
Valverde López, F. ....	50, 152, 197	van Eijck, C. H. J. ....	46, 63, 85	Vanoli, A. ....	160, 196	Velasco, M. ....	190
van 't Sant-jansen, I. ....	137	van Erp, M. ....	210	Vanuysel, T. ....	51, 71, 195, 199, 205, 245	Velasquez, J. G. ....	208
Van Assche, G. ....	39, 59, 91, 97, 143, 189	van Etten, B. ....	137, 194, 226	Varadarajulu, S. S. ....	56	Velázquez Aviña, J. ....	230
van Avesaat, M. ....	239	van Geenen, E. J. M. ....	197	Varchetta, S. ....	229	Velázquez Ortigas, J. ....	50
van Baar, A. C. G. ....	88, 206	van Gennep, S. ....	190	Vardanyan, A. V. ....	186	Veld, J. V. ....	238
van Ballegooijen, M. ....	87	van Ginneken, R. ....	192	Vardar, U. ....	153	Velegraki, M. ....	215
Van Beek, A. ....	198	Van Gossom, A. ....	85	Vardas, E. ....	215	Velickovic, J. ....	123
van Berge Henegouwen, M. I. ....	55, 78, 84, 226	Van Gossom, M. ....	253	Vardi, H. ....	48, 142	Velikova, T. ....	230
Van Bergeijk, J. D. ....	148, 192	van Gulik, T. M. ....	215	Varela, A. ....	151, 160	Vellone, M. ....	251
van Berkel, A.-M. ....	193	Van Halsema, E. E. ....	238	Varela, M. ....	64, 167	Velosa, J. ....	171, 176, 208, 219, 222-223, 241, 252
van Berkel, M. ....	207	van Herwaarden, Y. ....	62, 78	Varela, P. ....	49	Veloso, F. ....	124
van Berlo, J. ....	170	van Hilst, J. ....	84	Varela-Moreiras, G. ....	126	Veloso, N. ....	207
Van Beurden, Y. H. ....	75	van Hoboken, E. ....	239	Varga, M. ....	126-127, 171	Velzing, J. ....	137
Van Cutsem, E. ....	37, 78, 88	van Hooft, J. E. ....	42, 46, 54, 77, 84, 172, 182, 216-217, 238	Vargas Castillo, E. ....	158	Venalainen, M. ....	172
van Dam, G. M. ....	137, 194	van Huijgevoort, N. ....	182, 217	Varitimadias, L. ....	181	Vendrik, K. E. ....	75
van de Graaf, S. ....	91	Van Kemseke, C. ....	53	Varjú, P. ....	126, 171	Venerito, M. ....	58, 98, 204, 247
van de Laarschot, L. F. M. ....	59, 121	van Kuijk, S. ....	235, 251	Varley, R. ....	181	Venezia, I. ....	191
		van Laarhoven, C. ....	85, 215	Varma, S. ....	143	Venezia, L. ....	160
		van Laarhoven, C. J. H. M. ....	125	Varytimadias, L. ....	218		

Venglovecz, V.....	59	Villaruel, M.....	52, 56	Vos, F.....	231	Wang, H.....	139, 163, 187-189, 245
Ventimiglia, M.....	61, 233	Villaverde, A.....	222, 241	Vos, R.....	199	Wang, H. P.....	245
Venugopal, K.....	143	Villoria, A.....	93, 233	Voskuil, M. D.....	233	Wang, H.-P.....	155
Vepsalainen, J.....	172	Villotti, G.....	196, 206	Voudoukis, E.....	215	Wang, H.-Y.....	203
Vera, M.....	49, 93, 232	Vilmann, P.....	186	Voulgaris, T.....	168	Wang, J.....	139, 165, 172, 180, 210
Verbeure, W.....	207	Vincenzo, C.....	166	Vradelis, S.....	184	Wang, J.-D.....	147
Vercauteren, T.....	176, 245	Vincoli, G.....	153	Vraka, M.....	181	Wang, K.-Y.....	153
Verdejo Gil, C.....	233	Vincze, A.....	62, 84, 110, 126-127, 130, 171, 178, 190, 217, 232, 249	Vrakas, S.....	147	Wang, L.....	74, 196, 204, 219, 236
Verdelho Machado, M.....	208, 251	Vincze, Á.....	134	Vranesić Bender, D.....	230	Wang, M.....	128, 159, 205
Verdonk, R. C.....	85, 216	Vind, I.....	49	Vuik, F. E. R.....	95, 193	Wang, N.....	201
Veres, G.....	65, 93, 145	Vinet, O.....	141	Vujasinovic, M.....	127	Wang, P.....	47
Vergnolle, N.....	56, 71-72, 75	Vinnitskaya, E. V.....	162	Vullierme, M.-P.....	128	Wang, Q.-L.....	155
Verhaegh, B. P.....	184	Violi, A.....	150, 240	Vyalov, S.....	199, 211	Wang, R.....	169, 172, 180, 214
Verheij, J.....	82, 215	Virginijus Jonaitis, L.....	204	Vybornyi, M.....	137	Wang, S. H.....	121
Verhoeven, R.....	94, 215	Virili, C.....	243	Waage, S.....	195	Wang, T.....	65, 82, 98, 155, 165, 200
Verlaan, T.....	54	Visaggi, P.....	242	Wächter, L.....	122	Wang, T. C.....	82, 98, 155, 200
Vermeer, N. C.....	226	Visée, C.....	61	Wada, K.....	148	Wang, T.-N.....	153
Vermeire, S.....	75, 86, 97, 142-143, 189	Vissienon, C.....	235	Wada, M.....	148, 170	Wang, W.....	63, 79, 124, 145
Vernerey, D.....	128	Vitaglione, P.....	210	Wada, N.....	182	Wang, W.-L.....	155, 245
Vernia, F.....	248	Vitale, A.....	124, 196, 215	Wada, R.....	191	Wang, X.....	121, 127, 214, 216, 219, 221, 248
Vernia, P.....	145, 228	Vitale, M. A.....	206	Wada, T.....	129	Wang, Y.....	144, 165, 209, 245
Vernygorodskiy, S.....	156	Vitali, F.....	232, 241	Wada, Y.....	148	Wang, Z.....	72, 197
Verset, L.....	174	Vitális, Z.....	171	Wadie, W.....	227	Wang, Z. G.....	197
Verspaget, H. W.....	57, 75	Vitello, A.....	231	Wagenhäuser, K.....	142	Wani, S.....	62
Vesa, S.....	120	Vitte, R.-L.....	179	Wagner, A. D.....	77-78	Wanichagool, D.....	59
Veselov, V. V.....	186	Vitton, V.....	149, 198	Wagner-Golbs, A.....	210	Wannhoff, A.....	177, 219
Vespasiani, F.....	241	Vlachogiannakos, J.....	168	Wahba, M.....	129, 163-164	Wanten, G.....	207, 250-251
Vester-Andersen, M. K.....	49	Vlachou, E.....	39, 223, 248, 250	Wajima, T.....	76, 122	Warburton, L.....	243
Veyrard, P.....	233	Vladimirov, B.....	217	Wakamura, K.....	131-133, 175, 192, 194, 219-221	Wargenau, M.....	243
Veysey, M.....	206	Vleggaar, F. P.....	148, 192	Waked, I.....	124, 152	Warusavitarnre, J.....	73, 91, 227-228, 234
Viada Bris, J. F.....	190	Vlodavsky, I.....	127	Wala, I.....	187-189	Wasmann, K.....	145-146
Viazis, N.....	181, 185	Vodoturo, G.....	238	Walabies, M.....	198	Wasser, M. N. J. M.....	57
Vicario, S.....	170	Vodoleev, A.....	208	Walczak, P.....	187	Watabe, T.....	138-139
Vicaud, E.....	169	Vogel, T.....	182	Waldmann, E.....	74, 87, 221-222	Watanabe, A.....	129, 197, 204
Vicente Lidón, R.....	232	Vogrincic, M.....	161-162	Walker, G.....	190	Watanabe, H.....	58
Victor III, D. W.....	167	Vogt, C.....	241	Walker, H.....	164	Watanabe, K.....	80, 139, 170, 178
Victor, D. W.....	64	Voicu, S.....	169	Walker, M.....	95, 100, 158, 184, 199, 205, 228, 239, 243	Watanabe, M.....	57, 71, 80, 138-139, 183
Vidyaeva, N.....	129	Voiosu, T. A.....	168	Wallace, M. B.....	92, 172	Watanabe, N.....	133, 158
Vieira, A.....	140, 150, 186, 231	Vojnovic, M.....	141	Wallace, V.....	241	Watanabe, S.....	71, 179, 183
Vieira, A. M.....	150	Vojtechova, G.....	224	Wallenhorst, T.....	177, 198	Watanabe, T.....	129, 132, 134, 148, 196
Vieira, F.....	114	Vojtechová, G.....	177	Walsh, S.....	164	Watanabe, Y.....	181, 251
Vieira da Rocha, E. C.....	164	Vologzhanina, L.....	98, 204, 247	Walter, B.....	176, 225	Waterman, M.....	176
Viennot, S.....	61, 230, 233	Volpato Machado, N.....	202	Walterova, B.....	155	Watifah, J.....	91
Vieth, M.....	79, 84, 92	Volpe, M.....	139, 196, 200, 230	Walton, C.....	159	Watson, A.....	234, 236
Vigilio, A.....	160	Voltá, T.....	158	Waluga, M.....	175	Watts, D.....	234
Vignolo, P.....	206	Volta, U.....	160	Walz, J.....	135	Wauters, L.....	71
Vignsnaes, L. K.....	235	von Arnim, U.....	199	Walzel, C.....	212	Webb, M.....	48, 191
Vila, J. J.....	202, 237	von Bergwelt, M.....	172	Wang, A.....	56	Weber, L.....	235
Vilas, A. P.....	207	von Figura, G.....	59, 126	Wang, B.....	59, 154, 165-166, 245	Weber, M.....	238
Vilas Boas, F.....	172-173, 193, 225, 252	von Schönfels, W.....	210	Wang, C.....	161, 172, 183	Weber, S.....	150
Vilela, E. G.....	184	Vong, C.....	187	Wang, F.....	148	Weber, T.....	218
Villa, E.....	228	Vork, L.....	194-195, 220, 235, 239	Wang, G. Q.....	155		
Villanacci, V.....	160						
Villanueva Herrero, J. A.....	226, 230						
Villar Lucas, C.....	236						

Webster, G. ....	223	Wilder-Smith, C. ....	194-195, 238, 249	Wu, K. ....	142, 229	Yagi, N. ....	202-203
Wedemeyer, H. ....	68, 79, 103	Wildt, S. ....	100, 184	Wu, K.-L. ....	159, 178	Yagioka, H. ....	68
Weersma, R. K. ....	233	Wilhelm, D. ....	182	Wu, L. ....	236	Yahagi, N. ....	47, 80, 82, 94, 130, 156, 177, 182, 218
Weerts, Z. Z. R. M. ....	194-195, 239	Wilke, T. ....	189-190	Wu, M. ....	134	Yakabi, K. ....	163
Wegeberg, A. L. ....	136	Wilkinson-Smith, V. ....	225	Wu, M.-P. ....	165	Yakovleva, S. ....	121, 166
Wehbe, A. ....	241	Wille, K. ....	173	Wu, M.-S. ....	74, 247	Yalchin, M. ....	144-145
Wei, K.-L. ....	151	Willemoe, G. L. ....	120	Wu, N. ....	210	Yamada, A. ....	134
Wei, R. ....	210	Willert, R. ....	62	Wu, S. ....	124, 167	Yamada, D. ....	138
Weigmann, B. ....	46	Williams, D. ....	65	Wu, S.-F. ....	151	Yamada, K. ....	177
Weigt, J. ....	58, 215	Williams, L. ....	53	Wu, T. ....	208	Yamada, M. ....	130, 132, 191
Weijers, G. ....	210	Williams, S. J. ....	177	Wu, X. ....	245	Yamada, S. ....	132, 192
Weimers, P. ....	139	Williet, N. ....	75	Wu, Z. ....	166, 210, 216, 227	Yamada, T. ....	133, 219, 242
Wein, F. ....	82, 218	Willock, R. ....	232	Wuggenig, P. ....	46	Yamada, Y. ....	127, 135, 179
Weiss, E. ....	71	Winkens, B. ....	53, 85, 231, 251	Wylie, P. ....	39	Yamagami, H. ....	129, 134, 196
Weiss, F. U. ....	172	Winkvist, A. ....	250	Wynter, E. ....	69	Yamagami, M. ....	222
Wen, C. ....	197	Wirta, V. ....	50			Yamagata, T. ....	157
Wen, M. ....	165, 210	Wirth, T. ....	42, 87	<b>X</b>		Yamaguchi, A. ....	133, 167, 178, 225
Wen, X. ....	199	Witas, B. ....	233	Xavier, S. ....	71, 121, 145	Yamaguchi, D. ....	180
Wensaas, K.-A. ....	100-101, 195	Witteман, B. J. ....	187	Xavier Brito, L. ....	252	Yamaguchi, H. ....	131
Wenzl, H. H. ....	75	Witteман, B. J. M. ....	46	Xavier Jorge, J. ....	196-197, 238-239	Yamaguchi, K. ....	138, 245
Werge, M. ....	216	Witteман, E. ....	149	Xia, Z. ....	196	Yamaguchi, N. ....	130
Werkstetter, K. ....	64, 161-162	Wojciechowska, U. ....	222	Xiao, F. ....	152	Yamaguchi, S. ....	181, 251
Werner, J. ....	172	Wojcik, D. ....	201, 228, 235	Xiao, L. ....	183, 196	Yamaguchi, T. ....	157, 219
West, J. ....	157	Wolfhagen, F. H. J. ....	148, 192	Xiao, X. ....	47	Yamaguchi, Y. ....	179
West, R. L. ....	187	Woliński, J. ....	161	Xiao, Y. ....	200	Yamai, T. ....	134
Westerveld, D. ....	131, 135	Wolthuis, A. ....	54	Xie, C. ....	158, 248	Yamakawa, R. ....	174
Westhölter, D. ....	58	Won, S. H. ....	246	Xie, C.-N. ....	165	Yamakita, K. ....	133
Westhovens, R. ....	85	Wong, C. C. ....	147, 166, 236, 246	Xie, J. ....	126	Yamamichi, N. ....	175
Weusten, B. L. A. M. ....	62-63, 73, 101-102, 154-155	Wong, J. ....	137	Xie, S. ....	244	Yamamoto, E. ....	147, 177, 192
		Wong, M. ....	147, 154	Xie, S.-H. ....	155	Yamamoto, H. ....	61, 130, 152, 156, 160
Wex, T. ....	58	Wong, R. ....	131	Xie, Y. ....	148	Yamamoto, K. ....	56, 81, 120, 155, 166, 171, 174, 209, 225
Whary, M. ....	98	Wong, S. ....	227	Xie, Z. ....	237	Yamamoto, N. ....	58, 68
Whitaker, R. ....	206	Wong, T. ....	242	Xiong, H. ....	83	Yamamoto, T. ....	197
White, I. ....	189	Wong, V. W. ....	218	Xiorgias, V. ....	147	Yamamoto, Y. ....	149, 176-177
White, L. ....	141	Wong, Y. J. ....	209	Xu, B. ....	159	Yamano, H.-O. ....	177
Whitehouse, J. ....	122	Woo, A. ....	69, 98, 199	Xu, G. ....	47, 137, 156, 159	Yamaoka, H. ....	133
Whitham, D. ....	53	Wood, N. ....	70	Xu, J. ....	210, 227	Yamasaki, T. ....	81, 175, 204, 252
Whorwell, P. ....	195	Woodcock, A. ....	154	Xu, L. ....	126	Yamashina, T. ....	61
Whyte, S. ....	67	Woodcock, S. ....	162	Xu, M. ....	60	Yamashita, E. T. ....	250
Wicaksono, A. ....	94, 140	Woodland, P. ....	153	Xu, W. ....	74, 196	Yamashita, H. ....	126, 133
Wichmann, D. ....	163	Woods, A. ....	228	Xu, Z. ....	227	Yamashita, K. ....	53, 161
Wickbom, A. ....	68	Woodworth, D. A. ....	79, 97, 187	Xuan, W. ....	154, 245	Yamashita, M. ....	156
Widlak, M. M. ....	87, 94, 176	Wöran, K. ....	212	Xue, L. ....	155	Yamashita, T. ....	170, 245
Wiebe, B. ....	189	Wouters, K. ....	94	Xue, Q. ....	139	Yamashita, Y. ....	177
Wierdak, M. ....	201	Wouters, Y. ....	207, 250	Xue, R. ....	127	Yamato, H. ....	197
Wiestler, M. ....	142	Woźniak-Stolarska, B. ....	184	Xue, Y. ....	157, 241	Yamauchi, H. ....	135, 178
Wieszczy, P. ....	129, 177, 222	Wright, A. ....	234			Yamauchi, K. ....	155
Wijarnpreecha, K. ....	58, 170	Wright, D. ....	143	<b>Y</b>		Yamauchi, Y. ....	131
Wijmenga, C. ....	46	Wright, S. ....	87, 225	Yabe, Y. ....	138	Yamawaki, H. ....	243, 245
Wijnen, R. M. H. ....	95	Wronska, E. ....	224	Yacob, A. ....	176	Yan, K. ....	155
Wijnhoven, B. P. L. ....	77-78, 94, 101, 226	Wu, C.-H. ....	165	Yachha, S. K. ....	146, 162, 171	Yan, X. ....	82, 129, 157
Wijsman, P. ....	145	Wu, C.-S. ....	151	Yachimski, P. ....	135	Yanagisawa, D. ....	197
Wilcox, C. M. ....	201, 240	Wu, F. ....	58, 151	Yachnin, J. ....	50	Yanagita, K. ....	123
Wilczynska, B. ....	211	Wu, J. ....	110, 121, 156, 203, 216, 218, 235, 248	Yadav, T. D. ....	216	Yanai, H. ....	189, 234, 251
Wild, D. ....	173	Wu, J. C. ....	219-220	Yagawa, Y. ....	131, 192, 194, 219-220		
Wild, G. ....	185, 205	Wu, J. C. Y. ....	235	Yaghi, C. ....	130		
Wild, J. ....	242						



Yanai, S.....	146, 156	Yeh, C.-T.....	213	Yu, L. ....	159	Zelinkova, Z. ....	145
Yanai, Y.....	157, 191	Yeo, S. J.....	175	Yu, R.-B. ....	165	Zemmouchi, S. ....	125
Yanan, W.....	210	Yeoh, K. G. ....	131	Yu, X.....	155, 203	Zemmour, C. ....	225
Yanase, Y.....	192	Yi, H.-G. ....	165	Yu, X.-F. ....	154	Zen, Y.....	127, 135
Yane, K. ....	127, 173, 217	Yi, X.....	47	Yücel, S. ....	101, 209	Zeng, X.-P. ....	65
Yang, A. ....	154	Yigman, S. ....	237	Yue, M. ....	165	Zeni, N.....	169
Yang, C. ....	154	Yildirim, B.....	164	Yuge, R. ....	147	Zentar, A. ....	164
Yang, D. ....	56, 131, 135	Yilmaz, O. ....	196	Yuhara, H. ....	139	Zentilin, P.....	168, 200, 221
Yang, D.-H.....	176, 187, 192, 221	Yilmaz, Y. ....	210	Yui, S. ....	57, 183	Zerbi, A.....	49
Yang, J. ....	69, 96, 127, 133, 156, 163-164, 174, 178, 182, 245, 253	Ying, X. ....	198	Yuki, O. ....	206	Zerbib, F.....	49, 86, 243
Yang, J. K. ....	178	Yip, C. H. B.....	178	Yukimoto, A.....	173, 217	Zerboni, G.....	92, 172, 216
Yang, J.-J.....	165	Yılmaz, D.....	210	Yüksel, I. ....	185	Zezos, P.....	75
Yang, L. ....	76, 124, 165, 167, 210	Yoda, Y.....	88, 149, 176-177	Yun, B. C. ....	234	Zhan, Q.....	214, 237
Yang, M. ....	144, 174	Yoe, L.....	251	Yun, S. ....	174	Zhang, B. ....	63, 71, 86, 138
Yang, Q. ....	203	Yoh, T.....	158	Yunusa, T. ....	168	Zhang, C. ....	209
Yang, S.-K. ....	176, 187, 192	Yokota, H. ....	88, 176	Yuyama, K. ....	166	Zhang, C.-H.....	149
Yang, W. L. ....	131	Yokota, T. ....	173, 217	Yvellez, O. ....	189	Zhang, D. ....	47, 65
Yang, X. ....	124, 210	Yokoyama, J. ....	153	Yvon, S. ....	238, 250	Zhang, G. ....	114, 208, 218, 226, 240, 244
Yang, Y. J. ....	133, 149	Yonamine, K.....	125, 128, 170			Zhang, H. ....	97, 145, 183, 186-187
Yano, S.....	227	Yoneda, A. ....	130	Z		Zhang, J.....	58, 86, 147, 151, 227, 246
Yano, T.....	88, 129, 149, 160, 176-177	Yonemoto, Y. ....	197, 204	Z'hao, L. Z. ....	197	Zhang, L.....	121
Yantorno, M. ....	222, 233, 241	Yonezawa, M.....	141, 160	Zabalza, L. ....	158	Zhang, M. ....	153, 174, 200
Yao, B. ....	157	Yoo, C. H. ....	50	Zabana, Y. ....	159	Zhang, M.-M.....	153
Yao, C. ....	245	Yoo, I. K. ....	69	Zaccari, P. ....	196, 243	Zhang, N.....	187-189
Yao, C.-C. ....	159, 178	Yoon, G. ....	237	Zagari, R. M. ....	197	Zhang, Q. ....	237
Yao, R. ....	143	Yoon, H. ....	96, 157, 191, 203, 239	Zaghla, H. ....	214	Zhang, Q.-W.....	149
Yao, T.....	80, 129, 156-157, 191, 201	Yoon, J. H. ....	183	Zaghloul, H. ....	168	Zhang, S. ....	147, 197, 200
Yap, K. ....	177	Yoon, Y. H. ....	202	Zaghloul, M. S.....	252	Zhang, S.-L.....	163
Yardibi, O. ....	75, 185	Yorozu, A. ....	147	Zaika, S. ....	156	Zhang, W. ....	114, 159, 189, 198
Yashima, K. ....	170	Yoshida, A.....	197	Zaimi, Y.....	162, 212	Zhang, X. ....	59, 127, 133, 163, 215
Yassen, A. ....	169	Yoshida, K.....	99, 181	Zakareya, T.....	213	Zhang, X.-J.....	165
Yassin, K. ....	176, 217	Yoshida, M. ....	151	Zalar, A. ....	242	Zhang, Y.....	86, 96, 143-144, 155, 165-166,
Yassin, K. A. ....	217	Yoshida, N.....	221, 248	Zalata, K. ....	168		199, 204-205, 210, 214, 227
Yasuda, H. ....	156	Yoshida, S. ....	175	Zamani, F. ....	123	Zhang, Z. ....	47, 215
Yasuda, I. ....	68, 222	Yoshida, T.....	147, 179	Zambelli, A. ....	197	Zhao, C. ....	216, 237
Yasuda, M. ....	194	Yoshida, T.....	177	Zammit, C. ....	195	Zhao, D. ....	155
Yasuda, T.....	202-203	Yoshikawa, K.....	179	Zampaletta, C.....	150	Zhao, H.....	215
Yasuda, Y.....	202-203	Yoshiko, F. ....	72, 238-239	Zanati, S. ....	177	Zhao, K.....	243
Yasue, C. ....	133	Yoshimura, D.....	125, 131, 245	Zander, M. ....	120	Zhao, L.....	166, 206, 219, 221, 225, 252
Yasuhiro, K.....	141	Yoshinaga, S. ....	202	Zanetto, A. ....	169	Zhao, N.....	63
Yatagai, N. ....	129, 156-157, 191, 201	Yoshino, K. ....	197, 204	Zanne, P.....	220	Zhao, X. ....	172, 183, 186
Yaworski, R. ....	240	Yoshino, T. ....	74	Zanus, G. ....	169	Zhao, Y.....	127, 159
Yazaki, E. ....	199	Yoshio, T. ....	58, 88, 201	Zapata, E. ....	121	Zharkova, M. ....	167
Yazar, H.....	196	Yoshioka, M. ....	155, 209	Zapater, P.....	192	Zheng, W. ....	182, 204
Ye, B. D.....	85, 143, 176, 187, 192	Yoshioka, T.....	134	Zarate-Lopez, N.....	149-150, 153, 194, 239	Zhi, M.....	143
Ye, F. ....	215	Yoshito, A.....	174	Zarauza Soto, Y.....	187	Zholobak, N. ....	206
Ye, L.....	138, 159, 252	Yoshizawa, S. ....	136	Zargari, A.....	142	Zhong, J.....	142, 154
Ye, S. ....	236	Yosry, A.....	76	Zarraquiños, S.....	147	Zhong, S. ....	126
Ye, T.....	165	Youn, E. J. ....	187	Zarrouk, S.....	166	Zhong, Y.-S.....	60, 91, 128
Ye, X. ....	216	Youn, S.-J. ....	201	Zavoral, M.....	177, 224, 227, 236	Zhou, B.....	163
Ye, Y. ....	237	Youn, Y. H.....	176	Zaytseva, O. ....	161, 171	Zhou, D.....	210
Ye, Z. ....	152	Younes, R. ....	48	Zdarova Karasova, J. ....	153	Zhou, J.....	147, 157, 246
		Yousefinejad, V.....	210	Zeid, A. ....	206, 212		
		Yu, C. ....	124, 244	Zein, M. ....	123		
		Yu, J.....	58, 147-148, 151, 166, 186, 207, 227, 236, 246	Zeki, S.....	62, 237, 242-243		
		Yu, J. S. ....	186	Zeki, S. S.....	243		
				Zelber-Sagi, S. ....	48, 185, 191		
				Zelcer, M.....	185		

Zhou, L. ....	157, 175, 241	Zimmermann, T. ....	175	Zorn, L. ....	220
Zhou, P. ....	60, 130	Zimnytska, T. ....	200	Zovak, M. ....	251
Zhou, P.-H. ....	60, 91, 94, 128	Zinger, S. ....	88, 155, 217	Zozaya, J. M. ....	202, 237
Zhou, Q. ....	152	Zingone, F. ....	42, 64, 146, 209, 233	Zsigmond, F. ....	232
Zhou, W. ....	79, 142-143	Zini, O. ....	138	Zsobrak, K. ....	224
Zhou, X. ....	157	Zinober, K. ....	125	Zubiaurre, I. ....	233
Zhou, Y. ....	58, 151, 166	Zippi, M. ....	140, 145	Zubiaurre, L. ....	121
Zhu, F. ....	131	Zitron, C. ....	209	Zullo, A. ....	100, 150, 235, 247
Zhu, J. ....	63, 130	Zittan, E. ....	185	Zundler, S. ....	232
Zhu, S. ....	72, 128, 163	Zivkovic, M. ....	251	Zuo, T. ....	227
Zhu, X. ....	139, 142, 156, 174	Ziyatdinov, A. ....	58	Zuppardo, R. ....	49, 181, 236
Zhu, Y. ....	94, 124, 158, 194, 196	Zlatian, O. ....	166	Zurstrassen, C. E. ....	209
Zilberstein, B. ....	157	Zo, J. I. ....	218	Zvyaglova, M. ....	142
Zilli, A. ....	245	Zocco, M. A. ....	163, 167, 211, 251	Zwaginga, J. ....	57
Zilli, M. ....	150, 161	Zoller, H. ....	183	Zygo, B. ....	211
Zimmer, V. ....	150	Zopf, Y. ....	225		

UNITED EUROPEAN  
GASTROENTEROLOGY  
**ueg**


be part of  
the community

  
myUEG  
ueg.eu/myueg

Stop by the UEG Booth in the Entrance Foyer

**Floor Plans  
Austria Center Vienna**

# Level -2




# Level 0



# Level 1



# Level 2





UEG gratefully acknowledges the support  
of this year's Premium Partners:

abbvie **AMGEN**<sup>®</sup>

**FUJIFILM**  
Value from Innovation

**janssen**  
PHARMACEUTICAL COMPANY OF  
*johnson-johnson*



Get the App!  
Final Programme  
available for download  
[ueg.eu/week](http://ueg.eu/week)

**OLYMPUS**

**Pfizer**

**Takeda**